EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS

MSVirtual2020.org #MSVirtual2020

FULL SCIENTIFIC PROGRAM Full Scientific Program as of September 12, 2020. For the most up-to-date program, please visit the MSVirtual2020 Full Online Program.

Table of Contents Friday, September 11, 2020 ...... 4 Plenary Session 1 ...... 4 Plenary Session 1: Welcome and Paty Lecture ...... 4 Parallel Sessions 1-4 ...... 4 PS01 - Strategies for disease modification...... 4 PS02 - Innate immunity in MS pathology and repair ...... 5 PS03 - Biomarkers ...... 6 PS04 - Impact of the environment and lifestyle and MS risk and clinical course ...... 7 Parallel Sessions 5-8 ...... 8 PS05 - Pharmacological management of progressive MS ...... 8 PS06 - Lymphocyte subsets in MS ...... 9 PS07 - Radiological advances I (NAIMS/MAGNIMS) ...... 10 PS08 - Epigenetics and genetic factors ...... 11 Saturday, September 12, 2020 ...... 12 Parallel Session 9-12………………………………………………………………………………………………………………………….13

PS09 - Personalized approaches to MS ...... 12 PS10 - Gut-CNS axis and the microbiome in MS ...... 13 PS11 - Radiological advances II ...... 14 PS12 - Sex-related factors in pathogenesis and management ...... 15 European Charcot Foundation Symposium, Nurse’s Session 1, Young Investigator Session 1 ...... 16 CS01 - European Charcot Foundation Symposium ...... 16 NS01 - Advanced nursing activities ...... 17 YI01 - Young Investigators 1 ...... 17 Parallel Session 13-16 ...... 18 PS13 - Innovations in symptomatic and rehabilitative therapy ...... 18 PS14 - The impact of MS on neurons and glia ...... 18 PS15 - Visual outcome measures in MS (IMSVISUAL) ...... 19 PS16 - Machine learning approaches ...... 20 Sunday, September 13 ...... 22 Hot Topics 1-4 ...... 22 HT01 - Strategies to promote remyelination ...... 22 HT02 - Aging and multiple sclerosis ...... 22 HT03 - Developments in pediatric MS ...... 22 HT04 - Grey matter pathology ...... 22 Hot Topics 5-7 ...... 23 HT05 - Lymphoid follicles and meningeal involvement in MS ...... 23 HT06 - Global perspectives on neuromyelitis optica spectrum disorders ...... 23 HT07 - MOG mediated disease ...... 24 Nurse’s Session 2 and Young Investigator Session 2 ...... 24 NS02 - Unique contributions of MS nursing ...... 24 YI02 - Young Investigators 2 ...... 24 Free Communications 1-4 ...... 27 Free Communications 1 ...... 27 FC02 - Free Communications 2 ...... 28 FC03 - Free Communications 3 ...... 29 FC04 - Free Communications 4 ...... 30 Plenary Session 2 ...... 32 Plenary Session 2 - ACTRIMS-ECTRIMS Lecture and Closing ...... 32 Saturday, September 26 ...... 32 Late Breaking News ...... 32 LB01 - Late Breaking News ...... 32 Special Session: COVID-19 ...... 34 SS02 - COVID-19 ...... 34 On-Demand Program ...... 36 Burning Debates ...... 36 BD01 - DMTs prevent/slow down cognitive impairment in MS ...... 36 BD02 - DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity ...... 36 BD03 - Microglia are protective in MS ...... 36 Meet the Experts ...... 37 MTE01 - CNS in disorders in children ...... 37 MTE02 - Neuro-ophthalmology of MS ...... 37 MTE03 - B-cell-directed therapy in MS ...... 37 MTE04 - Choosing the right MS disease therapy for individual patients ...... 37 MTE05 - Immune disorders of the CNS other than MS ...... 37 Teaching Courses ...... 37 TC01 - Ultra-high-field (7T) MRI in MS (NAIMS) ...... 37 TC02 - Neurofilaments and other biomarkers of CNS disease...... 37 TC03 - NMO spectrum disorders: pathogenesis and treatment ...... 38 TC04 - Accurate diagnosis of MS: getting it right ...... 38 TC05 - Reproductive issues related to treatment in MS ...... 38 TC06 - Anti-MOG associated CNS disease: clinical characteristics and therapeutic management ...... 38 TC07 - Cognitive dysfunction in MS: from MRI to treatment (IMSCOGS) ...... 39 TC08 - Immunologic principles in MS and related disorders ...... 39 TC09 - Pathology of MS ...... 39 TC10 - Infections and MS: long-term immune suppression, benefits and risks of immunizations ...... 40 TC11 - Diagnosis and management of CNS inflammatory diseases mimicking MS ...... 40 TC12 - Progressive MS: clinical phenotypes, imaging, treatment ...... 40 TC13 - Spinal cord involvement in MS: imaging and impact on clinical course ...... 40 TC14 - Interpretation of the statistical results of MS studies ...... 41 TC15 - When does multiple sclerosis begin? MS prodrome and RIS ...... 41 TC16 - Role of sex / gendered factors in MS: focus on sex hormones ...... 41 TC17 - MS clinical manifestations, diagnostic and treatment considerations ...... 41 TC18 - Mechanisms of action of current immune therapies ...... 42 TC19 - Career paths in MS: clinical practice, clinical research, basic research ...... 42 TC20 - Frontiers in research: use of big data in molecular genetics and molecular biology in MS ...... 42 TC21 - Remyelination and neuroprotection ...... 42 TC23 - International 2020 MAGNIMS-CMSC-NAIMS consensus guidelines on the use of MRI in multiple sclerosis (MAGNIMS and NAIMS) ...... 43 On-Demand ePosters ...... 43 Late Breaking On-Demand ePosters ...... 243

Friday, September 11, 2020 Plenary Session 1 09:00 - 10:00 Plenary Session 1: Welcome and Paty Lecture

09:00-10:00 PL01.01 - The MS Prodrome

H. Tremlett, University of British Columbia/Vancouver/CA

Parallel Sessions 1-4 PS01 - Strategies for disease modification 10:15 - 11:45 Moderation: E. Kubala Havrdová1, D. Ontaneda2, 1Charles University//CZ, 2Cleveland Clinic/Cleveland/US

10:15 - 10:30 PS01.01 - Escalation Versus Aggressive Treatment Algorithms

E. Mowry, Johns Hopkins University/Baltimore/US

10:30 - 10:45 PS01.02 - When is it Appropriate to Discontinue DMT?

J. Corboy, University of Colorado/Denver/US

10:45 - 11:00 PS01.03 - Management of RIS

C. Lebrun-Frenay, Centre Hospitalier University de Nice/Nice/FR

11:00 - 11:12 PS01.04 - Comparison of disability trajectories in relapsing Multiple Sclerosis patients treated with early intensive or escalation treatment strategies

P. Iaffaldano1, G. Lucisano1, F. Caputo1, D. Paolicelli2, F. Patti3, M. Zaffaroni4, V. Brescia Morra5, C. Pozzilli6, G. De Luca7, M. Inglese8, G. Salemi9, C. Florio10, E. Cocco11, P. Sola12, G. Lus13, A. Conte6, M.P. Amato14, F. Granella15, S. Galgani16, D. Centonze17, R. Totaro18, M. Rovaris19, M. Salvetti6, R. Mantegazza20, R. Bergamaschi21, D. Maimone22, E. Scarpini23, A. Bertolotto24, G. Comi25, M. Filippi26, M. Trojano2, 1University of Bari “Aldo Moro”/Bari/IT, 2University of Bari/Bari/IT, 3Department of Medical and Surgical Sciences and 4 Advanced Technologies, GF Ingrassia, Catania/Catania/IT, Multiple Sclerosis Centre, Hospital of Gallarate, ASST della Valle Olona/Gallarate (VA)/IT, 5University of Naples Federico II/Naples/IT, 6Sapienza University of Rome/Rome/IT, 7Universita' G. D'Annunzio/Chieti/IT, 8University of Genoa//IT, 9University of Palermo/Palermo/IT, 10Ospedale A.Cardarelli/Napoli/IT, 11University of Cagliari/Cagliari/IT, 12Azienda Ospedaliero-Universitaria di Modena Ospedale Civile di Baggiovara/Modena/IT, 13Second University of Naples/Napoli/IT, 14University of Florence/Florence/IT, 15University of Parma/Parma/IT, 16Az. Osp. S. Camillo Forlanini/roma/IT, 17IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed/Pozzilli/IT, 18Clinica Neurologica, Ospedale San Salvatore/L'Aquila/IT, 19IRCCS Fondazione don Carlo Gnocchi ONLUS/Milano/IT, 20Fondazione IRCCS, Istituto Neurologico Carlo Besta/Milan/IT, 21IRCCS Mondino Foundation/Pavia/IT, 22Garibaldi Hospital/Catania/IT, 23Ospedale Policlinico Maggiore/Milano/IT, 24San Luigi Gonzaga Hospital/Orbassano (TO)/IT, 25San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 26IRCCS San Raffaele Scientific Institute/Milan/IT

11:12 - 11:24 PS01.05 - Rituximab treatment for MS: an observational multicentric dose comparison

L. Midaglia1, G. Alvarez Bravo2, R. Robles Cedeño2, A. Zabalza3, L. Quibus4, P. Carbonell- Mirabent3, J. Sastre-Garriga5, J. Río6, M. Comabella7, J. Castilló2, A. Vidal-Jordana8, G. Arrambide5, B. Rodríguez-Acevedo4, Í. Galán4, C. Nos4, C. Auger5, A. Rovira9, L. Ramió I Torrentà2, M. Tintore10, X. Montalban4, 1Dept. of Neurology-Neuroimmunology; Vall Hebron University Hospital; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 2Neuroimmunology and Multiple Sclerosis Unit of

Girona/Girona/ES, 3Vall d’Hebron Institut de Recerca/Barcelona/ES, 4Dept. of Neurology- Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 5Vall Hebron University Hospital/Barcelona/ES, 6CEMCAT, Hospital Universitario Vall d’Hebrón/Barcelona/ES, 7Universitat Autònoma//ES, 8Hospital Universitari Vall d’Hebron/Barcelona/ES, 9Vall d'Hebron University Hospital/Barcelona/ES, 10Multiple Sclerosis Centre of Catalonia/Barcelona/ES

PS02 - Innate immunity in MS pathology and repair 10:15 - 11:45 Moderation: T. Korn1, T. Benveniste2, 1University of Munich//DE, 2University of Alabama at Birmingham/Birmingham/US

10:15 - 10:30 PS02.01 - Neuroprotective and immunomodulatory effects of astrocytes in chronic EAE

B. Smith, M. Sinyuk, J. Jenkins, M. Psenicka, J. Williams, Cleveland Clinic, Lerner Research

Institute/Cleveland/US

10:30 - 10:45 PS02.02 - Granulocytes in MS pathogenesis

L. Vallieres, Laval University/Quebec City/CA

10:45 - 10:57 PS02.03 - Targeted Depletion of Alternatively-Activated Myeloid Cells Exacerbates Adoptive Transfer EAE

J. Atkinson1, B. Segal2, 1/Columbus/US, 2The Ohio State University/Columbus/US

10:57 - 11:09 PS02.04 - Relation between perivascular mononuclear infiltrates and plaque formation in the cortex and basal ganglia in progressive multiple sclerosis (MS).

1 2 3 4 5 6 B. Okutan , H. Broholm , H. Gaasland , G. Houen , M. Magyari , P. Soerensen , J.L. Frederiksen7, H. Lassmann8, S. Bramow5, 1Danish Multiple Sclerosis Centre /Glostrup/DK, 2Copenhagen University Hospital, Rigshospitalet/Copenhagen/DK, 3The State Serum Institute/Copenhagen/DK, 4Forskerparken/Glostrup/DK, 5Danish Multiple Sclerosis Center/Glostrup/DK, 6Copenhagen University Hospital, Rigshospitalet/Glostrup/DK, 7Rigshospitalet - Glostrup/Glostrup/DK, 8Medical University of Vienna/Vienna/AT

11:09 - 11:21 PS02.05 - Nanomodulation of microRNAs in Macrophages

F. Nally1, V. Lyons2, C. De Santi1, S.A. Cryan1, N. Payne3, C. Mccoy4, 1Royal College of Surgeons in Ireland/Dublin/IE, 2Australian Institute for Regenerative Medicine

Institute/melbourne/AU, 3Australian Institute for Regenerative Medicine/Melbourne/AU, 4Royal College of Surgeons in Ireland/Dublin 2/IE

PS03 - Biomarkers 10:15 - 11:45 Moderation: S. Gnanapavan1, P. Calabresi2, 1Barts Hospital and University of London/London/GB, 2Johns Hopkins University/Baltimore/US

10:15 - 10:30 PS03.02 - MRI Phenotypes and miRNA Signatures in MS

C. Hemond1, B. Healy2, S. Tauhid3, M. Mazzola4, F. Quintana5, R. Gandhi6, H. Weiner7, R. Bakshi8, 1University of Massachusetts/Worcester/US, 2Harvard Medical School/United States/US, 3Brigham & Women's Hospital/Boston/US, 4Lahey Clinic/Burlington/US, 5Harvard Medical School//US, 6Sanofi Genzyme/Cambridge/US, 7Harvard University, Brigham & Women's Hospital/Boston/US, 8Brigham and Women's Hospital/Boston/US

10:30 - 10:42 PS03.03 - Biomarkers of neurodegeneration, in particular Tau protein, may predict early disability in Multiple Sclerosis patients.

E. Virgilio1, D. Vecchio2, I. Crespi3, P. Naldi2, R. Cantello4, U. Dianzani5, C. Comi2, 1Ms Center , University of Piemonte Orientale/Novara/IT, 2Ms Center , Neurology Unit, University of Piemonte Orientale/Novara/IT, 3Azienda Ospedaliero Universitaria Maggiore della Carità of

Novara/Novara/IT, 4Neurology Unit, University of Piemonte Orientale/Novara/IT, 5Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Piemonte Orientale/Novara/IT

10:42 - 10:54 PS03.04 - Evidence for infection triggering mechanism in blood transcriptional profile of Radiologically isolated syndrome

M. Gurevich1, M. Golan1, R. Zilkha-Falb1, P. Sonis1, D. Magalashvili2, M. Dolev1, S. Menascu2, A. Achiron2, 1Sheba Medical Center/Ramat-Gan/IL, 2Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer/Tel-Hashomer/IL

10:54 - 11:06 PS03.05 - Serum glial fibrillary acidic protein, but not S100B or neurofilament light chain predicts future relapses in neuromyelitis optica spectrum disorders M. Watanabe1, N. Isobe2, T. Matsushita2, A. Maceski3, Y. Nakamura4, K. Masaki1, J.-I. Kira4, D. Leppert3, J. Kuhle5, 1Kyushu University/Fukuoka/JP, 2Kyushu University/Fukuoka 3 4 City/JP, University Hospital Basel and University of Basel/Basel/CH, International University of Health and Welfare/Okawa/JP, 5University of Basel/Switzerland/CH

PS04 - Impact of the environment and lifestyle and MS risk and clinical course 10:15 - 11:45 Moderation: M. Pugliatti1, D. Rotstein2, 1University of Ferrara//IT, 2University of Toronto/Toronto/CA

10:15 - 10:30 PS04.01 - Obesity and Metabolic Syndrome in MS

R.A. Marrie, University of Manitoba/Winnipeg/CA

10:30 - 10:45 PS04.02 - Modifiable Lifestyle Risk Factors in MS

A. Hedstrom, Karolinska Institutet/Stockholm/SE

10:45 - 11:00 PS04.03 - Environmental Exposures and MS Risk

K. Munger, Harvard TH Chan School of Public Health/Boston/US

11:00 - 11:12 PS04.04 - Evidence for an interaction between ozone pollution and HLA-DRB1*15 alleles in pediatric multiple sclerosis

A. Ziaei1, A. Lavery2, C. Adams3, T.C. Casper4, S. Roalstad5, M. Candee5, J. Rose6, B. Weinstock- Guttman7, G. Aaen8, J.-M. Tillema9, M. Rodriguez9, J. Graves10, L. Benson11, M. Gorman11, M. Rensel12, T. Chitnis13, T. Schreiner14, B. Greenberg15, I. Kahn16, L. Barcellos17, A. Waldman2, E. Waubant18, 1University of California, San Fransisco/San Francisco/US, 2Division of Child Neurology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania/Pennsylvania/US, 3University of California, Berkeley/Berkeley/US, 44University of Utah/Salt Lake City/US, 5University of Utah/Salt Lake City/US, 6University of Utah, George E. Wahlen Department of Veterans Affairs Medical Center/Salt Lake City/US, 7State University of New York at Buffalo/Buffalo/US, 8Loma Linda University Children’s Hospital/Loma Linda/US, 9Mayo Clinic Department of Neurology/Rochester/US, 10University of California, San Diego/San Diego/US, 11Boston Children’s Pediatric MS Center/Boston/US, 12Cleveland Clinic/Cleveland/US, 13Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US, 14Denver Children’s Hospital/Denver/US, 15Department of Neurology and Neurotherapeutics/Dallas/US, 16Children's National Medical Center/Washington DC/US, 17University of California, Berkley//US, 18UCSF/San Francisco/US

11:12 - 11:24 PS04.05 - Cardiovascular risk factors affect brain volume in young MS patients R. Bonacchi, D. Mistri, A. Meani, A. Zanghì, M. Filippi, M.A. Rocca, IRCCS San Raffaele Scientific

Institute/Milan/IT

Parallel Sessions 5-8 PS05 - Pharmacological management of progressive MS 12:45 - 14:15 Moderation: A. Thompson1, B. Weinstock-Guttman2, 1UCL Institute of Neurology, Queen Square MS Centre//GB, 2State University of New York at Buffalo/Buffalo/US

13:00 - 13:15 PS05.02 - Management of Progressive MS with Approved DMT

X. Montalban, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall

d’Hebron/Barcelona/ES

13:15 - 13:27 PS05.03 - Validation of three Secondary Progressive Multiple Sclerosis classification methods in five registries within the SPMS Research Collaboration Network

L. Forsberg1, A. Glaser2, A. Manouchehrinia2, R. Ramanujam2, T. Spelman3, P. Klyve4, J. Drahota5, D. Horakova5, H. Joensen6, M. Magyari6, D. Ellenberger7, A. Stahmann7, A. Van Der Walt8, J. Rodgers9, R. Middleton10, R. Nicholas11, V. Bezlyak12, N. Adlard12, T. Hach12, C. Lines12, J. Hillert13, 1/Nykvarn/SE, 2Karolinska Institutet/Stockholm/SE, 3Karolinska Institute/Stockholm/SE, 4Department of Clinical Neuroscience/Stockholm/SE, 5First Faculty of

Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 6Danish Multiple Sclerosis Center/Glostrup/DK, 7MS Forschungs- und Projektentwicklungs- gGmbH/Hannover/DE, 8Central Clinical School, Monash University/Melbourne/AU, 9Swansea University Medical School/Swansea/GB, 10Swansea University/Swansea/GB, 11Imperial College London/London/GB, 12Novartis Pharma AG/Basel/CH, 13Karolinska Institutet/Solna/SE

13:27 - 13:39 PS05.04 - Disease modifying treatment may delay time to wheelchair in primary progressive multiple sclerosis: a real-life cohort

M. Fonderico1, E. Portaccio2, P. Iaffaldano3, L. Pastò1, L. Razzolini4, A. Bellinvia1, R. Fratangelo1, L. Tudisco1, G. De Luca5, P. Ragonese6, F. Patti7, V. Brescia Morra8, E. Cocco9, P. Sola10, M. Inglese11, G. Lus12, C. Pozzilli13, D. Maimone14, A. Lugaresi15, P. Gazzola16, G. Comi17, I. Pesci18, D. Spitaleri19, M. Rezzonico20, M. Vianello21, C. Avolio22, F.O. Logullo23, F. Granella24, M. Salvetti25, M. Zaffaroni26, C. Guaschino26, A. Ghezzi27, G. Lucisano3, M. Filippi28, M. Trojano29, M.P. Amato4, 1University of Florence, Florence, Italy;/Florence/IT, 2Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy/Florence/IT, 3University of Bari “Aldo Moro”/Bari/IT, 4University of Florence/Florence/IT, 5Università "G. d'Annunzio", Chieti- Pescara/Chieti/IT, 6University of Palermo/Palermo/IT, 7Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 8University of Naples Federico II/Naples/IT, 9University of Cagliari/Cagliari/IT, 10Azienda Ospedaliero-Universitaria di Modena Ospedale Civile di Baggiovara/Modena/IT, 11University of Genoa//IT, 12Second University of Naples/Napoli/IT, 13Sapienza University of Rome/Rome/IT, 14Garibaldi Hospital/Catania/IT, 15IRCCS Istituto delle Scienze Neurologiche di Bologna/Bologna/IT, 16SC Neurologia - Ospedale P. Antero Micone - ASL 3 Genovese/Genova Sestri P./IT, 17San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 18Ospedale Di Vaio/Fidenza/IT, 19Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino/Avellino/IT, 20Ospedale S. Anna Como/San Fermo Della Battaglia-Como/IT, 21Centro Sclerosi Multipla - Ospedale Regionale 'Ca' Foncello', Neurology Unit/Treviso/IT, 22AOU Ospedali Riuniti Di Foggia/Foggia/IT, 23Ospedale di Macerata/Macerata/IT, 24University of Parma/Parma/IT, 25S. Andrea Hospital/Sapienza University/Rome/IT, 26Multiple Sclerosis Centre, Hospital of Gallarate, ASST della Valle Olona/Gallarate (VA)/IT, 27Gallarate Hospital, Varese/Gallarate/IT, 28IRCCS San Raffaele Scientific Institute/Milan/IT, 29University of Bari/Bari/IT

13:39 - 13:51 PS05.05 - Ongoing disease modifying treatment associated with mis-classification of secondary progressive as relapsing-remitting multiple sclerosis

J. Hillert1, L. Forsberg2, A. Manouchehrinia3, R. Ramanujam4, T. Spelman4, P. Klyve5, J. Drahota6, D. Horakova6, H. Joensen7, M. Magyari7, D. Ellenberger8, A. Stahmann8, A. Van Der Walt9, J. Rodgers10, R. Nicholas11, R. Middleton12, V. Bezlyak13, N. Adlard13, T. Hach13, C. Lines13, A. Glaser3, 1Karolinska Institute/Solna/SE, 2/Nykvarn/SE, 3Karolinska Institutet/Stockholm/SE, 4Karolinska Institute/Stockholm/SE, 5Department of Clinical Neuroscience/Stockholm/SE, 6First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 7Danish Multiple Sclerosis Center/Glostrup/DK, 8MS Forschungs- und Projektentwicklungs-gGmbH/Hannover/DE, 9Monash University/Melbourne/AU, 10Swansea University Medical School/Swansea/GB, 11Imperial College London/London/GB, 12Swansea University/Swansea/GB, 13Novartis Pharma AG/Basel/CH

PS06 - Lymphocyte subsets in MS 12:45 - 14:15 Moderation: B. Hemmer1, E. Bettelli2, 1University of Munich/Munich/DE, 2Benaroya Research Institute//US

12:45 - 13:00 PS06.01 - New insights into the role of T cell subsets during MS

N. Saligrama, Washington University in Saint Louis/Saint Louis/US

13:00 - 13:15 PS06.02 - Mechanisms of Action of B Cells

J. Bennett, University of Colorado School of Medicine/Aurora/US

13:15 - 13:27 PS06.03 - The antigenic repertoire of CSF-derived B cells in early untreated multiple sclerosis.

1 1 2 1 1 1 1 R. Loudermilk , C. Bartley , A. Greenfield , I. Hawes , J. Alexander , B. Alvarenga , E. Tran , R. Schubert3, R. Dandekar1, T. Ngo1, T. Huynh1, J. Zhou1, B. Tran1, B. Cree1, S. Pleasure1, S. Hauser1, M. Wilson1, 1University of California San Francisco/San Francisco/US, 2Palo Alto Medical Foundation/Mountain View/US, 3Asceneuron SA/Écublens/CH

13:27 - 13:39 PS06.04 - GlcNAc-signaling as a new target to reduce T cell pathogenicity in the CNS

B. Wasser1, D. Luchtman2, K. Birkner2, F. Zipp3, S. Bittner2, 1University Medical Center Mainz/Mainz/DE, 2University Medical Center of the Johannes Gutenberg University

Mainz/Mainz/DE, 3University Medical Center of the Johannes Gutenberg University Mainz//DE

13:39 - 13:51 PS06.05 - B cells regulate chronic CNS inflammation in an IL-10-dependent manner

A. Geladaris1, D. Häusler1, W. Brück1, M. Weber2, 1Institute of

Neuropathology/Goettingen/DE, 2University Medical Center Goettingen/Goettingen/DE

PS07 - Radiological advances I (NAIMS/MAGNIMS) 12:45 - 14:15 Moderation: M. Inglese1, D. Reich2, 1University of Genoa//IT, 2NINDS, NIH/Bethesda/US

12:45 - 13:00 PS07.01 - Spinal Cord Imaging

O. Ciccarelli, UCL Queen Square Institute of Neurology/London/GB

13:00 - 13:15 PS07.02 - 7-tesla high-resolution imaging of the MS brain

P. Sati, Cedars-Sinai Medical Center/Los Angeles/US

13:15 - 13:27 PS07.03 - Predicting disability progression and cognitive worsening in multiple sclerosis with gray matter network measures

E. Colato1, J. Stutters2, C. Tur3, S. Narayanan4, D.L. Arnold5, O. Ciccarelli6, D. Chard7, A. Eshaghi8, 1University College of London (UCL)/London/GB, 2University College London/BG/GB, 3UCL Queen Square Institute of Neurology, Faculty of Brain

Sciences/London/GB, 4McGill University/Montreal/CA, 5MNI, McGill/Quebec/CA, 6UCL Queen Square Institute of Neurology/London/GB, 7Institute of Neurology/London/GB, 8University College London/London/GB

13:27 - 13:39 PS07.04 - Fibre-specific white matter differences in children with pediatric acquired demyelinating syndromes compared to healthy children

S. Bells1, G. Longoni1, T. Berenbaum1, C. De Medeiros1, S. Narayanan2, D.L. Arnold3, R.-A. Marrie4, A. Bar-Or5, B. Banwell6, D. Mabbott1, E.A. Yeh1, 1The Hospital for Sick Children/Toronto/CA, 2McGill University/Montreal/CA, 3MNI, McGill/Quebec/CA, 4Max Rady College of Medicine/Winnipeg/CA, 5University of Pennsylvania/Philadelphia/US, 6Children’s Hospital of Philadelphia/Philadelphia/US 13:39 - 13:51 PS07.05 - Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis

F. Hildesheim1, D. Ramasamy2, N. Bergsland2, D. Jakimovski3, M. Dwyer4, D. Hojnacki5, A. Lizarraga5, C. Kolb5, S. Eckert5, B. Weinstock-Guttman6, R. Zivadinov2, 1Buffalo Neuroimaging Analysis Center (BNAC)/Buffalo/US, 2Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York/Buffalo/US, 3University at Buffalo, State University of New York/Buffalo/US, 4Buffalo Neuroimaging Analysis Center/Buffalo/US, 5Jacobs Comprehensive MS Treatment and Research Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo/Buffalo/US, 6State University of New York at Buffalo/Buffalo/US

PS08 - Epigenetics and genetic factors 12:45 - 14:15 Moderation: M. Guerau-De-Arellano, C. Cotsapas, The Ohio State University/Columbus/US

12:45 - 13:00 PS08.01 - The Epigenome and Multiple Sclerosis

P. Casaccia, Advanced Science Research Center at GC-CUNY/New York/US

13:00 - 13:15 PS08.02 - Mendelian Randomization in MS

B. Richards, McGill University/Montreal/CA

13:15 - 13:27 PS08.03 - Deconvolution of epigenetic profiles reveals blood cell-specific pathways associated with early stage Multiple Sclerosis in the AusImmune Study

R. Lea1, A. Xavier2, V. Maltby2, S. Burnard2, B. Taylor3, R. Lucas4, T. Kilpatrick5, A.-L. Ponsonby6, R. Scott2, J. Lechner-Scott7, 1Queensland University of Technology/Brisbane/AU, 2Hunter Medical Research Institute/New Lambton/AU, 3University of Tasmania/Hobart/AU, 4Australian National University/Canberra/AU, 5The Florey Institute of Neuroscience and Mental Health/Melbourne/AU, 6The Florey Institute of Neuroscience and Mental Health/Parkville/AU, 7Department of Neurology, John Hunter Hospital, Hunter New England Health/Newcastle/AU

13:27 - 13:39 PS08.04 - Polygenic Risk Score Analysis in Multiple Sclerosis

H. Shams1, X. Shao2, A. Santaniello1, G. Kirkish1, N. Patsopoulos3, S. Hauser1, L. Barcellos4, C. Schaefer5, R. Henry1, J. Oksenberg1, 1University of California San Francisco/San Francisco/US, 2University of California Berkeley/Berkeley/US, 3Brigham and Women's Hospital/Boston/US, 4University of California, Berkley//US, 5Kaiser Permanente Division of Research/Oakland/US 13:39 - 13:51 PS08.05 - Functional changes associated to the Multiple Sclerosis risk polymorphism in the HHEX gene

E. Urcelay1, P. López-Cotarelo1, A. González-Jiménez1, I. Casanova2, Y. Aladro Benito3, J.M. García-Domínguez4, L. Espino-Paisán1, 1Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC/Madrid/ES, 2Hospital Universitario de Torrejón/Madrid/ES, 3Hospital Universitario de Getafe/Madrid/ES, 4Hospital General Universitario Gregorio Marañón/Madrid/ES

Saturday, September 12, 2020 Parallel Sessions 9-12

PS09 - Personalized approaches to MS 09:15 - 10:45 Moderation: J. Chataway1, D. Okuda2, 1UCL Queen Square Institute of Neurology, University College//GB, 2UT Southwestern Medical Center//US

09:15 - 09:30 PS09.01 - Customized Management of Individuals with MS Using Approved Therapies

G. Giovannoni, The London School of Medicine and Dentistry/London/GB

09:30 - 09:45 PS09.02 - Trial design customized for clinical subsets of MS

M.P. Sormani, University of Genoa/Genoa/IT

09:45 - 09:57 PS09.03 - Predictive biomarkers of the development of autoimmunity in patients treated with alemtuzumab

P.E. Walo Delgado1, E. Monreal2, S. Medina2, E. Quintana3, S. Sainz De La Maza2, M. Comabella4, L. Ramió I Torrentà3, J.I. Fernandez-Velasco2, X. Montalban5, L. Midaglia6, N. Villarrubia2, J. Meca-Lallana7, V. Meca-Lallana8, J. Masjuan2, L. Costa-Frossard2, L.M. Villar2, 1Hospital Universitario Ramon y Cajal/Madrid/ES, 2Hospital Universitario Ramón y Cajal/Madrid/ES, 3Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 4Universitat Autònoma//ES, 5Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 6Dept. of Neurology-Neuroimmunology; Vall Hebron University Hospital; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 7Hospital Clínico Universitario Virgen de la Arrixaca/Murcia/ES, 8La Princesa Hospital/Madrid/ES

09:57 - 10:09 PS09.04 - A two-stage prediction model for heterogeneous effects of many treatment options: application to drugs for multiple sclerosis

K. Chalkou1, F. Pellegrini2, 1Institute of Social and Preventive Medicine, University of

Bern/Bern/CH, 2Biogen International/Baar/CH 10:09 - 10:21 PS09.05 - Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice

Ö. Yaldizli1, P. Benkert2, A. Maceski3, M. Barakovic4, R.-A. Todea3, A. Cagol3, S. Schaedelin1, G. Disanto5, J. Oechtering1, A. Orleth3, D. Rey3, T. Sinnecker6, R. Rahmanzadeh3, S. Zadic3, R. Galbusera3, L. Achtnichts7, S. Aeschbacher1, A. Chan8, D. Conen1, T. Derfuss9, O. Findling7, B. Fischer-Barnicol3, K. Hrusovsky10, H. Kropshofer11, P. Lalive12, J. Lieb1, J. Lorscheider1, P. Maggi13, C. Müller1, S. Müller14, Y. Naegelin3, J. Müller3, J. Oksenberg15, C. Pot16, R. Du Pasquier16, E.-W. Radue17, A. Salmen8, J. Vehoff14, E. Waubant18, S. Wellmann19, H. Wiendl20, J. Wuerfel21, C. Zecca5, K. Berger22, C. Gobbi5, L. Kappos23, D. Leppert3, C. Granziera3, J. Kuhle24, 1University Hospital Basel/Basel/CH, 2University Hospital Basel, University of Basel/Basel/CH, 3University Hospital Basel and University of Basel/Basel/CH, 4University of Basel/Basel/CH, 5Regional Hospital of Southern Switzerland (EOC)/Lugano/CH, 6Universitätsspital Basel/Basel/CH, 7Cantonal Hospital Aarau/Aarau/CH, 8Inselspital Bern, University Hospital and University of Bern/Bern/CH, 9University of Basel//CH, 10Quanterix/Billerica/US, 11Novartis Pharma AG/Basel/CH, 12Geneva University Hospitals/Geneva/CH, 13Lausanne University Hospital and University of Lausanne/Lausanne/CH, 14Cantonal Hospital St. Gallen/St. Gallen/CH, 15University of California San Francisco/San Francisco/US, 16University Hospital of Lausanne/Lausanne/CH, 17University Hospital Basel and University of Basel/Basel/SZ, 18UCSF/San Francisco/US, 19University Children's Hospital Regensburg (KUNO), University of Regensburg/Regensburg/DE, 20University of Münster/Germany/DE, 21Medical Image Analysis Center/Basel/CH, 22University of Münster/Münster/DE, 23University Hospital and University of Basel/Basel/CH, 24University of Basel/Switzerland/CH

PS10 - Gut-CNS axis and the microbiome in MS 09:15 - 10:45 Moderation: H. Wekerle1, T. Chitnis2, 1Max Planck Institute of Neruobiology//DE, 2Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US

09:15 - 09:30 PS10.01 - The Microbiome in Adult and Pediatric MS

E. Waubant, UCSF/San Francisco/US

09:30 - 09:45 PS10.02 - The Enteric Nervous System as a Potential Autoimmune Target in Multiple Sclerosis

S. Kürten, Friedrich-Alexander University Erlangen-Nürnberg/Erlangen/DE

09:45 - 09:57 PS10.03 - Functional survey of the pediatric multiple sclerosis microbiome

A. Mirza1, F. Zhu1, N. Knox2, J. Forbes3, G. Van Domselaar2, C. Bernstein4, M. Graham2, R.A. Marrie4, J. Hart5, E.A. Yeh6, A. Bar-Or7, J. O’Mahony6, W. Hsiao1, B. Banwell8, E. Waubant9, H. Tremlett1, 1University of British Columbia/Vancouver/CA, 2Public Health Agency of Canada/Winnipeg/CA, 3University of Toronto/Toronto/CA, 4University of Manitoba/Winnipeg/CA, 5University of California San Francisco/San Francisco/US, 6The Hospital for Sick Children/Toronto/CA, 7University of Pennsylvania/Philadelphia/US, 8Children’s Hospital of Philadelphia/Philadelphia/US, 9UCSF/San Francisco/US

09:57 - 10:09 PS10.04 - Effect of vancomycin on intestinal permeability during experimental autoimmune encephalomyelitis

E. Smith, S. Tankou, Icahn School of Medicine at Mount Sinai/New York/US

10:09 - 10:21 PS10.05 - Gut dysbiosis in neuromyelitis optica promotes CNS autoimmunity

Z. Moinfar1, S. Sagan1, C. Spencer1, J. Turnbaugh2, B. Cree3, S. Baranzini3, S. Zamvil1, 1University of California, San Francisco/San Francisco/US, 2UCSF, Gnotobiotic Core/San Francisco/US, 3University of California San Francisco/San Francisco/US

PS11 - Radiological advances II 09:15 - 10:45 Moderation: B. Stankoff1, J. Oh2, 1Sorbonne Université/Paris/FR, 2University of Toronto/Toronto/CA

09:15 - 09:30 PS11.01 - Quantitative Susceptibility Mapping (QSM): Clinical Applications for MS

S. Gauthier, Weill Cornell Medicine/New York/US

09:30 - 09:45 PS11.02 - PET Imaging of Microglial Activation

M. Hagens, Amsterdam UMC, location VUmc/Amsterdam/NL

09:45 - 09:57 PS11.03 - Lesion-specific perfusion levels affect myelin loss and repair in multiple sclerosis: a positron emission tomography study

A. Colombi1, V. Ricigliano1, E. Morena2, A. Yazdan Panah1, M. Tonietto1, B. Bodini1, B. Stankoff3, 1Institut du Cerveau et de la Moelle épinière - ICM/Paris/FR, 2ICM - Brain Institute/Paris/FR, 3Sorbonne Université/Paris/FR

09:57 - 10:09 PS11.04 - Quantitative susceptibility mapping classifies white matter lesions with different myelin and axonal content and quantifies diffuse pathology in MS

R. Rahmanzadeh1, P.-J. Lu2, M. Barakovic3, M. Weigel2, T.D. Nguyen4, P. Spincemaille4, S. Schiavi5, A. Daducci5, F. La Rosa6, D.S. Reich7, P. Sati8, M. Bach Cuadra9, E.-W. Radue10, J. Kuhle11, L. Kappos12, Y. Wang4, C. Granziera2, 1University of Basel/Basel/CH, 2University 3 Hospital Basel and University of Basel/Basel/CH, University of Basel/Allschwil/CH, 4Department of Radiology, Weill Cornell Medical College/New York/US, 5University of Verona/Verona/IT, 6École Polytechnique Fédérale de Lausanne/Lausanne/CH, 7Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke/Bethesda/US, 8Cedars-Sinai Medical Center/Los Angeles/US, 9Lausanne University Hospital and University of Lausanne/Lausanne/CH, 10University Hospital Basel and University of Basel/Basel/SZ, 11University of Basel/Switzerland/CH, 12University Hospital and University of Basel/Basel/CH

10:09 - 10:21 PS11.05 - Inclusion of small ovoid lesions in central vein sign assessment improves sensitivity for multiple sclerosis

O. Al-Louzi1, L. Daboul1, E. Beck1, S. Roy2, J. Ohayon1, D. Pham3, A. Solomon4, I. Cortese1, P. Sati4, D. Reich5, 1National Institute of Neurological Disorders and Stroke/Bethesda/US, 2National Institute of Mental Health/Bethesda/US, 3The Henry M. Jackson Foundation for the Advancement of Military Medicine/Bethesda/US, 4Cedars-Sinai Medical Center/Los Angeles/US, 5NINDS, NIH/Bethesda/US

PS12 - Sex-related factors in pathogenesis and management 09:15 - 10:45 Moderation: M.P. Amato1, S. Dunn2, 1University of Florence/Florence/IT, 2University of Toronto, Keenan Research Centre for Biomedical Science/Toronto/CA

09:15 - 09:30 PS12.01 - Gender Based Approach to MS Therapeutics

R. Bove, University of California, San Francisco/San Francisco/US

09:30 - 09:45 PS12.02 - Age Related Hormonal Changes and MS in Women

S. Vukusic, Lyon University Hospital/BRON/FR

09:45 - 10:00 PS12.03 - Sex Chromosomes in MS Susceptibility

R. Voskuhl, University of California, Los Angeles/Los Angeles/US

10:00 - 10:12 PS12.04 - Pregnancy in a modern day multiple sclerosis cohort: Predictors of relapse during pregnancy

W. Yeh1, P. Widyastuti1, A. Van Der Walt2, J. Stankovich1, M. Gresle1, E. Havrdova3, D. Horakova3, K. Vodehnalova4, S. Ozakbas5, S. Eichau6, P. Duquette7, T. Kalincik8, F. Patti9, C. Boz10, M. Terzi11, B. Yamout12, J. Lechner-Scott13, P. Sola14, O. Skibina15, M. Barnett16, M. Onofrj17, M.J. Sá18, P. Mccombe19, P. Grammond20, R. Ampapa21, F. Grand'Maison22, R. Bergamaschi23, D. Spitaleri24, V. Van Pesch25, E. Cartechini26, S. Hodgkinson27, A. Soysal28, A. 29 4 30 31 32 33 34 Saiz , T. Uher , D. Maimone , R. Turkoglu , R. Hupperts , M.P. Amato , F. Granella , C. Oreja-Guevara35, A. Altintas36, R. Macdonell37, T. Castillo-Trivino38, H. Butzkueven1, R. Alroughani39, V. Jokubaitis1, T.M. Study Group40, 1Monash University/Melbourne/AU, 2Central Clinical School, Monash University/Melbourne/AU, 3First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 4First Faculty of Medicine, Charles University and General University/Prague/CZ, 5Dokuz Eylul University/Izmir/TR, 6Hospital Universitario Virgen Macarena/Sevilla/ES, 7University of Montreal/Montreal/CA, 8Royal Melbourne Hospital/Melbourne/AU, 9Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 10KTU Medical Faculty Farabi Hospital/Trabzon/TR, 11Ondokuz Mayıs University/Sasun/TR, 12American University of Beirut/Beirut/LB, 13Department of Neurology, John Hunter Hospital, Hunter New England Health/Newcastle/AU, 14Azienda Ospedaliero- Universitaria di Modena Ospedale Civile di Baggiovara/Modena/IT, 15The Alfred Hospital/Melbourne/AU, 163. Brain and Mind Research Institute, University of Sydney/Sydney/AU, 17University G. d’Annunzio/Chieti/IT, 18Centro Hospitalar Universitario de Sao Joao/Porto/PT, 19University of Queensland/Brisbane/AU, 20CISSS Chaudière- Appalache/Levis/CA, 21Nemocnice Jihlava/Jihlava/CZ, 22Neuro Rive-Sud/Quebec/CA, 23IRCCS Mondino Foundation/Pavia/IT, 24Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino/Avellino/IT, 25Université Catholique de Louvain/Brussels/BE, 26UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3/Macerata/IT, 27Ingham Institute for Applied Medical Research, University of New South Wales Medicine/Sydney/AU, 28Bakırköy Prof. Dr. Mazhar Osman Education and Research Hospital for Psychiatry and Neurological Diseases/Istanbul/TR, 29Hospital Clínic i Provincial de Barcelona/Barcelona/ES, 30Garibaldi Hospital/Catania/IT, 31Haydarpasa Numune Training and Research Hospital/Istanbul/TR, 32Zuyderland Medical Center/Sittard-Geleen/NL, 33University of Florence/Florence/IT, 34University of Parma/Parma/IT, 35Hospital Universitario Clinico San Carlos/Madrid/ES, 36Koc University/Istambul/TR, 37Austin Health. University of Melbourne/Melbourne/AU, 38Hospital Universitario Donostia/San Sebastián/ES, 39Amiri Hospital/Kuweit/KW, 40MSBase/Melbourne/AU

10:12 - 10:24 PS12.05 - p38 MAP kinase signaling in microglia plays a sex-specific protective role in CNS autoimmunity by regulating microglial transcriptional states

M. Mcgill, A. Richman, J. Boyd, S. Frietze, D. Krementsov, University of Vermont/Burlington/US

European Charcot Foundation Symposium, Nurse’s Session 1, Young Investigator Session 1 CS01 - European Charcot Foundation Symposium

11:00 - 12:30 1 2 1 2 Moderation: B. Hemmer , L. Leocani , University of Munich/Munich/DE, Vita-Salute San Raffaele University/Milan/IT

11:00 - 11:20 CS01.01 - Lecture 1: Potential Targets for Remyelination

R. Franklin

11:20 - 11:40 CS01.02 - Lecture 2: Study Designs and Structural Biomarkers in Assessing Remyelination Interventions

A. Green, UCSF Multiple Sclerosis Center/United States/US 11:40 - 12:00 CS01.03 - Lecture 3: Is There a Role for Cellular Therapy to Enhance Remyelination?

G. Martino, San Raffaele Scientific Institute/Milan/IT

12:00 - 12:20 CS01.04 - Lecture 4: Ongoing and Future Remyelinating Treatments

C. Lubetzki, Hôpital Pitié-Salpêtrière/Paris/FR

NS01 - Advanced nursing activities 11:00 - 12:30 Moderation: J. Halper1, C. Harris2, 1CMSC/Fair Lawn/US, 2University of Calgary MS Clinic/Calgary/CA

11:00 - 11:25 NS01.01 - Integrative Medicine in MS: Evidence for Creating a Paradigm Shift to Improve Care

M. Weigel, First Coast Integrative Medicine/Jacksonville/US

11:25 - 11:50 NS01.02 - Pediatric MS: Caring for the Young Patient

J. Boyd, Hospital for Sick Children/Toronto/CA

11:50 - 12:15 NS01.03 - Clinical Implications for an Aging MS Population

M. Buhse, South Shore Neurologic Associates/Patchogue/US

YI01 - Young Investigators 1 11:00 - 12:30 1 2 1 Moderation: T. Berger , C. Azevedo , Medical University of Vienna/Vienna/AT, 2University of Southern California/Los Angeles/US 11:00 - 11:12 YI01.01 - Single-cell RNAseq of multiple sclerosis cerebrospinal fluid identifies T cell and myeloid subsets that are over-represented at disease onset T. Roostaei1, C. Diaconu1, H. Touil1, V. Menon2, P. De Jager3, 1Columbia University Medical Center/New York/US, 2Columbia University Irving Medical Center/New York/US, 3Columbia University Medical Center/United States/US 11:12 - 11:24 YI01.02 - BTK inhibition results in preferential reduction of pro-inflammatory B-cell responses through modulation of B-cell metabolism 1 2 2 1 1 R. Li , H. Tang , M. Mingueneau , A. Bar-Or , University of Pennsylvania/Philadelphia/US, 2Biogen/Boston/US 11:24 - 11:36 YI01.03 - Inhibition of neuronal RNA binding protein dysfunction as a treatment for neurodegeneration in multiple sclerosis 1 2 1 1 H. Salapa , C. Libner , M. Levin , University of Saskatchewan/Saskatoon/CA, 2/Saskatoon/CA 11:36 - 11:48 YI01.04 - Generation of MHC class I and MHC class II reporter mice for investigation of antigen presentation by oligodendroglia 1 2 2 2 2 1 E. Harrington , D. Heo , T.-Y. Lu , P. Calabresi , D. Bergles , Johns Hopkins/Baltimore/US, 2Johns Hopkins University/Baltimore/US 11:48 - 12:00 YI01.05 - BTK signaling regulates real-time microglial dynamics and prevents demyelination in a novel in vivo model of antibody-mediated cortical demyelination H. Barr1, K. Given1, C. Mcclain1, R. Gruber2, D. Ofengeim2, W. Macklin1, J. Bennett1, G. Owens3, E. Hughes1, 1University of Colorado School of Medicine/Aurora/US, 2Sanofi/Framingham/US, 3University of Colorado/Aurora/US

Parallel Session 13-16 PS13 - Innovations in symptomatic and rehabilitative therapy 12:45 - 14:15 Moderation: T. Gyang1, R. Spain2, 1University of Florida/Gainesville/US, 2Oregon Health & Science University, Portland VA Medical Center/Portland/US

12:45 - 13:00 PS13.01 - Rehabilitative and Pharmacological Therapies for MS Fatigue: Current Trends and Gaps in Knowledge

T. Braley, University of Michigan/Ann Arbor/US

13:15 - 13:27 PS13.03 - Randomized Trial of Amantadine, Modafinil and, Methylphenidate for Multiple Sclerosis Fatigue

B. Nourbakhsh1, N. Revirajan2, B. Morris1, C. Cordano2, J. Creasman2, M. Manguinao2, K. Krysko2, A. Rutatangwa2, S. Aljarallah2, C. Jin2, E. Mowry1, C.M. Mcculloch2, E. Waubant2, 1Johns Hopkins University/Baltimore/US, 2UCSF/San Francisco/US

13:27 - 13:39 PS13.04 - MRI correlates of Cognitive Improvement after Home-Based EEG Neurofeedback Training in MS: A Pilot Study

D. Pinter1, V. Fruhwirth1, S. Kober2, M. Khalil1, C. Neuper2, G. Wood2, C. Enzinger1, 1Medical 2 University of Graz/Graz/AT, University of Graz/Graz/AT

PS14 - The impact of MS on neurons and glia 12:45 - 14:15 Moderation: C. Stadelmann1, T. Desilva2, 1University Medical Center, Göttingen//DE, 2Cleveland Clinic/Cleveland/US

12:45 - 13:00 PS14.01 - Oligodendrocyte Heterogeneity in MS

G. Castelo-Branco, Karolinska Institutet/Stockholm/SE

13:00 - 13:15 PS14.02 - Contribution of Astrocyte Responses to MS Pathogenesis D. Pitt, Yale University/New Haven/US

13:15 - 13:30 PS14.03 - Neuronal Vulnerability in MS

L. Schirmer, Heidelberg University/Mannheim/DE

13:30 - 13:42 PS14.04 - Oncostatin M-induced astrocytic tissue inhibitor of metalloproteinases-1 drives remyelination

E. Houben1, K. Janssens1, D. Hermans1, J. Vandooren2, C. Van Den Haute3, M. Schepers1, T. Vanmierlo1, I. Lambrichts1, J. Van Horssen4, V. Baekelandt3, G. Opdenakker3, W. Baron5, B. Broux6, L. Slaets1, N. Hellings1, 1Biomedical Research Institute - Hasselt

University/Diepenbeek/BE, 2Rega Institute KULeuven/Leuven/BE, 3KULeuven/Leuven/BE, 4VU Medical Center/Amsterdam/NL, 5UMC Groningen/Groningen/NL, 6Hasselt University/Diepenbeek/BE

13:42 - 13:54 PS14.05 - Remyelinating satellite oligodendrocytes provide a rescue strategy to protect neurons after cortical demyelination in multiple sclerosis

F. Van Der Meer1, S. Nessler2, N. Lagumersindez-Denis2, C. Wrzos3, A. Winkler1, C. Nau- Gietz1, C. Sergiou1, V. Schultz4, I. Metz1, E. Rodriguez5, D. Merkler6, M. Simons7, C. Stadelmann1, 1University Medical Center Göttingen/Göttingen/DE, 2Medical University of

Göttingen/Göttingen/DE, 3Evotec/Göttingen/DE, 4College of Medical Veterinary and Life Sciences/Glasgow/GB, 5Charles River Laboratories/Bielefeld/DE, 6Department of Pathology and Immunology/Geneva/CH, 7Institute of Neuronal Cell Biology/München/DE

PS15 - Visual outcome measures in MS (IMSVISUAL) 12:45 - 14:15 Moderation: F. Paul1, D. Kimbrough2, 1Charite-Universitatmedizin Berlin/Berlin/DE, 2Harvard Medical School//US

12:45 - 13:00 PS15.01 - Disease Modifying Therapies and Retinal Atrophy

S. Saidha, Johns Hopkins University School of Medicine/Baltimore/US

13:00 - 13:15 PS15.02 - Evolution of Visual Outcomes in Clinical Trials for MS Disease-Modifying Therapies

L. Balcer, New York University//US

13:15 - 13:27 PS15.03 - Optical coherence tomography in aquaporin-4-IgG positive neuromyelitis optica spectrum disorders: a collaborative multi-center study

F.C. Oertel1, S. Specovius2, H. Zimmermann2, C. Chien3, S. Motamedi2, L. Cook4, M.A. Lana- 5 5 6 7 8 9 Peixoto , M. Fontenelle , H.J. Kim , J.-W. Hyun , J. Palace , A. Roca-Fernandez , F. Ashtari10, R. Kafieh11, L. Pandit12, A. D'Cunha12, O. Aktas13, M. Ringelstein13, E. May14, C. Tongco14, L. Leocani15, M. Pisa15, M. Radaelli16, E. Martinez-Lapiscina17, H. Stiebel-Kalish18, S. Siritho19, J. De Seze20, T. Senger20, J. Havla21, R. Marignier22, E. Nerrant22, A. Cobo Calvo23, D. Bichuetti24, I. Tavares24, N. Asgari25, K.K. Soelberg26, A. Altintas27, U. Tanriverdi27, A. Jacob28, S. Huda29, Z. Rimler30, Y. Mao-Draayer31, I. Soto De Castillo32, A. Green33, M. Yeaman34, T. Smith35, A. Brandt36, F. Paul37, 1/San Francisco/US, 2Charité – Universitätsmedizin Berlin/Berlin/DE, 3Charité-Universitätsmedizin Berlin/Berlin/DE, 4University of Utah School of Medicine/Salt Lake City/US, 5Hospital das Clínicas de Minas Gerais - UFMG/Belo Horizonte/BR, 6Research Institute and Hospital, National Cancer Center/Goyang/KR, 76) National Cancer Center Korea/Goyang-si/KR, 8Oxford University Hospitals/Oxford/GB, 9University of Oxford/Oxford/GB, 10Isfahan University of Medical Sciences/Isfahan/IR, 119) School of advanced technologies in medicine/Isfahan/IR, 12Nitte University/Mangalore/IN, 13Heinrich-Heine-Universität Düsseldorf/Dusseldorf/DE, 14Swedish Neuroscience Institute Neuro-Ophthalmology/Seattle/US, 15Vita-Salute San Raffaele University/Milan/IT, 16San Raffaele Hospital/Milan/IT, 17/Barcelona/ES, 18Tel Aviv University/Tel Aviv/IL, 19Siriraj Hospital and Bumrungrad International Hospital/Bangkok/TH, 20CHU de Strasbourg/Strasbourg/FR, 21Ludwig-Maximilians Universitaet Muenchen/Munich/DE, 22Lyon Neuroscience Research Center/Bron/FR, 23Centre d’Esclerosi Múltiple de Catalunya (Cemcat)/Barcelona/ES, 24Federal University of São Paulo/São Paulo/BR, 25Institute of Regional Health Research/Odense/DK, 26University of Southern Denmark and Odense University Hospital/Odense C/DK, 27Koc University/Istambul/TR, 2825) The Walton Centre for Neurology and Neurosurgery/Liverpool/GB, 29The Walton Centre for Neurology and Neurosurgery/Liverpool/GB, 30NYU School of Medicine/New York/US, 31Autoimmunity Center of Excellence/MI/US, 32Hospital Clínico de Maracaibo/Maracaibo/VE, 33UCSF Multiple Sclerosis Center/United States/US, 34University of California/Los Angeles/US, 35University of Michigan Medical School/Ann Arbor/US, 36Department of Neurology, University of California Irvine, Irvine, California, USA./Irvine/US, 37Charite-Universitatmedizin Berlin/Berlin/DE

13:27 - 13:39 PS15.04 - The presence of epiretinal membranes in multiple sclerosis may be associated with increased disability

G. Kalaitzidis1, H. Ehrhardt1, O. Murphy1, J. Lambe1, E. Vasileiou1, A. Filippatou1, E. Sotirchos2, P. Calabresi2, K. Fitzgerald1, S. Saidha1, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Johns Hopkins University/Baltimore/US

13:39 - 13:51 PS15.05 - Retinal neuro-axonal loss reflects disability accrual in progressive multiple sclerosis independently from disease activity

S. Guerrieri1, M. Pisa2, R. Reniè3, R. Santangelo1, S. Girola1, S.-C. Huang1, L. Moiola4, V. Martinelli4, M. Filippi4, G. Comi5, L. Leocani2, 1San Raffaele Hospital - Vita-Salute San Raffaele University/Milan/IT, 2Vita-Salute San Raffaele University/Milan/IT, 3Sapienza University/Rome/IT, 4IRCCS San Raffaele Scientific Institute/Milan/IT, 5San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT

PS16 - Machine learning approaches Moderation: L. Alfredsson1, J. Graves2, 1Karolinska Institutet//SE, 2University of California, 12:45 - 14:15 San Diego/San Diego/US

12:45 - 13:00 PS16.01 - Incorporating Machine Learning Approaches to Assess Putative Risk Factors for MS

F. Briggs, Case Western Reserve University, School of Medicine/Cleveland/US

13:00 - 13:15 PS16.02 - Machine Learning Techniques for Predicting MS Clinical Course

D. Sappey-Marinier, Université de Lyon/Lyon/FR

13:15 - 13:27 PS16.03 - Use of machine learning classifiers based on structural and functional visual metrics to predict diagnosis in children with acquired demyelination.

B. Ciftci1, C. Kavaklioglu2, L. Erdman1, A. Goldenberg1, T. Berenbaum1, C. Alexander3, S. Hossain3, H. Oppermann3, A. Patel3, A. Vincent1, F. Costello4, J.K. Mah4, A. Reginald1, B. Banwell5, G. Longoni1, E.A. Yeh1, 1The Hospital for Sick Children/Toronto/CA, 2Ryerson University/Toronto/CA, 3University of Toronto/Toronto/CA, 4University of Calgary/Calgary/CA, 5Children’s Hospital of Philadelphia/Philadelphia/US

13:27 - 13:39 PS16.04 - RimNet: A deep 3D multimodal MRI architecture for paramagnetic rim lesions assessment in multiple sclerosis

G. Barquero1, F. La Rosa2, H. Kebiri3, P.-J. Lu4, R. Rahmanzadeh5, M. Weigel4, M.J. Fartaria6, T. Kober6, M. Theaudin7, R. Du Pasquier7, P. Sati8, D. Reich9, M. Absinta10, C. Granziera5, P. Maggi11, M. Bach Cuadra11, 1Lausanne University and University Hospital/Lausanne/CH, 2École Polytechnique Fédérale de Lausanne/Lausanne/CH, 3Lausanne University Hospital and University of Lausanne, Switzerland/Lausanne/CH, 4University of

Basel/Allschwil/CH, 5University Hospital Basel and University of Basel/Basel/CH, 6Siemens Healthcare AG/Lausanne/CH, 7University Hospital of Lausanne/Lausanne/CH, 8Cedars-Sinai Medical Center/Los Angeles/US, 9NINDS, NIH/Bethesda/US, 10Johns Hopkins University/Baltimore/US, 11Lausanne University Hospital and University of Lausanne/Lausanne/CH

13:39 - 13:51 PS16.05 - Application of deep-learning to NMOSD and unclassified seronegative patients

L. Cacciaguerra1, L. Storelli1, M. Radaelli2, S. Mesaros3, L. Moiola1, J. Drulovic4, M.A. Rocca1, M. Filippi1, 1IRCCS San Raffaele Scientific Institute/Milan/IT, 2San Raffaele Hospital/Milan/IT, 3University of Belgrade/Belgrade/IT, 4University of Belgrade/Belgrade/RS

Sunday, September 13 Hot Topics 1-4 HT01 - Strategies to promote remyelination 09:15 - 10:00 Moderation: C. Lubetzki, A. Sas, Hôpital Pitié-Salpêtrière/Paris/FR 09:15 - 09:27 HT01.01 - Presentation 01 V. Miron, University of Edinburgh/Edinburgh/GB 09:27 - 09:39 HT01.02 - Presentation 02 M. Simons, Technical University of Munich/Munich/DE 09:39 - 09:51 HT01.03 - Presentation 03 J. Huang, Georgetown University/Washington/US HT02 - Aging and multiple sclerosis 09:15 - 10:00 1 2 1 Moderation: P. Duquette , R. Bollaert , University of Montreal/Montreal/CA, 2Marquette University/Milwaukee/US 09:15 - 09:27 HT02.01 - Presentation 01 B. Zeydan, Mayo Clinic /Rochester/US 09:27 - 09:39 HT02.02 - Presentation 02 O. Ciccarelli, UCL Queen Square Institute of Neurology/London/GB 09:39 - 09:51 HT02.03 - Presentation 03 C. Larochelle, Université de Montréal/Montreal/CA HT03 - Developments in pediatric MS 09:15 - 10:00 1 2 1 Moderation: J. Gartner , E.A. Yeh , University Medical Center Göttingen//DE, 2University of Toronto/Toronto/CA 09:15 - 09:27 HT03.01 - Presentation 01 K. Mckay, Karolinska Institutet/Stockholm/SE 09:27 - 09:39 HT03.02 - Presentation 02 - New Research in Peds MS Imaging B. Banwell, Children’s Hospital of Philadelphia/Philadelphia/US 09:39 - 09:51 HT03.03 - Presentation 03 C. Till, York University/Toronto/CA HT04 - Grey matter pathology 09:15 - 10:00 1 2 1 Moderation: M. Calabrese , N. De Stefano , University of Verona/Verona/IT, 2University of Siena//IT 09:15 - 09:27 HT04.01 - Presentation 01 - Gray Matter Pathology C. Mainerao, Harvard University//US 09:27 - 09:39 HT04.02 - Presentation 02 R. Dutta, Cleveland Clinic/Cleveland/US 09:39 - 09:51 HT04.03 - Presentation 03 - Cortical atrophy in multiple sclerosis may start at puberty L. Stawiarz1, T. Granberg2, A. Manouchehrinia3, E. Hagel1, J. Hillert4, L. Forsberg5, 1Karolinska Institutet/STOCKHOLM/SE, 2Karolinska Insitutet/Stockholm/SE, 3Karolinska Institutet/Stockholm/SE, 4Karolinska Institute/Solna/SE, 5/Nykvarn/SE

Hot Topics 5-7 HT05 - Lymphoid follicles and meningeal involvement in MS 10:15 - 11:00 Moderation: J. Gommerman1, R. Bevan2, 1University of Toronto/Toronto/CA, 2University Medical School//GB

10:15 - 10:27 HT05.01 - Presentation 01

R. Magliozzi, University of Verona/Verona/IT

10:27 - 10:39 HT05.02 - Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI

D. Harrison, University of Maryland School of Medicin/BALTIMORE/US

10:39 - 10:51 HT05.03 - Presentation 03 - 7T MRI cerebral leptomeningeal enhancement predicts gray and white matter lesion accumulation one year later in relapsing-remitting multiple sclerosis

J. Zurawski1, Y. Jalkh2, S. Tauhid2, R. Chu2, B. Healy3, H. Weiner4, R. Bakshi5, 1Brigham & Women's Hospital/Harvard Medical School/Boston/US, 2Brigham & Women's

Hospital/Boston/US, 3Harvard Medical School/United States/US, 4Harvard University, Brigham & Women's Hospital/Boston/US, 5Brigham and Women's Hospital/Boston/US

HT06 - Global perspectives on neuromyelitis optica spectrum disorders 10:15 - 11:00 Moderation: M. Levy1, S. Tenembaum2, 1Massachusetts General Hospital and Harvard Medical School/Boston/US, 2National Paediatric Hospital Dr. J. Garrahan/Buenos Aires/AR

10:15 - 10:27 HT06.01 - Presentation 01

H.J. Kim, Research Institute and Hospital, National Cancer Center/Goyang/KR

10:27 - 10:39 HT06.02 - Presentation 02

D. Sato, Pontifical Catholic U. of Rio Grande do Sul (PUCRS)/Porto Alegre/BR

10:39 - 10:51 HT06.03 - Naive B cells in neuromyelitis optica spectrum disorders: impact of steroid use and relapse occurrence M. Janssen1, A. Bruijstens1, J. Van Langelaar2, Y.Y. Wong1, A. Wierenga-Wolf3, M.J. Melief3, L. Rijvers3, D. Van Pelt1, J. Smolders2, B. Wokke1, M. Van Luijn1, 1MS Center ErasMS, Erasmus

MC/Rotterdam/NL, 2Erasmus University Medical Center/Rotterdam/NL, 3MS Center ErasMS, Erasmus University Medical Center/Rotterdam/NL

10:15 - 11:00 HT07 - MOG mediated disease

Moderation: D. Ontaneda1, J. De Seze2, 1Cleveland Clinic/Cleveland/US, 2CHU de

Strasbourg/Strasbourg/FR

10:15 - 10:27 HT07.01 - Presentation 01

M. Weber, University Medical Center Goettingen/Goettingen/DE

10:27 - 10:39 HT07.02 - Presentation 02

J. Palace, Oxford University Hospitals/Oxford/GB

10:39 - 10:51 HT07.03 - Prevalence of MOG-Ab in a large cohort of neurological patients

F. Held1, S. Kalluri2, A. Klein2, M. Reindl3, B. Hemmer4, 1Klinikum rechts der Isar, Technical University of Munich/München/DE, 2Klinikum rechts der Isar/Munich/DE, 3Medical University of Innsbruck/Innsbruck/AT, 4University of Munich/Munich/DE

Nurse’s Session 2 and Young Investigator Session 2 NS02 - Unique contributions of MS nursing 11:15 - 12:45 Moderation: P. Pagnotta, D. Bruen, Neurology Associates PA/Maitland/US

11:15 - 11:40 NS02.01 - Sustaining Adherence to Complex MS Protocols

A. Perrin Ross, Loyola University Chicago/Oak Brook/US

11:40 - 12:05 NS02.02 - Best Practices in MS Nursing: Advanced Practice

S. Agrella, Central Texas Neurology Consultants/Round Rock/US

12:05 - 12:30 NS02.03 - Evidence Based Practical Guidelines

M. Namey, Cleveland Clinic/CLEVELAND/US

YI02 - Young Investigators 2 1 Moderation: L. Leocani1, S. Krieger2, 1Vita-Salute San Raffaele University/Milan/IT, 2Icahn 11:15 - 12:45 School of Medicine at Mount Sinai/New York/US

11:15 - 11:27 YI02.01 - Optic Neuritis-Independent Retinal Atrophy In Neuromyelitis Optica Spectrum Disorders

E. Vasileiou1, A. Filippatou1, Y. He2, K. Fitzgerald1, G. Kalaitzidis1, J. Lambe1, M. Mealy1, M. Levy3, Y. Liu2, J. Prince2, E. Mowry2, S. Saidha1, P. Calabresi2, E. Sotirchos2, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Johns Hopkins University/Baltimore/US, 3Massachusetts General Hospital and Harvard Medical School/Boston/US

11:27 - 11:39 YI02.02 - Assessing No Evidence of Disease Activity in Pediatric Onset Multiple Sclerosis

J. Feng1, B. Barney2, M. Waltz3, T.C. Casper4, M. Rensel1, 1Cleveland Clinic/Cleveland/US, 2University of Utah/utah/US, 3University of Utah/Utah/US, 44University of Utah/Salt Lake City/US

11:39 - 11:51 YI02.03 - Identifying distinct cognitive phenotypes in multiple sclerosis

E. De Meo1, E. Portaccio2, A. Giorgio3, L. Ruano4, B. Goretti2, C. Niccolai2, F. Patti5, C. Chiasari5, P. Gallo6, P. Grossi6, A. Ghezzi7, M. Roscio7, F. Mattioli8, C. Stampatori8, M. Simone9, R.G. Viterbo9, M.A. Rocca10, N. De Stefano11, M. Filippi10, M.P. Amato12, 1San Raffaele Hospital/Milan/IT, 2Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy/Florence/IT, 3Department of Medicine, Surgery and Neuroscience, University of Siena, Italy/Siena/IT, 4EPIUnit, Instituto de Saúde Pública de Universidade do Porto, Porto, Portugal; Neurology Department, Centro Hospitalar de Entre Douro e Vouga, Santa Maria da Feira, Portugal/Port/PT, 5Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 6University of Padua/Padova/IT, 7Gallarate Hospital, Varese/Gallarate/IT, 8ASST Spedali Civili Brescia Neuropsychology Unit, Brescia, Italy;/Brescia/IT, 9Department of Basic Medical Sciences, Child and Adolescence Neuropsychiatry Unit, Neuroscience and Sense Organs University "Aldo Moro" Bari, Bari, Italy/Bari/IT, 10IRCCS San Raffaele Scientific Institute/Milan/IT, 11University of Siena//IT, 12University of Florence/Florence/IT

11:51 - 12:03 YI02.04 - Comparison of clinical characterization, risk of relapses and antibody dynamics between children and adults with MOGAD

A. Cobo Calvo1, A. Ruiz2, F. Rollot3, G. Arrambide4, R. Deschamps5, E. Maillart6, C. Papeix7, B. Audoin8, A.F. Lépine9, H. Maurey10, H. Zephir11, D. Biotti12, J. Ciron13, F. Durand-Dubief3, N. 14 15 15 16 17 18 Collongues , X. Ayrignac , P. Labauge , P. Meyer , E. Thouvenot , B. Bourre , A. Montcuquet19, M. Cohen20, P. Horellou21, M. Tintore22, J. De Seze23, S. Vukusic24, K. Deiva25, R. Marignier2, 1Centre d’Esclerosi Múltiple de Catalunya (Cemcat)/Barcelona/ES, 2Lyon Neuroscience Research Center/Bron/FR, 3CHU Lyon/Lyon/FR, 4Vall Hebron University Hospital/Barcelona/ES, 5Department of Neurology, Hôpital Fondation Adolphe de Rothschild Paris, France/Paris/FR, 6Pitié-Salpêtriere /Paris/FR, 7pitié-salpêtrière hospital/PARIS/FR, 8Hôpital La Timone/Marseille/FR, 9Timone Hospital, APHM, Marseille, France/Marseille/FR, 10Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin- Bicêtre, France/Paris/FR, 11University of Lille, U1172, CHU of Lille, CRC-SEp of Lille/Lille/FR, 12AssistancCRC-SEP, Toulouse University Hospital, Toulouse, Francee Publique- Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France/Toulouse/FR, 13CHU Toulouse/Toulouse/FR, 14Strasbourg University Hospital, Strasbourg, France/Strasbourg/FR, 15CHU de Montpellier/Montpellier/FR, 16Department Neurology/Montpellier/FR, 17CHU Nimes/Nimes/FR, 18CHU Rouen/Rouen/FR, 19Neurology department/Dupuytren/FR, 20CHU de Nice - Hopital Pasteur 2/Nice/FR, 21Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud 11, CEA, DSV/iMETI,/Paris/FR, 22Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 23CHU de Strasbourg/Strasbourg/FR, 24Lyon University Hospital/BRON/FR, 25Bicetre Hospital/LE KREMLIN BICETRE/FR

12:03 - 12:15 YI02.05 - Cognition and socio-professional attainment in paediatric onset multiple sclerosis: a reappraisal after 10 years

A. Bellinvia1, R. Fratangelo2, E. Portaccio3, M. Fonderico2, L. Tudisco2, L. Razzolini4, L. Pastò2, B. Goretti3, C. Niccolai3, A. Ghezzi5, M. Zaffaroni6, L. Pippolo5, L. Moiola7, M. Falautano8, C. Celico8, R.G. Viterbo9, F. Patti10, C.G. Chisari10, P. Gallo11, A. Riccardi11, M. Borghi12, M. Simone9, A. Bertolotto13, C. Pozzilli14, V. Bianchi15, M. Roscio5, V. Martinelli7, G. Comi16, M. Filippi7, M. Trojano17, M.P. Amato4, 1University of Florence/Firenze/IT, 2University of Florence, Florence, Italy;/Florence/IT, 3Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy/Florence/IT, 4University of Florence/Florence/IT, 5Gallarate Hospital, Varese/Gallarate/IT, 6Multiple Sclerosis Centre, Hospital of Gallarate, ASST della Valle Olona/Gallarate (VA)/IT, 7IRCCS San Raffaele Scientific Institute/Milan/IT, 8Department of Neurology, Multiple Sclerosis Center, IRCCS Ospedale San Raffaele, Milan, Italy/Milan/IT, 9Department of Basic Medical Sciences, Child and Adolescence Neuropsychiatry Unit, Neuroscience and Sense Organs University "Aldo Moro" Bari, Bari, Italy/Bari/IT, 10Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 11University of Padua/Padova/IT, 12Neurologia 2-Centro di Riferimento Regionale Sclerosi Multipla, AOU San Luigi Gonzaga (Borghi), Orbassano (TO), Italy/Turin/IT, 13San Luigi Gonzaga Hospital/Orbassano (TO)/IT, 14Sapienza University of Rome/Rome/IT, 15AO Sant'Andrea, La Sapienza University, Rome, Italy/Rome/IT, 16San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 17University of Bari/Bari/IT

12:15 - 12:27 YI02.06 - Central nervous system infections in adolescence and MS risk after age 20 years

K. Smith1, Y. Xu2, A. Hiyoshi2, F. Piehl3, T. Olsson3, S. Montgomery2, 1Karolinska

Insitutet/Stockholm/SE, 2Örebro University/Örebro/SE, 3Karolinska Institute/Stockholm/SE

Free Communications 1-4 Free Communications 1

13:00 - 14:15 1 2 1 2 Moderation: K. Selmaj , F. Zipp , Center for Neurology/Lodz/PL, University Medical Center of the Johannes Gutenberg University Mainz/Mainz/DE

13:00 - 13:12 FC01.01 - Long-term efficacy and safety of eculizumab monotherapy in AQP4+ neuromyelitis optica spectrum disorder

S. Pittock1, K. Fujihara2, J. Palace3, A. Berthele4, H.J. Kim5, C. Oreja-Guevara6, I. Nakashima7, M. Levy8, A. Pace9, M. Yountz9, L. Miller9, R. Armstrong10, D. Wingerchuk11, 1Mayo Clinic/Rochester/US, 2Fukushima Medical University/Fukushima/JP, 3Oxford University Hospitals/Oxford/GB, 4Klinikum rechts der Isar, Technical University of Munich/Munich/DE, 5Research Institute and Hospital, National Cancer Center/Goyang/KR, 6Hospital Universitario Clinico San Carlos/Madrid/ES, 7Tohoku University//JP, 8Massachusetts General Hospital and Harvard Medical School/Boston/US, 9Alexion Pharmaceuticals/Boston/US, 10Formerly of Alexion Pharmaceuticals/Boston/US, 11Mayo Clinic/Scottsdale/US

13:12 - 13:24 FC01.02 - Efficacy and safety of eculizumab in patients with neuromyelitis optica spectrum disorder previously treated with rituximab: findings from PREVENT

M. Levy1, A. Berthele2, H.J. Kim3, K. Fujihara4, I. Nakashima5, C. Oreja-Guevara6, J. Palace7, S. Pittock8, M. Terzi9, N. Totolyan10, S. Viswanathan11, K.-C. Wang12, A. Pace13, M. Yountz13, D. Lawson13, E. Laudon-Meyer13, D. Wingerchuk14, 1Massachusetts General Hospital and Harvard Medical School/Boston/US, 2Klinikum rechts der Isar, Technical University of Munich/Munich/DE, 3Research Institute and Hospital, National Cancer Center/Goyang/KR, 4Fukushima Medical University/Fukushima/JP, 5Tohoku University//JP, 6Hospital Universitario Clinico San Carlos/Madrid/ES, 7Oxford University Hospitals/Oxford/GB, 8Mayo Clinic/Rochester/US, 9Ondokuz Mayıs University/Sasun/TR, 10First Pavlov State Medical University of St Petersburg/St Petersburg/RU, 11Kuala Lumpur Hospital/Kuala Lumpur/MY, 12Cheng-Hsin General Hospital/Taipei/TW, 13Alexion Pharmaceuticals/Boston/US, 14Mayo Clinic/Scottsdale/US

13:24 - 13:36 FC01.03 - Effect of satralizumab on relapse severity in neuromyelitis optica spectrum disorder (NMOSD): results from the Phase III SAkura studies

J. Palace1, I. Kleiter2, A. Traboulsee3, T. Yamamura4, F. Patti5, D. Stokmaier6, G. Klingelschmitt6, T. Kuenzel6, H.C. Von Büdingen6, J. Bennett7, 1Oxford University Hospitals/Oxford/GB, 2Ruhr-Universität Bochum/Bochum/DE, 3The University of British

Columbia/Canada/CA, 4National Institute of Neuroscience, National Center of Neurology and Psychiatry/Tokyo/JP, 5University of Catania/Catania/IT, 6F. Hoffmann-La Roche Ltd/Basel/CH, 7University of Colorado School of Medicine/Denver/US

13:36 - 13:48 FC01.04 - Ependymocyte: a new target for aquaporin4-IgG in NMO? M. Bigotte1, A. Ruiz2, M. Poinsot2, P. Giraudon2, G. Malleret2, P. Salin2, R. Marignier2, 1INSERM U1028 - Centre de Recherche en Neurosciences de Lyon/Bron/FR, 2Lyon Neuroscience Research Center/Bron/FR

13:48 - 14:00 FC01.05 - GFAP auto-immunity: a French cohort study

A. Gravier Dumonceau1, R. Ameli2, V. Rogemond2, G. Picard2, M. Benaiteau3, K. Deiva4, T. De Broucker5, L. Kremer6, J. Honnorat1, R. Marignier7, 1Hopital Neurologique Pierre- Wertheimer/Lyon/FR, 2Hopital Neurologique Pierre-Wertheimer/Bron/FR, 3Hôpital Pierre-

Paul Riquet, CHU PURPAN/Toulouse/FR, 4Bicetre Hospital/LE KREMLIN BICETRE/FR, 5Hôpital Pierre Delafontaine Centre Hospitalier de Saint-Denis/Saint Denis/FR, 6CHU Strasbourg Hautepierre/Strasbourg/FR, 7Lyon Neuroscience Research Center/Bron/FR

FC02 - Free Communications 2 13:00 - 14:15 Moderation: A. Boiko1, M. Levin2, 1Pirogov Russian National Medical University//, 2University of Saskatchewan/Saskatoon/CA

13:00 - 13:12 FC02.01 - Safety of Alemtuzumab Over 9 Years in Patients With Non-MS Autoimmunity

A. Coles1, A. Bass2, G. Comi3, Ó. Fernández4, G. Giovannoni5, J. Jones1, E. Kubala Havrdova6, X. Montalban7, F. Piehl8, A. Traboulsee9, P. Vermersch10, T. Ziemssen11, E. Poole12, H. Wiendl13, 1University of Cambridge School of Medicine/Cambridge/GB, 2Neurology Center of San Antonio/San Antonio/US, 3Ospedale San Raffaele/Milan/IT, 4Fundación IMABIS, Hospital Universitario Carlos Haya/Málaga/ES, 5The London School of Medicine and Dentistry/London/GB, 6First Medical Faculty, Charles University/Prague/CZ, 7Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron/Barcelona/ES, 8Karolinska Institute/Stockholm/SE, 9University of British Columbia/Vancouver/CA, 10CHU de Lille/Lille/FR, 11Carl Gustav Carus University Hospital/Dresden/DE, 12Sanofi/Cambridge/US, 13University of Münster/Germany/DE

13:12 - 13:24 FC02.02 - Update on the risk estimates of progressive multifocal leukoencephalopathy related to fingolimod

R. Fox1, B. Cree2, B. Greenberg3, B. Hemmer4, B.J. Ward5, D. Ontaneda1, A. Moore6, Y. Zhang7, R. Sullivan7, P. Girase6, T. Hach6, J.R. Berger8, 1Cleveland Clinic//US, 2University of California San Francisco/San Francisco/US, 3Department of Neurology and Neurotherapeutics/Dallas/US, 4University of Munich/Munich/DE, 5Infectious Diseases

Division, Research Institute of the McGill University Health Centre/Montreal/CA, 6Novartis Pharma AG/Basel/CH, 7Novartis Pharmaceuticals Corporation/East Hanover/US, 8Department of Neurology, Perelman School of Medicine, University of Pennsylvania/Philadelphia/US 13:24 - 13:36 FC02.03 - Evaluation of T and B lymphocytopenia in patients treated with Ocrelizumab switching from other treatments compared to naive

D. Landi1, A. Grimaldi2, F. Bovis3, E. Signoriello4, C.G. Nicoletti2, G. Cola2, G. Lus4, M.P. Sormani3, G.A. Marfia2, 1UOSD Centro di Riferimento Regionale Sclerosi

Multipla/Roma/IT, 2UOSD Centro di Riferimetno Regionale Sclerosi Multipla/Rome/IT, 3University of Genoa/Genoa/IT, 4Second University of Naples/Napoli/IT

13:36 - 13:48 FC02.04 - Teriflunomide efficacy and safety in pediatric patients with relapsing forms of MS: Interim analysis of open-label TERIKIDS trial extension

T. Chitnis1, B. Banwell2, D.L. Arnold3, K. Gücüyener4, K. Deiva5, N. Skripchenko6, L.-Y. Cui7, S. Saubadu8, W. Hu9, M. Benamor8, A. Le-Halpere8, P. Truffinet10, M. Tardieu11, 1Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US, 2Children’s Hospital of Philadelphia/Philadelphia/US, 3MNI, McGill/Quebec/CA, 4Gazi Universitesi/Ankara/TR, 5Bicetre Hospital/LE KREMLIN BICETRE/FR, 6FSBI Research Inst. Ped. Infect. Dis./St. Petersburg/RU, 7Peking Union Medical College Hospital/Peking/CN, 8Sanofi-Aventis/Chilly-Mazarin/FR, 9Sanofi- Aventis/Cambridge/US, 10Sanofi-Aventis/Paris/FR, 11GHU Paris-Sud, Hôpital de Bicêtre/Le Kremlin-Bicêtre/FR

13:48 - 14:00 FC02.05 - Safety and Efficacy in Patients Treated With Dimethyl Fumarate and Followed For 13 Years: Final Results of ENDORSE

R. Gold1, G. Giovannoni2, J.T. Phillips3, A. Bar-Or4, R. Fox5, O. Mokliatchouk6, B. Parks6, C. Miller6, S. Kapadia6, 1St. Josef-Hospital, Ruhr University Bochum/Bochum/DE, 2The London School of Medicine and Dentistry/London/GB, 3Baylor Institute for Immunology 4 5 Research/Dallas/US, University of Pennsylvania/Philadelphia/US, Cleveland Clinic//US, 6Biogen/Cambridge/US

FC03 - Free Communications 3 13:00 - 14:15 Moderation: C. Tornatore1, M. Trojano2, 1Georgetown University Medical Center/Washington, DC/US, 2University of Bari/Bari/IT

13:00 - 13:12 FC03.01 - Defining controversies of benign MS using digital technology

L. Midaglia1, P. Carbonell-Mirabent2, R. Robles Cedeño3, J. Sastre-Garriga4, J. Río5, M. Comabella6, J. Castilló3, A. Vidal-Jordana7, G. Arrambide4, B. Rodríguez-Acevedo8, A. 2 8 8 4 9 8 10 1 Zabalza , Í. Galán , C. Nos , C. Auger , A. Rovira , X. Montalban , M. Tintore , Dept. of Neurology-Neuroimmunology; Vall Hebron University Hospital; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 2Vall d’Hebron Institut de Recerca/Barcelona/ES, 3Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 4Vall Hebron University Hospital/Barcelona/ES, 5CEMCAT, Hospital Universitario Vall d’Hebrón/Barcelona/ES, 6Universitat Autònoma//ES, 7Hospital Universitari Vall d’Hebron/Barcelona/ES, 8Dept. of Neurology-Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 9Vall d'Hebron University Hospital/Barcelona/ES, 10Multiple Sclerosis Centre of Catalonia/Barcelona/ES

13:12 - 13:24 FC03.02 - A step forward toward the fully automated assessment of the central vein sign

M.J. Fartaria1, O. Al-Louzi2, T. Huelnhagen1, L. Daboul2, P. Maggi3, D. Reich4, C. Granziera5, M. Bach Cuadra3, J. Richiardi3, P. Sati6, T. Kober1, 1Siemens Healthcare AG/Lausanne/CH, 2National Institute of Neurological Disorders and

Stroke/Bethesda/US, 3Lausanne University Hospital and University of Lausanne/Lausanne/CH, 4National Institute of Health/Bethesda/US, 5University Hospital Basel and University of Basel/Basel/CH, 6Cedars-Sinai Medical Center/Los Angeles/US

13:24 - 13:36 FC03.03 - Depicting multiple sclerosis pathology at 160μm isotropic resolution by human whole-brain postmortem 3T magnetic resonance imaging

M. Weigel1, P. Dechent2, R. Galbusera3, E. Bahn2, G. Nair4, L. Kappos5, W. Brück6, C. Stadelmann2, C. Granziera3, 1University of Basel/Allschwil/CH, 2University Medical Center Göttingen/Göttingen/DE, 3University Hospital Basel and University of Basel/Basel/CH, 4NINDS, NIH/Bethesda/US, 5University Hospital and University of Basel/Basel/CH, 6Institute of Neuropathology/Goettingen/DE

13:36 - 13:48 FC03.04 - Investigating the temporal relationship between inflammation and fdNIRS- measured hypoxia in an MS population

Q. Shafqat1, D. Adingupu1, T. Evans1, S. Jarvis2, L. Brown3, L. Metz1, J. Dunn1, 1Cumming School of Medicine/Calgary/CA, 2Cumming School of Medicine and Alberta Neurologic Centre, Calgary, Canada/N/CA, 3Cumming School of Medicine/N/CA

13:48 - 14:00 FC03.05 - Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO

D. Arnold1, T. Sprenger2, A. Bar-Or3, J. Wolinsky4, L. Kappos5, S. Kolind6, H.-M. Schneble7, S. Magon7, J. Van Beek7, H. Koendgen7, C. Bernasconi7, L. Gaetano7, A. Traboulsee8, 1McGill University and NeuroRx Research/Montreal/CA, 2DKD Helios/Wiesbaden/DE, 3University of Pennsylvania/Philadelphia/US, 4The University of Texas Health Science Center at Houston/Houston/US, 5University Hospital Basel, University of Basel/Basel/CH, 6University of British Columbia/Vancouver/CA, 7F. Hoffmann-La Roche Ltd/Basel/CH, 8The University of British Columbia/Canada/CA

FC04 - Free Communications 4 Moderation: I. Katz Sand1, A. Siva2, 1Mount Sinai/New York/US, 2Istanbul University 13:00 - 14:15 Cerrahpaşa School of Medicine/Istanbul/TR

13:00 - 13:12 FC04.01 - Masitinib in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis: Results from phase 3 study AB07002

P. Vermersch1, O. Hermine2, 1CHU de Lille/Lille/FR, 2Imagine Institute, INSERM UMR 1163 and CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implication, Hôpital Necker/Paris/FR

13:12 - 13:24 FC04.02 - Effects of natalizumab on patient-reported MS outcomes using prospective data from the Australian MS longitudinal study

J. Chen1, I. Diouf2, B. Taylor3, T. Kalincik4, I. Van Der Mei3, 1Menzies/Hobart/AU, 2University of Melbourne/Melbourne/AU, 3University of Tasmania/Hobart/AU, 4Royal Melbourne Hospital/Melbourne/AU

13:24 - 13:36 FC04.03 - High plasma glial fibrillary acidic protein levels predict disability milestone EDSS 7 in non-active secondary progressive multiple sclerosis

J. Kuhle1, A.M. Maceski2, R. Meinert3, T. Hach4, L. Kappos2, H. Kropshofer4, D. Leppert2, 1University of Basel/Switzerland/CH, 2Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel/Basel/CH, 3DATAMAP GmbH/Freiburg/DE, 4Novartis Pharma AG/Basel/CH

13:36 - 13:48 FC04.04 - Respiratory disorders in severe MS patients : an innovative study with evaluation of respiratory muscles during sleep.

E. Maillart1, C. Louapre2, M. Houot3, A. Ungureanu4, S. Redolfi5, P. Laveneziana6, C. Papeix7, C. Lubetzki8, C. Morelot-Panzini6, 1Pitié-Salpêtriere /Paris/FR, 2Pitié salpetrière/Paris/FR, 3ICM/Paris/FR, 4Pitié-Salpêtrière hospital and Saint-Antoine Hospital, APHP/PARIS/FR, 5Pitié-Salpêtrière Hospital, APHP/PARIS/FR, 6Pitié-Salpêtrière hospital, APHP/PARIS/FR, 7pitié-salpêtrière hospital/PARIS/FR, 8Hôpital Pitié-Salpêtrière/Paris/FR

13:48 - 14:00 FC04.05 - Understanding the relative contributions of obesity, vitamin D, leptin and adiponectin to MS risk: a Mendelian randomization mediation analysis

A. Harroud1, D. Manousaki2, R. Mitchell3, G. Davey Smith3, B. Richards2, S. Baranzini1, 1University of California San Francisco/San Francisco/US, 2McGill University/Montreal/CA, 3University of Bristol/Bristol/GB

Plenary Session 2 14:30 - 15:30 Plenary Session 2 - ACTRIMS-ECTRIMS Lecture and Closing

14:30 - 15:15 PL02.01 - New Insights on Immunopathogenesis

F. Zipp, University Medical Center of the Johannes Gutenberg University Mainz//DE

Saturday, September 26 Late Breaking News LB01 - Late Breaking News 09:00 - 10:30 Moderation: T. Derfuss1, A. Prat2, 1University Hospital Basel/Basel/CH, 2University of Montreal/Montreal/CA

09:00 - 09:12 LB01.01 - Primary astrocytopathy has a detrimental effect on remyelination efficacy of parenchymal oligodendrocyte precursor cells.

M. Lohrberg1, A. Winkler2, J. Franz1, F. Van Der Meer2, A. Barrantes-Freer3, C. Stadelmann2, 1University Medical Hospital Göttingen/Göttingen/DE, 2University Medical Center Göttingen/Göttingen/DE, 3University Medical Center Leipzig/Leipzig/DE

09:12 - 09:24 LB01.02 - Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis

J. Brown1, N. Cunniffe1, F. Prados2, B. Kanber2, J. Jones1, E. Needham1, Z. Georgieva1, D. Rog3, O. Pearson4, J. Overell5, D. Macmanus6, R. Samson6, J. Stutters7, C. Gandini Wheeler- Kingshott8, A. Michell1, P. Connick9, R. Franklin, S. Chandran10, D. Altmann11, D. Chard12, A. Coles1, 1University of Cambridge School of Medicine/Cambridge/GB, 2University College London/LONDON/GB, 3Salford Royal NHS Foundation Trust/Salford/GB, 4Swansea Bay University Health Board/Swansea/GB, 5F. Hoffmann-La Roche Ltd/Basel/CH, 6University

College London/London/GB, 7University College London/BG/GB, 8NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London/LONDON/GB, 9University of Edinburgh/Edinburgh/GB, 10The University of Edinburgh/Edinburgh/GB, 11The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London/AT/GB, 12Institute of Neurology/London/GB

09:24 - 09:36 LB01.03 - Neutrophil granulocyte markers in cerebrospinal fluid differentiate NMOSD and anti-MOG antibody associated disease from MS in acute disease phase

M. Watanabe1, S. Schaedelin2, A. Maceski3, D. Rey3, J. Oechtering2, J. Lambert4, T. Plavina4, P. Patel4, K. Masaki1, N. Isobe5, T. Matsushita5, J.-I. Kira6, P. Benkert7, L. Kappos8, J. Kuhle9, D. Leppert3, 1Kyushu University/Fukuoka/JP, 2University Hospital Basel/Basel/CH, 3University Hospital Basel and University of Basel/Basel/CH, 4Quanterix Corporation/Billerica/US, 5Kyushu University/Fukuoka City/JP, 6Translational Neuroscience Center, Graduate School of Medicine, and Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare/Fukuoka/JP, 7University Hospital Basel, University of Basel/Basel/CH, 8University of Basel//CH, 9University of Basel/Switzerland/CH

09:36 - 09:48 LB01.04 - Brain microstructural and metabolic alterations detected in vivo at the onset of the first demyelinating event.

S. Collorone1, F. Prados1, B. Kanber1, N. Cawley2, C. Tur3, F. Grussu2, B. Solanky4, M. Yiannakas5, I. Davagnanam6, C. Gandini Wheeler-Kingshott2, F. Barkhof1, O. Ciccarelli7, A. Toosy2, 1University College London/LONDON/GB, 2NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology,

Faculty of Brain Sciences, University College London/LONDON/GB, 3UCL Queen Square Institute of Neurology, Faculty of Brain Sciences/London/GB, 4University College London/BG/GB, 5UCL Institute of Neurology/London/GB, 6National Hospital for Neurology and Neurosurgery/London/NL, 7UCL Queen Square Institute of Neurology/London/GB

09:48 - 10:00 LB01.05 - Network analysis identifies gut bacteria associated with multiple sclerosis relapse among pediatric-onset patients

M. Horton1, K. Mccauley2, J. Graves3, J. Ness4, Y. Harris4, L. Benson5, B. Weinstock- Guttman6, A. Waldman7, M. Rodriguez8, L. Krupp9, A. Belman9, T.C. Casper10, J. Rose10, J. Hart11, X. Shao12, H. Tremlett13, S. Lynch2, L. Barcellos14, E. Waubant11, 1University of California, Berkeley/Oakland/US, 2University of California, San Francisco/San Francisco/US, 3University of California, San Diego/San Diego/US, 4University of Alabama, Birmingham/Birmingham/US, 5Boston Children’s Pediatric MS Center/Boston/US, 6State

University of New York at Buffalo/Buffalo/US, 7Children's Hospital of Philadelphia/Philadelphia/US, 8Mayo Clinic/Rochester/US, 9New York University Langone Medical Center/New York/US, 10University of Utah School of Medicine/Salt Lake City/US, 11UCSF/San Francisco/US, 12University of California Berkeley/Berkeley/US, 13University of British Columbia/Vancouver/CA, 14University of California, Berkley//US

10:00 - 10:12 LB01.06 - Interrupting disease modifying treatment for pregnancy in multiple sclerosis – effect on disease activity and serum neurofilament light chain

Ö. Yaldizli1, P. Benkert2, F. Bedussi3, S. Schaedelin1, J. Oechtering1, A. Ceschi3, A. Maceski4, A. Orleth4, A. Salmen5, C. Granziera4, L. Achtnichts6, C. Pot7, R. Du Pasquier7, P. Lalive8, S. Müller9, L. Kappos10, C. Gobbi11, D. Leppert4, C. Zecca11, J. Kuhle12, 1University Hospital Basel/Basel/CH, 2University Hospital Basel, University of Basel/Basel/CH, 3Neurocenter of Southern Switzerland/Lugano/CH, 4University Hospital Basel and University of Basel/Basel/CH, 5Inselspital Bern, University Hospital and University of Bern/Bern/CH, 6Cantonal Hospital Aarau/Aarau/CH, 7University Hospital of Lausanne/Lausanne/CH, 8Geneva University Hospitals/Geneva/CH, 9Cantonal Hospital St. Gallen/St. Gallen/CH, 10University Hospital and University of Basel/Basel/CH, 11Regional Hospital of Southern Switzerland (EOC)/Lugano/CH, 12University of Basel/Switzerland/CH

Special Session: COVID-19 SS02 - COVID-19 10:45 - 12:15 Moderation: B. Segal1, M. P. Amato2, 1The Ohio State University/Columbus/US, 2University of Florence/Florencel/IT

10:45 - 10:57 SS02.01 - COVID-19 in people with MS: A large community-based study of the UK MS Register

A. Garjani1, N. Evangelou1, R. Das Nair1, R. Hunter2, K. Tuite-Dalton2, A. Coles3, R. Dobson4, M. Duddy5, D. Ford2, S. Hughes6, O. Pearson7, L. Middleton8, D. Rog9, E. Tallantyre10, R. Middleton11, R. Nicholas12, 1University of Nottingham/Nottingham/GB, 2Swansea University Medical School/Swansea/GB, 3University of Cambridge School of Medicine/Cambridge/GB, 4Queen Mary University of

London/London/GB, 5Newcastle upon Tyne Hospitals NHS Trust/Newcastle upon Tyne/GB, 6Royal Victoria Hospital/Belfast/GB, 7Swansea Bay University Health Board/Swansea/GB, 8Swansea Bay University Health board/Swansea/GB, 9Salford Royal NHS Foundation Trust/Salford/GB, 10Cardiff University/Cardiff/GB, 11Swansea University/Swansea/GB, 12Imperial College London/London/GB

10:57 - 11:09 SS02.02 - Comparison of COVID-19 outcomes between racial groups in the COViMS registry

A. Salter1, G. Cutter2, R. Fox3, J. Halper4, B. Bebo5, P. Kanellis6, K. Costello7, A. Cross8, D. Li9, S. Newsome10, K. Rammohan11, 1Washington University School in St. Louis/St Louis/US, 2The University of Alabama at Birmingham/Birmingham/US, 3Cleveland Clinic//US, 4CMSC/Fair Lawn/US, 5National Multiple Sclerosis Society

(USA)/Portland/US, 6MS Society of Canada/Toronto/CA, 7National Multiple Sclerosis Society/New York/US, 8Washington University in St. Louis/St. Louis/US, 9//CA, 10Johns Hopkins University School of Medicine/Baltimore/US, 11University of Miami School of Medicine/Miami/US

11:09 - 11:21 SS02.03 - Evidence of an Increased Burden of Humoral Autoimmunity in the CSF and plasma of COVID-19 Patients with Comorbid Neurologic Dysfunction

C. Bartley1, S. Farhadian2, T. Ngo1, B. Phiney3, M. Salemi3, R. Dandekar1, B. Alvarenga1, I. Hawes1, R. Loudermilk1, T. Huynh1, S. Spudich2, S. Pleasure1, M. Wilson1, 1University of

California San Francisco/San Francisco/US, 2Yale University School of Medicine/New Haven/US, 3University of California, Davis/Davis/US 11:21 - 11:33 SS02.04 - First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti- CD20 DMTs are associated with worse COVID-19 outcomes

S. Simpson-Yap1, E. De Brouwer2, T. Kalincik3, N. Rijke4, J. Hillert5, C. Walton6, G. Edan7, Y. Moreau2, T. Spelman8, L. Geys9, T. Parciak10, C. Gautrais11, N. Lazovski12, A. Pirmani2, A. Ardeshirdavani11, L. Forsberg13, A. Glaser5, R. Mcburney14, H. Schmidt14, A. Bergmann15, S. Braune16, A. Stahmann17, R. Middleton18, A. Salter19, A. Van Der Walt20, J. Rojas21, I. Van Der Mei22, R. Ivanov23, G. Sciascia Do Olival24, A. Dias24, M. Magyari25, D. Brum26, M.F. Mendes27, R. Alonso28, R. Nicholas29, J. Bauer30, A. Chertcoff30, A. Zabalza31, G. Arrambide32, G. Comi33, L.M. Peeters34, 1The University of Melbourne/Melbourne/AU, 2KU Leuven/Leuven/BE, 3Royal Melbourne Hospital/Melbourne/AU, 4MS International Federation/London/GB, 5Karolinska Institute/Solna/SE, 6Multiple Sclerosis International Federation/London/GB, 7Centre hospitalier universitaire de Rennes, Hôpital Pontchaillou, Service de neurologie, CIC1414 INSERM/Rennes/FR, 8Karolinska Institute/Stockholm/SE, 9UHasselt/Diepenbeek/BE, 10University Medical Center Göttingen/Göttingen/DE, 11KU Leuven/Heverlee/BE, 12QMENTA/Barcelona/ES, 13/Nykvarn/SE, 14Accelerated Cure

Project/Waltham/US, 15NeuroTransData GmbH/Neuburg an der Donau/DE, 16NeuroTransData GmbH/Neuburg/DE, 17MS Forschungs- und Projektentwicklungs-gGmbH/Hannover/DE, 18Swansea University/Swansea/GB, 19Washington University School in St. Louis/St Louis/US, 20Monash University/Melbourne/AU, 21Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 22University of Tasmania/Hobart/AU, 23Bulgarian SmartMS/Sofia/BG, 24ABEM - Brazilian MS Patients Association/Sao Paulo/BR, 25Danish Multiple Sclerosis Center/Glostrup/DK, 26Universidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatu/BOTUCATU/BR, 27REDONE.BR - Brazilian MS Registry/Sao Paulo/BR, 28Hospital Ramos Mejía/Buenos Aires/AR, 29Imperial College London/London/GB, 30Esclerosis Múltiple Argentina (EMA)/Buenos Aires/AR, 31CEMCAT/Barcelona/ES, 32Vall Hebron University Hospital/Barcelona/ES, 33San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 34Hasselt University/Diepenbeek/BE

11:33 - 11:45 SS02.05 - COVID-19 in persons with multiple sclerosis treated with ocrelizumab: pharmacovigilance update

R. Hughes1, K. Fitovski1, L. Whitley1, N. Jessop1, H.-M. Schneble1, E. Muros-Le Rouzic2, A. Sauter1, R. Pedotti1, H. Koendgen1, 1F. Hoffmann-La Roche Ltd/Basel/CH, 2F. Hoffmann-La Roche Ltd,/Basel/CH

11:45 - 11:57 SS02.06 - Clinical Characteristics and Outcomes in Patients with Coronavirus Disease 2019 and Multiple Sclerosis

C. Louapre1, N. Collongues2, B. Stankoff3, C. Giannesini4, C. Papeix5, C. Bensa6, R. Deschamps7, A. Creange8, A. Wahab8, J. Pelletier9, O. Heinzlef10, P. Labauge11, L. Guilloton12, G. Ahle13, M. Goudot14, K. Bigaut2, D. Laplaud15, S. Vukusic16, C. Lubetzki17, J. De Seze18, 1Pitié salpetrière/Paris/FR, 2Strasbourg University Hospital, Strasbourg, France/Strasbourg/FR, 3Sorbonne Université/Paris/FR, 4Saint-Antoine Hospital APHP/Paris/FR, 5pitié-salpêtrière hospital/PARIS/FR, 6Fondation Rothschild/Paris/FR, 7Department of Neurology, Hôpital Fondation Adolphe de Rothschild Paris, France/Paris/FR, 8CHU Creteil/Creteil/FR, 9Aix Marseille Univ, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie/Marseilles/FR, 10CHI Poissy Saint Germain en Laye/Le pecq/FR, 11CHU de Montpellier/Montpellier/FR, 12Association des Neurologues Libéraux de Langue Française/Mornant/FR, 13Département de neurologie, Hôpitaux Civils de Colmar/Colmar/FR, 14Service de neurologie, GHR de Mulhouse/Mulhouse/FR, 15CHU de Nantes/Nantes/FR, 16Lyon University Hospital/BRON/FR, 17Hôpital Pitié-Salpêtrière/Paris/FR, 18CHU de Strasbourg/Strasbourg/FR

On-Demand Program Burning Debates

BD01 - DMTs prevent/slow down cognitive impairment in MS Moderation: D. Langdon1, L. Krupp2, 1University of London//GB, 2NYU Langone/New York City/US BD01.01 - Presentation 01 R. Benedict, University at Buffalo/Buffalo/US

BD01.02 - Presentation 02 C. Enzinger, Medical University of Graz/Graz/AT

BD02 - DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity Moderation: M. Tintore1, R. Fox2, 1Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 2Cleveland Clinic//US BD02.01 - Presentation 01 R. Bermel, Cleveland Clinic/Cleveland/US

BD02.02 - Presentation 02 P. Coyle, Stony Brook University/Stony Brook/US

BD03 - Microglia are protective in MS Moderation: H. Lassmann1, O. Butovsky2, 1Medical University of Vienna/Vienna/AT, 2Harvard Medical School//US YIBD03.02 - Presentation 02 T.L. Tay, University of Freiburg/Freiburg/DE

Meet the Experts

MTE01 - CNS in disorders in children Moderation: B. Banwell1, T. Chitnis2, 1Children’s Hospital of Philadelphia/Philadelphia/US, 2Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US MTE01.01 - Meet the Expert – CNS Disorders in Children T. Chitnis, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US MTE01.02 - Diagnosis and Management of MOG-AD B. Banwell, Children’s Hospital of Philadelphia/Philadelphia/US

MTE02 - Neuro-ophthalmology of MS Moderation: A. Green, UCSF Multiple Sclerosis Center/United States/US MTE03 - B-cell-directed therapy in MS Moderation: A. Cross1, F. Piehl2, 1Washington University in St. Louis/St. Louis/US, 2Karolinska Institute/Stockholm/SE

MTE04 - Choosing the right MS disease therapy for individual patients Moderation: M. Tintore1, A. Uccelli2, 1Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 2University of Genoa/Italy/IT

MTE05 - Immune disorders of the CNS other than MS Moderation: A. Siva1, D. Wingerchuk2, 1Istanbul University Cerrahpaşa School of 2 Medicine/Istanbul/TR, Mayo Clinic/United States/US

Teaching Courses

TC01 - Ultra-high-field (7T) MRI in MS (NAIMS) Moderation: F. Bagnato1, S. Narayanan2, 1Vanderbilt University Medical Center/Nashville/US, 2McGill University/Montreal/CA TC01.01 - Technical aspects of 7T imaging as it pertains to MS (at a level geared to neurologists) P. Sati, Cedars-Sinai Medical Center/Los Angeles/US TC01.02 - 7T MRI - pathology correlation/validation studies F. Bagnato, Vanderbilt University Medical Center/Nashville/US TC01.03 - Clinical Applications of 7T MRI in MS D. Harrison, University of Maryland School of Medicin/BALTIMORE/US

TC02 - Neurofilaments and other biomarkers of CNS disease Moderation: R. Furlan1, M. Freedman2, J. Kuhle3, 1San Raffaele Sicentific Institute/Milan/IT, 2University of Ottawa and the Ottawa Hospital Research Institute/Ottawa/CA, 3University of Basel/Switzerland/CH TC02.01 - Presentation 01 M. Freedman, The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA

TC02.02 - Quantifying therapy response in MS by neurofilaments? J. Kuhle1, M. Freedman2, R. Furlan3, 1University of Basel/Switzerland/CH, 2The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 3San Raffaele Sicentific Institute/Milan/IT

TC02.03 - Presentation 03 R. Furlan, San Raffaele Sicentific Institute/Milan/IT

TC03 - NMO spectrum disorders: pathogenesis and treatment Moderation: K. Fujihara1, J. Palace2, J. Bennett3, 1Fukushima Medical University/Fukushima/JP, 2Oxford University Hospitals/Oxford/GB, 3University of Colorado School of Medicine/Aurora/US TC03.01 - Understanding the pathophysiology of AQP4 and MOG antibody diseases J. Bennett, University of Colorado School of Medicine/Aurora/US

TC03.02 - 2 Antibody Neg Nmo like Syndromes: Unravelling the Diagnosis and How to Manage Them J. Palace, Oxford University Hospitals/Oxford/GB

TC03.03 - The Treatment of Nmosd: A New Era of Choice K. Fujihara, Fukushima Medical University/Fukushima/JP

TC04 - Accurate diagnosis of MS: getting it right Moderation: G. Arrambide1, W. Brownlee2, P. Coyle3, 1Vall Hebron University Hospital/Barcelona/ES, 2National Hospital for Neurology and Neurosurgery/United Kingdom/GB, 3Stony Brook University/Stony Brook/US TC04.01 - Presentation 01

W. Brownlee, National Hospital for Neurology and Neurosurgery/United Kingdom/GB TC04.02 - Presentation 02

P. Coyle, Stony Brook University/Stony Brook/US TC04.03 - Presentation 03 G. Arrambide, Vall Hebron University Hospital/Barcelona/ES

TC05 - Reproductive issues related to treatment in MS Moderation: K. Hellwig1, D. Rotstein2, S. Vukusic3, 1University of Bochum/Bochum/DE, 2University of Toronto/Toronto/CA, 3Lyon University Hospital/BRON/FR TC05.01 - Presentation 01

D. Rotstein, University of Toronto/Toronto/CA TC05.02 - Presentation 02

S. Vukusic, Lyon University Hospital/BRON/FR TC05.03 - Presentation 03 K. Hellwig, University of Bochum/Bochum/DE

TC06 - Anti-MOG associated CNS disease: clinical characteristics and therapeutic management Moderation: E. Meinl1, D. Sato2, E.A. Yeh3, 1LMU/Martinsried/DE, 2Pontifical Catholic U. of Rio Grande do Sul (PUCRS)/Porto Alegre/BR, 3University of Toronto/Toronto/CA TC06.01 - Presentation 01 E.A. Yeh, The Hospital for Sick Children/Toronto/CA TC06.02 - Presentation 02 E. Meinl, LMU/Martinsried/DE TC06.03 - Presentation 03 D. Sato, Pontifical Catholic U. of Rio Grande do Sul (PUCRS)/Porto Alegre/BR

TC07 - Cognitive dysfunction in MS: from MRI to treatment (IMSCOGS) Moderation: I.-K. Penner1, R. Benedict2, B. Brochet3, 1Cogito Center for Applied Neurocognition and Neuropsychological Research/Düsseldorf/DE, 2University At Buffalo/Buffalo/US, 3University of Bordeaux/Bordeaux/FR TC07.01 - Assessment and Monitoring of Cognitive Function in MS R. Benedict, University At Buffalo/Buffalo/US

TC07.02 - MRI Predictors of Cognitive Impairment B. Brochet, University of Bordeaux/Bordeaux/FR

TC07.03 - Treatment of Cognitive Deficits in MS Patients I.-K. Penner, Cogito Center for Applied Neurocognition and Neuropsychological Research/Düsseldorf/DE

TC08 - Immunologic principles in MS and related disorders Moderation: R. Hohlfeld1, R. Liblau2, S. Dhib-Jalbut3, 1Ludwig Maximilians University of Munich (LMU)/Munich/DE, 2University of Toulouse/France/FR, 3Rutgers University/New Brunswick/US TC08.01 - Presentation 01

R. Liblau, University of Toulouse/France/FR TC08.02 - Presentation 02

S. Dhib-Jalbut, Rutgers University/New Brunswick/US TC08.03 - What twin studies can tell us about the triggers of neuroinflammation: An introduction into the neuroimmunology of MS

R. Hohlfeld, Ludwig Maximilians University of Munich (LMU)/Munich/DE TC09 - Pathology of MS Moderation: C. Stadelmann1, C. Lucchinetti2, H. Lassmann3, 1University Medical Center, Göttingen//DE, 2Mayo Clinic/Minnesota/US, 3Medical University of Vienna/Vienna/AT TC09.01 - Pathology of early MS and its relation to NMOSD and MOGAD

C. Lucchinetti, Mayo Clinic/Minnesota/US TC09.02 - What is the pathological substrate of progressive MS

H. Lassmann, Medical University of Vienna/Vienna/AT TC09.03 - Demyelination and myelin repair in MS C. Stadelmann, University Medical Center, Göttingen//DE TC10 - Infections and MS: long-term immune suppression, benefits and risks of immunizations Moderation: C. Power1, J. Berger2, T. Derfuss3, 1//CA, 2University of Pennsylvania/Philadelphia/US, 3University Hospital Basel/Basel/CH TC10.01 - Presentation 01

J. Berger, University of Pennsylvania/Philadelphia/US TC10.02 - Presentation 02

T. Derfuss, University of Basel//CH TC10.03 - Presentation 03

C. Power, //CA TC11 - Diagnosis and management of CNS inflammatory diseases mimicking MS Moderation: J. De Seze1, E. Flanagan2, N. Evangelou3, 1CHU de Strasbourg/Strasbourg/FR, 2Mayo Clinic/United States/US, 3University of Nottingham/Nottingham/GB TC11.01 - Presentation 01

E. Flanagan, Mayo Clinic/United States/US TC11.02 - Presentation 02

N. Evangelou, University of Nottingham/Nottingham/GB TC11.03 - Presentation 03

J. De Seze, CHU de Strasbourg/Strasbourg/FR TC12 - Progressive MS: clinical phenotypes, imaging, treatment Moderation: J. Graves1, F. Lublin2, A. Thompson3, 1University of California, San Diego/San Diego/US, 2Icahn School of Medicine at Mount Sinai/New York/US, 3UCL Institute of Neurology, Queen Square MS Centre//GB TC12.01 - Presentation 01

F. Lublin, Mount Sinai School of Medicine/United States/US TC12.02 - Treatment of Progressive MS

A. Thompson , UCL Institute of Neurology, Queen Square MS Centre//GB TC12.03 - Presentation 03

J. Graves, University of California, San Diego/San Diego/US TC13 - Spinal cord involvement in MS: imaging and impact on clinical course Moderation: K. Parmar1, A. Traboulsee2, G. Wu3, 1University Hospital Basel/Basel/CH, 2University of British Columbia/Vancouver/CA, 3Washington University in St. Louis/United States/US TC13.01 - Presentation 01

A. Traboulsee, The University of British Columbia/Canada/CA TC13.02 - Presentation 02 G. Wu, Washington University in St. Louis/United States/US

TC13.03 - Presentation 03

K. Parmar, University Hospital Basel/Basel/CH TC14 - Interpretation of the statistical results of MS studies Moderation: E. Martinez-Lapiscina1, M.P. Sormani2, B. Healy3, 1/Barcelona/ES, 2University of Genova/Genova/IT, 3Brigham and Women’s Hospital/Boston/US TC14.01 - Presentation 01

M.P. Sormani, University of Genoa/Genoa/IT TC14.02 - Presentation 02

B. Healy, Harvard Medical School/United States/US TC14.03 - Propensity Score: Neither a Black Box nor a Magic Bullet

E. Martinez-Lapiscina, /Barcelona/ES TC15 - When does multiple sclerosis begin? MS prodrome and RIS Moderation: C. Lebrun Frenay1, G. Giovannoni2, D. Okuda3, 1CRCSEP nice Pasteur2/Nice/FR, 2QMUL/London/GB, 3UT Southwestern Medical Center//US TC15.01 - Presentation 01

G. Giovannoni, The London School of Medicine and Dentistry/London/GB TC15.02 - Presentation 02

D. Okuda, UT Southwestern Medical Center//US TC15.03 - Presentation 03

C. Lebrun Frenay, CRCSEP nice Pasteur2/Nice/FR TC16 - Role of sex / gendered factors in MS: focus on sex hormones Moderation: N. Collongues1, S. Dunn2, J. Correale3, 1University Hospital of Strasbourg/Strasbourg/FR, 2University of Toronto, Keenan Research Centre for Biomedical Science/Toronto/CA, 3Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR TC16.01 - Presentation 01

S. Dunn, University of Toronto, Keenan Research Centre for Biomedical Science/Toronto/CA TC16.02 - Presentation 02

J. Correale, Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR TC16.03 - Presentation 03

N. Collongues, University Hospital of Strasbourg/Strasbourg/FR TC17 - MS clinical manifestations, diagnostic and treatment considerations Moderation: H.J. Kim1, D. Ontaneda2, J. Becker3, 1Research Institute & Hospital of National Cancer Center/Goyang/KR, 2Cleveland Clinic/Cleveland/US, 3Pontifícia Universidade Católica do Rio Grande do Sul/Porto Alegre/BR TC17.01 - MS Clinical Manifestations, Diagnostic and Treatment Considerations - In the US/Hispanics

D. Ontaneda, Cleveland Clinic//US TC17.02 - MS Clinical Manifestations, Diagnostic and Treatment Considerations - In Latin America

J. Becker, Pontifical Catholic University of Rio Grande do Sul/Brazil/BR TC17.03 - MS Clinical Manifestations, Diagnostic and Treatment Considerations - In Asia H.J. Kim, Research Institute and Hospital, National Cancer Center/Goyang/KR

TC18 - Mechanisms of action of current immune therapies Moderation: A. Uccelli1, A. Bar-Or2, H. Wiendl3, 1University of Genoa/Italy/IT, 2Center for Neuroinflammation and Experimental Therapeutics, Perelman School of Medicine, University of Pennsylvania/Philadelphia/US, 3University of Münster/Münster/DE TC18.01 - Immunotherapy to concepts: from very specific targets to immune regulatory network modulation

H. Wiendl, University of Münster/Germany/DE TC18.02 - Presentation 02

A. Bar-Or, University of Pennsylvania/Philadelphia/US TC18.03 - Presentation 03

A. Uccelli, University of Genoa/Italy/IT TC19 - Career paths in MS: clinical practice, clinical research, basic research Moderation: E. Mowry1, P. Matthews2, H.P. Hartung3, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Imperial College/London/GB, 3/Dusseldorf/DE TC19.02 - Presentation 02

P. Matthews, Imperial College/London/GB TC19.03 - Presentation 03

E. Mowry, Johns Hopkins University/Baltimore/US TC20 - Frontiers in research: use of big data in molecular genetics and molecular biology in MS Moderation: P. De Jager1, B. Hemmer2, 1Columbia University/New York City/US, 2University of Munich/Munich/DE TC20.01 - Presentation 01

P. De Jager, Columbia University Medical Center/United States/US TC20.02 - Presentation 02

B. Hemmer, University of Munich/Munich/DE TC20.03 - Presentation 03 TC21 - Remyelination and neuroprotection Moderation: J. Chataway1, P. Calabresi2, C. Lubetzki3, 1UCL Queen Square Institute of Neurology, University College//GB, 2Johns Hopkins University/Baltimore/US, 3Hôpital Pitié-Salpêtrière/Paris/FR TC21.01 - Presentation 01

P. Calabresi, Johns Hopkins University/Baltimore/US TC21.02 - Presentation 02

C. Lubetzki, Hôpital Pitié-Salpêtrière/Paris/FR TC21.03 - Remyelination and Neuroprotection in MS: Designing Trials

J. Chataway, UCL Queen Square Institute of Neurology, University College//GB TC22 - Maintenance of function in MS: rehabilitation, co-morbidity, symptom management Moderation: C. Riley, V. Matthews1, J. Freeman2, 1//GB, 2University of Plymouth/Plymouth/GB TC22.01 - Maintenance of Function in MS: Rehabilitation, Co-Morbidity, Symptom Management

J. Freeman, University of Plymouth/Plymouth/GB TC22.02 - Presentation 02

C. Riley TC22.03 - Presentation 03

V. Matthews, //GB TC23 - International 2020 MAGNIMS-CMSC-NAIMS consensus guidelines on the use of MRI in multiple sclerosis (MAGNIMS and NAIMS) Moderation: A. Rovira1, M. Wattjes2, J. Oh3, D. Li4, C. Enzinger5, 1Vall d'Hebron University Hospital/Barcelona/ES, 2Hannover Medical School/Hannover/DE, 3University of Toronto/Toronto/CA, 4//CA, 5Medical University of Graz/Graz/AT TC23.01 - Presentation 01

M. Wattjes, Hannover Medical School/Hannover/DE TC23.02 - Presentation 02

J. Oh, University of Toronto/Toronto/CA TC23.03 - Presentation 03 A. Rovira, Vall d'Hebron University Hospital/Barcelona/ES

On-Demand ePosters P0001 - A new software and analysis suite for experimental autoimmune encephalomyelitis

C. Maguire1, B. Caslin2, S. Bazzi3, E. Melamed2, D. Wylie1, 1The University of Texas at Austin/Austin/US, 2University of Texas at Austin/Austin/US, 3/Austin/US

P0002 - Applying machine learning to multimodal neuroimaging data to predict visual episodic memory performance in multiple sclerosis

K. Buyukturkoglu1, Y. Li2, C. Tozlu2, A. Kuceyeski2, J. Sumowski3, V. Leavitt1, 1Columbia University Irving Medical Center/New York/US, 2Weill Cornell Medicine/New York/US, 3Icahn School of Medicine at Mount Sinai/New York City/US

P0003 - Combinatorial Genetic Interaction Analysis of Multiple Sclerosis Risk Variants

C. Sept1, F. Briggs2, 1/Chapel Hill/US, 2Case Western Reserve University, School of Medicine/Cleveland/US

P0004 - Convolutional neural network framework for predicting progression in early MS V. Fleischer1, D. Ciolac1, A. Radetz1, G. Gonzalez-Escamilla1, J. Kroth1, J. Krämer2, S. Meuth3, S. Groppa1, M. Muthuraman1, 1University Medical Center of the Johannes Gutenberg University Mainz/Mainz/DE, 2University Hospital Münster/Münster/DE, 3University Clinic Munster/Munster/DE

P0005 - Decoding the EDSS Scores of Multiple Sclerosis Patients from MRI Biomarkers

R. Paolella1, E. De La Rosa1, V. Anania1, S. Denissen2, J. Van Schependom3, G. Nagels3, D. Dive4, F. Durand-Dubief5, D. Sappey-Marinier6, D. Smeets7, D. Sima7, 1icometrix/Leuven/BE, 2Vrije Universiteit Brussel VUB/Ixellles/BE, 3Vrije Universiteit Brussel/Elsene/BE, 4University Hospital of Liège/Esneux/BE, 5CHU Lyon/Lyon/FR, 6Université de Lyon/Lyon/FR, 7Icometrix, Research and Development/Leuven/BE

P0006 - Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning

A. Krishnan1, Z. Song2, D. Clayton1, L. Gaetano3, A. De Crespigny1, T. Bengtsson1, R. Carano1, 1Genentech/South San Francisco/US, 2Genentech, Inc./SOUTH SAN FRANCISCO/US, 3F. Hoffmann-La Roche Ltd/Basel/CH

P0007 - Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning

A. Krishnan1, Z. Song2, D. Clayton1, L. Gaetano3, A. De Crespigny1, T. Bengtsson1, R. Carano1, 1Genentech/South San Francisco/US, 2Genentech, Inc./SOUTH SAN FRANCISCO/US, 3F. Hoffmann-La Roche Ltd/Basel/CH

P0008 - Divergent patterns of ventral attention network centrality relate to cognitive conversion in MS

M. Huiskamp1, A. Eijlers2, T. Broeders2, I. Dekker2, B. Uitdehaag3, F. Barkhof3, A.M. Wink3, J. Geurts2, H. Hulst4, M. Schoonheim2, 1Amsterdam UMC, location VUmc/No/NL, 2Amsterdam UMC, location VUmc/Amsterdam/NL, 3Amsterdam UMC, Location VUmc/Amsterdam/NL, 4Amsterdam UMC, VUmc/Amsterdam/NL

P0009 - ENTIMOS: a discrete event simulation model for maximizing efficiency of infusion suites in centres treating multiple sclerosis patients

R. Nicholas1, P. Dobay2, K. Lacinova3, R. Brennan4, M. Ziehn5, C. Lines5, N. Adlard5, 1Imperial College London/London/GB, 2IQVIA AG/Basel/CH, 3SIMUL8 Corporation Ltd./Glasgow/GB, 4Novartis Global Services Center/Dublin/IE, 5Novartis Pharma AG/Basel/CH

P0010 - Integration of the Extreme Gradient Boosting model with clinical data to enable the early diagnosis of multiple sclerosis

W. Qiu1, R. Wang2, W. Luo3, Z. Liu3, W. Liu4, C. Liu3, X. Liu5, H. Zhu6, R. Li3, J. Song6, X. Hu3, S. Han6, 1/Tianhe District, Guangzhou City/CN, 2Peking University Health Science Center/Beijing/CN, 3The Third Affiliated Hospital of Sun Yat-Sen University/Tianhe District, Guangzhou City/CN, 4Chengdu Medlinker Science and Technology Co., Ltd./Beijing/CN, 5The Third Affiliated Hospital of Sun Yat-Sen University/Guangzhou City/CN, 6International Research Center for Medicinal Administration, Peking University/Beijing/CN

P0011 - Lesion disconnectomics using atlas-based tractography

V. Ravano1, M. Andelova2, M.J. Fartaria1, M. Mahdi1, B. Maréchal1, R. Meuli3, T. Uher2, J. Krasensky4, M. Vaneckova4, D. Horakova4, T. Kober1, J. Richiardi3, 1Siemens Healthcare AG/Lausanne/CH, 2First Faculty of Medicine, Charles University and General University/Prague/CZ, 3Lausanne University Hospital and University of Lausanne/Lausanne/CH, 4First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ

P0012 - Machine-learning optimized Combinatorial MRI scale (COMRISv2) correlates highly with MS disability

E. Kelly1, M. Varosanec2, A. Wichman2, M. Sandford2, P. Kosa2, B. Bielekova2, 1National Insitutes of Health/Bethesda/US, 2National Institutes of Health/Bethesda/US

P0013 - Modeling a long-term virtual placebo arm for SPMS population in the EXPAND study: Comparing different statistical methods

N. Rouyrre1, B.A.C. Cree2, R. Fox3, P. Vermersch4, G. Giovannoni5, A. Bar-Or6, R. Gold7, D. Piani- Meier1, G. Karlsson1, L. Kappos8, 1Novartis Pharma AG/Basel/CH, 2UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco/San Francisco/US, 3Cleveland Clinic//US, 4CHU de Lille/Lille/FR, 5The London School of Medicine and Dentistry/London/GB, 6University of Pennsylvania/Philadelphia/US, 7St. Josef-Hospital, Ruhr University Bochum/Bochum/DE, 8Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel/Basel/CH

P0014 - Personalized and dynamic prognostic model from the Barcelona CIS cohot

M. Tintore1, P. Carbonell-Mirabent2, S. Otero-Romero3, A. Cobo Calvo4, G. Arrambide5, J. Río6, C. Tur7, M. Comabella8, C. Nos9, M.J. Arévalo-Navinés9, L. Midaglia10, Í. Galán9, A. Vidal-Jordana11, J. Castilló12, B. Rodríguez-Acevedo9, A. Zabalza2, M. Rodríguez9, A. Sao-Avilés9, A. Barros5, C. Auger5, J. Sastre-Garriga5, A. Rovira3, X. Montalban9, 1Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 2Vall d’Hebron Institut de Recerca/Barcelona/ES, 3Vall d'Hebron University Hospital/Barcelona/ES, 4Centre d’Esclerosi Múltiple de Catalunya (Cemcat)/Barcelona/ES, 5Vall Hebron University Hospital/Barcelona/ES, 6CEMCAT, Hospital Universitario Vall d’Hebrón/Barcelona/ES, 7UCL Queen Square Institute of Neurology, Faculty of Brain Sciences/London/GB, 8Universitat Autònoma//ES, 9Dept. of Neurology-Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 10Dept. of Neurology-Neuroimmunology; Vall Hebron University Hospital; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 11Hospital Universitari Vall d’Hebron/Barcelona/ES, 12Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES

P0015 - Predicted brain age as a cognitive biomarker in Multiple Sclerosis

S. Denissen1, A. De Cock1, L. Costers1, J. Baijot1, J. Laton1, M. D’Hooghe2, M. D'Haeseleer3, D. Dive4, J. De Mey5, J. Van Schependom1, D. Sima6, G. Nagels1, 1Vrije Universiteit Brussel/Elsene/BE, 2National MS Center Melsbroek/Melsbroek/BE, 3Vrije Universiteit Brussel/Jette/BE, 4University Hospital of Liège/Esneux/BE, 5UZ Brussel/Brussels/BE, 6Icometrix, Research and Development/Leuven/BE

P0016 - Progressive multifocal leukoencephalopathy lesion and brain parenchymal segmentation from MRI using serial deep convolutional neural networks

O. Al-Louzi1, S. Roy2, I. Osuorah1, P. Parvathaneni1, B. Smith1, J. Ohayon1, P. Sati3, D. Pham4, S. Jacobson1, A. Nath1, D. Reich5, I. Cortese1, 1National Institute of Neurological Disorders and Stroke/Bethesda/US, 2National Institute of Mental Health/Bethesda/US, 3Cedars-Sinai Medical Center/Los Angeles/US, 4The Henry M. Jackson Foundation for the Advancement of Military Medicine/Bethesda/US, 5NINDS, NIH/Bethesda/US

P0017 - Translating MPRAGE to MP2RAGE improves the automatic tissue and lesion segmentation in Multiple Sclerosis patients

F. La Rosa1, T. Yu1, G. Barquero2, J.-P. Thiran3, C. Granziera4, M. Bach Cuadra5, 1École Polytechnique Fédérale de Lausanne/Lausanne/CH, 2Lausanne University and University Hospital/Lausanne/CH, 3École Polytechnique Fédérale de Lausanne/Lausanne/CH, 4University Hospital Basel and University of Basel/Basel/CH, 5Lausanne University Hospital and University of Lausanne/Lausanne/CH

P0018 - Variability of the response to immunotherapy among sub-groups of patients with multiple sclerosis

I. Diouf1, C. Malpas2, D. Horakova3, E. Kubala Havrdová4, F. Patti5, V. Shaygannejad6, S. Ozakbas7, G. Izquierdo8, S. Eichau8, M. Zakaria9, M. Onofrj10, A. Lugaresi11, R. Alroughani12, A. Prat13, M. Girard13, P. Duquette13, M. Terzi14, C. Boz15, F. Grand'Maison16, S. Hamdy17, P. Sola18, D. Ferraro19, P. Grammond20, R. Turkoglu21, H. Butzkueven22, B. Yamout23, A. Altintas24, V. Van Pesch25, D. Maimone26, J. Lechner-Scott27, R. Bergamaschi28, R. Karabudak29, F. Giuliano30, C. Mcguigan31, E. Cartechini32, M. Barnett33, S. Hughes34, M. Sa35, L. Kappos36, C. Ramo-Tello37, E. Cristiano38, S. Hodgkinson39, D. Spitaleri40, A. Soysal41, T. Petersen42, M. Slee43, E. Butler44, F. Granella45, F. Verheul46, P. Mccombe47, R. Ampapa48, O. Skibina49, J. Prevost50, L.G.F. Sinnige51, J.L. Sánchez-Menoyo52, S. Vucic53, G. Laureys54, L. Van Hijfte54, D. Khurana55, R. Macdonell56, T. Castillo-Trivino57, O. Gray58, E. Agüera59, I. Kister60, C. Shaw61, N. Deri62, T. Al-Harbi63, Y. Fragoso64, T. Csepany65, A. Sempere66, T. Kalincik67, 1University of Melbourne/Melbourne/AU, 2Royal Melbourne Hospital/Melbourne/AU, 3First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 4Charles University//CZ, 5Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 6Isfahan neuroscience research center/Isfahan/IR, 7Dokuz Eylul University/Izmir/TR, 8Hospital Universitario Virgen Macarena/Sevilla/ES, 9Ain Shams University Hospital/Cairo/EG, 10University G. d’Annunzio/Chieti/IT, 11IRCCS Istituto delle Scienze Neurologiche di Bologna/Bologna/IT, 12Amiri Hospital/Kuweit/KW, 13University of Montreal/Montreal/CA, 14Ondokuz Mayıs University/Sasun/TR, 15KTU Medical Faculty Farabi Hospital/Trabzon/TR, 16Neuro Rive- Sud/Quebec/CA, 17Kasr Al Ainy MS research Unit (KAMSU),/Cairo/EG, 18Azienda Ospedaliero- Universitaria di Modena Ospedale Civile di Baggiovara/Modena/IT, 19University of Modena and Reggio Emilia/Modena/IT, 20CISSS Chaudière-Appalache/Levis/CA, 21Haydarpasa Numune Training and Research Hospital/Istanbul/TR, 22Monash University/Melbourne/AU, 23American University of Beirut/Beirut/LB, 24Koc University/Istambul/TR, 25Université Catholique de Louvain/Brussels/BE, 26Garibaldi Hospital/Catania/IT, 27Department of Neurology, John Hunter Hospital, Hunter New England Health/Newcastle/AU, 28IRCCS Mondino Foundation/Pavia/IT, 29Hacettepe University Faculty of Medicine/Ankara/TR, 30University of Campania “Luigi Vanvitelli”/Naples/IT, 31St. Vincent’s University Hospital/Dublin/IE, 32UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3/Macerata/IT, 333. Brain and Mind Research Institute, University of Sydney/Sydney/AU, 34Royal Victoria Hospital/Belfast/GB, 35Hospital de Sao Joao/Porto/PT, 36University of Basel//CH, 37Hospital Germans Trias i Pujol/Badalona/ES, 38Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 39Ingham Institute for Applied Medical Research, University of New South Wales Medicine/Sydney/AU, 40Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino/Avellino/IT, 41Bakırköy Prof. Dr. Mazhar Osman Education and Research Hospital for Psychiatry and Neurological Diseases/Istanbul/TR, 42Aarhus University Hospital/Arhus C/DK, 43Flinders University/Adelaide/AU, 44Monash Medical Centre/Melbourne/AU, 45University of Parma/Parma/IT, 46Groene Hart Ziekenhuis/Gouda/NL, 47University of Queensland/Brisbane/AU, 48Nemocnice Jihlava/Jihlava/CZ, 49The Alfred Hospital/Melbourne/AU, 50CSSS Saint-Jérôme/Saint-Jerome/CA, 51Medical Center Leeuwarden/Leeuwarden/NL, 52Hospital de Galdakao- Usansolo/Galdakao/ES, 53Westmead Hospital/Sydney/AU, 54UZ Gent/Gent/BE, 55PGIMER/Chandigarh/IN, 56Austin Health. University of Melbourne/Melbourne/AU, 57Hospital Universitario Donostia/San Sebastián/ES, 58South East Trust/Belfast/GB, 59Hospital Universitario Reina Sofía/Córdoba/ES, 60New York University/New York City/US, 61Geelong Hospital/Geelong/AU, 62Centro de Investigaciones DIABAID/Buenos Aires/AR, 63King Fahad Specialist Hospital-Dammam/Khobar/SA, 6462Universidade Metropolitana de Santos/Santos/BR, 65University of Debrecen/Debrecen/HU, 66Hospital General Universitario de Alicante/Alicante/ES, 67Royal Melbourne Hospital, University of Melbourne/Melbourne/AU

P0019 - A Comparison of Digital Gait Technologies in a Population of People with MS –When the Same Isn’t Always Exactly the Same

O. Kaczmarek1, J. Srinivasan2, C. Burke2, A. Khokhar3, M. Zarif4, B. Bumstead2, D. Golan5, M. Buhse1, E. Ofori6, M. Gudesblatt1, 1South Shore Neurologic Associates/Patchogue/US, 2South Shore Neurologic Associates, P.C./Patchogue/US, 3Albert Einstein College of Medicine/Poughkeepsie/US, 4Comprehensive Multiple Sclerosis Care Center/Patchogue/US, 5Carmel Medical Center/haifa/IL, 6Arizona State University/Phoenix/US

P0020 - A down-regulation of the type I interferon signaling pathway is associated with the response to teriflunomide in multiple sclerosis.

S. Malhotra1, J. Río2, J.C. Triviño3, A. Vidal-Jordana4, A. Zabalza5, G. Arrambide6, B. Rodríguez- Acevedo1, Í. Galán1, M. Castillo1, J. Castilló7, L. Midaglia8, J. Sastre-Garriga6, M. Tintore9, X. Montalban1, M. Comabella10, 1Dept. of Neurology-Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 2CEMCAT, Hospital Universitario Vall d’Hebrón/Barcelona/ES, 3Genomic Systems/Valencia/ES, 4Hospital Universitari Vall d’Hebron/Barcelona/ES, 5Vall d’Hebron Institut de Recerca/Barcelona/ES, 6Vall Hebron University Hospital/Barcelona/ES, 7Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 8Dept. of Neurology-Neuroimmunology; Vall Hebron University Hospital; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 9Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 10Universitat Autònoma//ES

P0021 - A propensity-matched comparison of long-term disability progression in MS patients treated with dimethyl fumarate or fingolimod

R. Fox1, S. Lancia2, G. Cutter3, R.-A. Marrie4, J. Mendoza5, J. Lewin5, A. Salter6, 1Cleveland Clinic//US, 2Washington University School in St. Louis/St. Louis/US, 3Mellen Center for Multiple Sclerosis Treatment and Research/Cleveland/US, 4Max Rady College of Medicine/Winnipeg/CA, 5Biogen/Cambridge/US, 6Washington University School in St. Louis/St Louis/US

P0022 - A systematic literature review and meta-analysis of the efficacy and effectiveness of PR- fampridine in patients with multiple sclerosis

T. Haider1, B. Lokke1, L. Tran1, A. Spidalieri2, A. Adeyemi3, C. Acosta2, Ø. Torkildsen4, 1Link Medical Research AS/Oslo/NO, 2Biogen/Baar/CH, 3Biogen/Cambridge/US, 4University of Bergen/Haukeland University Hospital/BERGEN/NO

P0023 - Alemtuzumab Real World Evidence in a Private Practice Setting

C. Laganke1, L. Martin2, J. Bowen1, E. Poole2, N. Greene2, R. Robinson2, A. Patel2, J. Chia2, L. Hashemi2, 1North Central Neurology Assoc./Cullman/US, 2Sanofi Genzyme/Cambridge/US

P0024 - Alemtuzumab slowed brain atrophy over 6 years in patients without relapse and MRI disease activity: post hoc analysis of the pooled CARE-MS studies

D.L. Arnold1, M.P. Amato2, M. Barnett3, D. Barone4, D. Brandes5, M. Carraro6, G. Comi7, S. Eichau8, A. Mazhari9, K. Nakamura10, D. Pelletier11, A. Rovira12, M. Tintore13, A. Traboulsee14, Z. Choudhry15, N. Daizadeh15, E. Poole15, H. Wiendl16, 1MNI, McGill/Quebec/CA, 2University of Florence/Florence/IT, 33. Brain and Mind Research Institute, University of Sydney/Sydney/AU, 4Cooper Medical School of Rowan University/Camden/US, 5Hope MS Center/knoxville/US, 6Novant Health/Charlotte/US, 7San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 8Hospital Universitario Virgen Macarena/Seville/ES, 9Dent Neurologic Institute/Buffalo/US, 10Cleveland Clinic Foundation/Cleveland/US, 11USC/Los Angeles/US, 12Vall d'Hebron University Hospital/Barcelona/ES, 13Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 14The University of British Columbia/Canada/CA, 15Sanofi/Cambridge/US, 16University of Münster/Germany/DE

P0025 - Analysis fo the results of the establishment of a SARS-CoV-2 safety protocol for Multiple Sclerosis patients V. Meca-Lallana1, C. Aguirre1, C. Díaz1, L. Cardeñoso2, A. Figuerola-Tejerina1, M. Ruiz1, J. Vivancos1, 1La Princesa Hospital/Madrid/ES, 2La Princesa Hosptal/Madrid/ES

P0026 - Analysis of association between expanded disability status scale and patient determined disease steps

C. Makin1, A. Altincatal2, M. Gudesblatt3, B. Kieseier1, C. De Moor1, 1Biogen/Cambridge/US, 2Biogen/Boston/US, 3South Shore Neurologic Associates/Islip/US

P0027 - Are we ready for precision medicine in Multiple Sclerosis? A web-based survey across Europe

F. Martinelli Boneschi1, S. D'Alfonso2, A. Caserini3, B. Hemmer4, E. Celius5, P. Villoslada6, A. Goris7, S. Kalra8, P. Tienari9, F. Piehl10, I. Kockum11, 1University of Milan /Milan/IT, 2Università del Piemonte Orientale/Novara/IT, 3University of Milano-Bicocca/milan/IT, 4University of Munich/Munich/DE, 5Departement of Neurology, Oslo University Hospital, Oslo Norway/Oslo/NO, 6Hospital Clinic Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona/Barcelona/ES, 7KU Leuven/Leuven/BE, 8Royal Stoke MS Centre of Excellence University Hospital/North Midlands NHS Trust/GB, 9Helsinki University Hospital/Helsinki/FI, 10Karolinska Institute/Stockholm/SE, 11Department of Clinical Neuroscience, Karolinska Institutet/Stockholm/SE

P0028 - Assessing the temporal relationship of serum neurofilament light and subclinical disease activity: Findings from APLIOS trial

A. Bar-Or1, X. Montalban2, R. Willi3, H. Kropshofer3, P. Kukkaro3, I. Ludwig3, M. Zalesak3, K. Ramanathan3, D.A. Häring3, X. Hu4, N. Coello3, M. Bagger3, E. Fox5, 1University of Pennsylvania/Philadelphia/US, 2Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron/Barcelona/ES, 3Novartis Pharma AG/Basel/CH, 4Novartis Pharmaceuticals Corporation/NJ/US, 5Central Texas Neurology Consultants and Dell Medical School, The University of Texas at Austin, Round Rock/Austin/US

P0029 - Assessment of Multiple Sclerosis Severity Score and Age-Related Multiple Sclerosis Severity Score as health indicators in a population-based cohort

L. Bau1, E. Matas1, L. Romero-Pinel2, I. León3, S. Martínez-Yélamos3, A. Martínez-Yélamos3, 1Hospital Universitari de Bellvitge/L'Hospitalet de Llobregat/ES, 2Hospital Universitari de Bellvitge/Barcelona/ES, 3Hospital Universitari de Bellvitge-IDIBELL/L'Hospitalet de Llobregat/ES

P0030 - Association of average blood cell telomere length with the clinical course of MS over a 10- year period

M. Hecker, B. Fitzner, K. Jäger, J. Bühring, M. Schwartz, M. Walter, U. Zettl, Rostock University Medical Center/Rostock/DE

P0031 - Asymptomatic anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes

M. Pisa1, T. Croese2, G. Dalla Costa3, S. Guerrieri4, S.-C. Huang4, L. Fabbella2, A. Finardi2, B. Colombo5, F. Sangalli5, L. Moiola5, V. Martinelli5, G. Comi6, R. Furlan7, L. Leocani1, 1Vita-Salute San Raffaele University/Milan/IT, 2Clinical Neuroimmunology Unit, Institute of Experimental Neurology (INSPE), Division of Neuroscience, San Raffaele Scientific Institute/Milan/IT, 3San Raffaele Hospital/Milan/IT, 4San Raffaele Hospital - Vita-Salute San Raffaele University/Milan/IT, 5IRCCS San Raffaele Scientific Institute/Milan/IT, 6San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 7San Raffaele Sicentific Institute/Milan/IT

P0032 - Baseline serum Neurofilament light chain levels predict conversion to McDonald 2005 MS within 2 yrs of a first clinical demyelinating event in REFLEX

J. Kuhle1, D. Leppert2, G. Comi3, N. De Stefano4, L. Kappos2, M. Freedman5, D. Issard6, S. Roy7, 1University of Basel/Switzerland/CH, 2University Hospital Basel and University of Basel/Basel/CH, 3San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 4University of Siena/Siena/IT, 5The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 6Cytel Inc/Geneza/CH, 7Merck/Aubonne/CH

P0033 - Baseline serum neurofilament light levels have prognostic value for on-study MRI activity: Results from ASCLEPIOS trials

J. Kuhle1, L. Kappos2, A.H. Cross3, R. Willi4, B. Li5, P. Kukkaro4, H. Kropshofer4, D.A. Häring4, K. Ramanathan4, M. Merschhemke4, S. Hauser6, 1University of Basel/Switzerland/CH, 2University Hospital and University of Basel/Basel/CH, 3Department of Neurology, Division of Neuroimmunology, Washington University School of Medicine/Saint Louis/US, 4Novartis Pharma AG/Basel/CH, 5Novartis Pharmaceuticals Corporation/East Hanover/US, 6University of California San Francisco/San Francisco/US

P0034 - Can Digital Biomarkers Acquired on a Smarphone Distinguish Healthy Controls from Radiologically Isolated Syndrome Subjects?

M. Cohen1, S. Fakir1, L. Mondot2, C. Landes1, C. Lebrun-Frenay3, 1CHU de Nice - Hopital Pasteur 2/Nice/FR, 2CHU de Nice/Nice/FR, 3Centre Hospitalier University de Nice/Nice/FR

P0035 - Can gait modelling predict disease progression in MS? A study using small body worn sensors in a clincial setting.

D. Paling1, L. Angelini2, E. Buckley2, T. Bonci2, A. Radford1, B. Sharrack3, S. Nair1, C. Mazza2, 1Royal Hallamshire Hospital/Sheffield/GB, 2University of Sheffield/JD/GB, 3Sheffield Teaching Hospitals NHS Foundation Trust/Sheffield/GB

P0036 - Cerebral hypometabolism is a marker of disease severity in multiple sclerosis: a non-invasive imaging study using T2-Relaxation-Under-Spin-Tagging MRI O. Murphy1, Z. Lin1, G. Kalaitzidis1, E. Vasileiou1, A. Filippatou1, K. Fitzgerald1, H. Ehrhardt1, J. Lambe1, E. Sotirchos2, B. Dewey2, Y. Liu2, J. Prince2, P. Calabresi2, H. Lu1, S. Saidha1, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Johns Hopkins University/Baltimore/US

P0037 - Change in serum neurofilament light chain levels: ENSEMBLE 1-year interim results

R. Bermel1, T. Berger2, B. Brochet3, M. Freedman4, T. Holmøy5, J. Killestein6, F. Patti7, A. Perrin Ross8, T. Vollmer9, J. Beltra10, R. Buffels10, T. Kuenzel11, H.P. Hartung12, 1Mellen Center for Multiple Sclerosis, Cleveland Clinic/Cleveland/US, 2Medical University of Vienna/Vienna/AT, 3University of Bordeaux/Bordeaux/FR, 4The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 5Akerhus University Hospital/Nordbyhagen/NO, 6Amsterdam UMC, Location VUmc/Amsterdam/NL, 7University of Catania/Catania/IT, 8Loyola University Chicago/Oak Brook/US, 9University of Colorado School of Medicine/Aurora/US, 10F. Hoffmann-La Roche Ltd/Basel/CH, 11F Hoffmann-La Roche Ltd/Basel/CH, 12/Dusseldorf/DE

P0038 - CHIT1 at Diagnosis Reflects Long-Term Multiple Sclerosis Disease Activity

E. Oldoni, I. Smets, K. Mallants, M. Vandebergh, L. Van Horebeek, K. Poesen, P. Dupont, B. Dubois, A. Goris, KU Leuven/Leuven/BE

P0039 - Circulating microRNAs as potential inflammatory biomarkers of acute exacerbation in relapsing-remitting multiple sclerosis

T. Koudriavtseva1, A. Stefanile1, S. Donzelli1, G. Blandino1, A. Sacconi1, L. Conti1, S. Lorenzano2, S. Zannino1, F. Pimpinelli3, G. D'Agosto4, E.G. Di Domenico4, M. Maschio1, M. Salvetti2, M. Inglese5, 1IRCCS REGINA ELENA NATIONAL CANCER INSTITUTE/ROMA/IT, 2Sapienza University of Rome/Rome/IT, 3IRCCS San Gallicano Institute/ROMA/IT, 4IRCCS San Gallicano Dermatological Institute/ROMA/IT, 5Mount Sinai Hospital/New York/US

P0040 - Cladribine tablets versus other DMT in achieving disability improvement in relapsing remitting multiple sclerosis patients – network meta-analysis

K. Piasecka-Stryczynska1, M. Rolka2, L. Kaczynski2, M. Gorecka2, R. Wojcik2, I. Adamek3, M. Kaczor4, K. Rejdak5, 1University of Medical Science, Poznan, Poland/Poznan/PL, 2Aestimo/Krakow/PL, 3Merck/Warszawa/PL, 4Jagiellonian University Medical College/Krakow/PL, 5Medical University of Lublin/Lublin/PL

P0041 - Clinical characteristics and outcome of late onset Multiple Sclerosis

E. Iacobaeus1, A. Berglund2, K. Mckay3, L. Brundin1, J. Hillert4, 1Karolinska University Hospital and Karolinska Institute/Solna/SE, 2Karolinska Institute/Stockholm/SE, 3Karolinska Institutet/Stockholm/SE, 4Karolinska Institute/Solna/SE

P0042 - Clinical evolution of spasticity in adults with multiple sclerosis: systematic review T. Jones-Hughes1, C. Vila Silván2, J. Campbell1, D. Ortin Sulbaran2, R. Stork3, L. Crathorne1, 1ROBOLEO & CO/Southampton/GB, 2Almirall S.A./Barcelona/ES, 3Almirall S.A./Uxbridge/GB

P0043 - Clinical practice experience with Cladribine in Multiple Sclerosis

V. Meca-Lallana1, C. Aguirre1, J. Torres2, C. Díaz1, B. Del Río1, R. Martín1, J. Vivancos1, 1La Princesa Hospital/Madrid/ES, 2Universidad Autonoma de Madrid/Madrid/ES

P0044 - CogEval in the Real World: Feasibility, Implementation, and Real World Implications

J. Kramer, /Nashville/US

P0045 - Comorbidities present before the MS diagnosis are not predictors for progression

M. De Caneda, C. Batista, M.C. De Vecino, MOINHOS DE VENTO HOSPITAL/Porto Alegre/BR

P0046 - Comparative Effectiveness of Ozanimod Versus Dimethyl Fumarate: Results of a Matching- Adjusted Indirect Comparison

S. Cohan1, J. Kumar2, S. Arndorfer3, X. Zhu4, M. Zivkovic3, T. Tencer2, 1Providence MS Center/Portland/US, 2Bristol Myers Squibb/Princeton/US, 3Genesis Research/Hoboken/US, 4Genesis Reseach/Hoboken/US

P0047 - Comparative Efficacy and Safety of Ozanimod Versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: a Matching-Adjusted Indirect Comparison

S. Cohan1, J. Kumar2, S. Arndorfer3, X. Zhu4, M. Zivkovic3, T. Tencer2, 1Providence MS Center/Portland/US, 2Bristol Myers Squibb/Princeton/US, 3Genesis Research/Hoboken/US, 4Genesis Reseach/Hoboken/US

P0048 - Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Longitudinal Model-Based Meta-Analysis for Confirmed Disability Accumulation

M. Zierhut1, H. Kracker2, T. Scherz2, A. Keenan3, B. Hennessy2, 1Janssen Research & Devlopment, LLC/San Diego/US, 2Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies/Allschwil/CH, 3Janssen Research & Development, LLC/19477/US

P0049 - Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Model-Based Meta- Analysis for Annual Relapse Rate

M. Zierhut1, H. Kracker2, T. Scherz2, A. Keenan3, B. Hennessy2, 1Janssen Research & Development/San Diego/US, 2Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies/Allschwil/CH, 3Janssen Research & Development, LLC/19477/US

P0050 - Comparative transcriptomics of multiple sclerosis vs. viral infections, including SARS-CoV-2 G. Vavougios1, M. Breza2, T. Mavridis2, S. Zarogiannis1, K. Krogfelt3, E.S. Pelidou4, T. Doskas5, 1University of Thessaly/Larisa/GR, 2Eginition Hospital/Athens/GR, 3Roskilde University/Roskilde/DK, 4University of Ioannina/Ioannina/GR, 5Athens Naval Hospital/Athens/GR

P0051 - Comparison of serum and CSF fluid biomarkers for predicting long term disease progression in MS

S. Thebault1, M. Abdoli1, S.M. Fereshtehnejad1, D. Tessier1, V. Tabard-Cossa1, M. Freedman2, 1University of Ottawa/Ottawa/CA, 2The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA

P0052 - Completion rates by clinicians in global MS studies for the electronic EDSS compared to paper

J. Ly, R. Yamamoto, ERT/Boston/US

P0053 - Correlation Between Spinal Fluid and Blood Levels of Neurofilament Light, GFAP, Tau, and UCHL1: Do We Need a Correction Factor?

E. Alvarez1, A. Ritchie1, K. Nair2, R. Gross1, A. Piquet1, C. Knapp1, S. Selva1, S. Sillau3, J. Bennett4, G. Owens1, T. Vollmer3, 1University of Colorado/Aurora/US, 2Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus/Aurora/US, 3Rocky Mountain MS Center at the University of Colorado Anschutz Medical Campus/Aurora/US, 4University of Colorado School of Medicine/Aurora/US

P0054 - Cost of a relapse-free patient in relapsing-remitting multiple sclerosis, a reliable result-based health indicator.

L. Romero-Pinel1, L. Bau2, E. Matas2, I. León1, R. Juvany2, R. Jódar2, A. Martínez-Yélamos2, S. Martínez- Yélamos2, 1Hospital Universitari de Bellvitge/Barcelona/ES, 2Hospital Universitari de Bellvitge/L'Hospitalet de Llobregat-Barcelona/ES

P0055 - Cross-sectional and longitudinal estimation of radiographic and clinical endpoints to quantify MS disease trajectory with blood serum protein levels.

J. Kuhle1, D. Leppert2, P. Benkert3, J. Oechtering4, A. Orleth2, Ö. Yaldizli4, M. Becich5, V. Gehman5, A. Katrib6, F. Rubio Da Costa5, F. Qureshi7, C. Granziera2, 1University of Basel/Switzerland/CH, 2University Hospital Basel and University of Basel/Basel/CH, 3University Hospital Basel, University of Basel/Basel/CH, 4University Hospital Basel/Basel/CH, 5Octave Bioscience Inc./Menlo Park/US, 6Octave Bioscience/Menlo Park/US, 7Octave Bioscience, Inc./Fremont/US

P0056 - CSF inflammatory profile of primary progressive multiple sclerosis

D. Marastoni, S. Rossi, A. Bolzan, A. Pisani, V. Mazziotti, M. Castellaro, R. Magliozzi, S. Monaco, M. Calabrese, University of Verona/Verona/IT

P0057 - Decline in serum neurofilament is associated with decreased clinical and radiological disease activity over two years of dimethyl fumarate treatment

K. Akgün1, M. Schreiner2, J. Bohn3, K. Fitzgerald4, J. Messer3, E. Mowry5, E. Sotirchos5, P. Calabresi5, B. Kieseier3, T. Ziemssen1, 1Carl Gustav Carus University Hospital/Dresden/DE, 2Center of Clinical Neuroscience, Carl Gustav Carus University Hospital/Dresden/DE, 3Biogen/Cambridge/US, 4Johns Hopkins University School of Medicine/Baltimore/US, 5Johns Hopkins University/Baltimore/US

P0058 - Decrease of peripheral CD19+ IgG+ B-cells with age and immunotherapy in patients with relapsing remitting Multiple sclerosis.

T. Keiner1, A. Hapfelmeier2, B. Hemmer3, 1Klinikum rechts der Isar, Munich/Munich/DE, 2TUM School of Medicine, Technical University of Munich/Munich/DE, 3University of Munich/Munich/DE

P0059 - Defining predictors of disease activity and worsening in multiple sclerosis: an analysis of the CombiRx trial

Y. Zhang1, S. Cofield2, G. Cutter2, S. Krieger1, J. Wolinsky3, F. Lublin4, 1Mount Sinai/New York/US, 2The University of Alabama at Birmingham/Birmingham/US, 3The University of Texas Health Science Center at Houston/Houston/US, 4Mount Sinai School of Medicine/United States/US

P0060 - Descriptive study on recruitment effort for a remote monitoring study in Multiple Sclerosis: RADAR study

A. Zabalza1, A.I. Guerrero2, M. Buron3, G. Dalla Costa4, M.L. La Porta5, M. Martinis3, M. Magyari6, J. Melchert3, L. Rosselli5, C. Nos2, L. Leocani7, P.S. Sorensen3, X. Montalban2, B. Kieseier8, G. Comi9, 1Vall d’Hebron Institut de Recerca/Barcelona/ES, 2Dept. of Neurology-Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 3Rigshospitalet and University of Copenhagen/Copenhagen/DK, 4San Raffaele Hospital/Milan/IT, 5Vita-Salute San Raffaele University/Milano/IT, 6Danish Multiple Sclerosis Center/Glostrup/DK, 7Vita-Salute San Raffaele University/Milan/IT, 8Biogen/Cambridge/US, 9San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT

P0061 - Determining the effect of blood anticoagulants on the detection level of neurobiomarkers in headache and control patients on the SIMOA platform

A. Ritchie1, S. Selva1, G. Owens1, C. Knapp1, J. Parra Gonzalez1, E. Alvarez1, K. Nair2, T. Vollmer3, 1University of Colorado/Aurora/US, 2Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus/Aurora/US, 3Rocky Mountain MS Center at the University of Colorado Anschutz Medical Campus/Aurora/US

P0062 - Developing standard data of cognitive function using Processing Speed Test in Japanese healthy volunteers and comparison to the US normative data M. Niino1, Y. Miyazaki2, M. Kanda3, M. Edwards4, C. De Moor4, A. Altincatal5, J.R. Williams4, B. Kieseier4, S. Rao6, 1National Hospital Organization Hokkaido Medical Center/Sapporo/JP, 2Hokkaido Medical Center/Sapporo/JP, 3Biogen/Tokyo/JP, 4Biogen/Cambridge/US, 5Biogen/Boston/US, 6Schey Center for Cognitive Neuroimaging/Cleveland/US

P0063 - Development of a Custom Multivariate Proteomic Serum Based Assay for Association with Radiographic and Clinical Endpoints in MS

T. Chitnis1, M. Becich2, R. Bove3, B. Cree4, V. Gehman2, R. Gomez4, S. Hauser4, R. Henry4, A. Katrib5, H. Lokhande6, J. Oksenberg4, A. Paul6, F. Qureshi7, A. Santaniello4, N. Sattarnezhad8, S. Saxena6, H. Weiner6, M. Wilson4, H. Yano6, S. Baranzini4, 1Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US, 2Octave Bioscience Inc./Menlo Park/US, 3University of California, San Francisco/San Francisco/US, 4University of California San Francisco/San Francisco/US, 5Octave Bioscience/Menlo Park/US, 6Harvard University, Brigham & Women's Hospital/Boston/US, 7Octave Bioscience, Inc./Fremont/US, 8University of Illinois at Chicago/Chicago/US

P0064 - Development of the international, multidisciplinary, patient-relevant standard outcome set for Multiple Sclerosis: the S.O.S.MS project

K. Daniels, St. Antonius Hospital/Nieuwegein/NL

P0065 - Differential neuroinflammation genes expression in benign and highly active multiple sclerosis

M. Ivanova, A. Voronkova, M. Zakharova, Research Center of Neurology/Moscow/RU

P0066 - Dimethyl fumarate decreases serum neurofilament light chain in relapsing-remitting multiple sclerosis patients.

S. Sainz De La Maza1, P.E. Walo Delgado2, N. Villarrubia1, E. Monreal1, M. Espiño1, J.I. Fernandez- Velasco1, J. Masjuan1, L. Costa-Frossard1, L.M. Villar1, 1Hospital Universitario Ramón y Cajal/Madrid/ES, 2Hospital Universitario Ramon y Cajal/Madrid/ES

P0067 - Disability improvement by Multiple Sclerosis Functional Composite in progressive MS patients and MRI features

T. Chitnis1, M. Mcadams2, M. Anderson2, M. Polgar-Turcsanyi2, M. Rosso2, B. Glanz2, T. Saraceno2, R. Kern3, S. Ward3, M. Mehra4, H. Weiner5, B. Healy6, 1Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US, 2Brigham and Women's Hospital/Boston/US, 3BrainStorm Cell Therapeutics/New York/US, 4Tigermed/Somerset/US, 5Harvard University, Brigham & Women's Hospital/Boston/US, 6Massachusetts General Hospital/Boston/US

P0068 - Disability Progression in MS Participants Treated with Delayed-release Dimethyl Fumarate: Age-related Subgroup Analysis of the NARCOMS Registry A. Salter1, S. Lancia2, G. Cutter3, R. Fox4, R.-A. Marrie5, J. Mendoza6, J. Lewin6, 1Washington University School in St. Louis/St Louis/US, 2Washington University School in St. Louis/St. Louis/US, 3Mellen Center for Multiple Sclerosis Treatment and Research/Cleveland/US, 4Cleveland Clinic//US, 5Max Rady College of Medicine/Winnipeg/CA, 6Biogen/Cambridge/US

P0069 - dreams: developing a comprehensive, sensitive and validated set of digital biomarkers for MS

Y. Naegelin1, J. Lorscheider2, T. Woelfle2, S. Pless2, J. Kuhle3, O. Reyes4, A. Wiencierz2, L. Kappos5, 1University Hospital Basel and University of Basel/Basel/CH, 2University Hospital Basel/Basel/CH, 3University of Basel/Switzerland/CH, 4Healios GmbH/Basel/CH, 5University Hospital Basel, University of Basel/Basel/CH

P0070 - Effect of evobrutinib, a BTK inhibitor, on immune cell and immunoglobulin levels in relapsing MS: an open-label extension to a phase II study

X. Montalban1, J. Shaw2, F. Dangond3, E. Martin4, R. Grenningloh5, M. Weber6, Y. Li4, 1Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 2EMD Serono (a business of Merck KGaA, Darmstadt, Germany)/Billerica/US, 3EMD Serono, Inc./Rockland/US, 4EMD Serono/Billerica/US, 5EMD Serono Research & Development Institute, Inc./Billerica/US, 6University Medical Center Goettingen/Goettingen/DE

P0071 - Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study

L. Kappos1, M. Burcklen2, M. Freedman3, R. Fox4, E. Kubala Havrdová5, B. Hennessy6, R. Hohlfeld7, F. Lublin8, X. Montalban9, C. Pozzilli10, T. Scherz6, P. Linscheid6, M. Pirozek-Lawniczek6, L. Ford11, H. Kracker6, J. Wuerfel12, T. Sprenger13, 1Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering University Hospital Basel, University of Basel/Basel/CH, 2Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies of Johnson & Johnson/Allschwil/CH, 3The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 4Cleveland Clinic//US, 5Charles University//CZ, 6Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies/Allschwil/CH, 7Ludwig Maximilians University of Munich (LMU)/Munich/DE, 8Mount Sinai School of Medicine/United States/US, 9Dept. of Neurology- Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 10Sapienza University of Rome/Rome/IT, 11Janssen Research & Development, LLC/Titusville/US, 12Medical Image Analysis Center/Basel/CH, 13DKD Helios/Wiesbaden/DE

P0072 - Effect of switching disease modifying drugs on relapse rate in stable relapsing remitting multiple sclerosis patients planning for pregnancy.

L. Almouzain1, F. Hamilton1, F. Stevenson1, D. Chard2, N. Abdulrahman1, 1Institution of Epidemiology,UCL/London/GB, 2Institute of Neurology/London/GB

P0073 - Effectiveness of peginterferon beta-1a versus non-pegylated interferons and glatiramer acetate in a real-world setting using propensity score matching

S. Braune1, A. Bergmann1, F. Roßnagel1, K. Taipale2, F. Pellegrini3, T. Koster4, K. Rehberg- Weber2, 1NeuroTransData GmbH/Neuburg an der Donau/DE, 2Biogen GmbH/München/DE, 3Biogen International/Baar/CH, 4Biogen/Cambridge/US

P0074 - Effects of Ocrelizumab on Cognition-Real World Evidence Using the CogEval App

J. Kramer, /Nashville/US

P0075 - Efficacy of Rituximab in Adult and Pediatric Myelin Oligodendrocyte Glycoprotein Antibody- Associated Disease: A Systematic Review and Meta-analysis

S. Thakolwiboon1, J. Pan1, A. Karukote1, H. Zhao-Fleming2, M. Avila1, 1Texas Tech University Health Sciences Center/Lubbock/US, 2Mayo Clinic/Rochester/US

P0076 - Evaluation of diagnosis and treatment practices in patients with Multiple Sclerosis by Brazilian neurologists’ experts in demyelinating disorders.

C.E. Marin1, D. Callegaro2, M.A. Lana-Peixoto3, Ó. Fernández4, A.P. Gomes Neto5, C.C.F. Vasconcelos6, J.A.C. D’Almeida7, M.V.M. Gonçalves8, M.F. Mendes9, M.K.F. Parolin10, O. Nascimento11, P.D. Gama12, R.P.C. Dias-Carneiro9, R.M. Dias13, A. Damasceno14, J. Becker15, 1Hospital São Lucas da PUCRS/000/BR, 2Hospital das Clínicas – Faculdade de Medicina de São Paulo/São Paulo/BR, 3Hospital das Clínicas de Minas Gerais - UFMG/Belo Horizonte/BR, 4Fundacion IMABIS, Hospital Universitario Carlos Haya/Málaga/ES, 5Santa Casa de Belo Horizonte/Belo Horizonte/BR, 6Universidade Federal do Estado do Rio de Janeiro/Rio de Janeiro/BR, 7Hospital Geral de Fortaleza/Fortaleza/BR, 8Universidade da Região de Joinville/Joinville/BR, 9Faculdade de Ciências Médicas da Santa Casa de São Paulo/São Paulo/BR, 10Associação Paranaense de Ciências Neurológicas/Curitiba/BR, 11Universidade Federal Fluminense/Rio de Janeiro/BR, 12Pontifícia Universidade Católica de São Paulo/São Paulo/BR, 13Hospital de Base do Distrito Federal/Brasília/BR, 14Universidade Estadual de Campinas/Campinas/BR, 15Pontifical Catholic University of Rio Grande do Sul/Brazil/BR

P0077 - Evaluation of Quality of Life and Fatigue in Patients Followed in Multiple Sclerosis Outpatient Clinic

G. Genç, Ü. Yalaz Tekan, E.A. Özbek, N. Konakçı, S. Bulut, Şişli Etfal Training and Research Hospital/Istanbul/TR

P0078 - Evidence for the efficacy of nabiximols oromucosal spray in the management of patients with spasticity: A systematic review

L. Crathorne1, J. Campbell1, C. Vila Silván2, R. Stork3, D. Ortin Sulbaran2, 1ROBOLEO & CO/Southampton/GB, 2Almirall S.A./Barcelona/ES, 3Almirall S.A./Uxbridge/GB

P0079 - Experience in Multiple Sclerosis Patients with SARS CoV-2 Infection

V. Meca-Lallana, C. Aguirre, C. Díaz, B. Del Río, R. Martín, J. Vivancos, La Princesa Hospital/Madrid/ES

P0080 - Exploring neurofilament light in CSF as a biomarker for multiple sclerosis in clinical practice

I. Rosenstein1, L. Novakova2, M. Axelsson2, K. Blennow3, H. Zetterberg1, J. Lycke2, 1Gothenburg university, Sahlgrenska academy, Institute for Neuroscience and Physiology/Gothenburg/SE, 2Institute of Neuroscience and Physiology/Gothenburg/SE, 3Gothenburg university, Sahlgrenska academy, Institute for Neuroscience and Physiology/Mölndal/SE

P0081 - Exploring the usability and patient satisfaction of a virtual rehabilitation program in multiple sclerosis: The RehabVR study protocol

D. Prefasi1, V. Meca-Lallana2, W. Alabarcez3, T. Hernandez4, F. Garcia4, A. Portaña3, D. Gomis3, N. Tellez5, C. Garcia-Bernaldez6, J. Mauriño6, N. Medrano6, A. Vazquez4, 1Roche/Madrid/ES, 2La Princesa Hospital/Madrid/ES, 3La Frontera/madrid/ES, 4La Princesa Hospital/madrid/ES, 5Hospital Clinico Valladolid/Valladolid/ES, 6Roche/madrid/ES

P0082 - From proteome to interactome: a mechanistic approach to MS biomarker discovery

A. Katrib1, F. Qureshi2, M. Becich3, V. Gehman3, S. Goelz4, 1Octave Bioscience/Menlo Park/US, 2Octave Bioscience, Inc./Fremont/US, 3Octave Bioscience Inc./Menlo Park/US, 4Myelin Repair Foundation/Saratoga/US

P0083 - Gadolinium improves detection of central vein lesions in MS using 3T FLAIR*.

L. Daboul1, C. O'Donnell2, D. Moreno-Dominguez3, P. Rodrigues3, J. Derbyshire4, C. Azevedo5, A. Bar- Or6, E. Caverzasi7, P. Calabresi8, B. Cree9, L. Freeman10, R. Henry9, E. Longbrake11, J. Oh12, N. Papinutto7, D. Pelletier13, R. Samudralwar14, M. Schindler15, E. Sotirchos8, N. Sicotte16, A. Solomon16, R. Shinohara2, D. Reich17, P. Sati16, D. Ontaneda18, 1National Institute of Neurological Disorders and Stroke/Bethesda/US, 2University of Pennsylvania Perelman School of Medeicine/Philadelphia/US, 3QMENTA Inc./Boston/US, 4National Institute of Mental Health/Bethesda/US, 5University of Southern California/Los Angeles/US, 6University of Pennsylvania/Philadelphia/US, 7University of California at San Francisco/San Francisco/US, 8Johns Hopkins University/Baltimore/US, 9University of California San Francisco/San Francisco/US, 10Dell Medical School, The University of Texas at Austin/Austin/US, 11Yale University/New Haven/US, 12University of Toronto/Toronto/CA, 13USC/Los Angeles/US, 14University of Texas Health Science Center at Houston/Houston/US, 15University of Pennsylvania Perelman School of Medicine/Philadelphia/US, 16Cedars-Sinai Medical Center/Los Angeles/US, 17NINDS, NIH/Bethesda/US, 18Cleveland Clinic//US

P0084 - Gene expression profiling and TCR diversity of ATA188, an off-the-shelf, allogeneic EBV- targeted T-cell immunotherapy for progressive MS P. Foubert1, S. Srihari2, L. Le Texier2, R.R. Shen3, F. Forozan3, C. Smith4, R. Khanna4, B.T. Aftab1, 1Atara Biotherapeutics/South San Francisco/US, 2QIMR Berghofer Medical Research Institute, QIMR Berghofer Centre for Immunotherapy and Vaccine Development/Brisbane/AU, 3Atara Biotherapeutics/Thousand Oaks/US, 4QIMR Centre for Immunotherapy and Vaccine Development, QIMR Berghofer Medical Research Institute/Brisbane/AU

P0085 - Harmonization of real-world studies in multiple sclerosis: retrospective analysis from the RIReMS group

M. Moccia1, P. Annovazzi2, M.C. Buscarinu3, M. Calabrese4, P. Cavalla5, C. Cordioli6, M. Di Filippo7, D. Ferraro8, A. Gajofatto4, A. Gallo9, R. Lanzillo1, A. Laroni10, L. Lorefice11, S. Malucchi12, V. Nociti13, D. Paolicelli14, F. Pinardi15, L. Prosperini16, M. Radaelli17, P. Ragonese18, V. Tomassini19, C. Tortorella16, E. Cocco11, C. Gasperini16, C. Solaro20, 1Federico II University of Naples, Italy/Napoli/IT, 2Gallarate Hospital/Varese/IT, 3Sapienza University/Rome/IT, 4University of Verona/Verona/IT, 5City of Health & Science University Hospital/Turin/IT, 6ASST Spedali Civili di Brescia/Brescia/IT, 7University of Perugia/Perugia/IT, 8University of Modena and Reggio Emilia/Modena/IT, 9University of Campania "L. Vanvitelli"/Naples/IT, 10University of Genova/Genova/IT, 11University of Cagliari/Cagliari/IT, 12San Luigi Gonzaga Hospital/Orbassano (TO)/IT, 13'A. Gemelli' IRCCS/Romes/IT, 14University of Bari/Bari/IT, 15UOSI Multiple Sclerosis Rehabilitation/Bologna/IT, 16Ospedale San Camillo Forlanini/Rome/IT, 17San Raffaele Hospital/Milan/IT, 18University of Palermo/Palermo/IT, 19University of Chieti/Chieti/IT, 20Moncrivello Hospital/Varese/IT

P0086 - Highly sensitive quantitation of CXCL13 as an intrathecal biomarker in optic neuritis

M.N. Olesen1, A.C. Nilsson1, G. Pihl-Jensen2, K.K. Soelberg3, D.A. Olsen4, I. Brandslund5, S.T. Lillevang1, J.S. Madsen5, J.L. Frederiksen2, N. Asgari6, 1Odense University Hospital/Odense C/DK, 2Rigshospitalet - Glostrup/Glostrup/DK, 3University of Southern Denmark and Odense University Hospital/Odense C/DK, 4Vejle Hospital/Vejle/DK, 5Vejle Hospital and University of Southern Denmark/Vejle/DK, 6Institute of Regional Health Research/Odense/DK

P0087 - Identification of proteins associated with ageing in patients with progressive multiple sclerosis

N. Fissolo1, L. Midaglia2, B. Oliver3, L.M. Villar4, A.J. Sánchez-López5, A. Saiz6, R. Alvarez-Lafuente7, L. Ramió I Torrentà8, S. Martínez-Yélamos9, X. Montalban10, M. Comabella11, 1Hospital Vall d'Hebron/Barcelona/ES, 2Dept. of Neurology-Neuroimmunology; Vall Hebron University Hospital; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 3Hospitales Universitarios Regional de Málaga y Virgen de la Victoria/Málaga/ES, 4Hospital Universitario Ramón y Cajal/Madrid/ES, 5Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana/Madrid/ES, 6Hospital Clínic i Provincial de Barcelona/Barcelona/ES, 7Hospital Clínico San Carlos/Madrid/ES, 8Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 9Hospital Universitari de Bellvitge-IDIBELL/L'Hospitalet de Llobregat/ES, 10Dept. of Neurology-Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 11Universitat Autònoma//ES

P0088 - Identification of putative multiple sclerosis biomarkers in CSF by targeted-mass spectrometry

D. Sohaei1, S. Thebault2, I. Batruch3, I. Prassas3, M. Freedman4, E. Diamandis3, 1University of Toronto/Toronto/CA, 2University of Ottawa/Ottawa/CA, 3Mount Sinai Hospital/Toronto/CA, 4The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA

P0089 - IFP35 as biomolecular marker of neuroinflammation and treatment response in Multiple Sclerosis

R. De Masi, S. Orlando, Multiple Sclerosis Centre - F. Ferrari Casarano Hospital/Casarano/IT

P0090 - Immune cell profiles associated with CIS progression and stability using RNA-seq single-cell analysis

J. Giarraputo1, V. Jain1, S. Arvai1, D. Smilek2, K. Harris3, S. Gregory1, 1Duke University/Durham/US, 2Immune Tolerance Network/San Francisco/US, 3Immune Tolerance Network/Bethesda/US

P0091 - Improving patient outcomes through a comprehensive care management platform (MOVING MS)

A. Miner1, M. Becich2, V. Gehman2, J. Graves3, 1University of California, San Diego/La Jolla/US, 2Octave Bioscience Inc./Menlo Park/US, 3University of California, San Diego/San Diego/US

P0092 - Incidence of recurrence of disease activity after fingolimod discontinuation in older patients

V. Pantazou, C. Pot, G. Le Goff, R. Du Pasquier, M. Theaudin, University Hospital of Lausanne/Lausanne/CH

P0093 - Increased serum GFAP associates with microstructural white matter damage in multiple sclerosis

M. Saraste1, S. Bezukladova2, M. Matilainen2, M. Sucksdorff3, J. Kuhle4, D. Leppert5, L. Airas2, 1Turku University Central Hospital/Turku/FI, 2Turku University Hospital and University of Turku/Turku/FI, 3Turku University Hospital/Turku/FI, 4University of Basel/Switzerland/CH, 5University Hospital Basel and University of Basel/Basel/CH

P0094 - Inter-laboratory evaluation of cerebrospinal fluid and serum kappa free light chain measurements

D. Ferraro1, R. Bedin1, P. Natali2, D. Franciotta3, G. Bernardi4, E. Corsini4, E. Cocco5, G. Costa5, I. Crespi6, M. Lamonaca6, A. Sala7, C. Nicolò7, M. Di Filippo8, A. Villa8, V. Nociti9, T. De Michele9, P. Cavalla10, P. Caropreso10, F. Vitetta11, M. Gastaldi3, T. Trenti2, S. Meletti1, P. Sola11, 1University of Modena and Reggio Emilia/Modena/IT, 2Azienda Ospedaliero-Universitaria and Azienda/Modena/IT, 3IRCCS Mondino Foundation/pavia/IT, 4Fondazione IRCCS Istituto Neurologico Carlo Besta/Milan/IT, 5University of Cagliari/Cagliari/IT, 6Azienda Ospedaliero Universitaria Maggiore della Carità of Novara/Novara/IT, 7Azienda Ospedaliero Universitaria San Luigi Gonzaga/Orbassano/IT, 8University of Perugia/Perugia/IT, 9'A. Gemelli' IRCCS/Romes/IT, 10City of Health & Science University Hospital/Turin/IT, 11Azienda Ospedaliero-Universitaria di Modena Ospedale Civile di Baggiovara/Modena/IT

P0095 - Intracortical motor conduction is associated with dexterity in progressive multiple sclerosis

M. Pisa1, R. Chieffo2, M. Congiu2, F. Esposito2, M. Romeo3, M. Comola4, G. Comi5, L. Leocani1, 1Vita- Salute San Raffaele University/Milan/IT, 2IRCCS San Raffaele Scientific Institute/Milan/IT, 3IRCCS San Raffaele/milano/IT, 4San Raffaele Scientific Institute and University Hospital/Milan/IT, 5San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT

P0096 - Intrathecal immunoglobulin M synthesis is associated with higher disease activity and severity in Multiple Sclerosis

J. Oechtering1, S. Schaedelin1, P. Benkert2, S. Müller3, L. Achtnichts4, J. Vehoff3, G. Disanto5, O. Findling4, B. Fischer-Barnicol6, A. Orleth6, A. Chan7, A. Salmen7, C. Pot8, C. Granziera6, I. Heijnen6, P. Lalive9, J. Wuerfel10, T. Lincke6, J. Lieb1, Ö. Yaldizli1, T. Sinnecker11, T. Derfuss12, A. Regeniter1, C. Zecca5, C. Gobbi5, L. Kappos12, D. Leppert6, J. Kuhle13, 1University Hospital Basel/Basel/CH, 2University Hospital Basel, University of Basel/Basel/CH, 3Cantonal Hospital St. Gallen/St. Gallen/CH, 4Cantonal Hospital Aarau/Aarau/CH, 5Regional Hospital of Southern Switzerland (EOC)/Lugano/CH, 6University Hospital Basel and University of Basel/Basel/CH, 7Inselspital Bern, University Hospital and University of Bern/Bern/CH, 8University Hospital of Lausanne/Lausanne/CH, 9Geneva University Hospitals/Geneva/CH, 10Medical Image Analysis Center/Basel/CH, 11Universitätsspital Basel/Basel/CH, 12University of Basel//CH, 13University of Basel/Switzerland/CH

P0097 - Intrathecal immunoglobulin M synthesis is associated with higher serum neurofilament light chain levels and increased MRI disease activity in MS

J. Oechtering1, S. Schaedelin1, P. Benkert2, M. Barakovic3, A. Maceski4, A. Orleth4, D. Rey4, T. Sinnecker5, R. Rahmanzadeh4, S. Zadic4, R. Galbusera4, R.-A. Todea4, A. Cagol4, L. Achtnichts6, S. Aeschbacher1, K. Berger7, A. Chan8, D. Conen1, T. Derfuss9, G. Disanto10, O. Findling6, B. Fischer- Barnicol4, I. Heijnen4, K. Hrusovsky11, H. Kropshofer12, P. Lalive13, J. Lieb1, T. Lincke4, J. Lorscheider1, P. Maggi14, C. Müller1, S. Müller15, Y. Naegelin4, J. Oksenberg16, C. Pot17, R. Du Pasquier17, E.-W. Radue18, A. Regeniter1, A. Salmen8, J. Vehoff15, E. Waubant19, S. Wellmann20, H. Wiendl21, J. Würfel22, Ö. Yaldizli1, C. Zecca10, D. Leppert4, C. Gobbi10, L. Kappos9, C. Granziera4, J. Kuhle23, 1University Hospital Basel/Basel/CH, 2University Hospital Basel, University of Basel/Basel/CH, 3University of Basel/Basel/CH, 4University Hospital Basel and University of Basel/Basel/CH, 5Universitätsspital Basel/Basel/CH, 6Cantonal Hospital Aarau/Aarau/CH, 7University of Münster/Münster/DE, 8Inselspital Bern, University Hospital and University of Bern/Bern/CH, 9University of Basel//CH, 10Regional Hospital of Southern Switzerland (EOC)/Lugano/CH, 11Quanterix/Billerica/US, 12Novartis Pharma AG/Basel/CH, 13Geneva University Hospitals/Geneva/CH, 14Lausanne University Hospital and University of Lausanne/Lausanne/CH, 15Cantonal Hospital St. Gallen/St. Gallen/CH, 16University of California San Francisco/San Francisco/US, 17University Hospital of Lausanne/Lausanne/CH, 18University Hospital Basel and University of Basel/Basel/SZ, 19UCSF/San Francisco/US, 20Barmherzige Brüder Klinik St. Hedwig/Regensburg/DE, 21University of Münster/Germany/DE, 22MIAC AG/Basel/CH, 23University of Basel/Switzerland/CH

P0098 - Investigation of biomarkers in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

B. Arslan1, G. Arslan2, A. Dinçel3, R. Karabudak2, A. Tuncer2, 1Etlik Zubeyde Hanim Women's Health Training and Research Hospital/Ankara/TR, 2Hacettepe University Faculty of Medicine/Ankara/TR, 3Gazi University Faculty of Medicine/Ankara/TR

P0099 - Is disease activity prior to fingolimod initiation in treatment-naive patients predictive of response?

V. Pantazou, R. Du Pasquier, G. Le Goff, C. Pot, M. Theaudin, University Hospital of Lausanne/Lausanne/CH

P0100 - Italian prospective multicentric observational real-life study of aggressive Relapsing Remitting Multiple Sclerosis treated with alemtuzumab

L. Moiola1, M. Di Cristinzi2, A. Sultana3, C. Zanetta3, F. Rinaldi4, L. Brambilla5, J. Frau6, S. Malucchi7, P. Annovazzi8, G. Puorro9, A. Bianco10, G. Lus11, P. Cavalla12, F. Sangalli13, M. Romeo14, G. Marfia15, A. Gallo16, V. Barcella17, S. Bucello18, M.T. Ferrò19, C. Lapucci20, L. Chiveri21, C.G. Chisari22, E. Baldi23, R. Clerici24, P. Banfi25, C. Tortorella26, R. Totaro27, R. Cerqua28, S. Tonietti29, V. Mantero30, G. Santuccio31, M. Filippi1, 1IRCCS San Raffaele Scientific Institute/Milan/IT, 2Multiple Sclerosis Centre, Neurology 2,/Florence/IT, 3Multiple sclerosis center, IRCCS San Raffaele Scientific Institute/Milan/IT, 4Multiple Sclerosis Center, Department of Neurosciences DNS, University Hospital, University of Padua/Padua/IT, 5IRCCS Foundation Neurological Institute Carlo Besta/Milan/IT, 6Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/Cagliari/IT, 7San Luigi Gonzaga Hospital/Orbassano (TO)/IT, 8Multiple Sclerosis Centre, Hospital of Gallarate, ASST della Valle Olona/Gallarate (VA), Italy/IT, 9Multiple Sclerosis Clinical Care and Research Centre, Departement of Neuroscience, Reproductive Science and Odontostomatology, Federico II University,/Naple/IT, 10Fondazione Policlinico A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore,/Rome/IT, 11Second University of Naples/Napoli/IT, 12Neurologia IU, Department of Neuroscience, AOU Città della Salute e della Scienza di Torino,/Torino/IT, 13Ospedale San Raffaele/Milano/IT, 14IRCCS San Raffaele/milano/IT, 15UOSD Centro di Riferimento Regionale per la Sclerosi Multipla, Policlinico Tor Vergata/rome/IT, 16University of Campania "L. Vanvitelli"/Naples/IT, 17ASST Papa Giovanni XXIII/Bergamo/IT, 18Multiple sclerosis center, Muscatello Augusta Hospital/Siracusa/IT, 19Neuroimmunology, Multiple Sclerosis Center, Neurological Department, Ospedale Maggiore, Crema,/Crema/IT, 20Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 21Multiple sclerosis center – Neuroscience and Neurology department -Stroke Unit ASST Ovest Milanese/Legnano/IT, 22Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 23Azienda Ospedaliera-Universitaria S. Anna/Ferrara/IT, 24Neurology Department, Valduce Hospital/como/IT, 25Banfi Neurology Department, ASST Settelaghi, Circolo Hospital/varese/IT, 26Neuroscience department San Camillo Forlanini hospital/Rome/IT, 27Clinica Neurologica, Ospedale San Salvatore/L'Aquila/IT, 28Neurology Department, Marche University, Torrette di Ancon/ancona/IT, 29ASST Santi Paolo e Carlo - PO San Carlo Borromeo Milan, Italy/Milan/IT, 30MS center, ASST/Lecco/IT, 31Neurology Department, MS center/sondrio/IT

P0101 - Kinematic assessment of upper limb function in progressive multiple sclerosis

L. Fernandes1, A. Hafeez2, R. Coats2, M. Mon-Williams2, H. Ford3, 1/Leeds/GB, 2University of Leeds/Leeds/GB, 3Leeds Teaching Hospitals NHS Trust/Leeds/GB

P0102 - KonectomTM smartphone-based digital outcome assessment of cognitive and motor function in multiple sclerosis

C. Guo1, E. Cahir-Mcfarland1, J. Dumail1, T. Guymard1, J. Mcloughlin1, S. Bieuvelet2, M. Vallée2, S. Zinaï2, V. Beynon1, M. Scaramozza1, N. Franchimont1, S. Belachew1, 1Biogen/Cambridge/US, 2Ad Scientiam/Paris Cedex/FR

P0103 - Liothyronine treatment of MS patients alters proteins in CSF related to angiogenesis and immune function

P. Bhargava1, T. Shoemaker2, S. Snoops1, S. Cassard1, F. Tian1, K. Fitzgerald1, D. Cooper1, J. Mammen1, E. Mowry3, P. Calabresi3, S. Newsome1, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Rush University Medical Center/Chicago/US, 3Johns Hopkins University/Baltimore/US

P0104 - Long term disability trajectories in multiple sclerosis: a group-based trajectory analysis of the AusLong cohort

M. Hussain1, I. Van Der Mei1, R. Lucas2, A.-L. Ponsonby3, B. Taylor1, 1University of Tasmania/Hobart/AU, 2Australian National University/Canberra/AU, 3Murdoch Children’s Research Institute, Melbourne,, Australia/Melbourne/AU

P0105 - Longitudinal proteomic analysis of MS patients before and after autologous hematopoietic stem cell transplantation

S. Thebault1, S.M. Fereshtehnejad1, V. Laforte2, M. Freedman3, D. Juncker2, A. Bar-Or4, 1University of Ottawa/Ottawa/CA, 2McGill University/Montreal/CA, 3The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 4University of Pennsylvania/Philadelphia/US

P0106 - Long-term single-centre experience with natalizumab.

P. Duquette, P.-O. Despault, E. Roger, A. Prat, C. Larochelle, M. Girard, University of Montreal/Montreal/CA

P0107 - Lymphocyte response in standard and extended interval dosing of natalizumab

S. Rafee1, L. Kennelly2, C. Mcguigan2, 1St Vincent's Hospital/D04 T6F4/IE, 2St Vincent's Hospital/D TF/IE

P0108 - Meta-analysis of randomized controlled trials and real-world evidence comparing natalizumab and fingolimod for relapsing-remitting multiple sclerosis

O. Efthimiou1, C. Acosta2, P. Saunders-Hastings3, F. Pellegrini4, 1Univesity of Bern/Bern/CH, 2Biogen/Baar/CH, 3University of Ottawa/Ottawa/CA, 4Biogen International/Baar/CH

P0109 - microRNA expression and its association with disability and brain atrophy

C. Lopez De Silanes1, Y. Aladro Benito2, L. De Torres3, I. Casanova3, S. Abellán Ayuso3, S. Pérez- Pérez4, M.Á. García-Martínez4, M. Eimil Ortiz3, B. Oyanguren Rodeño3, M.J. Gil Moreno3, R. Terrero Carpio3, M.Á. Saiz Sepúlveda3, B.P. Diaz Montoya3, E. De Antonio Sanz3, M. González Salaices3, M.I. Domínguez-Mozo4, R. Alvarez-Lafuente5, 1Hospital Universitario de Torrejón/Madrid/ES, 2Hospital Universitario de Getafe/Madrid/ES, 3Hospital Universitario de Torrejón/Torrejón de Ardoz. Madrid/ES, 4Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Madrid/ES, 5Hospital Clínico San Carlos/Madrid/ES

P0110 - Modulation of cerebrospinal fluid immunoglobulins by ocrelizumab treatment

M. Weber1, H.C. Von Büdingen2, A. Bar-Or3, A. Herman4, C. Harp5, J. Pei5, R. Winger5, J. Bennett6, R. Carruthers7, K. Edwards8, R. Fallis9, J. Gelfand10, P. Giacomini11, B. Greenberg12, D.A. Hafler13, E. Longbrake14, C. Ionete15, U.W. Kaunzner16, C. Lock17, G. Pardo18, F. Piehl19, T. Ziemssen20, A.H. Cross21, 1University Medical Center Goettingen/Goettingen/DE, 2F. Hoffmann-La Roche Ltd/Basel/CH, 3University of Pennsylvania/Philadelphia/US, 4Genentech, Inc./San Francisco/US, 5Genentech, Inc./South San Francisco/US, 6University of Colorado School of Medicine/Denver/US, 7University of British Columbia Hospital/Vancouver/CA, 8KMS Center of NE New York/Latham/US, 9The Ohio State University Medical Center/Columbus/US, 10University of California San Francisco/San Francisco/US, 11McGill University/Montreal/CA, 12Department of Neurology and Neurotherapeutics/Dallas/US, 13Yale School of Medicine/New Haven/US, 14Yale University/New Haven/US, 15University of Massachusetts Medical School/Worcester/US, 16Weill Cornell Medicine/New York City/US, 17Stanford University/Stanford/US, 18Oklahoma Medical Research Foundation/Oklahoma City/US, 19Karolinska Institute/Stockholm/SE, 20Carl Gustav Carus University Hospital/Dresden/DE, 21Washington University School of Medicine/Saint Louis/US

P0111 - Monitoring Multiple Sclerosis Treatment with Plasma Biomarkers: NfL, GFAP, UCH-L1, and Tau

R. Gross1, A. Ritchie1, S. Selva1, J. Parra Gonzalez1, C. Knapp1, S. Sillau2, G. Owens1, K. Nair3, T. Vollmer2, E. Alvarez1, 1University of Colorado/Aurora/US, 2Rocky Mountain MS Center at the University of Colorado Anschutz Medical Campus/Aurora/US, 3Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus/Aurora/US

P0113 - MRI activity as a predictor of suboptimal response to natalizumab treatment: single center prospective cohort trial D. Kasatkin1, N. Spirin2, N. Spirina2, E. Kiseleva2, S. Molchanova2, 1Yaroslavl State Medical University/Yarosvavl/RU, 2Yaroslavl State Medical University/Yaroslavl/RU

P0114 - MS Biomarker Discovery: a multi-modal approach to identify biomarkers of myelin repair by leveraging a preclinical rodent model of MS

Y.J. Kaeser-Woo, E. Morozova, P.C.-T. Chou, W. Zeng, B. Wang, J. Dion, B. Harvey, D. Koske, D. Ferretti, H.-H. Tsai, D.P. Bradley, K. Sigrist, R. Sriperumbudur, T.-Y. Liu, W. Wang, Biogen/Cambridge/US

P0115 - mSteps: A pilot study using a phone application with GPS, accelerometers and Wi-Fi positioning to measure walking distance in MS, indoors and outdoors

S. Alexander1, M. Braisher2, C. Tur2, J. Chataway3, 1University College London/London/GB, 2UCL Queen Square Institute of Neurology, Faculty of Brain Sciences/London/GB, 3UCL Queen Square Institute of Neurology, University College//GB

P0116 - Multiple Sclerosis and Cognitive Impairment: Computerized Cognitive Assessment and PROMIS-Cognitive Function Questionnaire: An Unfulfilled Promis

O. Kaczmarek1, J. Srinivasan2, M. Zarif3, B. Bumstead2, M. Buhse1, D. Golan4, J. Wilken5, K. Jaenicke1, W. Doroski1, D. Lund1, M. Gudesblatt1, 1South Shore Neurologic Associates/Patchogue/US, 2South Shore Neurologic Associates, P.C./Patchogue/US, 3Comprehensive Multiple Sclerosis Care Center/Patchogue/US, 4Carmel Medical Center/haifa/IL, 5Neuropsychological Associates/Fairfax/US

P0117 - Mystery of MRZ reaction in multiple sclerosis

S. Wachamo, R. Masvekar, P. Kosa, M. Varosanec, B. Bielekova, National Institutes of Health/Bethesda/US

P0118 - Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials

S. Harris1, G. Comi2, B. Cree3, D.L. Arnold4, L. Steinman5, J. Sheffield1, H. Southworth6, L. Kappos7, J. Cohen8, 1Bristol-Myers Squibb Company/Princeton/US, 2San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 3University of California San Francisco/San Francisco/US, 4MNI, McGill/Quebec/CA, 5Beckman Center for Molecular Medicine, Stanford University Medical Center/Stanford/US, 6Data Clarity Consulting Ltd./Stockport/GB, 7University Hospital and University of Basel/Basel/CH, 8Mellen Center for MS Treatment and Research, Cleveland Clinic/Cleveland/US

P0119 - Neurofilament light chain levels correlate with lesion activity and axonal damage in MS

A. Van Den Bosch1, N. Fransen1, M. Mason1, A. Rozemuller2, C. Teunissen2, J. Smolders3, I. Huitinga1, 1Netherlands Institute for Neuroscience/Amsterdam/NL, 2Amsterdam UMC/Amsterdam/NL, 3Erasmus University Medical Center/Rotterdam/NL

P0120 - Neuroperformance test outcomes as predictors of employment in a large, heterogeneous real world MS populations: Results from MS PATHS

C. De Moor1, J. Williams2, L. Krupp3, M. Mcginley4, K. Fitzgerald5, S. Rao6, R. Rudick1, 1Biogen/Cambridge/US, 2Biogen/Boston/US, 3NYU Langone/New York City/US, 4Cleveland Clinic Foundation/Cleveland/US, 5Johns Hopkins University School of Medicine/Baltimore/US, 6Schey Center for Cognitive Neuroimaging/Cleveland/US

P0121 - Objective measurement of speech correlates with disease status and quality of life in people with MS without dysarthria

G. Noffs1, F. Boonstra2, T. Perera3, H. Butzkueven2, S. Kolbe2, F. Maldonado1, E. Lizama1, M. Galea4, J. Stankovich2, A. Evans5, A. Vogel1, A. Van Der Walt2, 1University of Melbourne/Parkville/AU, 2Monash University/Melbourne/AU, 3Bionics Insitute/Melbourne/AU, 4University of Melbourne/Melbourne/AU, 5Royal Melbourne Hospital/Parkville/AU

P0122 - Ocrelizumab in patients with multiple sclerosis: A single center experience.

C. Brady1, D. Lakhani1, B. Hou1, J. Carpenter1, W. Luo2, S. Magda2, R. Haxton2, R. Tripathi3, G. Deib1, S. Sriwastava4, 1West Virginia University/Morgantown/US, 2Cortechs Laboratory/San Diego/US, 31 Medical Center Drive/Morgantown/US, 41 Medical Center Drive /Morgantown/US

P0123 - Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NfL and other measures of disease severity

A. Bar-Or1, G. Thanei2, C. Harp3, C. Bernasconi2, U. Bonati2, A.H. Cross4, S. Fischer3, L. Gaetano2, S. Hauser5, R. Hendricks3, J. Kuhle6, D. Leppert7, F. Model2, H. Koendgen2, X. Jia3, A. Herman8, 1University of Pennsylvania/Philadelphia/US, 2F. Hoffmann-La Roche Ltd/Basel/CH, 3Genentech, Inc./South San Francisco/US, 4Washington University School of Medicine/Saint Louis/US, 5University of California San Francisco/San Francisco/US, 6University of Basel/Switzerland/CH, 7University Hospital Basel and University of Basel/Basel/CH, 8Genentech, Inc./San Francisco/US

P0124 - Ocrelizumab treatment in patients with relapsing-remitting multiple sclerosis: a single-center real-world experience

C. Lapucci1, G. Boffa2, M. Cellerino3, G. Novi2, E. Sbragia2, N. Bruschi2, E. Mancuso4, F. Tazza2, A. Laroni5, E. Capello2, A. Uccelli6, M. Inglese7, 1Ospedale Policlinico San Martino IRCCS Genoa/Genoa/IT, 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 3University of Genoa/Genoa/IT, 4Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI)/Genova/IT, 5University of Genova/Genova/IT, 6University of Genoa/Italy/IT, 7University of Genoa//IT

P0125 - Ocrelizumab treatment induces a sustained blood NfL reduction in patients with PPMS and RMS A. Bar-Or1, G. Thanei2, C. Harp3, C. Bernasconi2, U. Bonati2, A. Cross4, S. Fischer3, L. Gaetano2, S. Hauser5, R. Hendricks3, J. Kuhle6, D. Leppert7, F. Model2, H. Koendgen2, X. Jia3, A. Herman8, 1University of Pennsylvania/Philadelphia/US, 2F. Hoffmann-La Roche Ltd/Basel/CH, 3Genentech, Inc./South San Francisco/US, 4Washington University in St. Louis/St. Louis/US, 5University of California San Francisco/San Francisco/US, 6University of Basel/Switzerland/CH, 7University Hospital Basel and University of Basel/Basel/CH, 8Genentech, Inc./San Francisco/US

P0126 - Olfactory threshold as a biomarker predicting treatment response in relapsing multiple sclerosis

G. Bsteh1, H. Hegen2, K. Berek2, A. Zinganell2, S. Wurth3, M. Auer2, F. Di Pauli2, F. Deisenhammer2, T. Berger1, 1Medical University of Vienna/Vienna/AT, 2Medical University of Innsbruck/Innsbruck/AT, 3Medical University of Graz/Innsbruck/AT

P0127 - Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria

M. Guger1, C. Enzinger2, F. Leutmezer3, J. Kraus4, S. Kalcher5, E. Kvas5, T. Berger3, 1Kepler University Hospital GmbH/Linz/AT, 2Medical University of Graz/Graz/AT, 3Medical University of Vienna/Vienna/AT, 4Paracelsus Medical University and Salzburger Landeskliniken/Salzburg/AT, 5Hermesoft/Graz/AT

P0128 - Outcomes in Alemtuzumab-Treated Patients With Thyroid Adverse Events: 6-Year Pooled CARE-MS Data

C. Dayan1, B. Lecumberri2, I. Muller3, S. Ganesananthan1, S. Hunter4, K. Selmaj5, H.P. Hartung6, E. Havrdova7, C. Laganke8, T. Ziemssen9, B. Van Wijmeersch10, S. Meuth11, D. Margolin12, S. Afsar12, N. Daizadeh13, E. Poole13, D. Baker13, P. Senior14, 1Cardiff University/Cardiff/GB, 2La Paz University Hospital/Madrid/ES, 3Cardiff University - School of Medicine/Cardiff/GB, 4Advanced Neurosciences Institute/Franklin/US, 5Department of Neurology, University of Warmia and Mazury/Olsztyn/PL, 6/Dusseldorf/DE, 7First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 8North Central Neurology Associates/Cullman/US, 9Carl Gustav Carus University Hospital/Dresden/DE, 10Universiteit Hasselt/Hasselt/BE, 11Clinic of Neurology With Institute of Translational Neurology, UKM, University of Münster/Münster/DE, 12Sanofi- Aventis/Boston/US, 13Sanofi/Cambridge/US, 14University of Alberta/Edmonton/CA

P0129 - Pattern of brain attack occurrence in neuromyelitis optica spectrum disorder: effect of treatment

M.Y. Lee1, J.-W. Hyun2, S.-H. Kim1, H.J. Kim3, 1Research Institute and Hospital of National Cancer Center/Goyang/KR, 26) National Cancer Center Korea/Goyang-si/KR, 3Research Institute and Hospital, National Cancer Center/Goyang/KR

P0130 - Pediatric MS: different disease course, different impact, different measurement approach needed N. Ow1, A. Karp1, J. Ogeil1, M.-E. Dilenge2, G. Sébire2, N. Mayo3, 1RIMUHC - Center for Outcomes Research and Evaluation/Montreal/CA, 2McGill University Health Center/Montreal/CA, 3McGill University Health Centre Research Institute/Montreal/CA

P0131 - Predicting long-term sustained disability progression in multiple sclerosis: application in the CLARITY trial

S. Sharmin1, F. Bovis2, M.P. Sormani2, H. Butzkueven3, T. Kalincik4, 1University of Melbourne/Melbourne/AU, 2University of Genoa/Genoa/IT, 3Monash University/Melbourne/AU, 4Royal Melbourne Hospital/Melbourne/AU

P0132 - Prediction of 15-year MS outcomes in BENEFIT trial patients using serum neurofilament light chain concentrations

J. Kuhle1, L. Kappos2, M. Freedman3, G. Edan4, X. Montalban5, H.P. Hartung6, F. Barkhof7, R. Koelbach8, E.-M. Wicklein9, 1University of Basel/Switzerland/CH, 2University of Basel//CH, 3The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 4Centre hospitalier universitaire de Rennes, Hôpital Pontchaillou, Service de neurologie, CIC1414 INSERM/Rennes/FR, 5Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 6/Dusseldorf/DE, 7University College London/LONDON/GB, 8PAREXEL/Berlin/DE, 9Bayer AG/Berlin/DE

P0133 - Prediction of MS disability status in Japanese claims database using principal component analysis

H. Otaka1, K. Ueda1, K. Iwasaki2, T. Takeshima2, I. Kawachi3, 1Novartis Pharma K.K./Tokyo/JP, 2Milliman, Inc./Tokyo/JP, 3Niigata University/Niigata/JP

P0134 - Preliminary validation of static posturography as a disability outcome measure in progressive multiple sclerosis.

S.M. Yap1, M.S. Etzelmueller2, C. O'Keeffe3, M. Gaughan4, R.B. Reilly4, C. Mcguigan4, 1St. Vincent's University Hospital/Dublin 4/IE, 2Tinity College, The University of Dublin/Dublin/IE, 3Trinity College, The University of Dublin/Dublin/IE, 4St. Vincent's University Hospital/Dublin/IE

P0135 - Preventing multiple sclerosis misdiagnosis using the “central vein sign”: A real-world study

M. Kaisey, A. Solomon, B. Guerrero, B. Renner, Z. Fan, N. Ayala, M. Luu, M. Diniz, P. Sati, N. Sicotte, Cedars-Sinai Medical Center/Los Angeles/US

P0136 - Profiling of small non-coding RNAs across cellular and biofluid compartments in patients with Multiple Sclerosis

G. Zheleznyakova1, E. Piket2, M. Needhamsen1, M. Hagemann-Jensen2, D. Ekman3, M. Khademi1, F. Al Nimer1, P. Scicluna1, O. Faridani1, T. Olsson2, F. Piehl2, M. Jagodic2, 1Karolinska Institutet/Stockholm/SE, 2Karolinska Institute/Stockholm/SE, 3Stockholm University/Stockholm/SE

P0137 - Prognostic value of NK/T ratios for disease activity in multiple sclerosis

M. Mimpen1, A.-H. Muris1, L. Rolf1, O. Gerlach2, J. Kuhle3, R. Hupperts4, J. Smolders5, J. Damoiseaux6, 1Maastricht University/Maastricht/NL, 2Department of Neurology, Zuyderland Medical Center, Sittard-Geleen/Sittard-Geleen/NL, 3University of Basel/Switzerland/CH, 4Zuyderland Medical Center/Sittard-Geleen/NL, 5Erasmus University Medical Center/Rotterdam/NL, 6Maastricht University Medical Center/Maastricht/NL

P0138 - "Progressive Multifocal Leukoencephalopathy outcomes in Multiple Sclerosis: A Systemic review and Metanalysis "

S. Sriwastava1, S. Kazemlou2, H. Saber3, S. Srivastava4, S. Peterson5, R. Gwinn5, S. Kataria5, R. Tripathi6, Z. Sheikh5, S. Wen5, S. Gao5, D. Lakhani5, E. Bernitsas7, 11 Medical Center Drive /Morgantown/US, 2Danaher Digital/San Jose/US, 3University of California Los Angeles/Los Angeles/US, 4Chongqing Medical University/Chongqing/CN, 5West Virginia University/Morgantown/US, 61 Medical Center Drive/Morgantown/US, 7Wayne State University/Detroit/US

P0139 - Real World Clinical and Imaging Outcomes in Relapsing MS Patients treated with Alemtuzumab in a US Regional MS Center

B. Khatri1, C. Murphy2, L. Sershon1, O. Olapo1, T. Perea1, S. Beals1, L. Lindman1, E. Poole2, R. Robinson2, A. Patel2, R. Gandhi2, L. Hashemi2, 1Ascension Medical Group/Milwaukee/US, 2Sanofi Genzyme/Cambridge/US

P0140 - Real World Experience of Oral Immune Reconstitution therapy (Cladribine) in the treatment of multiple sclerosis in the United Arab Emirates

M. Thakre1, J. Inshasi2, 1Al Zahra Hospital /154412/AE, 2Rashid Hospital/Dubai/AE

P0141 - Real-world data on the use of Ocrelizumab, among MS patients: B-cell suppression and clinical outcomes.

C. Neo1, V. Singh-Curry2, A. Nandoskar2, O. Malik2, R. Dorsey1, P. Muraro1, R. Nicholas1, A. Scalfari1, 1Imperial College London/London/GB, 2Imperial College of London/London/GB

P0142 - Real-world effectiveness of dimethyl fumarate versus fingolimod using novel outcomes in a heterogeneous patient cohort

C. Hersh1, Y. Lei2, A. Altincatal3, C. De Moor2, R. Rudick2, J.R. Williams2, C. Miller2, B. Kieseier2, I. Koulinska2, 1Cleveland Clinic/Las Vegas/US, 2Biogen/Cambridge/US, 3Biogen/Boston/US

P0143 - Real-World Experience in RRMS and SPMS Patients with Higher Disability and Substantial Lymphopenia Switching from Prior DMTs to Teriflunomide R. Berkovich1, N. Greene2, M. Fernandez2, S. Fadaee2, C. Quach2, Y. Pyatkevich3, 1Regina Berkovich MD, PhD Inc./West Hollywood/US, 2Sanofi Genzyme/Cambridge/US, 3Sanofi/Cambridge/US

P0144 - Real-world outcomes in patients with relapsing forms of multiple sclerosis treated with intramuscular interferon beta-1a or peginterferon beta-1a

A. Salter1, S. Lancia2, G. Cutter3, R. Fox4, R.A. Marrie5, R. Avila6, M. Vignos6, 1Washington University School in St. Louis/St Louis/US, 2Washington University School of Medicine in St. Louis/St. Louis/US, 3The University of Alabama at Birmingham/Birmingham/US, 4Cleveland Clinic//US, 5University of Manitoba/Winnipeg/CA, 6Biogen/Cambridge/US

P0145 - Relation of EDSS to patient-reported outcome measurements in MS: Real-world data from a Swedish nationwide study of fingolimod (IMSE 2)

Å. Leandersson1, S. Kågström2, L. Forsberg1, J. Hillert1, P. Nilsson3, C. Dahle4, A. Svenningsson5, J. Lycke6, A.-M. Landtblom7, J. Burman7, C. Martin8, P. Sundström9, M. Gunnarsson10, F. Piehl2, T. Olsson2, 1Karolinska Institutet/Solna/SE, 2Karolinska Institute/Stockholm/SE, 3Lund University/Lund/SE, 4Linköping University/Linköping/SE, 5Danderyd Hospital/Stockholm/SE, 6University of Gothenburg/Gothenburg/SE, 7Uppsala University/Uppsala/SE, 8Danderyd Hospital/Danderyd/SE, 9Umeå University/Umeå/SE, 10Örebro University/Örebro/SE

P0146 - Reliability, concurrent and ecological validity of smartphone-based cognition and walking tests

K.H. Lam1, P. Van Oirschot2, F. Dorssers2, B. Den Teuling2, B. Uitdehaag1, V. De Groot3, J. Killestein1, 1Amsterdam UMC, Location VUmc/Amsterdam/NL, 2Orikami Digital Health Products/Nijmegen/NL, 3VU University//NL

P0148 - Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis

G. Bsteh1, H. Hegen2, P. Altmann1, K. Berek2, S. Wurth3, M. Auer2, A. Zinganell2, F. Di Pauli2, P. Rommer1, F. Leutmezer1, F. Deisenhammer2, T. Berger1, 1Medical University of Vienna/Vienna/AT, 2Medical University of Innsbruck/Innsbruck/AT, 3Medical University of Graz/Innsbruck/AT

P0149 - Retinal layer thinning rate as a biomarker predicting treatment response in relapsing multiple sclerosis

G. Bsteh1, H. Hegen2, K. Berek2, P. Altmann1, S. Wurth3, M. Auer2, A. Zinganell2, F. Di Pauli2, P. Rommer1, F. Leutmezer1, F. Deisenhammer2, T. Berger1, 1Medical University of Vienna/Vienna/AT, 2Medical University of Innsbruck/Innsbruck/AT, 3Medical University of Graz/Innsbruck/AT

P0150 - REWORD-MS: REal WOrld study to assess the Response to Dimethyl fumarate in patients with Multiple Sclerosis

M.F. Creta1, I. Tramacere2, E. Tomas Roldan2, P. Confalonieri2, V. Torri Clerici2, C. Antozzi2, R. Mantegazza2, A. Tozzo2, L. Brambilla2, 1/Milano/IT, 2IRCCS Foundation Neurological Institute Carlo Besta/Milano/IT

P0151 - Serum contactin-1 levels as a biomarker of long-term disease progression in natalizumab- treated multiple sclerosis.

Z. Van Lierop1, L. Wieske2, E. Willemse3, I. Dekker4, C. Leurs1, M. Koel-Simmelink5, B. Moraal1, F. Barkhof6, B. Uitdehaag1, J. Killestein1, C. Teunissen7, 1Amsterdam UMC, Location VUmc/Amsterdam/NL, 2Amsterdam University Medical centers, AMC/Amsterdam/NL, 3Amsterdam Neuroscience, Neurochemistry Laboratory and Biobank, Amsterdam University medical centers, Vrije Universiteit/Amsterdam/NL, 4Amsterdam UMC, location VUmc/Amsterdam/NL, 5Amsterdam Neuroscience, Neurochemistry Laboratory and Biobank, Amsterdam University Medical centers, Vrije Universiteit/Amsterdam/NL, 6University College London/LONDON/GB, 7Amsterdam UMC/Amsterdam/NL

P0152 - Serum Neurofilament levels of multiple sclerosis patients before and after treatment with injectable therapies

A. Huss1, M. Senel2, A. Abdelhak2, B. Mayer2, J. Kassubek2, A. Ludolph2, M. Otto2, H. Tumani2, 1University Hospital Ulm/Ulm/DE, 2University Ulm/Ulm/DE

P0153 - Serum neurofilament light chain and retinal layer thickness measurements are complementary predictors of disease activity in early multiple sclerosis.

T.-Y. Lin1, V. Vitkova1, I. Serra1, R. Cunningham1, S. Asseyer2, S. Motamedi1, J. Kuhle3, J. Bellmann- Strobl2, K. Ruprecht2, F. Paul4, A. Brandt5, H. Zimmermann1, 1Charité – Universitätsmedizin Berlin/Berlin/DE, 2NeuroCure Clinical Research Center, Experimental and Clinical Research Center, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany/Berlin/DE, 3University of Basel/Switzerland/CH, 4Charite-Universitatmedizin Berlin/Berlin/DE, 5Department of Neurology, University of California Irvine, Irvine, California, USA./Irvine/US

P0154 - Serum Neurofilament light chain captures and predicts disability progression independent of relapses (PIRA) in multiple sclerosis

J. Lorscheider1, P. Benkert2, Ö. Yaldizli1, G. Disanto3, J. Oechtering1, S. Schädelin2, J. Würfel4, A. Chan5, L. Achtnichts6, O. Findling6, T. Derfuss7, H. Kropshofer8, A. Orleth9, B. Fischer-Barnicol9, A. Maceski9, D. Rey9, S. Zadic9, C. Müller1, S. Aeschbacher1, E. Waubant10, J. Oksenberg11, S. Wellmann12, H. Wiendl13, L. Kappos7, A. Salmen5, R. Hoepner5, P. Lalive14, R. Du Pasquier15, C. Pot14, P. Maggi16, C. Zecca3, Y. Naegelin9, S. Müller17, K. Hrusovsky18, K. Berger19, D. Conen20, M. Barakovic21, T. Sinnecker22, C. Gobbi3, C. Granziera9, D. Leppert9, J. Kuhle23, 1University Hospital Basel/Basel/CH, 2Clinical Trial Unit/Basel/CH, 3Regional Hospital of Southern Switzerland (EOC)/Lugano/CH, 4MIAC AG/Basel/CH, 5Inselspital Bern, University Hospital and University of Bern/Bern/CH, 6Cantonal Hospital Aarau/Aarau/CH, 7University of Basel//CH, 8Novartis Pharma AG/Basel/CH, 9University Hospital Basel and University of Basel/Basel/CH, 10UCSF/San Francisco/US, 11University of California San Francisco/San Francisco/US, 12Barmherzige Brüder Klinik St. Hedwig/Regensburg/DE, 13University of Münster/Germany/DE, 14Geneva University Hospitals/Geneva/CH, 15University Hospital of Lausanne/Lausanne/CH, 16Lausanne University Hospital and University of Lausanne/Lausanne/CH, 17Cantonal Hospital St. Gallen/St. Gallen/CH, 18Quanterix/Billerica/US, 19University of Münster/Münster/DE, 20McMaster University/Hamilton/CA, 21University of Basel/Basel/CH, 22Universitätsspital Basel/Basel/CH, 23University of Basel/Switzerland/CH

P0155 - Serum neurofilament light chain levels correlate with attack-related disability in neuromyelitis optica spectum disorder

O. Aktas1, H.P. Hartung2, M. Smith3, W. Rees3, K. Fujihara4, F. Paul5, R. Marignier6, J. Bennett7, H.J. Kim8, B. Weinshenker9, S. Pittock10, D. Wingerchuk11, G. Cutter12, A. Green13, M. Mealy3, J. Drappa3, D. She3, D. Cimbora3, J. Ratchford3, E. Katz3, B. Cree14, 1Heinrich-Heine-Universität Düsseldorf/Dusseldorf/DE, 2/Dusseldorf/DE, 3Viela Bio/Gaithersburg/US, 4Fukushima Medical University/Fukushima/JP, 5Charite-Universitatmedizin Berlin/Berlin/DE, 6Lyon Neuroscience Research Center/Bron/FR, 7University of Colorado School of Medicine/Aurora/US, 8Research Institute and Hospital, National Cancer Center/Goyang/KR, 9Mayo Clinic Department of Neurology/Rochester/US, 10Mayo Clinic/Rochester/US, 11Mayo Clinic/United States/US, 12Mellen Center for Multiple Sclerosis Treatment and Research/Cleveland/US, 13UCSF Multiple Sclerosis Center/United States/US, 14University of California San Francisco/San Francisco/US

P0156 - Serum neurofilament light levels correlate with reduced grey matter volume in advanced multiple sclerosis.

A. Buchmann1, L. Pirpamer2, D. Pinter2, M. Voortman2, B. Helmlinger2, A. Pichler2, G. Bachmaier2, S. Ropele2, C. Enzinger2, M. Khalil2, 1Medical University Graz/Graz/AT, 2Medical University of Graz/Graz/AT

P0157 - Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing- remitting multiple sclerosis (RRMS) patients in the CombiRx trial

G. Cutter1, R. Rudick2, C. De Moor2, C. Singh2, E. Fisher2, F. Lublin3, J. Wolinsky4, H. Mcfarland5, S. Jacobson6, B. Kieseier2, M. Naylor2, 1The University of Alabama at Birmingham/Birmingham/US, 2Biogen/Cambridge/US, 3Mount Sinai School of Medicine/United States/US, 4The University of Texas Health Science Center at Houston/Houston/US, 5National Institute of Neurological Disorders and Stroke, National Institutes of Health/Bethesda/US, 6National Institutes of Health/Bethesda/US

P0158 - Serum neurofilaments in Secondary Progressive Multiple Sclerosis: analysis from the MS- STAT trial T. Williams1, K. Holdsworth2, J. Nicholas2, T. Katsanouli2, H. Wellington1, A. Heslegrave1, H. Zetterberg3, C. Frost2, J. Chataway4, 1University College London/London/GB, 2London School of Hygiene and Tropical Medicine/London/GB, 3Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg/Mölndal/SE, 4UCL Queen Square Institute of Neurology, University College//GB

P0159 - Serum NfL predicts disability progression in MS in a six year longitudinal cohort study

T. Uphaus1, F. Steffen1, V. Fleischer1, J. Loos1, F. Zipp2, S. Bittner1, 1University Medical Center of the Johannes Gutenberg University Mainz/Mainz/DE, 2University Medical Center of the Johannes Gutenberg University Mainz//DE

P0160 - Serum NfL z-scores derived from a large healthy control group reflect different levels of treatment effect in a real-world setting

P. Benkert1, S. Schaedelin2, A. Maceski3, G. Disanto4, J. Oechtering2, M. Barakovic5, A. Orleth3, D. Rey3, T. Sinnecker6, Ö. Yaldizli2, R. Rahmanzadeh3, S. Zadic3, R. Galbusera3, R.-A. Todea3, A. Cagol3, L. Achtnichts7, S. Aeschbacher2, A. Chan8, D. Conen2, T. Derfuss9, O. Findling7, B. Fischer-Barnicol3, K. Hrusovsky10, H. Kropshofer11, P. Lalive12, J. Lieb2, J. Lorscheider2, P. Maggi13, C. Müller2, S. Müller14, Y. Naegelin3, J. Oksenberg15, C. Pot16, R. Du Pasquier16, E.-W. Radue17, A. Salmen8, J. Vehoff14, E. Waubant18, S. Wellmann19, H. Wiendl20, J. Wuerfel21, C. Zecca4, C. Gobbi4, L. Kappos9, K. Berger22, C. Granziera3, D. Leppert3, J. Kuhle23, 1Clinical Trial Unit/Basel/CH, 2University Hospital Basel/Basel/CH, 3University Hospital Basel and University of Basel/Basel/CH, 4Regional Hospital of Southern Switzerland (EOC)/Lugano/CH, 5University of Basel/Basel/CH, 6Universitätsspital Basel/Basel/CH, 7Cantonal Hospital Aarau/Aarau/CH, 8Inselspital Bern, University Hospital and University of Bern/Bern/CH, 9University of Basel//CH, 10Quanterix/Billerica/US, 11Novartis Pharma AG/Basel/CH, 12Geneva University Hospitals/Geneva/CH, 13Lausanne University Hospital and University of Lausanne/Lausanne/CH, 14Cantonal Hospital St. Gallen/St. Gallen/CH, 15University of California San Francisco/San Francisco/US, 16University Hospital of Lausanne/Lausanne/CH, 17University Hospital Basel and University of Basel/Basel/SZ, 18UCSF/San Francisco/US, 19Barmherzige Brüder Klinik St. Hedwig/Regensburg/DE, 20University of Münster/Germany/DE, 21Medical Image Analysis Center/Basel/CH, 22University of Münster/Münster/DE, 23University of Basel/Switzerland/CH

P0161 - Short-term evaluation of alemtuzumab to ocrelizumab switch in MS patients with disease activity after alemtuzumab: an Italian multicentric study.

C. Lapucci1, J. Frau2, E. Cocco3, P. Cavalla4, M. Vercellino4, M. Petracca5, R. Lanzillo6, P. Grossi7, M.T. Ferrò8, C. Guaschino9, M. Zaffaroni9, F. Tazza10, G. Novi10, A. Uccelli11, M. Inglese12, 1Ospedale Policlinico San Martino IRCCS Genoa/Genoa/IT, 2Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/Cagliari/IT, 3University of Cagliari/Cagliari/IT, 4Neurologia IU, Department of Neuroscience, AOU Città della Salute e della Scienza di Torino,/Torino/IT, 5University of Naples Federico II/Naples/IT, 6Federico II University of Naples, Italy/Napoli/IT, 7University of Padua/Padova/IT, 8Neuroimmunology, Multiple Sclerosis Center, Neurological Department, Ospedale Maggiore, Crema,/Crema/IT, 9Multiple Sclerosis Centre, Hospital of Gallarate, ASST della Valle Olona/Gallarate (VA)/IT, 10Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 11University of Genoa/Italy/IT, 12University of Genoa//IT

P0162 - Single cell RNA-seq of MS CSF cells reveals a bias toward expanded CD8 T cells

G. Feuer1, J. Vernejoul1, J. Lin2, S. Sadiq1, 1Tisch MS Research Center of New York/New York City/US, 2Tisch MS Research Center of New York/New York/US

P0163 - Smartphone keystroke dynamics are sensitive to changes in disease activity and clinical disability measures in multiple sclerosis

K.H. Lam1, J. Twose2, H. Mcconchie2, G. Licitra2, B. Moraal1, F. Barkhof1, B. Uitdehaag1, V. De Groot3, J. Killestein1, 1Amsterdam UMC, Location VUmc/Amsterdam/NL, 2Neurocast B.V./Amsterdam/NL, 3VU University//NL

P0164 - Smoking is associated with increased plasma neurofilament light levels in multiple sclerosis

A. Manouchehrinia1, H. Larsson1, J. Huang1, L. Alfredsson2, F. Piehl3, J. Kuhle4, T. Olsson3, I. Kockum5, 1Karolinska Institutet/Stockholm/SE, 2Karolinska Institutet//SE, 3Karolinska Institute/Stockholm/SE, 4University of Basel/Switzerland/CH, 5Department of Clinical Neuroscience, Karolinska Institutet/Stockholm/SE

P0165 - Social Matters: Social support is linked to mental health, quality of life, and motor function in multiple sclerosis

A. Kever1, K. Buyukturkoglu2, C. Riley2, P. De Jager3, V. Leavitt2, 1Columbia University Irving Medical Center/new York/US, 2Columbia University Irving Medical Center/New York/US, 3Columbia University Medical Center/United States/US

P0166 - Sociodemographic features and disability in African-American and Caucasian patients with Multiple Sclerosis

M. Petracca1, A. Droby2, M.M. El Mendili2, S. Paduri2, N. Graziano2, N. Saba2, A. Falcone2, D. Kurz2, C. Riley3, J. Howard4, S. Klineova2, F. Lublin5, M. Inglese6, 1University of Naples Federico II/Naples/IT, 2Icahn School of Medicine at Mount Sinai/New York/US, 3Columbia University Irving Medical Center/New York/US, 4New York University School of Medicine/New York/US, 5Mount Sinai School of Medicine/United States/US, 6Mount Sinai Hospital/New York/US

P0167 - Ten-Foot Tandem Walk: Detection of subtle gait changes and future fall risk in MS

R. Brandstadter1, R. Graney2, J. Sumowski2, 1University of Pennsylvania Perelman School of Medicine/Philadelphia/US, 2Icahn School of Medicine at Mount Sinai/New York/US

P0168 - Test-retest reliability of the mini-BESTest in people with mild to moderate multiple sclerosis A. Wallin, M. Kierkegaard, E. Franzén, S. Johansson, Karolinska Institutet/Huddinge/SE

P0169 - The association between spontaneous MxA mRNA level and disease activity in multiple sclerosis

E. Coerver1, L. Van Der Voort2, J. Killestein3, E. Strijbis1, 1Amsterdam UMC/Amsterdam/NL, 2Maidstone and Tunbridge Wells NHS Trust/Kent/GB, 3Amsterdam UMC, Location VUmc/Amsterdam/NL

P0170 - The GNDS is suitable for changes in walking performance in progressive multiple sclerosis

C. Van 'T Hullenaar, /Amsterdam/NL

P0171 - The gut mycobiome in pediatric multiple sclerosis: establishing a bioinformatics pipeline

N. Mok1, N. Knox2, D.L. Arnold3, A. Bar-Or4, C. Bernstein5, J. Forbes6, M. Graham2, J. Hart7, R.A. Marrie5, J. O’Mahony8, E.A. Yeh8, F. Zhu9, G. Van Domselaar2, B. Banwell10, E. Waubant11, H. Tremlett9, 1National Microbiology Laboratory/Winnipeg/CA, 2Public Health Agency of Canada/Winnipeg/CA, 3MNI, McGill/Quebec/CA, 4University of Pennsylvania/Philadelphia/US, 5University of Manitoba/Winnipeg/CA, 6University of Toronto/Toronto/CA, 7University of California San Francisco/San Francisco/US, 8The Hospital for Sick Children/Toronto/CA, 9University of British Columbia/Vancouver/CA, 10Children’s Hospital of Philadelphia/Philadelphia/US, 11UCSF/San Francisco/US

P0172 - The prognostic value of lipid-specific IgM oligoclonal bands versus IgM index in patients with a clinical isolated syndrome: a comparative study.

E. Monreal, S. Sainz De La Maza, J.I. Fernandez-Velasco, P. Walo Delgado, M. Espiño, N. Villarrubia, A. Gómez López, J. Masjuan, L. Costa-Frossard, L.M. Villar, Hospital Universitario Ramón y Cajal/Madrid/ES

P0173 - The serum levels of Interleukin 17 in patients with neuromyelitis optica spectrum disorder

T. Varzandi1, A. Omidifar2, M. Torkamani3, N. Rezaeimanesh4, R. Kazemi1, M.A. Sahraian1, A.N. Moghadasi1, Z. Maghbooli1, 1Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran./Tehran/IR, 2Faculty of Paramedical Sciences Shahid Beheshti University of Medical Sciences Tehran,Iran/Tehran/IR, 3Food industry department, Shahid Beheshti University of Medical Sciences Tehran,Iran/Tehran/IR, 4Multiple sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran./Tehran/IR

P0174 - TNFα and IL-6 levels in Relapsing-Remitting Multiple Sclerosis Patients on Dimethylfumarate: a Biomarker Study

W. Baek1, S. Zhai2, E. Morrison2, 1Parkside Medical Group/Upland/US, 2University of California at Riverside/Riverside/US

P0175 - Towards optimized monitoring of serum neurofilament light chain in MS T. Uher1, J. Kuhle2, N. Bergsland3, J. Krasensky4, A. Javor5, B. Srpová6, C. Barro7, M. Dwyer8, M. Tyblova9, P. Benkert10, D. Leppert11, E. Havrdova12, M. Vaneckova4, R. Zivadinov3, T. Kalincik13, D. Horakova12, 1First Faculty of Medicine, Charles University and General University/Prague/CZ, 2University of Basel/Switzerland/CH, 3Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York/Buffalo/US, 4Charles University and General University Hospital/Prague/CZ, 5Biogen International GmbH/Baar/CH, 6Charles University and General University/Prague/CZ, 7Brigham and Women’s Hospital/boston/US, 8Buffalo Neuroimaging Analysis Center/Buffalo/US, 9Charles University/Prague/CZ, 10University Hospital Basel, University of Basel/Basel/CH, 11University Hospital Basel and University of Basel/Basel/CH, 12First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 13Royal Melbourne Hospital/Melbourne/AU

P0176 - Treatment and care management, clinical outcomes and mobility impairment in people with or without MS aged ≥ 50 years: observational 6-year analysis

L. Freeman1, A. Lucas1, J. Zhou2, B. Hayward2, T. Livingston2, 1Dell Medical School, The University of Texas at Austin/Austin/US, 2EMD Serono, Inc., USA (an affiliate of Merck KGaA, Darmstadt, Germany)/Rockland/US

P0177 - Treatment Persistency for Patients in a Phase 2 Long-Term Extension Study of Ponesimod

A. Keenan1, V. Breu2, H. Le3, M. Cole4, B. Hennessy5, 1Janssen Research & Development/Titusville/US, 2Janssen Research and Development/allschwil/CH, 3Janssen Scientific Affairs, LLC/Titusville/US, 4Janssen Research and Development/Titusville/US, 5Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies/Allschwil/CH

P0178 - Use of wearable biosensors to collect real-world patient activity data in two randomized phase 2 studies of elezanumab in multiple sclerosis

K. Pfleeger1, A. Ziemann2, B. Cree3, 1AbbVie/North Chicago/US, 2AbbVie Inc/North Chicago/US, 3University of California San Francisco/San Francisco/US

P0179 - Using NIH Toolbox Standing Balance Test to quantify subtle balance impairment in patients with multiple sclerosis

G. Boffa1, C. Lapucci1, F. Tazza1, E. Mancuso2, E. Sbragia1, N. Bruschi1, M. Cellerino3, M. Inglese4, 1Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI)/Genova/IT, 3University of Genoa/Genoa/IT, 4University of Genoa//IT

P0180 - Utility of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in tracking treatment response in PPMS patients J. Giarraputo, S. Giamberardino, S. Arvai, C. Eckstein, S. Maichle, L. Newby, S. Gregory, Duke University/Durham/US

P0182 - Validation of the FeetMe® System versus GAITRite® to Assess Gait Characteristics in Patients with Multiple Sclerosis: Subpopulation analysis

A. Granja Domínguez1, A. Hochsprung1, S. Palao1, C. Páramo1, A. Alemán Rodríguez1, C. Durán1, G. Navarro1, A. Venegas1, R. Romero Sevilla2, M.J. Moreno Jiménez2, G. Izquierdo1, 1Fundación para el desarrollo de la Investigación y asistencia de enfermedades Neurológicas y Afines Crónicas (DINAC)/Castilleja de la Cuesta, Sevilla/ES, 2Novartis Farmacéutica, S.A./Barcelona/ES

P0183 - Wearable technologies: where can we focus on next in Multiple Sclerosis?

S. Alexander1, G. Peryer2, E. Gray3, F. Barkhof4, J. Chataway5, 1University College London/London/GB, 2University of East Anglia/Norfolk/GB, 3UK MS Society/London/GB, 4Amsterdam UMC, Location VUmc/Amsterdam/NL, 5UCL Queen Square Institute of Neurology, University College//GB

P0184 - A novel approach to conducting Phase IV studies: The design of the global diroximel fumarate EXPERIENCE study initiative

J. Lewin, J. Messer, S. Kapadia, I. Koulinska, S. Luca, M. Rosales, C. De Moor, J.P. Mendoza, C. Miller, Biogen/Cambridge/US

P0185 - A phase II randomised controlled trial of a cognitive behavioral therapy intervention for depression in those newly diagnosed with MS

L. Kiropoulos1, T. Kilpatrick2, T. Kalincik3, L. Cherulov2, N. Shuey4, T. Wijeratne5, 1University of Melbourne/Parkville/AU, 2The Florey Institute of Neuroscience and Mental Health/Melbourne/AU, 3Royal Melbourne Hospital/Melbourne/AU, 4St Vincent's Hospital/Fitzroy/AU, 5Western Health/Melbourne/AU

P0186 - A Phase 1 study of BIIB091, a Bruton’s tyrosine kinase (BTK) inhibitor, in healthy adult participants: preliminary results

M. Scaramozza1, M. Arefayene1, X. Peng1, M. Palte1, J. Kam2, A. Graham1, K. Riester1, A. Coppell1, E. Bame1, M. Mingueneau1, B. Hopkins1, S. Belachew1, N. Franchimont1, 1Biogen/Cambridge/US, 2Covance Clinical Research Unit/Dallas/US

P0187 - A prospective randomized open-label blinded endpoint multicenter non-inferiority study of oral cladribine and rituximab in Multiple Sclerosis (NOR-MS)

G. Nygaard1, Å. Lorentzen2, T. Hognestad3, C. Simonsen4, M. Kampman5, H. Flemmen6, K. Wesnes7, A. Bhan8, S. Bjelland9, C. Natvig10, K. Breivik11, K. Blennow12, H. Zetterberg13, L. Westlye14, E. Celius15, M. Wendel-Haga1, M. Leblanc1, J. Gehin1, H. Stangeland1, T. Berge1, E. Høgestøl1, P. Sowa16, H. Harbo15, 1Oslo University Hospital/Oslo/NO, 2Sørlandet Hospital and The Norwegian National Advisory Unit on Tick-borne diseases/Arendal/NO, 3Innlandet sykehus/Lillehammer/NO, 4Drammen Hospital/Drammen/NO, 5Universitetssykehuset i Nord-Norge/Tromsø/NO, 6Telemark Hospital/Skien/NO, 7St Olavs Hospital/Trondheim/NO, 8Stavanger Universitetssykehus/Stavanger/NO, 9Sykehuset i Vestfold/Tønsberg/NO, 10Sykehuset i Østfold/Grålum/NO, 11Helse Førde/Førde/NO, 12Gothenburg university, Sahlgrenska academy, Institute for Neuroscience and Physiology/Mölndal/SE, 13Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg/Mölndal/SE, 14Division of Mental Health and Addiction,/Oslo/NO, 15Departement of Neurology, Oslo University Hospital, Oslo Norway/Oslo/NO, 16Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway/Oslo/NO

P0188 - A Tablet-Based Cognitive Battery to Assess Cognitive Function in People with MS: Sensitivity to Change in A Randomized Controlled Trial

W.-Y. Hsu, W. Rowles, J. Anguera, A. Anderson, A. Gazzaley, R. Bove, University of California, San Francisco/San Francisco/US

P0189 - AQP4-IgG seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder

S. Pittock1, F. Paul2, R. Marignier3, H.J. Kim4, J. Bennett5, B. Weinshenker6, D. Wingerchuk7, A. Green8, K. Fujihara9, G. Cutter10, O. Aktas11, H.P. Hartung12, J. Drappa13, J. Ratchford13, D. She13, D. Cimbora13, E. Katz13, B. Cree14, 1Mayo Clinic/Rochester/US, 2Charite-Universitatmedizin Berlin/Berlin/DE, 3Lyon Neuroscience Research Center/Bron/FR, 4Research Institute and Hospital, National Cancer Center/Goyang/KR, 5University of Colorado School of Medicine/Aurora/US, 6Mayo Clinic Department of Neurology/Rochester/US, 7Mayo Clinic/United States/US, 8UCSF Multiple Sclerosis Center/United States/US, 9Fukushima Medical University/Fukushima/JP, 10Mellen Center for Multiple Sclerosis Treatment and Research/Cleveland/US, 11Heinrich-Heine-Universität Düsseldorf/Dusseldorf/DE, 12/Dusseldorf/DE, 13Viela Bio/Gaithersburg/US, 14University of California San Francisco/San Francisco/US

P0190 - ASPIRE Study: Protocol for a double-blind RCT of aspirin for overheating during exercise in MS

V. Leavitt1, A. Kever2, K. Nelson1, I. Aguerre1, C. Riley1, P. De Jager3, A. Boehme1, R. Straus Farber3, S. Levin1, N. Lee1, J. Stein2, 1Columbia University Irving Medical Center/New York/US, 2Columbia University Irving Medical Center/new York/US, 3Columbia University Medical Center/United States/US

P0191 - Autologous Stem Cell Transplantation versus Alemtuzumab or Ocrelizumab in Relapsing Remitting Multiple Sclerosis (StarMS)

B. Sharrack1, J. Snowden1, P. Muraro2, 1Sheffield Teaching Hospitals NHS Foundation Trust/Sheffield/GB, 2Imperial College London/London/GB

P0192 - Benefit-risk of ofatumumab in treatment-naïve early relapsing multiple sclerosis patients J. Gartner1, S. Hauser2, A. Bar-Or3, X. Montalban4, J. Cohen5, A.H. Cross6, K. Deiva7, D.A. Häring8, B. Li9, R. Pingili9, K. Ramanathan8, W. Su9, L. Kappos10, 1University Medical Center Göttingen//DE, 2University of California San Francisco/San Francisco/US, 3University of Pennsylvania/Philadelphia/US, 4Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron/Barcelona/ES, 5Mellen Center for MS Treatment and Research, Cleveland Clinic/Cleveland/US, 6Department of Neurology, Division of Neuroimmunology, Washington University School of Medicine/Saint Louis/US, 7Department of pediatric neurology, University hospitals Paris Saclay, Hôpital Bicêtre, National Reference Center for Rare Inflammatory Brain and Spinal Diseases/Le Kremlin Bicêtre/FR, 8Novartis Pharma AG/Basel/CH, 9Novartis Pharmaceuticals Corporation/East Hanover/US, 10Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel/Basel/CH

P0193 - BEST-MS: A standardized and prospective study comparing the efficacy of natalizumab versus fingolimod in active relapsing multiple sclerosis

M. Cohen1, L. Mondot2, F. Bucciarelli3, B. Pignolet3, D. Laplaud4, B. Brochet5, G. Defer6, P. Vermersch7, M. Debouverie8, E. Berger9, P. Labauge10, J. De Seze11, D. Brassat3, C. Lebrun- Frenay12, 1CHU de Nice - Hopital Pasteur 2/Nice/FR, 2CHU de Nice/Nice/FR, 3CHU de Toulouse/Toulouse/FR, 4CHU de Nantes/Nantes/FR, 5University of Bordeaux/Bordeaux/FR, 6CHU de Caen/Caen/FR, 7CHU de Lille/Lille/FR, 8CHU de Nancy/Nancy/FR, 9CHU de Besançon/Besançon/FR, 10CHU de Montpellier/Montpellier/FR, 11CHU de Strasbourg/Strasbourg/FR, 12Centre Hospitalier University de Nice/Nice/FR

P0194 - Cardiac Safety of Ponesimod in Relapsing Multiple Sclerosis in the Randomized, Active- Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study

T. Sprenger1, A. Vaclavkova2, M. Burcklen2, M. Freedman3, R. Fox4, E. Havrdová5, B. Hennessy2, V. Walter2, R. Hohlfeld6, F. Lublin7, X. Montalban8, C. Pozzilli9, T. Scherz2, P. Linscheid2, M. Pirozek- Lawniczek2, H. Kracker2, A. Camm10, L. Kappos11, 1DKD Helios/Wiesbaden/DE, 2Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies/Allschwil/CH, 3The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 4Cleveland Clinic//US, 5Charles University, Department of Neurology/Prague/CZ, 6Ludwig Maximilians University of Munich (LMU)/Munich/DE, 7Mount Sinai School of Medicine/United States/US, 8Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron/Barcelona/ES, 9Sapienza University of Rome/Rome/IT, 10Cardiology Clinical Academic Group Molecular & Clinical Sciences Institute, St George's University of London/London/GB, 11University of Basel//CH

P0195 - Characteristics of Therapeutic Sequences of Patients Enrolled in the PRO-MSACTIVE Study Evaluating Ocrelizumab in Active Relapsing Multiple Sclerosis

C. Lebrun-Frenay1, S. Vukusic2, P. Labauge3, C. Bensa4, B. Bourre5, E. Manchon6, P.-H. Depoortere7, M. Lotz7, R. Niarra7, D. Laplaud8, 1Centre Hospitalier University de Nice/Nice/FR, 2Lyon University Hospital/BRON/FR, 3CHU de Montpellier/Montpellier/FR, 4Fondation Rothschild/Paris/FR, 5CHU Rouen Normandie/Rouen/FR, 6Centre Hospitalier de Gonesse/Gonesse/FR, 7Roche/Boulogne- Billancourt/FR, 8CHU de Nantes/Nantes/FR

P0196 - Cladribine to halt deterioration in people with advanced multiple sclerosis (ChariotMS)

D. Lieberman1, H. Mangat2, K. Allen-Philbey1, D. Baker2, F. Barkhof3, S. Chandran4, C. Chapman2, J. Chataway5, H. Ford6, G. Giovannoni7, J. Hobart8, R. Hooper2, T. Hussain9, N. Walker2, D. Macmanus10, B. Mihaylova2, S. Pavitt11, K. Schmierer2, 1Royal London Hospital-Barts Health NHS Trust/London/GB, 2Queen Mary University London/London/GB, 3University College London/LONDON/GB, 4The University of Edinburgh/Edinburgh/GB, 5UCL Queen Square Institute of Neurology, University College//GB, 6Leeds Teaching Hospitals NHS Trust/Leeds/GB, 7The London School of Medicine and Dentistry/London/GB, 8University of Plymouth/Plymouth/GB, 9Queen Mary University London/AB/GB, 10University College London/London/GB, 11University of Leeds/Leeds/GB

P0197 - Clinical relapse rates in relapsing MS patients treated with the BTK inhibitor evobrutinib: results of an open-label extension to a Phase II study

X. Montalban1, D.L. Arnold2, M. Weber3, I. Staikov4, K. Piasecka-Stryczynska5, E. Martin6, M. Mandel6, V. Ona7, F. Dangond8, J. Wolinsky9, 1Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron/Barcelona/ES, 2MNI, McGill/Quebec/CA, 3University Medical Center Goettingen/Goettingen/DE, 4Acibadem City Clinic Tokua Hospital/Sofia/BG, 5University of Medical Science, Poznan, Poland/Poznan/PL, 6EMD Serono/Billerica/US, 7EMD Serono (a business of Merck KGaA, Darmstadt, Germany)/Billerica/US, 8EMD Serono, Inc./Rockland/US, 9The University of Texas Health Science Center at Houston/Houston/US

P0198 - Comparative effectiveness of different DMT strategies in new onset RRMS; First results of the CombatMS trial

S. Virtanen1, F. Piehl2, T. Frisell1, 1Karolinska Institutet/Stockholm/SE, 2Karolinska Institute/Stockholm/SE

P0199 - Declining to participate in a randomised controlled trial of a cognitive occupation-based program for people with multiple sclerosis.

A. Moses1, C.P. Dwyer2, R. Joyce2, D. Casey1, S.M. Hynes1, 1National University of Ireland Galway/Galway/IE, 2National university of Ireland Galway/Galway/IE

P0200 - Diroximel Fumarate in Patients With Relapsing-Remitting Multiple Sclerosis: Interim Safety and Efficacy Results From the Phase 3 EVOLVE-MS-1 Study

S. Wray1, B. Singer2, J. Drulovic3, H. Chen4, J. Hanna4, J. Lyons4, F. Then Bergh5, D. Negroski6, S. Kapadia4, 1Hope Neurology MS Center/Knoxville/US, 2Baptist Medical Center/St Louis/US, 3University of Belgrade/Belgrade/RS, 4Biogen/Cambridge/US, 5University of Leipzig/Leipzig/DE, 6MS Center of Sarasota/Sarasota/US

P0201 - Disability improvement in relapsing-remitting multiple sclerosis patients receiving cladribine tablets, evaluated by expanded disability status scale

M.P. Sormani1, G. Giovannoni2, A. Signori1, N. Alexandri3, 1University of Genoa/Genoa/IT, 2The London School of Medicine and Dentistry/London/GB, 3Merck KGaA/Darmstadt/DE

P0202 - Durable efficacy of cladribine tablets: cumulative relapse incidence over 5 years in CLARITY and CLARITY Extension

G. Giovannoni1, K. Rammohan2, T. Leist3, P. Coyle4, B. Keller5, D. Jack5, N. Alexandri5, 1The London School of Medicine and Dentistry/London/GB, 2University of Miami School of Medicine/Miami/US, 3Jefferson University/Philadelphia/US, 4Stony Brook University/Stony Brook/US, 5Merck KGaA/Darmstadt/DE

P0203 - Effect of teriflunomide on MRI lesion activity across age groups in patients with relapsing multiple sclerosis from the TEMSO study

J. Oh1, J. Wuerfel2, B. Khatri3, A. Miller4, J. Inshasi5, A. Saiz6, A. Lublin7, E. Poole7, T. Sprenger8, 1University of Toronto/Toronto/CA, 2Medical Image Analysis Center/Basel/CH, 3Ascension Medical Group/Milwaukee/US, 4Mount Sinai Hospital/New York City/US, 5Rashid Hospital/Dubai/AE, 6Hospital Clínic i Provincial de Barcelona/Barcelona/ES, 7Sanofi/Cambridge/US, 8DKD Helios/Wiesbaden/DE

P0204 - Effect on disability measures and MSFC in patients with relapsing multiple sclerosis from the phase 3 ponesimod versus teriflunomide optimum study

R. Fox1, L. Kappos2, M. Burcklen3, M. Freedman4, E. Havrdova5, B. Hennessy3, R. Hohlfeld6, F. Lublin7, X. Montalban8, C. Pozzilli9, T. Scherz3, P. Linscheid3, L. Ford10, M. Pirozek-Lawniczek3, H. Kracker3, T. Sprenger11, 1Cleveland Clinic//US, 2University of Basel//CH, 3Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies/Allschwil/CH, 4The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 5First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 6Ludwig Maximilians University of Munich (LMU)/Munich/DE, 7Mount Sinai School of Medicine/United States/US, 8Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 9Sapienza University of Rome/Rome/IT, 10Janssen Research & Development, LLC/Titusville/US, 11DKD Helios/Wiesbaden/DE

P0205 - Effects of Diroximel Fumarate on Brain Volume Change and Disability Progression in Adults With Relapsing-Remitting Multiple Sclerosis From EVOLVE-MS-1

D.L. Arnold1, J. Oh2, B.A. Singer3, H. Chen4, J. Hanna4, C. Miller4, R.T. Naismith5, 1MNI, McGill/Quebec/CA, 2University of Toronto/Toronto/CA, 3The MS Center for Innovations in Care, Missouri Baptist Medical Center/St Louis/US, 4Biogen/Cambridge/US, 5Washington University/Saint Louis/US

P0206 - Effects of nanocatalysis on CNS bioenergetic markers in patients treated with CNM-Au8: Interim results from two Phase 2 31Phosphorous imaging studies

J. Ren1, A. Rynders2, J. Evan2, B. Greenberg3, R. Dewey, Jr.1, K. Ho, Phd2, R. Glanzman, Md, Faan2, M. Hotchkin2, 1University of Texas Southwestern Medical Center/Dallas/US, 2Clene Nanomedicine Inc/Holladay/US, 3Department of Neurology and Neurotherapeutics/Dallas/US

P0207 - Effects of Nurse Practitioner Care compared to Community Neurologist Care on Depression and Anxiety Levels in People with MS: a randomized trial

P. Smyth, K. Watson, K. Turpin, R. Tsuyuki, University of Alberta/Edmonton/CA

P0208 - Effects of Wahls Elimination and Swank Dietary Patterns on Multiple Sclerosis Related Fatigue, Quality of Life, Processing Speed and Waking Distance

T. Wahls, W. Darling, K. Hoth, J. Kamholz, L. Rubenstein, P. Ten Eyck, B. Bisht, T. Titcomb, L. Snetselaar, University of Iowa/Iowa City/US

P0209 - Efficacy and safety of ofatumumab versus placebo in relapsing multiple sclerosis patients in Japan and Russia: Results from the Phase 2 APOLITOS study

J.-I. Kira1, J. Nakahara2, D.V. Sazonov3, T. Kurosawa4, I. Tsumiyama4, R. Willi5, M. Zalesak5, D.A. Häring5, K. Ramanathan5, M. Merschhemke5, R. Pingili6, T. Saida7, 1Translational Neuroscience Center, Graduate School of Medicine, and Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare/Fukuoka/JP, 2Department of Neurology, Keio University School of Medicine/Tokyo/JP, 3Siberian District Medical Centre of the Federal Medical and Biological Agency of Russia/Novosibirsk/RU, 4Novartis Pharma KK/Tokyo/JP, 5Novartis Pharma AG/Basel/CH, 6Novartis Pharmaceuticals Corporation/NJ/US, 7Kansai Multiple Sclerosis Center and Kyoto Min-iren Central Hospital/Kyoto/JP

P0210 - Elezanumab in patients with different disease courses of multiple sclerosis: study design and baseline analysis from two phase 2 studies

B. Cree1, A. Ziemann2, K. Pfleeger3, B. Schwefel4, A. Wundes5, M. Freedman6, 1University of California San Francisco/San Francisco/US, 2AbbVie Inc/North Chicago/US, 3AbbVie/North Chicago/US, 4AbbVie Inc./North Chicago/US, 5University of Washington Medical Center/Seattle/US, 6The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA

P0211 - Examination of fenebrutinib, a highly selective BTKi, on disease progression of multiple sclerosis

S. Hauser1, A. Bar-Or2, G. Francis3, G. Giovannoni4, L. Kappos5, J. Nicholas6, J. Oh7, M.P. Sormani8, S. Stoll9, M. Weber10, A. Viaccoz11, V. Levesque12, H. Mackey12, A. Goodyear12, 1University of California San Francisco/San Francisco/US, 2University of Pennsylvania/Philadelphia/US, 3Queen’s University/San Francisco/US, 4The London School of Medicine and Dentistry/London/GB, 5University of Basel//CH, 6OhioHealth Multiple Sclerosis Center/Columbus/US, 7University of Toronto/Toronto/CA, 8University of Genoa/Genoa/IT, 9Yale School of Medicine/New Haven/US, 10University Medical Center Goettingen/Goettingen/DE, 11Roche/Basel/CH, 12Genentech, Inc./South San Francisco/US

P0212 - Ginseng as a possible candidate for fatigue management in neuromyelitis optica spectrum disorder: a double-blind randomized clinical trial

S. Aslzadeh1, S. Shahmirzaei2, M.A. Sahraian3, R.S. Kazemi Mozdabadi2, H. Rezaei Aliabadi3, M.R. Gheini2, N. Rezaeimanesh1, S. Eskandarieh4, F. Majidi5, A.N. Moghadasi3, 1Multiple sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran./Tehran/IR, 2Multiple sclerosis research center, Sina hospital/Tehran/IR, 3Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran./Tehran/IR, 4Multiple Sclerosis Research Center/1136746911/IR, 5Research Development Center, Sina Hospital, Tehran University of Medical Sciennces, Tehran, Iran/Tehran/IR

P0213 - Immune cell profiles and clinical and safety outcomes with fingolimod in the 12 month FLUENT study of patients with relapsing multiple sclerosis

Y. Mao-Draayer1, J. Cohen2, A. Bar-Or3, M. Han4, B. Singer5, S. Kolodny6, C. Elam6, X. Meng6, M. Ziehn7, B. Cree8, 1Autoimmunity Center of Excellence/MI/US, 2Mellen Center for MS Treatment and Research, Cleveland Clinic/Cleveland/US, 3University of Pennsylvania/Philadelphia/US, 4Stanford University/Stanford/US, 5Baptist Medical Center/St Louis/US, 6Novartis Pharmaceuticals Corporation/NJ/US, 7Novartis Pharma AG/Basel/CH, 8University of California San Francisco/San Francisco/US

P0214 - Improved GI tolerability with diroximel fumarate Is associated with clinically meaningful benefits on QoL compared to dimethyl fumarate in EVOLVE-MS-2

A. Wundes1, S. Wray2, E. Jasinska3, T. Ziemssen4, H. Chen5, J. Hanna5, J. Lyons5, J. Messer5, R.T. Naismith6, 1University of Washington Medical Center/Seattle/US, 2Hope Neurology MS Center/Knoxville/US, 3Collegium Medicum UJK, and Clinical Center, RESMEDICA/Kielce/PL, 4Carl Gustav Carus University Hospital/Dresden/DE, 5Biogen/Cambridge/US, 6Washington University/Saint Louis/US

P0215 - Long-term efficacy and safety of ponesimod: Results from randomized phase II core and extension studies in relapsing-remitting multiple sclerosis

M. Freedman1, C. Pozzilli2, E. Kubala Havrdová3, P. Coyle4, A. Lemle5, M. Burcklen5, A. Larbalestier5, B. Hennessy5, T. Scherz5, A. Vaclavkova5, T. Olsson6, 1The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 2Sapienza University of Rome/Rome/IT, 3Charles University//CZ, 4Stony Brook University/Stony Brook/US, 5Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies/Allschwil/CH, 6Karolinska Institute/Stockholm/SE

P0216 - Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS G. Giovannoni1, L. Kappos2, J. De Seze3, S. Hauser4, J. Overell5, H. Koendgen5, H.-M. Schneble5, K. Prajapati6, Q. Wang5, J. Wolinsky7, 1The London School of Medicine and Dentistry/London/GB, 2University Hospital Basel, University of Basel/Basel/CH, 3CHU de Strasbourg/Strasbourg/FR, 4University of California San Francisco/San Francisco/US, 5F. Hoffmann-La Roche Ltd/Basel/CH, 6GCE Solutions Inc./Amsterdam/NL, 7The University of Texas Health Science Center at Houston/Houston/US

P0217 - Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in DAYBREAK: an open-label extension study of ozanimod phase 1−3 trials

K. Selmaj1, L. Steinman2, G. Comi3, A. Bar-Or4, D. Arnold5, H.P. Hartung6, X. Montalban7, E. Havrdova8, J. Sheffield9, T. Chen9, N. Minton9, D. Silva9, L. Kappos10, J. Cohen11, B. Cree12, 1Department of Neurology, University of Warmia and Mazury/Olsztyn/PL, 2Beckman Center for Molecular Medicine, Stanford University Medical Center/Stanford/US, 3San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 4University of Pennsylvania/Philadelphia/US, 5McGill University and NeuroRx Research/Montreal/CA, 6/Dusseldorf/DE, 7Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 8First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 9Bristol- Myers Squibb Company/Princeton/US, 10University Hospital and University of Basel/Basel/CH, 11Mellen Center for MS Treatment and Research, Cleveland Clinic/Cleveland/US, 12University of California San Francisco/San Francisco/US

P0218 - Long-term safety, compliance, and effectiveness of ofatumumab in patients with relapsing multiple sclerosis: ALITHIOS Phase 3b study

E.J. Fox1, L. Mayer1, A. Aungst2, L. Mancione3, N. Rennie4, A. Roustan4, D. Stoneman4, W. Su5, A. Das Gupta6, M. Zalesak4, M.O. Ziehn4, D. Robertson7, J. Cohen8, 1Central Texas Neurology Consultants, University of Texas Dell Medical School/Round Rock/US, 2Multiple Sclerosis Division, Department of Neurology, University of South Florida, FL, USA/Multiple Sclerosis Division, Department of Neurology, University of South Florida, Florida/US, 3Novartis Pharmaceuticals Corporation/Novartis Pharmaceuticals Corporation, EastHanover/US, 4Novartis Pharma AG/Basel/CH, 5Novartis Pharmaceuticals Corporation/East Hanover/US, 6Novartis Healthcare Pvt. Ltd./Hyderabad/IN, 7University of South Florida Morsani College of Medicine/Tampa/US, 8Mellen Center for MS Treatment and Research, Cleveland Clinic/Cleveland/US

P0219 - Ocrelizumab Phase IIIb efficacy from CASTING: 2-year NEDA (MRI re-baselined) subgroup rates in RRMS patients with a suboptimal response to prior DMTs

H. Wiendl1, G. Comi2, C. Oreja-Guevara3, A. Siva4, B. Van Wijmeersch5, J. Wuerfel6, R. Buffels7, K. Kadner7, T. Kuenzel8, P. Vermersch9, 1University of Münster/Germany/DE, 2San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 3Hospital Universitario Clinico San Carlos/Madrid/ES, 4Istanbul University Cerrahpaşa School of Medicine/Istanbul/TR, 5Universiteit Hasselt/Hasselt/BE, 6Medical Image Analysis Center/Basel/CH, 7F. Hoffmann-La Roche Ltd/Basel/CH, 8F Hoffmann-La Roche Ltd/Basel/CH, 9CHU de Lille/Lille/FR

P0220 - Ocrelizumab Phase IIIb efficacy: 1-year NEDA rates (with MRI re-baselining) from the ENSEMBLE study in early-stage relapsing-remitting MS patients

H.P. Hartung1, T. Berger2, R. Bermel3, B. Brochet4, T. Holmøy5, R. Karabudak6, J. Killestein7, C. Nos8, F. Patti9, A. Perrin Ross10, T. Vollmer11, J. Wuerfel12, R. Buffels13, T. Kuenzel14, M. Freedman15, 1/Dusseldorf/DE, 2Medical University of Vienna/Vienna/AT, 3Mellen Center for Multiple Sclerosis, Cleveland Clinic/Cleveland/US, 4University of Bordeaux/Bordeaux/FR, 5Akerhus University Hospital/Nordbyhagen/NO, 6Hacettepe University Faculty of Medicine/Ankara/TR, 7Amsterdam UMC, Location VUmc/Amsterdam/NL, 8Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari/Bercelona/ES, 9Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 10Loyola University Chicago/Oak Brook/US, 11University of Colorado School of Medicine/Aurora/US, 12Medical Image Analysis Center/Basel/CH, 13F. Hoffmann- La Roche Ltd/Basel/CH, 14F Hoffmann-La Roche Ltd/Basel/CH, 15The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA

P0221 - Ocrelizumab treatment in patients with RRMS who had a suboptimal response with one or more prior disease-modifying therapies: CHORDS 2-year results

B. Weinstock-Guttman1, R. Bermel2, G. Cutter3, M. Freedman4, T. Leist5, J. Pei6, D. Kile7, B. Musch7, A. Reder8, J. Wolinsky9, 1State University of New York at Buffalo/Buffalo/US, 2Cleveland Clinic/Cleveland/US, 3The University of Alabama at Birmingham/Birmingham/US, 4The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 5Jefferson University/Philadelphia/US, 6Genentech, Inc./South San Francisco/US, 7Genentech/South San Francisco/US, 8University of Chicago/Burr Ridge/US, 9The University of Texas Health Science Center at Houston/Houston/US

P0222 - OLIKOS study design: exploring maintained ofatumumab efficacy in relapsing MS patients who transition from intravenous anti-CD20 therapy

B. Greenberg1, E. Alvarez2, J. Foley3, R. Henry4, J. Brown5, E. Camacho5, X. Meng5, M. Ziehn6, B. Brown5, L.H. Hua7, 1Department of Neurology and Neurotherapeutics/Dallas/US, 2University of Colorado/Aurora/US, 3Rocky Mountain Multiple Sclerosis Clinic/Salt Lake City/US, 4UCSF Weill Institute for Neurosciences, Department of Neurology, University of California/San Francisco/US, 5Novartis Pharmaceuticals Corporation/NJ/US, 6Novartis Pharma AG/Basel/CH, 7Cleveland Clinic Lou Ruvo Center for Brain Health/Las Vegas/US

P0223 - “Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis – a prospective multicenter trial in The Netherlands"

A. Toorop1, T. Rispens2, B. Uitdehaag3, J. Killestein3, Z. Van Kempen1, 1Amsterdam UMC/Amsterdam/NL, 2Sanquin Research Amsterdam/Amsterdam/NL, 3Amsterdam UMC, Location VUmc/Amsterdam/NL

P0224 - Pharmacokinetic-Pharmacodynamic Models of Lymphocyte Count and Heart Rate Following Ponesimod Dosing in a Phase 2 Study in Multiple Sclerosis Patients

I. Poggesi1, B. Valenzuela Jiménez2, S. Ouwerkerk-Mahadevan3, A. Lemle4, M. Burcklen4, A. Larbalestier4, B. Hennessy4, T. Scherz4, A. Vaclavkova4, Q. Leirens5, J.J. Perez-Ruixo6, 1Janssen Research & Development/Cologno Monzese/IT, 2Janssen Research & Development/Jan-Cil/ES, 3Janssen Research & Development/Beerse/BE, 4Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies/Allschwil/CH, 5SGS Exprimo NV/Geneva/CH, 6Janssen Research & Development/Antwerp/BE

P0225 - Phase 3 Study Results Assessing the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in MS Patients with Walking Impairment

J. Cohen1, M. Cameron2, M. Goldman3, A. Goodman4, A. Miller5, A. Rollins6, R. Johnson7, L. Llorens6, R. Patni8, R. Elfont8, 1Mellen Center for MS Treatment and Research, Cleveland Clinic/Cleveland/US, 2Oregon Health & Science University/Portland/US, 3Virginia Commonewalth University/Richmond/US, 4University of Rochester Medical Center/Rochester/US, 5Mount Sinai Hospital/New York City/US, 6Adamas Pharmaceuticals, Inc/Emeryville/US, 7Adamas Pharmaceuticals, Inc./Emeryville/US, 8Formerly with Adamas Pharmaceuticals, Inc/Emeryville/US

P0226 - Phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive forms of multiple sclerosis

M.P. Pender1, S.J. Hodgkinson2, S. Broadley3, J. Lindsey4, Z.A. Ioannides1, B. Bagert5, R. Khanna6, C. Smith6, L. Gamelin7, W. Ye7, J. Willmer7, A. Bar-Or8, 1The University of Queensland/Brisbane/AU, 2University of New South Wales/Sydney/AU, 3Griffith University/Southport/AU, 4University of Texas Health Science Center at Houston/Houston/US, 5Ochsner Health/New Orleans/US, 6QIMR Centre for Immunotherapy and Vaccine Development, QIMR Berghofer Medical Research Institute/Brisbane/AU, 7Atara Biotherapeutics/South San Francisco/US, 8University of Pennsylvania/Philadelphia/US

P0227 - Phase I, multicenter, two-part study of ATA188, an open-label, dose-escalation and double- blind, placebo-controlled dose-expansion study

A. Bar-Or1, L. Gamelin2, W. Ye2, J. Willmer2, B.T. Aftab2, P. Foubert2, M.P. Pender3, 1University of Pennsylvania/Philadelphia/US, 2Atara Biotherapeutics/South San Francisco/US, 3The University of Queensland/Brisbane/AU

P0228 - Post-treatment recovery of lymphocyte subsets in healthy volunteers treated with ozanimod

S. Harris1, J. Tran1, P. Zhang1, H. Southworth2, 1Bristol-Myers Squibb Company/Princeton/US, 2Data Clarity Consulting Ltd./Stockport/GB

P0229 - Quiescent MRI activity in neuromyelitis optica spectrum disorder: results from the N- MOmentum randomized placebo-controlled trial F. Paul1, D. Wingerchuk2, B. Weinshenker3, J. Bennett4, H.J. Kim5, S. Pittock6, K. Fujihara7, G. Cutter8, R. Marignier9, O. Aktas10, H.P. Hartung11, A. Green12, J. Drappa13, M. Smith13, W. Rees13, J. Ratchford13, D. She13, D. Cimbora13, D. Stefani-Hunyady13, E. Katz13, B. Cree14, 1Charite-Universitatmedizin Berlin/Berlin/DE, 2Mayo Clinic/Scottsdale/US, 3Mayo Clinic Department of Neurology/Rochester/US, 4University of Colorado School of Medicine/Aurora/US, 5Research Institute and Hospital, National Cancer Center/Goyang/KR, 6Mayo Clinic/Rochester/US, 7Fukushima Medical University/Fukushima/JP, 8Mellen Center for Multiple Sclerosis Treatment and Research/Cleveland/US, 9Lyon Neuroscience Research Center/Bron/FR, 10Heinrich-Heine-Universität Düsseldorf/Dusseldorf/DE, 11/Dusseldorf/DE, 12UCSF Multiple Sclerosis Center/United States/US, 13Viela Bio/Gaithersburg/US, 14University of California San Francisco/San Francisco/US

P0230 - Rationale and design of two Phase IIIb studies of ocrelizumab at higher than the approved dose in patients with RMS and PPMS

S. Hauser1, A. Bar-Or2, G. Francis3, L. Kappos4, J. Nicholas5, J. Oh6, M.P. Sormani7, S. Stoll8, M. Weber9, K. Fitovski10, M. Garas10, H. Kletzl10, H. Koendgen10, M. Manfrini10, F. Model10, H.-M. Schneble10, S. Yiu11, G. Giovannoni12, 1University of California San Francisco/San Francisco/US, 2University of Pennsylvania/Philadelphia/US, 3Queen’s University/San Francisco/US, 4University Hospital Basel, University of Basel/Basel/CH, 5OhioHealth Multiple Sclerosis Center/Columbus/US, 6University of Toronto/Toronto/CA, 7University of Genoa/Genoa/IT, 8Yale School of Medicine/New Haven/US, 9University Medical Center Goettingen/Goettingen/DE, 10F. Hoffmann-La Roche Ltd/Basel/CH, 11Roche Products Limited/Welwyn Garden City/GB, 12The London School of Medicine and Dentistry/London/GB

P0231 - Reduced grey matter atrophy in patients with relapsing multiple sclerosis treated with cladribine tablets

M. Battaglini1, M.P. Sormani2, L. Luchetti1, G. Gentile1, R. Cortese3, N. Alexandri4, N. De Stefano5, 1University of Siena/Siena/IT, 2University of Genoa/Genoa/IT, 3University of Siena and University College London, UK/Siena/IT, 4Merck KGaA/Darmstadt/DE, 5University of Siena//IT

P0232 - Safety and efficacy of dimethyl fumarate in patients with primary progressive multiple sclerosis: A double-blind, randomized phase 2 trial

H. Højsgaard Chow, University Hospital Rigshospitalet/Glostrup/DK

P0233 - Safety and tolerability of conversion to siponimod in patients with relapsing multiple sclerosis: interim results of the EXCHANGE study

A. Bar-Or1, B. Weinstock-Guttman2, Y. Mao-Draayer3, G. Cox4, L.-A. Cruz4, X. Meng5, W. Su5, S. Cohan6, 1University of Pennsylvania/Philadelphia/US, 2State University of New York at Buffalo/Buffalo/US, 3Autoimmunity Center of Excellence/MI/US, 4Novartis Pharmaceuticals Corporation/East Hanover/US, 5Novartis Pharmaceuticals Corporation/NJ/US, 6Providence MS Center/Portland/US

P0234 - Safety experience with extended exposure to ofatumumab in patients with relapsing multiple sclerosis from Phase 2 and 3 clinical trials

A.H. Cross1, E. Fox2, J. De Seze3, A. Bar-Or4, H. Wiendl5, A. Das Gupta6, D.A. Häring7, V. Jehl7, C. Kerloeguen7, M. Gufran6, R. Pingili8, W. Su9, M. Zalesak7, S. Hauser10, L. Kappos11, 1Department of Neurology, Division of Neuroimmunology, Washington University School of Medicine/Saint Louis/US, 2Central Texas Neurology Consultants and Dell Medical School, The University of Texas at Austin, Round Rock/Austin/US, 3University Hospital of Strasbourg/Strasbourg/FR, 4University of Pennsylvania/Philadelphia/US, 5University of Münster/Germany/DE, 6Novartis Healthcare Pvt. Ltd./Hyderabad/IN, 7Novartis Pharma AG/Basel/CH, 8Novartis Pharmaceuticals Corporation/NJ/US, 9Novartis Pharmaceuticals Corporation/East Hanover/US, 10University of California San Francisco/San Francisco/US, 11Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel/Basel/CH

P0235 - Safety of the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis during an open-label extension to a phase II study

X. Montalban1, D.L. Arnold2, M. Weber3, I. Staikov4, K. Piasecka-Stryczynska5, E. Martin6, M. Mandel6, V. Ona7, Y. Zima7, D. Tomic8, J. Wolinsky9, F. Dangond10, 1Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 2MNI, McGill/Quebec/CA, 3University Medical Center Goettingen/Goettingen/DE, 4Acibadem City Clinic Tokua Hospital/Sofia/BG, 5Hanka Hertmanowska MS Care Center/Plewiska/PL, 6EMD Serono/Billerica/US, 7EMD Serono (a business of Merck KGaA, Darmstadt, Germany)/Billerica/US, 8Merck KGaA/Darmstadt/DE, 9The University of Texas Health Science Center at Houston/Houston/US, 10EMD Serono, Inc./Rockland/US

P0236 - Serum immunoglobulin levels and infection risk in the Phase 3 trials of ofatumumab in relapsing multiple sclerosis

H. Wiendl1, J. De Seze2, A. Bar-Or3, J. Correale4, A.H. Cross5, L. Kappos6, K. Selmaj7, A. Das Gupta8, D.A. Haering9, V. Jehl9, C. Kerloeguen9, R. Pingili10, W. Su10, R. Sullivan10, M. Zalesak9, S. Hauser11, 1University of Münster/Germany/DE, 2University Hospital of Strasbourg/Strasbourg/FR, 3University of Pennsylvania/Philadelphia/US, 4Institute for Neurological Research Dr. Raul Carrea/Buenos Aires/AR, 55Washington University School of Medicine/Saint Louis/US, 6University Hospital Basel and University of Basel/Basel/CH, 7Department of Neurology, University of Warmia and Mazury/Olsztyn/PL, 8Novartis Healthcare Pvt. Ltd./Hyderabad/IN, 9Novartis Pharma AG/Basel/CH, 10Novartis Pharmaceuticals Corporation/East Hanover/US, 11University of California San Francisco/San Francisco/US

P0237 - Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the ORATORIO OLE: 7-year follow-up

J. Wolinsky1, P. Vermersch2, H.P. Hartung3, R.T. Naismith4, L. Airas5, K. Coutant6, H. Koendgen6, H.-M. Schneble6, J. Overell6, A. Sauter6, K. Prajapati7, L. Kappos8, 1The University of Texas Health Science Center at Houston/Houston/US, 2CHU de Lille/Lille/FR, 3/Dusseldorf/DE, 4Washington University/Saint Louis/US, 5University of Turku/Turku/FI, 6F. Hoffmann-La Roche Ltd/Basel/CH, 7GCE Solutions Inc./Amsterdam/NL, 8University of Basel//CH

P0238 - Sustained reduction of disability and cognitive decline with long-term siponimod treatment in patients with active SPMS: EXPAND data up to 5 years

G. Giovannoni1, L. Kappos2, R. Fox3, P. Vermersch4, B.A.C. Cree5, R. Benedict6, A. Bar-Or7, N. Rouyrre8, D. Piani-Meier8, T. Hach8, S. Ritter9, A. Kilaru8, F. Dahlke8, G. Karlsson8, R. Gold10, 1The London School of Medicine and Dentistry/London/GB, 2Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel/Basel/CH, 3Cleveland Clinic//US, 4CHU de Lille/Lille/FR, 5UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco/San Francisco/US, 6University At Buffalo/Buffalo/US, 7University of Pennsylvania/Philadelphia/US, 8Novartis Pharma AG/Basel/CH, 9Novartis Pharmaceuticals Corporation/East Hanover/US, 10St. Josef-Hospital, Ruhr University Bochum/Bochum/DE

P0239 - Temelimab for prevention of neurodegeneration: preclinical safety profile and design of the ProTEct-MS (temelimab following rituximab in RMS) study

F. Piehl1, G. Kornmann2, B. Cree3, H.P. Hartung4, C. Granziera5, T. Granberg6, J. Kuhle7, B. Buffet2, N. Berthuy2, J. Leja-Jarblad8, G. Törnqvist8, J. Medina9, P. Küry10, T. Rückle2, D. Leppert5, 1Karolinska Institute/Stockholm/SE, 2GeNeuro/Plan-les-Ouates/CH, 3University of California San Francisco/San Francisco/US, 4/Dusseldorf/DE, 5University Hospital Basel and University of Basel/Basel/CH, 6Karolinska Insitutet/Stockholm/SE, 7University of Basel/Switzerland/CH, 8Immuneed/Uppsala/SE, 9GeNeuro Innovation/Lyon/FR, 10Department of Neurology, UKD, Heinrich-Heine-University Düsseldorf/Dusseldorf/DE

P0240 - Therapeutic Decisions in MS Care: An International Study comparing Clinical Judgement vs. Information from Artificial Intelligence-Based Models

G. Saposnik1, X. Montalban2, M.P. Amato3, Ó. Fernández4, F. Caceres5, H.J. Kim6, A. Costa7, V. Popescu8, E. Kubala Havrdová9, M. Magyari10, H. Wiendl11, T. Kalincik12, E. Celius13, M. Terzaghi1, R. Bermel14, F. Zuo15, J. Oh16, 1Saint Michael´s Hospital/Toronto/CA, 2Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 3University of Florence/Florence/IT, 4Fundacion IMABIS, Hospital Universitario Carlos Haya/Málaga/ES, 5INERE/Buenos Aires/AR, 6Research Institute and Hospital, National Cancer Center/Goyang/KR, 7University of Porto/Porto/PT, 8Revalidatie & MS Centrum VZW/Overpelt/BE, 9Charles University//CZ, 10Danish Multiple Sclerosis Center/Glostrup/DK, 11University of Münster/Germany/DE, 12Royal Melbourne Hospital, University of Melbourne/Melbourne/AU, 13Departement of Neurology, Oslo University Hospital, Oslo Norway/Oslo/NO, 14Mellen Center for Multiple Sclerosis, Cleveland Clinic/Cleveland/US, 15LI Ka Shing Knowledge Institute/Toronto/CA, 16University of Toronto/Toronto/CA

P0241 - Top-line Results of EMPhASIS, a Phase 2 Clinical Trial of Vidofludimus Calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis R. Fox1, H. Wiendl2, N. De Stefano3, J. Sellner4, A. Mühler5, 1Cleveland Clinic//US, 2University of Münster/Germany/DE, 3University of Siena//IT, 4Landesklinikum Mistelbach- Gänserndorf/Mistelbach/AT, 5Immunic, Inc/New York/US

P0242 - Treating minority patients with multiple sclerosis: development of the CHIMES trial

M. Williams1, L. Amezcua2, T. Vartanian3, G. Wu4, N. Monson5, E. Bernitsas6, C. Harp7, X. Jia7, J. Pei7, A. Kothari7, A. Reder8, 1Morehouse School of Medicine/Atlanta/US, 2USC/Los Angeles/US, 3Weill Cornell Medicine/New York City/US, 4Washington University in St. Louis/United States/US, 5UT Southwestern/Dallas/US, 6Wayne State University/Detroit/US, 7Genentech, Inc./South San Francisco/US, 8University of Chicago/Burr Ridge/US

P0243 - VISIONARY-MS: A Phase 2 clinical trial of catalytic gold nanocrystals, CNM-Au8, for the treatment of chronic optic neuropathy

R. Glanzman, Md, Faan1, H. Beadnall Mbbs Fracp2, M. Hotchkin1, A. Klistorner2, M. Barnett, Md2, R. Sergott3, A. Rynders1, K. Ho, Phd1, M. Mortenson1, 1Clene Nanomedicine Inc/Holladay/US, 2Brain Mind Institute/Camperdown/AU, 3Wills Eye Hospital/Philadelphia/US

P0244 - A simple two-step test based on CSF flow cytometry helps to discriminate MS from other inflammatory and non-inflammatory neurologic disorders

I. Kister1, I. Lotan2, A. Wallach3, T. Bacon4, G. Cutter5, A. Arbini2, 1New York University/New York City/US, 2New York University Langone Medical Center/New York City/US, 3Holy Name MS Center/Teaneck/US, 4New York University Langone Medical Center/New York/US, 5Mellen Center for Multiple Sclerosis Treatment and Research/Cleveland/US

P0245 - An unusual mimic of progression in Multiple Sclerosis patients

G. Alvarez Bravo, L. Ramió I Torrentà, R. Robles Cedeño, E. Quintana, J. Gich, M. González, Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES

P0246 - Clinical relevance of Kappa Free Light Chain index to evaluate intrathecal IgG synthesis: prospective study compared to oligoclobal bands

T. Alberto1, J.-D. Pekar2, J. Petit3, S. Schraen4, B. Onraed4, H. Zephir5, 1university of Lille/Lille/FR, 2CHU of Lille, University of Lille/Lille/FR, 3CHU of Lille, CRC-SEP of Lille/Lille/FR, 4CHU of Lille/Lille/FR, 5University of Lille, U1172, CHU of Lille, CRC-SEp of Lille/Lille/FR

P0247 - Comparison of the 2017 and 2010 revisions of the McDonald criteria in patients with cis suggestive of MS: a multicentre MAGNIMS study

M. Filippi1, P. Preziosa1, A. Meani1, A. Rovira2, S. Mesaros3, O. Ciccarelli4, J.L. Frederiksen5, C. Enzinger6, F. Barkhof7, C. Gasperini8, E. Fainardi9, W. Brownlee10, J. Drulovic11, X. Montalban12, S. Cramer5, M. Kalil6, M. Hagens13, S. Ruggieri8, G. Dalla Costa14, V. Martinelli1, K. Miszkiel4, M. Tintore12, G. Comi15, I. Dekker13, B. Uitdehaag16, J. Ivanović11, M.P. Amato9, M.A. Rocca1, 1IRCCS San Raffaele Scientific Institute/Milan/IT, 2Vall d'Hebron University Hospital/Barcelona/ES, 3University of Belgrade/Belgrade/IT, 4UCL Queen Square Institute of Neurology/London/GB, 5Rigshospitalet - Glostrup/Glostrup/DK, 6Medical University of Graz/Graz/AT, 7University College London/LONDON/GB, 8Ospedale San Camillo Forlanini/Rome/IT, 9University of Florence/Florence/IT, 10National Hospital for Neurology and Neurosurgery/United Kingdom/GB, 11University of Belgrade/Belgrade/RS, 12Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 13Amsterdam UMC, location VUmc/Amsterdam/NL, 14San Raffaele Hospital/Milan/IT, 15San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 16Amsterdam UMC, Location VUmc/Amsterdam/NL

P0248 - Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients

C. Oreja-Guevara1, B. Casanova-Estruch2, J.A. García-Merino3, L. Costa-Frossard4, D. Fernández- Uría5, J.R. Ara6, J. Prieto7, C. Calles8, M.Á. Hernandez9, J. Río10, C. Durán11, G. Izquierdo12, S. Eichau12, A. Rodríguez-Antigüedad13, M.J. Moreno14, D. Fernández14, J. Meca- Lallana15, 1Dynamic/Barcelona/ES, 2Hospital La Fe/Valencia/ES, 3Hospital Universitario Puerta de Hierro/Madrid/ES, 4Hospital Universitario Ramón y Cajal/Madrid/ES, 5Hospital Universitario de Cabueñes//Gijón/ES, 6Hospital Universitario Miguel Servet/Zaragoza/ES, 77Hospital Clínico Universitario de Santiago/Santiago de Compostela/ES, 8Hospital Universitari Son Espases/Palma de Mallorca/ES, 9Hospital Universitario Nuestra Señora de la Candelaria/Santa Cruz de Tenerife/ES, 10CEMCAT, Hospital Universitario Vall d’Hebrón/Barcelona/ES, 11Hospital Universitario de Badajoz/Badajoz/ES, 12Hospital Universitario Virgen Macarena/Sevilla/ES, 13Hospital Universitario de Cruces/Barakaldo/ES, 14Novartis/Barcelona/ES, 15Hospital Clínico Universitario Virgen de la Arrixaca/Murcia/ES

P0249 - Demyelinating events following initiation of anti-TNFɑ therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis

T. Taylor1, J. Galloway2, R. Adam3, K. Hyrich4, R. Dobson5, 1/London/GB, 2Kings College London/London/GB, 3University of Manchester/Manchester/GB, 4The University of Manchester/Manchester/GB, 5Queen Mary University London/London/GB

P0250 - Diagnostic Dilemma in a case of suspected Anti-phospholipid Syndrome

N. Lightfoot1, M. Scaperotti2, A. Streseman3, L. Bahroo4, S. Whelton4, 1/Washington/US, 2Medstar Georgetown University Hospital/washington/US, 3School of Medicine at Texas Tech University/Lubbock/US, 4Medstar Georgetown University Hospital/Washington/US

P0251 - Early factors associated with later conversion to multiple sclerosis in patients presenting with isolated myelitis

O. Murphy, L. Mukharesh, A. Salazar-Camelo, C. Pardo, S. Newsome, Johns Hopkins University School of Medicine/Baltimore/US

P0252 - Evolving diagnosis and treatment of secondary progressive multiple sclerosis in the United States

V. Schobel1, R.T. Naismith2, 1Spherix Global Insights/Exton/US, 2Washington University/Saint Louis/US

P0253 - Gaps in characterization of bladder dysfunction in clinical care and research

A. Gopal1, V. Block2, J. Gelfand3, A. Green4, C.-Y. Guo3, A. Suskind3, R. Bove1, 1University of California, San Francisco/San Francisco/US, 2University of California San Francisco /San Francisco/US, 3University of California San Francisco/San Francisco/US, 4UCSF Multiple Sclerosis Center/United States/US

P0254 - Healthcare Professionals (HCPs) categorisation of active and non-active Secondary Progressive Multiple Sclerosis (SPMS) patients

J. White1, S. Teoh2, S. Gabriele3, J. Vindici4, 1/London/GB, 2Ipsos Sdn Bhd/Kuala Lumpur/MY, 3Ipsos MORI UK/London/GB, 4Ipsos Insight LLC/New Jersey/US

P0255 - Improvement during the last decades in the time of diagnosis but not in the time of starting DMD in MS patients in Argentina

J. Rojas1, L. Patrucco2, A. Papolla3, E. Cristiano4, 1Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 2Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 3Hospital Italiano/Buenos Aires/AR, 4Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR

P0256 - Inclusion of optic nerve assessed by visual evoked potentials in dissemination in space criteria for the diagnosis of Multiple Sclerosis

S. Delgado1, Â. Timóteo2, J. Dionísio3, A. Rodrigues2, A. Arraiolos2, P. Neves3, A. Rêgo3, J. Vale2, V. Salgado3, M. Santos3, 1Hospital Prof. Doutor Fernando Fonseca /Amadora/PT, 2Hospital Beatriz Ângelo/Loures/PT, 3Hospital Prof. Doutor Fernando Fonseca/Amadora/PT

P0257 - Infratentorial MS relapse presenting as hemifacial continuous myokymia

M. Salavisa, P. Pires, F. Serrazina, A.S. Correia, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental/Lisboa/PT

P0258 - MS Progression Discussion Tool (MSProDiscuss™) Usability and Usefulness Assessment in Clinical Practice in Chile.

C. Cárcamo1, E. Ciampi2, R. Fernández3, L. Galleguillos4, S. Oporto5, J. Scherpenisse6, M. Rivera5, A. Araya7, M. Hitschfeld7, 1Pontificia Universidad Católica de Chile/Santiago/CL, 2Pontificia Universidad Católica de Chile y Hospital Dr. Sótero del Río/Santiago/CL, 3Hospital Clínico de Magallanes/Punta Arenas/CL, 4Clínica Alemana/Santiago/CL, 5Clínica Dávila/Santiago/CL, 6Clínica Las Condes/Santiago/CL, 7Novartis Chile S.A./Santiago/CL

P0259 - Multiple Sclerosis, variant Marburg, an uncommon form: about a case.

M. Martínez Zarco1, I. Pellicer Espinosa2, E. Gómez López3, E. Marín Conesa3, J. Marín Marín3, 1General University Hospital Reina Sofía /Murcia/ES, 2Northwest Regional Hospital/Caravaca de la Cruz/ES, 3General University Hospital Reina Sofía/Murcia/ES

P0260 - Obinutuzumab use complicated by progressive multifocal leukoencephalopathy: a case report.

G. Turine1, F. London2, 1CHU UCL Namur site Sainte-Elisabeth/Namur/BE, 2CHU UCL Namur site Godinne/Yvoir/BE

P0261 - Paramagnetic rim lesions are specific to multiple sclerosis: an international multicenter 3T MRI study

P. Maggi1, P. Sati2, G. Nair3, I. Cortese4, S. Jacobson4, B. Smith4, A. Nath4, J. Ohayon4, V. Van Pesch5, G. Perrotta6, C. Pot7, M. Theaudin7, V. Martinelli8, R. Scotti8, T. Wu3, R. Du Pasquier7, P. Calabresi9, M. Filippi8, D. Reich3, M. Absinta9, 1Lausanne University Hospital and University of Lausanne/Lausanne/CH, 2Cedars-Sinai Medical Center/Los Angeles/US, 3NINDS, NIH/Bethesda/US, 4National Institute of Neurological Disorders and Stroke/Bethesda/US, 5Université Catholique de Louvain/Brussels/BE, 6Hôpital Erasme/Brussels/BE, 7University Hospital of Lausanne/Lausanne/CH, 8IRCCS San Raffaele Scientific Institute/Milan/IT, 9Johns Hopkins University/Baltimore/US

P0262 - Searching for Fabry disease in previously diagnosed CIS and defined MS patients: a cohort study.

M. Fronza1, E. Sunda2, L. Lorefice3, G. Coghe3, G. Fenu3, L. Musu2, G. Spinicci2, E. Cocco4, J. Frau3, 1Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/cagliari/IT, 2Multiple Sclerosis Center, ATS Sardegna, University of Cagliari/cagliari/IT, 3Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/Cagliari/IT, 4University of Cagliari/Cagliari/IT

P0263 - Serum neurofilament predicts clinical progression and increases diagnostic accuracy in patients with early multiple sclerosis

S. Bittner1, F. Steffen1, T. Uphaus1, M. Muthuraman1, V. Fleischer1, A. Salmen2, F. Luessi1, A. Berthele3, L. Klotz4, S. Meuth5, A. Bayas6, F. Paul7, H.P. Hartung8, R. Linker9, C. Heesen10, M. Stangel11, B. Wildemann12, F. Then Bergh13, B. Tackenberg14, T. Kuempfel15, F. Weber16, U. Zettl17, U. Ziemann18, H. Tumani19, S. Groppa1, M. Mühlau3, C. Lukas20, B. Hemmer21, H. Wiendl22, R. Gold23, F. Zipp24, 1University Medical Center of the Johannes Gutenberg University Mainz/Mainz/DE, 2Inselspital Bern, University Hospital and University of Bern/Bern/CH, 3Klinikum rechts der Isar, Technical University of Munich/Munich/DE, 4University of Muenster/Muenster/DE, 5University of Munster/Munster/DE, 6University of Augsburg/Augsburg/DE, 7Charite-Universitatmedizin Berlin/Berlin/DE, 8/Dusseldorf/DE, 9University of Regensburg/Regensburg/DE, 10Universitätsklinikum Hamburg-Eppendorf/Hamburg/DE, 11Hannover Medical School/Hannover/DE, 12University of Heidelberg/Heidelberg/DE, 13University of Leipzig/Leipzig/DE, 14University of Marburg/Marburg/DE, 15Ludwig Maximilian University of Munich/Munich/DE, 16Max-Planck Institute of Psychiatry/Munich/DE, 17Rostock University Medical Center/Rostock/DE, 18University of Tuebingen/Tuebingen/DE, 19University of Ulm/Ulm/DE, 20Ruhr University Bochum/Bochum/DE, 21University of Munich/Munich/DE, 22University of Münster/Germany/DE, 23St. Josef-Hospital, Ruhr University Bochum/Bochum/DE, 24University Medical Center of the Johannes Gutenberg University Mainz//DE

P0264 - Simultaneous bilateral optic neuropathy and myelitis revealing paraneoplastic neurological syndrome associated with multiple onconeuronal antibodies

T. Carette1, N. Mulquin1, V. Van Pesch2, F. London3, 1UCLouvain, CHU UCL Namur site Godinne/Yvoir/BE, 2Université Catholique de Louvain/Brussels/BE, 3CHU UCL Namur site Godinne/Yvoir/BE

P0265 - Sjogren-larsson Syndrome:Another Differential Diagnosis of Multiple Sclerosis in Imaging of White Matter Diseases.

S. Zamanian1, E. Pourakbar2, 1SOCIAL SECURITY ORGANIZATION,IRAN,MASHHAD/Mashhad/IR, 2Mashhad Social Security Organization/Mashhad/IR

P0266 - Susac syndrome: A rare cause of encephalopathy

J. Decker1, M. Singh2, J. Koshorek1, 1Medical University of South Carolina/Charleston/US, 2Medical University of South Carolina/Charleson/US

P0267 - The Contribute of CSF Free Ligh Chain assay in the diagnosis of Multiple Sclerosis and other Neurological Diseases in an Italian multicentric study

G. Bernardi1, I. Crespi1, T. Biagioli2, T. De Michele3, P. Malpassi4, 1Fondazione IRCCS Istituto Neurologico Carlo Besta/Milan/IT, 2Central Diagnostic Laboratory, Careggi University Hospital, Florence, Italy,/Firenze/IT, 3Policlinico Agostino Gemelli di Roma/Roma/IT, 4Laboratorio Unico Metropolitano AUSL Bologna/Bologna/IT

P0268 - Time interval between disease onset and MS diagnosis during the last decades in Latin America

J. Rojas1, E. Carnero Contentti2, P. Henestroza3, S. Giachello3, J. Correale4, 1Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 2Hospital Alemán/Buenos Aires/AR, 3Asociación de Lucha Contra la Esclerosis Múltiple (ALCEM)/Buenos Aires/AR, 4Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR

P0269 - Vitamin B12 deficiency or MS!? Vitamin B12 deficiency can mimic Multiple Sclerosis. E. Pourakbar1, S. Zamanian2, 1Mashhad Social Security Organization/Mashhad/IR, 2SOCIAL SECURITY ORGANIZATION,IRAN,MASHHAD/Mashhad/IR

P0270 - 2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglia cells

F. Aybar1, M. Perez1, S. Marcora1, M. Samman1, J. Pasquini1, J. Correale2, 1Facultad de Farmacia y Bioquimica/Buenos Aires/AR, 2Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR

P0271 - A Case of Drug Induced Myocarditis Associated With the Administration of Alemtuzumab

M. Ross, K. Lawrence, A. Subei, Memorial Healthcare System/Hollywood/US

P0272 - A case series of late onset neutropenia following Ocrelizumab therapy in Multiple Sclerosis (MS)

M. Talaei1, K. Petheram2, G. Ingram1, A. Trip3, O. Pearson4, 1Morriston Hospital/Swansea/GB, 2South Tyneside and Sunderland NHS Foundation Trust/Sunderland/GB, 3UCL Institute of Neurology/London/GB, 4Swansea Bay University Health Board/Swansea/GB

P0273 - A multicentre, real-life study on the risk of lymphopenia and infections discloses a favourable safety profile of cladribine in MS patients.

M. Margoni1, P. Annovazzi2, L. Prosperini3, R. Capuano4, A. Gallo5, J. Frau6, E. Cocco7, A. Nozzolillo8, L. Moiola8, M. Capobianco9, M. Zaffaroni10, P. Perini1, 1University of Padua/Padova/IT, 2Multiple Sclerosis Centre, Hospital of Gallarate, ASST della Valle Olona/Gallarate (VA), Italy/IT, 3Department of Neurosciences, S. Camillo-Forlanini Hospital/Rome/IT, 4Multiple Sclerosis Centre, I Division of Neurology, University of Campania “Luigi Vanvitelli”/SALERNO/IT, 5Multiple Sclerosis Centre, I Division of Neurology, University of Campania “Luigi Vanvitelli”/Napoli/IT, 6Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/Cagliari/IT, 7University of Cagliari/Cagliari/IT, 8IRCCS San Raffaele Scientific Institute/Milan/IT, 9San Luigi Gonzaga Hospital/Orbassano (TO)/IT, 10Multiple Sclerosis Centre, Hospital of Gallarate, ASST della Valle Olona/Gallarate (VA)/IT

P0274 - A Swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated for at least 36 months

Å. Leandersson1, S. Kågström2, L. Forsberg2, J. Hillert3, P. Nilsson4, C. Dahle5, A. Svenningsson6, J. Lycke7, A.-M. Landtblom8, J. Burman8, C. Martin6, P. Sundström9, M. Gunnarsson10, F. Piehl2, T. Olsson2, 1Karolinska Institutet/Solna/SE, 2Karolinska Institute/Stockholm/SE, 3Karolinska Institute/Solna/SE, 4Lund University/Lund/SE, 5Linköping University/Linköping/SE, 6Danderyd Hospital/Danderyd/SE, 7University of Gothenburg/Gothenburg/SE, 8Uppsala University/Uppsala/SE, 9Umeå University/Umeå/SE, 10Örebro University/Örebro/SE

P0275 - A Swedish Post-Market Surveillance Study of the Long-Term Effectiveness and Safety of Teriflunomid (IMSE 4) for Patients Treated at least 36 Months L. Forsberg1, S. Kågström2, Å. Leandersson1, J. Hillert3, P. Nilsson4, C. Dahle5, A. Svenningsson6, J. Lycke7, A.-M. Landtblom8, J. Burman8, C. Martin9, M. Gunnarsson10, F. Piehl2, T. Olsson2, 1Karolinska Institutet/Solna/SE, 2Karolinska Institute/Stockholm/SE, 3Karolinska Institute/Solna/SE, 4Lund University/Lund/SE, 5Linköping University/Linköping/SE, 6Danderyd Hospital/Stockholm/SE, 7Institute of Neuroscience and Physiology/Gothenburg/SE, 8Uppsala University/Uppsala/SE, 9Danderyd Hospital/Danderyd/SE, 10Örebro University/Örebro/SE

P0276 - A Swedish Post-Market Surveillance Study: Long-Term Effectiveness and Safety of Cladribine Tablets (IMSE 10) for Patients Treated at least 12 Months

L. Forsberg1, S. Kågström2, Å. Leandersson1, J. Hillert3, P. Nilsson4, C. Dahle5, A. Svenningsson6, J. Lycke7, A.-M. Landtblom8, J. Burman8, C. Martin9, P. Sundström10, M. Gunnarsson11, F. Piehl2, T. Olsson2, 1Karolinska Institutet/Solna/SE, 2Karolinska Institute/Stockholm/SE, 3Karolinska Institute/Solna/SE, 4Lund University/Lund/SE, 5Linköping University/Linköping/SE, 6Danderyd Hospital/Stockholm/SE, 7Institute of Neuroscience and Physiology/Gothenburg/SE, 8Uppsala University/Uppsala/SE, 9Danderyd Hospital/Danderyd/SE, 10Umeå University/Umeå/SE, 11Örebro University/Örebro/SE

P0277 - A Swedish Post-Market Surveillance Study: Long-Term Effectiveness and Safety of Dimethyl Fumarate (IMSE 5) for Patients Treated at least 36 Months

L. Forsberg1, S. Kågström2, Å. Leandersson1, A. Berglund2, J. Hillert3, P. Nilsson4, C. Dahle5, A. Svenningsson6, J. Lycke7, A.-M. Landtblom8, J. Burman8, C. Martin9, P. Sundström10, M. Gunnarsson11, F. Piehl2, T. Olsson2, 1Karolinska Institutet/Solna/SE, 2Karolinska Institute/Stockholm/SE, 3Karolinska Institute/Solna/SE, 4Lund University/Lund/SE, 5Linköping University/Linköping/SE, 6Danderyd Hospital/Stockholm/SE, 7Institute of Neuroscience and Physiology/Gothenburg/SE, 8Uppsala University/Uppsala/SE, 9Danderyd Hospital/Danderyd/SE, 10Umeå University/Umeå/SE, 11Örebro University/Örebro/SE

P0278 - A Systematic Review and Meta-analyses of Pregnancy and Fetal Outcomes in Women with Multiple Sclerosis. IMI2 ConcePTION

S. Lopez-Leon1, Y. Geissbuehler2, M. Sabidó3, M. Turkson4, C. Wahlich5, J. Morris5, 1Novartis Pharmaceuticals Corporation/East Hanover/US, 2Novartis Pharma AG/Basel/CH, 3Merck Healthcare KGaA/Darmstadt/DE, 4Cognizant Solution/CW/GB, 5Population Health Research Institute/London/GB

P0279 - ACAPELLA: B-cell Reconstitution in Ocrelizumab-Treated Patients

I. Stribling, H. Geils, J. Katz, E. Lathi, E. Douglas, A. Bouley, The Elliot Lewis Center for MS Care/Wellesley/US

P0280 - ACAPELLA: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Two Data H. Geils, I. Stribling, J. Katz, E. Lathi, E. Douglas, A. Bouley, The Elliot Lewis Center for MS Care/Wellesley/US

P0281 - ACAPELLA: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Three

H. Geils, I. Stribling, J. Katz, E. Lathi, E. Douglas, A. Bouley, The Elliot Lewis Center for MS Care/Wellesley/US

P0282 - Advancing antigen-specific T cell therapy for progressive multifocal leukoencephalopathy

S. Gupta1, P. Muranski2, I. Cortese3, M. Wilson4, 1University of California, San Fransisco/San Francisco/US, 2NewYork-Presbyterian/Columbia University Medical Center/New York/US, 3National Institute of Neurological Disorders and Stroke/Bethesda/US, 4University of California San Francisco/San Francisco/US

P0283 - Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database

N. Gonzalez Caldito1, A. Shirani2, A. Salter3, O. Stuve1, 1UTSW/Dallas/US, 2University of Nebraska Medical Center/Omaha/US, 3Washington University School in St. Louis/St Louis/US

P0284 - Age-related efficacy of cladribine tablets in patients with relapsing-remitting MS in the CLARITY Extension study

M. Freedman1, G. Pardo2, N. De Stefano3, J. Aldridge4, Y. Hyvert5, A. Galazka5, C. Lemieux6, G. Giovannoni7, N. White8, 1The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 2Oklahoma Medical Research Foundation/Oklahoma City/US, 3University of Siena/Siena/IT, 4EMD Serono, Inc./Billerica/US, 5Merck KGaA, Darmstadt, Germany/Darmstadt/DE, 6EMD Inc. (an affiliate of Merck KGaA, Darmstadt, Germany)/Missassauga/CA, 7The London School of Medicine and Dentistry/London/GB, 8Ashfield Healthcare/New York/US

P0285 - Alemtuzumab depletion failure and neutralizing anti-drug antibodies: a case report and call for monitoring

K. Munger1, A. Kang2, D. Baker2, A. Goodman1, L. Samkoff1, 1University of Rochester Medical Center/Rochester/US, 2Queen Mary University London/London/GB

P0286 - Alemtuzumab following natalizumab: a multicentric Italian real-world experience

S. Malucchi1, M. Capobianco1, M. Malentacchi1, M. Lo Re1, F. Sperli1, R. Bottero1, A. Oggero1, F. Rinaldi2, P. Perini2, M. Radaelli3, A. Laroni4, A. Gallo5, A. Bertolotto1, 1San Luigi Gonzaga Hospital/Orbassano (TO)/IT, 2University of Padua/Padova/IT, 3San Raffaele Hospital/Milan/IT, 4University of Genova/Genova/IT, 5University of Campania/Napoli/IT

P0287 - Alemtuzumab induces changes in the innate immune system in patients with relapsing- remitting multiple sclerosis

A. Ladwig1, J. Suh1, F. Schweitzer1, P. Roeth1, G. Remke1, C. Warnke1, M. Schroeter1, E. Izquierdo- Alvarez1, E. Bonmann2, G.R. Fink1, C. Pallasch1, H. Lehmann1, 1University Hospital of Cologne/Köln/DE, 2Merheim Hospital/Köln/DE

P0288 - Analysis of CD3 T lymphocyte count in patients under treatment with Ocrelizumab regarding development of infections

A. Gonzalez-Martinez1, V. Meca-Lallana2, C. Aguirre2, C. Díaz2, J. Vivancos2, 1HospitalUniversitariodeLaPrincesa/MADRID/ES, 2La Princesa Hospital/Madrid/ES

P0290 - Anti-CD20 therapy interferes with the immune response to the Hepatitis B virus vaccine in MS patients

S. Otero-Romero1, S. Cárdenas-Robledo2, M. Rodríguez3, S. Uriona1, A. Rando1, A. Vidal-Jordana4, J. Esperalba1, E. Del Amo1, J. Rodrigo-Pendás1, M. Campins1, X. Martínez1, M. Tintore5, X. Montalban3, 1Vall d'Hebron University Hospital/Barcelona/ES, 2Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron Barcelona Hospital Campus/Barcelona/ES, 3Dept. of Neurology- Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 4Hospital Universitari Vall d’Hebron/Barcelona/ES, 5Multiple Sclerosis Centre of Catalonia/Barcelona/ES

P0291 - Association of Headache with B-cell Targeted Therapies in Multiple Sclerosis patients.

T. Mavridis1, N. Papagiannakis2, M. Breza2, A. Laskaratos3, D. Mitsikostas2, 1Eginition Hospital/Athens/GR, 2Eginition Hospital, National and Kapodistrian University of Athens/Athens/GR, 3Medical School, National and Kapodistrian University of Athens/Athens/GR

P0292 - Associations between treatment satisfaction, medication beliefs, and adherence to DMT in MS patients: Saudi Tertiary Care Center Experience

R. Alarieh, King Fahad Medical City/Riyadh/SA

P0293 - Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab.

W. Conte, Methodist Hospitals/Merrillville/US

P0294 - Autoinmunity secondary to alemtuzumab in clinical practice: 5 years of RWE

J. Dotor García-Soto1, R. López Ruiz2, S. Eichau Madueño2, M. Ruiz De Arcos3, J.L. Ruiz-Peña2, M.D. Páramo Camino2, G. Navarro Mascarell2, 1Hospital Universitario Virgen Macarena/Sevilla/ES, 2Universitary Hospital Virgen Macarena/Seville/ES, 3Universitary Hospital Virgen Macarena/Sevilla/ES

P0295 - Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis (aHSCT-in-MS): The Zurich Experience 24 Months after Approval

I. Jelcic, A. Müller, M. Hilty, N. Wolfensberger, P. Stathopoulos, J. Ruder, A. Thesenvitz, K. Ritter, A. Bachofner, M. Foege, A. Lutterotti, U. Schanz, R. Martin, University Hospital Zurich/Zurich/CH

P0296 - Automated extraction of multiple sclerosis treatment timelines

M. Davis, M. Rimmasch, K. Reynolds, J. Beales, Brigham Young University/Provo/US

P0297 - Autonomic nervous system abnormalities may predict cardiovascular changes after initiation of siponimod in the treatment of SPMS

L. Crnosija1, A. Junakovic1, I. Adamec1, B. Barun1, T. Gabelic1, M. Krbot Skoric1, M. Habek2, 1University Hospital Center Zagreb/Zagreb/HR, 2University of Zagreb, School of Medicine/Croatia/HR

P0298 - Azathioprine as a disease-modifying therapy for multiple sclerosis. Experience of department of Neurology: HASSAN II UHC of Fez; Morocco

R. Benkhadra1, S. Bouchal2, N. Chtaou3, A. Elmidaoui3, Z. Souirti3, M. Belahsen3, 1UHC Hassan II of Fez/FEZ/MA, 2CHU HASSAN II FEZ/fez/MA, 3Hassan II UHC of Fez/FEZ/MA

P0300 - Baseline features in DISCOntinuation of disease modifying therapies in Multiple Sclerosis (DISCOMS)

R. Seale1, G. Cutter2, R. Fox3, I. Kister4, A. Miller5, C. Morgan6, S. Sillau7, J. Corboy8, 1University of Colorado/Aurora/US, 2Mellen Center for Multiple Sclerosis Treatment and Research/Cleveland/US, 3Cleveland Clinic//US, 4New York University/New York City/US, 5Mount Sinai Hospital/New York City/US, 6University of Alabama at Birmingham/Birmingham/US, 7Rocky Mountain MS Center at the University of Colorado Anschutz Medical Campus/Aurora/US, 8University of Colorado/Denver/US

P0301 - Beyond pivotal trials inclusion criteria: real world clinical profile of multiple sclerosis patients under disease modifying treatment in Argentina.

A. Barboza1, J. Rojas2, M. Gaitán3, S. Liwacki4, C. Vrech5, A. Papolla6, J. Miguez7, L. Patrucco7, J. Correale3, M. Marrodan8, M. Fiol8, L. Negrotto8, C. Ysrraelit3, E. Cristiano9, A. Carrá10, A. Chertcoff10, J. Steinberg10, A. Martinez10, C. Curbelo10, L. Cohen11, R. Alonso11, O. Garcea11, C. Pita11, B. Silva12, G. Luetic13, N. Deri14, M.E. Balbuena15, V. Tkachuk15, E. Carnero Contentti16, P. Lopez16, J. Pettinicchi16, A. Caride16, M. Burgos17, F. Leguizamon18, E. Knorre18, R. Piedrabuena4, P. Nofal19, G. Volman20, A. Alvez Pinheiro21, J. Hryb22, D. Tavolini23, P. Blaya24, L. Recchia25, C. Mainella26, M. Kohler27, E. Kohler27, J. Blanche28, S. Tizio29, M. Saladino30, F. Caceres31, N. Fernandez Liguori32, L. Lazaro32, E. Silva33, G. Zanga34, M. Parada Marcilla35, M.E. Fracaro36, F. Pagani Cassará37, G. Vazquez38, V. Sinay37, G. Sgrilli39, P. Divi40, M. Jacobo40, E. Reich41, L. Cabrera42, M. Menichini43, M. Coppola44, I. Martos45, J. Viglione46, G. Jose47, S. Bestoso48, R. Manzi49, D. Giunta6, M. Doldan50, M. Alonso Serena51, 1Hospital Central/Mendoza/AR, 2Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 3FLENI/Buenos Aires/AR, 4Clinica Universitaria Reina SOfía/Córdoba/AR, 5Sanatorio Allende/Cordoba/AR, 6Hospital Italiano/Buenos Aires/AR, 7Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 8Raúl Carrea Institute for Neurological Research/Argentina/AR, 9Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 10Hospital Británico De Buenos Aires/Buenos Aires/AR, 11Hospital Ramos Mejía/Buenos Aires/AR, 12Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR, 13Instituto de Neurociencias de Rosario/Rosario./AR, 14Centro de Investigaciones DIABAID/Buenos Aires/AR, 15Hospital de Clínicas José de San Martín/Buenos Aires/AR, 16Hospital Alemán/Buenos Aires/AR, 17Hospital San Bernardo/Salta/AR, 18Hospital de Agudos TEodoro Alvarez/Buenos Aires/AR, 19Hospital de Clínicas Nuestra Señora del Carmen/Tucuman/AR, 2021. Hospital Presidente Perón de Avellaneda/Avellaneda/AR, 21Hospital San Martín/Paraná/AR, 22Hospital Carlos Durand/Buenos Aires/AR, 23INECO Neurociencias Oroño/Rosario/AR, 24Neurocomp/Trelew/AR, 25Hospital Central de Mendoza/Mendoza/AR, 26Hospital Español/ROsario/AR, 27Fundación Sinapsis/Santa Rosa/AR, 2829. IRNEC (Instituto Regional de Neurociencias)/Tucumán/AR, 29Hospital Español de La Plata/La PLata/AR, 30INEBA Instituto De Neurociencias Buenos Aires/Buenos Aires/AR, 31INERE/Buenos Aires/AR, 32Sanatorio Guemes/Buenos Aires/AR, 33Predigma/Posadas/AR, 34Unidad Asistencial Cesar Milstein/capital federal/AR, 35SIENES/Buenos Aires/AR, 36Clinica del Castano/San Juan/AR, 37Hospital Universitario Fundación Favaloro/Buenos Aires/AR, 38Fundacion Favaloro/Buenos Aires/AR, 39Axis Neurociencias/Bahia Blanca/AR, 40RIAPEM/Santiago del Estero/AR, 41Hospital Municipal Dr Julio Mendez/Buenos Aires/AR, 42Hospital Militar Campo de Mayo/Buenos Aires/AR, 43Sanatorio Britanico/Rosario/AR, 44Hospital Ramon Santamarina/Tandil/AR, 45Clinica San Jorge/Ushuaia/AR, 46Clinica Regional del Sud/Rio Cuarto/AR, 47Hospital Padilla/Tucuman/AR, 48Hospital Escuela Jose de San Martin/Corrientes/AR, 49Sanatorio Pasteur/Catamarca/AR, 50Centro de Esclerosis Multiple de Buenos Aires/Buenos Aires/AR, 51CEMIC/Buenos Aires/AR

P0302 - Bruton tyrosine kinase inhibitor suppresses disease progression in Thieler’s Murine Enchephalomyelitis Virus mouse model of multiple sclerosis

S. Pol1, R. Dhanraj1, R. Zivadinov2, 1University at Buffalo/Buffalo/US, 2Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York/Buffalo/US

P0303 - Calculated steroid dose needed for multiple scleroses relapses

J. Gili-Kovacs1, R. Hoepner1, A. Salmen2, M. Bagnoud3, R. Gold4, A. Chan2, M. Briner1, 1Inselspital University Hospital/Bern/CH, 2Inselspital Bern, University Hospital and University of Bern/Bern/CH, 3Inselspital Bern, University Hospital and University of Bern/Berne/CH, 4St. Josef- Hospital, Ruhr University Bochum/Bochum/DE

P0304 - Can the induction of thyroid autoimmune antibodies after alemtuzumab treatment predict secondary autoimmune thyroid disorder? S. Sandgren1, L. Novakova1, M. Axelsson1, F. Amirbeagi1, I. Kockum2, T. Olsson3, C. Malmeström1, J. Lycke1, 1Institute of Neuroscience and Physiology/Gothenburg/SE, 2Department of Clinical Neuroscience, Karolinska Institutet/Stockholm/SE, 3Karolinska Institute/Stockholm/SE

P0305 - Can We Predict Ocrelizumab Super Responder Status in Relapsing Remitting Multiple Sclerosis Patients?

N. Edgar1, T. Hoyt1, J. Foley2, 1Rocky Mountain MS Research Group/Salt Lake City/US, 2Rocky Mountain Multiple Sclerosis Clinic/Salt Lake City/US

P0306 - Cardiovascular monitoring during alemtuzumab infusion in Multiple Sclerosis patients

R. Giossi1, E. Tomas Roldan2, M. Costanza2, C. Antozzi2, R. Frangiamore3, V. Torri Clerici2, P. Confalonieri2, A. Tozzo2, R. Mantegazza2, L. Brambilla2, 1Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta/Milano/IT, 2IRCCS Foundation Neurological Institute Carlo Besta/Milano/IT, 3Neurological Institute C. Besta, IRCCS Foundation/Milano/IT

P0307 - Changes in immune blood cells in patients on teriflunomide treatment

I. Gómez_Estévez1, J. Díaz-Díaz2, C. Oreja-Guevara3, 1Hospital clínico San Carlos/Madrid/ES, 2Hospital Universitario Clínico San Carlos/Madrid/ES, 3Hospital Universitario Clinico San Carlos/Madrid/ES

P0308 - Changing patterns of first line and first switch ocrelizumab use in the United States: Analysis of subtype, gender, age, and disability

P. Coyle1, M. Stabb2, V. Schobel2, 1Stony Brook University/Stony Brook/US, 2Spherix Global Insights/Exton/US

P0309 - Cladribine is a safe and effective treatment for highly active relapsing-remitting multiple sclerosis

T. Suslak1, N. Macdougall2, L. Murray3, 1/Glasgow/GB, 2NHSGGC/NHSL/Glasgow/GB, 3NHSGGC/Glasgow/GB

P0310 - Cladribine tablets in patients with RRMS and active SPMS after suboptimal response to prior DMD (MASTER-2 and CLICK-MS): initial baseline demographics

A. Miravalle1, J. Katz2, D. Robertson3, B. Hayward4, J. Walsh4, D. Harlow5, L. Lebson4, J. Sloane6, A. Bass7, E. Fox8, N. White9, 1University of Colorado/Fort Collins/US, 2Elliot Lewis Center for Multiple Sclerosis Care/Wellesley/US, 3University of South Florida Morsani College of Medicine/Tampa/US, 4EMD Serono, Inc., USA (an affiliate of Merck KGaA, Darmstadt, Germany)/Rockland/US, 5EMD Serono, Inc./Rockland/US, 6Harvard Medical School/Boston/US, 7Neurology Center of San Antonio/Boston/US, 8Central Texas Neurology Consultants/Central Texas Neurology Consultants, Multiple Sclerosis Clinic of Central Texas, The University of Texas at Austin, Round Rock, Austin/US, 9Ashfield Healthcare/New York/US

P0311 - Decoding Bruton’s tyrosine kinase signalling in neuroinflammation

R. Gruber1, M. Dufault1, N. Chretien1, J. Proto1, M. Zhang1, M. Lamorte1, E. Havari1, T. Turner2, A. Chomyk3, E. Christie3, B. Trapp3, D. Ofengeim1, 1Sanofi/Framingham/US, 2Sanofi/Cambridge/US, 3Cleveland Clinic/Cleveland/US

P0312 - Differential effects of dimethyl fumarate, monomethyl fumarate and cannabidiol in the activation of transcription factor Nrf2 in neurons and microglia

A. Sánchez-Sanz1, M.J. Coronado-Albi2, R. García-Hernández3, J. Sabín-Muñoz4, O. Rodríguez-De La Fuente5, J.A. García-Merino5, A.J. Sánchez-López2, 1Puerta de Hierro Health Research Institute/Majadahonda/ES, 2Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana/Madrid/ES, 3Puerta de Hierro-Segovia de Arana Health Research Institute/Madrid/ES, 4Puerta de Hierro University Hospital/Madrid/ES, 5Hospital Universitario Puerta de Hierro/Madrid/ES

P0313 - Dimethyl fumarate-induced changes in lymphocyte subpopulations could identify "NEDA" patients

S. Presas-Rodríguez1, A. Teniente-Serra1, A. Selles-Rius1, M.J. Mansilla1, B. Quirant-Sánchez1, E. Martínez-Cáceres1, C. Ramo-Tello2, 1Hospital Universitari Germans Trias i Pujol/Badalona/ES, 2Hospital Germans Trias i Pujol/Badalona/ES

P0315 - Disease modifying therapies in patients with aggressive MS

F. Fneish1, D. Ellenberger1, N. Frahm1, A. Stahmann1, P. Rommer2, U. Zettl3, 1MS Forschungs- und Projektentwicklungs-gGmbH/Hannover/DE, 2Medical University of Vienna/Vienna/AT, 3Rostock University Medical Center/Rostock/DE

P0316 - Dose-dependent tolerability of intravenous and subcutaneous ofatumumab in clinical studies

A. Bar-Or1, A. Annette Schubert-Tennigkeit2, N. Mairon2, C. Kerloeguen2, M. Gufran3, S. Shaikh3, A. Das Gupta3, E. Gunisetti3, G. Weckbecker2, W. Su4, K. Ramanathan2, R. Pingili5, 1University of Pennsylvania/Philadelphia/US, 2Novartis Pharma AG/Basel/CH, 3Novartis Healthcare Pvt. Ltd./Hyderabad/IN, 4Novartis Pharmaceuticals Corporation/Novartis Pharmaceuticals Corporation, EastHanover/US, 5Novartis Pharmaceuticals Corporation/NJ/US

P0317 - Dual mode of action of siponimod in secondary progressive multiple sclerosis: A hypothesis based on the relevance of pharmacological properties

M. Bigaud1, F. Dahlke1, T. Hach1, D. Piani-Meier1, R. Gold2, 1Novartis Pharma AG/Basel/CH, 2St. Josef- Hospital, Ruhr University Bochum/Bochum/DE

P0318 - Early monitoring of B cells on ocrelizumab may help to identify those at risk of adverse effects R. Dorsey-Campbell1, C. Radia2, J. Hill3, T. Felongco2, D. Delacruz4, V. Singh-Curry5, A. Nandoskar5, A. Scalfari6, O. Malik5, R. Nicholas6, 1Imperial College NHS Trust/London/GB, 2Imperial College Healthcare NHS Trust/RF/GB, 3Imperial College/RF/GB, 4Imperial College Helathcare NHS Trust/RF/GB, 5Imperial College of London/London/GB, 6Imperial College London/London/GB

P0319 - Early Real-World Safety, Tolerability, and Efficacy of Cladribine Tablets: A Single Center Experience

J. Bain1, J. Oh2, A. Jones3, D. Selchen3, S. Overholt3, M. Guenette3, 1/Ottawa/CA, 2University of Toronto/Toronto/CA, 3St. Michael's Hospital/Toronto/CA

P0320 - Effect of age on effectiveness and discontinuation of subcutaneous interferon beta-1a, and healthcare utilization, in patients with multiple sclerosis

M. Sabidó1, A. Allignol1, K. Marhardt2, P. Vermersch3, E. Boutmy4, 1Merck Healthcare KGaA/Darmstadt/DE, 2Merck Gesellschaft mbH/Vienna/AT, 3CHU de Lille/Lille/FR, 4Merck KGaA/Darmstadt/DE

P0321 - Effect of anti-CD20 antibody-induced B-cell depletion on the susceptibility to Streptococcus pneumoniae infections

G. Ercoli1, E. Ramos-Sevillano2, M. Folkmanaite2, M. Leandro3, G. Cambridge4, G. Weckbecker5, J. Brown6, 1Rayne Institute/London/GB, 2Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College Medical School, Rayne Institute, London, UK/London/GB, 3Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, UK/London/GB, 4Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London/London/GB, 5Novartis Pharma AG/Basel/CH, 6Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College Medical School, Rayne Institute/London/GB

P0322 - Effect of anti-CD20 antibody-mediated B-cell depletion on susceptibility to a Pneumocystis infection in mice

G. Dai1, G. Weckbecker2, J. K. Kolls3, 1Center for Translational Research in Infection and Inflammation Tulane School of Medicine, Tulane School of Medicine/New Orleans/US, 2Novartis Pharma AG/Basel/CH, 3Tulane School of Medicine/Los Angeles/US

P0323 - Effect of neutralizing antibodies on pharmacodynamic biomarkers of subcutaneous interferon β-1a in REFLEX and REFLEXION

M. Freedman1, K. Holmberg2, M. Fluck3, Y. Hyvert4, S. Stinchi4, V. D’Urso4, F. Dangond5, 1The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 2EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany./Billerica/US, 3Merck KGaA/Darmstadt/DE, 4Merck KGaA, Darmstadt, Germany/Darmstadt/DE, 5EMD Serono, Inc./Rockland/US

P0324 - Effect of ocrelizumab treatment in peripheral blood leukocyte subsets of Primary Progressive Multiple Sclerosis patients

J.I. Fernandez-Velasco1, J. Kuhle2, E. Monreal1, V. Meca-Lallana3, J. Meca-Lallana4, G. Izquierdo5, F. Gascón Giménez6, S. Sainz De La Maza1, P. Walo Delgado1, A. Maceski7, E. Rodríguez-Martin1, E. Roldán1, N. Villarrubia1, A. Saiz8, Y. Blanco9, P. Sánchez3, E. Carreón Guarnizo10, Y. Aladro11, L. Brieva12, C. Íñiguez13, I. González-Suárez14, L. Rodríguez De Antonio15, J. Masjuan1, L. Costa-Frossard1, L.M. Villar1, 1Hospital Universitario Ramón y Cajal/Madrid/ES, 2University of Basel/Switzerland/CH, 3La Princesa Hospital/Madrid/ES, 4Hospital Clínico Universitario Virgen de la Arrixaca/Murcia/ES, 5Hospital Universitario Virgen Macarena/Sevilla/ES, 6Hospital Clínico de Valencia/Valencia/ES, 7University Hospital Basel and University of Basel/Basel/CH, 8Hospital Clínic i Provincial de Barcelona/Barcelona/ES, 9Hospital Clinic Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona/Barcelona/ES, 10Hospital Clinico Universitario Virgen de la Arrixaca/Murcia/ES, 11Hospital Universitario de Getafe/Getafe. Madrid/ES, 12Hospital Arnau de Vilanova/LLEIDA/ES, 13Hospital Clinico Universitario Lozano Blesa/Zaragoza/ES, 14Complejo Hospitalario Universitario de Vigo/Vigo/ES, 15Hospital Universitario de Fuenlabrada/Madrid/ES

P0325 - Effect of ozanimod on proportions of leukocyte subsets in patients with relapsing multiple sclerosis

S. Harris1, J. Tran1, H. Southworth2, C. Spencer3, B. Cree4, S. Zamvil3, 1Bristol-Myers Squibb Company/Princeton/US, 2Data Clarity Consulting Ltd./Stockport/GB, 3University of California, San Francisco/San Francisco/US, 4University of California San Francisco/San Francisco/US

P0326 - Effect of Teriflunomide on Epstein-Barr Virus Shedding in Relapsing-Remitting Multiple Sclerosis Patients: Outcomes From a Real-world Cohort Study

J. Gold1, D. Holden2, J. Parratt3, C. Yiannikas4, R. Ahmad1, G. Giovannoni5, 1South Eastern Sydney Local Health District/NSW/AU, 2Queen Mary University of London, Blizard Institute/London/GB, 3Northern Sydney LHD/St. Leonards/AU, 4Inner West Neurology/Burwood/AU, 5The London School of Medicine and Dentistry/London/GB

P0327 - Effectiveness and safety profile of the Natalizumab extended interval dosing in a Spanish cohort

L. Costa-Frossard, S. Sainz De La Maza, E. Monreal, A. Gómez López, J.I. Fernandez-Velasco, P. Walo Delgado, M. Espiño, N. Villarrubia, J. Masjuan, L.M. Villar, Hospital Universitario Ramón y Cajal/Madrid/ES

P0328 - Effectiveness of cladribine in multiple sclerosis – clinical experience of two tertiary centers

A. Barros1, M. Santos2, J. Sequeira1, M. Brum1, J. Parra1, L. Leitão1, F. Ladeira1, J. Ferreira3, J. De Sá3, C. Capela1, 1Centro Hospitalar Universitário de Lisboa Central/Lisbon/PT, 2Hospital de Santa Maria/Lisbon/PT, 3Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte/Lisbon/PT

P0329 - Effects of adrenocorticotropic hormone on melanocortin receptors, regulatory immune cells, and MRI in MS

Q. Howlett-Prieto1, A. Reder2, X. Feng1, T. Houston1, A. Javed1, 1University of Chicago/Chicago/UM, 2University of Chicago/Burr Ridge/US

P0330 - Effects of cladribine on proliferation, survival and cytokine release of human astrocytes

H. Eixarch1, L. Calvo-Barreiro1, N. Fissolo2, U. Boschert3, M. Comabella4, X. Montalban1, C. Espejo5, 1Dept. of Neurology-Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 2Hospital Vall d'Hebron/Barcelona/ES, 3Ares Trading SA/Eysin/CH, 4Universitat Autònoma//ES, 5Hospital Universitario Vall D´Hebron/Barcelona/ES

P0331 - Efficacy and safety in patients treated with Natalizumab for at least 10 years - Real-world data from a Swedish national surveillance study (IMSE 1)

S. Kågström1, Å. Leandersson2, L. Forsberg2, A. Berglund1, J. Hillert3, P. Nilsson4, C. Dahle5, A. Svenningsson6, J. Lycke7, A.-M. Landtblom8, J. Burman8, P. Sundström9, C. Martin6, M. Gunnarsson10, F. Piehl1, T. Olsson1, 1Karolinska Institute/Stockholm/SE, 2Karolinska Institutet/Solna/SE, 3Karolinska Institute/Solna/SE, 4Lund University/Lund/SE, 5Linköping University/Linköping/SE, 6Danderyd Hospital/Danderyd/SE, 7Institute of Neuroscience and Physiology/Gothenburg/SE, 8Uppsala University/Uppsala/SE, 9Umeå University/Umeå/SE, 10Örebro University/Örebro/SE

P0332 - Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE)

K. Smoot1, T. Gervasi-Follmar1, C. Chen2, P. Repovic3, H.-J. Zhang4, C. Moreno1, S. Cohan1, 1Providence MS Center/Portland/US, 2Providence St. Joseph Health/Portland/US, 3Swedish MS Center/Seattle/US, 4Kadlec/Richland/US

P0334 - Evobrutinib, a highly selective BTK inhibitor, prevents antigen-activation of B cells and ameliorates experimental autoimmune encephalomyelitis

S. Torke1, R. Pretzsch1, D. Häusler1, R. Grenningloh2, U. Boschert3, W. Brück1, M. Weber4, 1Institute of Neuropathology/Goettingen/DE, 2EMD Serono Research & Development Institute, Inc./Billerica/US, 3Ares Trading SA/Eysin/CH, 4University Medical Center Goettingen/Goettingen/DE

P0335 - Exploring the rate, persistence and associations of lymphopaenia in people with multiple sclerosis treated with dimethyl fumarate.

T. Flamini1, J. Harley2, J. Truman1, T. Button1, 1York Teaching Hospital NHS FT/York/GB, 2Hull University Teaching Hospitals NHS FT/Hull/GB

P0336 - Exposure to Natalizumab during pregnancy: A French national retrospective study P. Bouchard1, S. Demortière2, F. Rollot3, A. Ruet4, M. Deloire1, M. Debouverie5, J. De Seze6, T. Moreau7, J. Ciron8, O. Casez9, S. Vukusic10, R. Casey11, C. Dulau1, J.-C. Ouallet1, K.-K. Kounkou1, A. Rico2, A. Maarouf2, C. Boutière2, B. Audoin2, J. Pelletier12, B. Brochet4, 1Centre Hospitalier Universitaire de Bordeaux/BORDEAUX/FR, 2Hôpital La Timone/Marseille/FR, 3OFSEP/Lyon/FR, 4University of Bordeaux/Bordeaux/FR, 5CHU de Nancy/Nancy/FR, 6CHU Strasbourg/Strasbourg/FR, 7CHU Dijon/Dijon/FR, 8CHU Toulouse/Toulouse/FR, 9CHU Grenoble/Grenoble/FR, 10Lyon University Hospital/BRON/FR, 11Université de Lyon, Université Claude Bernard Lyon 1/Lyon/FR, 12Aix Marseille Univ, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie/Marseilles/FR

P0337 - Extensive healthy donor age/gender adjustments and propensity score matching reveal physiology of multiple sclerosis through immunophenotyping

P. Hannikainen1, P. Kosa1, C. Barbour2, S. Wachamo2, B. Bielekova2, 1National Institute of Allergy and Infectious Diseases/Bethesda/US, 2National Institutes of Health/Bethesda/US

P0338 - Fenebrutinib, a noncovalent, highly selective, long residence time investigational Btk inhibitor for the treatment of MS

A. Johnson, C. Harp, J. Yu, A. Goodyear, J. Crawford, Genentech, Inc./South San Francisco/US

P0339 - Fingolimod immune suppression does not inhibit long-term efficacy of AAV gene immunotherapy

A. Sagadevan1, I. Cote2, G. Keeler2, C. Gaddie2, B. Hoffman2, 1Hoffman Lab/Gainesville/US, 2University of Florida/Gainesville/US

P0340 - High-dimensional immune profiling of dimethyl fumarate and ocrelizumab in multiple sclerosis

Y. Zhang1, B. Lee1, H. Xie1, J. Rockoff1, R. Brandstadter2, S. Kim-Schulze1, F. Lublin3, A. Ntranos1, 1Mount Sinai/New York/US, 2University of Pennsylvania Perelman School of Medicine/Philadelphia/US, 3Mount Sinai School of Medicine/United States/US

P0342 - Immune reconstitution inflammatory syndrome in a patient treated with alemtuzumab a few years earlier

A. Jamroz-Wiśniewska1, U. Chyrchel2, E. Belniak2, M. Janczarek2, H. Bartosik-Psujek3, K. Rejdak2, 1Lublin Medical University/Lublin/PL, 2Medical University of Lublin/Lublin/PL, 3University of Rzeszów/Rzeszów/PL

P0343 - Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod P. Zhang, A. Ghosh, M. Thomas, X. Wang, M. Palmisano, J. Tran, Bristol-Myers Squibb Company/Princeton/US

P0344 - Injectable versus oral first-line disease-modifying therapies: results from Italian MS register

E. D'Amico1, A. Zanghì2, M. Romeo3, E. Cocco4, G.T. Maniscalco5, V. Bresciamorra6, D. Paolicelli7, G. De Luca8, S. Galgani9, M.P. Amato10, G. Salemi11, M. Inglese12, P.A. Confalonieri13, G. Lus14, A. Gallo15, M. Vianello16, M. Onofrj17, C. Pozzilli18, M. Filippi2, M. Trojano7, F. Patti19, 1/catania/IT, 2IRCCS San Raffaele Scientific Institute/Milan/IT, 3IRCCS San Raffaele/milano/IT, 4University of Cagliari/Cagliari/IT, 5Neurological Clinic and Multiple Sclerosis Centre of “AORN A.Cardarelli”/Napoli/IT, 6university of naples/naples/IT, 7University of Bari/Bari/IT, 8Università "G. d'Annunzio", Chieti-Pescara/Chieti/IT, 9Az. Osp. S. Camillo Forlanini/roma/IT, 10University of Florence/Florence/IT, 11University of Palermo/Palermo/IT, 12University of Genoa//IT, 13irccs carlo besta/milano/IT, 14Second University of Naples/Napoli/IT, 15Multiple Sclerosis Centre, I Division of Neurology, University of Campania “Luigi Vanvitelli”/Napoli/IT, 16Centro Sclerosi Multipla - Ospedale Regionale 'Ca' Foncello', Neurology Unit/Treviso/IT, 17University G. d’Annunzio/Chieti/IT, 18Sapienza University of Rome/Rome/IT, 19Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT

P0345 - Interim Analysis of Pregnancy Outcomes Following Exposure to Dimethyl Fumarate in a Prospective International Registry

K. Hellwig1, D. Rog2, C. Mcguigan3, O. Mokliatchouk4, F. Branco4, X. Peng4, C. Jones4, 1University of Bochum/Bochum/DE, 2Salford Royal NHS Foundation Trust/Salford/GB, 3St. Vincent’s University Hospital/Dublin/IE, 4Biogen/Cambridge/US

P0346 - Is the gut a relevant reservoir for persistent JCPyV infection?

F. Schweitzer1, A. Ladwig1, S. Laurent1, M. Schroeter1, S. Goelz2, U. Wieland1, S. Silling1, C. Warnke1, 1University Hospital of Cologne/Köln/DE, 2Biogen Inc/Cambridge/US

P0347 - Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab

M. Auer1, G. Bsteh2, H. Hegen1, S. Wurth3, A. Zinganell1, T. Berger2, F. Deisenhammer1, F. Di Pauli1, 1Medical University of Innsbruck/Innsbruck/AT, 2Medical University of Vienna/Vienna/AT, 3Medical University of Graz/Innsbruck/AT

P0348 - Lipoic acid modulates inflammatory responses of monocytes and monocyte-derived macrophages via cyclic-AMP and Nrf2-dependent mechanisms.

S. Fiedler1, S. Salinthone2, 1VA Portland Health Care System/Portland/US, 2Oregon Health & Science University/Portland/US

P0349 - Long term effectiveness and safety of teriflunomide in Relapsing Remitting Multiple Sclerosis, and improvement in quality of life: Tericare study

J.M. Prieto González1, J. Meca2, A. Caminero3, J. Olaskoaga4, V. Casanova5, N. Herrera Varo6, M. Llaneza7, L. Berenguer8, R. Casademont9, S. Martinez9, 1Hospital Clínico Universitario de Santiago/Santiago de Compostela/ES, 2Hospital Virgen de la Arrixaca/MURCIA/ES, 3Complejo Asistencial de Ávila/AVILA/ES, 4Hospital Universitario Donostia/SAN SEBASTIAN/ES, 5Hospital Universitari i Politècnic La Fe/VALENCIA/ES, 6Hospital Universitario de Burgos/Burgos/ES, 7Hospital Ferrol/Ferrol/ES, 8Hospital Marina Baixa (Villajoyosa)/VALENCIA/ES, 9SANOFI/BARCELONA/ES

P0350 - Long-term drug persistence in natalizumab JCV negative patients in the Swedish post-market surveillance study IMSE-1

A. Berglund, S. Kågström, F. Piehl, T. Olsson, Karolinska Institute/Stockholm/SE

P0351 - Lymphocyte reconstitution following discontinuation of Dimethyl fumarate (DMF) due to lymphopenia in the Swedish post-market surveillance study IMSE-5

A. Berglund, L. Forsberg, F. Piehl, T. Olsson, Karolinska Institute/Stockholm/SE

P0352 - Lymphocyte Subtypes Repopulation Pattern and Secondary Autoimmunity in patients with RRMS treated with Alemtuzumab in a Real World setting

N. Fakas1, V. Kotzamanis1, A. Akrivaki1, T. Mavridis2, D. Tzavella1, S. Triantafyllou1, G. Papadopoulos1, P. Apostolopoulos1, 1401 General Military Hospital of Athens/Athens/GR, 2Eginition Hospital/Athens/GR

P0353 - Lymphopenia in patients treated with dimethyl fumarate. Risk factors and clinical significance. Experience in daily clinical practice

G. Valero López1, M.T. Alba Isasi2, E. Carreón Guarnizo1, R. Hernandez Clares3, M. Canovas Iniesta1, M. Morales De La Prida4, F. Iniesta Martinez1, A. Morales Ortiz3, J. Meca-Lallana1, 1Hospital Clínico Universitario Virgen de la Arrixaca/Murcia/ES, 2H. Virgen del Castillo/Yecla/ES, 3Hospital Clinico Universitario Virgen de la Arrixaca/Murcia/ES, 4Virgen de la Arrixaca University Hospital/El Palmar, Murcia/ES

P0354 - Management of infectious risk in multiple sclerosis: implication for screening, prophylaxis and therapies

M.A. Zingaropoli1, V. Perri2, P. Pasculli1, M. Tartaglia3, S. Crisafulli3, C. Merluzzo3, V. Baione3, F. Pauri3, M. Altieri3, M. Frontoni3, A. Conte3, C.M. Mastroianni1, M.R. Ciardi1, 1Sapienza University/Roma/IT, 2/Roma/IT, 3Sapienza University of Rome/Rome/IT

P0355 - Management of lymphopenia associated with dimethylfumarate and fingolimod

B. Bharkhada, A. Shields, The National Hospital for Neurology and Neurosurgery/London/GB

P0356 - MOG-derived Imotopes, a new class of MHC-II epitope modification, inducing cytolytic CD4 T- cells as novel immunotherapy in multiple sclerosis

D. Walgraffe, I. Ote, R. Roohi Ahangarani, M. Erak, M. Van Mechelen, A. Van Oosterhout, L. Vander Elst, V. Carlier, Imcyse/Liège/BE

P0357 - Mouse astrocytes exhibit agonist-induced functional S1P1 receptor antagonism

N. Ben Yakoub, T. Uffelmann, S. Tisserand, M. Bigaud, Novartis Pharma AG/Basel/CH

P0358 - Multiple Sclerosis with anti-N-methyl-D-aspartate receptor immunoglobulin G antibodies. An unusual relationship.

M. Morales De La Prida1, M. Canovas Iniesta2, G. Valero López3, J. López Sánchez1, E. Carreón Guarnizo2, R. Hernandez Clares2, F. Iniesta Martinez3, J. Jiménez Veiga3, A. Morales Ortiz2, J. Meca- Lallana3, 1Virgen de la Arrixaca University Hospital/El Palmar, Murcia/ES, 2Hospital Clinico Universitario Virgen de la Arrixaca/Murcia/ES, 3Hospital Clínico Universitario Virgen de la Arrixaca/Murcia/ES

P0359 - Natalizumab and eosinophilia: epidemiological characteristics and clinical associations

L. Diem1, R. Hoepner2, M. Bagnoud1, A. Salmen2, A. Chan2, C. Friedli1, 1Inselspital Bern, University Hospital and University of Bern/Berne/CH, 2Inselspital Bern, University Hospital and University of Bern/Bern/CH

P0360 - No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS

L. Zhovtis-Ryerson1, R.T. Naismith2, L. Krupp3, L. Charvet3, R. Su4, E. Fisher4, C. De Moor5, J. Williams4, N. Campbell4, 1NYU Langone Health, New York University/New York City/US, 2Washington University/Saint Louis/US, 3NYU Langone/New York City/US, 4Biogen/Boston/US, 5Biogen/Cambridge/US

P0361 - Non-thyroid secondary autoimmune diseases after alemtuzumab treatment: real-world data from a nationwide prospective observational cohort in Sweden.

S. Sandgren1, L. Novakova1, M. Axelsson1, F. Amirbeagi1, I. Kockum2, T. Olsson3, C. Malmeström1, J. Lycke1, 1Institute of Neuroscience and Physiology/Gothenburg/SE, 2Department of Clinical Neuroscience, Karolinska Institutet/Stockholm/SE, 3Karolinska Institute/Stockholm/SE

P0363 - Ocrelizumab as exit strategy from natalizumab: results from a clinical series

E. Tsantes, E. Curti, A. Fiore, V. Bazzurri, F. Granella, University of Parma/Parma/IT

P0364 - Ocrelizumab real-world safety and effectiveness in the two years of treatment in multiple sclerosis. B. Vollmer1, A. Declusin2, K. Nair3, S. Sillau2, J. Corboy4, T. Vollmer2, E. Alvarez1, 1University of Colorado/Aurora/US, 2Rocky Mountain MS Center at the University of Colorado Anschutz Medical Campus/Aurora/US, 3Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus/Aurora/US, 4University of Colorado/Denver/US

P0365 - Ocrelizumab treatment in patients with progressive multiple sclerosis: a single-center real- world experience

M. Cellerino1, G. Boffa2, C. Lapucci2, E. Sbragia2, N. Bruschi2, E. Mancuso3, F. Tazza2, I. Poirè2, A. Laroni4, E. Capello2, A. Uccelli5, G. Novi2, M. Inglese6, 1University of Genoa/Genoa/IT, 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 3Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI)/Genova/IT, 4University of Genova/Genova/IT, 5University of Genoa/Italy/IT, 6University of Genoa//IT

P0366 - Ocrelizumab-Therapy associated Lymphopenia is linked to age in patients with Multiple Sclerosis in a Single-Centre Retrospective Cohort Study.

J. Plenge, T. Beyer, F. Leypoldt, K.H. Stürner, University Hospital of Schleswig-Holstein/Kiel/DE

P0367 - Online Medical Simulation Identifies Rationales for the Use and Avoidance of DMTs for Highly Active MS Among Neurologists

T. Finnegan1, A. Armagan2, M. Warters2, P. Coyle3, 1Medscape Education/Newtown Square/US, 2Medscape Education/New York/US, 3Stony Brook University/Stony Brook/US

P0368 - Persistent severe lymphopenia of at least one-year duration after dimethyl fumarate discontinuation: three case reports

N. Gonzalez Caldito1, S. O'Leary2, O. Stuve1, 1UTSW/Dallas/US, 2VA North Texas/Dallas/US

P0369 - Posibble Risk Factors in Fingolimod Rebound Syndrome

C. Goncuoglu1, C. Ayvacioglu Cagan2, M. Cakan2, N.P. Acar Ozen2, A. Bayraktar-Ekincioglu1, A. Tuncer2, R. Karabudak2, 1Hacettepe University Faculty of Pharmacy/Ankara/TR, 2Hacettepe University Faculty of Medicine/Ankara/TR

P0370 - Post-approval safety of subcutaneous interferon β-1a in the treatment of multiple sclerosis, with particular reference to respiratory viral infections

M. Freedman1, H. Guehring2, Z. Murgasova3, D. Jack2, 1The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 2Merck KGaA/Darmstadt/DE, 3Merck spol. s r.o./Bratislava/SK

P0371 - Practice improvement by retrospective analysis of changes in lymphocyte levels in patients with multiple sclerosis on dimethyl fumarate. M.-E. Baeva, P. Baev, J. Nelson, A. Kazimirchik, G. Vorobeychik, Fraser Health Multiple Sclerosis Clinic/Burnaby/CA

P0372 - Predictors of Therapeutic Adherence in Multiple Sclerosis in Argentina

E. Drzewiscki1, G. Zanga2, D. Caruso3, P. Tagliani3, M. Esnaola Y Rojas3, 1Cesar Milstein Hospital./Capital Federal/AR, 2Unidad Asistencial Cesar Milstein/capital federal/AR, 3Unidad Asistencial Cesar Milstein/Capital Federal/AR

P0373 - Profile of multiple sclerosis patients on treatment with ocrelizumab and socio-economic impact of the disease

I. Barbov, T. Boskova, I. Kuzmanovski, University Clinic for neurology/Skopje/MK

P0374 - Progressive MS patients of older age on ocrelizumab: real-world experience at Columbia University Irving Medical Center

S. Epstein1, K. Fong2, P. De Jager3, C. Riley2, L. Levine2, W. Vargas4, R. Farber2, 1Columbia University Irving Medical Center; Neurologic Institute/New York/US, 2Columbia University Irving Medical Center/New York/US, 3Columbia University Medical Center/United States/US, 4Columbia University Medical Center/New York/US

P0375 - Quantifying the risk of disease reactivation after DMT discontinuation – the VIAADISC score

G. Bsteh1, H. Hegen2, K. Riedl1, P. Altmann1, M. Auer2, K. Berek2, F. Di Pauli2, R. Ehling3, B. Kornek1, T. Monschein1, W. Rinner1, C. Schmied1, S. Wurth4, A. Zinganell2, G. Zulehner1, T. Zrzavy1, F. Deisenhammer2, P. Rommer1, F. Leutmezer1, T. Berger1, 1Medical University of Vienna/Vienna/AT, 2Medical University of Innsbruck/Innsbruck/AT, 3Clinic for Rehabilitation Münster/Münster/AT, 4Medical University of Graz/Innsbruck/AT

P0376 - RAM-589.555 favors neuroprotective/anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice

R.I. Zilkha-Falb, T. Rachutin-Zalogin, L. Kleaver, M. Gurevich, A. Achiron, Sheba medical center/Tel- Hashomer/IL

P0377 - Real world experience with cladribine: patient profile, efficacy and safety.

J. Dotor García-Soto1, R. López Ruiz2, S. Eichau Madueño2, M. Ruiz De Arcos3, J.L. Ruiz-Peña2, M.D. Páramo Camino2, G. Navarro Mascarell2, 1Hospital Universitario Virgen Macarena/Sevilla/ES, 2Universitary Hospital Virgen Macarena/Seville/ES, 3Universitary Hospital Virgen Macarena/Sevilla/ES

P0378 - Real World Experience with Ocrelizumab in patiens with Relapsing-Remitting Multiple Sclerosis R. López Ruiz1, J. Dotor García-Soto2, J.D.G. Hiraldo3, J.L. Ruiz-Peña1, M.D. Páramo Camino1, M. Ruiz De Arcos4, G. Navarro Mascarell1, S. Eichau Madueño1, 1Universitary Hospital Virgen Macarena/Seville/ES, 2Hospital Universitario Virgen Macarena/Sevilla/ES, 3Hospital universitario Virgen Macarena/Seville/ES, 4Universitary Hospital Virgen Macarena/Sevilla/ES

P0379 - Real World Experience with Ocrelizumab in patients with Primary Progressive Multiple Sclerosis

R. López Ruiz1, J. Dotor García-Soto1, J.D.G. Hiraldo2, J.L. Ruiz-Peña1, M.D. Páramo Camino1, M. Ruiz De Arcos3, G. Navarro Mascarell1, S. Eichau Madueño1, 1Universitary Hospital Virgen Macarena/Seville/ES, 2Hospital universitario Virgen Macarena/Seville/ES, 3Universitary Hospital Virgen Macarena/Sevilla/ES

P0380 - Real-world data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) – effectiveness and safety profile

S. Kågström1, Å. Leandersson2, L. Forsberg2, A. Berglund1, J. Hillert3, P. Nilsson4, C. Dahle5, A. Svenningsson6, J. Lycke7, A.-M. Landtblom8, J. Burman8, C. Martin6, P. Sundström9, M. Gunnarsson10, F. Piehl1, T. Olsson1, 1Karolinska Institute/Stockholm/SE, 2Karolinska Institutet/Solna/SE, 3Karolinska Institute/Solna/SE, 4Lund University/Lund/SE, 5Linköping University/Linköping/SE, 6Danderyd Hospital/Danderyd/SE, 7Institute of Neuroscience and Physiology/Gothenburg/SE, 8Uppsala University/Uppsala/SE, 9Umeå University/Umeå/SE, 10Örebro University/Örebro/SE

P0381 - Reduced sphingosine kinase gene expression in SPMS vs. RRMS astrocytes revealed by single- nucleus RNA-seq

Y. Kihara1, Y. Zhu1, D. Jonnalagadda1, W. Romanow1, C. Palmer1, B. Siddoway1, R. Rivera1, R. Dutta2, B. Trapp2, J. Chun1, 1Sanford Burnham Prebys Medical Discovery Institute/La Jolla/US, 2Cleveland Clinic/Cleveland/US

P0382 - Reduction in CUA MRI lesions in the first 6 months of cladribine tablets treatment for highly active relapsing multiple sclerosis: MAGNIFY-MS study

N. De Stefano1, F. Barkhof2, X. Montalban3, A. Achiron4, T. Derfuss5, A. Chan6, S. Hodgkinson7, A. Prat8, L. Leocani9, K. Schmierer10, F. Sellebjerg11, P. Vermersch12, H. Wiendl13, B. Keller14, S. Roy15, 1University of Siena//IT, 2Amsterdam UMC, Location VUmc/Amsterdam/NL, 3Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron/Barcelona/ES, 4Multiple Sclerosis Center, Sheba Academic Medical Center/Ramat Gan/IL, 5University of Basel//CH, 6University Hospital of Berne, University of Berne/Berne/CH, 7Ingham Institute for Applied Medical Research, University of New South Wales Medicine/Sydney/AU, 8University of Montreal/Montreal/CA, 9Vita-Salute San Raffaele University/Milan/IT, 10Queen Mary University London/London/GB, 11Danish MS Center, University of Copenhagen/Copenhagen/DK, 12CHU de Lille/Lille/FR, 13University of Münster/Germany/DE, 14Merck KGaA/Darmstadt/DE, 15Merck/Aubonne/CH

P0383 - Resistance of CD11c+ B cells to anti-CD20 depletion with treatment initiation and early preferential repopulation of anti-inflammatory B cells in MS

K. Shinoda, R. Li, A. Rezk, A. Bar-Or, University of Pennsylvania/Philadelphia/US

P0384 - Risk Factors for Developing Lymphopenia and Hypogammaglobulinemia in anti-CD20 Treated Patients with Multiple Sclerosis

B. Vollmer1, T. Vollmer2, J. Corboy3, E. Alvarez1, 1University of Colorado/Aurora/US, 2Rocky Mountain MS Center at the University of Colorado Anschutz Medical Campus/Aurora/US, 3University of Colorado/Denver/US

P0385 - Risk factors for ocrelizumab infusion reaction in a rural Appalachian population

E. Seachrist1, S. Sriwastava2, V. Casuccio3, M. Ward3, E. Blackwell3, A. Petrone3, 1West Virginia University/Morgantown/US, 21 Medical Center Drive /Morgantown/US, 31 Medical Center Drive/Morgantown/US

P0386 - Safety and Effectiveness of Dimethyl Fumarate Maintained Over 5 Years in Multiple Sclerosis Patients Treated in Routine Medical Practice

K. Pandey1, K. Giles2, K. Balashov3, R. Macdonell4, J. Windsheimer5, A. Okai6, M. Martinez7, O. Mokliatchouk8, B. Parks8, S. Kapadia8, C. Jones8, 1Hackensack University Medical Center/Hackensack/US, 2Cambridge Memorial Hospital/Ontario/CA, 3Rutgers-Robert Wood Johnson Medical School/New Brunswick/US, 4Austin Health. University of Melbourne/Melbourne/AU, 5Praxis für Neurologie und Psychiatrie/Nürnberg/DE, 6Multiple Sclerosis Treatment Center of Dallas/Dallas/US, 7Centre Hospitalier Dax/Dax/FR, 8Biogen/Cambridge/US

P0387 - Safety and tolerability of cladribine in multiple sclerosis – clinical experience of two tertiary centers

M. Santos1, A. Barros2, J. Sequeira2, M. Brum2, J. Parra2, L. Leitão2, F. Ladeira2, J. Ferreira3, C. Capela2, J. De Sá3, 1Hospital de Santa Maria/Lisbon/PT, 2Centro Hospitalar Universitário de Lisboa Central/Lisbon/PT, 3Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte/Lisbon/PT

P0388 - Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis

G. Liang1, J. Chai2, H.S. Ng2, H. Tremlett2, 1/Vancouver/CA, 2University of British Columbia/Vancouver/CA

P0389 - Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis

S. Hauser1, L. Kappos2, X. Montalban3, C. Chognot4, L. Craveiro4, A. Pradhan5, K. Prajapati6, J. Wolinsky7, 1University of California San Francisco/San Francisco/US, 2University Hospital Basel, University of Basel/Basel/CH, 3Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron/Barcelona/ES, 4F. Hoffmann-La Roche Ltd/Basel/CH, 5Genentech, Inc/South San Francisco/US, 6GCE Solutions Inc./Amsterdam/NL, 7The University of Texas Health Science Center at Houston/Houston/US

P0390 - Seroconversion rate following HBV vaccination in clinical practice: the role of immunosenescence and concomitant DMT treatment

P. Faustino1, M. Coutinho1, L. Leitão2, C. Capela2, M. Brum2, J. Parra2, J. Sequeira2, A. Barros2, C. Araújo2, A. Sousa2, F. Ladeira2, 1Centro Hospitalar Lisboa Central/Lisboa/PT, 2Centro Hospitalar Universitário de Lisboa Central/Lisbon/PT

P0391 - Severe neutropenia after cladribine first cycle in a patient with Multiple Sclerosis

C. Aguirre, V. Meca-Lallana, B. Del Río, J. Vivancos, La Princesa Hospital/Madrid/ES

P0392 - Shorter infusion time of ocrelizumab: results from the ENSEMBLE PLUS study in patients with relapsing-remitting multiple sclerosis

B. Brochet1, T. Berger2, R. Bermel3, M. Freedman4, H.P. Hartung5, T. Holmøy6, J. Killestein7, A. Perrin Ross8, R. Buffels9, M. Garas9, K. Kadner9, H.-M. Schneble9, Q. Wang9, C. Nos10, 1University of Bordeaux/Bordeaux/FR, 2Medical University of Vienna/Vienna/AT, 3Mellen Center for MS, Cleveland Clinic/Cleveland/US, 4The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA, 5/Dusseldorf/DE, 6Akerhus University Hospital/Nordbyhagen/NO, 7Amsterdam UMC, Location VUmc/Amsterdam/NL, 8Loyola University Chicago/Oak Brook/US, 9F. Hoffmann-La Roche Ltd/Basel/CH, 10Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari/Bercelona/ES

P0393 - Similar clinical outcomes for natalizumab patients switching to every-6-week dosing versus remaining on every-4-week dosing in real-world practice

H. Butzkueven1, L. Kappos2, T. Spelman3, M. Trojano4, H. Wiendl5, R. Su6, R. Hyde7, S. Licata8, P.-R. Ho9, N. Campbell6, 1Monash University/Melbourne/AU, 2University Hospital and University of Basel/Basel/CH, 3Karolinska Institute/Stockholm/SE, 4University of Bari/Bari/IT, 5University of Münster/Germany/DE, 6Biogen/Boston/US, 7Biogen/Baar/CH, 8Biogen/Cambridge/US, 9Biogen at the time of these analyses/Cambridge/US

P0394 - Siponimod treatment leads to a dose-dependent reduction of EAE severity associated with downregulation of microglial activity.

L. Husseini1, A. Geladaris1, M. Steinleitner2, K. Grondey2, J. Koch2, D. Häusler2, M. Weber3, 1University Medical Center Göttingen/Göttingen/DE, 2University medical center Göttingen/Göttingen/DE, 3University Medical Center Goettingen/Goettingen/DE

P0395 - Species variation in sphingosine 1-phosphate receptor subtype 5 affects response to ozanimod in preclinical models of multiple sclerosis J. Selkirk, G. Yan, N. Ching, S. Biswas, K. Dines, S. Smith, C. Lopez, I. Ruiz, R. Hargreaves, Bristol-Myers Squibb Company/Princeton/US

P0396 - Sustained and rapid B-cell depletion with ofatumumab: Population pharmacokinetic B-cell modeling in relapsing MS patients

G. Graham1, J. Kahn2, M. Savelieva1, H. Yu1, R. Pingili3, R. Willi2, K. Ramanathan1, O. David1, D.A. Haering1, M. Bagger1, 1Novartis Pharma AG/Basel/CH, 2Novartis Pharmaceuticals Corporation/East Hanover/US, 3Novartis Pharmaceuticals Corporation/NJ/US

P0397 - Switches to immune-reconstitution therapies in Europe and the United States: Analyses from annual retrospective patient chart audits

S. Saidha1, M. Stabb2, N. Robinson2, V. Schobel2, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Spherix Global Insights/Exton/US

P0398 - Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis.

Z. Van Lierop1, A. Toorop2, E. Willemse3, E. Strijbis2, N. Kalkers4, B. Moraal1, F. Barkhof5, C. Teunissen2, J. Killestein1, Z. Van Kempen2, 1Amsterdam UMC, Location VUmc/Amsterdam/NL, 2Amsterdam UMC/Amsterdam/NL, 3Amsterdam Neuroscience, Neurochemistry Laboratory and Biobank, Amsterdam University medical centers, Vrije Universiteit/Amsterdam/NL, 4MS Center Amsterdam, Amsterdam UMC, location VUmc/Amsterdam/NL, 5University College London/LONDON/GB

P0399 - Switching from ocrelizumab to cladribine: real world data

D. O'Neill1, M. Sharma2, B. Gonzales2, M. Vandenheuval2, B. Tse3, S. Hodgkinson4, 1Liverpool Hospital /Sydney/AU, 2Liverpool Hospital/Sydney/AU, 3Ingham Institute for Medical Research/Sydney/AU, 4Ingham Institute for Applied Medical Research, University of New South Wales Medicine/Sydney/AU

P0400 - Switching to Ocrelizumab from other second line treatments in relapsing-remitting Multiple Sclerosis: a single Center cohort

M.B. Pasanisi1, M. Vercellino2, V. Schillaci2, C. Bosa2, A. Alteno2, G. Costantini2, A. Chiò2, P. Cavalla3, 1City of Health and Science University Hospital of Turin /Torino/IT, 2City of Health and Science University Hospital of Turin/Turin/IT, 3City of Health & Science University Hospital/Turin/IT

P0401 - Switching disease modifying treatment in relapsing multiple sclerosis: Delphi consensus of the Demyelinating Group of the Spanish Society of Neurology

L. Brieva, Hospital Arnau de Vilanova/LLEIDA/ES

P0402 - Targeting monocyte migration for treatment of MS: Human ex-vivo proof-of-concept for Anti-MOSPD2 mAbs in patients with RR and progressive MS

Y. Salem1, A. Karni2, I. Vigiser2, K. Regev2, P. Kafri1, O. Propheta-Meiran1, N. Yacov1, E. Breitbart1, I. Mendel1, 1VBL Therapeutics/Modiin/IL, 2Tel Aviv Medical Center/Tel Aviv/IL

P0403 - T-bet+ B-cell development in MS: Association with Bruton’s Tyrosine Kinase activity and targeting by evobrutinib

L. Rijvers1, M.J. Melief1, J. Van Langelaar2, A. Wierenga-Wolf1, S.M. Van Ham3, U. Boschert4, R. Grenningloh5, J. Smolders2, M. Van Luijn6, 1MS Center ErasMS, Erasmus University Medical Center/Rotterdam/NL, 2Erasmus University Medical Center/Rotterdam/NL, 3Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center/Amsterdam/NL, 4Ares Trading SA/Eysin/CH, 5EMD Serono Research & Development Institute, Inc./Billerica/US, 6MS Center ErasMS, Erasmus MC/Rotterdam/NL

P0404 - The Bruton’s tyrosine kinase inhibitor evobrutinib ameliorates meningeal inflammation in experimental autoimmune encephalomyelitis

S. Kim1, U. Boschert2, R. Grenningloh3, P. Bhargava4, 1Johns Hopkins University/Baltimore/US, 2Ares Trading SA (an affiliate of Merck KgaA, Darmstadt, Germany)/Eysins/CH, 3EMD Serono Research & Development Institute, Inc./Billerica/US, 4Johns Hopkins University School of Medicine/Baltimore/US

P0405 - The consequences of switching from Gilenya to generics for Fingolimod

L. Menendez1, M. Osherov2, Z. Nitsan2, N. Hovel3, R. Milo4, 1/ashkelon/IL, 2Barzilai Medical Center/ashkelon/IL, 3Barzilai University Medical Center/ashkelon/IL, 4Barzilai University Medical Center/Ben Gurion University of the Negev/ashkelon/IL

P0406 - The effect of cladribine upon naïve and activated CD4+ T regulatory cells in MS patients.

N. Verma1, D. O'Neill2, R. Al-Atiyah1, M. Sharma3, G. Tran1, B. Hall1, S. Hodgkinson4, 1Ingham Institute for Applied Medical Research/Sydney/AU, 2Liverpool Hospital /Sydney/AU, 3Liverpool Hospital/Sydney/AU, 4Ingham Institute for Applied Medical Research, University of New South Wales Medicine/Sydney/AU

P0407 - The Impact of Ocrelizumab on Immunoglobulin Levels and the Risk of Infection.

K. Smoot1, C. Moreno1, T. Stuchiner1, C. Chen2, S. Cohan1, 1Providence MS Center/Portland/US, 2Providence St. Joseph Health/Portland/US

P0408 - Therapeutic Plasma Exchange in MS relapses: long term outcome M. Marrodan1, S. Crema2, L. Alessandro2, A. Rubstein3, J. Correale4, M. Ysrraelit2, 1FLENI/CIUDAD DE BUENOS AIRES/AR, 2Fleni/Ciudad de Buenos Aires/AR, 3Merck/Ciudad de Buenos Aires/AR, 4Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR

P0409 - Treatment Failure in patients with multiple sclerosis initiating frequently used first line therapies

D. Conway1, C. Hersh2, M. Wang3, F. Yang4, C. Deshpande5, 1Cleveland Clinic Foundation/Cleveland/US, 2Cleveland Clinic/Las Vegas/US, 3KMK Consulting Inc./Morristown/US, 4Novartis Pharmaceuticals Corporation One Health Plaza/East Hanover/US, 5Novartis Pharmaceuticals Corporation/East Hanover, NJ/US

P0410 - Treatment with ocrelizumab during Sars-Cov2 pandemic: efficacy and safety outcomes

F. Tazza1, C. Lapucci2, G. Boffa2, M. Cellerino3, E. Sbragia2, N. Bruschi2, G. Novi2, S. Minguzzi2, M. Traversa2, I. Poirè2, A. Laroni4, E. Capello2, M. Inglese5, 1Università degli Studi di Genova/Genova/IT, 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 3University of Genoa/Genoa/IT, 4University of Genova/Genova/IT, 5University of Genoa//IT

P0411 - Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis

J. Oh1, B. Walker2, G. Giovannoni3, D. Jack4, F. Dangond5, A. Nolting4, J. Aldridge6, L. Lebson7, T. Leist8, 1University of Toronto/Toronto/CA, 2Duke University School of Medicine/Durham/US, 3The London School of Medicine and Dentistry/London/GB, 4Merck KGaA/Darmstadt/DE, 5EMD Serono, Inc./Rockland/US, 6EMD Serono, Inc./Billerica/US, 7EMD Serono, Inc., USA (an affiliate of Merck KGaA, Darmstadt, Germany)/Rockland/US, 8Jefferson University/Philadelphia/US

P0412 - Treatment-induced BAFF expression alters B cell biology in multiple sclerosis

I. Smets, T. Prezzemolo, M. Imbrechts, K. Mallants, T. Mitera, S. Humblet-Baron, B. Dubois, P. Matthys, A. Liston, A. Goris, KU Leuven/Leuven/BE

P0413 - Tumefactive demyelinating lesions under fingolimod. A Tunisian case report

A. Ghariani, S. Sakka, K.S. Moalla, N. Farhat, M. Damak, C. Mhiri, Habib Bourguiba Hospital/sfax/TN

P0414 - Tumefactive demyelination in association with B-cell therapy

S. Gomezelj, A. Horvat Ledinek, U. Rot, G. Brecl Jakob, University Medical Centre Ljubljana/Ljubljana/SI

P0415 - Updated post-approval safety of cladribine tablets in the treatment of multiple sclerosis, with particular reference to respiratory viral infections G. Giovannoni1, J. Berger2, T. Leist3, D. Jack4, A. Galazka5, A. Nolting4, D. Damian6, 1The London School of Medicine and Dentistry/London/GB, 2University of Pennsylvania/Philadelphia/US, 3Jefferson University/Philadelphia/US, 4Merck KGaA/Darmstadt/DE, 5Merck/Aubonne/CH, 6EMD Serono Research & Development Institute, Inc./Billerica/US

P0416 - Use of Dimethyl fumarate in real clinical practice and strategy to minimize adverse effects and health resources

L. Ramos-Rúa1, A. Rodríguez Regal2, L. Anibarro-García3, M.C. Amigo-Jorrín4, 1Hospital Público de Monforte/Monforte de Lemos/ES, 2Hospital Pontevedra/Pontevedra/ES, 3Complejo Hospitalario Universitario de Pontevedra (CHUP)/Pontevedra/ES, 4MSC/Madrid/ES

P0417 - Utilization, safety, and tolerability of ocrelizumab: year 3 data from the Providence Ocrelizumab Registry

K. Smoot1, T. Stuchiner1, C. Chen2, L. Grote1, S. Cohan1, 1Providence MS Center/Portland/US, 2Providence St. Joseph Health/Portland/US

P0418 - Withdrawal of fingolimod treatment: results from a single-cohort observational study

M. Cellerino1, E. Mancuso2, S. Lenti3, N. Bruschi3, G. Boffa3, C. Lapucci3, L. Roccatagliata4, G. Novi3, A. Laroni5, E. Capello3, A. Uccelli6, M. Inglese7, 1University of Genoa/Genoa/IT, 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI)/Genova/IT, 3Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 4Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy; 4. Department of Neuroradiology, Ospedale Policlinico San Martino IRCCS, Genoa, Italy/Genova/IT, 5University of Genova/Genova/IT, 6University of Genoa/Italy/IT, 7University of Genoa//IT

P0419 - Racial inequalities in multiple sclerosis research participation: underreporting and underrepresentation

H. Onuorah1, A. Lucas2, O. Charron1, A. Montague3, A. Crispino3, A. Aguirre1, V. Kallhoff1, T. Hall1, E. Meltzer1, L. Freeman2, 1Dell Medical School - The University of Texas at Austin/Austin/US, 2Dell Medical School, The University of Texas at Austin/Austin/US, 3Multiple Sclerosis Association of America/Cherry Hill/US

P0420 - Performance on Symbol Digits Modalities Test preceding conversion to Secondary Progressive Multiple Sclerosis

V.D. Karrenbauer1, L. Forsberg2, J. Hillert3, 1Karolinska Institutet, Karolinska university hospital/Stockholm/SE, 2/Nykvarn/SE, 3Karolinska Institutet/Solna/SE

P0421 - SARS-CoV-2 infection in multiple sclerosis patients: a single center experience in the province of Bergamo, Italy M. Radaelli1, V. Barcella2, M. Conti2, M. Sessa2, 1San Raffaele Hospital/Milan/IT, 2ASST Papa Giovanni XXIII/Bergamo/IT

P0422 - A Case of Multiple Sclerosis in an 18-year-old Female with Juvenile Idiopathic Arthritis on Abatacept

K. Poisson1, K. Schultz1, T. Ting1, A. Zabeti2, 1Cincinnati Children's Hospital/Cincinnati/US, 2University of Cincinnati/Cincinnati/US

P0423 - A history of migraine headache may not be associated with worse disability or worse neurologic function

A. Damian1, C. Hu1, K. Fitzgerald1, E. Mowry2, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Johns Hopkins University/Baltimore/US

P0424 - A Longitudinal Analysis of Functional Outcomes among Young People with MS Using Group- Based Trajectory Modelling

N. Ow1, A. Kuspinar2, N. Mayo3, 1RIMUHC - Center for Outcomes Research and Evaluation/Montreal/CA, 2McMaster University/Hamilton/CA, 3McGill University Health Centre Research Institute/Montreal/CA

P0425 - A real-world analysis of ocrelizumab treatment patterns among multiple sclerosis patients in Saskatchewan, Canada

A. Saini1, I. Poliakov2, K. Knox2, C. Kahovec3, A. Jata3, S. Macgowan4, M. Levin5, 1Office of the Saskatchewan MS Clinical Research Chair, College of medicine, University of Saskatchewan/Saskatoon/CA, 2University of Saskatchewan/SK M/CA, 3Saskatchewan Health Authority/SK M/CA, 4Saskatchewan MS Drugs Research Program/SK M/CA, 5University of Saskatchewan/Saskatoon/CA

P0426 - A systematic assessment of medical diseases and symptoms preceding the first diagnosis of multiple sclerosis

C. Gasperi1, A. Hapfelmeier2, T. Daltrozzo3, E. Donnachie4, A. Schneider5, B. Hemmer6, 1Klinikum rechts der Isar, Technical University of Munich/Munich/DE, 2TUM School of Medicine, Technical University of Munich/Munich/DE, 3Klinikum rechts der Isar, TUM School of Medicine, Technical University of Munich/Munich/DE, 4Bavarian Association of Statutory Health Insurance Physicians/Munich/DE, 5TUM School of Medicine, Technical University Munich/Munich/DE, 6University of Munich/Munich/DE

P0427 - Absence of latitudinal gradient in oligoclonal bands prevalence in Argentina

L. Negrotto1, M. Marrodan1, M. Fiol1, M. Gaitán2, M. Ysrraelit1, C. Vrech3, A. Pappolla4, J. Miguez4, L. Patrucco4, E. Cristiano5, J. Rojas6, A. Carra7, A. Chertcoff8, J. Steinberg8, A. Martinez8, C. Curbelo8, L. Cohen9, R. Alonso9, O. Garcea9, C. Pita9, B. Silva10, G. Luetic11, N. Deri12, M.E. Balbuena13, V. Tkachuk13, E. Carnero Contentti14, P. Lopez14, J. Pettinicchi14, A. Caride14, M. Burgos15, F. Leguizamon16, E. Knorre16, R. Piedrabuena17, A. Barboza18, S. Liwacki17, P. Nofal19, G. Volman20, A. Alves Pinheiro21, J. Hryb22, D. Tavolini23, P. Blaya24, L. Recchia25, C. Mainella26, M. Kohler27, E. Kohler27, J. Blanche28, S. Tizio29, M. Saladino30, F. Caceres31, N. Fernandez Liguori32, L. Lazaro32, G. Zanga33, M. Parada Marcilla34, M.E. Fracaro35, F. Pagani Cassará36, G. Vazquez37, V. Sinay36, G. Sgrilli38, P. Divi39, M. Jacobo39, E. Silva40, E. Reich41, L. Cabrera42, M. Menichini43, M. Coppola44, I. Martos45, J. Viglione46, G. Jose47, S. Bestoso48, R. Manzi49, D. Giunta50, M. Doldan51, M. Alonso Serena52, J. Correale53, 1FLENI/CIUDAD DE BUENOS AIRES/AR, 2FLENI/Buenos Aires/AR, 3Sanatorio Allende/Cordoba/AR, 4Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 5Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 6Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 7Hospital Britanico/CIUDAD DE BUENOS AIRES/AR, 8Hospital Británico De Buenos Aires/Buenos Aires/AR, 9Hospital Ramos Mejía/Buenos Aires/AR, 10Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR, 11Instituto de Neurociencias de Rosario/Rosario./AR, 12Centro de Investigaciones DIABAID/Buenos Aires/AR, 13Hospital de Clínicas José de San Martín/Buenos Aires/AR, 14Hospital Alemán/Buenos Aires/AR, 15Hospital San Bernardo/Salta/AR, 16Hospital de Agudos TEodoro Alvarez/Buenos Aires/AR, 17Clinica Universitaria Reina SOfía/Córdoba/AR, 18Hospital Central/Mendoza/AR, 19Hospital de Clínicas Nuestra Señora del Carmen/Tucuman/AR, 2021. Hospital Presidente Perón de Avellaneda/Avellaneda/AR, 21Hospital San Martin de Parana/Parana/AR, 22Hospital Carlos Durand/Buenos Aires/AR, 23INECO Neurociencias Oroño/Rosario/AR, 24Neurocomp/Trelew/AR, 25Hospital Central de Mendoza/Mendoza/AR, 26Hospital Español/ROsario/AR, 27Fundación Sinapsis/Santa Rosa/AR, 2829. IRNEC (Instituto Regional de Neurociencias)/Tucumán/AR, 29Hospital Español de La Plata/La PLata/AR, 30INEBA Instituto De Neurociencias Buenos Aires/Buenos Aires/AR, 31INERE/Buenos Aires/AR, 32Sanatorio Guemes/Buenos Aires/AR, 33Hospital Cesar Milstein/Buenos Aires/AR, 34SIENES/Buenos Aires/AR, 35Clinica del Castano/San Juan/AR, 36Hospital Universitario Fundación Favaloro/Buenos Aires/AR, 37Fundacion Favaloro/Buenos Aires/AR, 38Axis Neurociencias/Bahia Blanca/AR, 39RIAPEM/Santiago del Estero/AR, 40Predigma/Posadas/AR, 41Hospital Municipal Dr Julio Mendez/Buenos Aires/AR, 42Hospital Militar Campo de Mayo/Buenos Aires/AR, 43Sanatorio Britanico/Rosario/AR, 44Hospital Ramon Santamarina/Tandil/AR, 45Clinica San Jorge/Ushuaia/AR, 46Clinica Regional del Sud/Rio Cuarto/AR, 47Hospital Padilla/Tucuman/AR, 48Hospital Escuela Jose de San Martin/Corrientes/AR, 49Sanatorio Pasteur/Catamarca/AR, 50Hospital Italiano/Buenos Aires/AR, 51Centro de Esclerosis Multiple de Buenos Aires/Buenos Aires/AR, 52CEMIC/Buenos Aires/AR, 53Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR

P0428 - Acculturation and lower socioeconomic status are associated with early disability in Hispanic/Latinx with Multiple Sclerosis.

A. Diaz1, A. Martinez2, C. Manrique3, C. Chan2, M. Robers4, S. Delgado3, I. Vicente1, M. Burnett2, A. Chinea1, J. Mccauley3, L. Amezcua5, 1San Juan MS Center/San Juan/PR, 2University of Southern California/Los Angeles/US, 3Miller School of Medicine, University of Miami/Miami/US, 4Barrow Neurological Institute/Phoenix/US, 5USC/Los Angeles/US

P0429 - Adverse childhood experiences and psychiatric comorbidity in multiple sclerosis and other immune mediated inflammatory disorders A. Wan1, C. Bernstein2, L. Graff2, S. Patten3, J. Sareen2, J. Fisk4, J. Bolton2, C. Hitchon2, J. Marriott2, R.A. Marrie2, 1Health Sciences Centre/Winnipeg/CA, 2University of Manitoba/Winnipeg/CA, 3University of Calgary/Calgary/CA, 4Dalhousie University/Halifax/CA

P0430 - Anti-TNF induced lupus-like disease and progressive multifocal leukoencephalopathy: a unifying underlying mechanism?

V. Papadopoulos1, C. Mavragani2, T. Argyrakos3, G. Velonakis4, G. Stranjalis5, L. Stefanis6, C. Kilidireas6, M.E. Evangelopoulos6, 1Aeginition University Hospital, NKUA/Athens/GR, 2School of Medicine, NKUA/Athens/GR, 3Evangelismos General Hospital/Athens/GR, 4Research Unit of Radiology, 2nd Department of Radiology, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece/Athens/GR, 5NKUA, Evangelismos Hospital/Athens/GR, 6Eginition Hospital, National and Kapodistrian University of Athens/Athens/GR

P0431 - Assessment of clinical, genetic and immune repertoire data to predict disease activity and progression in RRMS

L. Ferre'1, S. Santoro2, M. Tosi2, E. Mascia2, M. Sorosina2, F. Clarelli2, L. Moiola2, V. Martinelli2, G. Comi3, M. Filippi4, F. Esposito2, 1San Raffaele Scientific Institute/Milan/IT, 2IRCCS San Raffaele Scientific Institute/Milan/IT, 3IRCCS SVita-Salute San Raffaele University/Milan/IT, 4IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University/Milan/IT

P0432 - Assessment of Depression, Anxiety and Fatigue in relation to diet quality in Multiple Sclerosis

A. Saul1, B. Taylor2, W. Oddy2, S. Simpson-Yap3, I. Van Der Mei2, 1 University of Tasmania /Hobart/AU, 2University of Tasmania/Hobart/AU, 3The University of Melbourne/Melbourne/AU

P0433 - Association between MS and depression on the risk of macrovascular disease and mortality in England: a population-based matched cohort study

R. Palladino1, R.A. Marrie2, A. Majeed1, J. Chataway3, 1Imperial College/London/GB, 2University of Manitoba/Winnipeg/CA, 3UCL Queen Square Institute of Neurology, University College//GB

P0434 - Associations of depression and anxiety with disease-activity and disability in multiple sclerosis: an analysis of baseline participant characteristics from the CombiRx trial

Y. Zhang1, C. Glenn2, S. Cofield2, G. Cutter2, S. Krieger1, J. Wolinsky3, F. Lublin4, 1Mount Sinai/New York/US, 2The University of Alabama at Birmingham/Birmingham/US, 3The University of Texas Health Science Center at Houston/Houston/US, 4Mount Sinai School of Medicine/United States/US

P0435 - Atlas of MS third edition: Methodology for evaluating the validity of country-specific epidemiology data

L. Rechtman1, W. Kaye1, R. King2, C. Walton2, 1McKing Consulting Corporation/Atlanta/US, 2Multiple Sclerosis International Federation/London/GB

P0436 - Atlas of MS third edition: Worldwide incidence and clinical features of MS

L. Rechtman1, W. Kaye1, R. King2, C. Walton2, 1McKing Consulting Corporation/Atlanta/US, 2Multiple Sclerosis International Federation/London/GB

P0437 - Atlas of MS third edition: Worldwide prevalence of multiple sclerosis

L. Rechtman1, W. Kaye1, R. King2, C. Walton2, 1McKing Consulting Corporation/Atlanta/US, 2Multiple Sclerosis International Federation/London/GB

P0439 - Cannabis Use Among People with MS: A 2020 NARCOMS Survey

A. Salter1, R. Ann Marie2, G. Cutter3, J. Steinerman4, K. Smith4, 1Washington University School in St. Louis/St Louis/US, 2Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba/Winnipeg/CA, 3The University of Alabama at Birmingham/Birmingham/US, 4Greenwich Biosciences, Inc./Carlsbad/US

P0441 - Cerebrospinal fluid chitinase-3-like protein 1 is associated with disability progression in primary progressive multiple sclerosis

A. Emersic, G. Brecl Jakob, S. Šega-Jazbec, A. Horvat Ledinek, S. Čučnik, U. Rot, University Medical Centre Ljubljana/Ljubljana/SI

P0442 - Cerebrovascular disease and Alzheimer’s disease neuropathology in multiple sclerosis.

T. Kaplan1, B. Ouyang1, D. Stefoski1, T. Shoemaker1, M. Ko1, P. De Jager2, S. Nag1, D. Bennett1, Z. Arvanitakis1, F. Sierra Morales1, 1Rush University Medical Center/Chicago/US, 2Columbia University Medical Center/United States/US

P0443 - Characteristics of a population exposed to a disease-modifying drug for multiple sclerosis in the real-world setting (1996-2017)

H.S. Ng1, F. Zhu1, E. Kingwell1, Y. Zhao1, C. Evans2, L. Svenson3, J. Fisk4, R.A. Marrie5, H. Tremlett1, 1University of British Columbia/Vancouver/CA, 2University of Saskatchewan/Saskatoon/CA, 3Alberta Ministry of Health/Edmonto/CA, 4Dalhousie University/Halifax/CA, 5University of Manitoba/Winnipeg/CA

P0444 - Characterization of US-based Hispanic Americans with multiple sclerosis

L. Zhovtis Ryerson1, T. Bacon1, W. Castro-Borrero2, J. Williams3, K. Fitzgerald4, R.T. Naismith5, E. Mowry6, P. Calabresi6, L. Charvet7, L. Krupp7, 1NYU Langone Health/New York/US, 2Biogen/Cambridge/US, 3Biogen/Boston/US, 4Johns Hopkins University School of Medicine/Baltimore/US, 5Washington University/Saint Louis/US, 6Johns Hopkins University/Baltimore/US, 7NYU Langone/New York City/US

P0445 - Cohort description of Project Y: Searching for the cause of phenotype diversity in MS

F. Loonstra1, L. De Ruiter2, D. Doesburg3, K.H. Lam2, Z. Van Lierop2, J. Killestein2, B. Uitdehaag2, 1Amterdam UMC, location VUMC/Amsterdam/NL, 2Amsterdam UMC, Location VUmc/Amsterdam/NL, 3Amsterdam Neuroscience, Amsterdam MS Center, Amsterdam University Mecial centers, Vrije Universiteit/Amsterdam/NL

P0446 - Comorbid Anxiety, Depression, and Fatigue Symptoms by Disease Modifying Therapy: A National Multiple Sclerosis Cohort

D. Pimentel Maldonado1, C. Hemond2, J. Eusebio3, R. Umeton4, I. Berrios Morales4, E. Mowry1, C. Ionete4, K. Fitzgerald5, 1Johns Hopkins University/Baltimore/US, 2University of Massachusetts/Worcester/US, 3Edward M. Kennedy Community Health Center/Worcester/US, 4University of Massachusetts Medical School/Worcester/US, 5Johns Hopkins University School of Medicine/Baltimore/US

P0447 - Comorbidities and multiple sclerosis in the west of Algeria

Z. Barka Bedrane, D. Bouchenak Khelladi, université Abou Bekr Belkaid Tlemcen -CHU Tlemcen/Tlemcen/DZ

P0448 - Comorbidities as predictors of all-cause emergency room usage in multiple sclerosis

E. Gromisch1, A. Turner2, S. Leipertz2, J. Beauvais3, J. Haselkorn2, 1Mount Sinai Rehabilitation Hospital, Trinity Health Of New England/Hartford/US, 2VA Puget Sound Health Care System/Seattle/US, 3VA Connecticut Healthcare System/West Haven/US

P0449 - Comorbidities at MS diagnosis in Immigrants in Ontario, Canada

D. Rotstein1, C. Maxwell1, K. Tu1, J. Gatley2, P. Pequeno2, A. Kopp2, R.A. Marrie3, 1University of Toronto/Toronto/CA, 2ICES/Toronto/CA, 3University of Manitoba/Winnipeg/CA

P0450 - Comorbidity patterns in people with multiple sclerosis: A latent class analysis of the Australian Multiple Sclerosis Longitudinal Study

L.M. Lo, B. Taylor, I. Van Der Mei, University of Tasmania/Hobart/AU

P0451 - Comparing infection-related outcomes in patients with multiple sclerosis and matched controls using administrative claims data

R. Bove1, C. Kozma2, A. Phillips3, D. Harlow3, C. Lobo3, 1University of California, San Francisco/San Francisco/US, 2CK Consulting Associates, LLC/Saint Helena Island/US, 3EMD Serono, Inc./Rockland/US

P0452 - Continued increase of multiple sclerosis and neuromyelitis optica and the north-south gradient in Japan; updates from the 5th nationwide survey N. Isobe1, M. Niino2, T. Matsushita1, Y. Nakamura3, I. Nakashima4, M. Watanabe5, Y. Sakai5, A. Sakoda6, J. Nakahara7, I. Kawachi8, H. Ochi9, Y. Nakatsuji10, Y. Miyazaki11, J. Fujimori12, K. Kufukihara13, T. Okuno14, S. Fukumoto1, F. Hayashi1, K. Yonemoto5, R. Taira5, Y. Nakamura15, K. Nakamura16, K. Sakata17, R. Shimada1, M. Matsui18, J.-I. Kira3, 1Kyushu University/Fukuoka City/JP, 2National Hospital Organization Hokkaido Medical Center/Sapporo/JP, 3International University of Health and Welfare/Okawa/JP, 4Tohoku University//JP, 5Kyushu University/Fukuoka/JP, 6Fukuoka Central Hospital, International University of Health and Welfare/Fukuoka/JP, 7Department of Neurology, Keio University School of Medicine/Tokyo/JP, 8Niigata University/Niigata/JP, 9Ehime University Graduate School of Medicine/Matsuyama/JP, 10Toyama University Hospital/Toyama/JP, 11Hokkaido Medical Center/Sapporo/JP, 12Tohoku Medical and Pharmaceutical University/Sendai/JP, 13Keio University School of Medicine/Tokyo/JP, 14Osaka University Graduate School of Medicine/Osaka/JP, 15Jichi Medical University/Shimotsuke/JP, 16University of the Ryukyus/Okinawa/JP, 17Iwate Medical University/Morioka/JP, 18Kanazawa Medical University/Kanazawa/JP

P0453 - Diagnosis- to-Treatment Interval Has Implication on Quality of Life of patients with Multiple Sclerosis in Montenegro.

J. Erakovic, B. Vujovic, D. Milikic, S. Perunicic, Z. Idrizovic, M. Roganovic, L. Radulovic, Clinical Centre of Montenegro/Podgorica/ME

P0454 - Diagnosis-to-Treatment Interval Is an Important Factor on the Productivity of Multiple Sclerosis patients in Montenegro.

J. Erakovic, B. Vujovic, D. Milikic, S. Perunicic, Z. Idrizovic, M. Roganovic, L. Radulovic, Clinical Centre of Montenegro/Podgorica/ME

P0455 - Disability progression independent of relapse and brain MRI activity and relapse-associated worsening in RRMS patients in Poland

K. Kapica-Topczewska1, I.S.C. Collin2, J. Tarasiuk3, A. Czarnowska3, M. Chorąży3, A. Mirończuk3, J. Kochanowicz3, A. Kułakowska3, 1Medical University of Bialystok/Bialystok/PL, 2Independent statistical consultant/Katowice/PL, 3Medical University of Bialystok/Białystok/PL

P0456 - Epidemiology and MS prevalence in Tehran province, Iran

S. Eskandarieh1, M. Nasiri2, M.A. Sahraian3, 1Multiple Sclerosis Research Center/1136746911/IR, 2Multiple Sclerosis Research Center/Tehran/IR, 3Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran./Tehran/IR

P0457 - Evidence of Clostridium perfringens epsilon toxin involvement in neuromyelitis optica

H. Morcrette1, N. Lewis2, M. Popoff3, R. Everett4, J. Palace5, R. Titball1, 1University of Exeter/Exeter/GB, 2MS Sciences Ltd/HD/GB, 3Institut Pasteur/Paris/FR, 4John Radcliffe Hospital/Oxford/GB, 5Oxford University Hospitals/Oxford/GB

P0458 - Exploring the polypharmacy phenomenon in newly diagnosed Relapsing Remitting Multiple Sclerosis

E. D'Amico1, A. Zanghì2, F. Patti3, 1/catania/IT, 2IRCCS San Raffaele Scientific Institute/Milan/IT, 3Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT

P0459 - Factors associated with access to disability certificate in patients with MS and NMOSD in Argentina

B. Silva1, M.B. Eizaguirre2, A. Chertcoff3, J. Bauer4, C. Curbelo3, V. Tkachuk5, F. Pagani Cassará6, O.B.R.S.G. Relevarem7, 1Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR, 2Hospital Ramos Mejía/Buenos Aires/AR, 3Hospital Británico De Buenos Aires/Buenos Aires/AR, 4Esclerosis Múltiple Argentina (EMA)/Buenos Aires/AR, 5Hospital de Clínicas José de San Martín/Buenos Aires/AR, 6Hospital Universitario Fundación Favaloro/Buenos Aires/AR, 7RelevarEM/Buenos Aires/AR

P0460 - Factors Associated with Treatment Escalation in MS care: Results from an International Conjoint Study

G. Saposnik1, X. Montalban2, Ó. Fernández3, H.J. Kim4, H. Wiendl5, E. Kubala Havrdová6, M. Foss7, E. Celius8, F. Caceres9, M. Magyari10, R. Bermel11, A. Costa12, M. Terzaghi1, T. Kalincik13, V. Popescu14, M.P. Amato15, J. Oh16, 1Saint Michael´s Hospital/Toronto/CA, 2Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 3Fundacion IMABIS, Hospital Universitario Carlos Haya/Málaga/ES, 4Research Institute and Hospital, National Cancer Center/Goyang/KR, 5University of Münster/Germany/DE, 6Charles University//CZ, 7Boostrap Analytics/Calgary/CA, 8Departement of Neurology, Oslo University Hospital, Oslo Norway/Oslo/NO, 9INERE/Buenos Aires/AR, 10Danish Multiple Sclerosis Center/Glostrup/DK, 11Mellen Center for Multiple Sclerosis, Cleveland Clinic/Cleveland/US, 12University of Porto/Porto/PT, 13Royal Melbourne Hospital/Melbourne/AU, 14Revalidatie & MS Centrum VZW/Overpelt/BE, 15University of Florence/Florence/IT, 16University of Toronto/Toronto/CA

P0461 - First clinical presentation of multiple sclerosis; Correlation of gender differences, localisation and prognosis

H. Efendi, S.D. Bünül, Kocaeli University/Kocaeli/TR

P0462 - Framingham score, sedentary behaviors, and association with disease activity in Relapsing- Remitting Multiple Sclerosis

E. D'Amico1, A. Zanghì2, M. Ciaorella3, F. Patti4, 1/catania/IT, 2IRCCS San Raffaele Scientific Institute/Milan/IT, 3University of Catania/catania/IT, 4Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT

P0463 - Healthy-lifestyle-scores associated with lower subsequent fatigue risk in multiple sclerosis using inverse probability treatment weighting T. Weiland1, N. Nag2, A. De Livera3, G. Jelinek2, K. Taylor1, S. Neate2, W. Bevens1, S. Simpson-Yap2, 1The University of Melbourne/Carlton/AU, 2The University of Melbourne/Melbourne/AU, 3Baker Heart & Diabetes Institute/Melbourne/AU

P0464 - High prevalence of hypovitaminosis D and its impact on disability in Ecuadorian patients with multiple sclerosis

E.P. Correa-Diaz1, M. Altamirano-Brito2, 1Universidad Central del Ecuador/Quito/EC, 2HOSPITAL CARLOS ANDRADE MARIN/QUITO/EC

P0465 - Higher mortality related to disability and social deprivation in a cohort of people with MS in Scotland.

E. Deans1, N. Macdougall2, P. Kearns3, C. Purdie4, C. Millar4, J. Wilkie4, 1/Glasgow/GB, 2NHSGGC/NHSL/Glasgow/GB, 3The University of Edinburgh/Edinburgh/GB, 4NHS Lanarkshire/East Kilbride/GB

P0466 - Hypertension is Undertreated in Patients with Multiple Sclerosis

S. Bassi1, D. Conway2, 1/Millersville/US, 2Cleveland Clinic Foundation/Cleveland/US

P0467 - Hypertension, cholesterol levels, and Type II Diabetes are not associated with multiple sclerosis risk: Mendelian randomization analyses

E. Misicka1, F. Briggs2, 1Case Western Reserve University/Cleveland/US, 2Case Western Reserve University, School of Medicine/Cleveland/US

P0468 - Increasing Frequency of Multiple Sclerosis in Yaroslavl, Russia: A 20 Year Epidemiological Survey

D. Kasatkin1, N. Spirin2, I. Stepanov3, V. Shadrichev2, N. Baranova2, 1Yaroslavl State Medical University/Yarosvavl/RU, 2Yaroslavl State Medical University/Yaroslavl/RU, 3Clinical Hospital#2 of Yaroslavl/Yaroslavl/RU

P0469 - Increasing prevalence of multiple sclerosis in Qatar: 27-year data

F. Ibrahim, B. Canibano, D. Deleu, Hamad Medical Corporation/Doha/QA

P0470 - Initial findings from a dynamic cohort study of patients with multiple sclerosis: A proactive approach for safety and comparative effectiveness

M. Sabidó1, M. Batech2, C. Foch2, E. Boutmy2, P. Verpillat2, 1Merck Healthcare KGaA/Darmstadt/DE, 2Merck KGaA/Darmstadt/DE

P0471 - Intra-individual variations in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis

B. Bessing1, S. Claflin2, M. Hussain2, J. Chen3, C.L. Blizzard2, P. Van Dijk4, A. Kirk-Brown4, B. Taylor2, I. Van Der Mei2, 1University of Tasmania /Hobart/AU, 2University of Tasmania/Hobart/AU, 3Menzies/Hobart/AU, 4Monash University/Frankston/AU

P0472 - Investigating the possible role of dietary supplements intake and risk of primary progressive multiple sclerosis

N. Rezaeimanesh1, S. Eskandarieh2, A.N. Moghadasi3, M.A. Sahraian3, 1Multiple sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran./Tehran/IR, 2Multiple Sclerosis Research Center/1136746911/IR, 3Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran./Tehran/IR

P0473 - Laboral Status in multiple sclerosis patients whith EDSS 3.5 in Argentina

A. Alves Pinheiro, A. Secchi, N. Valiero, M. Chaves, M. Abdala, Hospital San Martin de Parana/Parana/AR

P0474 - MS is associated with higher comorbidity, adverse health behaviors, and healthcare resource usage: population based case-control study in Catalonia.

S. Cárdenas-Robledo1, S. Otero-Romero2, M. Passarell-Bacardit3, J. Sastre-Garriga4, X. Montalban5, M. Tintore5, 1Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron Barcelona Hospital Campus/Barcelona/ES, 2Vall d'Hebron University Hospital/Barcelona/ES, 3Jordi Gol University Institute for Research in Primary Care/Barcelona/ES, 4Vall Hebron University Hospital/Barcelona/ES, 5Multiple Sclerosis Centre of Catalonia/Barcelona/ES

P0475 - Multiple sclerosis (MS) features are related to headache frequency in users of MS Care ConnectTM, a self-efficacy digital application

A. Dix1, J. Foley2, K. Geist3, D. Kantor4, S. Hunter5, 1Nova Southeastern University/Fort Lauderdale/US, 2Rocky Mountain Multiple Sclerosis Clinic/Salt Lake City/US, 3Iowa State University/Ames/US, 4Florida Atlantic University/Fort Lauderdale/US, 5Advanced Neurosciences Institute/Franklin/US

P0476 - Multiple sclerosis and acute stroke: are we missing something?

M. Leal Rato1, M. Santos2, T. Pinho E Melo1, J. Ferreira1, 1Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte/Lisbon/PT, 2Hospital de Santa Maria/Lisbon/PT

P0477 - Multiple Sclerosis and Disability Progression in South America, Africa, Asia and the Middle East: A Systematic Review M. Wallin1, S. Bonomi2, S. Jin3, W. Culpepper4, 1George Washington University/Washington/US, 2University of Verona/Verona/IT, 3VA MS Center of Excellence/Baltimore/US, 4University of Maryland/VA MSCoE/Baltimore/US

P0478 - Multiple sclerosis disability predictors in a Mexican tertiary-care center

R. García-Bermúdez, B. Bertado-Cortés, R. Carrera-Pineda, Mexican Social Security Institute/Mexico city/MX

P0479 - Multiple sclerosis predisposes affected individuals for an earlier onset of hypertension.

F. Briggs1, D. Krill2, E. Hill3, D. Conway4, 1Case Western Reserve University, School of Medicine/Cleveland/US, 2Point Park University/Pittsburgh/US, 3UC San Diego School of Medicine/La Jolla/US, 4Cleveland Clinic Foundation/Cleveland/US

P0480 - Multiple Sclerosis: Is there a risk of worsening after yellow fever vaccination?

C. Papeix1, J. Mazoyer1, E. Maillart2, C. Lebrun-Frenay3, V. Pourcher1, J.-S. Vidal4, C. Lubetzki5, 1pitié- salpêtrière hospital/PARIS/FR, 2Pitié-Salpêtriere /Paris/FR, 3Centre Hospitalier University de Nice/Nice/FR, 4Broca hospital/PARIS/FR, 5Hôpital Pitié-Salpêtrière/Paris/FR

P0481 - Natalizumab discontinuation in a Dutch real-world cohort

E. Coerver1, M. Wessels1, Z. Van Lierop2, Z. Van Kempen1, J. Killestein2, E. Strijbis1, 1Amsterdam UMC/Amsterdam/NL, 2Amsterdam UMC, Location VUmc/Amsterdam/NL

P0482 - Objective classification methods result in an increased proportion of secondary progressive multiple sclerosis in five patient registries

A. Glaser1, L. Forsberg2, A. Manouchehrinia1, R. Ramanujam3, T. Spelman3, P. Klyve4, J. Drahota5, D. Horakova5, H. Joensen6, M. Magyari6, D. Ellenberger7, A. Stahmann7, A. Van Der Walt8, J. Rodgers9, R. Middleton10, R. Nicholas11, V. Bezlyak12, N. Adlard12, T. Hach12, C. Lines12, J. Hillert13, 1Karolinska Institutet/Stockholm/SE, 2/Nykvarn/SE, 3Karolinska Institute/Stockholm/SE, 4Department of Clinical Neuroscience/Stockholm/SE, 5First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 6Danish Multiple Sclerosis Center/Glostrup/DK, 7MS Forschungs- und Projektentwicklungs-gGmbH/Hannover/DE, 8Monash University/Melbourne/AU, 9Swansea University Medical School/Swansea/GB, 10Swansea University/Swansea/GB, 11Imperial College London/London/GB, 12Novartis Pharma AG/Basel/CH, 13Karolinska Institute/Solna/SE

P0483 - Prevalence of cancer in multiple sclerosis patients in Argentina: cross sectional study from RelevarEM

G. Luetic1, M. Menichini2, C. Vrech3, A. Pappolla4, J. Miguez4, L. Patrucco4, J. Correale5, M. Marrodan6, M. Gaitán7, M. Fiol6, L. Negrotto6, M. Ysrraelit6, E. Cristiano8, A. Carrá9, A. Chertcoff9, J. Steinberg9, A. Martinez9, C. Curbelo9, L. Cohen10, R. Alonso10, O. Garcea10, C. Pita10, B. Silva11, N. Deri12, M.E. Balbuena13, V. Tkachuk13, E. Carnero Contentti14, P. Lopez14, J. Pettinicchi14, A. Caride14, M. Burgos15, F. Leguizamon16, E. Knorre16, R. Piedrabuena17, A. Barboza18, S. Liwacki17, P. Nofal19, G. Volman20, A. Alves Pinheiro21, J. Hryb22, D. Tavolini23, P. Blaya24, L. Recchia25, C. Mainella26, E. Silva27, J. Blanche28, S. Tizio29, M. Saladino30, F. Caceres31, N. Fernandez Liguori32, L. Lazaro32, G. Zanga33, M. Parada Marcilla34, M.E. Fracaro35, F. Pagani Cassará36, G. Vazquez37, V. Sinay36, G. Sgrilli38, P. Divi39, M. Jacobo39, E. Reich40, L. Cabrera41, M. Coppola42, I. Martos43, M. Kohler44, E. Kohler44, J. Viglione45, G. Jose46, S. Bestoso47, R. Manzi48, J. Rojas49, M. Alonso Serena50, O.B.R.S.G. (Relevarem)51, 1Instituto de Neurociencias de Rosario/Rosario./AR, 2Sanatorio Britanico/Rosario/AR, 3Sanatorio Allende/Cordoba/AR, 4Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 5Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR, 6FLENI/CIUDAD DE BUENOS AIRES/AR, 7FLENI/Buenos Aires/AR, 8Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 9Hospital Británico De Buenos Aires/Buenos Aires/AR, 10Hospital Ramos Mejía/Buenos Aires/AR, 11Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR, 12Centro de Investigaciones DIABAID/Buenos Aires/AR, 13Hospital de Clínicas José de San Martín/Buenos Aires/AR, 14Hospital Alemán/Buenos Aires/AR, 15Hospital San Bernardo/Salta/AR, 16Hospital de Agudos TEodoro Alvarez/Buenos Aires/AR, 17Clinica Universitaria Reina SOfía/Córdoba/AR, 18Hospital Central/Mendoza/AR, 19Hospital de Clínicas Nuestra Señora del Carmen/Tucuman/AR, 2021. Hospital Presidente Perón de Avellaneda/Avellaneda/AR, 21Hospital San Martin de Parana/Parana/AR, 22Hospital Carlos Durand/Buenos Aires/AR, 23INECO Neurociencias Oroño/Rosario/AR, 24Neurocomp/Trelew/AR, 25Hospital Central de Mendoza/Mendoza/AR, 26Hospital Español/ROsario/AR, 27Predigma/Posadas/AR, 28Instituto Regional de Neurociencias/San Miguel de Tucumán/AR, 29Hospital Español de La Plata/La PLata/AR, 30INEBA Instituto De Neurociencias Buenos Aires/Buenos Aires/AR, 31INERE/Buenos Aires/AR, 32Sanatorio Guemes/Buenos Aires/AR, 33Hospital Cesar Milstein/Buenos Aires/AR, 34SIENES/Buenos Aires/AR, 35Clinica del Castano/San Juan/AR, 36Hospital Universitario Fundación Favaloro/Buenos Aires/AR, 37Fundacion Favaloro/Buenos Aires/AR, 38Axis Neurociencias/Bahia Blanca/AR, 39RIAPEM/Santiago del Estero/AR, 40Hospital Municipal Dr Julio Mendez/Buenos Aires/AR, 41Hospital Militar Campo de Mayo/Buenos Aires/AR, 42Hospital Ramon Santamarina/Tandil/AR, 43Clinica San Jorge/Ushuaia/AR, 44Fundación Sinapsis/Santa Rosa/AR, 45Clinica Regional del Sud/Rio Cuarto/AR, 46Hospital Padilla/Tucuman/AR, 47Hospital Escuela Jose de San Martin/Corrientes/AR, 48Sanatorio Pasteur/Catamarca/AR, 49Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 50CEMIC/Buenos Aires/AR, 51on behalf RelevarEM study group/Buenos Aires/AR

P0484 - Prevalence of fatigue in multiple sclerosis

L. Broch1, C. Simonsen2, H. Flemmen3, Å. Skardhamar4, E. Celius4, 1Vestre Viken Hospital Trust/Drammen/NO, 2Vestre Viken health trust/Drammen/NO, 3Telemark Hospital/Skien/NO, 4Departement of Neurology, Oslo University Hospital, Oslo Norway/Oslo/NO

P0485 - Prevalence of multiple sclerosis in the OneFlorida Data Trust

A. Carlson1, C. Vervloet Sollero2, Q. Wu3, T. Gyang3, Z. Li3, M. Armstrong3, 1University of Colorado, Anschutz Medical Campus/Denver/US, 2University of Rochester/Rochester/US, 3University of Florida/Gainesville/US

P0486 - Rate of latent infections and vaccination in a cohort of Multiple Sclerosis patients assessed for disease modifying therapies.

A. Tageldin1, M. Mahmud2, L. Fisniku1, S. Jawad3, 1Brighton and Sussex university hospitals NHS trust/Hayward’s Heath/GB, 2Imperial college healthcare NHS trust/London/GB, 3St Georges University NHS Trust/London/GB

P0487 - RDW as a predictor of disability in RRMS

R. Rocha1, L. Ribeiro2, F. Correia2, 1Hospital Pedro Hispano/Matosinhos/PT, 2Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos/Matosinhos/PT

P0488 - Relapse recovery in MS: Effect of treatment and contribution to long-term disability

M. Sotiropoulos1, H. Lokhande2, B. Healy3, M. Polgar-Turcsanyi1, B. Glanz1, R. Bakshi1, H. Weiner2, T. Chitnis4, 1Brigham and Women's Hospital/Boston/US, 2Harvard University, Brigham & Women's Hospital/Boston/US, 3Harvard Medical School/United States/US, 4Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US

P0489 - Relationship between comorbidities and health-related quality of life in patients with multiple sclerosis

M. Barzegar1, O. Mirmosayyeb1, M. Rezaei2, A. Afshari-Safavi1, V. Shaygannejad1, 1Isfahan neuroscience research center/Isfahan/IR, 2Isfahan neuroscience research center, Isfahan University of medical sceince, Isfahan, Iran/Isfahan/IR

P0490 - Restless leg syndrome in patients with multiple sclerosis

M. Bouhlal1, N. Chtaou2, S. Bouchal3, A. Elmidaoui2, Z. Souirti2, M. Belahsen2, 1CHU Hassan II /Fez/MA, 2Hassan II UHC of Fez/FEZ/MA, 3CHU HASSAN II FEZ/fez/MA

P0491 - Safety Outcomes after Treatment with Alemtuzumab or Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients

P. Alping1, J. Burman2, J. Lycke3, T. Frisell1, F. Piehl4, 1Karolinska Institutet/Stockholm/SE, 2Uppsala University/Uppsala/SE, 3Institute of Neuroscience and Physiology/Gothenburg/SE, 4Karolinska Institute/Stockholm/SE

P0492 - Selective serotonin-reuptake inhibitors as potential add-on agents in relapsing-remitting multiple sclerosis patients with suboptimal response

D. Kasatkin1, S. Molchanova2, I. Stepanov3, 1Yaroslavl State Medical University/Yarosvavl/RU, 2Yaroslavl State Medical University/Yaroslavl/RU, 3Clinical Hospital#2 of Yaroslavl/Yaroslavl/RU

P0493 - Severe infections in patients with multiple sclerosis: a nationwide registry study in Argentina E. Silva1, C. Vrech2, A. Pappolla3, J. Miguez3, L. Patrucco3, J. Correale4, M. Marrodan5, M. Gaitán6, M. Fiol5, L. Negrotto5, C. Ysrraelit6, E. Cristiano7, A. Carrá8, A. Chertcoff8, J. Steinberg8, A. Martinez8, C. Curbelo8, L. Cohen9, R. Alonso9, O. Garcea9, C. Pita9, B. Silva10, G. Luetic11, N. Deri12, M.E. Balbuena13, V. Tkachuk13, E. Carnero Contentti14, P. Lopez14, J. Pettinicchi14, A. Caride14, M. Burgos15, F. Leguizamon16, E. Knorre16, R. Piedrabuena17, A. Barboza18, S. Liwacki17, P. Nofal19, G. Volman20, A. Alvez Pinheiro21, J. Hryb22, D. Tavolini23, P. Blaya24, L. Recchia25, C. Mainella26, M. Kohler27, E. Kohler27, J. Blanche28, S. Tizio29, M. Saladino30, F. Caceres31, N. Fernandez Liguori32, L. Lazaro32, G. Zanga33, M. Parada Marcilla34, M. Fracaro35, F. Pagani Cassará36, G. Vazquez37, V. Sinay36, G. Sgrilli38, P. Divi39, M. Jacobo40, E. Reich41, L. Cabrera42, M. Menichini43, M. Coppola44, I. Martos45, J. Viglione46, G. Jose47, S. Bestoso48, R. Manzi49, D. Giunta50, M. Doldan51, M. Alonso Serena52, J. Rojas53, 1Predigma/Posadas/AR, 2Sanatorio Allende/Cordoba/AR, 3Hospital Italiano de Buenos Aires/Buenos Aires/AR, 4Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR, 5Raúl Carrea Institute for Neurological Research/Argentina/AR, 6FLENI/Buenos Aires/AR, 7Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 8Hospital Británico De Buenos Aires/Buenos Aires/AR, 9Hospital Ramos Mejía/Buenos Aires/AR, 10Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR, 11Instituto de Neurociencias de Rosario/Rosario./AR, 12Centro de Investigaciones DIABAID/Buenos Aires/AR, 13Hospital de Clínicas José de San Martín/Buenos Aires/AR, 14Hospital Alemán/Buenos Aires/AR, 15Hospital San Bernardo/Salta/AR, 16Hospital de Agudos TEodoro Alvarez/Buenos Aires/AR, 17Clinica Universitaria Reina SOfía/Córdoba/AR, 18Hospital Central/Mendoza/AR, 19Hospital de Clínicas Nuestra Señora del Carmen/Tucuman/AR, 2021. Hospital Presidente Perón de Avellaneda/Avellaneda/AR, 21Hospital San Martín/Paraná/AR, 22Hospital Carlos Durand/Buenos Aires/AR, 23INECO Neurociencias Oroño/Rosario/AR, 24Neurocomp/Trelew/AR, 25Hospital Central de Mendoza/Mendoza/AR, 26Hospital Español/ROsario/AR, 27Fundación Sinapsis/Santa Rosa/AR, 2829. IRNEC (Instituto Regional de Neurociencias)/Tucumán/AR, 29Hospital Español de La Plata/La PLata/AR, 30INEBA Instituto De Neurociencias Buenos Aires/Buenos Aires/AR, 31INERE/Buenos Aires/AR, 32Sanatorio Guemes/Buenos Aires/AR, 33Hospital Cesar Milstein/Buenos Aires/AR, 34SIENES/Buenos Aires/AR, 35San Juan/San Juan/AR, 36Hospital Universitario Fundación Favaloro/Buenos Aires/AR, 37Fundacion Favaloro/Buenos Aires/AR, 38Axis Neurociencias/Bahia Blanca/AR, 39Universidad de SAntiago del Esterol/Santiago del Estero/AR, 40RIAPEM/Santiago del Estero/AR, 41Hospital Municipal Dr Julio Mendez/Buenos Aires/AR, 42Hospital Militar Campo de Mayo/Buenos Aires/AR, 43Sanatorio Britanico/Rosario/AR, 44Hospital Ramon Santamarina/Tandil/AR, 45Clinica San Jorge/Ushuaia/AR, 46Clinica Regional del Sud/Rio Cuarto/AR, 47Hospital Padilla/Tucuman/AR, 48Hospital Escuela Jose de San Martin/Corrientes/AR, 49Sanatorio Pasteur/Catamarca/AR, 50Hospital Italiano/Buenos Aires/AR, 51Centro de Esclerosis Multiple de Buenos Aires/Buenos Aires/AR, 52CEMIC/Buenos Aires/AR, 53Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR

P0494 - Socio-demographic and clinical characteristics of patients with multiple sclerosis by race and ethnicity (NARCRMS registry)

V. Rivera1, P. Repovic2, A. Adeyemi3, A. Altincatal4, C. Perez-Bajandas3, T. Saldana-King3, W. Castro- Borrero3, 1Baylor College of Medicine/Houston/US, 2Swedish MS Center/Seattle/US, 3Biogen/Cambridge/US, 4Biogen/Boston/US

P0495 - Socioeconomic status and stressful life events risks in development of neuromyelitis Optica spectrum disorder

S. Eskandarieh1, F. Rafiee2, A.N. Moghadasi3, M.A. Sahraian3, A. Azimi3, 1Multiple Sclerosis Research Center/1136746911/IR, 2Multiple Sclerosis Research Center/Tehran/IR, 3Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran./Tehran/IR

P0496 - Telemedicine utilization trends among patients with multiple sclerosis and controls in the United States Veterans Health Administration: 2008-2020

H. Abdel Magid1, S. Jin2, W. Culpepper3, L. Nelson4, M. Wallin5, 1Stanford University/Stanford/US, 2VA MS Center of Excellence/Baltimore/US, 3University of Maryland/VA MSCoE/Baltimore/US, 4VA Palo Alto Healthcare System/Menlo Park/US, 5George Washington University/Washington/US

P0497 - The association between dietary food groups intake and risk of primary progressive multiple sclerosis

N. Rezaeimanesh1, S. Eskandarieh2, A.N. Moghadasi3, M.A. Sahraian3, 1Multiple sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran./Tehran/IR, 2Multiple Sclerosis Research Center/1136746911/IR, 3Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran./Tehran/IR

P0498 - The effect of national disease modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis

S. Claflin1, J. Campbell1, D. Mason2, T. Kalincik3, H. Butzkueven4, W. Carroll5, A. Palmer1, S. Simpson- Yap6, C.L. Blizzard1, I. Van Der Mei1, B. Taylor1, 1University of Tasmania/Hobart/AU, 2New Zealand Brain Research Institute/Christchurch/NZ, 3Royal Melbourne Hospital/Melbourne/AU, 4Monash University/Melbourne/AU, 5Perron Institute/Nedlands/AU, 6The University of Melbourne/Melbourne/AU

P0499 - The epidemiology of optic neuritis in the United Kingdom and implications for consensus diagnostic criteria for multiple sclerosis.

A. Petzold1, A. Subramanian2, J. Galloway3, N. Adderley2, S. Mollan4, G. Plant1, K. Nirantharakumar2, A. Denniston2, T. Braithwaite5, 1UCL Institute of Neurology/United Kingdom/GB, 2University of Birmingham/Birmingham/GB, 3Kings College London/London/GB, 4University Hospitals Birmingham/Birmingham/GB, 5St. Thomas Hospital/London/GB

P0500 - The impact of seasonal fluctuations of vitamin D on long-term disability progression in MS

K. Wesnes1, K.M. Myhr2, T. Riise3, S. Kvistad2, Ø. Torkildsen2, S. Wergeland4, T. Holmøy5, R. Midgard6, A. Bru7, A. Edland8, R. Eikeland9, S. Gosal10, H. Harbo11, G. Kleveland12, Y. Sørenes13, N. Øksendal14, K. Bjørnevik15, 1St Olavs Hospital/Trondheim/NO, 2University of Bergen/Haukeland University Hospital/BERGEN/NO, 3University of Bergen/BERGEN/NO, 4Haukeland University Hospital/BERGEN/NO, 5Akerhus University Hospital/Nordbyhagen/NO, 6Molde hospital/Molde/NO, 7Stavanger University Hospital/Stavanger/NO, 8Vestre Viken Hospital/Drammen/NO, 9Sørlandet Hospital Arendal/Arendal/NO, 10Østfold Hospital Kalnes/Grålum/NO, 11Oslo University Hospital/Oslo/NO, 12Lillehammer hospital/Lillehammer/NO, 13Haugesund Hospital/Haugesund/NO, 14Nordland Hospital Trust/Bodø/NO, 15Harvard T.H. Chan School of Public Health/Boston/US

P0501 - The impact of socioeconomic status on the access to disease modifying therapy in people with multiple sclerosis.

J. Das1, R. Nicholas2, R. Middleton3, J. Rodgers4, D. Rog5, 1Salford Royal NHS Foundation Trust /Salford/GB, 2Imperial College London/London/GB, 3Swansea University/Swansea/GB, 4Swansea University Medical School/Swansea/GB, 5Salford Royal NHS Foundation Trust/Salford/GB

P0502 - The Natural Course of Multiple Sclerosis Rewritten: A Population Based Study on Disease Demographics and Progression

C. Simonsen1, H. Flemmen2, L. Broch3, C. Brunborg4, P. Berg-Hansen5, S.M. Moen6, E. Celius5, 1Vestre Viken health trust/Drammen/NO, 2Telemark Hospital/Skien/NO, 3Vestre Viken Hospital Trust/Drammen/NO, 4Oslo University Hospital/Oslo/NO, 5Departement of Neurology, Oslo University Hospital, Oslo Norway/Oslo/NO, 6Hakadal MS Centre/Hakadal/NO

P0503 - The Relationship Between Restless Leg Syndrome and Lesion Localization, Effect of Sleep Quality and Fatigue in Multiple Sclerosis Patients

F. Akkoyun Arıkan, G. Akdag, A. Bardakci, M. Cetiner, S. Canbaz Kabay, Kütahya University of Health Sciences Faculty of Medicine/Kutahya/TR

P0504 - The relative contribution of comorbidities on the severity of symptoms in people with Multiple Sclerosis

L.M. Lo, B. Taylor, I. Van Der Mei, University of Tasmania/Hobart/AU

P0505 - Therapeutic sequences of disease-modifying therapies in patients with multiple sclerosis in France over the period 2010-2015

S. Leblanc, EHESP School of Public Health /RENNES/FR

P0506 - Towards a validated Secondary Progressive Multiple Sclerosis definition: A study from the Italian MS Register

P. Iaffaldano1, G. Lucisano1, M. Filippi2, G. Comi3, M. Onofrj4, F. Patti5, V. Brescia Morra6, M. Zaffaroni7, C. Pozzilli8, E. Cocco9, P. Sola10, G. Salemi11, M. Inglese12, R. Bergamaschi13, S. Galgani14, M.P. Amato15, A. Conte8, M. Salvetti16, G. Lus17, C. Florio18, R. Totaro19, M. Vianello20, F. Granella21, E. Ferraro22, U. Aguglia23, M. Gatto24, B. Orlando1, F. Sangalli2, G. De Luca4, C.G. Chisari5, A. Carotenuto6, D. Baroncini25, D. Colombo26, M. Nica26, D. Paolicelli27, M. Trojano27, 1University of Bari “Aldo Moro”/Bari/IT, 2IRCCS San Raffaele Scientific Institute/Milan/IT, 3San Raffaele Scientific Institute, Vita- Salute San Raffaele University/Milan/IT, 4University G. d’Annunzio/Chieti/IT, 5Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 6University of Naples Federico II/Naples/IT, 7Multiple Sclerosis Centre, Hospital of Gallarate, ASST della Valle Olona/Gallarate (VA)/IT, 8Sapienza University of Rome/Rome/IT, 9University of Cagliari/Cagliari/IT, 10Azienda Ospedaliero-Universitaria di Modena Ospedale Civile di Baggiovara/Modena/IT, 11University of Palermo/Palermo/IT, 12University of Genoa//IT, 13IRCCS Mondino Foundation/Pavia/IT, 14Az. Osp. S. Camillo Forlanini/roma/IT, 15University of Florence/Florence/IT, 16S. Andrea Hospital/Sapienza University/Rome/IT, 17Second University of Naples/Napoli/IT, 18Ospedale A.Cardarelli/Napoli/IT, 19Clinica Neurologica, Ospedale San Salvatore/L'Aquila/IT, 20Centro Sclerosi Multipla - Ospedale Regionale 'Ca' Foncello', Neurology Unit/Treviso/IT, 21University of Parma/Parma/IT, 22PO San Filippo Neri - ASL Roma 1/Rome/IT, 23Grande Ospedale Metropolitano Bianchi Melacrino Morelli/Reggio Calabria/IT, 24Ospedale Generale Regionale F. Miulli/Acquaviva delle Fonti/IT, 25Centro Sclerosi Multipla - Presidio ospedaliero di Gallarate - ASST Valle Olona/Gallarate/IT, 26Novartis Italia/Origgio/IT, 27University of Bari/Bari/IT

P0507 - Treatment of multiple sclerosis during lactation with interferon-beta 1a or glatiramer acetate

A. Ciplea1, A. Stahl1, S. Thiel1, R. Gold2, K. Hellwig3, 1St. Josef Hospital, Katholisches Klinikum Bochum, Klinikum der Ruhr-Universität Bochum/Bochum/DE, 2St. Josef-Hospital, Ruhr University Bochum/Bochum/DE, 3University of Bochum/Bochum/DE

P0508 - Unusual associations of Scleroderma-specific autoantibodies with MS-like disease. Case series and literature review.

D. Karathanasis1, G. Velonakis2, C. Kilidireas1, C. Mavragani3, M.E. Evangelopoulos1, 1Eginition Hospital, National and Kapodistrian University of Athens/Athens/GR, 2Research Unit of Radiology, 2nd Department of Radiology, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece/Athens/GR, 3School of Medicine, NKUA/Athens/GR

P0509 - Utility of NEDA-3 status as a predictor of future disease activity

O. Hoffmann1, H. Zimmermann2, C. Chien3, G. Cooper4, J. Kuchling2, S. Asseyer5, A. Brandt6, K. Ruprecht5, J. Bellmann-Strobl5, F. Paul7, 1St.Josefs-Krankenhaus Potsdam- Sanssouci/Potsdam/DE, 2Charité – Universitätsmedizin Berlin/Berlin/DE, 3Charité-Universitätsmedizin Berlin/Berlin/DE, 4Charité - Universitätsmedizin Berlin/Berlin/DE, 5NeuroCure Clinical Research Center, Experimental and Clinical Research Center, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany/Berlin/DE, 6Department of Neurology, University of California Irvine, Irvine, California, USA./Irvine/US, 7Charite-Universitatmedizin Berlin/Berlin/DE

P0510 - Vascular comorbidity is associated with lower brain volumes in a large multiple sclerosis cohort K. Fitzgerald1, A. Damian1, D. Conway2, E. Mowry3, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Cleveland Clinic Foundation/Cleveland/US, 3Johns Hopkins University/Baltimore/US

P0512 - Vitamin-D-supplement use but not sun exposure associated with higher quality of life in multiple sclerosis

S. Simpson-Yap1, P. Jelinek2, T. Weiland3, N. Nag1, S. Neate1, G. Jelinek1, 1The University of Melbourne/Melbourne/AU, 2Sir Charles Gairdner Hospital/Nedlands/AU, 3The University of Melbourne/Carlton/AU

P0513 - Work productivity trajectories in Australians living with multiple sclerosis: a group-based modelling approach

B. Bessing1, S. Claflin2, M. Hussain2, J. Chen3, C.L. Blizzard2, P. Van Dijk4, A. Kirk-Brown4, B. Taylor2, I. Van Der Mei2, 1University of Tasmania /Hobart/AU, 2University of Tasmania/Hobart/AU, 3Menzies/Hobart/AU, 4Monash University/Frankston/AU

P0514 - Analysis of short chain fatty acids levels in serum and CSF samples of patients with multiple sclerosis and other neurological diseases

R. Alvarez-Lafuente1, S. Pérez-Pérez2, M.I. Domínguez-Mozo2, M.Á. García-Martínez2, R. Arroyo3, 1Hospital Clínico San Carlos/Madrid/ES, 2Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Madrid/ES, 3Hospital Universitario Quirónsalud Madrid/Pozuelo de Alarcón. Madrid/ES

P0515 - Application of Metabolomics to Identify Biofluid Biomarkers for Multiple Sclerosis Diagnosis

S. Jack1, R. Powers2, F. Bhinderwala3, A. Chase1, H. Roth2, 1Saunders Medical Center/Wahoo/US, 2University of Nebraska - Lincoln/Lincoln/US, 3University of Nebraska- Lincoln/Lincoln/US

P0516 - BDNF Val66Met polymorphism effect on hippocampal subfields in multiple sclerosis patients

E. De Meo1, E. Prestipino2, E. Portaccio3, B. Nacmias2, S. Bagnoli2, L. Razzolini4, L. Pastò5, C. Niccolai3, B. Goretti3, R. Fratangelo5, L. Tudisco5, A. Bellinvia5, M. Fonderico5, A. Giorgio6, M.L. Stromillo7, M. Filippi8, S. Sorbi3, N. De Stefano9, M.P. Amato4, 1San Raffaele Hospital/Milan/IT, 2Department NEUROFARBA; Section Neurosciences, University of Florence, Italy/Florence/IT, 3Azienda Ospedaliero- Universitaria Careggi, Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy/Florence/IT, 4University of Florence/Florence/IT, 5University of Florence, Florence, Italy;/Florence/IT, 6Department of Medicine, Surgery and Neuroscience, University of Siena, Italy/Siena/IT, 7University of Siena/Siena/IT, 8IRCCS San Raffaele Scientific Institute/Milan/IT, 9University of Siena//IT

P0517 - Circulating miRNA signatures in PPMS M. Muñoz San Martín1, R. Robles Cedeño2, M. Buxó3, L.M. Villar4, J. Castillo5, B. Casanova-Estruch6, I. Gómez7, H. Perkal8, E. Quintana2, L. Ramió I Torrentà2, 1Girona Biomedical Research Institute/Salt/ES, 2Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 3Girona Biomedical Research Institute (IDIBGI), Salt-Spain/Salt/ES, 4Hospital Universitario Ramón y Cajal/Madrid/ES, 5Unit of Neuroimmunology, Department of Neurology, Hospital Universitari i Politècnic La Fe, Valencia, Spain/Valencia/ES, 6Hospital La Fe/Valencia/ES, 7Neurodegeneration and Neuroinflammation Group, Girona Biomedical Research Institute (IDIBGI), Salt-Spain/Salt/ES, 8Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Girona/Salt-Spain. Neurodegeneration and Neuroinflammation Group, Girona Biomedical Research Institute (IDIBGI), Sa/Girona/ES

P0518 - Clinical and outcome characteristics in familial Multiple Sclerosis

S. Mrabet1, E. Derbel2, M. Nour2, A. Nasri2, L. Hmissi2, M. Bendjebara2, A. Gargouri-Berrechid2, I. Kacem2, R. Gouider2, 1Razi Hospital /Mannouba/TN, 2Razi Hospital/Mannouba/TN

P0519 - Differential expression of miRNAs in CSF of MS patients depending on their ethnic origin

M. Muñoz San Martín1, R. Robles Cedeño2, M. Buxó3, I. Gómez4, H. Perkal5, G. Alvarez Bravo2, E. Quintana2, L. Ramió I Torrentà2, 1Girona Biomedical Research Institute/Salt/ES, 2Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 3Girona Biomedical Research Institute (IDIBGI), Salt- Spain/Salt/ES, 4Neurodegeneration and Neuroinflammation Group, Girona Biomedical Research Institute (IDIBGI), Salt-Spain/Salt/ES, 5Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Girona/Salt-Spain. Neurodegeneration and Neuroinflammation Group, Girona Biomedical Research Institute (IDIBGI), Sa/Girona/ES

P0520 - Effect of genetic polymorphisms on 25-hydroxyvitamin D levels and supplementation response in patients with relapsing-remitting multiple sclerosis

S. Gselman1, U. Potočnik2, M. Gorenjak3, T. Hojs Fabjan1, 1University Medical Centre Maribor/Maribor/SI, 2Medical Faculty Maribpr/Maribor/SI, 3Medical Faculty Maribor/Maribor/SI

P0521 - Gene network interpretation of genetic variants and brain tissue expression yields potential drug repositioning strategies for multiple sclerosis

A. Manuel1, Y. Dai2, L. Freeman3, P. Jia4, Z. Zhao5, 1University of Texas Health Science Center at Houston/77030/US, 2University of Texas health science center at Houston/Houston/US, 3Dell Medical School, The University of Texas at Austin,/Austin/US, 4University of Texas Health Science Center at Houston/Hoston/US, 5University of Texas Health Science Center at Houston/Houston/US

P0522 - Gene-environment interactions in Multiple Sclerosis: a UK Biobank study B. Jacobs1, A. Noyce2, J. Bestwick2, D. Belete1, G. Giovannoni3, R. Dobson2, 1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London/London/GB, 2Queen Mary University of London/London/GB, 3The London School of Medicine and Dentistry/London/GB

P0523 - Genetic polymorphisms associated with multiple sclerosis and atherosclerosis

T. Omerzu1, J. Magdič1, U. Potočnik2, M. Gorenjak3, R. Hojs1, T. Hojs Fabjan4, 1University Medical Center Maribor/Maribor/SI, 2Medical Faculty Maribpr/Maribor/SI, 3Medical Faculty Maribor/Maribor/SI, 4University Medical Centre Maribor/Maribor/SI

P0524 - Importance of control group selection for differential miRNA profile studies

E. Quintana1, M. Muñoz-San Martín2, R. Robles Cedeño1, O. Belchí1, A. Villalonga3, E. Muliterno3, I. Gómez2, H. Perkal4, L. Ramió I Torrentà1, 1Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 2Girona Biomedical Research Institute (IDIBGI)/Salt-Spain/ES, 3Dr. Josep Trueta University Hospital/Girona/ES, 4Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Girona/Salt-Spain. Neurodegeneration and Neuroinflammation Group, Girona Biomedical Research Institute (IDIBGI), Sa/Girona/ES

P0525 - Investigating a role of B cells and their depletion in relapsing-remitting Multiple Sclerosis using DNA methylation patterns

E. Ewing1, F. Al Nimer1, L. Kular1, K. Carlström1, P. Stridh1, T. Olsson2, M. Khademi1, D. Gomez- Cabrero3, F. Piehl2, M. Jagodic2, 1Karolinska Institutet/Stockholm/SE, 2Karolinska Institute/Stockholm/SE, 3Complejo Hospitalario de Navarra/Pamplona/ES

P0526 - Methylome and transcriptome analysis implicates NBPF locus in PPMS etiopathology

M. Pahlevan Kakhki1, Y. Liu2, A. Gyllenberg1, T. Venkata Satya Badam3, T. James1, C. Starvaggi Cucuzza1, M. Gustafsson3, L. Alfredsson4, J. Hillert5, T. Olsson6, P. Casaccia7, I. Kockum8, L. Kular1, M. Jagodic6, 1Karolinska Institutet/Stockholm/SE, 2Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education; Department of Biochemistry and Molecular Biology, Fudan University Shanghai Medical College, China/Fudan/CN, 3Bioinformatics unit,/Linköping/SE, 4Karolinska Institutet//SE, 5Karolinska Institute/Solna/SE, 6Karolinska Institute/Stockholm/SE, 7Advanced Science Research Center at GC-CUNY/New York/US, 8Department of Clinical Neuroscience, Karolinska Institutet/Stockholm/SE

P0527 - Smoking and multiple sclerosis risk: A Mendelian randomization study

M. Vandebergh, A. Goris, KU Leuven/Leuven/BE

P0528 - T cell composition and polygenic multiple sclerosis risk: a population-based study in children

L. De Mol1, K. Looman1, M. Van Luijn2, P. Jansen3, M. Van Zelm4, J. Smolders5, T. White1, H. Moll1, R. Neuteboom6, 1Erasmus MC/Rotterdam/NL, 2MS Center ErasMS, Erasmus MC/Rotterdam/NL, 3Amsterdam UMC/Amsterdam/NL, 4Monash University/Melbourne/AU, 5Erasmus University Medical Center/Rotterdam/NL, 6MS Center ErasMS, Erasmus University Medical Center/Rotterdam/NL

P0529 - The prevalence of HLA-DRB1*1501 gene polymorphisms in familial cases of multiple sclerosis

Y. Vorokhta1, T. Muratova2, S. Dribina2, S. Oliynik2, 1/Odessa/UA, 2Odessa National Medical University/Odesa/UA

P0530 - Understanding the metabolic profile of relapses in multiple sclerosis

T. Yeo1, F. Probert1, M. Sealey1, L. Saldana1, S. Hoeckner2, E. Schiffer2, T. Claridge1, D. Leppert3, G. Deluca4, J. Palace5, J. Kuhle6, D. Anthony1, 1University of Oxford/Oxford/GB, 2numares AG/Regensburg/DE, 3University Hospital Basel and University of Basel/Basel/CH, 4Nuffield Department of Clinical Neurosciences, University of Oxford/Oxford/GB, 5Oxford University Hospitals/Oxford/GB, 6University of Basel/Switzerland/CH

P0531 - 11C-PIB PET showed a distinct cerebrospinal fluid pattern in patients with progressive multiple sclerosis

M. Pitombeira1, F. Duran1, K. Campanholo2, A. Souza2, S. Apóstolos-Pereira2, C. Medeiros Rimkus3, M.F. Mendes4, G. Busatto Filho4, D. Callegaro5, C. Buchpiguel4, D. De Paula Faria4, 1University of Sao Paulo/Sao Paulo/BR, 2Faculdade de Medicina, Universidade de São Paulo/Sao Paulo/BR, 3USP/SÃO PAULO/BR, 4Faculdade de Medicina, Universidade de Sao Paulo/Sao Paulo/BR, 5Hospital das Clínicas – Faculdade de Medicina de São Paulo/São Paulo/BR

P0532 - 2D conventional and synthetic brain MRI in the assessment of multiple sclerosis

F.X. Aymerich1, C. Auger2, J. Alonso2, A. Barros2, M. Clarke3, J. Mora2, G. Arrambide2, J.F. Corral2, J. Sastre-Garriga2, A. Rovira4, 1Institut de Diagnòstic per la Imatge/Barcelona/ES, 2Vall Hebron University Hospital/Barcelona/ES, 3Vanderbilt University Medical Center/Nashville/US, 4Vall d'Hebron University Hospital/Barcelona/ES

P0533 - A Promising Biomarker Based on T1 Relaxation Time Mapping for Early MS

M. Vaneckova1, J. Krasensky1, T. Uher2, B. Srpová3, E. Kubala Havrdová4, M. Andelova2, K. Vodehnalova2, D. Horakova5, B. Maréchal6, M.J. Fartaria6, V. Ravano6, G.F. Piredda6, T. Kober6, 1Charles University and General University Hospital/Prague/CZ, 2First Faculty of Medicine, Charles University and General University/Prague/CZ, 3Charles University and General University/Prague/CZ, 4Charles University//CZ, 5First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 6Siemens Healthcare AG/Lausanne/CH

P0534 - Advanced magnetic resonance imaging for myelin and axonal density in MS: correlation with clinical disability and serum neurofilament levels R. Rahmanzadeh1, P.-J. Lu2, M. Barakovic3, M. Weigel2, S. Schaedelin4, T.D. Nguyen5, S. Schiavi6, A. Daducci6, F. La Rosa7, Y. Wang5, M. Bach Cuadra8, E.-W. Radue9, J. Kuhle10, L. Kappos11, C. Granziera2, 1University of Basel/Basel/CH, 2University Hospital Basel and University of Basel/Basel/CH, 3University of Basel/Allschwil/CH, 4University Hospital Basel/Basel/CH, 5Department of Radiology, Weill Cornell Medical College/New York/US, 6University of Verona/Verona/IT, 7École Polytechnique Fédérale de Lausanne/Lausanne/CH, 8Lausanne University Hospital and University of Lausanne/Lausanne/CH, 9University Hospital Basel and University of Basel/Basel/SZ, 10University of Basel/Switzerland/CH, 11University Hospital and University of Basel/Basel/CH

P0535 - Age-related magnetic susceptibility changes in brain of normal subjects

L. Lambert1, P. Dusek2, A. Pudlac2, M. Vaneckova2, D. Horakova2, J. Krasensky2, A. Burgetova2, 1First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague 2/CZ, 2First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ

P0536 - An X-Ray Fluorescence Histopathological Correlative Study of a Chronic MS Autopsy

C. Vasquez1, Y. Guo2, B. Popescu3, A. Kalinowska-Lyszczarz4, O. Gakh2, C. Lucchinetti5, 1/Providence/US, 2Mayo Clinic/Rochester/US, 3College of Medicine, University of Saskatchewan/Saskatoon/CA, 4Poznan University of Medical Sciences/Poznan/PL, 5Mayo Clinic/Minnesota/US

P0537 - Analysis of Vascular abnormalities for lesions in MS using USPIO

S. Buch1, K. Subramanian1, P. Jella1, Y. Chen1, K. Shah1, Y. Ge2, E. Bernitsas1, E. Haacke1, 1Wayne State University/Detroit/US, 2New York University/New York/US

P0538 - Applying advanced diffusion MRI in MS: a comparison of 20 diffusion MRI models to identify microstructural features of focal damage

M. Barakovic1, L. Melie-Garcia2, M. Weigel1, R. Rahmanzadeh2, J. Kuhle3, L. Kappos4, C. Granziera2, 1University of Basel/Allschwil/CH, 2University Hospital Basel and University of Basel/Basel/CH, 3University of Basel/Switzerland/CH, 4University of Basel//CH

P0539 - Artificial double inversion recovery images for cortical lesion visualization in multiple sclerosis

P. Bouman1, V. Strijbis2, L. Jonkman2, H. Hulst1, J. Geurts2, M. Steenwijk1, 1Amsterdam UMC, VUmc/Amsterdam/NL, 2Amsterdam UMC, location VUmc/Amsterdam/NL

P0540 - Assessing the relationship between the ratio of T1- T2-weighted images and MRI sequences by using the structural similarity index D. Pareto1, A. Garcia-Vidal2, J.F. Corral1, G. Piella3, A. Rovira4, 1Vall Hebron University Hospital/Barcelona/ES, 2Vall Hebron Research Institute/Barcelona/ES, 3Universitat Pompeu Fabra/Barcelona/ES, 4Vall d'Hebron University Hospital/Barcelona/ES

P0541 - Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients

J.F. Corral1, J. Alonso1, C. Auger1, S. Valverde2, A. Vidal-Jordana3, A. Oliver2, A. Barros1, K. Ng Wong1, M. Tintore4, F.X. Aymerich5, X. Montalban4, X. Lladó2, A. Rovira6, 1Vall Hebron University Hospital/Barcelona/ES, 2University of Girona/Girona/ES, 3Hospital Universitari Vall d’Hebron/Barcelona/ES, 4Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 5Institut de Diagnòstic per la Imatge/Barcelona/ES, 6Vall d'Hebron University Hospital/Barcelona/ES

P0542 - Assessment of central vein sign conspicuity in multicenter 3T FLAIR* imaging

M. Martin1, Q. Cao1, B. Renner2, L. Daboul3, C. O'Donnell4, D. Moreno-Dominguez5, P. Rodrigues5, J. Derbyshire6, C. Azevedo7, A. Bar-Or1, E. Caverzasi8, P. Calabresi9, B. Cree10, L. Freeman11, R. Henry10, E. Longbrake12, J. Oh13, N. Papinutto8, R. Samudralwar14, M. Schindler15, E. Sotirchos9, N. Sicotte2, A. Solomon2, R. Shinohara4, D. Reich16, D. Ontaneda17, P. Sati2, 1University of Pennsylvania/Philadelphia/US, 2Cedars-Sinai Medical Center/Los Angeles/US, 3National Institute of Neurological Disorders and Stroke/Bethesda/US, 4University of Pennsylvania Perelman School of Medeicine/Philadelphia/US, 5QMENTA Inc./Boston/US, 6National Institute of Mental Health/Bethesda/US, 7University of Southern California/Los Angeles/US, 8University of California at San Francisco/San Francisco/US, 9Johns Hopkins University/Baltimore/US, 10University of California San Francisco/San Francisco/US, 11Dell Medical School, The University of Texas at Austin/Austin/US, 12Yale University/New Haven/US, 13University of Toronto/Toronto/CA, 14University of Texas Health Science Center at Houston/Houston/US, 15University of Pennsylvania Perelman School of Medicine/Philadelphia/US, 16NINDS, NIH/Bethesda/US, 17Cleveland Clinic//US

P0543 - Associations between Corpus Callosum Damage, Clinical Disability, and Surface-based Homologous Inter-hemispheric Connectivity in Multiple Sclerosis

A. Russo1, K. Stockel2, S. Tobyne2, C. Ngamsombat2, K. Brewer2, S. Huang2, E. Klawiter2, 1Massachusetts General Hospital /Charlestown/US, 2Massachusetts General Hospital/Charlestown/US

P0544 - Atrophy of different cortical and subcortical compartments contributes to explain clinical disability in patients with MS: a multicenter study

M. Hidalgo De La Cruz1, M.A. Rocca1, P. Valsasina1, C. Gobbi2, A. Gallo3, C. Zecca2, A. Bisecco4, M. Filippi1, 1IRCCS San Raffaele Scientific Institute/Milan/IT, 2Regional Hospital of Southern Switzerland (EOC)/Lugano/CH, 3University of Campania "L. Vanvitelli"/Naples/IT, 4University of Campania /Naples/IT

P0545 - Automatic MS lesions segmentation using LeMan-PV as a clinical decision-support tool: a longitudinal analysis R. Todea1, G. Barquero2, M. Barakovic3, T. Kober4, M.J. Fartaria4, A. Cagol5, R. Rahmanzadeh5, R. Galbusera5, M. Psychogios1, J. Lieb6, L. Kappos7, J. Kuhle8, M. Bach Cuadra9, C. Granziera5, 1University Hospital of Basel/Basel/CH, 2Lausanne University and University Hospital/Lausanne/CH, 3University of Basel/Allschwil/CH, 4Siemens Healthcare AG/Lausanne/CH, 5University Hospital Basel and University of Basel/Basel/CH, 6University Hospital Basel/Basel/CH, 7University of Basel//CH, 8University of Basel/Switzerland/CH, 9Lausanne University Hospital and University of Lausanne/Lausanne/CH

P0546 - Axonal and myelin volume fractions and imaging g-ratio in pediatric MS and MOG-associated disorders.

G. Longoni1, S. Bells1, R. Brown2, T. Berenbaum1, C. De Medeiros1, D. Fetco3, S. Narayanan3, A. Bar- Or4, R.A. Marrie5, D.L. Arnold6, B. Banwell7, J. Sled1, E.A. Yeh1, D. Mabbott1, 1The Hospital for Sick Children/Toronto/CA, 2ShadowLab Research Inc./Toronto/CA, 3McGill University/Montreal/CA, 4University of Pennsylvania/Philadelphia/US, 5University of Manitoba/Winnipeg/CA, 6MNI, McGill/Quebec/CA, 7Children’s Hospital of Philadelphia/Philadelphia/US

P0547 - Axonal injury in multiple sclerosis: a multi-compartment diffusion MRI study using high- resolution probabilistic tractography

K. Yoon1, D. Archer1, M. Clarke1, R. Dortch1, S. Smith1, G. Cutter2, J. Xu1, F. Bagnato1, 1Vanderbilt University Medical Center/Nashville/US, 2Mellen Center for Multiple Sclerosis Treatment and Research/Cleveland/US

P0548 - Baseline MRI lesions as predictors of clinically definite multiple sclerosis: a post hoc analysis of RENEW and RENEWED

S. Galetta1, L. Balcer2, A. Altincatal3, R. Su3, O. Aktas4, A. Klistorner5, M. Naylor3, 1NYU School of Medicine/New York/US, 2New York University//US, 3Biogen/Boston/US, 4Heinrich-Heine-Universität Düsseldorf/Dusseldorf/DE, 5Macquarie University/Sydney/AU

P0549 - Baseline neuroaxonal integrity is associated with upper limb function at 96 weeks in secondary progressive multiple sclerosis

N. John1, B. Solanky2, F. De Angelis2, J. Stutters2, F. Prados3, A. Doshi2, R. Parker4, C. Weir4, A. Calvi5, T. Williams5, T. Schneider5, D. Plantone5, A. Monteverdi6, D. Macmanus5, I. Marshall4, F. Barkhof3, C. Wheeler-Kingshott5, J. Chataway7, 1University College London/5EH/GB, 2University College London/BG/GB, 3University College London/LONDON/GB, 4University of Edinburgh/Edinburgh/GB, 5University College London/London/GB, 6University of Pavia/Pavia/IT, 7UCL Queen Square Institute of Neurology, University College//GB

P0550 - BOLD signal within and around white matter lesions distinguishes multiple sclerosis and non- specific white matter disease: a 3-dimensional approach

D. Sivakolundu1, K. West2, M. Zuppichini2, A. Wilson2, T. Moog3, A. Blinn3, B. Newton4, Y. Wang2, T. Stanley2, X. Guo2, B. Rypma2, D. Okuda5, 1Yale University/New Haven/US, 2University of Texas at Dallas/Dallas/US, 3UT Southwestern Medical Center/Dallas/US, 4University of Calgary/Calgary/CA, 5UT Southwestern Medical Center//US

P0551 - Brain volumes alterations in relapsing-remitting multiple sclerosis patients versus healthy controls in comparison to QyScore® normative database

P. Tran, E. Cavedo, C. Longo Dos Santos, J.-B. Martini, U. Thoprakarn, Qynapse/Paris/FR

P0552 - BrainGraph A Novel Visualization of MRI Data as a 3D Graph to Reveal Temporal Features of Disease Progression In Patients with Multiple Sclerosis

D. Hughes1, W. Yang2, K. Leyden1, M. Iv1, A. Keshavan1, 1Octave Bioscience/Menlo Park/US, 2Kineviz/San Francisco/US

P0553 - Bundle-specific microstructural alterations in normal appearing white matter of cognitively preserved MS patients using advanced diffusion MRI

J. Bitterli1, F. Morency2, L. Gaetano3, A. Pfister4, A. Altermatt5, P. Zuber6, C. Tsagkas7, A. Papadopoulou7, J. Wuerfel5, T. Sprenger8, L. Kappos7, M. Descoteaux2, S. Magon3, 1Universitätsspital Basel/Basel/CH, 2Imeka Solutions/Sherbrooke/CA, 3F. Hoffmann-La Roche Ltd/Basel/CH, 4University Hospital/Basel/CH, 5Medical Image Analysis Center/Basel/CH, 6Faculty of Psychology/Basel/CH, 7University Hospital Basel/Basel/CH, 8DKD Helios/Wiesbaden/DE

P0554 - Cervical disc disease is not associated with demyelanting lesions in multiple sclerosis

M. Alkrenawi1, S. Appel2, M. Osherov3, A. Simonovich2, J. Droujin4, R. Milo3, 1barzili medical center/7830604/IL, 2Barzilai University Medical Center, Ben-Gurion Unbiversity of the Negev/Ashkelon/IL, 3Barzilai Medical Center/ashkelon/IL, 4Barzilai University Medical Center/Ashkelon/IL

P0555 - Characterization of MRI Activity Following Treatment with Ocrelizumab for Multiple Sclerosis

S. Bhattacharyya, A. Ali, R. Bakshi, Brigham and Women's Hospital/Boston/US

P0556 - Characterization of multiple sclerosis lesions with distinct clinical correlates through diffusion MRI properties

E. Martinez-Heras1, E. Solana1, F. Prados2, M. Andorra1, A. Solanes3, E. Lopez-Soley1, C. Montejo1, I. Pulido-Valdeolivas1, S. Alba-Arbalat1, N. Sola-Valls1, M. Sepulveda1, Y. Blanco1, A. Saiz4, J. Radua5, S. Llufriu6, 1Hospital Clinic Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona/Barcelona/ES, 2University College London/LONDON/GB, 3idibaps/Barcelona/ES, 4Hospital Clínic i Provincial de Barcelona/Barcelona/ES, 5IDIBAPS and CIBERSAM/Barcelona/ES, 6Hospital Clínic de Barcelona e Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)/Barcelona/ES

P0557 - Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: a voxel-wise, multicenter analysis

P. Valsasina1, M.A. Rocca1, C. Gobbi2, C. Zecca2, A. Rovira3, J. Sastre-Garriga4, H. Kirney5, O. Ciccarelli6, L. Matthews7, J. Palace8, A. Gallo9, A. Bisecco10, A. Gass11, P. Eisele11, M. Filippi1, 1IRCCS San Raffaele Scientific Institute/Milan/IT, 2Regional Hospital of Southern Switzerland (EOC)/Lugano/CH, 3Vall d'Hebron University Hospital/Barcelona/ES, 4Vall Hebron University Hospital/Barcelona/ES, 5University College London/London/GB, 6UCL Queen Square Institute of Neurology/London/GB, 7University of Oxford/Oxford/GB, 8Oxford University Hospitals/Oxford/GB, 9University of Campania "L. Vanvitelli"/Naples/IT, 10University of Campania /Naples/IT, 11Universitätsmedizin Mannheim, University of Heidelberg/Mannheim/DE

P0558 - Clinical predictors of brain MRI gadolinium enhancing lesions in Multiple Sclerosis patients

F. Serrazina, M. Salavisa, A.S. Correia, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental/Lisboa/PT

P0559 - Cluster Analysis discriminates Multiple Sclerosis Patients based on Lesion Size and Myelin Content

U.W. Kaunzner1, S. Hurtado Rua2, S. Pandya3, A. Kuceyeski4, C. Tozlu5, E. Sweeney5, N. Nealon1, J. Perumal1, T. Vartanian1, T.D. Nguyen6, S. Gauthier5, 1Weill Cornell Medicine/New York City/US, 2Cleveland State University/Cleveland/US, 3Weill-Cornell/New York/US, 4Weill Cornell Medicine/Ithaca/US, 5Weill Cornell Medicine/New York/US, 6Department of Radiology, Weill Cornell Medical College/New York/US

P0560 - Comparative Myelin Water Imaging in Relapsing Remitting and Secondary Progressive Multiple Sclerosis

C. Koehler1, P. Kuntke2, H. Wahl2, S. Fischer2, T. Ziemssen1, J. Linn2, H.H. Kitzler2, 1Carl Gustav Carus University Hospital/Dresden/DE, 2Carl Gustav Carus University Hospital Dresden/Dresden/DE

P0561 - Comparison of different global network measures and tissue microstructural features to capture the ongoing brain damage in multiple sclerosis

S. Bosticardo1, S. Schiavi1, M. Barakovic2, M. Weigel3, L. Kappos3, C. Granziera3, A. Daducci1, 1University of Verona/Verona/IT, 2University of Basel/Basel/CH, 3University Hospital Basel and University of Basel/Basel/CH

P0562 - Cortical lesions are not associated with leptomeningeal enhancement in a cohort of adults with MS.

M. Morrison1, E. Beck2, P. Sati3, H. Kolb2, D. Reich4, 1/Parker/US, 2National Institute of Neurological Disorders and Stroke/Bethesda/US, 3Cedars-Sinai Medical Center/Los Angeles/US, 4National Institute of Health/Bethesda/US

P0563 - Could light scattering measured with frequency domain near-infrared spectroscopy provide new information on cerebral edema in MS?

A. Hansen1, D. Adingupu1, T. Evans1, Q. Shafqat1, S. Jarvis2, L. Brown3, L. Metz1, J. Dunn1, 1Cumming School of Medicine/Calgary/CA, 2Cumming School of Medicine and Alberta Neurologic Centre, Calgary, Canada/N/CA, 3Cumming School of Medicine/N/CA

P0564 - Depth-dependent cortical distributions of quantitative 7 T MRI parameters are associated with disability in MS

A. Lema Dopico1, S. Choi2, D. Harrison2, 1University Maryland School of Medicine/Baltimore/US, 2University of Maryland School of Medicin/BALTIMORE/US

P0565 - Different Temporal Evolution of Diffusely Abnormal White Matter Volumes in Relapsing Remitting and Secondary Progressive MS

M. Dadar1, S. Mahmoud2, M. Zhernovaia2, S. Narayanan3, L. Collins3, D.L. Arnold4, J. Maranzano2, 1Laval University/Quebec/CA, 2University of Quebec in Trois-Rivieres/Trois-Rivieres/CA, 3McGill University/Montreal/CA, 4MNI, McGill/Quebec/CA

P0566 - Diffusion tensor imaging of the nucleus basalis of Meynert reveals associations with cognitive state in patients with multiple sclerosis

F. Hildesheim1, R. Benedict2, R. Zivadinov3, M. Dwyer4, T. Fuchs5, D. Jakimovski6, B. Weinstock- Guttman7, N. Bergsland3, 1Buffalo Neuroimaging Analysis Center (BNAC)/Buffalo/US, 2University At Buffalo/Buffalo/US, 3Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York/Buffalo/US, 4Buffalo Neuroimaging Analysis Center/Buffalo/US, 5University at Buffalo, Jacobs School of Medicine/Buffalo/US, 6University at Buffalo, State University of New York/Buffalo/US, 7State University of New York at Buffalo/Buffalo/US

P0567 - Diffusion-based Structural connectivity abnormalities in MS phenotypes.

E. Solana1, E. Martinez-Heras1, E. Lopez-Soley1, A. Saiz2, E. Martinez-Lapiscina3, P. Villoslada1, D. Meng4, R. Dineen4, M.A. Rocca5, M. Filippi5, O. Ciccarelli6, S. Collorone7, A. Toosy8, F. Prados7, S. Groppa9, V. Fleischer9, A. Rovira10, D. Pareto11, J. Sastre-Garriga11, S. Llufriu12, 1Hospital Clinic Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona/Barcelona/ES, 2Hospital Clínic i Provincial de Barcelona/Barcelona/ES, 3/Barcelona/ES, 4University of Nottingham/Nottingham/GB, 5IRCCS San Raffaele Scientific Institute/Milan/IT, 6UCL Queen Square Institute of Neurology/London/GB, 7University College London/LONDON/GB, 8Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK. National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Re/London/GB, 9University Medical Center of the Johannes Gutenberg University Mainz/Mainz/DE, 10Vall d'Hebron University Hospital/Barcelona/ES, 11Vall Hebron University Hospital/Barcelona/ES, 12Hospital Clínic de Barcelona e Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)/Barcelona/ES

P0568 - Disappearance of spinal cord lesions in multiple sclerosis. A longitudinal study of 8 patients.

V. Tsydenzhapova1, C. Dalliere2, X. Ayrignac3, P. Labauge3, 1/Paris/FR, 2private address/Paris/FR, 3CHU de Montpellier/Montpellier/FR

P0569 - Distribution profile of T1 relaxation time in white matter lesions on 7-Tesla MRI in multiple sclerosis reflects disease severity and phenotype

S. Choi1, R. Mizell2, M. Spini3, J. Hua4, D. Harrison1, 1University of Maryland School of Medicin/BALTIMORE/US, 2Baltimore VA Medical Center/Baltimore/US, 3University of Maryland School of Medicine/Baltimore/US, 4Johns Hopkins University School of Medicine/Baltimore/US

P0570 - Dynamic functional connectivity as a neural correlate of fatigue in multiple sclerosis

F. Tijhuis1, T. Broeders1, F. Santos1, J. Killestein2, C. Leurs2, Q. Van Geest1, J. Geurts1, L. Douw1, H. Hulst3, 1Amsterdam UMC, location VUmc/Amsterdam/NL, 2Amsterdam UMC, Location VUmc/Amsterdam/NL, 3MS Center Amsterdam/Amsterdam/NL

P0571 - Evaluating agreement between Mean Upper Cervical Cord Area measurements from 3D- FLAIR and 3D-T1 brain images

G. Costantini1, F. Prados2, C. Bosa1, M.B. Pasanisi3, V. Schillaci1, A. Alteno1, M. Ferraris1, U. Gava1, A. Chiò1, M. Vercellino1, P. Cavalla4, 1City of Health and Science University Hospital of Turin/Turin/IT, 2University College London/LONDON/GB, 3City of Health and Science University Hospital of Turin /Torino/IT, 4City of Health & Science University Hospital/Turin/IT

P0572 - Evaluation of cerebellar function scores in relation to cerebellar axonal loss in multiple sclerosis.

F. Boonstra1, S. Gajamange2, G. Noffs3, T. Perera4, M. Strik3, A. Vogel3, H. Butzkueven1, A. Evans5, A. Van Der Walt1, S. Kolbe1, 1Monash University/Melbourne/AU, 2Walter and Eliza Hall Institute of Medical Research/Parkville/AU, 3University of Melbourne/Parkville/AU, 4Bionics Insitute/Melbourne/AU, 5Royal Melbourne Hospital/Parkville/AU

P0573 - Evolution of Diffusely Abnormal White Matter and its relationship to Progression in Primary Progressive MS

M. Dadar1, S. Mahmoud2, M. Zhernovaia2, S. Narayanan3, L. Collins3, D.L. Arnold4, J. Maranzano2, 1Laval University/Quebec/CA, 2University of Quebec in Trois-Rivieres/Trois-Rivieres/CA, 3McGill University/Montreal/CA, 4MNI, McGill/Quebec/CA

P0574 - Expansion of chronic lesions associated with disease progression in RRMS patients.

A. Klistorner1, M. Barnett, Md2, C. Yiannikas3, J. Barton2, S. Graham1, S. Klistorner4, 1Macquarie University/Sydney/AU, 2Brain Mind Institute/Camperdown/AU, 3Inner West Neurology/Burwood/AU, 4Sydney University/Sydney/AU

P0575 - Exploring demyelination and brain atrophy in multiple sclerosis using quantitative magnetic resonance imaging

L. Novakova, M. Axelsson, C. Malmeström, J. Lycke, Institute of Neuroscience and Physiology/Gothenburg/SE

P0576 - Exploring the Corticospinal Tract in Progressive Multiple Sclerosis: A Transcranial Magnetic Stimulation and Magnetic Resonance Imaging Study

P. Kauv1, M.A. Chalah2, A. Créange3, J.-P. Lefaucheur4, J. Hodel1, S.S. Ayache4, 1Service de Neuroradiologie, Hôpital Henri-Mondor, AP-HP; EA 4391, Excitabilité Nerveuse Et Thérapeutique/Créteil/FR, 2Hopital Henri Mondor/CRÉTEIL/FR, 3Service de Neurologie, Hôpital Henri- Mondor, AP-HP; EA 4391, Excitabilité Nerveuse Et Thérapeutique/Créteil/FR, 4Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri-Mondor, AP-HP; EA 4391, Excitabilité Nerveuse Et Thérapeutique/Créteil/FR

P0577 - Feasibility of thalamic atrophy measurement in clinical routine using artificial intelligence: Results from multi-center study in RRMS patients

R. Zivadinov1, N. Bergsland1, M. Millman1, D. Jakimovski2, D. Ramasamy1, B. Weinstock-Guttman3, M. Zarif4, M. Freedman5, S. Hunter6, S. Cohan7, K. Edwards8, B. Steingo9, R. Zabad10, M. Baker11, M. Belkin12, P. Repovic13, A. Mazhari14, A. Chase15, J. Silversteen16, D. Smith17, D. Negroski18, M. Feinberg19, S. Newman20, G. Pardo21, J. Riolo22, D. Silva22, M. Dwyer23, 1Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York/Buffalo/US, 2University at Buffalo, State University of New York/Buffalo/US, 3State University of New York at Buffalo/Buffalo/US, 4Comprehensive Multiple Sclerosis Care Center/Patchogue/US, 5Raleigh Neurology/Raleigh/US, 6Advanced Neurosciences Institute/Franklin/US, 7Providence MS Center/Portland/US, 8KMS Center of NE New York/Latham/US, 9Infinity Clinical Research, LLC/Sunrise/US, 10University of Nebraska Medical Center/Omaha/US, 11Collier Neurologic Specialists, LLC/Naples/US, 12Michigan Institute for Neurological Disorders (MIND)/Farmington Hills/US, 13Swedish MS Center/Seattle/US, 14Dent Neurologic Institute/Buffalo/US, 15Saunders Medical Center/Wahoo/US, 16Christiana Care Health Services, Inc/Newark/US, 17Thames Neurological Institute/Norwich/US, 18MS Center of Sarasota/Sarasota/US, 19SFM Clinical Research LLC/Boca Raton/US, 20Island Neurological Association/Plainview/US, 21Oklahoma Medical Research Foundation/Oklahoma City/US, 22Bristol Myers Squibb/Summit/US, 23Buffalo Neuroimaging Analysis Center/Buffalo/US

P0578 - Five years functional connectivity reorganization without clinical or cognitive decline in MS E. Høgestøl1, S. Ghezzo2, G. Nygaard1, T. Espeseth3, P. Sowa4, M. Beyer4, H. Harbo1, L. Westlye5, H. Hulst6, 1Oslo University Hospital/Oslo/NO, 2Division of Mental Health and Addiction/Oslo/NO, 3University of Oslo/Oslo/NO, 4Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway/Oslo/NO, 5Division of Mental Health and Addiction,/Oslo/NO, 6MS Center Amsterdam/Amsterdam/NL

P0579 - FLAIR-only joint volumetric analysis of brain lesions and atrophy in clinically isolated syndrome (CIS) suggestive of MS

O. Goodkin1, F. Prados1, S. Vos1, H. Pemberton1, S. Collorone1, M. Hagens2, M.J. Cardoso3, T. Yousry4, J. Thornton4, C. Sudre3, F. Barkhof1, 1University College London/LONDON/GB, 2Amsterdam UMC, location VUmc/Amsterdam/NL, 3King's College London/London/GB, 4UCL Queen Square Institute of Neurology/LONDON/GB

P0580 - Focal inflammatory activity and lesion repair are associated with brain atrophy rates in MS patients

A. Cagol1, M. Barakovic2, P. Benkert3, R.-A. Todea1, R. Rahmanzadeh1, R. Galbusera1, S. Schaedelin4, P.-J. Lu1, M. Weigel1, E.-W. Radue5, Ö. Yaldizli4, J. Lorscheider4, T. Sinnecker6, M.J. Fartaria7, S. Müller8, L. Achtnichts9, J. Vehoff8, G. Disanto10, O. Findling9, A. Chan11, A. Salmen11, C. Pot12, P. Lalive13, C. Zecca10, T. Derfuss14, J. Lieb4, L. Remonda9, F. Wagner15, M. Vargas16, P. Maeder17, E. Pravata18, J. Weber8, C. Gobbi10, D. Leppert1, V. Silani19, J. Wuerfel20, L. Kappos21, J. Kuhle22, C. Granziera1, 1University Hospital Basel and University of Basel/Basel/CH, 2University of Basel/Basel/CH, 3University Hospital Basel, University of Basel/Basel/CH, 4University Hospital Basel/Basel/CH, 5University Hospital Basel and University of Basel/Basel/SZ, 6Universitätsspital Basel/Basel/CH, 7Siemens Healthcare AG/Lausanne/CH, 8Cantonal Hospital St. Gallen/St. Gallen/CH, 9Cantonal Hospital Aarau/Aarau/CH, 10Regional Hospital of Southern Switzerland (EOC)/Lugano/CH, 11Inselspital Bern, University Hospital and University of Bern/Bern/CH, 12University Hospital of Lausanne/Lausanne/CH, 13Geneva University Hospitals/Geneva/CH, 14University of Basel//CH, 15Inselspital, Bern University Hospital and University of Bern/Bern/CH, 16Geneva University Hospital and Faculty of Medicine/Geneva/CH, 17Lausanne University Hospital (CHUV) and University of Lausanne/Lausanne/CH, 18Ospedale Civico/Lugano/CH, 19IRCCS Istituto Auxologico Italiano, University of Milan Medical School/Milan/IT, 20Medical Image Analysis Center/Basel/CH, 21University Hospital and University of Basel/Basel/CH, 22University of Basel/Switzerland/CH

P0581 - Gradient echo magnetic resonance imaging to detect central vein sign in patients with Multiple Sclerosis

V. Levasseur1, B. Xiang2, A. Salter3, S. Lancia4, D. Yablonskiy2, A. Cross5, 1Washington University/Saint Louis/US, 2Washington University School of Medicine/Saint Louis/US, 3Washington University School in St. Louis/St Louis/US, 4Washington University School in St. Louis/St. Louis/US, 5Washington University in St. Louis/St. Louis/US

P0582 - High resolution functional mapping of upper and lower limb sensorimotor function in minimally disabled people with multiple sclerosis using 7T MRI

M. Strik1, C. Shanahan2, A. Van Der Walt3, F. Boonstra3, R. Glarin2, M. Galea2, T. Kilpatrick4, J. Geurts5, M. Schoonheim5, S. Kolbe3, 1Amsterdam UMC - location VUmc/Amsterdam/NL, 2University of Melbourne/Melbourne/AU, 3Monash University/Melbourne/AU, 4The Florey Institute of Neuroscience and Mental Health/Melbourne/AU, 5Amsterdam UMC, location VUmc/Amsterdam/NL

P0583 - High throughput lesion evaluation and quality control for incorporating quantitative imaging metrics into clinical practice

A. Keshavan1, K. Leyden1, M. Iv1, B. Dappert1, M. Becich2, M. Towbin1, D. Hughes1, A. Miner3, R. Kinkel4, J. Graves4, 1Octave Bioscience/Menlo Park/US, 2Octave Bioscience Inc./Menlo Park/US, 3University of California, San Diego/La Jolla/US, 4University of California, San Diego/San Diego/US

P0584 - Histological analysis of slowly expanding lesions in multiple sclerosis: case report

Y. Zheng1, B. Trapp2, D. Ontaneda3, K. Nakamura4, 1Lerner Research Institute/Cleveland/US, 2Cleveland Clinic/Cleveland/US, 3Cleveland Clinic//US, 4Cleveland Clinic Foundation/Cleveland/US

P0585 - Hurst exponent as an imaging biomarker of impairment in multiple sclerosis

C. Tozlu1, K. Jamison2, A. Simon3, E. Dhamala3, S. Gauthier1, A. Kuceyeski2, 1Weill Cornell Medicine/New York/US, 2Weill Cornell Medicine/Ithaca/US, 3Weill Cornell Medicine/NYC/US

P0586 - Impact of Cladribine Tablets on Brain Volume Protection in Highly Active MS

A. Raji1, G. Winkler2, 1Neurozentrum Hamburg/Hamburg/DE, 2Center of Neurology Hamburg/Hamburg/DE

P0587 - Impact of siponimod on myelination as assessed by MTR across SPMS subgroups: Post-hoc analysis from the EXPAND MRI substudy

D.L. Arnold1, A. Bar-Or2, B.A.C. Cree3, G. Giovannoni4, R. Gold5, P. Vermersch6, D. Piani-Meier7, T. Hach7, S. Arnould7, G. Karlsson7, L. Kappos8, R. Fox9, 1NeuroRx Research/Montreal/CA, 2University of Pennsylvania/Philadelphia/US, 3UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco/San Francisco/US, 4The London School of Medicine and Dentistry/London/GB, 5St. Josef-Hospital, Ruhr University Bochum/Bochum/DE, 6CHU de Lille/Lille/FR, 7Novartis Pharma AG/Basel/CH, 8Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital, University of Basel/Basel/CH, 9Cleveland Clinic//US

P0588 - Implementation strategy of an international standardized MRI protocol for the diagnosis and follow-up of MS patients A. Traboulsee1, J. Oh2, S. Newsome3, F. Barkhof4, D. Reich5, J. Halper6, L. Saslow7, D. Li8, T. Cmsc Mri Guidelines Working Group7, 1The University of British Columbia/Canada/CA, 2University of Toronto/Toronto/CA, 3Johns Hopkins University School of Medicine/Baltimore/US, 4University College London/LONDON/GB, 5NINDS, NIH/Bethesda/US, 6CMSC/Fair Lawn/US, 7Consortium of MS Centers/Hackensack/US, 8//CA

P0589 - Implications of registration of white matter structures for MS connectome analysis

J. Garber1, M. Barnett2, F. Calamante3, C. Wang4, 1Brain and Mind Centre/Camperdown/AU, 23. Brain and Mind Research Institute, University of Sydney/Sydney/AU, 3University of Sydney/Camperdown/AU, 4The University of Sydney, Sydney Neuroimaging Analysis Centre/Sydney/AU

P0590 - Improved detection of clinically relevant MRI findings in Multiple Sclerosis radiology reports using FDA-approved quantitative software

K. Leyden, A. Keshavan, M. Iv, Octave Bioscience/Menlo Park/US

P0591 - In vivo cortical lesions detection as an early hallmark of multiple sclerosis.

P. Durozard1, A. Maarouf2, A. Rico2, C. Boutière2, S. Demortière2, S. Confort-Gouny3, J.-P. Stellmann4, W. Zaaraoui3, M. Guye3, J.P. Ranjeva5, B. Audoin2, J. Pelletier6, 1Aix Marseille Univ, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie - CRMBM CEMEREM UMR7339/Marseille/FR, 2Hôpital La Timone/Marseille/FR, 3Aix Marseille Univ, APHM, Hôpital de la Timone, CRMBM CEMEREM UMR7339/Marseille/FR, 41. Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg 2. APHM, Hopital de la Timone, CEMEREM, Marseille 3. Aix Marseille Univ, CNRS, CRMBM, UMR 7339, Marseille/Hamburg/DE, 5Aix Marseille Univ, APHM, Hôpital de la Timone, CRMBM CEMEREM UMR7339/Masreille/FR, 6Aix Marseille Univ, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie/Marseilles/FR

P0592 - In-clinic performance of MSPie, an image analysis prototype for automated MRI quantitative point-of-care metrics in MS

H.H. Kitzler1, S. Jones2, M. Blefari3, R. Corredor-Jerez4, T. Huelnhagen4, S. Liao5, M.J. Fartaria4, A. Tsang3, R. Perea3, P. Kuntke1, S. Makaretz3, J.R. Williams3, R. Rudick3, T. Kober4, E. Fisher6, 1Carl Gustav Carus University Hospital Dresden/Dresden/DE, 2Cleveland Clinic Foundation/Cleveland/US, 3Biogen/Cambridge/US, 4Siemens Healthcare AG/Lausanne/CH, 5Biogen/Cambride/US, 6Biogen/Boston/US

P0593 - Increased perfusion and microstructural damage precede demyelination in newly forming MS lesions

E. Morena1, V. Ricigliano2, A. Colombi2, A. Yazdan Panah2, M. Hamzaoui3, B. Bodini2, M. Tonietto2, B. Stankoff4, 1ICM - Brain Institute/Paris/FR, 2Institut du Cerveau et de la Moelle épinière - ICM/Paris/FR, 3Paris Brain Institute - ICM/Paris/FR, 4Sorbonne Université/Paris/FR

P0594 - Interpreting brain parenchymal fraction by comparison to healthy volunteers: Initial results from the MS PATHS normative sub-study

S. Jones1, A. Tsang2, R. Perea2, S. Liao3, Y.-C. Su2, T. Benzinger4, M. Blefari2, R. Corredor-Jerez5, M.J. Fartaria5, T. Huelnhagen5, H.H. Kitzler6, T. Kober5, S. Makaretz2, A. Rovira7, M. Tivarus8, J.R. Williams2, R. Rudick2, E. Fisher9, 1Cleveland Clinic Foundation/Cleveland/US, 2Biogen/Cambridge/US, 3Biogen/Cambride/US, 4Washington University in St. Louis/St Louis/US, 5Siemens Healthcare AG/Lausanne/CH, 6Carl Gustav Carus University Hospital Dresden/Dresden/DE, 7Vall d'Hebron University Hospital/Barcelona/ES, 8University of Rochester Medical Center/Rochester/US, 9Biogen/Boston/US

P0595 - Investigating the relation between global structural network measures and serum neurofilament light in multiple sclerosis

S. Bosticardo1, S. Schiavi1, M. Barakovic2, M. Weigel3, E.-W. Radue4, L. Kappos5, J. Kuhle6, A. Daducci1, C. Granziera3, 1University of Verona/Verona/IT, 2University of Basel/Basel/CH, 3University Hospital Basel and University of Basel/Basel/CH, 4University Hospital Basel and University of Basel/Basel/SZ, 5Translational Imaging in Neurology (ThINk)/Basel/CH, 6University of Basel/Switzerland/CH

P0596 - Investigation of lesion volume dynamics in MS patients as detected by Voxel-Guided Morphometry – A multi center study

M. Kraemer1, A. Dabringhaus2, J. Gregori3, S. Hoffmann4, U. Schulze-Topphoff5, B. Rauser6, B. Ettle5, A. Gass7, 1Hospital zum Heiligen Geist/Kempen/DE, 2BfArM/Köln/DE, 3mediri GmbH/Heidelberg/DE, 4mediri/Heidelberg/DE, 5Novartis/Nürnberg/DE, 6Novartis Pharma GmbH/Nuremberg/DE, 7Universitätsmedizin Mannheim, University of Heidelberg/Mannheim/DE

P0597 - Lesional myelin repair, as measured with positron emission tomography, effectively protects the integrity of surrounding tissues

V. Ricigliano1, M. Tonietto1, E. Poirion2, B. Stankoff3, B. Bodini1, 1Institut du Cerveau et de la Moelle épinière - ICM/Paris/FR, 2Hospital Foundation Adolph De Rotschild/Paris/FR, 3Sorbonne Université/Paris/FR

P0598 - LesionQuant for assessment of MRI in multiple sclerosis- a promising supplement to the visual scan inspection

S. Brune1, E. Høgestøl2, V. Cengija3, P. Berg-Hansen4, P. Sowa3, G. Nygård4, H. Harbo4, M. Beyer3, 1/Oslo/NO, 2Oslo University Hospital/Oslo/NO, 3Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway/Oslo/NO, 4Departement of Neurology, Oslo University Hospital, Oslo Norway/Oslo/NO

P0599 - Linking microstructural integrity and motor cortex excitability in multiple sclerosis A. Radetz1, K. Mladenova1, D. Ciolac1, G. Gonzalez-Escamilla1, V. Fleischer1, J. Krämer2, J. Trotter3, S. Meuth2, M. Muthuraman1, S. Groppa1, 1University Medical Center of the Johannes Gutenberg University Mainz/Mainz/DE, 2University Hospital Münster/Münster/DE, 3Johannes Gutenberg University Mainz/Mainz/DE

P0600 - Longitudinal evolution of cortical lesions in an Italian cohort of multiple sclerosis patients

E. Curti1, S. Graziuso2, V. Bazzurri1, A. Fiore1, C. Ganazzoli2, G. Ogliari1, E. Tsantes1, F. Granella1, 1University of Parma/Parma/IT, 2Parma University Hospital/Parma/IT

P0601 - Longitudinal functional modularisation and causality dynamics during de- and remyelination

M. Muthuraman1, M. Cerina2, G. Gonzalez-Escamilla1, V. Fleischer1, M. Gallus2, A. Dik2, L. Wachsmuth2, P. Hundehege2, P. Schiffler2, J.-G. Tenberge2, V. Narayanan2, J. Krämer2, T. Budde2, C. Faber2, S. Meuth3, S. Groppa1, 1University Medical Center of the Johannes Gutenberg University Mainz/Mainz/DE, 2University Hospital Münster/Münster/DE, 3University Clinic Munster/Munster/DE

P0602 - Long-lasting effects of optic neuritis on anatomical and functional visual network patterns

Y. Backner1, S. Zamir1, P. Petrou1, F. Paul2, D. Karussis1, N. Levin1, 1Hadassah-Hebrew University Medical Center/Jerusalem/IL, 2Charite-Universitatmedizin Berlin/Berlin/DE

P0603 - MAGNON – Implementation and Contribution of Lublin Criteria and quantitative MRI- Analysis for daily clinical routine of MS Patients

O. Hoffmann1, K. Schuh2, V. Winkelmann3, 1St.Josefs-Krankenhaus Potsdam- Sanssouci/Potsdam/DE, 2Novartis Pharma GmbH/Nuremberg/DE, 3Novartis Pharma GmbH/Nürnberg/DE

P0604 - Mild Gray Matter Atrophy in Patients with Longstanding Multiple Sclerosis and Favorable Clinical Course

R. Cortese1, M. Battaglini2, F. Parodi2, M.L. Stromillo2, E. Portaccio3, L. Razzolini4, A. Giorgio5, M.P. Sormani6, M.P. Amato4, N. De Stefano7, 1University of Siena and University College London, UK/Siena/IT, 2University of Siena/Siena/IT, 3Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy/Florence/IT, 4University of Florence/Florence/IT, 5Department of Medicine, Surgery and Neuroscience, University of Siena, Italy/Siena/IT, 6University of Genoa/Genoa/IT, 7University of Siena//IT

P0605 - More dynamic functional network switching in cognitively declining multiple sclerosis patients

T. Broeders1, L. Douw1, A. Eijlers1, I. Dekker1, B. Uitdehaag2, F. Barkhof2, H. Hulst3, C. Vinkers1, J. Geurts1, M. Schoonheim1, 1Amsterdam UMC, location VUmc/Amsterdam/NL, 2Amsterdam UMC, Location VUmc/Amsterdam/NL, 3MS Center Amsterdam/Amsterdam/NL

P0606 - MRI changes over the disease course in a large multiple sclerosis clinical cohort

G. Macaron1, K. Nakamura2, R. Honomischl3, N. Thompson2, S. Husak2, S. Jones2, R. Bermel4, K. Mahajan2, J. Cohen5, D. Ontaneda6, 1Hotel Dieu de France Hospital/Beirut/LB, 2Cleveland Clinic Foundation/Cleveland/US, 3Cleveland Clinic/Cleveland/US, 4Mellen Center for Multiple Sclerosis, Cleveland Clinic/Cleveland/US, 5Mellen Center for MS Treatment and Research, Cleveland Clinic/Cleveland/US, 6Cleveland Clinic//US

P0607 - MRI Characterization of Damage in and Around Lesions in Pediatric MS and MOG-Associated Disorders

R. Brown1, S. Bells2, T. Berenbaum2, C. De Medeiros2, D. Fetco3, S. Narayanan3, A. Bar-Or4, R.A. Marrie5, D.L. Arnold6, B. Banwell7, J. Sled2, D. Mabbott2, E.A. Yeh2, G. Longoni2, 1ShadowLab Research Inc./Toronto/CA, 2The Hospital for Sick Children/Toronto/CA, 3McGill University/Montreal/CA, 4University of Pennsylvania/Philadelphia/US, 5University of Manitoba/Winnipeg/CA, 6MNI, McGill/Quebec/CA, 7Children’s Hospital of Philadelphia/Philadelphia/US

P0608 - MRI-based clustering of MS patients in the perspective of personalized medicine

R. Bonacchi, M.A. Rocca, A. Meani, E. Pagani, M. Filippi, IRCCS San Raffaele Scientific Institute/Milan/IT

P0609 - Multimodal MRI of the Brain to Improve Prediction of Disease Progression in Multiple Sclerosis

B. Helmlinger, D. Pinter, S. Ropele, L. Pirpamer, M. Khalil, C. Enzinger, Medical University of Graz/Graz/AT

P0610 - Multiparametric MRI investigation of enlarging and shrinking MS lesions

P. Eisele1, M. Kraemer2, A. Dabringhaus3, A. Ebert1, L. Bracoud4, M. Platten1, I. Metz5, L. Schirmer6, A. Gass1, 1Universitätsmedizin Mannheim, University of Heidelberg/Mannheim/DE, 2Hospital zum Heiligen Geist/Kempen/DE, 3BfArM/Köln/DE, 4Bioclinica/Lyon/FR, 5University Medical Center Göttingen/Göttingen/DE, 6Heidelberg University/Mannheim/DE

P0611 - Neurite density explains cortical T1-/T2-weighted ratio in multiple sclerosis

P. Preziosa1, P. Bouman2, S. Kiljan2, M. Steenwijk2, P. Pouwels2, M.A. Rocca1, M. Filippi1, J. Geurts3, L. Jonkman3, 1IRCCS San Raffaele Scientific Institute/Milan/IT, 2Amsterdam UMC, VUmc/Amsterdam/NL, 3Amsterdam UMC, location VUmc/Amsterdam/NL

P0612 - New cortical lesions are rare in an MS cohort with stable white matter lesions: a 7T multicontrast longitudinal study

E. Beck1, J. Maranzano2, P. Sati3, S. Filippini1, M. Morrison1, N. Luciano1, D. Suto1, I. Cortese1, S. Narayanan4, D. Reich5, 1National Institute of Neurological Disorders and Stroke/Bethesda/US, 2University of Quebec in Trois-Rivieres/Trois-Rivieres/CA, 3Cedars-Sinai Medical Center/Los Angeles/US, 4McGill University/Montreal/CA, 5NINDS, NIH/Bethesda/US

P0613 - Ocrelizumab Reduces Regional Brain Atrophy in Relapsing Multiple Sclerosis as Assessed by Longitudinal Deformation-based Morphometry

Z. Song1, A. Krishnan2, L. Gaetano3, D. Clayton2, A. De Crespigny2, T. Bengtsson2, R. Carano2, 1Genentech, Inc./SOUTH SAN FRANCISCO/US, 2Genentech/South San Francisco/US, 3F. Hoffmann-La Roche Ltd/Basel/CH

P0614 - Perilesional neurodegenerative injury in MS: relations with focal lesions and disability

M. Clarke1, D. Lakhani2, S. Wen2, S. Gao2, S. Smith1, R. Dortch1, J. Xu1, F. Bagnato1, 1Vanderbilt University Medical Center/Nashville/US, 2West Virginia University/Morgantown/US

P0615 - Physical disability is related to resting-state network atrophy and altered MEG-based functional network topology in multiple sclerosis.

L. De Ruiter1, S. Kulik1, I. Nauta2, J. Geurts3, C. Stam1, A. Hillebrand1, B. Uitdehaag1, E. Strijbis2, M. Schoonheim3, 1Amsterdam UMC, Location VUmc/Amsterdam/NL, 2Amsterdam UMC/Amsterdam/NL, 3Amsterdam UMC, location VUmc/Amsterdam/NL

P0616 - PiB-PET and MRI myelin water fraction provide complementary information about myelin

I. Vavasour1, N. Vafai1, P. Beauchemain2, A. Badalan1, C. Kanjilal1, A. Traboulsee3, E. Shahinfard1, V. Sossi1, S. Kolind1, R. Carruthers4, 1University of British Columbia/Vancouver/CA, 2Université Laval/Quebec City/CA, 3The University of British Columbia/Canada/CA, 4University of British Columbia Hospital/Vancouver/CA

P0617 - Predicting Disease Progression in Multiple Sclerosis from Clinical Routine T2-FLAIR MRI

T. Fuchs1, M. Dwyer2, D. Jakimovski3, N. Bergsland4, D. Ramasamy4, B. Weinstock-Guttman5, R. Benedict6, R. Zivadinov4, 1University at Buffalo, Jacobs School of Medicine/Buffalo/US, 2Buffalo Neuroimaging Analysis Center/Buffalo/US, 3University at Buffalo, State University of New York/Buffalo/US, 4Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York/Buffalo/US, 5State University of New York at Buffalo/Buffalo/US, 6University At Buffalo/Buffalo/US

P0618 - Prednisolone treatment during the first episode in multiple sclerosis is associated with cortical thinning in the right medial orbitofrontal cortex.

M. Tahedl, University of Regensburg/Regensburg/DE

P0619 - Prefrontal Metabolism Explains Processing Speed Ability in Multiple Sclerosis: A Calibrated fMRI study M. Zuppichini1, D. Sivakolundu2, K. West1, D. Okuda3, B. Rypma1, 1University of Texas at Dallas/Dallas/US, 2Yale University/New Haven/US, 3UT Southwestern Medical Center//US

P0620 - QSM detects greater rate of reduction in lesion magnetic susceptibility in patients treated with Dimethyl Fumarate over Glatiramer Acetate treatment

N. Zinger1, T.D. Nguyen2, E. Sweeney3, J. Comunale3, W. Huang3, X. Luo3, L. Zexter1, M. Marcille1, U.W. Kaunzner1, N. Nealon1, J. Perumal1, T. Vartanian1, Y. Wang2, D. Pitt4, S. Gauthier3, 1Weill Cornell Medicine/New York City/US, 2Department of Radiology, Weill Cornell Medical College/New York/US, 3Weill Cornell Medicine/New York/US, 4Yale University/New Haven/US

P0621 - q-Space Myelin Map imaging for longitudinal analysis of remyelination in multiple sclerosis patients treated with dimethyl fumarate

K. Kufukihara1, S. Kitagawa1, Y. Sato2, M. Tanikawa1, J. Hata3, S. Suzuki1, M. Nakamura1, H. Okano1, 1Keio University School of Medicine/Shinjuku/JP, 2Biogen Japan/Tokyo/JP, 3Keio University School of Medicine/Tokyo/JP

P0622 - Quanitifying the T1 hypointensity of MS lesions

J. Garber1, M. Barnett, Md2, 1Brain and Mind Centre/Camperdown/AU, 2Brain Mind Institute/Camperdown/AU

P0623 - Quantifying Cervical and Thoracic Cord Atrophy in Multiple Sclerosis

Y. Mina1, S. Azodi2, T. Dubuche2, F. Andrada2, I. Osuorah3, J. Ohayon3, I. Cortese3, T. Wu2, K. Johnson2, D. Reich2, G. Nair2, S. Jacobson3, 1/ROCKVILLE/US, 2NINDS, NIH/Bethesda/US, 3National Institute of Neurological Disorders and Stroke/Bethesda/US

P0624 - Quantitative multiparametric 3T-MRI of postmortem multiple sclerosis whole brains

R. Galbusera1, M. Barakovic2, M. Weigel1, P.-J. Lu3, P. Dechent4, E. Bahn4, F. Van Der Meer4, L. Kappos5, W. Brück6, C. Stadelmann4, C. Granziera1, 1University Hospital Basel and University of Basel/Basel/CH, 2University of Basel/Basel/CH, 3University of Basel/Allschwil/CH, 4University Medical Center Göttingen/Göttingen/DE, 5University Hospital and University of Basel/Basel/CH, 6Institute of Neuropathology/Goettingen/DE

P0625 - Quantitative Susceptibility Mapping in the cortical ribbon of MS patients and its dependence on cortical thinning.

M. Castellaro1, A. Tamanti1, R. Magliozzi1, A. Palombit2, F. Crescenzo1, S. Montemezzi3, F. Pizzini1, A. Bertoldo2, M. Calabrese1, 1University of Verona/Verona/IT, 2University of Padova/Padova/IT, 3University Hospital of Verona/Verona/IT

P0626 - Quantitative Susceptibility Mapping at 7 Tesla detects ongoing active lesions in relapse-free RRMS patients

N.H. Mohd Shukur1, M. Strik2, N. Yaghmaie3, A. Van Der Walt4, T. Kilpatrick5, W. Syeda3, L. Johnston3, J. Cleary3, M. Law1, E. Lui6, F. Boonstra4, S. Kolbe4, 1Central Clinical School, Monash University, The Alfred Centre, Level 6/Melbourne/AU, 2Amsterdam UMC - location VUmc/Amsterdam/NL, 3University of Melbourne/Melbourne/AU, 4Monash University/Melbourne/AU, 5The Florey Institute of Neuroscience and Mental Health/Melbourne/AU, 6Royal Melbourne Hospital, University of Melbourne/Melbourne/AU

P0627 - Quantitative T1 changes relate to infratentorial pathology in early multiple sclerosis.

M. Andelova1, G.F. Piredda2, K. Vodehnalova1, J. Krasensky3, T. Hrnciarova4, B. Srpová5, T. Uher1, I. Menkyova6, D. Stastna1, D. Horakova7, V. Ravano2, B. Maréchal2, M.J. Fartaria2, T. Hilbert2, T. Kober2, M. Vaneckova3, 1First Faculty of Medicine, Charles University and General University/Prague/CZ, 2Siemens Healthcare AG/Lausanne/CH, 3Charles University and General University Hospital/Prague/CZ, 4First Faculty of Medicine, Charles University and General University Hospital/Prague/CZ, 5Charles University and General University/Prague/CZ, 6Faculty of Medicine, Comenius University, Bratislava, Slovakia/Bratislava/SK, 7First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ

P0628 - Quantitative T1 deviations in brain lesions and NAWM improve the clinico-radiological correlation in early MS

G.F. Piredda1, T. Hilbert1, M. Vaneckova2, J. Krasensky2, T. Uher3, B. Srpová4, E. Havrdova5, M. Andelova3, K. Vodehnalova3, D. Horakova5, V. Ravano1, M.J. Fartaria1, B. Maréchal1, J.-P. Thiran6, T. Kober1, 1Siemens Healthcare AG/Lausanne/CH, 2Charles University and General University Hospital/Prague/CZ, 3First Faculty of Medicine, Charles University and General University/Prague/CZ, 4Charles University and General University/Prague/CZ, 5First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 6École Polytechnique Fédérale de Lausanne/Lausanne/CH

P0629 - QUANTUM – Quantitative and standardized imaging in daily clinical routine of multiple sclerosis patients

K. Schuh1, L. Spies2, R. Opfer2, M. Jankovic3, B. Elias-Hamp4, M. Jauss5, 1Novartis Pharma GmbH/Nuremberg/DE, 2jung diagnostics GmbH/Hamburg/DE, 34Sauerlandklinik Hachen/Sundern- Hachen/DE, 43Praxis für Neurologie und Psychiatrie/Hamburg/DE, 5Ökumenisches Hainich Klinikum gGmbH/Muehlhausen/DE

P0630 - Racial/ethnic disparities in volumetric MRI correlates of clinical disability between Hispanic/Latino and Caucasian multiple sclerosis patients

C.A. Pérez, A. Salehbeiki, J. Wolinsky, J.A. Lincoln, The University of Texas Health Science Center at Houston/Houston/US

P0631 - Recommendations for the coordination of Neurology and Neuroradiology departments in the management of patients with multiple sclerosis

S. Llufriu1, E. Agüera2, F. Bravo2, L. Costa-Frossard3, V. Galán4, L. Koren4, A. Labiano4, L. Landete5, A. León6, D. Lourido3, P. Martín4, J. Meca-Lallana7, M.D. Monedero5, E. Moral8, L. Requeni5, I. Zubizarreta8, À. Rovira9, 1Hospital Clínic de Barcelona e Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)/Barcelona/ES, 2Hospital Universitario Reina Sofía/Córdoba/ES, 3Hospital Universitario Ramón y Cajal/Madrid/ES, 4Hospital Universitario 12 de Octubre/Madrid/ES, 5Hospital Universitario Dr. Peset/Valencia/ES, 6Hospital Clínico Universitario Virgen de la Arrixaca/El Palmar, Murcia/ES, 7Hospital Clínico Universitario Virgen de la Arrixaca/Murcia/ES, 8Hospital de Sant Joan Despí Moisès Broggi/Barcelona/ES, 9Hospital Universitario Vall d’Hebrón/Barcelona/ES

P0632 - Reduced brain integrity slows down and increases low alpha power in multiple sclerosis

J. Van Schependom1, D. Vidaurre2, L. Costers1, M. Sjogard3, D. Sima4, D. Smeets4, M. D'Hooghe1, M. D'Haeseleer5, G. Deco6, V. Wens3, X. De Tiège3, S. Goldman3, M. Woolrich7, G. Nagels4, 1Vrije Universiteit Brussel/Elsene/BE, 2University of Oxford/JX/GB, 3Université Libre de Bruxelles/Brussels/BE, 4Icometrix, Research and Development/Leuven/BE, 5Vrije Universiteit Brussel/Jette/BE, 6Universitat Pompeu Fabra/Barcelona/ES, 7University of Oxford/Oxford/GB

P0634 - Relationship Between Cognitive Functioning and 7T Thalamic Imaging Metrics in Fingolimod- Treated MS Patients and Healthy Controls

D. Conway1, S. Planchon1, S.H. Oh2, K. Nakamura1, N. Thompson1, K. Sakaie1, D. Ontaneda3, 1Cleveland Clinic Foundation/Cleveland/US, 2Hankuk University of Foreign Studies/Yongin/KR, 3Cleveland Clinic//US

P0635 - Relationship between mood disturbance and cerebellar volume and structural connectivity in multiple sclerosis

C. Roman1, P. Arnett2, 1/Providence/US, 2The Pennsylvania State University/University Park/US

P0636 - Relationship of real-world brain atrophy to MS disability using icobrain: 4 centre pilot study

A.-L. Nguyen1, D. Horakova2, E. Havrdova2, M. Barnett3, M.P. Sormani4, E. Lui5, F. Gaillard5, P. Desmond5, H. Prime6, M. Datta6, A. Van Der Walt7, V. Jokubaitis7, B. Weinstock-Guttman8, M. D’Hooghe9, G. Nagels10, V. Van Pesch11, G. Laureys12, L. Van Hijfte12, J. Lechner-Scott13, F. Patti14, E. Cristiano15, J. Rojas16, D. Sima10, W. Van Hecke10, T. Kalincik5, H. Butzkueven7, 1Royal Melbourne Hospital/Melbourne/AU, 2First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 33. Brain and Mind Research Institute, University of Sydney/Sydney/AU, 4University of Genoa/Genoa/IT, 5Royal Melbourne Hospital, University of Melbourne/Melbourne/AU, 6Box Hill Hospital/Melbourne/AU, 7Monash University/Melbourne/AU, 8State University of New York at Buffalo/Buffalo/US, 9National MS Center Melsbroek/Melsbroek/BE, 10Icometrix, Research and Development/Leuven/BE, 11Université Catholique de Louvain/Brussels/BE, 12UZ Gent/Gent/BE, 13John Hunter Hospital, University of Newcastle/Newcastle/AU, 14University of Catania/Catania/IT, 15Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 16Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR

P0637 - Relevance of NODDI to characterise in vivo the microstructural abnormalities of multiple sclerosis cortex and cortical lesions: a 3T study

P. Preziosa, E. Pagani, R. Bonacchi, L. Cacciaguerra, M. Filippi, M.A. Rocca, IRCCS San Raffaele Scientific Institute/Milan/IT

P0638 - Role of Gadolinium-based contrast agents to detect subclinical disease activity in clinically stable patients in the Swiss MS Cohort Study

T. Sinnecker1, E. Ruberte2, Ö. Yaldizli3, R. Rahmanzadeh4, R. Galbusera4, R.-A. Todea4, A. Cagol4, S. Subramaniam5, P. Benkert6, S. Müller7, L. Achtnichts8, J. Vehoff7, G. Disanto9, O. Findling8, A. Chan10, A. Salmen10, C. Pot11, P. Lalive12, C. Zecca9, T. Derfuss13, J. Lieb3, E.-W. Radue14, L. Remonda8, F. Wagner15, M. Vargas16, P. Maeder17, E. Pravata18, J. Weber7, D. Leppert4, L. Kappos19, C. Gobbi9, C. Granziera4, J. Würfel20, J. Kuhle21, 1Universitätsspital Basel/Basel/CH, 23Medical Image Analysis Center (MIAC) and qbig/Basel/CH, 3University Hospital Basel/Basel/CH, 4University Hospital Basel and University of Basel/Basel/CH, 5University Hospital Basel, University of Basel/Basel/CH, 6Clinical Trial Unit/Basel/CH, 7Cantonal Hospital St. Gallen/St. Gallen/CH, 8Cantonal Hospital Aarau/Aarau/CH, 9Regional Hospital of Southern Switzerland (EOC)/Lugano/CH, 10Inselspital Bern, University Hospital and University of Bern/Bern/CH, 11University Hospital of Lausanne/Lausanne/CH, 12Geneva University Hospitals/Geneva/CH, 13University of Basel//CH, 14University Hospital Basel and University of Basel/Basel/SZ, 15Inselspital, Bern University Hospital and University of Bern/Bern/CH, 16Geneva University Hospital and Faculty of Medicine/Geneva/CH, 17Lausanne University Hospital (CHUV) and University of Lausanne/Lausanne/CH, 18Ospedale Civico/Lugano/CH, 19University Hospital and University of Basel/Basel/CH, 20MIAC AG/Basel/CH, 21University of Basel/Switzerland/CH

P0639 - Sensorimotor cerebellar functional connectivity changes as compensatory mechanisms of structural damage in patients with MS and no disability

S. Tommasin1, V. Iakovleva1, M.A. Rocca2, G. Tedeschi3, N. De Stefano4, C. Pozzilli1, P. Zaratin5, M. Filippi2, P. Pantano1, 1Sapienza University of Rome/Rome/IT, 2IRCCS San Raffaele Scientific Institute/Milan/IT, 3University of Campania “Luigi Vanvitelli”/Naples/IT, 4University of Siena//IT, 5Italian Multiple Sclerosis Foundation/Genoa/IT

P0640 - Sensorimotor network dynamics predicts loss of upper and lower limb function in people with multiple sclerosis

M. Strik1, A. Eijlers2, I. Dekker2, T. Broeders2, L. Douw2, J. Killestein3, S. Kolbe4, J. Geurts2, M. Schoonheim2, 1Amsterdam UMC - location VUmc/Amsterdam/NL, 2Amsterdam UMC, location VUmc/Amsterdam/NL, 3Amsterdam UMC, Location VUmc/Amsterdam/NL, 4Monash University/Melbourne/AU

P0641 - Serum neurofilament light chain levels are associated with poorer thalamic perfusion in multiple sclerosis: cross-sectional DSC-PWI study

D. Jakimovski1, N. Bergsland2, M. Dwyer3, M. Ramanathan4, B. Weinstock-Guttman5, R. Zivadinov2, 1University at Buffalo, State University of New York/Buffalo/US, 2Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York/Buffalo/US, 3Buffalo Neuroimaging Analysis Center/Buffalo/US, 4Department of Pharmaceutical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York/Buffalo/US, 5State University of New York at Buffalo/Buffalo/US

P0642 - Spatial distribution of cortical lesions in multiple sclerosis correlates to clinical and cognitive decline

P. Bouman1, N. Nguyen2, M. Van Dam2, L. Jonkman2, H. Hulst3, J. Geurts2, M. Steenwijk1, 1Amsterdam UMC, VUmc/Amsterdam/NL, 2Amsterdam UMC, location VUmc/Amsterdam/NL, 3MS Center Amsterdam/Amsterdam/NL

P0644 - Spinal cord atrophy in a primary progressive multiple sclerosis trial: improved sample size using GBSI

M. Moccia1, N. Valsecchi2, O. Ciccarelli3, R. Van Schijndel4, F. Barkhof5, F. Prados5, 1Federico II University of Naples, Italy/Napoli/IT, 2University College London/London/GB, 3UCL Queen Square Institute of Neurology/London/GB, 4VU University Medical Center/Amsterdam/NL, 5University College London/LONDON/GB

P0645 - Spinal cord pathology in a large cohort of MS patients with different levels of disability and MS phenotypes

M. Vaneckova1, T. Hrnciarova2, J. Krasensky1, T. Uher3, M. Andelova3, E. Hardubejova2, E. Kubala Havrdová4, L. Friedova2, V. Ravano5, B. Maréchal5, T. Kober5, D. Horakova6, 1Charles University and General University Hospital/Prague/CZ, 2First Faculty of Medicine, Charles University and General University Hospital/Prague/CZ, 3First Faculty of Medicine, Charles University and General University/Prague/CZ, 4Charles University//CZ, 5Siemens Healthcare AG/Lausanne/CH, 6First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ

P0646 - Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis

I. Koubiyr1, M. Deloire2, B. Brochet3, P. Besson4, J. Charré-Morin2, A. Saubusse2, T. Tourdias2, A. Ruet3, 1INSERM U1215/Bordeaux/FR, 2Centre Hospitalier Universitaire de Bordeaux/BORDEAUX/FR, 3University of Bordeaux/Bordeaux/FR, 4Northwestern University/Chicago/US

P0647 - Studying intralesional axonal damage in MS white matter lesions with diffusion MRI biophysical models

M. Barakovic1, R. Rahmanzadeh1, P.-J. Lu1, P. Maggi2, M. Absinta3, F. La Rosa4, M. Bach-Cuadra2, S. Schiavi5, A. Daducci5, P. Sati6, D. Reich7, J. Kuhle8, M. Weigel1, L. Kappos9, C. Granziera10, 1University of Basel/Allschwil/CH, 2Lausanne University Hospital and University of Lausanne/Lausanne/CH, 3Johns Hopkins University/Baltimore/US, 4École Polytechnique Fédérale de Lausanne/Lausanne/CH, 5University of Verona/Verona/IT, 6Cedars-Sinai Medical Center/Los Angeles/US, 7NINDS, NIH/Bethesda/US, 8University of Basel/Switzerland/CH, 9University of Basel//CH, 10University Hospital Basel and University of Basel/Basel/CH

P0648 - The central vein sign as a biomarker for MS in the infratentorial brain

M. Gaitán, M. Paday Formenti, J. Correale, P. Yañez, FLENI/Buenos Aires/AR

P0649 - The Central Vein Sign discriminates multiple sclerosis from its radiological mimics in the clinical setting

M.E. Paday Formenti1, P. Yañez1, M.T. Goicochea1, M.V. Pujol Lereis1, H. Chaves1, J. Correale2, M. Gaitán1, 1FLENI/Buenos Aires/AR, 2Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR

P0650 - The contribution of cortical lesions to fatigue and depression in relapsing remitting multiple sclerosis.

R. Capuano1, A. Bisecco2, A. D'Ambrosio3, R. Docimo3, M. Altieri4, M. Risi3, G. Caiazzo3, T. Cuomo5, M. Cirillo3, G. Tedeschi3, A. Gallo3, 1Multiple Sclerosis Centre, I Division of Neurology, University of Campania “Luigi Vanvitelli”/SALERNO/IT, 2University of Campania /Naples/IT, 3University of Campania “Luigi Vanvitelli”/Naples/IT, 4Multiple Sclerosis Centre, I Division of Neurology, University of Campania “Luigi Vanvitelli”/Casalnuovo di Napoli/IT, 5Umberto I Hospital/Nocera Inferiore/IT

P0651 - The effects of amiloride, fluoxetine and riluzole over 96 weeks on metabolic markers of brain injury in secondary progressive multiple sclerosis.

N. John1, B. Solanky2, F. De Angelis2, J. Stutters2, F. Prados3, A. Doshi2, R. Parker4, C. Weir4, A. Calvi5, T. Williams5, T. Schneider5, D. Plantone5, A. Monteverdi6, D. Macmanus5, I. Marshall4, F. Barkhof3, C. Wheeler-Kingshott5, J. Chataway7, 1University College London/5EH/GB, 2University College London/BG/GB, 3University College London/LONDON/GB, 4University of Edinburgh/Edinburgh/GB, 5University College London/London/GB, 6University of Pavia/Pavia/IT, 7UCL Queen Square Institute of Neurology, University College//GB

P0652 - The relationship among leptomeningeal enhancement clinical, radiological activity and cerebrospinal fluid markers

N. Bruschi1, C. Lapucci2, M. Cellerino3, G. Boffa2, E. Sbragia2, E. Mancuso4, G. Rebella5, F. Tazza2, L. Castellan6, M. Inglese7, 1/Genoa/IT, 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 3University of Genoa/Genoa/IT, 4Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI)/Genova/IT, 5University of Genoa/genoa/IT, 6IRCCS San Martino University Hospital,/genoa/IT, 7University of Genoa//IT

P0653 - The value of grey matter microglial activation measurement by TSPO-PET in predicting clinical disease progression in multiple sclerosis

O. Misin1, M. Matilainen2, E. Rissanen2, M. Sucksdorff3, L. Airas2, 1Kanta-Häme Central Hospital/Hämeenlinna/FI, 2Turku University Hospital and University of Turku/Turku/FI, 3Turku University Hospital/Turku/FI

P0654 - Time course of hippocampal functional connectivity in relation with memory performances at the early stage of multiple sclerosis

I. Koubiyr1, J. Boscheron1, M. Deloire2, B. Brochet3, J. Charré-Morin2, A. Saubusse2, A. Ruet3, T. Tourdias2, 1INSERM U1215/Bordeaux/FR, 2Centre Hospitalier Universitaire de Bordeaux/BORDEAUX/FR, 3University of Bordeaux/Bordeaux/FR

P0655 - Tissue destruction and blood-brain barrier breakdown in chronic-active vs. inactive MS lesions by 7T MP2RAGE and susceptibility MRI

S. Lake1, S. Choi2, D. Harrison2, 1University of Maryland School of Medicine/Baltimore/US, 2University of Maryland School of Medicin/BALTIMORE/US

P0656 - Unraveling deep grey matter atrophy, iron and myelin changes in Multiple Sclerosis

M. Petracca1, G. Pontillo1, S. Monti2, M. Quarantelli2, C. Criscuolo1, R. Lanzillo3, E. Tedeschi1, A. Elefante1, V. Brescia Morra1, S. Cocozza1, G. Palma2, A. Brunetti1, 1University of Naples Federico II/Naples/IT, 2Institute of Biostructure and Bioimaging, National Research Council/Naples/IT, 3Federico II University of Naples, Italy/Napoli/IT

P0657 - Utility of Gadolinium in Multiple Sclerosis Radiographic Monitoring

A. Thuringer, S. Lynch, University of Kansas Medical Center/Kansas City/US

P0658 - Vascular Disease Risk Factors in Multiple Sclerosis

V. Yadav1, M. Lane2, A. Fryman2, F. Bittner2, M. Sammi2, V. Anderson2, W. Rooney2, 1VA Medical Center - Portland Oregon/Portland/US, 2Oregon Health Science University/Portland/US

P0659 - White matter tracts that overlap with hubs are preferentially protected against multiple sclerosis pathology M. Clarke1, D. Archer1, K. Yoon1, R. Dortch1, S. Smith1, J. Xu1, G. Cutter2, F. Bagnato1, 1Vanderbilt University Medical Center/Nashville/US, 2The University of Alabama at Birmingham/Birmingham/US

P0660 - Yield and potential value of spinal cord MRI surveillance in treated relapsing multiple sclerosis

C. Valencia-Sanchez1, J. Carter2, D. Wingerchuk3, 1Mayo Clinic Rochester/Rochester/US, 2Mayo Clinic Arizona/Scottsdale/US, 3Mayo Clinic/Scottsdale/US

P0661 - A 164 second multi-format film successfully conveys the importance of early intervention in MS

D. Wilkie1, R. Middleton2, J. Cook3, R. Nicholas1, 1Imperial College London/London/GB, 2Swansea University/Swansea/GB, 3James Cook Film Production/Durham/GB

P0662 - How patients utilize online data sources to engage with the Multiple Sclerosis (MS) community and search for information on their condition

J. White1, S. Teoh2, S. Gabriele3, J. Vindici4, 1/London/GB, 2Ipsos Sdn Bhd/Kuala Lumpur/MY, 3Ipsos MORI UK/London/GB, 4Ipsos Insight LLC/New Jersey/US

P0663 - Real-time internet-based teleconsultations for neurological follow-up of patients with multiple sclerosis: an interim feasibility analysis

M. D'Haeseleer1, N. Sadeghi1, P. Eelen2, C. Cuvelier2, M. D'Hooghe3, G. Nagels4, K. Van Gils2, J. Van Schependom3, 1Vrije Universiteit Brussel/Jette/BE, 2National MS Center/Melsbroek/BE, 3Vrije Universiteit Brussel/Elsene/BE, 4Icometrix, Research and Development/Leuven/BE

P0664 - Smartphone based Symbol Digit Modalities Test reliably measures cognitive function in multiple sclerosis patients

L. Pham1, T. Harris2, M. Varosanec1, P. Kosa1, V. Morgan3, B. Bielekova1, 1National Institutes of Health/Bethesda/US, 2NIH/Bethesda/US, 3/Bethesda/US

P0665 - Social Listening: Digital Profile of the Multiple Sclerosis Patient in Mexico

F. Rodríguez, M. Jiménez, D. Mireles Jacobo, Novartis Corporativo SA de CV/Mexico City/MX

P0666 - Telemedicine in/outside the pandemic: a survey about satisfaction of this tool in a cohort of multiple sclerosis patients and their neurologists

L. Moiola1, M. Di Cristinzi2, S. Guerrieri3, A. Nozzolillo1, M. Orrico4, S. Gelibter4, L. Bosco4, C. Zanetta4, F. Sangalli1, M. Filippi5, 1IRCCS San Raffaele Scientific Institute/Milan/IT, 2Multiple Sclerosis Centre, Neurology 2,/Florence/IT, 3San Raffaele Hospital - Vita-Salute San Raffaele University/Milan/IT, 4Multiple sclerosis center, IRCCS San Raffaele Scientific Institute/Milan/IT, 5IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University/Milan/IT

P0667 - The Dutch MS Patient Voice Survey: The search for information.

J. Muis1, C. Schouten2, E. De Wolf2, L. Avis3, L. Hoeijmakers4, A. Buurman5, 1/Hoef en Haag/NL, 2MS Association/Den Dolder/NL, 3DVJ/Utrecht/NL, 4Novartis/Amsterdam/NL, 5novartis/amsterdam/NL

P0668 - Understanding Multiple Sclerosis Massive Open Online Course: Closing The Gap On Information Asymmetry

S. Claflin, B. Taylor, J. Campbell, University of Tasmania/Hobart/AU

P0669 - Using WebEx Technology to Increase Knowledge and Awareness About Multiple Sclerosis via Documentary Film “When We Walk” as an Educational Intervention

S. Boyd, S. Jones, S. Veri, The University of North Carolina at Charlotte, School of Social Work/Charlotte/US

P0670 - Ecological and functional alterations of the gut microbiome in different stages of multiple sclerosis

D. Takewaki1, W. Suda2, W. Sato3, L. Takayasu2, S. Miyake4, M. Hattori5, T. Yamamura3, 1NationalCenterofNeurologyandPsychiatry/Kodaira/JP, 2RIKEN/Yokohama/JP, 3National Center of Neurology and Psychiatry/Kodaira/JP, 4Juntendo University/Tokyo/JP, 5Waseda University/Tokyo/JP

P0671 - Exploring the gut microbiome in multiple sclerosis via the international MS Microbiome Study (iMSMS)

X. Zhou1, S. Singh1, M. Mendoza1, R. Baumann1, J. Landefeld1, P. Casaccia2, I. Katz Sand3, Z. Xia4, H. Weiner5, T. Chitnis6, S. Chandran7, P. Connick8, D. Oteagui9, T. Castillo-Trivino10, S. Caillier1, A. Santaniello11, G. Ackermann12, G. Humphrey12, L. Negrotto13, M. Farez14, R. Hohlfeld15, A.-K. Pröbstel16, X. Jia17, J. Graves12, A. Bar-Or18, H. Wekerle19, J. Oksenberg11, T. West20, J. Correale21, B. Cree11, S. Hauser11, R. Knight12, S. Baranzini11, 1University of California, San Francisco/San Francisco/US, 2Advanced Science Research Center at GC-CUNY/New York/US, 3Mount Sinai/New York/US, 4University of Pittsburgh/Pittsburgh/US, 5Harvard University, Brigham & Women's Hospital/Boston/US, 6Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US, 7The University of Edinburgh/Edinburgh/GB, 8University of Edinburgh/Edinburgh/GB, 9Biodonostia Health Research Institute/San Sebastián/ES, 10Hospital Universitario Donostia/San Sebastián/ES, 11University of California San Francisco/San Francisco/US, 12University of California, San Diego/San Diego/US, 13Raúl Carrea Institute for Neurological Research/Argentina/AR, 14FLENI/CIUDAD DE BUENOS AIRES/AR, 15Ludwig Maximilians University of Munich (LMU)/Munich/DE, 16University Hospital Basel/Basel/CH, 17Genentech, Inc./South San Francisco/US, 18University of Pennsylvania/Philadelphia/US, 19Max Planck Institute of Neruobiology//DE, 20Rocky Mountain MS Clinic/Salt Lake City/US, 21Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR

P0672 - Human commensal Prevotella histicola ameliorates disease in an animal model of multiple sclerosis as effectively as interferon-beta

S. Shahi1, S. Jensen1, A. Murra1, K. Gibson-Corley1, N. Karandikar1, J. Murray2, A. Mangalam3, 1University of Iowa/Iowa City/US, 2Mayo Clinic/Rochester/US, 3University of Iowa/IOWA CITY/US

P0673 - Induction of human IL-10 and protection against murine EAE by a manufactured human gut derived microflora antigen

J. Ochoa-Reparaz1, L. Kasper2, 1Eastern Washington University/Cheney/US, 2/Arroyo Seco/US

P0674 - “Lactobacillus species differentially alter CNS autoimmunity via distinct immunomodulatory genomic loci and modulation of gut microbial composition.”

T. Montgomery1, K. Eckstrom1, A. Kunstner2, J. Kennedy1, R. Culp-Hill3, A. D’Alessandro3, H. Busch2, M. Wargo1, D. Krementsov4, 1University of Vermont/Burlington/US, 2University of Lubeck/Lubeck/DE, 3University of Colorado/Aurora/US, 4University of Vermont/Burlington/UM

P0675 - Multi-OMICS of the host-gut microbiome dynamics in multiple sclerosis

L. Ghezzi1, C. Cantoni1, A. Locca1, P. Newland2, A.E. Lovett-Racke3, Y. Zhou4, L. Piccio5, 1Washington University in St. Louis - School of Medicine/Saint Louis/US, 2Goldfarb School of Nursing Barnes Jewish College/Saint Louis/US, 3The Ohio State University/Columbus/US, 4University of Connecticut/Farmington/US, 5Washington University in St. Louis/Saint Louis/US

P0676 - Ocrelizumab impacts IgA coating of immunomodulatory gut bacteria in multiple sclerosis patients

G. Janda, I. Cohen, W. Ruff, E. Longbrake, Yale University/New Haven/US

P0677 - Possible association between miRNAs and gut microbiota in pathogenesis of Multiple sclerosis

M. Manu1, T. Yamamura2, H. Hohjoh2, W. Sato3, S. Oki2, 1National Institute of Neuroscience/Tokyo/JP, 2National Institute of Neuroscience, National Center of Neurology and Psychiatry/Tokyo/JP, 3National Center of Neurology and Psychiatry/Kodaira/JP

P0678 - Selected Clostridia strains increase responses related to interferon beta signaling and butyrate levels in experimental autoimmune encephalomyelitis

L. Calvo-Barreiro1, H. Eixarch1, T. Cornejo2, M. Castillo1, L. Mestre3, C. Guaza3, J.J. González López2, X. Montalban1, C. Espejo4, 1Dept. of Neurology-Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 2Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona/Barcelona/ES, 3nstituto Cajal, CSIC/Madrid/ES, 4Hospital Universitario Vall D´Hebron/Barcelona/ES

P0679 - The gut microbiota: a case-control study of children with multiple sclerosis, monophasic acquired demyelinating syndromes and unaffected controls

H. Tremlett1, F. Zhu1, D.L. Arnold2, A. Bar-Or3, C. Bernstein4, J. Forbes5, M. Graham6, J. Hart7, N. Knox6, R.A. Marrie4, A. Mirza1, J. O’Mahony8, G. Van Domselaar6, E.A. Yeh8, Y. Zhao1, B. Banwell9, E. Waubant7, 1University of British Columbia/Vancouver/CA, 2MNI, McGill/Quebec/CA, 3University of Pennsylvania/Philadelphia/US, 4University of Manitoba/Winnipeg/CA, 5University of Toronto/Toronto/CA, 6Public Health Agency of Canada/Winnipeg/CA, 7UCSF/San Francisco/US, 8The Hospital for Sick Children/Toronto/CA, 9Children’s Hospital of Philadelphia/Philadelphia/US

P0680 - The role of gut microbiota in the Egyptian relapsing remitting multiple sclerosis patients.

S. Elgendy, E. Daef, S. Mohammed, M. El-Mokhtar, H.A. Hassan, R. El.Hameed, E. Khedr, A. Nasreldein, Assiut University/Assiut/EG

P0681 - A severe case of tetraparesis with conus involvement in neuromyelitis optica spectrum disorder

A. Safadi1, C. Myers2, N. Hu2, B. Osborne2, 1Georgetown University Hospital/Washington, DC/US, 2Georgetown University Hospital/Washington/US

P0682 - Aggressive and fulminant course of Anti-myelin oligodendrocyte glycoprotein antibody associated disease in a solid organ receptor

G.D. Vazquez1, J.B. Couto2, C. Bolaño2, F. Appiani2, S. Claverie2, J. Pszenyckyj2, V. Sinay3, A. Carra4, 1Fundación Favaloro/solis 461/AR, 2Hospital Fundación Favaloro/buenos aires/AR, 3Hospital Universitario Fundación Favaloro/Buenos Aires/AR, 4Hospital Britanico/CIUDAD DE BUENOS AIRES/AR

P0683 - Altered resting state dynamic functional connectivity of precuneus contributes to cognition and depression in neuromyelitis optica spectrum disorders

L. Cacciaguerra, D. Mistri, P. Valsasina, V. Martinelli, M. Filippi, M.A. Rocca, IRCCS San Raffaele Scientific Institute/Milan/IT

P0684 - Anti-IL-6 receptor antibody prevents blood-brain barrier disruption in mice with experimental autoimmune encephalomyelitis (EAE)

K. Serizawa, S. Miyake, H. Tomizawa-Shinohara, K. Yogo, Y. Matsumoto, Chugai Pharmaceutical Co., Ltd/Kanagawa/JP

P0685 - AQP4-IgG and MOG-IgG related optic neuritis – prevalence, optical coherence tomography findings, visual outcomes: systematic review and meta-analysis A. Filippatou1, L. Mukharesh1, S. Saidha1, P. Calabresi2, E. Sotirchos2, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Johns Hopkins University/Baltimore/US

P0686 - Aquaporin-4 antibody seroreversion in patients with neuromyelitis optica spectrum disorder treated with rituximab.

K. Rammohan1, L. Tornes1, S. Delgado2, N. Garg1, C. Dixon1, M. Ortega1, J. Hernandez1, N. Hughes1, M. Botero1, M. Mccarthy1, 1University of Miami School of Medicine/Miami/US, 2Miller School of Medicine, University of Miami/Miami/US

P0687 - Aquaporin-4 neuromyelitis optica spectrum disorder in a 5-year-old girl presenting with neuropsychiatric symptoms

C. Chow Haws1, R. Narayan2, 1Phoenix Children's Hospital/Phoenix/US, 2Barrow Neurological Institute/Phoenix/US

P0688 - Area postrema syndrome and longitudinally extensive transverse myelitis in a patient with prostatic adenocarcinoma and Aquaporin-4 antibodies.

A. Dinoto1, A. Bosco1, A. Sartori2, M. Cheli1, G. Bellavita1, F. Pasquin1, A. Bratina1, P. Manganotti1, 1Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Cattinara University Hospital ASUGI, University of Trieste/Trieste/IT, 2Neurology Unit, Azienda Sanitaria Univeristaria Integrata Clinica Neurologica, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Trieste/Trieste/IT

P0689 - Autoimmune comorbidity increases healthcare cost burden in patients with NMOSD in the United States: a retrospective commercial claims analysis

A. Exuzides1, D. Sheinson1, P. Sidiropoulos2, S. Gholizadeh2, F. Magrini3, A. Surinach4, L. Cook5, C. Meyer2, M. Yeaman6, C. Reyeswright7, 1Genentech/South San Francisco/US, 2Genentech Inc./South San Francisco/US, 3Genentech Inc./Genentech, Inc., South San Francisco/US, 4Genesis Research/Hoboken/US, 5University of Utah School of Medicine/Salt Lake City/US, 6University of California/Los Angeles/US, 7Health Interactions/San Francisco/US

P0690 - Autologous hematopoietic stem cell transplantation in a pediatric patient with aquaporin-4 neuromyelitis optica spectrum disorder

T. Khan1, C. Wang2, 1University of Texas Southwestern Medical Center/Dallas/US, 2University of Texas Southwestern Medical Center/dallas/US

P0691 - Autologous Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica – Year 5 Update

J. Burton1, J. Storek2, F. Costello2, P. Duggan2, L. Metz3, 1/Calgary/CA, 2University of Calgary/Calgary/CA, 3University of Calgary/Canada/CA

P0692 - Benefit of eculizumab for a broad range of patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from PREVENT

K. Fujihara1, A. Berthele2, H.J. Kim3, M. Levy4, I. Nakashima5, C. Oreja-Guevara6, J. Palace7, S. Pittock8, M. Terzi9, N. Totolyan10, S. Viswanathan11, K.-C. Wang12, A. Pace13, M. Yountz13, L. Miller13, I. Tanvir13, R. Armstrong14, D. Wingerchuk15, 1Fukushima Medical University/Fukushima/JP, 2Klinikum rechts der Isar, Technical University of Munich/Munich/DE, 3Research Institute and Hospital, National Cancer Center/Goyang/KR, 4Massachusetts General Hospital and Harvard Medical School/Boston/US, 5Tohoku University//JP, 6Hospital Universitario Clinico San Carlos/Madrid/ES, 7Oxford University Hospitals/Oxford/GB, 8Mayo Clinic/Rochester/US, 9Ondokuz Mayıs University/Sasun/TR, 10First Pavlov State Medical University of St Petersburg/St Petersburg/RU, 11Kuala Lumpur Hospital/Kuala Lumpur/MY, 12Cheng-Hsin General Hospital/Taipei/TW, 13Alexion Pharmaceuticals/Boston/US, 14Formerly of Alexion Pharmaceuticals/Boston/US, 15Mayo Clinic/Scottsdale/US

P0693 - Brainstem and cerebellar involvement in MOG-IgG Associated Disorder versus Aquaporin-4- IgG and Multiple Sclerosis

S. Banks1, P. Morris1, J. Chen2, S. Pittock2, E. Sechi1, A. Kunchok1, J.-M. Tillema1, J. Fryer2, B. Weinshenker1, K. Krecke1, A. Lopez-Chiriboga3, A. Nguyen2, T. Greenwood2, C. Lucchinetti4, S. Messina2, E. Flanagan5, 1Mayo Clinic Department of Neurology/Rochester/US, 2Mayo Clinic/Rochester/US, 3Mayo Clinic Department of Neurology/Jacksonville/US, 4Mayo Clinic/Minnesota/US, 5Mayo Clinic/United States/US

P0694 - Burden of autoimmune comorbidity in patients with NMOSD in the United States revealed by retrospective commercial claims analysis

A. Exuzides1, D. Sheinson1, P. Sidiropoulos2, S. Gholizadeh2, F. Magrini3, A. Surinach4, L. Cook5, C. Meyer2, M. Yeaman6, 1Genentech/South San Francisco/US, 2Genentech Inc./South San Francisco/US, 3Genentech Inc./Genentech, Inc., South San Francisco/US, 4Genesis Research/Hoboken/US, 5University of Utah School of Medicine/Salt Lake City/US, 6University of California/Los Angeles/US

P0695 - Burden of disease in patients with neuromyelitis optica spectrum disorder: insights from the CIRCLES study cohort

M. Royston1, I. Tanvir1, J. Rose2, K. Lewis2, C. Palmer2, J. Sinnott2, A. Jolley2, J. Behne3, M. Behne3, T. Blaschke4, T. Smith5, O. Morteau1, L. Cook2, A. Kielhorn1, M. Yeaman6, 1Alexion Pharmaceuticals/Boston/US, 2University of Utah School of Medicine/Salt Lake City/US, 3The Guthy- Jackson Charitable Foundation/Beverly Hills/US, 4Stanford University/Stanford/US, 5University of Michigan Medical School/Ann Arbor/US, 6University of California/Los Angeles/US

P0696 - Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody Positive Children with Demyelinating Disorders J. Chong1, A. Lui1, A. Abrams1, E. Flanagan2, K. Krysko3, C. Francisco1, A. Rutatangwa4, E. Waubant4, A. Ziaei5, 1University of California, San Francisco/San Francisco/US, 2Mayo Clinic/United States/US, 3University of California San Francisco/San Francisco/US, 4UCSF/San Francisco/US, 5University of California, San Fransisco/San Francisco/US

P0697 - Child with MOG antibodies, synringomyelia and MRI mimicking Langerhansian hystiocytosis

S. Hatteb1, N. Mesbahi2, S. Daoudi3, 1Medical school, Mouloud Mammeri University of Tizi Ouzou/Tizi Ouzou/DZ, 2Nedir Mohamed University hospital of Tizi ouzou/Tizi Ouzou/DZ, 3medical school, Mouloud Mammeri University of Tizi Ouzou/Tizi Ouzou/DZ

P0698 - Clinical and MRI correlates of autonomic dysfunction in neuromyelitis optica spectrum disorder

J.-H. Min, S. Kwon, Y.S. Kim, J. Kim, H. Kwon, J.H. Shin, B.J. Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine/Seoul/KR

P0699 - Clinical and radiological features of a hospital cohort of Neuromyelitis optica.

G. Alvarez Bravo, L. Ramió I Torrentà, R. Robles Cedeño, E. Quintana, J. Gich, M. González, Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES

P0700 - Clinical characteristics of neuromyelitis optica spectrum disorder and multiple sclerosis in Iranian pediatric patients

M. Barzegar, O. Mirmosayyeb, V. Shaygannejad, Isfahan neuroscience research center/Isfahan/IR

P0701 - Clinical characteristics of Neuromyelitis optica spectrum disorder Peruvian patients: a government-run tertiary level neurological center cohort

C. Caparó-Zamalloa, S. Castro-Suarez, W. Aguirre-Quispe, M. Meza-Vega, Instituto Nacional de Ciencias Neurológicas/LIMA/PE

P0702 - Clinical characteristics of neuromyelitis optica spectrum disorders in a Spanish population.

J.D.G. Hiraldo1, R. López Ruiz2, F. Sánchez Fernández2, J. Dotor García-Soto2, J.L. Ruiz-Peña2, M.D. Páramo Camino2, G. Navarro Mascarell2, S. Eichau Madueño2, 1Hospital universitario Virgen Macarena/Seville/ES, 2Universitary Hospital Virgen Macarena/Seville/ES

P0703 - Clinical, radiological features and management of twenty patients diagnosed with anti-MOG demyelinating syndrome in a tertiary referral centre.

M. Gaughan, C. O'Brien, C. Mcguigan, St. Vincent's University Hospital/Dublin/IE

P0704 - Cortical involvement in MOG IgG–positive patients : a multicenter MRI study D. Tzanetakos1, J. Tzartos1, A. Vakrakou1, M. Breza1, M.E. Evangelopoulos1, G. Koutsis1, M. Anagnostouli2, G. Velonakis3, E. Pantou4, I. Markakis5, D. Papadimitriou6, E. Karavasilis4, P. Toulas4, L. Stefanis1, C. Kilidireas1, 1Eginition Hospital, National and Kapodistrian University of Athens/Athens/GR, 2Aeginition Hospital, Medical School, National and Kapodistrian University of Athens/Athens/GR, 3Research Unit of Radiology, 2nd Department of Radiology, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece/Athens/GR, 4Research Unit of Radiology, 2nd Department of Radiology, National and Kapodistrian University of Athens, Athens, Greece/Athens/GR, 5Department of Neurology, General Hospital of Nikaia, Piraeus, Greece./Piraeus/GR, 6Department of Neurology, Henry Dunant Hospital, Athens, Greece./Athens/GR

P0705 - Cost of illness for patients with NMOSD and nonautoimmune disease estimated from claims databases in the United States

A. Exuzides1, D. Sheinson1, P. Sidiropoulos2, S. Gholizadeh2, F. Magrini3, A. Surinach4, L. Cook5, C. Meyer2, M. Yeaman6, 1Genentech/South San Francisco/US, 2Genentech Inc./South San Francisco/US, 3Genentech Inc./Genentech, Inc., South San Francisco/US, 4Genesis Research/Hoboken/US, 5University of Utah School of Medicine/Salt Lake City/US, 6University of California/Los Angeles/US

P0706 - Cost of neuromyelitis optica spectrum disorder in US clinical practice

A. Kielhorn1, M. Royston1, D. Weycker2, M. Shaff2, L. Houde2, I. Tanvir1, M. Levy3, 1Alexion Pharmaceuticals/Boston/US, 2Policy Analysis Inc. (PAI)/Brookline/US, 3Massachusetts General Hospital and Harvard Medical School/Boston/US

P0707 - Costs and health-related quality of life in patients with neuromyelitis optica spectrum disorder and MOG-antibody associated disease (CHANCENMO-Study)

M.W. Hümmert1, L. Schöppe1, J. Bellmann-Strobl2, N. Siebert2, F. Paul3, A. Duchow2, H. Pellkofer4, T. Kuempfel5, J. Havla6, S. Jarius7, B. Wildemann8, F. Then Bergh9, M. Pawlitzki10, L. Klotz11, I. Kleiter12, M. Stangel13, S. Gingele1, M. Weber14, J.H. Faiss15, R. Pul16, A. Walter17, U. Zettl18, M. Senel19, J.-P. Stellmann20, V. Häußler21, K. Hellwig22, I. Ayzenberg23, O. Aktas24, M. Ringelstein24, O. Schreiber-Katz1, C. Trebst25, 1Medical School Hannover/Hannover/DE, 2NeuroCure Clinical Research Center, Experimental and Clinical Research Center, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany/Berlin/DE, 3Charite-Universitatmedizin Berlin/Berlin/DE, 4Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet Muenchen/Munich/DE, 5Ludwig Maximilian University of Munich/Munich/DE, 6Ludwig-Maximilians Universitaet Muenchen/Munich/DE, 7Mollecular Neuroimmunology Group, Department of Neurology, University of Heidelberg/Heidelberg/DE, 8University of Heidelberg/Heidelberg/DE, 9University of Leipzig/Leipzig/DE, 101. Department of Neurology with Institute of Translational Neurology, University Hospital Münster; 2. Department of Neurology, Otto-von-Guericke University, Magdeburg/Münster/DE, 11University of Muenster/Muenster/DE, 12Ruhr-Universität Bochum/Bochum/DE, 13Hannover Medical School/Hannover/DE, 14University Medical Center Goettingen/Goettingen/DE, 15Department of Neurology, Asklepios Expert Clinic Teupitz/Teupitz/DE, 16University Hospital Essen/Essen/DE, 17Department of Neurology, Herford Hospital/Herford/DE, 18Rostock University Medical Center/Rostock/DE, 19University Ulm/Ulm/DE, 201. Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg 2. APHM, Hopital de la Timone, CEMEREM, Marseille 3. Aix Marseille Univ, CNRS, CRMBM, UMR 7339, Marseille/Hamburg/DE, 21Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg/Hamburg/DE, 22University of Bochum/Bochum/DE, 23Ruhr University Bochum/Bochum/DE, 24Heinrich-Heine-Universität Düsseldorf/Dusseldorf/DE, 25Department of Neurology, Hannover Medical School/Hannover/DE

P0708 - Differential MRI biomarkers between MOGAD, AQP4-NMOSD and RRMS: a MAGNIMS multicenter study

R. Cortese1, M. Battaglini2, F. Prados3, A. Bianchi4, L. Haider4, L. Kappos5, Ö. Yaldizli6, J. Müller7, C. Lukas8, B. Bellenberg8, R. Schneider8, S. Groppa9, M. Grothe10, Y. Liu11, Y. Duan11, S. Llufriu12, M. Sepulveda13, G. Arrambide14, J. Sastre-Garriga14, A. Rovira15, F. Paul16, J. Wuerfel17, A. Jacob18, F. Barkhof3, N. De Stefano19, O. Ciccarelli20, 1University of Siena and University College London, UK/Siena/IT, 2University of Siena/Siena/IT, 3University College London/LONDON/GB, 4UCL Institute of Neurology/London/GB, 5University of Basel//CH, 6University Hospital Basel/Basel/CH, 7University of Basel/Basel/CH, 8Ruhr University Bochum/Bochum/DE, 9University Medical Center of the Johannes Gutenberg University Mainz/Mainz/DE, 10University Medicine of Greifswald/Greifswald/DE, 11Beijing Tiantan Hospital, Capital Medical University/Beijing/CN, 12Hospital Clínic de Barcelona e Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)/Barcelona/ES, 13Center of Neuroimmunology, Service of Neurology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona, Barcelona, Spai/Barcelona/ES, 14Vall Hebron University Hospital/Barcelona/ES, 15Vall d'Hebron University Hospital/Barcelona/ES, 16Charite-Universitatmedizin Berlin/Berlin/DE, 17Medical Image Analysis Center/Basel/CH, 18The Walton Centre for Neurology and Neurosurgery/Liverpool/GB, 19University of Siena//IT, 20UCL Queen Square Institute of Neurology/London/GB

P0709 - Discontinuation of therapy may lead to an increased risk of relapse in patients with neuromyelitis optica even after 5 years of remission

S.-H. Kim1, H. Jang1, N.Y. Park1, Y. Kim1, S.-Y. Kim1, M.Y. Lee1, J.-W. Hyun2, H.J. Kim3, 1Research Institute and Hospital of National Cancer Center/Goyang/KR, 26) National Cancer Center Korea/Goyang- si/KR, 3Research Institute and Hospital, National Cancer Center/Goyang/KR

P0711 - Efficacy of satralizumab in neuromyelitis optica spectrum disorder (NMOSD): Results from open-label extension periods of SAkuraSky and SAkuraStar

B. Greenberg1, J. Bennett2, J. De Seze3, I. Kleiter4, L. Szczechowski5, T. Yamamura6, E. Fox7, B. Weinshenker8, H.C. Von Büdingen9, D. Stokmaier9, G. Klingelschmitt9, K. Weber9, C. Costantino10, A. Traboulsee11, 1Department of Neurology and Neurotherapeutics/Dallas/US, 2University of Colorado School of Medicine/Denver/US, 3CHU Strasbourg/Strasbourg/FR, 4Ruhr-Universität Bochum/Bochum/DE, 5Multi Klinika Salute/Katowice/PL, 6National Institute of Neuroscience, National Center of Neurology and Psychiatry/Tokyo/JP, 7Central Texas Neurology Consultants, University of Texas Dell Medical School/Round Rock/US, 8Mayo Clinic/Rochester/US, 9F. Hoffmann-La Roche Ltd/Basel/CH, 10Roche Product Development Medical Affairs (PDMA) Genentech/South San Francisco/US, 11The University of British Columbia/Canada/CA

P0712 - Estimating the cost of illness for patients with neuromyelitis optica spectrum disorder from US commercial claims

A. Exuzides1, D. Sheinson1, P. Sidiropoulos2, S. Gholizadeh2, A. Surinach3, L. Cook4, C. Meyer2, M. Yeaman5, 1Genentech/South San Francisco/US, 2Genentech Inc./South San Francisco/US, 3Genesis Research/Hoboken/US, 4University of Utah School of Medicine/Salt Lake City/US, 5University of California/Los Angeles/US

P0713 - Evidence of subclinical quantitative retinal layer abnormalities in aquaporin-4-IgG seropositive NMOSD

A. Filippatou1, E. Vasileiou1, Y. He2, K. Fitzgerald1, G. Kalaitzidis1, J. Lambe1, M. Mealy1, M. Levy3, Y. Liu2, J. Prince2, E. Mowry2, S. Saidha1, P. Calabresi2, E. Sotirchos2, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Johns Hopkins University/Baltimore/US, 3Massachusetts General Hospital and Harvard Medical School/Boston/US

P0714 - Experience with subcutaneous Tocilizumab in Neuromyelitis Optica spectrum disorders during SARS-CoV-2 pandemic

C. Aguirre, V. Meca-Lallana, B. Del Río, J. Vivancos, La Princesa Hospital/Madrid/ES

P0715 - Failure of Age-Expected Brain Growth in Children with ADEM is Independent of MOG- Antibody Status

F. Bartels1, B. Baumgartner2, G. Cooper1, A. Blaschek3, E. Wendel4, K. Marquardt4, M. Karenfort5, M. Baumann6, R. Cleaveland2, A. Wegener-Panzer2, S. Leiz7, M. Salandin8, P. Krieg9, T. Reindl10, M. Reindl11, C. Finke1, K. Rostásy2, 1Charité - Universitätsmedizin Berlin/Berlin/DE, 2Witten/Herdecke University/Datteln/DE, 3Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-University of Munich/Munich/DE, 4Olgahospital/Stuttgart/DE, 5University Children’s Hospital Dusseldorf/Düsseldorf/DE, 6Pediatric Neurology, Medical University of Innsbruck/Innsbruck/AT, 7Hospital Dritter Orden/Munich/DE, 8Regional Hospital of Bolzano/Bolzano/IT, 9Städtisches Klinikum Karlsruhe/Karlsruhe/DE, 10Helios Klinik Hohenstücken/Brandenburg/DE, 11Medical University of Innsbruck/Innsbruck/AT

P0716 - Fall frequency and risk factors in patients with neuromyelitis optica spectrum disorder

M. Barzegar1, O. Mirmosayyeb1, R. Azarbayejani2, S. Brand3, A. Afshari-Safavi1, V. Shaygannejad1, D. Sadeghi Bahmani4, 1Isfahan neuroscience research center/Isfahan/IR, 2Isfahan neuroscience research center, Isfahan University of medical sceince, Isfahan, Iran/Isfahan/IR, 3University of Basel, Psychiatric Clinics, Center for Affective, Stress and Sleep Disorders, Basel, Switzerland/Basel/CH, 4Departments of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL 35209, USA/Birmingham/US

P0717 - Frequency of comorbidities in Neuromyelitis Optica spectrum disorder

M. Barzegar1, O. Mirmosayyeb1, N. Nehzat1, S. Vaheb1, V. Shaygannejad1, N. Asgari2, 1Isfahan neuroscience research center/Isfahan/IR, 2Institute of Regional Health Research/Odense/DK

P0718 - Impact of relapse on disability and quality of life in patients with neuromyelitis optica spectrum disorder: findings from the Phase 3 PREVENT study

A. Berthele1, M. Levy2, D. Wingerchuk3, C. Oreja-Guevara4, I. Nakashima5, H.J. Kim6, K.-C. Wang7, K. Fujihara8, N. Totolyan9, S. Pittock10, S. Shang11, A. Kielhorn11, M. Royston11, G. Sabatella11, J. Palace12, 1Klinikum rechts der Isar, Technical University of Munich/Munich/DE, 2Massachusetts General Hospital and Harvard Medical School/Boston/US, 3Mayo Clinic/Scottsdale/US, 4Hospital Universitario Clinico San Carlos/Madrid/ES, 5Tohoku University//JP, 6Research Institute and Hospital, National Cancer Center/Goyang/KR, 7Cheng-Hsin General Hospital/Taipei/TW, 8Fukushima Medical University/Fukushima/JP, 9First Pavlov State Medical University of St Petersburg/St Petersburg/RU, 10Mayo Clinic/Rochester/US, 11Alexion Pharmaceuticals/Boston/US, 12Oxford University Hospitals/Oxford/GB

P0719 - Incidence of NMOSD relapses and seasonal influence in an equatorial country cohort

L. Giraldo1, C. Restrepo-Aristizábal1, C. Franco1, J. Tobon1, J. Asencio1, M. Zuluaga Rodas2, 1University CES/Medellin/CO, 2Medicarte S.A.S/MEDELLIN/CO

P0720 - Incidence of relapses in NMOSD patients under immunosupressive therapies in Argentina: observational study from RelevarEM.

V. Tkachuk1, M. Alonso Serena2, M.E. Balbuena1, P. Lopez3, J. Pettinicchi3, A. Pappolla4, J. Miguez4, L. Patrucco4, E. Cristiano5, C. Vrech6, S. Liwacki7, J. Correale8, M. Marrodan9, M. Gaitán10, M. Fiol9, L. Negrotto9, M. Ysrraelit9, M. Burgos11, F. Leguizamon12, D. Tavolini13, N. Deri14, C. Mainella15, G. Luetic16, P. Blaya17, J. Hryb18, M. Menichini19, A. Alves Pinheiro20, P. Nofal21, G. Zanga22, A. Barboza23, I. Martos24, L. Lazaro25, E. Silva26, S. Bestoso27, M.E. Fracaro28, A. Carra29, O. Garcea30, N. Fernandez Liguori25, A. Caride3, J. Rojas31, E. Carnero Contentti3, 1Hospital de Clínicas José de San Martín/Buenos Aires/AR, 2CEMIC/Buenos Aires/AR, 3Hospital Alemán/Buenos Aires/AR, 4Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 5Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 6Sanatorio Allende/Cordoba/AR, 7Clínica Universitaria Reina Fabiola - Hospital Córdoba, Argentina./Cordoba/AR, 8Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR, 9FLENI/CIUDAD DE BUENOS AIRES/AR, 10FLENI/Buenos Aires/AR, 11Hospital San Bernardo/Salta/AR, 12Hospital de Agudos TEodoro Alvarez/Buenos Aires/AR, 13INECO Neurociencias Oroño/Rosario/AR, 14Centro de Investigaciones DIABAID/Buenos Aires/AR, 15Hospital Español/ROsario/AR, 16Instituto de Neurociencias de Rosario/Rosario./AR, 17Neurocomp/Trelew/AR, 18Hospital Carlos Durand/Buenos Aires/AR, 19Sanatorio Britanico/Rosario/AR, 20Hospital San Martin de Parana/Parana/AR, 21Hospital de Clínicas Nuestra Señora del Carmen/Tucuman/AR, 22Unidad Asistencial Cesar Milstein/capital federal/AR, 23Hospital Central/Mendoza/AR, 24Clinica San Jorge/Ushuaia/AR, 25Sanatorio Guemes/Buenos Aires/AR, 26Predigma/Posadas/AR, 27Hospital Escuela Jose de San Martin/Corrientes/AR, 28Clinica del Castano/San Juan/AR, 29Hospital Britanico/CIUDAD DE BUENOS AIRES/AR, 30Hospital Ramos Mejía/Buenos Aires/AR, 31Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR

P0721 - Infection rates with satralizumab in patients with neuromyelitis optica spectrum disorder (NMOSD): results from the phase 3 SAkura studies

B. Weinshenker1, K. Blondeau2, X. Kou2, C. Marcillat2, K. Weber2, B. Greenberg3, 1Mayo Clinic Department of Neurology/Rochester/US, 2F. Hoffmann-La Roche Ltd/Basel/CH, 3Department of Neurology and Neurotherapeutics/Dallas/US

P0722 - Inter-attack astrocyte damage in NMOSD – does it exist? : Longitudinal analysis of serum GFAP

J.-W. Hyun1, Y. Kim2, S.-Y. Kim2, M.Y. Lee3, S.-H. Kim2, H.J. Kim3, 16) National Cancer Center Korea/Goyang-si/KR, 2Research Institute and Hospital of National Cancer Center/Goyang/KR, 3Research Institute and Hospital, National Cancer Center/Goyang/KR

P0723 - Internuclear Ophthalmoplegia Characterizes Multiple Sclerosis Rather Than Neuromyelitis Optica Spectrum Disease

M. Hamza1, B. Alas2, M. Robers3, L. Amezcua4, K. Gokoffski5, 1/Santa Monica/US, 2Keck School of Medicine of USC/Los Angeles/US, 3Barrow Neurological Institute/Phoenix/US, 4USC/Los Angeles/US, 5University of Southern California/Los Angeles/US

P0724 - Isolated recurrent non longitudinally extensive myelitis in two MOG positive patients

G. Valero López1, E. Carreón Guarnizo2, M.D.L.P. Moreno Arjona2, R. Hernandez Clares2, M. Morales De La Prida3, M. Canovas Iniesta2, F. Iniesta Martinez1, A. Morales Ortiz2, J. Meca-Lallana1, 1Hospital Clínico Universitario Virgen de la Arrixaca/Murcia/ES, 2Hospital Clinico Universitario Virgen de la Arrixaca/Murcia/ES, 3Virgen de la Arrixaca University Hospital/El Palmar, Murcia/ES

P0725 - Life After Tetra Hit: Anti-Nmdar Encephalitis After HSV Encephalitis In a NMOSD Coexistent With Sjogren’s Syndrome Patient

C. Ayvacioglu Cagan, N.P. Acar Ozen, A. Tuncer, Hacettepe University Faculty of Medicine/Ankara/TR

P0726 - Longitudinally extensive transverse myelitis and NMOSD associated with dengue infection: a case report and systematic review of cases

J. Comtois1, C.R. Camara-Lemarroy2, J.K. Mah1, C. Curtis1, S. Kuhn1, M. Braun1, R. Tellier3, J. Burton4, 1University of Calgary/Calgary/CA, 2MS Program, University of Calgary/Calgary/CA, 3McGill University Health Centre/Montreal/CA, 4/Calgary/CA

P0727 - Long-term efficacy and safety of eculizumab in AQP4+ neuromyelitis optica spectrum disorder

D. Wingerchuk1, A. Berthele2, K. Fujihara3, C. Oreja-Guevara4, H.J. Kim5, M. Levy6, I. Nakashima7, J. Palace8, S. Shang9, M. Yountz9, L. Miller9, S. Pittock10, 1Mayo Clinic/Scottsdale/US, 2Klinikum rechts der Isar, Technical University of Munich/Munich/DE, 3Fukushima Medical University/Fukushima/JP, 4Hospital Universitario Clinico San Carlos/Madrid/ES, 5Research Institute and Hospital, National Cancer Center/Goyang/KR, 6Massachusetts General Hospital and Harvard Medical School/Boston/US, 7Tohoku University//JP, 8Oxford University Hospitals/Oxford/GB, 9Alexion Pharmaceuticals/Boston/US, 10Mayo Clinic/Rochester/US

P0728 - Long-term follow-up of rituximab treatment in 10 Spanish patients with neuromyelitis optica spectrum disorder.

J.D.G. Hiraldo1, R. López Ruiz2, J. Dotor García-Soto2, M.D. Páramo Camino2, J.L. Ruiz-Peña2, G. Navarro Mascarell2, S. Eichau Madueño2, 1Hospital universitario Virgen Macarena/Seville/ES, 2Universitary Hospital Virgen Macarena/Seville/ES

P0729 - MOG antibody disease: treatment and disability data from a Canadian cohort

H. Cross1, V. Devonshire2, R. Carruthers3, A.L. Sayao2, A. Schabas4, N. Ackermans5, M. Fritzler6, P. Waters7, A. Traboulsee8, 1University of British Columbia MS Clinic/Vancouver/CA, 2University of British Columbia MS/NMO Center/Vancouver/CA, 3University of British Columbia Hospital/Vancouver/CA, 4University of British Columbia/Vancouver/CA, 5UClouvain/Ottignies-Louvain- la-Neuve/BE, 6University of Calgary/Calgary/CA, 7University of Oxford/Oxford/GB, 8The University of British Columbia/Canada/CA

P0730 - More rapid recovery and improved outcome with early steroid therapy in MOG-IgG associated optic neuritis

J. Chen1, E. Flanagan2, M. Bhatti1, S. Jamali1, A. Kunchok3, E. Eggenberger4, M. Acierno5, A. Arnold6, E. Seleme6, A. Meija-Vergara6, H. Moss7, T. Padungkiatsagul8, H. Stiebel-Kalish9, S. Pittock1, 1Mayo Clinic/Rochester/US, 2Mayo Clinic/United States/US, 3Mayo Clinic Department of Neurology/Rochester/US, 4Mayo Clinic/Jacksonville/US, 5Mayo Clinic/Scottsdale/US, 6University of California Los Angeles/Los Angeles/US, 7Stanford University/Palo Alto/US, 8Ramathibodi Hospital, Mahidol University/Bangkok/TH, 9Tel Aviv University/Tel Aviv/IL

P0731 - Multiple sclerosis and NMOSD testing and treatment availability in Latin America

J. Rojas1, F. Gracia2, L. Patrucco3, E. Cristiano4, 1Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 2Clinica de Esclerosis Multiple, Servicio de Neurologia Hospital Santo Tomas, Panama. Universidad Interamericana de Panama/Panama/PA, 3Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 4Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR

P0732 - Neuromyelitis Optica Spectrum Disorder in the U.S. Active-Duty Military

N. Tagg1, K. Groshans2, D. Horvat2, J. Galli3, S. Clardy3, 1Uniformed Services University of the Health Sciences/Bethesda/US, 2Walter Reed National Military Medical Center/Bethesda/US, 3University of Utah/Salt Lake City/US

P0733 - Neuromyelitis Optica Spectrum Disorder with Interstitial Pneumonia as the First Episode: A Case Report

N. Fakas, A. Akrivaki, G. Papadopoulos, V. Kotzamanis, D. Tzavella, E. Sfikas, S. Triantafyllou, P. Apostolopoulos, 401 General Military Hospital of Athens/Athens/GR

P0735 - Neuromyelitis Optica spectrum disorder, characterization of a population in a specialized center in Colombia

M. Zuluaga Rodas1, C. Orozco Gonzalez1, P. Ortiz-Salas2, J. Camacho-Barbosa1, J. Donado-Gómez1, N. Duque-Zapata1, 1Medicarte S.A.S/MEDELLIN/CO, 2Medicarte S.A.S/Bogotá/CO

P0736 - NMOSD incidence and prevalence estimates in Western Mexico

F. Cortés-Enríquez1, R. Valdivia-Tangarife2, M. Mireles-Ramírez1, N. Sanchez-Rosales1, J. Hernandez- Priego1, M. Macías-Islas2, 1Instituto Mexicano del Seguro Social/Guadalajara/MX, 2Universidad de Guadalajara, CUCS/Guadalajara/MX

P0738 - Onset of neuromyelitis optica spectrum disorder with limbic encephalitis or coexistence of those conditions in a single patient?

Z. Toledo-Nieves, I. Dujmovic-Basuroski, University of North Carolina/Chapel Hill/US

P0739 - Optic chiasm involvement in MS, aquaporin-4 antibody-positive NMOSD, and MOG antibody- associated disease

A. Bianchi1, R. Cortese1, F. Prados2, C. Tur3, B. Kanber2, M. Yiannakas1, F. De Angelis4, L. Magnollay1, A. Jacob5, W. Brownlee6, A. Trip1, R. Nicholas7, Y. Hacohen1, F. Barkhof2, O. Ciccarelli8, A. Toosy9, 1UCL Institute of Neurology/London/GB, 2University College London/LONDON/GB, 3UCL Queen Square Institute of Neurology, Faculty of Brain Sciences/London/GB, 4University College London/BG/GB, 5The Cleveland Clinic/Abu Dhabi/AE, 6National Hospital for Neurology and Neurosurgery/United Kingdom/GB, 7Imperial College London/London/GB, 8UCL Queen Square Institute of Neurology/London/GB, 9Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK. National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Re/London/GB

P0741 - Pain, depression and quality of life in adults with MOG-antibody associated disease

S. Asseyer1, E. Henke2, C. Trebst3, M.W. Hümmert3, B. Wildemann4, S. Jarius5, M. Ringelstein6, O. Aktas7, M. Pawlitzki8, M. Korsen9, L. Klotz10, N. Siebert1, K. Ruprecht1, J. Bellmann-Strobl1, K.-D. Wernecke11, V. Häußler12, J. Havla13, A. Gahlen2, R. Gold14, F. Paul15, I. Kleiter16, I. Ayzenberg2, 1NeuroCure Clinical Research Center, Experimental and Clinical Research Center, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany/Berlin/DE, 2Ruhr University Bochum/Bochum/DE, 3Department of Neurology, Hannover Medical School/Hannover/DE, 4University of Heidelberg/Heidelberg/DE, 5Mollecular Neuroimmunology Group, Department of Neurology, University of Heidelberg/Heidelberg/DE, 6Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf/Düsseldorf/DE, 7Heinrich-Heine-Universität Düsseldorf/Dusseldorf/DE, 81. Department of Neurology with Institute of Translational Neurology, University Hospital Münster; 2. Department of Neurology, Otto-von-Guericke University, Magdeburg/Münster/DE, 9Department of Neurology with Institute of Translational Neurology, University Hospital Münster/Münster/DE, 10University of Muenster/Muenster/DE, 11NeuroCure Clinical Research Center, Experimental and Clinical Research Center, Department of Neurology, Charité - Universitätsmedizin Berlin, CRO Sostana GmbH, Berlin, Germany/Berlin/DE, 12Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg/Hamburg/DE, 13Ludwig-Maximilians Universitaet Muenchen/Munich/DE, 14St. Josef-Hospital, Ruhr University Bochum/Bochum/DE, 15Charite-Universitatmedizin Berlin/Berlin/DE, 16Ruhr-Universität Bochum/Bochum/DE

P0742 - Pain, depression and quality of life in NMOSD: a cross-sectional study of 166 AQP4-antibody seropositive patients in Europe

I. Ayzenberg1, D. Richter1, E. Henke1, S. Asseyer2, F. Paul3, C. Trebst4, M.W. Hümmert5, T. Kümpfel6, J. Havla6, M. Ringelstein7, O. Aktas8, S. Jarius9, B. Wildemann10, V. Häußler11, J.-P. Stellmann12, M. Senel13, L. Klotz14, H. Pellkoffer15, M. Weber16, M. Pawlitzki17, P. Rommer18, A. Berthele19, K. Hellwig20, R. Gold21, I. Kleiter22, 1Ruhr University Bochum/Bochum/DE, 2NeuroCure Clinical Research Center, Experimental and Clinical Research Center, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany/Berlin/DE, 3Charite-Universitatmedizin Berlin/Berlin/DE, 4Department of Neurology, Hannover Medical School/Hannover/DE, 5Medical School Hannover/Hannover/DE, 6Ludwig- Maximilians Universitaet Muenchen/Munich/DE, 7Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf/Düsseldorf/DE, 8Heinrich-Heine-Universität Düsseldorf/Dusseldorf/DE, 9Mollecular Neuroimmunology Group, Department of Neurology, University of Heidelberg/Heidelberg/DE, 10University of Heidelberg/Heidelberg/DE, 11Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg/Hamburg/DE, 121. Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg 2. APHM, Hopital de la Timone, CEMEREM, Marseille 3. Aix Marseille Univ, CNRS, CRMBM, UMR 7339, Marseille/Hamburg/DE, 13University Ulm/Ulm/DE, 14University of Muenster/Muenster/DE, 151. Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet Muenchen/Munich/DE, 16University Medical Center Goettingen/Goettingen/DE, 171. Department of Neurology with Institute of Translational Neurology, University Hospital Münster; 2. Department of Neurology, Otto-von-Guericke University, Magdeburg/Münster/DE, 18Medical University of Vienna/Vienna/AT, 19Klinikum rechts der Isar, Technical University of Munich/Munich/DE, 20University of Bochum/Bochum/DE, 21St. Josef-Hospital, Ruhr University Bochum/Bochum/DE, 22Ruhr-Universität Bochum/Bochum/DE

P0743 - Patients with neuromyelitis optica spectrum disorder who experience relapses take more chronic pain medication

S. Clardy1, R. Kadish1, I. Tanvir2, T. Parker3, J. Biskupiak3, A. Kielhorn2, M. Royston2, 1University of Utah/Salt Lake City/US, 2Alexion Pharmaceuticals/Boston/US, 3Pharmacotherapy Outcomes Research Center, University of Utah/Salt Lake City/US

P0744 - Posterior Reversible Encephalopathy Syndrome Complicating Plasmapheresis In Neuromyelitis Optica

G. Perez1, N. Anadani2, 1Oklahoma University Health Sciences Center/Oklahoma City/US, 2Oklahoma University Health Sciences Center/Oklahoma city/US

P0745 - Predictors of Diagnosis With A First Presenting Symptom Of Optic Neuritis

M.O. Subei, A. Serra, M. Morgan, H. Abboud, University Hospitals Cleveland Medical Center/Cleveland/US

P0746 - Purinergic inhibitors protect astrocytes from aquaporin-4 antibody-mediated complement- dependent death

S. Kalluri1, R. Srivastava2, S. Kenet3, G. Tanti2, J. Bennett4, K. Dornmair5, T. Misgeld3, B. Hemmer6, M. Herwerth2, 1Klinikum rechts der Isar/München/DE, 2Klinikum rechts der Isar, Technische Universität München/München/DE, 3Technical University Munich/München/DE, 4University of Colorado School of Medicine/Denver/US, 5Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich/Planegg-Martinsried/DE, 6University of Munich/Munich/DE

P0747 - Rapid improvement in neurologic symptoms of neuromyelitis optica spectrum disorder with eculizumab monotherapy: Case report

P. Pagnotta, D. Honeycutt, Neurology Associates PA/Maitland/US

P0748 - Relapse-associated visual impairment and disability in patients with neuromyelitis optica spectrum disorder

R. Kadish1, S. Clardy1, M. Royston2, I. Tanvir2, T. Parker3, J. Biskupiak3, A. Kielhorn2, 1University of Utah/Salt Lake City/US, 2Alexion Pharmaceuticals/Boston/US, 3Pharmacotherapy Outcomes Research Center, University of Utah/Salt Lake City/US

P0749 - Relapses and associated healthcare resource utilization among patients with neuromyelitis optica spectrum disorder in US clinical practice M. Royston1, A. Kielhorn1, D. Weycker2, M. Shaff2, L. Houde2, I. Tanvir1, M. Levy3, 1Alexion Pharmaceuticals/Boston/US, 2Policy Analysis Inc. (PAI)/Brookline/US, 3Massachusetts General Hospital and Harvard Medical School/Boston/US

P0750 - Relation between helicobacter pylori infection and double seronegative neuromyelitis optica spectrum disorder

M. Barzegar1, H. Nouri2, G. Bjørklund3, O. Mirmosayyeb1, H. Motedayyen2, V. Shaygannejad1, 1Isfahan neuroscience research center/Isfahan/IR, 2Isfahan neuroscience research center, Isfahan University of medical sceince, Isfahan, Iran/Isfahan/IR, 3ouncil for Nutritional and Environmental Medicine (CONEM), Toften 24, 8610, Mo i Rana, Norway/Mo i Rana/NO

P0751 - Risk factors related to relapse after first immunosuppressive treatment in patients with neuromyelitis optica spectrum disorders.

F. Morales-Ramírez1, I. Treviño-Frenk2, G. Barriga-Maldonado2, 1/Ciudad de México/MX, 2Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"/Ciudad de México/MX

P0752 - Safety of eculizumab in NMOSD and MG – analysis of the phase 3 studies PREVENT and REGAIN and their extensions

R. Mantegazza1, T. Levine2, C. Oreja-Guevara3, C. Carrillo-Infante4, E. Laudon-Meyer4, S. Shang4, S. Pittock5, J. Howard6, 1Fondazione IRCCS, Istituto Neurologico Carlo Besta/Milan/IT, 2Phoenix Neurological Associates/Phoenix/US, 3Hospital Universitario Clinico San Carlos/Madrid/ES, 4Alexion Pharmaceuticals/Boston/US, 5Mayo Clinic/Rochester/US, 6University of North Carolina/Chapel Hill/US

P0753 - Safety of satralizumab based on pooled data from phase 3 studies in patients with neuromyelitis optica spectrum disorder

B. Greenberg1, J. De Seze2, E. Fox3, A. Saiz4, T. Yamamura5, M. Yeaman6, C. Marcillat7, X. Kou7, K. Weber7, K. Blondeau7, B. Weinshenker8, 1Department of Neurology and Neurotherapeutics/Dallas/US, 2University Hospital of Strasbourg/Strasbourg/FR, 3Central Texas Neurology Consultants/Central Texas Neurology Consultants, Multiple Sclerosis Clinic of Central Texas, The University of Texas at Austin, Round Rock, Austin/US, 4Hospital Clínic i Provincial de Barcelona/Barcelona/ES, 5National Institute of Neuroscience, National Center of Neurology and Psychiatry/Tokyo/JP, 6David Geffen School of Medicine at UCLA/Los Angeles/US, 7F. Hoffmann-La Roche Ltd/Basel/CH, 8Mayo Clinic/Rochester/US

P0754 - Satralizumab in first incident treatment-naïve AQP4-IgG seropositive NMOSD patients enrolled to SAkuraStar: a case series

J. Palace1, J. Bennett2, D. Stokmaier3, H.C. Von Büdingen3, G. Klingelschmitt3, A. Traboulsee4, 1Oxford University Hospitals/Oxford/GB, 2University of Colorado School of Medicine/Denver/US, 3F. Hoffmann- La Roche Ltd/Basel/CH, 4The University of British Columbia/Canada/CA

P0755 - Study of Sleep Abnormalities in patients with Neuromyelitis Optica Spectrum Disorder – AQP-4, Seronegative NMOSD and MOG associated disorders

A. Oommen, R. Yadav, N. M, National Institute of Mental Health and Neurosciences (NIMHANS)/Bangalore/IN

P0756 - Subcortical structures shape analysis of fatigue in neuromyelitis optica spectrum disorder

J.M. Seok1, D.-H. Son2, J.H. Shin3, E.B. Cho4, B.J. Kim3, J.-K. Seong2, J.-H. Min3, 1Soonchunhyang University Hospital Cheonan/Cheonan/KR, 2Korea University/Seoul/KR, 3Samsung Medical Center, Sungkyunkwan University School of Medicine/Seoul/KR, 4Gyeongsang National University Changwon Hospital/Changwon/KR

P0757 - The neutrophil-to-lymphocyte ratio in aquaporin-4-positive NMOSD patients: A Latin American multicenter study

E. Carnero Contentti1, J. Criniti1, P. Lopez1, J. Pettinicchi1, E. Cristiano2, J. Miguez3, E.P. Correa- Diaz4, M.O. Alvarez Pucha5, J. Miño Zambrano6, E. Gomez Figueroa7, G. Garcia-Delgado7, V. Rivas- Alonso7, J. Flores-Rivera7, V. Tkachuk8, A. Caride1, J. Rojas9, 1Hospital Alemán/Buenos Aires/AR, 2Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 3Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 4Universidad Central del Ecuador/Quito/EC, 5Unversidad Catolica del Ecuador/Quito/EC, 6Hospital Carlos Andrade Marín/Quito/EC, 7National Institute of Neurology and Neurosurgery/Mexico City/MX, 8Hospital de Clínicas José de San Martín/Buenos Aires/AR, 9Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR

P0758 - The role of peripheral autoreactive antibodies in initiation and propagation of central nervous system demyelinating disorders

M. Freier1, S. Häusser-Kinzel2, M. Weber3, 1University-Medical-Center- Goettingen/Goettingen/DE, 2University medical center Göttingen/Göttingen/DE, 3University Medical Center Goettingen/Goettingen/DE

P0759 - Treatment patterns in patients with neuromyelitis optica spectrum disorder

J. Mouchet1, T. Spelman2, C. Costantino3, T. Kalincik4, P. Nytrova5, V. Shaygannejad6, F. Patti7, R. Alroughani8, M. Terzi9, S. Ozakbas10, R. Turkoglu11, J. Avasarala12, P. Mccombe13, M. Simo14, F. Granella15, J. Yung Hor16, H. Butzkueven17, 1F. Hoffmann-La Roche Ltd/Basel/CH, 2Burnet Institute/Melbourne/AU, 3Roche Product Development Medical Affairs (PDMA) Genentech/South San Francisco/US, 4University of Melbourne/Melbourne/AU, 5Charles univeristy, Univerzita Karlova/Prague/CZ, 6Isfahan University of Medical Sciences/Isfahan/IR, 7University of Catania/Catania/IT, 8Al Seef Hospital/Salmiya/KW, 9Ondokuz Mayıs University/Sasun/TR, 10Dokuz Eylul University/Konak/TR, 11Haydarpasa Numune Training and Research Hospital/Istanbul/TR, 12University of Kentucky Medical Center/Lexington/US, 13Royal Brisbane and Women's Hospital/Brisbane/AU, 14Semmelweis University Budapest/Budapest/HU, 15University of Parma/Parma/IT, 16Penang General Hospital/Penang/MY, 17Monash University/Melbourne/AU

P0760 - Tumefactive demyelination following rituximab in an anti-MOG positive NMOSD patient: evidence of T-cell and NK-cell involvement

M. Breza1, J. Tzartos1, N. Paschalidis2, D. Tzanetakos1, M.E. Evangelopoulos1, G. Koutsis1, K. Karagiorgou3, A. Vakrakou1, E. Strataki1, G. Velonakis4, V. Panoutsakopoulou2, M. Anagnostouli5, L. Stefanis1, C. Kilidireas1, 1Eginition Hospital, National and Kapodistrian University of Athens/Athens/GR, 2Cellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens/Athens/GR, 3Tzartos Neurodiagnostics/Athens/GR, 4Research Unit of Radiology, 2nd Department of Radiology, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece/Athens/GR, 5Aeginition Hospital, Medical School, National and Kapodistrian University of Athens/Athens/GR

P0761 - What is seronegative neuromyelitis optica spectrum disorder?

E. Gibbons1, G. Campagna1, K. O'Connell2, T. Yeo2, D. Whittam1, M. Leite2, J. Palace3, A. Jacob1, S. Huda1, 1The Walton Centre for Neurology and Neurosurgery/Liverpool/GB, 2John Radcliffe Hospital/Oxford/GB, 3Oxford University Hospitals/Oxford/GB

P0762 - What percentage of AQP4-Ab-negative NMOSD patients are MOG-Ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)

E. Carnero Contentti1, P. Lopez1, J. Pettinicchi1, A. Pappolla2, J. Miguez3, L. Patrucco2, E. Cristiano4, C. Vrech5, V. Tkachuk6, S. Liwacki7, J. Correale8, M. Marrodan9, M. Gaitán10, M. Fiol9, L. Negrotto9, M. Ysrraelit9, M. Burgos11, F. Leguizamon12, D. Tavolini13, N. Deri14, M.E. Balbuena6, C. Mainella15, G. Luetic16, P. Blaya17, J. Hryb18, M. Menichini19, A. Alves Pinheiro20, P. Nofal21, G. Zanga22, A. Barboza23, I. Martos24, L. Lazaro25, E. Silva26, S. Bestoso27, M.E. Fracaro28, A. Carra29, O. Garcea30, N. Fernandez Liguori25, M. Alonso Serena31, A. Caride1, J. Rojas32, 1Hospital Alemán/Buenos Aires/AR, 2Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 3Hospital Italiano de Buenos Aires/Buenos Aires/AR, 4Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 5Sanatorio Allende/Cordoba/AR, 6Hospital de Clínicas José de San Martín/Buenos Aires/AR, 7Clinica Universitaria Reina SOfía/Córdoba/AR, 8Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR, 9FLENI/CIUDAD DE BUENOS AIRES/AR, 10FLENI/Buenos Aires/AR, 11Hospital San Bernardo/Salta/AR, 12Hospital de Agudos TEodoro Alvarez/Buenos Aires/AR, 13INECO Neurociencias Oroño/Rosario/AR, 14Centro de Investigaciones DIABAID/Buenos Aires/AR, 15Hospital Español/ROsario/AR, 16Instituto de Neurociencias de Rosario/Rosario./AR, 17Neurocomp/Trelew/AR, 18Hospital Carlos Durand/Buenos Aires/AR, 19Sanatorio Britanico/Rosario/AR, 20Hospital San Martin de Parana/Parana/AR, 21Hospital de Clínicas Nuestra Señora del Carmen/Tucuman/AR, 22Hospital Cesar Milstein/Buenos Aires/AR, 23Hospital Central/Mendoza/AR, 24Clinica San Jorge/Ushuaia/AR, 25Sanatorio Guemes/Buenos Aires/AR, 26Predigma/Posadas/AR, 27Hospital Escuela Jose de San Martin/Corrientes/AR, 28Clinica del Castano/San Juan/AR, 29Hospital Britanico/CIUDAD DE BUENOS AIRES/AR, 30Hospital Ramos Mejía/Buenos Aires/AR, 31CEMIC/Buenos Aires/AR, 32Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR

P0763 - A longitudinal study validating the optical coherence tomography inter-eye difference as a robust diagnostic test in multiple sclerosis

J. Nij Bijvank1, B. Uitdehaag2, A. Petzold3, 1Amsterdam UMC/Amsterdam/NL, 2Amsterdam UMC, Location VUmc/Amsterdam/NL, 3UCL Institute of Neurology/United Kingdom/GB

P0764 - A prognostically relevant functional-structural relationship in acute optic neuritis

I. Kleerekooper1, S. Leo2, I. Davagnanam3, L. Del Porto2, J.M. Guajardo2, L. Dell'Arti4, A. Robson2, S.A. Trip3, G. Holder2, G. Plant5, A. Petzold5, 1/London/GB, 2Moorfields Eye Hospital/London/GB, 3National Hospital for Neurology and Neurosurgery/London/NL, 4Universita Degli Studi di Milano/Milan/IT, 5UCL Institute of Neurology/United Kingdom/GB

P0765 - CRION versus Atypical MOG in a 61 Year-Old Woman

J. Burton1, F. Costello2, 1/Calgary/CA, 2University of Calgary/Calgary/CA

P0766 - Demographics of multiple sclerosis associated uveitis at Moorfields Eye Hospital

T. Taylor1, J. Luis2, R. Dobson3, H. Petrushkin2, 1/London/GB, 2Moorfields Eye Hospital/London/GB, 3Queen Mary University of London/London/GB

P0767 - Increase Sensitivity in Detecting Neurodegeneration in Multiple Sclerosis: a Voxel-Based Morphometry Study with Optical Coherence Tomography

S.-C. Huang1, M. Pisa2, S. Guerrieri1, G. Dalla Costa3, F. Esposito4, L. Leocani2, 1San Raffaele Hospital - Vita-Salute San Raffaele University/Milan/IT, 2Vita-Salute San Raffaele University/Milan/IT, 3San Raffaele Hospital/Milan/IT, 4IRCCS San Raffaele Scientific Institute/Milan/IT

P0768 - Optical Coherence Tomography and unconventional neuro-ophthalmological evaluation of patients with Multiple Sclerosis

L. Cohen1, M.B. Eizaguirre1, R. Alonso1, C. Pita1, D. Gonzalez Moron1, O. Garcea1, B. Silva2, 1Hospital Ramos Mejía/Buenos Aires/AR, 2Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR

P0769 - Saccadic eye movements reflect functional connectivity of the oculomotor brain network in MS patients

J. Nij Bijvank1, E. Strijbis1, I. Nauta1, S. Kulik2, L. Balk1, C. Stam2, A. Hillebrand2, J. Geurts3, B. Uitdehaag2, L. Van Rijn1, A. Petzold4, M. Schoonheim3, 1Amsterdam UMC/Amsterdam/NL, 2Amsterdam UMC, Location VUmc/Amsterdam/NL, 3Amsterdam UMC, location VUmc/Amsterdam/NL, 4UCL Institute of Neurology/United Kingdom/GB

P0770 - Serum neurofilaments predict recovery after acute optic neuritis G. Dalla Costa1, M. Pisa2, L. Fabbella3, R. Furlan4, G. Comi5, L. Leocani2, 1San Raffaele Hospital/Milan/IT, 2Vita-Salute San Raffaele University/Milan/IT, 3Clinical Neuroimmunology Unit, Institute of Experimental Neurology (INSPE), Division of Neuroscience, San Raffaele Scientific Institute/Milan/IT, 4San Raffaele Sicentific Institute/Milan/IT, 5San Raffaele Scientific Institute, Vita- Salute San Raffaele University/Milan/IT

P0771 - Susac syndrome – a differential diagnosis of demyelinating process

A. Jamroz-Wiśniewska1, K. Sapko1, A. Woźniak1, M. Marciniec1, M. Kulczyński1, R. Rejdak2, K. Rejdak2, 1Lublin Medical University/Lublin/PL, 2Medical University of Lublin/Lublin/PL

P0772 - The optic nerve as a 5th location for dissemination in space for multiple sclerosis criteria: a role for optical coherence tomography

A. Petzold1, S. Chua2, A. Khawaja2, P. Keane2, S.P. Khaw2, C. Reisman3, B. Dhillon4, N. Strouthidis5, P. Foster2, P. Patel5, 1UCL Institute of Neurology/United Kingdom/GB, 2Institute of Ophthalmology/London/GB, 3Topcon Healthcare Solutions/oakland/US, 4Centre for Clinical Brain Sciences/Edinburgh/GB, 5Moorfields Eye Hospital/London/GB

P0773 - Variation of RNFL thickness in MS patients and DMTs: a longitudinal study.

J. Frau1, G. Coghe1, B. Pintus1, M. Fronza1, L. Lorefice1, G. Fenu1, E. Cocco2, 1Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/Cagliari/IT, 2University of Cagliari/Cagliari/IT

P0774 - Bryostatin-1 modulates CNS innate immunity and augments remyelination

E. Abramson1, P. Gharibani1, J. Hu2, M. Smith1, S. Hwang1, P. Calabresi1, J. Huang3, P. Kim1, M. Kornberg1, 1Johns Hopkins University/Baltimore/US, 2Georgetown University/Washington, DC/US, 3Georgetown University/Washington/US

P0775 - Development of a screening platform that uses genome engineered hPSC-Derived OPCs for the discovery of remyelination promoting compounds

X. Chamling1, C. Berlinicke1, F. Takaesu1, Y. Duan1, X. Chang1, P. Calabresi2, D. Zack1, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Johns Hopkins University/Baltimore/US

P0776 - Dual threats of CSPGs in multiple sclerosis through inhibiting oligodendrocyte repair and polarizing Th17 cells

S. Ghorbani1, P. Zhang2, D. Kaushik3, B. Buehner4, C. Li2, C. Ling5, V. Yong6, 1Univercity of calgary/Calgary/CA, 2Univercity of Calgary/Calgary/CA, 3/Calgary/CA, 4University of Calgary/calgary/CA, 5bAlberta Glycomics Centre, Department of Chemistry, University of Calgary/TN N/CA, 6University of Calgary/Calgary/CA

P0777 - High-content drug screening in human iPSC-derived oligodendrocytes identifies novel pathways to promote oligodendrocyte differentiation

L. Telford-Cooke1, D. Magnani1, R. Holloway1, J. Longden2, J. Dawson1, K. Burr1, D. Story1, V. Miron3, S. Chandran1, N. Carragher1, 1The University of Edinburgh/Edinburgh/GB, 2PhenoTherapeutics/Edinburgh/GB, 3University of Edinburgh/Edinburgh/GB

P0778 - IL-10 promotes myelin repair in an ex vivo model of remyelination and microRNA signatures of ex vivo remyelination

C. Duffy1, C. Mccoy1, M. Muñoz San Martín2, 1Royal College of Surgeons in Ireland/Dublin 2/IE, 2Institut d'Investigació Biomèdica de Girona/Girona/ES

P0779 - Lipid handling by macrophages and microglia is impaired in the aging CNS after demyelination

M. Mishra1, D. Cisterna1, N. Michaels1, V. Yong2, 1Hotchkiss brain institute/Calgary/CA, 2University of Calgary/Calgary/CA

P0781 - Myeloid-Derived Suppressor Cells associated to a mild disease course are good bioindicators of a higher remyelinating capability in Multiple Sclerosis

C. Camacho-Toledano, R. Lebrón-Galán, I. Machín-Díaz, J. García-Arocha, M.C. Ortega, D. Clemente, National Hospital for Paraplegics/Toledo/ES

P0782 - Myeloid-derived suppressor cells in progressive multiple sclerosis: important factors for clinical course severity

M.C. Ortega, J. García-Arocha, V. Quintanero-Casero, R. Lebrón-Galán, I. Machín-Díaz, C. Camacho- Toledano, D. Clemente, National Hospital for Paraplegics/Toledo/ES

P0783 - Neuromodulation through anodal tDCS promotes recovery of demyelination-induced motor impairments in cuprizone demyelination/remyelination mouse model

R. D'Isa1, S. Marenna1, V. Castoldi1, G. Comi2, L. Leocani3, 1San Raffaele Scientific Institute/Milan/IT, 2San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 3Vita- Salute San Raffaele University/Milan/IT

P0784 - RENEWED:Long-term mfVEP latency outcomes in Participants Previously Enrolled in the Opicinumab Phase 2 Study RENEW.

A. Klistorner1, M. Naylor2, B. Zhu2, 1Macquarie University/Sydney/AU, 2Biogen/Boston/US

P0785 - Super-low combination therapy as a pathway to treatment against disease progression. R. Fern1, V. Mitchener1, C. Matute2, 1University of Plymouth/Plymouth/GB, 2EHU/Bilboa/ES

P0786 - Anti-NMDA receptor encephalitis presenting as focal temporal lobe seizures with mixed transcortical aphasia.

A. Varma-Doyle1, R. Evans2, M. Lewis2, C. Clines2, E. Mckinnies2, E. Mader2, L. Branch2, 11542 Tulane Ave/New Orleans/US, 2LSUHSC/New Orleans/US

P0787 - Associations between cognitive and clinical disability across MS subtypes: the role of the underlying brain damage

L. Gois1, A. Damasceno2, B. Damasceno1, L. Pimentel-Silva2, 1University of Campinas (UNICAMP)/Campinas/BR, 2Universidade Estadual de Campinas/Campinas/BR

P0788 - Atrophy of the posterior cerebellar lobules is related to episodic memory difficulties in patients with multiple sclerosis: a 3T MRI study.

E. Mancuso1, G. Boffa2, C. Lapucci2, M. Moro2, E. Colombo2, F. Tazza2, M. Cellerino3, N. Bruschi2, E. Sbragia2, R. Meli2, M. Inglese2, 1Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI)/Genova/IT, 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 3University of Genoa/Genoa/IT

P0789 - Benchmarks of meaningful improvement on neurocognitive tests

C. Wojcik1, M. Dwyer2, M. Jaworski3, M. Youngs3, M. Unverdi3, B. Weinstock-Guttman4, R. Benedict5, 1University at Buffalo/Buffalo/US, 2Buffalo Neuroimaging Analysis Center/Buffalo/US, 3University at Buffalo, Jacobs School of Medicine/Buffalo/US, 4State University of New York at Buffalo/Buffalo/US, 5University At Buffalo/Buffalo/US

P0790 - Brain Reserve and Cognitive Reserve on Social Cognition in Multiple Sclerosis: What roles?

R. Machado1, C. Lima2, O.C. D´almeida3, A. Afonso4, C. Macário1, M. Castelo-Branco3, L. Sousa1, I. Santana1, S. Batista1, 1Coimbra Hospital and University Centre (CHUC)/Coimbra/PT, 2Centro Hospitalar e Universitario de Coimbra/Coimbra/PT, 3Visual Neuroscience Laboratory, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra/Coimbra/PT, 4Faculty of Medicine, University of Coimbra/Coimbra/PT

P0791 - Cerebellar dysfunction correlates with cognitive impairment in relapsing-remitting multiple sclerosis: A cross-sectional study

M. Salavisa1, A.F. Graça2, F. Serrazina1, J. Graça1, A.S. Correia1, 1Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental/Lisboa/PT, 2Instituto Superior de Engenharia de Lisboa/Lisboa/PT

P0792 - Cerebrospinal fluid amyloid-β as potential biomarker for cognitive functioning in multiple sclerosis.

M. Van Dam1, E. Willemse2, I. Nauta3, M. Huiskamp4, M. Klein1, B. Moraal5, J. Geurts1, B. Uitdehaag5, C. Teunissen3, B. De Jong6, H. Hulst7, 1Amsterdam UMC, location VUmc/Amsterdam/NL, 2Amsterdam Neuroscience, Neurochemistry Laboratory and Biobank, Amsterdam University medical centers, Vrije Universiteit/Amsterdam/NL, 3Amsterdam UMC/Amsterdam/NL, 4Amsterdam UMC, location VUmc/No/NL, 5Amsterdam UMC, Location VUmc/Amsterdam/NL, 6Amsterdam University Medical Centers/Amsterdam/NL, 7MS Center Amsterdam/Amsterdam/NL

P0793 - Clinical course impacts on the association between general cognition and mentalizing deficits in MS

M. Pardini1, E. Colombo2, R. Meli1, C. Lapucci2, N. Bruschi3, G. Boffa2, M. Cellerino4, E. Sbragia2, A. Uccelli5, M. Inglese6, 1University of Genoa & Policlinico S. Martino/Genova/IT, 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 3/Genoa/IT, 4University of Genoa/Genoa/IT, 5University of Genoa/Italy/IT, 6University of Genoa//IT

P0794 - Clinical utility of the Processing Speed Test in patients with multiple sclerosis

Y. Miyazaki1, M. Niino2, E. Takahashi2, R. Naganuma2, I. Amino2, F. Nakano2, S. Akimoto2, N. Minami2, S. Kikuchi2, 1Hokkaido Medical Center/Sapporo/JP, 2National Hospital Organization Hokkaido Medical Center/Sapporo/JP

P0795 - Cognitive and psychological predictors of self-management behaviors in persons with multiple sclerosis

E. Gromisch1, L. Neto1, A. Turner2, 1Mount Sinai Rehabilitation Hospital, Trinity Health Of New England/Hartford/US, 2VA Puget Sound Health Care System/Seattle/US

P0796 - Cognitive differences in aging patients with multiple sclerosis compared to healthy controls

Y. Higueras1, M.L. Martínez-Ginés2, V. Meca-Lallana3, A. Meldaña-Rivera1, J.M. García-Domínguez2, J.P. Cuello2, A. Lozano-Ros2, H. Goicochea Briceño2, R.G. González-Cuenca4, C. Aguirre3, J. González- Marqués4, J. Vivancos3, F. García-Vaz4, 1IISGM/Madrid/ES, 2Hospital General Universitario Gregorio Marañón/Madrid/ES, 3La Princesa Hospital/Madrid/ES, 4Universidad Complutense/Madrid/ES

P0797 - Cognitive Event-Related Potentials in Multiple Sclerosis.

A. Artemiadis1, C. Bakirtzis2, G. Nikolaou3, G. Hadjigeorgiou1, M. Anagnostouli4, 1Medical School, University of Cyprus/Nicosia/CY, 2Medical School, Aristotle University of Thessaloniki/Thessaloniki/GR, 3Army Share Fund Hospital/Athens/GR, 4Aeginition Hospital, Medical School, National and Kapodistrian University of Athens/Athens/GR

P0799 - Cognitive impairment in pediatric multiple sclerosis: the age of onset as a probable predictive variable.

M. Bogdanova1, Y. Mikadze2, T. Batysheva3, R. Bembeeva4, E. Volkova5, 1First Moscow State Medical University (Sechenov University)/Moscow/RU, 2M.V. Lomonosov Moscow State University/Moscow/RU, 3Research and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health/Moscow/RU, 4N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia/Moscow/RU, 5Russian Children's Clinical Hospital/Moscow/RU

P0800 - Cognitive-Motor Interference and Cortical Activation during Walking and Turning in Individuals with Multiple Sclerosis

M. Vannostrand, B. Belanger, S. Kasser, M. Cannizzaro, University of Vermont/Burlington/US

P0801 - Default Mode Network functioning and Multiple Sclerosis: the importance of phenotypes and cognition

J.M. García-Domínguez1, Y. Higueras2, J. Alvarez Linera3, A. Meldaña-Rivera1, J.P. Cuello1, G. Garcia Marti4, A. Lozano-Ros1, H. Goicochea Briceño1, M.L. Martínez-Ginés1, 1Hospital General Universitario Gregorio Marañón/Madrid/ES, 2IISGM/Madrid/ES, 3Hospital Ruber Internacional/Madrid/ES, 4Grupo Hospitalario Quirón Salud/Valencia/ES

P0802 - Differences in Regional Cortical Thickness and Subcortical Volumes Among Cognitively Impaired and Unimpaired Multiple Sclerosis Patients

C. Tyshkov1, M. Marcille2, A. Jaywant2, U.W. Kaunzner2, J. Perumal2, N. Nealon2, T. Vartanian2, N. Zinger2, L. Zexter2, S. Hurtado Rua3, S. Gauthier4, 1Weill Cornell Medical Center/10065/US, 2Weill Cornell Medicine/New York City/US, 3Cleveland State University/Cleveland/US, 4Weill Cornell Medicine/New York/US

P0803 - Discriminating Spatialised Speech in Complex Environments in Multiple Sclerosis

P. Iva1, R. Martin1, J. Fielding1, M. Clough1, O. White1, G. Noffs2, B. Godic1, A. Van Der Walt1, R. Rajan1, 1Monash University/Melbourne/AU, 2University of Melbourne/Parkville/AU

P0804 - Dual task during walking in patients with Multiple Sclerosis: cognitive or motor interference?

M.B. Eizaguirre1, N. Ciufia2, A. Marinangeli3, M. Román2, C. Diven Arguello3, L. Cohen1, B. Silva4, R. Alonso1, S. Vanotti2, O. Garcea1, 1Hospital Ramos Mejía/Buenos Aires/AR, 2Buenos Aires University. Faculty of Psychology. Research Institute in Psychology./Buenos Aires/AR, 3Ramos Mejía Hospital/Buenos Aires/AR, 4Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR

P0805 - Dynamics of cognitive decline along the disease course in multiple sclerosis E. Lopez-Soley1, E. Solana1, M. Andorra1, E. Martinez-Heras1, C. Montejo1, I. Pulido-Valdeolivas1, M. Sepulveda1, Y. Blanco1, S. Alba-Arbalat1, E. Martinez-Lapiscina2, P. Villoslada1, A. Saiz3, S. Llufriu4, 1Hospital Clinic Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona/Barcelona/ES, 2/Barcelona/ES, 3Hospital Clínic i Provincial de Barcelona/Barcelona/ES, 4Hospital Clínic de Barcelona e Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)/Barcelona/ES

P0806 - Effect of siponimod on cognitive processing speed in SPMS patients with active and non- active disease

I.-K. Penner1, G. Giovannoni2, B.A.C. Cree3, R. Fox4, A. Bar-Or5, R. Gold6, P. Vermersch7, T. Hach8, K. Goeril8, S. Ritter9, N. Rouyrre8, D. Piani-Meier8, R. Benedict10, 1Cogito Center for Applied Neurocognition and Neuropsychological Research/Düsseldorf/DE, 2The London School of Medicine and Dentistry/London/GB, 3UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco/San Francisco/US, 4Cleveland Clinic//US, 5University of Pennsylvania/Philadelphia/US, 6St. Josef-Hospital, Ruhr University Bochum/Bochum/DE, 7CHU de Lille/Lille/FR, 8Novartis Pharma AG/Basel/CH, 9Novartis Pharmaceuticals Corporation/East Hanover/US, 10University At Buffalo/Buffalo/US

P0807 - Evaluating cognitive functioning in Multiple Sclerosis, compared to other neurological disorders, using an online cognitive battery

C. Di Bella1, W. Trender2, P. Hellyer2, S. Knowles3, J. Hill3, S. Sandrone2, R. Nicholas4, A. Hampshire2, 1Imperial college London /London/GB, 2Imperial college London/London/GB, 3Imperial college healthcare NHS trust/London/GB, 4Imperial College London/London/GB

P0809 - Extended Interval Dosing Natalizumab and cognitive function in Relapsing-Remitting Multiple Sclerosis patients: A retrospective audit

E. Mc Manus, K. Clark, J. Macniven, J. Schepel, Waikato General Hospital/Hamilton/NZ

P0810 - Great Expectations in Multiple Sclerosis (GEMS): Does effortful reading improve cognitive performance in multiple sclerosis?

K. French, E. Duffy, SCL Health/Billings/US

P0811 - Higher hippocampal functional connectivity in preclinical and initial stages of multiple sclerosis

J. Salavedra-Pont1, O. Contreras-Rodriguez2, C. Biarnés-Duran3, E. Quintana4, C. Coll-Martinez5, B. Moreno5, M. Buxó6, R. Robles Cedeño4, L. Ramió-Torrentà7, J. Gich4, 1Dr. Josep Trueta University Hospital and Santa Caterina Hospital/Girona/ES, 2Department of Psychiatry, Bellvitge University Hospital-IDIBELL, and CIBERSAM, Barcelona-Spain/Barcelona/ES, 3Department of Radiology, Girona Biomedical Research Institute (IDIBGI). Salt-Spain/Salt/ES, 4Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 5Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Girona/Salt-Spain. Neurodegeneration and Neuroinflammation Group, Girona Biomedical Research Institute (IDIBGI), Sa/Girona/ES, 6Girona Biomedical Research Institute (IDIBGI), Salt-Spain/Salt/ES, 7Dr. Josep Trueta University Hospital/Girona/ES

P0812 - Hippocampal resting-state functional connectivity in Multiple Sclerosis subtypes

J. Salavedra-Pont1, O. Contreras-Rodriguez2, C. Biarnés-Duran3, E. Quintana4, C. Coll-Martinez5, B. Moreno5, R. Robles Cedeño4, L. Ramió-Torrentà6, J. Gich4, 1Dr. Josep Trueta University Hospital and Santa Caterina Hospital/Girona/ES, 2Department of Psychiatry, Bellvitge University Hospital-IDIBELL, and CIBERSAM, Barcelona-Spain/Barcelona/ES, 3Department of Radiology, Girona Biomedical Research Institute (IDIBGI). Salt-Spain/Salt/ES, 4Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 5Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Girona/Salt-Spain. Neurodegeneration and Neuroinflammation Group, Girona Biomedical Research Institute (IDIBGI), Sa/Girona/ES, 6Dr. Josep Trueta University Hospital/Girona/ES

P0813 - Impact of multiple sclerosis on cognitive aging: a multicenter study

D. Mistri1, A. Meani1, G. Tedeschi2, P. Pantano3, P. Zaratin4, N. De Stefano5, P. Preziosa1, M.A. Rocca1, M. Filippi1, 1IRCCS San Raffaele Scientific Institute/Milan/IT, 2University of Campania “Luigi Vanvitelli”/Naples/IT, 3Università La Sapienza/Roma/IT, 4Fondazione Italiana Sclerosi Multipla/Genoa/IT, 5University of Siena//IT

P0814 - Is Trait anxiety a predictor of dysexecutive complaints in multiple sclerosis?

F. Garcia-Vaz1, V. Meca-Lallana2, C. Aguirre2, B. Del Río2, M. Mayoral3, P. Martin-Rojas3, J. Gonzalez Marques3, J. Vivancos2, 1/Madrid/ES, 2La Princesa Hospital/Madrid/ES, 3Universidad Complutense de Madrid/Madrid/ES

P0816 - Neurocognition, anxiety, depression and its relation with quality of life in patients with relapsing remitting multiple sclerosis

V. Yadav1, S. Hegde2, N. M2, 1National institute of mental health and neurosciences (NIMHANS)/Bangalore/IN, 2National Institute of Mental Health and Neurosciences (NIMHANS)/Bangalore/IN

P0817 - Neurocognitive performance in multiple sclerosis patients correlates with hippocampal metabolite abnormalities - 1H MRS study

E. Kantorová1, P. Hnilicová2, E. Kurča2, W. Bogner3, 1Jessenius Faculty of Medicine in Martin/Martin/SK, 2Jessenius Faculty of Medicine in Martin, Comenius University Bratislava/Martin/SK, 3Medical University of Vienna/Vienna/AT

P0819 - Perceived Social Support in Multiple Sclerosis: Impact on patient’s quality of life. M.B. Eizaguirre1, C. Yastremiz2, A. Merino2, D. Rodrigo2, D. Taboada2, C. Pita1, B. Silva3, R. Alonso1, S. Vanotti4, O. Garcea1, 1Hospital Ramos Mejía/Buenos Aires/AR, 2Ramos Mejía Hospital/Buenos Aires/AR, 3Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR, 4Buenos Aires University. Faculty of Psychology. Research Institute in Psychology./Buenos Aires/AR

P0820 - Phase II trial of cognitive rehabilitation in patients with multiple sclerosis: preliminary results

E. Lopez-Soley1, E. Solana1, E. Martinez-Heras1, E. Munteis2, C. Ramo3, S. Presas-Rodríguez3, M. Hervas4, L. Romero-Pinel5, R. Pelayo6, R. Sanchez-Carrion7, M. Bernabeu6, C. Montejo1, M. Sepulveda1, N. Sola-Valls1, Y. Blanco1, I. Pulido-Valdeolivas1, M. Andorra1, S. Alba-Arbalat1, A. Saiz8, S. Llufriu9, 1Hospital Clinic Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona/Barcelona/ES, 2Hospital del Mar Medical Research Institute/Barcelona/ES, 3Hospital Universitari Germans Trias i Pujol/Badalona/ES, 4Hospital de Sabadell Parc Taulí/Sabadell/ES, 5Hospital Universitari de Bellvitge/Barcelona/ES, 6Institut Guttmann,/Badalona/ES, 7Institut Guttmann/Badalona/ES, 8Hospital Clínic i Provincial de Barcelona/Barcelona/ES, 9Hospital Clínic de Barcelona e Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)/Barcelona/ES

P0821 - Prevalence data of Cognitive Impairment in patients with Multiple Sclerosis of good clinical evolution in a cohort of patients from the city of Lleida

A. Gil1, M. Canudes1, L. Nogueras1, C. Gonzalez-Mingot1, J.V. Hervás-García1, S. Peralta1, M.J. Solana1, L. Brieva2, 1Hospital Universitari Arnau de Vilanova de Lleida/Lleida/ES, 2Hospital Arnau de Vilanova/LLEIDA/ES

P0822 - Processing speed improves prediction of physical impairment in patients with multiple sclerosis

S. Hechenberger, D. Pinter, B. Helmlinger, A. Pichler, M. Khalil, C. Enzinger, Medical University of Graz/Graz/AT

P0823 - Resting state functional connectivity correlates of executive function in patients with multiple sclerosis

O. Marchesi, P. Valsasina, L. Conti, D. Mistri, P. Preziosa, M. Filippi, M.A. Rocca, IRCCS San Raffaele Scientific Institute/Milan/IT

P0824 - Serum neurofilaments and Cognition in Secondary Progressive Multiple Sclerosis

T. Williams1, C. Tur2, A. Doshi3, H. Wellington1, D. Chan4, S. Banks5, A. Heslegrave1, H. Zetterberg6, J. Chataway7, 1University College London/London/GB, 2UCL Queen Square Institute of Neurology, Faculty of Brain Sciences/London/GB, 3University College London/BG/GB, 4UCL Institute of Cognitive Neuroscience/London/GB, 5Oxford Autoimmune Neurology Group/Oxford/GB, 6Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg/Mölndal/SE, 7UCL Queen Square Institute of Neurology, University College//GB

P0825 - Social cognition impairment - a clinical biomarker of Multiple Sclerosis?

C. Lima1, R. Machado2, A. Afonso3, C. Macário2, L. Sousa2, I. Santana2, S. Batista2, 1Centro Hospitalar e Universitario de Coimbra/Coimbra/PT, 2Coimbra Hospital and University Centre (CHUC)/Coimbra/PT, 3Faculty of Medicine, University of Coimbra/Coimbra/PT

P0826 - Social emotions in patients with multiple sclerosis

F. Pagani Cassará1, S. Maid2, J. Gutnisky2, S. Fittipaldi2, S. Báez3, A. Ibáñez2, A.M. García2, V. Sinay1, 1Hospital Universitario Fundación Favaloro/Buenos Aires/AR, 2Universidad de San Andrés/Buenos Aires/AR, 3Universidad de San Andrés/Bogotá/CO

P0827 - Speed of Lexical Access Contributes to Verbal Memory Retrieval in MS.

E. Dvorak1, R. Brandstadter2, J. Sumowski3, 1/New York/US, 2University of Pennsylvania Perelman School of Medicine/Philadelphia/US, 3Icahn School of Medicine at Mount Sinai/New York City/US

P0828 - Synaptic plasticity is reduced in patients with RRMS compared to healthy controls and associated with neuropsychological outcomes

C. Balloff1, S. Groiss2, M. Ma2, L. Scala2, I. Georgiades2, N. Troullinakis2, J. Graf2, O. Aktas2, H.P. Hartung3, A. Schnitzler2, I.-K. Penner4, P. Albrecht2, 1Heinrich-Heine-University, Medical Faculty/Duesseldorf/DE, 2Heinrich-Heine-University/Duesseldorf/DE, 3/Dusseldorf/DE, 4Cogito Center for Applied Neurocognition and Neuropsychological Research/Düsseldorf/DE

P0829 - The adapted Symbol Digit Modalities Test: a proof of concept study

S. Costa1, L. Strober1, T. Alvarez2, K. Costanza1, A. Degraaf1, H. Talasan2, J. Deluca1, N. Chiaravalloti1, 1Kessler Foundation/East Hanover/US, 2New Jersey Institute of Technology/Newark/US

P0830 - Unraveling the substrates of cognitive impairment in multiple sclerosis: the contribution of a multiparametric structural and functional MRI approach

L. Conti, P. Preziosa, A. Meani, C. Vizzino, G. Riccitelli, E. Pagani, P. Valsasina, O. Marchesi, M. Filippi, M.A. Rocca, IRCCS San Raffaele Scientific Institute/Milan/IT

P0831 - Validation of longitudinal reaction time trajectories in multiple sclerosis using the MSReactor computerized battery and latent class analysis.

D. Merlo1, J. Stankovich2, C. Bae3, T. Kalincik4, M. Gresle2, J. Lechner-Scott5, T. Kilpatrick6, M. Barnett7, B. Taylor8, D. Darby6, H. Butzkueven2, A. Van Der Walt2, 1Level 6, 99 Commercial Road/Melbourne/AU, 2Monash University/Melbourne/AU, 3University of Melbourne/Melbourne/AU, 4Royal Melbourne Hospital/Melbourne/AU, 5Department of Neurology, John Hunter Hospital, Hunter New England Health/Newcastle/AU, 6The Florey Institute of Neuroscience and Mental Health/Melbourne/AU, 73. Brain and Mind Research Institute, University of Sydney/Sydney/AU, 8University of Tasmania/Hobart/AU

P0832 - XO as a new screening test of cognitive impairment in multiple sclerosis

P. Paris1, D. Cregut2, V. Germain3, M. Izaute3, M. Gibelin4, B. Pereira2, F. Taithe2, D. Aufauvre2, X. Moisset2, P. Clavelou5, 1Clermont-Ferrand's University Hospital /Clermont-Ferrand/FR, 2Clermont- Ferrand's University Hospital/Clermont-Ferrand/FR, 3Clermont Auvergne University/Clermont- Ferrand/FR, 4NeuroSep Auvergne/Aubiere/FR, 5CHU Clermont-Ferrand/Clermont-Ferrand/FR

P0833 - “Stable” vs. “Silent Progressive Multiple Sclerosis”: A Real World Retrospective Clinical Imaging Brazilian Study

F. Figueira, G. Figueira, P. Soares, R. Silveira, Hospital São Francisco na Providencia de Deus/Rio de Janeiro/BR

P0834 - A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry

T. Spelman1, J. Hillert2, J. Tsai3, M. Nouhi3, A. Glaser4, 1Karolinska Institute/Stockholm/SE, 2Karolinska Institutet/Solna/SE, 3Sanofi Sweden/Stockholm/SE, 4Karolinska Institutet/Stockholm/SE

P0835 - A First Look at the Characteristics of Patients with Multiple Sclerosis Initiating Siponimod Therapy in the United States

R. Shah1, M. Gorritz2, R. Wade2, J. Multani2, H.-C. Chang2, K. Shelley1, G. Cox1, K. Johnson1, 1Novartis Pharmaceuticals Corporation/East Hanover/US, 2IQVIA, Inc./Plymouth Meeting/US

P0836 - Aggressive multiple sclerosis in Argentina: data from the nationwide registry RelevarEM

M. Kohler1, E. Kohler1, C. Vrech2, A. Pappolla3, J. Miguez3, L. Patrucco3, J. Correale4, M. Marrodan5, M. Gaitán6, M. Fiol5, L. Negrotto5, M. Ysrraelit5, E. Cristiano7, A. Carra8, A. Chertcoff9, J. Steinberg9, A. Martinez9, C. Curbelo9, L. Cohen10, R. Alonso10, O. Garcea10, C. Pita11, B. Silva11, G. Luetic12, N. Deri13, M.E. Balbuena14, V. Tkachuk14, E. Carnero Contentti15, P. Lopez15, J. Pettinicchi16, A. Caride15, M. Burgos17, F. Leguizamon18, E. Knorre18, R. Piedrabuena19, A. Barboza20, S. Liwacki19, P. Nofal21, G. Volman22, A. Alves Pinheiro23, J. Hryb24, D. Tavolini25, P. Blaya26, L. Recchia27, C. Mainella28, E. Silva29, J. Blanche30, S. Tizio31, M. Saladino32, F. Caceres33, N. Fernandez Liguori34, L. Lazaro34, G. Zanga35, M. Parada Marcilla36, M.E. Fracaro37, F. Pagani Cassará38, G. Vazquez39, V. Sinay38, G. Sgrilli40, P. Divi41, M. Jacobo41, E. Reich42, L. Cabrera43, M. Menichini44, M. Coppola45, I. Martos46, J. Viglione47, G. Jose48, S. Bestoso49, R. Manzi50, D. Giunta51, M. Doldan52, M. Alonso Serena53, J. Rojas54, 1Fundación Sinapsis/Santa Rosa/AR, 2Sanatorio Allende/Cordoba/AR, 3Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 4Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR, 5FLENI/CIUDAD DE BUENOS AIRES/AR, 6FLENI/Buenos Aires/AR, 7Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 8Hospital Britanico/CIUDAD DE BUENOS AIRES/AR, 9Hospital Británico De Buenos Aires/Buenos Aires/AR, 10Hospital Ramos Mejía/Buenos Aires/AR, 11Ramos Mejia/Buenos Aires/AR, 12Instituto de Neurociencias de Rosario/Rosario./AR, 13Centro de Investigaciones DIABAID/Buenos Aires/AR, 14Hospital de Clínicas José de San Martín/Buenos Aires/AR, 15Hospital Alemán/Buenos Aires/AR, 16Hospital Aleman/Buenos Aires/AR, 17Hospital San Bernardo/Salta/AR, 18Hospital de Agudos TEodoro Alvarez/Buenos Aires/AR, 19Clinica Universitaria Reina SOfía/Córdoba/AR, 20Hospital Central/Mendoza/AR, 21Hospital de Clínicas Nuestra Señora del Carmen/Tucuman/AR, 2221. Hospital Presidente Perón de Avellaneda/Avellaneda/AR, 23Hospital San Martin de Parana/Parana/AR, 24Hospital Carlos Durand/Buenos Aires/AR, 25INECO Neurociencias Oroño/Rosario/AR, 26Neurocomp/Trelew/AR, 27Hospital Central de Mendoza/Mendoza/AR, 28Hospital Español/ROsario/AR, 29Predigma/Posadas/AR, 3029. IRNEC (Instituto Regional de Neurociencias)/Tucumán/AR, 31Hospital Español de La Plata/La PLata/AR, 32INEBA Instituto De Neurociencias Buenos Aires/Buenos Aires/AR, 33INERE/Buenos Aires/AR, 34Sanatorio Guemes/Buenos Aires/AR, 35Hospital Cesar Milstein/Buenos Aires/AR, 36SIENES/Buenos Aires/AR, 37Clinica del Castano/San Juan/AR, 38Hospital Universitario Fundación Favaloro/Buenos Aires/AR, 39Fundacion Favaloro/Buenos Aires/AR, 40Axis Neurociencias/Bahia Blanca/AR, 41RIAPEM/Santiago del Estero/AR, 42Hospital Municipal Dr Julio Mendez/Buenos Aires/AR, 43Hospital Militar Campo de Mayo/Buenos Aires/AR, 44Sanatorio Britanico/Rosario/AR, 45Hospital Ramon Santamarina/Tandil/AR, 46Clinica San Jorge/Ushuaia/AR, 47Clinica Regional del Sud/Rio Cuarto/AR, 48Hospital Padilla/Tucuman/AR, 49Hospital Escuela Jose de San Martin/Corrientes/AR, 50Sanatorio Pasteur/Catamarca/AR, 51Hospital Italiano/Buenos Aires/AR, 52Centro de Esclerosis Multiple de Buenos Aires/Buenos Aires/AR, 53CEMIC/Buenos Aires/AR, 54Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR

P0837 - Assessing the real-world effectiveness of ocrelizumab in patients with multiple sclerosis – CONFIDENCE one-year interim analysis

M. Buttmann1, S. Meuth2, M. Weber3, P. Dirks4, J. Eggebrecht4, S. Hieke-Schulz4, J. Leemhuis4, T. Ziemssen5, 1Caritas Hospital Bad Mergentheim/Bad Mergentheim/DE, 2University Clinic Munster/Munster/DE, 3University Medical Center Goettingen/Goettingen/DE, 4Roche/Grenzach- Wyhlen/DE, 5Carl Gustav Carus University Hospital/Dresden/DE

P0838 - Autonomic dysfunction in patients with relapsing-remitting multiple sclerosis treated with different oral disease modifying therapies – a pilot study

M. Wnuk1, M. Tutaj2, L. Drabik1, M. Marona1, M. Gliniak1, A. Kepinska-Wnuk1, K. Porebska1, K. Nowak1, K. Sawczynska1, M. Wlodarczyk3, A. Slowik1, 1Jagiellonian University Medical College/Krakow/PL, 2Jagiellonian University Medical College/-/PL, 3University Hospital in Krakow/Krakow/PL

P0839 - Baseline Characteristics of AMASIA: First Real World Data of Siponimod Treated Patients with Secondary Progressive Multiple Sclerosis

M. Weber1, L. Klotz2, H. Schreiber3, B. Rauser4, T. Ziemssen5, 1University Medical Center Goettingen/Goettingen/DE, 2St. Josefs-Krankenhaus/Potsdam/DE, 3Nervenärztliche Gemeinschaftspraxis & Neuropoint Academy/Ulm/DE, 4Novartis Pharma GmbH/Nuremberg/DE, 5Carl Gustav Carus University Hospital/Dresden/DE

P0840 - Benign Multiple Sclerosis: Is the EDSS scale enough to define it?

E. Matas1, L. Bau2, L. Romero-Pinel3, I. León2, A. Martínez-Yélamos2, S. Martínez-Yélamos2, 1Hospital Universitari de Bellvitge/L'Hospitalet de Llobregat/ES, 2Hospital Universitari de Bellvitge- IDIBELL/L'Hospitalet de Llobregat/ES, 3Hospital Universitari de Bellvitge/Barcelona/ES

P0841 - Brain volume loss during the first year and physical and cognitive impairment over 3 years in naïve multiple sclerosis patients under fingolimod

J. Rojas1, F. Sanchez2, L. Patrucco3, A. Papolla4, J. Miguez5, E. Cristiano6, 1Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 2Centro de Esclerosis Múltiple de Buenos Aires (CEMBA)/Buenos Aires/AR, 3Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 4Hospital Italiano/Buenos Aires/AR, 5Hospital Italiano de Buenos Aires/Buenos Aires/AR, 6Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR

P0842 - Changes in Copaxone usage of MS patients within British Columbia upon recommended switch to generic.

K. Shete, M.-E. Baeva, J. Nelson, A. Kazimirchik, G. Vorobeychik, Fraser Health Multiple Sclerosis Clinic/Burnaby/CA

P0843 - Characteristics and clinical outcomes of older patients with MS treated with peginterferon beta-1a or intramuscular interferon beta-1a in MS PATHS

L.H. Hua1, S. Liao2, C. Hersh3, K. Fitzgerald4, A. Altincatal5, M. Naylor6, 1Cleveland Clinic Lou Ruvo Center for Brain Health/Las Vegas/US, 2Biogen/Cambride/US, 3Cleveland Clinic/Las Vegas/US, 4Johns Hopkins University School of Medicine/Baltimore/US, 5Biogen/Boston/US, 6Biogen/Cambridge/US

P0844 - Characteristics and treatment patterns of older MS patients treated with peginterferon beta- 1a or intramuscular interferon beta-1a in the real world

M. Vignos, A. Altincatal, J. Mendoza, R. Avila, C. Makin, Biogen/Cambridge/US

P0845 - Characteristics of patients initiating ocrelizumab vs other disease-modifying therapies in a US national multiple sclerosis registry

D. Kantor1, N. Engmann2, W. Malley3, R. Mclean3, A. Cronin3, B. Dube3, A. Miller4, 1Kantor Neurology/Coconut Creek/US, 2Genentech, Inc./South San Francisco/US, 3Corrona, LLC/Waltham/US, 4Mount Sinai Hospital/New York City/US

P0846 - Characteristics of relapsing multiple sclerosis patients treated with cladribine tablets in five European countries: multi-year chart review F. Zeng1, G. Harty1, S. Wong1, E. Maslova2, R. Schade2, B. Row3, 1EMD Serono, Inc./Billerica/US, 2ICON plc/London/GB, 3ICON plc/Raleigh-Durham/US

P0847 - Characterization of relapsing multiple sclerosis patients treated with cladribine tablets in Germany since marketing authorization

F. Zeng1, G. Harty1, S. Wong1, S. Uebler2, E. Maslova3, R. Schade3, B. Row4, D. Ellenberger5, A. Stahmann5, 1EMD Serono, Inc./Billerica/US, 2Merck Serono GmbH/Darmstadt/DE, 3ICON plc/London/GB, 4ICON plc/Raleigh-Durham/US, 5MS Forschungs- und Projektentwicklungs- gGmbH/Hannover/DE

P0848 - Characterization of Retinal Nerve Fiber Layer Thickness in a Cohort with Glutamic Acid Decarboxylase and Glycine Receptor Autoimmunity

R. Kadish1, K.-H. Wong1, J. Galli1, J. Greenlee1, J. Klein1, M. Paz Soldán1, S. Clardy1, A. Loughran- Fjeldstad2, J. Rose3, 1University of Utah/Salt Lake City/US, 2Virginia Commonwealth Univsrsity/Richmond/US, 3University of Utah, George E. Wahlen Department of Veterans Affairs Medical Center/Salt Lake City/US

P0849 - CLADQoL (CLADribine Tablets – evaluation of Quality of Life) study: evaluating Qol 12 months after treatment initiation with cladribine tablets

I.-K. Penner1, R. Pul2, B.-A. Kallmann3, A. Raji4, J. Richter5, T. Wagner5, B. Mueller5, T. Buescher5, A. Posevitz-Fejfar5, 1Cogito Center for Applied Neurocognition and Neuropsychological Research/Düsseldorf/DE, 2University Hospital Essen/Essen/DE, 3Multiple Sklerose Zentrum Bamberg/Bamberg/DE, 4Neurozentrum Hamburg/Hamburg/DE, 5Merck Serono GmbH/Darmstadt/DE

P0850 - Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients

K. Allen-Philbey1, S. De Trane1, A. Stennett2, O. Yildiz1, A. Adams3, B. Turner1, M. Marta1, S. Gnanapavan1, L. Bianchi4, J. Mathews3, D. Altmann4, G. Giovannoni5, D. Baker4, K. Schmierer3, 1Royal London Hospital-Barts Health NHS Trust/London/GB, 2Royal London Hospital, Barts Health NHS Trust/London/GB, 3Royal London Hospital-Barts Health NHS Trust/FR/GB, 4The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London/AT/GB, 5The London School of Medicine and Dentistry/London/GB

P0851 - Clinical & demographic determinants of self-reported diet program adherence in people living with multiple sclerosis

M. Jakaria, N. Nag, S. Neate, G. Jelinek, T. Weiland, S. Simpson-Yap, The University of Melbourne/Melbourne/AU

P0852 - Clinical activity after fingolimod treatment in naïve RRMS patients compared to patients previously treated with other drugs M. Cannizzaro1, L. Ferrè2, F. Sangalli2, B. Colombo2, L. Moiola3, V. Martinelli3, M. Filippi3, F. Esposito3, 1Ospedale San Raffaele/Milan/IT, 2Ospedale San Raffaele/Milano/IT, 3IRCCS San Raffaele Scientific Institute/Milan/IT

P0853 - Clinical and videonystagmographical evaluation of vestibular manifestations in multiple sclerosis.

S. El Alaoui El Rhoul1, M. Ridal1, N. Ouattassi1, S. Bouchal2, M. El Amine El Alami1, M. Belahssen2, 1univerity Hospital Hassan II/Fes/MA, 2CHU HASSAN II/FES/MA

P0854 - Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b in the BEACON study

F. Patti1, J.N. Penaherrera2, E.-M. Wicklein3, 1Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 2/Hennigsdorf/DE, 3Bayer AG/Berlin/DE

P0855 - Clinical Course and Therapeutic Management of SPMS in France: a retrospective real world multicentric observational study (ODYSSEP Study)

E. Leray1, A. Bastien2, K. Rerat2, A. Cognée-Chauvin2, E. Raponi2, S. Vukusic3, 1Rennes University, EHESP, REPERES – EA 7449/Rennes/FR, 2Novartis Pharma/Rueil Malmaison/FR, 3Lyon University Hospital/BRON/FR

P0856 - Collecting real world MRI in MS: preliminary results from FlywheelMS

A. Traboulsee1, W. Van Hecke2, D. Smeets2, G. Hanson3, K. Mace3, A. Rovira4, R. Henry5, D. Li6, R. Gan7, L. Julian7, K. Belediuk7, L. Gaetano8, 1The University of British Columbia/Canada/CA, 2Icometrix, Research and Development/Leuven/BE, 3PicnicHealth/San Francisco/US, 4Vall d'Hebron University Hospital/Barcelona/ES, 5University of California San Francisco/San Francisco/US, 6University of British Columbia/Vancouver/CA, 7Genentech, Inc./South San Francisco/US, 8F. Hoffmann-La Roche Ltd/Basel/CH

P0857 - Comorbidity and Economic Burdens of Fatigue Among Patients with Relapsing-Remitting Multiple Sclerosis in the United States

H. Le1, J. Ken-Opurum2, M. Maculaitis2, J. Sheehan1, 1Janssen Scientific Affairs, LLC/Titusville/US, 2Kantar/New York/US

P0858 - Comparative effectiveness of dimethyl fumarate versus other disease-modifying therapies in Multiple Sclerosis: a large population-based cohort study

P. Bosco-Lévy1, P. Blin2, S. Lignot-Maleyran2, R. Lassalle2, A. Abouelfath2, P. Diez-Andreu2, M. Debouverie3, B. Brochet4, F. Guillemin5, N. Moore6, D.-P. Cécile2, 1Bordeaux PharmacoEpi/Bordeaux/FR, 2Bordeaux PharmacoEpi (BPE)/Bordeaux cedex/FR, 3CHU de Nancy/Nancy/FR, 4University of Bordeaux/Bordeaux/FR, 5CHRU de Nancy/Nancy/FR, 6CHU de Bordeaux/Bordeaux/FR

P0859 - Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis

T. Spelman1, C. Acosta2, R. Hyde2, N. Campbell3, E. Havrdova4, D. Horakova4, M. Trojano5, G. De Luca6, A. Lugaresi7, G. Izquierdo8, P. Grammond9, P. Duquette10, R. Alroughani11, E. Pucci12, F. Granella13, J. Lechner-Scott14, P. Sola15, D. Ferraro15, F. Grand-Maison16, M. Terzi17, C. Rozsa18, C. Boz19, R. Hupperts20, A. Van Der Walt21, V. Van Pesch22, C. Oreja-Guevara23, V. Jokubaitis1, T. Kalincik24, H. Butzkueven25, 1Monash University/Melbourne/AU, 2Biogen International/Baar/CH, 3Biogen/Boston/US, 4Charles University and General University Hospital in Prague/Prague/CZ, 5University of Bari/Bari/IT, 6“SS. Annunziata” Hospital/Chieti/IT, 7IRCCS Istituto delle Scienze Neurologiche di Bologna and Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy/Bologna/IT, 8Hospital Universitario Virgen Macarena/Seville/ES, 9CISSS Chaudičre-Appalache/Levis/CA, 10University of Montreal/Montreal/CA, 11Amiri Hospital/Sharq/KW, 12UOC Neurologia, Azienda Sanitaria Unica Regionale Marchef— AV3/Macerata/IT, 13University of Parma/Parma/IT, 14School of Medicine and Public Health, University Newcastle, Newcastle, Australia; Department of Neurology, John Hunter Hospital, Hunter New England Health/Newcastle/AU, 15Azienda Ospedaliera Universitaria/Modena/IT, 16Neuro Rive-Sud/Greenfield Park/CA, 1719 Mayis University/Samsun/TR, 18Jahn Ferenc Teaching Hospital/Budapest/HU, 19KTU Medical Faculty Farabi Hospital/Trabzon/TR, 20Zuyderland Ziekenhuis/Sittard/NL, 21Alfred Health, Clinical Neurosciences; Department of Neuroscience, Central Clinical School, Monash University/Melbourne/AU, 22Cliniques Universitaires Saint-Luc/Brussels/BE, 23IdISSC, Hospital Clínico San Carlos; Hospital Universitario La Paz, Universito Complutense/Madrid/ES, 24CORe, Department of Medicine, University of Melbourne; Department of Neurology, Royal Melbourne Hospital/Melbourne/AU, 25Central Clinical School, Monash University; Department of Neurology, Alfred Hospital; Department of Neurology, Box Hill Hospital, Monash University/Melbourne/AU

P0862 - Disability accrual in primary-progressive & secondary-progressive multiple sclerosis

S. Harding-Forrester1, I. Roos2, S. Sharmin3, I. Diouf3, C. Malpas2, A.-L. Nguyen2, N. Moradi3, D. Horáková4, E. Kubala Havrdová5, F. Patti6, G. Izquierdo7, S. Eichau7, A. Prat8, M. Girard8, P. Duquette8, M. Onofrj9, A. Lugaresi10, F. Grand'Maison11, B. Weinstock-Guttman12, M.P. Amato13, P. Grammond14, O. Gerlach15, S. Ozakbas16, P. Sola17, D. Ferraro18, H. Butzkueven19, J. Lechner-Scott20, C. Boz21, R. Alroughani22, V. Van Pesch23, E. Cartechini24, M. Terzi25, D. Maimone26, C. Ramo-Tello27, D. Spitaleri28, L. Kappos29, B. Yamout30, M. Sá31, M. Slee32, Y. Blanco33, R. Bergamaschi34, E. Butler35, G. Iuliano36, F. Granella37, Y. Sidhom38, R. Gouider39, R. Ampapa40, B. Van Wijmeersch41, R. Karabudak42, J. Prevost43, J.L. Sánchez-Menoyo44, F. Verheul45, P. Mccombe46, T. Castillo-Triviño47, R. Macdonell48, A. Altintas49, G. Laureys50, L. Van Hijfte50, A. Van Der Walt19, S. Vucic51, R. Turkoglu52, M. Barnett53, E. Cristiano54, M. Zakaria55, V. Shaygannejad56, S. Hodgkinson57, A. Soysal58, T. Kalincik2, 1/Surrey Hills/AU, 2Royal Melbourne Hospital/Melbourne/AU, 3University of Melbourne/Melbourne/AU, 4Charles University in Prague and General University Hospital/Prague/CZ, 5Charles University//CZ, 6Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 7Hospital Universitario Virgen Macarena/Sevilla/ES, 8University of Montreal/Montreal/CA, 9University G. d’Annunzio/Chieti/IT, 10IRCCS Istituto delle Scienze Neurologiche di Bologna/Bologna/IT, 11Neuro Rive- Sud/Quebec/CA, 12State University of New York at Buffalo/Buffalo/US, 13University of Florence/Florence/IT, 14CISSS Chaudière-Appalache/Levis/CA, 15Department of Neurology, Zuyderland Medical Center, Sittard-Geleen/Sittard-Geleen/NL, 16Dokuz Eylul University/Izmir/TR, 17Azienda Ospedaliero-Universitaria di Modena Ospedale Civile di Baggiovara/Modena/IT, 18University of Modena and Reggio Emilia/Modena/IT, 19Monash University/Melbourne/AU, 20John Hunter Hospital, University of Newcastle/Newcastle/AU, 21KTU Medical Faculty Farabi Hospital/Trabzon/TR, 22Amiri Hospital/Kuweit/KW, 23Cliniques Universitaires Saint-Luc/Brussels/BE, 24UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3/Macerata/IT, 25Ondokuz Mayıs University/Sasun/TR, 26Garibaldi Hospital/Catania/IT, 27Hospital Germans Trias i Pujol/Badalona/ES, 28Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino/Avellino/IT, 29University of Basel//CH, 30American University of Beirut/Beirut/LB, 31Centro Hospitalar, Universitário de São João/Porto/PT, 32Flinders University/Adelaide/AU, 33Hospital Clinic Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona/Barcelona/ES, 34IRCCS Mondino Foundation/Pavia/IT, 35Monash Medical Centre/Melbourne/AU, 36Ospedali Riuniti di Salerno/Salerno/IT, 37University of Parma/Parma/IT, 38Razi Hospital/Manouba/TN, 39Razi Hospital/Mannouba/TN, 40Nemocnice Jihlava/Jihlava/CZ, 41Rehabilitation and MS-Centre Overpelt and Hasselt University/Hasselt/BE, 42Hacettepe University Faculty of Medicine/Ankara/TR, 43CSSS Saint-Jérôme/Saint-Jerome/CA, 44Hospital de Galdakao- Usansolo/Galdakao/ES, 45Groene Hart Ziekenhuis/Gouda/NL, 46University of Queensland/Brisbane/AU, 47Hospital Universitario Donostia/San Sebastián/ES, 48Austin Health. University of Melbourne/Melbourne/AU, 49Koc University/Istambul/TR, 50UZ Gent/Gent/BE, 51Westmead Hospital/Sydney/AU, 52Haydarpasa Numune Training and Research Hospital/Istanbul/TR, 53Brain and Mind Centre/Sydney/AU, 54Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 55Ain Shams University Hospital/Cairo/EG, 56Isfahan neuroscience research center/Isfahan/IR, 57Ingham Institute for Applied Medical Research, University of New South Wales Medicine/Sydney/AU, 58Bakırköy Prof. Dr. Mazhar Osman Education and Research Hospital for Psychiatry and Neurological Diseases/Istanbul/TR

P0863 - Discontinuation and dose reduction of rituximab in patients with relapsing remitting multiple sclerosis

M. Boremalm, P. Sundström, J. Salzer, Umeå University/Umeå/SE

P0864 - Disease Modifying Therapies in People Newly Diagnosed with Multiple Sclerosis

G. Von Geldern1, A. Wundes2, D. Mehta1, S. Bet-Shlimon1, K. Alschuler1, 1University of Washington/Seattle/US, 2University of Washington Medical Center/Seattle/US

P0865 - Disease modifying therapy utilization is influenced by system-level factors: Real-world evidence from the MS-CQI improvement collaborative study. B. Oliver1, F. Mehta1, K. Walsh2, L. N'Dri2, D. Waters2, 1DARTMOUTH HITCHCOCK MEDICAL CENTER/Lebanon/US, 2Thomas Jefferson University/Philadelphia/US

P0866 - Disease-Modifying Therapy of Multiple Sclerosis with Ocrelizumab: a two years experience of MS Clinic in the Eastern Region of Abu Dhabi Emirate, UAE

A. Hassan1, H. Elhasin1, N. Soliman1, M. Szolics2, 1Tawam Hospital/Al Ain/AE, 2Tawam hospitap/Al Ain/AE

P0867 - Dynamics of brain volume loss during 3 years in multiple sclerosis patients with cognitive impairment: prospective cohort study

J. Rojas1, F. Sanchez2, L. Patrucco3, A. Papolla4, E. Cristiano5, 1Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 2Centro de Esclerosis Múltiple de Buenos Aires (CEMBA)/Buenos Aires/AR, 3Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 4Hospital Italiano/Buenos Aires/AR, 5Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR

P0868 - Early experience with ocrelizumab in Denmark. A population-based registry study

M. Magyari1, L. Pontieri2, M. Blinkenberg1, V. Papp3, P. Rasmussen4, J. Schäfer5, J. Berg6, M. Kant7, H. Mathiesen8, M. Jensen9, G. Sirakov10, A. Petersen11, S. Bramow1, F. Sellebjerg1, 1Danish Multiple Sclerosis Center/Glostrup/DK, 2The Danish Multiple Sclerosis Registry/Glostrup/DK, 3Odense University Hospital/Odense/DK, 4Aarhus University Hospital/Aarhus/DK, 5University Hospital Aalborg/Aalborg/DK, 6Viborg regional hospital/Viborg/DK, 7Hospital of Southern Jutland/Sønderborg/DK, 8Copenhagen University Hospital Herlev and Gentofte/Herlev/DK, 9Nordsjællands Hospital - Hillerød/Hillerød/DK, 10Regional Hospital West Jutland/Holstebro/DK, 11Sydvestjysk Sygehus/Esbjerg/DK

P0869 - effectiveness and safety of rituximab in routine clinical practice: a retrospective analysis of mexican patients with progressive multiple sclerosis

D. Bernal Varela1, L. Molina Carrion2, 1Instituto Mexicano del Seguro Social/Ciudad de México/MX, 2INSTITUTO MEXICANO DEL SEGURO SOCIAL/CIUDAD DE MEXICO/MX

P0870 - Effectiveness of Disease-Modifying Therapies in Relapsing Multiple Sclerosis in South China.

V. Tao1, L. Zhao2, C. Au2, A. Ng2, V. Mok2, A. Lau2, 1Prince of Wales Hospital/Hong Kong/HK, 2The Chinese University of Hong Kong/Hong Kong/HK

P0871 - Efficacy and safety of dimethyl fumarate in progressive multiple sclerosis

V.F. Moreira Ferreira1, Y. Liu1, B. Healy2, J. Stankiewicz1, 1Brigham and Women's Hospital/Boston/US, 2Harvard Medical School/United States/US

P0872 - Efficacy and Safety of Intravenous and Subcutaneous Cladribine in Relapsing and Progressive Multiple Sclerosis: a 24-year retrospective

M. Ko1, G. Katsamakis2, R. Balabanov3, D. Stefoski1, 1Rush University Medical Center/Chicago/US, 2Northwest Neurology/Lake Barrington/US, 3Regenstein Center for Neurological Care/Chicago/US

P0873 - Experience with teriflunomide in a specialized multiple sclerosis unit

L. Ramió-Torrentà1, G. Alvarez Bravo2, H. Perkal3, M. Merchán3, M. González2, R. Robles Cedeño2, 1Dr. Josep Trueta University Hospital/Girona/ES, 2Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 3Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Girona/Salt-Spain. Neurodegeneration and Neuroinflammation Group, Girona Biomedical Research Institute (IDIBGI), Sa/Girona/ES

P0874 - Fingolimod therapy in real world relapsing MS patients: Cognition, quantitative MRI and deep gray matter quantitative susceptibility mapping

H. Beadnall1, B. Weinstock-Guttman2, C. Wang3, J. Hagemeier4, N. Bergsland5, D. Jakimovski6, M. Ramanathan7, L. Ly8, M. Dwyer9, F. Schweser9, T. Hardy10, R. Benedict11, M. Barnett12, R. Zivadinov5, 1/Glebe/AU, 2State University of New York at Buffalo/Buffalo/US, 3The University of Sydney, Sydney Neuroimaging Analysis Centre/Sydney/AU, 4Buffalo Neuroimaging Analysis Center, State University of New York at Buffalo/Buffalo/US, 5Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York/Buffalo/US, 6University at Buffalo, State University of New York/Buffalo/US, 7Department of Pharmaceutical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York/Buffalo/US, 8Sydney Neuroimaging Analysis Centre/Sydney/AU, 9Buffalo Neuroimaging Analysis Center/Buffalo/US, 10Brain and Mind Centre/Sydney/AU, 11University At Buffalo/Buffalo/US, 12The University of Sydney, Royal Prince Alfred Hospital/Sydney/AU

P0875 - FlywheelMS: The prevalence of multiple sclerosis subtypes in digitized health records

R. Gan1, S. Rizzo1, J. Chia1, G. Hanson2, K. Mace2, L. Julian1, L. Gaetano3, K. Belendiuk1, 1Genentech, Inc./South San Francisco/US, 2PicnicHealth/San Francisco/US, 3F. Hoffmann-La Roche Ltd/Basel/CH

P0876 - High and low efficacy therapy in secondary progressive multiple sclerosis after accounting for therapeutic lag.

I. Roos1, E. Leray2, R. Casey3, D. Horakova4, E. Kubala Havrdová5, G. Izquierdo6, S. Eichau Madueño7, F. Patti8, G. Edan9, M. Debouverie10, J. Pelletier11, S. Ozakbas12, M.P. Amato13, P. Clavelou14, P. Grammond15, C. Boz16, J. Ciron17, O. Gerlach18, F. Grand'Maison19, J. Lechner-Scott20, C. Malpas1, H. Butzkueven21, S. Vukusic22, T. Kalincik1, 1Royal Melbourne Hospital/Melbourne/AU, 2Rennes University, EHESP, REPERES – EA 7449/Rennes/FR, 3Université de Lyon, Université Claude Bernard Lyon 1/Lyon/FR, 4First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 5Charles University//CZ, 6Hospital Universitario Virgen Macarena/Sevilla/ES, 7Universitary Hospital Virgen Macarena/Seville/ES, 8Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 9Centre hospitalier universitaire de Rennes, Hôpital Pontchaillou, Service de neurologie, CIC1414 INSERM/Rennes/FR, 10CHU de Nancy/Nancy/FR, 11Aix Marseille Univ, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie/Marseilles/FR, 12Dokuz Eylul University/Izmir/TR, 13University of Florence/Florence/IT, 14CHU Clermont-Ferrand/Clermont- Ferrand/FR, 15CISSS Chaudière-Appalache/Levis/CA, 16KTU Medical Faculty Farabi Hospital/Trabzon/TR, 17CHU Toulouse/Toulouse/FR, 18Department of Neurology, Zuyderland Medical Center, Sittard-Geleen/Sittard-Geleen/NL, 19Neuro Rive-Sud/Quebec/CA, 20Department of Neurology, John Hunter Hospital, Hunter New England Health/Newcastle/AU, 21Monash University/Melbourne/AU, 22Lyon University Hospital/BRON/FR

P0877 - Is multiple sclerosis a length-dependent central axonopathy ? Some empiric data from the TONiC study

R. Mills1, D. Schlüter2, P. Diggle3, C. Young1, A. Tennant4, 1Walton Centre Foundation Trust/Liverpool/GB, 2University of Liverpool/Liverpool/GB, 3Lancaster University/Lancaster/GB, 4University of Leeds/Leeds/GB

P0878 - Lifestyle characteristics of adherence to diet programs in an international cohort of people with MS

X. Lin1, N. Nag1, S. Neate1, G. Jelinek1, T. Weiland2, S. Simpson-Yap1, 1The University of Melbourne/Melbourne/AU, 2The University of Melbourne/Carlton/AU

P0879 - Long term consequences of high titre neutralizing antibodies to interferon-β in multiple sclerosis

N. Dunn1, A. Fogdell-Hahn1, J. Hillert2, T. Spelman1, 1Karolinska Institute/Stockholm/SE, 2Karolinska Institute/Solna/SE

P0880 - Low discontinuation rate and side-effect burden after switching to cladribine tablets: Canadian experience from the adveva® patient support program

J. Oh1, P. Giacomini2, V. Devonshire3, F. Clift4, C. Lemieux5, M. Sabidó6, A. Allignol6, M. Freedman7, 1University of Toronto/Toronto/CA, 2McGill University/Montreal/CA, 3University of British Columbia MS/NMO Center/Vancouver/CA, 4Memorial University of Newfoundland/St John's/CA, 5EMD Inc./Mississauga/CA, 6Merck Healthcare KGaA/Darmstadt/DE, 7The University of Ottawa and The Ottawa Hospital Research Institute/Ottawa/CA

P0881 - “Mild disease course of carry-over progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab”

A. Toorop1, Z. Van Lierop2, E. Strijbis1, C. Teunissen1, A. Petzold2, M. Wattjes3, F. Barkhof2, B. De Jong4, Z. Van Kempen1, J. Killestein2, 1Amsterdam UMC/Amsterdam/NL, 2Amsterdam UMC, Location VUmc/Amsterdam/NL, 3Hanover Medical School/Hanover/DE, 4Amsterdam University Medical Centers/Amsterdam/NL

P0882 - Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis

K. Rammohan1, D. Li2, J. Halper3, S. Murphy4, T. Wallace4, L. Patton4, S. Chrisant4, C. Zheng1, S. Khurana1, 1University of Miami School of Medicine/Miami/US, 2//CA, 3CMSC/Fair Lawn/US, 4Social & Scientific Systems/DLH/Silver Spring/US

P0883 - MRI activity and extended interval of Natalizumab dosing: a multicenter Italian study

M. Clerico1, S.F. De Mercanti1, A. Signori2, M. Iudicello3, C. Cordioli4, E. Signoriello5, G. Lus5, S. Bonavita6, L. Lavorgna6, G.T. Maniscalco7, E. Curti8, L. Lorefice9, E. Cocco10, V. Nociti11, M. Mirabella11, D. Baroncini12, G. Mataluni13, D. Landi14, M. Petruzzo15, R. Lanzillo15, I. Gandoglia16, A. Laroni16, R. Frangiamore17, A. Sartori18, P. Cavalla19, G. Costantini20, M.P. Sormani21, R. Capra4, 1Ospedale San Luigi Gonzaga/Orbassano/IT, 2Section of Biostatistics, University of Genova/Genova/IT, 3Neurology Unit - Ospedale San Luigi Gonzaga/Orbassano/IT, 4ASST Spedali Civili di Brescia/Brescia/IT, 5Second University of Naples/Napoli/IT, 6Clinic of Neurology, AOU - University of Campania “Luigi Vanvitelli”,/Napoli/IT, 7Neurological Clinic and Multiple Sclerosis Centre of “AORN A.Cardarelli”/Napoli/IT, 8University of Parma/Parma/IT, 9Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/Cagliari/IT, 10University of Cagliari/Cagliari/IT, 11'A. Gemelli' IRCCS/Romes/IT, 12Centro Sclerosi Multipla - Presidio ospedaliero di Gallarate - ASST Valle Olona/Gallarate/IT, 13UOSD Centro di Riferimetno Regionale Sclerosi Multipla/Roma/IT, 14UOSD Centro di Riferimento Regionale Sclerosi Multipla/Roma/IT, 15Multiple Sclerosis Centre, Federico II University/Napoli/IT, 16University of Genova/Genova/IT, 17Neurological Institute C. Besta, IRCCS Foundation/Milano/IT, 18Neurology Unit, Azienda Sanitaria Univeristaria Integrata Clinica Neurologica, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Trieste/Trieste/IT, 19City of Health & Science University Hospital/Turin/IT, 20City of Health and Science University Hospital of Turin/Turin/IT, 21University of Genoa/Genoa/IT

P0884 - MS disease modifying therapy sequencing – natalizumab to cladribine tablets – experience in 46 patients

T. Ziemssen1, I.-K. Penner2, T. Wagner3, M. Huebschen3, B. Mueller3, T. Buescher3, J. Richter3, A. Posevitz-Fejfar3, 1Carl Gustav Carus University Hospital/Dresden/DE, 2Cogito Center for Applied Neurocognition and Neuropsychological Research/Düsseldorf/DE, 3Merck Serono GmbH/Darmstadt/DE

P0885 - MSProDiscussTM is a useful tool to aid discussion of multiple sclerosis disease progression: Results from a large, real-world qualitative survey

T. Ziemssen1, G. Giovannoni2, E. Alvarez3, V. Bhan4, C. Hersh5, O. Hoffmann6, C. Oreja-Guevara7, R. Robles-Cedeño8, M. Trojano9, P. Vermersch10, P. Dobay11, M. Khwaja12, B. Stadler12, T. Hach12, D. Piani- Meier12, J. Burton13, 1University Hospital Carl Gustav Carus Dresden/Dresden/DE, 2The London School of Medicine and Dentistry/London/GB, 3University of Colorado/Aurora/US, 4Dalhousie University/Halifax/CA, 5Cleveland Clinic/Las Vegas/US, 6St.Josefs-Krankenhaus Potsdam- Sanssouci/Potsdam/DE, 7Multiple Sclerosis Center at the University Hospital San Carlos/Madrid/ES, 8Catalan Health Institute/Barcelona/ES, 9University of Bari/Bari/IT, 10CHU de Lille/Lille/FR, 11IQVIA/Basel/CH, 12Novartis Pharma AG/Basel/CH, 13Centre for Neuromuscular and Neurological Disorders, Western Australian Neuroscience Research Institute, The University of Western Australia/Nedlands/AU

P0886 - Multiple Sclerosis diagnosis at USNS Comfort during the aftermath of Hurricane Maria: A Case Report

L. Velez1, A. Diaz2, V. Martinez3, I. Vicente2, A. Chinea3, 1San Juan Bautista School of Medicine/Caguas/PR, 2San Juan MS Center/San Juan/PR, 3San Juan MS Center/Guaynabo/PR

P0887 - Multiple sclerosis evaluation and diagnosis may be delayed in male and African American patients

A. Safadi, B. Barry, R. Shin, Georgetown University Hospital/Washington, DC/US

P0888 - Multiple Sclerosis Patients' Perceptions of Using an Accelerometer and Mobile App for Clinical Research

M. Kossoff1, J. Ritter2, J. Keller3, E. Mowry4, K. Mendez5, 1Cornell University/Ithaca/US, 2Johns Hopkins University School of Medicine/Baltimore/US, 3Kennedy Krieger Institute/Baltimore/US, 4Johns Hopkins University/Baltimore/US, 5Johns Hopkins University School of Nursing/Baltimore/US

P0889 - Natural history of relapsing-remitting multiple sclerosis in a 30 years-lasting Portuguese cohort

D. Ferro1, A. Marcolino1, A. Rocha1, M. Seabra1, T. Mendonça1, P. Abreu1, J. Guimarães1, A. Macedo2, M.J. Sá1, 1Centro Hospitalar Universitario de Sao Joao/Porto/PT, 2Keypoint/Lisbon/PT

P0890 - Neurologic manifestations of IgG4-related disease: A single-center case series

M. Graber1, H. Hammer2, N. Kamber2, L. Diem2, A. Salmen3, A. Chan3, R. Hoepner3, C. Friedli2, 1Inselspital /Bern/CH, 2Inselspital Bern, University Hospital and University of Bern/Berne/CH, 3Inselspital Bern, University Hospital and University of Bern/Bern/CH

P0891 - Neurological manifestations of GAD-65 antibodies

A. Abulaban1, N. Abo Ghaddara1, S. Wesley1, D.A. Hafler2, E. Longbrake1, 1Yale University/New Haven/US, 2Yale School of Medicine/New Haven/US

P0892 - Ocrelizumab as an immune reconstitution therapy? A case report.

J. Hrastelj1, G. Ingram1, R. Smith1, S. Sadiq1, O. Pearson2, 1Morriston Hospital/Swansea/GB, 2Swansea Bay University Health Board/Swansea/GB

P0893 - Olfactory dysfunction in patients with relapsing-remitting multiple sclerosis treated with disease modifying therapies

M. Wnuk, L. Drabik, M. Marona, J. Szaleniec, A. Bryll, P. Karcz, J. Kolasinska, M. Kolasinska, M. Ziekiewicz, J. Skladzien, T. Popiela, A. Slowik, Jagiellonian University Medical College/Krakow/PL

P0894 - One year real-life data on efficacy, safety, and retention of Teriflunomide in Cypriot patients with Relapsing-Remitting Multiple Sclerosis

E. Kkolou1, T. Roussos2, E. Papanicolaou1, K. Kleopa1, E. Leonidou1, Y.-P. Christou1, S. Lambrianides1, T. Kyriakides1, M. Pantzaris1, 1The Cyprus Institute of Neurology and Genetics/Nicosia/CY, 2European University Cyprus/Nicosia/CY

P0895 - Outcomes from a prospective observational registry of repository corticotropin injection for the treatment of multiple sclerosis relapse

J. Kaplan1, T. Miller2, M. Baker3, B. Due4, E. Zhao4, G. Wan4, 1Kansas City MS and Headache Center/Overland Park/US, 2Advanced Neurology of Colorado, LLC/Fort Collins/US, 3Collier Neurologic Specialists, LLC/Naples/US, 4Mallinckrodt Pharmaceuticals/Bedminster/US

P0896 - PANGAEA 2.0 EVOLUTION: Unraveling patient and treatment characteristics for SPMS and at risk for SPMS patients in clinical routine

T. Ziemssen1, B. Rauser2, 1Carl Gustav Carus University Hospital/Dresden/DE, 2Novartis Pharma GmbH/Nuremberg/DE

P0897 - Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis for up to 18 months in the US

N. Engmann1, D. Sheinson2, C. Ng1, L. Julian1, G. Pardo3, 1Genentech, Inc./South San Francisco/US, 2Genentech/South San Francisco/US, 3Oklahoma Medical Research Foundation/Oklahoma City/US

P0898 - Preliminary data from the 5-year Hungarian fingolimod registry

K. Bencsik1, T. Biernacki1, A. Szentesi2, J. Füvesi1, C. Rózsa3, S. Komoly4, P. Ács4, E. Dobos5, L. Horváth6, J. Nikl7, S. Péntek7, G. Rum8, A. Csányi8, Á. Köves9, K. Kovács10, G. Jakab11, M. Simo12, T. Csepany13, K. Bihari14, Z. Jobbagy14, A. Jori-Birkas15, L. Vecsei1, 1University of Szeged, Szent-Györgyi Albert Research Center, Szeged/Szeged/HU, 2Novartis Hungary Ltd, Medical Department, Budapest/Budapest/HU, 3Jahn Ferenc Hospital/Budapest/HU, 4University of Pécs/Pécs/HU, 5Szent Imre Hospital/Budapest/HU, 6Borsod-Abaúj-Zemplén County and Teaching Hospital/Miskolc/HU, 7Zala County Teaching Hospital/Zalaegerszeg/HU, 8Petz Aladár County Teaching Hospital/Győr/HU, 9Bajcsy- Zsilinszky Street Hospital/Budapest/HU, 10Hospital/Budapest/HU, 11Uzsoki Street Hospital/Budapest/HU, 12Semmelweis University Budapest/Budapest/HU, 13University of Debrecen/Debrecen/HU, 14Bács-Kiskun County and Teaching Hospital/Kecskemét/HU, 15National Institute of Clinical Neurosciences,/Budapest/HU

P0899 - Prevalence of late-onset Multiple Sclerosis in Argentina: cross sectional study from RelevarEM

R. Piedrabuena1, S. Liwacki2, A. Barboza3, P. Nofal4, M. Burgos5, J. Hryb6, J. Rojas7, E. Kohler8, E. Knorre9, M. Kohler8, M. Jacobo10, S. Bestoso11, J. Viglione12, P. Divi10, G. Sgrilli13, G. Jose14, M. Coppola15, 1Clinica Reina Fabiola - Instituto Lennox/Cordoba/AR, 2Clinica Universitaria Reina SOfía/Córdoba/AR, 3Hospital Central/Mendoza/AR, 4Hospital de Clínicas Nuestra Señora del Carmen/Tucuman/AR, 5Hospital San Bernardo/Salta/AR, 6Hospital Carlos Durand/Buenos Aires/AR, 7Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 8Fundación Sinapsis/Santa Rosa/AR, 9Hospital de Agudos TEodoro Alvarez/Buenos Aires/AR, 10RIAPEM/Santiago del Estero/AR, 11Hospital Escuela Jose de San Martin/Corrientes/AR, 12Clinica Regional del Sud/Rio Cuarto/AR, 13Axis Neurociencias/Bahia Blanca/AR, 14Hospital Padilla/Tucuman/AR, 15Hospital Ramon Santamarina/Tandil/AR

P0900 - Rabies vaccination and the risk of multiple sclerosis relapse

P. Lalive, Geneva University Hospitals/Geneva/CH

P0901 - Real life efficacy and tolerability of Teriflunomide: 3 years of following in a multicentre study in Galicia (TERIGAL 2019).

A. Pato1, E. Alvarez2, E. Costa3, D. García4, A. García Pelayo5, M. Rodriguez6, A. Rodríguez Regal7, M. Llaneza8, A. Martínez9, L. Ramos10, I. Gonzalez2, M. Amigo7, J.R. Lorenzo González1, J.M. Prieto González3, 1Povisa Hospital/Vigo/ES, 2Hospital Alvaro Cunqueiro/Vigo/ES, 3Hospital Clínico Santiago de Compostela/Santiago de Compostela/ES, 4Hospital de Ourense/Ourense/ES, 5Hospital A Coruña/A Coruña/ES, 6Hospital Lucus Augusti/Lugo/ES, 7Hospital Pontevedra/Pontevedra/ES, 8Hospital Ferrol/Ferrol/ES, 9Hospital Da Costa/Burela/ES, 10Hospital de Monforte de Lemos/Monforte de Lemos/ES

P0902 - Real world evidence of progression independent of relapsing activity among MS patients treated with Alemtuzumab.

E. Rigoni1, V. Singh-Curry2, A. Nandoskar2, O. Malik2, R. Dorsey-Campbell3, R. Bergamaschi4, P. Muraro5, R. Nicholas2, A. Scalfari5, 1IRCCS Mondino Foundation/pavia/IT, 2Imperial College of London/London/GB, 3Imperial College NHS Trust/London/GB, 4IRCCS Mondino Foundation/Pavia/IT, 5Imperial College London/London/GB

P0903 - Real world patterns and outcomes of seropositive autoimmune encephalitis

A. Abulaban1, N. Abo Ghaddara1, S. Wesley1, D.A. Hafler2, E. Longbrake1, 1Yale University/New Haven/US, 2Yale School of Medicine/New Haven/US

P0904 - Real-world demographics, clinical characteristics and treatment patterns in relapsing multiple sclerosis patients on disease-modifying therapy

T. Ziemssen1, A. Kurzeja2, J. Haas3, J. Alexander4, M. Driessen2, 1University Hospital Carl Gustav Carus Dresden/Dresden/DE, 2Teva Pharmaceuticals Europe B.V./Amsterdam/NL, 3Xcenda GmbH/Hanover/DE, 4Teva Pharmaceutical Industries Ltd/Parsippany/US

P0905 - Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America

J. Rojas1, L. Patrucco2, M. Fruns3, J. Flores-Rivera4, E. Carnero Contentti5, L. Galleguillos6, R. Alonso7, E. Cristiano8, 1Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 2Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 3Clínica las Condes, Santiago de Chile, Chile/Santiago/CL, 4National Institute of Neurology and Neurosurgery/Mexico City/MX, 5Neuroimmunology Unit, Department of Neuroscience, Hospital Alemán, Buenos Aires, Argentina/Buenos Aires/AR, 6Unidad de neuroinmunología, Clínica Alemana de Santiago/Santiago/CL, 7Hospital Ramos Mejía/Buenos Aires/AR, 8Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR

P0906 - Real-world Experience of Ocrelizumab initiation in a Diverse MS population

H. Coban1, S. Germaine2, I. Dimaandal2, N. Haberli2, C. Padam2, M. Creed2, J. Imitola2, 1263 Farmington Ave./Farmington/US, 2University of Connecticut SOM/Farmington/US

P0907 - Real-world experience with Cladribine Tablets in the MSBase Registry

H. Butzkueven1, T. Spelman2, S. Hodgkinson3, T. Kalincik4, K. Buzzard5, O. Skibina6, S. Eichau Madueño7, G. Izquierdo8, A. Van Der Walt9, F. Grand-Maison10, E. Butler11, J. Prevost12, P. Mccombe13, J. Oh14, R. Macdonell15, J. Lechner-Scott16, V. Van Pesch17, P. Duquette18, A. Prat18, M. Girard18, A. Kermode19, J. Fabris And The Msbase Investigators Study Group20, 1Alfred Hospital/Melbourne/AU, 2Karolinska Institute/Stockholm/SE, 3Ingham Institute for Applied Medical Research, University of New South Wales Medicine/Sydney/AU, 4Royal Melbourne Hospital/Melbourne/AU, 5Box Hill Hospital/Box Hill/AU, 6The Alfred Hospital/Melbourne/AU, 7Universitary Hospital Virgen Macarena/Seville/ES, 8Hospital Universitario Virgen Macarena/Sevilla/ES, 9Monash University/Melbourne/AU, 10Neuro Rive-Sud/Greenfield Park/CA, 11Monash Medical Centre/Melbourne/AU, 12CSSS Saint-Jérôme/Saint-Jerome/CA, 13University of Queensland/Brisbane/AU, 14University of Toronto/Toronto/CA, 15Austin Health. University of Melbourne/Melbourne/AU, 16Department of Neurology, John Hunter Hospital, Hunter New England Health/Newcastle/AU, 17Université Catholique de Louvain/Brussels/BE, 18University of Montreal/Montreal/CA, 19University of Western Australia/Nedlands/AU, 20Merck Healthcare Pty Ltd/Macquarie Park/AU

P0908 - Real-World Experience with Ocrelizumab - a Safety and Efficacy Clinical Analysis

J. Bolling1, T. Rempe2, M. Vasquez3, C. Vervloet Sollero4, A. Carlson5, T. Gyang3, 1University of Florida /Gainesville/US, 2University of California San Diego/La Jolla/US, 3University of Florida/Gainesville/US, 4University of Rochester/Rochester/US, 5University of Colorado, Anschutz Medical Campus/Denver/US

P0909 - Real-world experience with Ocrelizumab in the MSBase Registry

H. Butzkueven1, T. Spelman2, S. Ozakbas3, T. Kalincik4, C. Boz5, K. Buzzard6, O. Skibina7, R. Alroughani8, R. Karabudak9, A. Van Der Walt10, J. Lechner-Scott11, S. Hodgkinson12, G. Laureys13, L. Van Hijfte13, M. Terzi14, E. Butler15, R. Macdonell16, F. Patti17, V. Van Pesch18, M. Slee19, M. Barnett20, P. Grammond21, J. Prevost22, F. Grand-Maison23, B. Taylor24, A. Kermode25, P. Mccombe26, P. Duquette27, A. Prat27, M. Girard27, S. Eichau Madueño28, G. Izquierdo29, A. Soysal30, J.L. Sánchez- Menoyo31, J. Sotoca32, E. Muros-Le Rouzic33, P. Dirks34, 1Alfred Hospital/Melbourne/AU, 2Karolinska Institute/Stockholm/SE, 3Dokuz Eylul University/Izmir/TR, 4Royal Melbourne Hospital/Melbourne/AU, 5KTU Medical Faculty Farabi Hospital/Trabzon/TR, 6Box Hill Hospital/Box Hill/AU, 7The Alfred Hospital/Melbourne/AU, 8Amiri Hospital/Kuweit/KW, 9Hacettepe University Faculty of Medicine/Ankara/TR, 10Monash University/Melbourne/AU, 11Department of Neurology, John Hunter Hospital, Hunter New England Health/Newcastle/AU, 12Ingham Institute for Applied Medical Research, University of New South Wales Medicine/Sydney/AU, 13UZ Gent/Gent/BE, 14Ondokuz Mayıs University/Sasun/TR, 15Monash Medical Centre/Melbourne/AU, 16Austin Health. University of Melbourne/Melbourne/AU, 17Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 18Université Catholique de Louvain/Brussels/BE, 19Flinders University/Adelaide/AU, 203. Brain and Mind Research Institute, University of Sydney/Sydney/AU, 21CISSS Chaudière-Appalache/Levis/CA, 22CSSS Saint-Jérôme/Saint- Jerome/CA, 23Neuro Rive-Sud/Greenfield Park/CA, 24University of Tasmania/Hobart/AU, 25University of Western Australia/Nedlands/AU, 26University of Queensland/Brisbane/AU, 27University of Montreal/Montreal/CA, 28Universitary Hospital Virgen Macarena/Seville/ES, 29Hospital Universitario Virgen Macarena/Sevilla/ES, 30Bakırköy Prof. Dr. Mazhar Osman Education and Research Hospital for Psychiatry and Neurological Diseases/Istanbul/TR, 31Hospital de Galdakao- Usansolo/Galdakao/ES, 32Hospital Universitario Mutua de Terrassa/Terrassa. Barcelona/ES, 33F. Hoffmann-La Roche Ltd,/Basel/CH, 34Roche/Grenzach-Wyhlen/DE

P0910 - Relapse-free and NEDA status with Cladribine in a real life population: a multicentre study

P. Annovazzi1, L. Prosperini2, R. Capuano3, A. Gallo4, J. Frau5, E. Cocco6, A. Nozzolillo7, L. Moiola7, M. Margoni8, P. Perini8, M. Capobianco9, M. Zaffaroni10, 1Multiple Sclerosis Centre, Hospital of Gallarate, ASST della Valle Olona/Gallarate (VA), Italy/IT, 2Department of Neurosciences, S. Camillo-Forlanini Hospital/Rome/IT, 3Multiple Sclerosis Centre, I Division of Neurology, University of Campania “Luigi Vanvitelli”/SALERNO/IT, 4University of Campania "L. Vanvitelli"/Naples/IT, 5Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/Cagliari/IT, 6University of Cagliari/Cagliari/IT, 7IRCCS San Raffaele Scientific Institute/Milan/IT, 8University of Padua/Padova/IT, 9San Luigi Gonzaga Hospital/Orbassano (TO)/IT, 10Multiple Sclerosis Centre, Hospital of Gallarate, ASST della Valle Olona/Gallarate (VA)/IT

P0911 - Relapses and all-cause hospitalizations are influenced by system-level factors: Real-world evidence from the MS-CQI improvement collaborative study. B. Oliver1, F. Mehta1, K. Walsh2, 1DARTMOUTH HITCHCOCK MEDICAL CENTER/Lebanon/US, 2Thomas Jefferson University/Philadelphia/US

P0913 - Risks associated with wash-out duration when switching from fingolimod to cell-depleting agents

D. Ferraro1, P. Iaffaldano2, T. Guerra2, M. Inglese3, A. Bertolotto4, V. Brescia Morra5, M. Zaffaroni6, M. Mirabella7, G. Lus8, F. Patti9, P. Cavalla10, M. Cellerino11, M. Capobianco4, F. Vitetta12, D. Paolicelli13, P. Sola12, M. Trojano13, 1University of Modena and Reggio Emilia/Modena/IT, 2University of Bari “Aldo Moro”/Bari/IT, 3University of Genoa//IT, 4San Luigi Gonzaga Hospital/Orbassano (TO)/IT, 5University of Naples Federico II/Naples/IT, 6Multiple Sclerosis Centre, Hospital of Gallarate, ASST della Valle Olona/Gallarate (VA)/IT, 7'A. Gemelli' IRCCS/Romes/IT, 8Second University of Naples/Napoli/IT, 9Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 10City of Health & Science University Hospital/Turin/IT, 11University of Genoa/Genoa/IT, 12Azienda Ospedaliero-Universitaria di Modena Ospedale Civile di Baggiovara/Modena/IT, 13University of Bari/Bari/IT

P0914 - Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis: PLEGRIDY Observational Program fourth interim results

M. Salvetti1, G. Nelles2, S. Wray3, M. Naylor4, A. Altincatal4, A. Kumar4, N. Grimes4, T. Koster4, 1Sapienza University, S. Andrea Hospital/Rome/IT, 2NeuroMed Campus Hohenlind/Cologne/DE, 3Hope Neurology MS Center/Knoxville/US, 4Biogen/Cambridge/US

P0915 - Safety and effectiveness of ocrelizumab in multiple sclerosis: a real-world study from Spain

A. Sempere1, L. Berenguer-Ruiz2, A. Burgos-San Jose1, M. Aragones2, M.D. Navarro-Lopez1, 1Hospital General Universitario de Alicante/Alicante/ES, 2Hospital Marina Baixa/Villajoyosa/ES

P0916 - Safety and tolerability in patients with multiple sclerosis receiving ocrelizumab in a real- world setting – CONFIDENCE one-year interim analysis

M. Buttmann1, S. Meuth2, M. Weber3, P. Dirks4, J. Eggebrecht4, S. Hieke-Schulz4, J. Leemhuis4, T. Ziemssen5, 1Caritas Hospital Bad Mergentheim/Bad Mergentheim/DE, 2University of Munster/Munster/DE, 3University Medical Center Goettingen/Goettingen/DE, 4Roche/Grenzach- Wyhlen/DE, 5Carl Gustav Carus University Hospital/Dresden/DE

P0917 - Sleep-related disorders and their relationship with fatigue in patients with Relapsing- Remitting Multiple Sclerosis.

D. Tavolini1, C. Mainella2, M. Oviedo1, S. Micchielli1, R. Torri1, F. Perone1, A. Zingale1, 1INECO Neurociencias Oroño/Rosario/AR, 2Hospital Español/ROsario/AR

P0918 - Teriflunomide safety and efficacy in advanced progressive multiple sclerosis V.F. Moreira Ferreira1, D. Caefer2, N. Erlich-Malona3, B. Healy4, T. Chitnis5, J. Stankiewicz1, 1Brigham and Women's Hospital/Boston/US, 2University of Connecticut, School of Engineering/Storrs/US, 3Warren Alpert Medical School of Brown University/Providence/US, 4Harvard Medical School/United States/US, 5Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US

P0919 - The Canadian Prospective Cohort (CanProCo) Study to Understand Progression in Multiple Sclerosis: Rationale and Baseline Characteristics

J. Oh1, N. Arbour2, F. Giuliani3, S. Kolind4, L. Lynd4, R.A. Marrie5, L. Metz6, S. Patten7, A. Prat8, A. Schabas4, P. Smyth3, R. Tam4, A. Traboulsee9, V. Yong7, 1University of Toronto/Toronto/CA, 2Universite de Montreal and CHUM/Montreal/CA, 3University of Alberta/Edmonton/CA, 4University of British Columbia/Vancouver/CA, 5University of Manitoba/Winnipeg/CA, 6University of Calgary/Canada/CA, 7University of Calgary/Calgary/CA, 8University of Montreal/Montreal/CA, 9The University of British Columbia/Canada/CA

P0920 - The effect of alemtuzumab treatment in relapsing remitting multiple sclerosis: real-world data from a four-year prospective one center study.

S. Sandgren1, L. Novakova1, M. Axelsson1, C. Malmeström1, J. Lycke1, H. Zetterberg2, 1Institute of Neuroscience and Physiology/Gothenburg/SE, 2Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg/Mölndal/SE

P0921 - The impact of Latent Tuberculosis in Multiple Sclerosis management: a cohort study from a tertiary Multiple Sclerosis centre

A. Novo1, I. Correia1, P. Faustino1, C. Nunes1, C. Macário2, L. Correia1, J. Serra1, S. Batista1, L. Sousa1, 1Centro Hospitalar e Universitário de Coimbra/Coimbra/PT, 2Coimbra Hospital and University Centre (CHUC)/Coimbra/PT

P0922 - The positive impact of dimethyl fumarate and patient services to address relapsing-remitting multiple sclerosis patients’ unmet medical needs

M. Rock1, N. Dell1, M. Tempest1, J. Randell1, L. Franchetta Ortelli1, G. Niemczyk2, E. Jones3, J. Husbands3, J. Pike3, S. Kenny1, 1Biogen/Cambridge/US, 2Biogen GmbH/Ismaning/DE, 3Adelphi Real World/Bollington/GB

P0923 - The presence of SARS CoV2 antibodies in MS patients

A. Wallach, S. Melvin, M. Schiebel, M. Picone, Holy Name MS Center/Teaneck/US

P0924 - The prevalence of daytime sleepiness in multiple sclerosis (MS)

D. Tlemcani Mhandez, facute of medicine fes/FEZ/MA

P0925 - Therapeutic Inertia in Relapsing-Remitting Multiple Sclerosis

R. Rodrigues1, R. Rocha2, G. Bonifácio3, D. Ferro4, F. Sabença5, A.I. Gonçalves6, F. Correia7, J. Pinheiro5, J.L. Loureiro1, R.P. Guerreiro3, J. Vale6, M.J. Sá4, A. Costa4, 1Centro Hospitalar de Entre o Douro e Vouga/Santa Maria da Feira/PT, 2Hospital Pedro Hispano/Matosinhos/PT, 3Centro Hospitalar de Setúbal/Setúbal/PT, 4Centro Hospitalar Universitario de Sao Joao/Porto/PT, 5Centro Hospitalar Vila Nova de Gaia/Espinho/Vila Nova de Gaia/PT, 6Hospital Beatriz Angelo/Loures/PT, 7Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos/Matosinhos/PT

P0926 - Therapeutic Practices in Multiple Sclerosis (MS) Amongst General Neurologists and MS Specialists

A. Subei1, R. Bermel2, C. Gianatasio3, W. Cerenzia4, B. Moss3, 1Memorial Healthcare System/Hollywood/US, 2Mellen Center for Multiple Sclerosis, Cleveland Clinic/Cleveland/US, 3Efficient LLC/Fort Lauderdale/US, 4CE Outcomes LLC/Birmingham/US

P0927 - Treatment discontinuation and restart among patients with multiple sclerosis using disease- modifying therapies

R. Fox1, R. Mehta2, T. Pham2, J. Park3, K. Wilson3, M. Bonafede3, 1Cleveland Clinic//US, 2Bristol-Myers Squibb Company/Princeton/US, 3IBM Watson Health/Cambridge/US

P0928 - Treatment patterns in Relapsing-Remitting Multiple Sclerosis patients starting injectable versus oral first-line Drug Modifying Therapies

M. Coutinho1, P. Faustino1, L. Leitão2, C. Capela2, M. Brum2, J. Parra2, J. Sequeira2, A. Barros2, C. Araújo2, A. Sousa2, F. Ladeira2, 1Centro Hospitalar Lisboa Central/Lisboa/PT, 2Centro Hospitalar Universitário de Lisboa Central/Lisbon/PT

P0929 - Two-Year Interim Analysis of the TREAT-MS Alemtuzumab Study in Germany Differentiated by the Number of Previous Disease-Modifying Therapies

T. Ziemssen1, R. White2, U. Engelmann2, R. Haase1, K. Akgün1, 1Carl Gustav Carus University Hospital/Dresden/DE, 2Sanofi Deutschland GmbH/Neu-Isenburg/DE

P0930 - Usage trend of oral drugs for multiple sclerosis in Argentina

R. Alonso1, B. Silva2, M.B. Eizaguirre1, F. Man1, A. Lopez Bisso1, L. Cohen1, C. Pita1, J. Rojas3, L. Patrucco4, E. Cristiano5, V. Tkachuk6, M.E. Balbuena6, E. Carnero Contentti7, P. Lopez7, J. Pettinicchi7, N. Deri8, J. Miguez9, A. Pappolla9, N. Fernandez Liguori10, J. Correale11, A. Carrá12, O. Garcea1, 1Hospital Ramos Mejía/Buenos Aires/AR, 2Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR, 3Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 4Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 5Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 6Hospital de Clínicas José de San Martín/Buenos Aires/AR, 7Hospital Alemán/Buenos Aires/AR, 8Centro de Investigaciones DIABAID/Buenos Aires/AR, 9Hospital Italiano de Buenos Aires/Buenos Aires/AR, 10Sanatorio Guemes/Buenos Aires/AR, 11Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR, 12Hospital Británico De Buenos Aires/Buenos Aires/AR

P0931 - Using real-world data from a large, multi-specialty health care system to longitudinally phenotype multiple sclerosis

A. Greenfield1, S. Robinson2, P. Kenkare3, K. Gillespie3, M. Harms3, J. Farnan3, K. Christensen2, H. Law2, G. Tranah4, 1Palo Alto Medical Foundation/Mountain View/US, 2Sutter Health/Walnut Creek/US, 3Palo Alto Medical Foundation Research Institute/Palo Alto/US, 4California Pacific Medical Center Research Institute/San Francisco/US

P0932 - Vitamin D levels and clinical outcomes and quantitative MRI metrics in a real-world MS cohort

A. Mahadeen1, J. Abbatemarco2, I. Briskin1, D. Ontaneda3, 1Cleveland Clinic/Cleveland/US, 2University of Utah/Utah City/US, 3Cleveland Clinic//US

P0933 - Inhibition of protein disulfide isomerase has neuroprotective effects in a mouse model of experimental autoimmune encephalomyelitis

M.H. Harirchian1, M. Kamarehei2, S. Pejman2, S. Kaboudanian Ardestani2, H. Zahednasab2, M. Firouzi2, 1Tehran University of Medical Sciences, Iranian Center for Neurological Research/Tehran/IR, 2a Institute of Biochemistry and Biophysics, University of Tehran/Tehran/IR

P0934 - A novel experimental model to assess the contribution of heterogeneous nuclear ribonucleoprotein A1 (A1) mutations to neurodegeneration in MS.

J.-P. Clarke, D. Kim, C. Hutchinson, M. Levin, University of Saskatchewan/Saskatoon/CA

P0935 - Absence of B cells in brainstem and white matter lesions associates with a less severe disease and absence of oligoclonal bands in MS autopsy cases

N. Fransen1, B. De Jong2, K. Hess3, T. Kuhlmann3, M. Vincenten1, J. Hamann2, I. Huitinga1, J. Smolders4, 1Netherlands Institute for Neuroscience/Amsterdam/NL, 2Amsterdam University Medical Centers/Amsterdam/NL, 3University Hospital Münster/Münster/DE, 4Erasmus University Medical Center/Rotterdam/NL

P0936 - Active MS patients revealed a higher expression of EBV-DNA in their CD19+ cells in comparison to stable MS patients and controls

M.C. Monaco, NIH/Bethesda/US

P0937 - Altered expression of myelin-related RNA binding proteins in a mouse model of multiple sclerosis A. Jahanbazi Jahan-Abad1, C. Libner2, H. Salapa3, M. Levin3, 1Office of the Saskatchewan Multiple Sclerosis Clinical Research Chair/Saskatoon/CA, 2/Saskatoon/CA, 3University of Saskatchewan/Saskatoon/CA

P0938 - An effective gene-immunotherapy for Multiple Sclerosis in mice.

G. Keeler1, I. Cote1, A. Sagadevan2, C. Gaddie1, B. Hoffman1, 1University of Florida/Gainesville/US, 2Hoffman Lab/Gainesville/US

P0939 - Antibody titters against EBV and HHV-6A/B and expression of MSRV ENV in the serum of pregnant multiple sclerosis patients

R. Alvarez-Lafuente1, S. Pérez-Pérez2, J.P. Cuello3, M.L. Martínez-Ginés3, B. Pardo-Rodríguez2, J.M. García-Domínguez3, M.I. Domínguez-Mozo2, A. Lozano-Ros3, M.Á. García-Martínez2, Y. Higueras4, A. Meldaña-Rivera3, H. Goicoechea-Briceño3, A. Tejada-Velarde5, J.I. Fernandez-Velasco5, S. Medina5, R. Arroyo6, L.M. Villar5, 1Hospital Clínico San Carlos/Madrid/ES, 2Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Madrid/ES, 3Hospital General Universitario Gregorio Marañón/Madrid/ES, 4IISGM/Madrid/ES, 5Hospital Universitario Ramón y Cajal/Madrid/ES, 6Hospital Universitario Quirónsalud Madrid/Pozuelo de Alarcón. Madrid/ES

P0940 - Anti-CD20 therapy prevents cortical demyelination in a new rat model

M.T. Haindl1, M. Üçal1, L. Tögl1, B. Klaus1, J. Dohrmann1, M. Adzemovic2, C. Enzinger3, S. Hochmeister1, 1Medical_University_Graz/Graz/AT, 2Karolinska Institutet/Stockholm/SE, 3Medical University of Graz/Graz/AT

P0941 - Anti-myelin oligodendrocyte glycoprotein autoantibodies trigger an Fc-Receptor and BTK- dependent proliferative response in microglia

K. Pellerin1, S. Rubino1, J. Burns1, B. Smith1, J. Zhu1, R. Basile1, L. Jandreski1, T. Reynolds1, B. Zhang1, E. Cahir-Mcfarland1, R. Ransohoff2, T. Cameron1, M. Mingueneau1, 1Biogen/Cambridge/US, 2Third Rock Ventures/Boston/US

P0942 - Astrocyte Topography Throughout the Multiple Sclerosis Motor Cortex and its Relationships with Genotype and Pathological Outcome

S. Yee1, R. Yates1, M. Esiri1, G. Deluca2, 1University of Oxford/Oxford/GB, 2Nuffield Department of Clinical Neurosciences, University of Oxford/Oxford/GB

P0943 - Autofluorescence identifies two subsets of microglia in healthy brain and defines their differential modulation by aging.

J. Burns1, B. Cotleur1, D. Walther1, B. Bajrami1, S. Rubino1, R. Wei1, N. Franchimont1, S. Cotman2, R. Ransohoff3, M. Mingueneau1, 1Biogen/Cambridge/US, 2Harvard Medical School/Boston/US, 3Third Rock Ventures/Boston/US

P0944 - B-cells uptake citrullinated myelin basic protein in MS meningeal tissue: cause or consequence?

A. Luchicchi1, K. Doetjes2, G. Schenk2, J. Geurts3, B. ´t Hart2, 1Amsterdam UMC, location VU medical center /Amsterdam/NL, 2Amsterdam UMC, location VU medical center/Amsterdam/NL, 3Amsterdam UMC, location VUmc/Amsterdam/NL

P0945 - Brain choroid plexus volume in Multiple Sclerosis versus Neuromyelitis Optica Spectrum Disease

J. Müller1, T. Sinnecker2, M.J. Wendebourg3, R. Schlaeger3, J. Kuhle4, P. Benkert5, T. Derfuss6, P. Cattin3, C. Jud3, F. Spiess3, M. Amann7, T. Lincke8, M. Barakovic9, A. Cagol8, S. Asseyer10, A. Duchow10, A. Brandt11, K. Ruprecht10, F. Paul12, N. Hadjikhani13, L. Kappos6, J. Wuerfel14, C. Granziera8, Ö. Yaldizli15, 1University of Basel/Basel/CH, 2Universitätsspital Basel/Basel/CH, 3Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering [Translational Imaging in Neurology (ThINk) Basel], University Hospital and University of Basel, Basel, Switzerland/Basel/CH, 4University of Basel/Switzerland/CH, 5University Hospital Basel, University of Basel/Basel/CH, 6University of Basel//CH, 7Medical Image Analysis Center Basel AG, Basel, Switzerland/Basel/CH, 8University Hospital Basel and University of Basel/Basel/CH, 9University of Basel/Allschwil/CH, 10NeuroCure Clinical Research Center, Experimental and Clinical Research Center, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany/Berlin/DE, 11Department of Neurology, University of California Irvine, Irvine, California, USA./Irvine/US, 12Charite-Universitatmedizin Berlin/Berlin/DE, 13Martinos Center for Biomedical Imaging, Massachussetts General Hospital and Harvard Medical School, Boston, MA, USA/Boston/US, 14Medical Image Analysis Center/Basel/CH, 15University Hospital Basel/Basel/CH

P0946 - CCR2+ monocytes require EMMPRIN for migration into EAE/MS brains

D. Kaushik1, J. Hahn2, C. Silva2, T. Vo3, A. Dufour3, V. Yong3, 1/Calgary/CA, 2Hotchkiss Brain Institute/Calgary/CA, 3University of Calgary/Calgary/CA

P0947 - CD11c+CD88+CD317+ myeloid cells are critical mediators of persistent CNS autoimmunity

N. Manouchehriardestani1, R. Hussain1, G. Wu2, B. Edelson2, M. Artyomov2, A. Cross3, E. Esaulova2, R. Doelger1, P. Cravens1, N. Loof4, T. Eagar5, L. Calvier6, J. Herz6, T. Forsthuber7, O. Stuve6, 1UT Southwestern medical center/Dallas/US, 2Washington University in St. Louis/United States/US, 3Washington University in St. Louis/St. Louis/US, 4Children's Medical center research institute UTSW/Dallas/US, 5Houston Methodist/Houston/US, 6UTSW/Dallas/US, 7UTSA/San Antonio/US

P0948 - CD20+ T cells emerge from pathogenic B cell- T cell interaction

J. Ochs1, N. Nissimov2, J. Koch2, K. Grondey2, M. Freier2, S. Häusser-Kinzel2, M. Weber3, 1University medical center Göttingen (UMG)/Göttingen/DE, 2University medical center Göttingen/Göttingen/DE, 3University Medical Center Goettingen/Goettingen/DE

P0949 - Cell population analysis in a patient-derived cerebral organoid model of multiple sclerosis.

E. Chen, N. Daviaud, S. Sadiq, Tisch MS Research Center of New York/New York City/US

P0950 - Cerebrospinal fluid IgM associates with specific inflammatory profile and disease features in early multiple sclerosis.

V. Mazziotti1, R. Magliozzi1, D. Marastoni1, L. Montibeller1, A. Pisani1, A. Tamanti1, S. Rossi2, F. Crescenzo1, M. Calabrese1, 1University of Verona/Verona/IT, 2National Institute of Health/Rome/IT

P0951 - Challenge to creation of neuromyelitis optica mice model by AQP4 peptide immunization

K. Serizawa, S. Miyake, H. Tomizawa-Shinohara, K. Yogo, Y. Matsumoto, Chugai Pharmaceutical Co., Ltd/Kanagawa/JP

P0952 - Characterization of age-related changes in circulating T cells in multiple sclerosis and normal controls: a pilot study

L. Zuroff1, R. Li2, K. Shinoda2, A. Rezk2, A. Bar-Or2, 1Hospital of the University of Pennsylvania/Philadelphia/US, 2University of Pennsylvania/Philadelphia/US

P0953 - Damage of the subventricular zone: relation with striatal atrophy and cognitive performance in MS

A. Zanghì, L. Cacciaguerra, A. Meani, O. Marchesi, M. Filippi, M.A. Rocca, IRCCS San Raffaele Scientific Institute/Milan/IT

P0954 - Dectin-1 limits central nervous system autoimmunity through a non-canonical pathway

M. Deerhake1, K. Danzaki1, M. Inoue2, E. Cardakli1, T. Nonaka1, N. Aggarwal1, W. Barclay1, R.R. Ji1, M. Shinohara1, 1Duke University/Durham/US, 2University of Illinois at Urbana-Champaign/Urbana/US

P0955 - Diffuse inflammation relates to demyelination and clinical parameters in primary (PP) and secondary progressive multiple sclerosis (SP).

S. Bramow1, H. Broholm2, J. Christensen3, M. Paunovic4, B. Okutan3, M. Magyari1, H. Laursen2, P. Soerensen3, H. Siebner5, J. Frischer6, M. Von Essen3, H. Lassmann7, F. Sellebjerg8, 1Danish Multiple Sclerosis Center/Glostrup/DK, 2Copenhagen University Hospital, Rigshospitalet/Copenhagen/DK, 3Copenhagen University Hospital, Rigshospitalet/Glostrup/DK, 4Center for Brain Research/Medical University of Vienna/Vienna/AT, 5Copenhagen University Hospital, Hvidovre/Hvidovre/DK, 6Medical Unicversity of Vienna, Allgemeines Krankenhaus Wien/Vienna/AT, 7Medical University of Vienna/Vienna/AT, 8Danish MS Center, University of Copenhagen/Copenhagen/DK

P0956 - DNA methylation of cerebrospinal fluid cells in Multiple Sclerosis G. Zheleznyakova1, Y. Han2, E. Ivanova3, M. Khademi1, F. Piehl4, T. Olsson4, G. Kelsey3, M. Needhamsen1, M. Jagodic4, 1Karolinska Institutet/Stockholm/SE, 2/Stockholm/SE, 3The Babraham Institute/Cambridge/GB, 4Karolinska Institute/Stockholm/SE

P0957 - Does peripheral immune profile reflect intrathecal inflammation in multiple sclerosis patients at time of diagnosis?

R. Magliozzi, A. Vella, D. Postinghel, V. Mazziotti, S. Rossi, A. Giacomazzi, M. Castellaro, D. Marastoni, F. Crescenzo, V. Bronte, S. Monaco, M. Calabrese, University of Verona/Verona/IT

P0958 - Drug library screen identifies inhibitors of toxic astrogliosis

R. Masvekar, P. Kosa, C. Barbour, B. Bielekova, National Institutes of Health/Bethesda/US

P0959 - Dysfunction of the RNA binding protein hnRNP A1 contributes to disease progression and neurodegeneration in an animal model of multiple sclerosis

C. Libner1, H. Salapa2, M. Levin2, 1/Saskatoon/CA, 2University of Saskatchewan/Saskatoon/CA

P0960 - Effect of systemic inflammation on repaired cortical lesions: from innate to adaptive response

B. Silva1, M. Leal2, M. Farías2, J. Avalos3, E. Miglietta2, F. Pitossi2, C. Ferrari4, 1Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR, 2Leloir Institute Fundation/Buenos Aires/AR, 3Italian Hospital/Buenos Aires/AR, 4Leloir Institute Fundation-IMTIB/Buenos Aires/AR

P0961 - Excitation-inhibition balance in multiple sclerosis: a quantification of glutamatergic and GABA-ergic synapse loss

M. Huiskamp1, S. Kiljan2, L. Jonkman3, J. Bol2, G. Schenk4, H. Hulst5, J. Geurts3, 1Amsterdam UMC, location VUmc/No/NL, 2Amsterdam UMC, VUmc/Amsterdam/NL, 3Amsterdam UMC, location VUmc/Amsterdam/NL, 4Amsterdam UMC, location VU medical center/Amsterdam/NL, 5MS Center Amsterdam/Amsterdam/NL

P0962 - Expression of Bruton’s tyrosine kinase in B cell-rich meningeal infiltrates in two models of progressive MS

H. Kebir1, G. Ceja1, M. Miller1, C. Li1, M. May1, C. Vite1, M. Church1, R. Grenningloh2, U. Boschert3, J. Alvarez1, 1University of Pennsylvania/Philadelphia/US, 2EMD Serono Research & Development Institute, Inc./Billerica/US, 3Ares Trading SA (an affiliate of Merck KgaA, Darmstadt, Germany)/Eysins/CH

P0963 - Filtration of primary progressive MS CSF removes factors causing delayed remyelination of lysolecithin lesions J. Beaty1, T. Shue2, A. Roselle2, J. Wong2, S. Sadiq3, 1Tisch MS Research Center/New York/US, 2Tisch Multiple Sclerosis Research Center of New York/New York/US, 3Tisch MS Research Center of New York/New York City/US

P0964 - Herpesvirus serology in primary progressive multiple sclerosis

R. Alvarez-Lafuente1, M.I. Domínguez-Mozo2, S. Pérez-Pérez2, M.Á. García-Martínez2, Y. Aladro3, B. Pilo3, M.L. Martínez-Ginés4, J.M. García-Domínguez4, I. González-Suárez5, P. Salgado-Cámara6, C. López De Silanes7, I. Casanova7, J. Sotoca8, R. Arroyo9, 1Hospital Clínico San Carlos/Madrid/ES, 2Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Madrid/ES, 3Hospital Universitario de Getafe/Getafe. Madrid/ES, 4Hospital General Universitario Gregorio Marañón/Madrid/ES, 5Complejo Hospitalario Universitario de Vigo/Vigo/ES, 6Hospital Universitario 12 de Octubre/Madrid/ES, 7Hospital Universitario de Torrejón/Torrejón de Ardoz. Madrid/ES, 8Hospital Universitario Mutua de Terrassa/Terrassa. Barcelona/ES, 9Hospital Universitario QuirónSalud Madrid/Pozuelo de Alarcón. Madrid/ES

P0965 - HGF/c-Met pathway and CD4+ T cell functions in EAE

P. Lalive, Geneva University Hospitals/Geneva/CH

P0966 - How Do Exosome Enriched Fractions from Multiple Sclerosis Patients Cultured B Cells Kill Oligodendroglia

R. Lisak1, L. Nedelkoska1, H. Touil1, P. Stemmer1, N. Carruthers1, L. Zuroff2, A. Bar-Or2, J. Benjamins1, 1Wayne State University School of Medicine/Detroit/US, 2University of Pennsylvania/Philadelphia/US

P0967 - Identification and Characterization of Adherence Trajectory Subgroups in Patients with MS Initiating Once- or Twice-Daily Oral Disease-Modifying Drugs

M. Cisternas1, D. Rajagopalan1, M. Leszko1, K. Andrade1, A. Phillips2, N. White3, 1Optum/Eden Prairie/US, 2EMD Serono, Inc./Rockland/US, 3Ashfield Healthcare/New York/US

P0968 - Imaging butyrylcholinesterase in multiple sclerosis

M. Thorne1, M. Cash1, G.A. Reid2, D. Luke2, D. Burley3, I. Pottie3, S. Darvesh1, 1Dalhousie/Halifax/CA, 2Dalhousie University/Halifax/CA, 3Mount St. Vincent University/Halifax/CA

P0969 - Imbalance of TNF and TNF receptors in the cerebrospinal fluid of naïve multiple sclerosis patients

R. Magliozzi1, S. Rossi1, F. Pezzini1, D. Marastoni1, M. Pucci1, V. Mazziotti1, F. Crescenzo1, F. Facchiano2, G. Lippi1, R. Reynolds3, M. Calabrese1, 1University of Verona/Verona/IT, 2Istituto superiore di Sanità/Rome/IT, 3Imperial College London/London/GB

P0970 - Immunoelectron microscopy for ultrastructural studies of oligodendrocyte progenitors

M.J. Ulloa-Navas1, J.M. García-Verdugo1, V. Herranz-Pérez2, 1University of Valencia/Paterna/ES, 2University of Valencia-CIBERNED/Paterna/ES

P0971 - Immunoglobulins specific for Epstein-Barr virus proteins bind to microglia

J. Lindsey, M. Hernandez, X. Zhao, University of Texas Health Science Center at Houston/Houston/US

P0972 - Impact of age on the immune system and the central nervous system in experimental autoimmune encephalomyelitis

M. Dema1, H. Eixarch1, L. Calvo-Barreiro1, M. González1, M. Castillo1, L.M. Villar2, X. Montalban1, C. Espejo3, 1Dept. of Neurology-Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 2Hospital Universitario Ramón y Cajal/Madrid/ES, 3Hospital Universitario Vall D´Hebron/Barcelona/ES

P0973 - Impact of Epstein-Barr virus infection on CXCR3+ B-cell development: lessons learned from immunotherapies in MS

J. Van Langelaar1, A. Wierenga-Wolf2, J. Samijn3, C. Luijks2, L. Rijvers2, M.J. Melief2, T. Siepman2, P. Van Doorn2, A. Bell4, M. Van Zelm5, H. De Vries6, P.P. Unger7, S.M. Van Ham7, J. Smolders1, M. Van Luijn8, 1Erasmus University Medical Center/Rotterdam/NL, 2MS Center ErasMS, Erasmus University Medical Center/Rotterdam/NL, 3Maastad Hospital/Rotterdam/NL, 4University of Birmingham/Birmingham/GB, 5Monash University/Melbourne/AU, 6Amsterdam University Medical Center, MS Center Amsterdam/Amsterdam/NL, 7Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center/Amsterdam/NL, 8MS Center ErasMS, Erasmus MC/Rotterdam/NL

P0974 - Is salt consumption an envorimental risk factor for multiple sclerosis?

S.D. Bünül, H. Efendi, Kocaeli University/Kocaeli/TR

P0975 - Lipid-specific oligoclonal IgM bands condition age-related changes in multiple sclerosis

C. Picón1, A. Tejeda-Velarde1, J.I. Fernandez-Velasco1, M. Comabella2, R. Alvarez-Lafuente3, E. Quintana4, S. Sainz De La Maza1, E. Monreal1, N. Villarrubia1, J.C. Álvarez-Cermeño1, M.I. Domínguez- Mozo5, L. Ramió I Torrentà4, E. Rodríguez-Martin1, E. Roldán1, Y. Aladro6, S. Medina1, M. Espiño1, J. Masjuan1, C. Matute-Blanch7, M. Muñoz-San Martin8, C. Espejo7, C. Guaza9, L. Costa-Frossard1, L.M. Villar1, 1Hospital Universitario Ramón y Cajal/Madrid/ES, 2Universitat Autònoma//ES, 3Hospital Clínico San Carlos/Madrid/ES, 4Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 5Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Madrid/ES, 6Hospital Universitario de Getafe/Getafe. Madrid/ES, 7Hospital Universitario Vall D´Hebron/Barcelona/ES, 8Hospital Josep Trueta/Girona/ES, 9Instituto Cajal/Madrid/ES

P0976 - Lymphotoxin alpha overexpression in the meninges causes lymphoid-like tissue development and subsequent neurodegeneration

R. James, C. Picon Munoz, E. Browne, N. Mazarakis, R. Reynolds, Imperial College London/London/GB

P0977 - Melatonin reduces disability in experimental autoimmune encephalomyelitis by impairing immune cells migration and entry into the CNS

A.I. Álvarez-López1, I. Cruz-Chamorro1, G. Santos-Sánchez1, E. Ponce-España1, J.M. Fernández- Santos2, J.C. Utrilla Alcolea2, I. Bejarano-Hernando1, P.J. Lardone1, N. Álvarez-Sánchez1, A. Carrillo- Vico1, 1Instituto de Biomedicina de Sevilla (IBiS), Lab 210/Sevilla/ES, 2Departmento de Citología e Histología Normal y Patológica, Universidad de Sevilla/Sevilla/ES

P0978 - Metabotropic glutamate receptors are associated with cerebellar dysfunction in multiple sclerosis

J. Granato1, T. Edwards2, A. Iacoangeli2, S. Sadiq1, 1Tisch MS Research Center of New York/New York City/US, 2Tisch Multiple Sclerosis Research Center of New York/New York/US

P0979 - Methylome and transcriptome signature of bronchoalveolar cells from Multiple Sclerosis patients in relation to smoking

M. Ringh1, M. Hagemann-Jensen1, M. Needhamsen1, S. Kullberg2, J. Wahlström1, J. Grunewald1, B. Brynedal1, M. Jagodic1, T. Ekström1, J. Öckinger1, L. Kular3, 1Karolinska Institute/Stockholm/SE, 2Karolinska University Hospital/Stockholm/SE, 3Karolinska Institutet/Stockholm/SE

P0980 - MicroRNA-150 controls experimental autoimmune encephalomyelitis by regulating CD4 T cell differentiation and function

E. Piket1, M. N'Diaye1, E. Ewing2, L. Williams1, A. Olofsson1, L. Mrugalla1, G.A. Zisiadis1, I. Lavrnja1, W. Nyberg1, A. Espinosa1, L. Kular2, A. Ortlieb Guerreiro-Cacais1, M. Jagodic1, 1Karolinska Institute/Stockholm/SE, 2Karolinska Institutet/Stockholm/SE

P0981 - Monitoring of encephalitogenic cells treated with nanoparticles in adoptively transferred experimental autoimmune encephalomyelitis.

R. García-Hernández1, A. Nakal-Chidiac2, A. Sánchez-Sanz3, M.R.A. Aguilar2, A. Garcia-Grande1, M.J. Coronado-Albi4, L. García-Fernández5, M. Criado-González2, C. Zamora Cañadas1, J.A. García- Merino6, A.J. Sánchez-López4, 1Puerta de Hierro-Segovia de Arana Health Research Institute/Madrid/ES, 2Institute of Polymer Science and Technology/Madrid/ES, 3Puerta de Hierro Health Research Institute/Majadahonda/ES, 4Instituto de Investigación Sanitaria Puerta de Hierro- Segovia de Arana/Madrid/ES, 5Networking Biomedical Research Centre in Bioengineering, Biomaterials and Nanomedicine/Madrid/ES, 6Hospital Universitario Puerta de Hierro/Madrid/ES

P0982 - MR T2-relaxation time as an indirect measure of brain water accumulation in Neuromyelitis Optica Spectrum Disorders

L. Cacciaguerra1, M.A. Rocca1, E. Pagani1, M. Radaelli2, S. Mesaros3, V. Martinelli1, J. Ivanović4, M. Filippi1, 1IRCCS San Raffaele Scientific Institute/Milan/IT, 2San Raffaele Hospital/Milan/IT, 3University of Belgrade/Belgrade/IT, 4University of Belgrade/Belgrade/RS

P0983 - Multiple therapeutic approaches for Baló’s Concentric Sclerosis : study of 10 cases

D. Tzanetakos1, A. Vakrakou1, J. Tzartos1, G. Velonakis2, M.E. Evangelopoulos1, M. Anagnostouli3, G. Koutsis1, E. Dardiotis4, E. Karavasilis5, P. Toulas5, L. Stefanis1, C. Kilidireas1, 1Eginition Hospital, National and Kapodistrian University of Athens/Athens/GR, 2Research Unit of Radiology, 2nd Department of Radiology, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece/Athens/GR, 3Aeginition Hospital, Medical School, National and Kapodistrian University of Athens/Athens/GR, 4Department of Neurology, University of Thessaly, University Hospital of Larissa, Larissa, Greece./Larissa/GR, 5Research Unit of Radiology, 2nd Department of Radiology, National and Kapodistrian University of Athens, Athens, Greece/Athens/GR

P0984 - Neuron-specific activation of necroptosis signaling in multiple sclerosis cortical grey matter

C. Picon Munoz1, R. James1, A. Jayaraman2, M. Witte3, J. Van Horssen4, N. Mazarakis1, R. Reynolds1, 1Imperial College London/London/GB, 2Nanyang Technological University/Singapore/SG, 3Amsterdam UMC/Amsterdam/NL, 4VU Medical Center/Amsterdam/NL

P0985 - Obesity and Multiple Sclerosis risk. The role of Leptin

M. Marrodan1, M. Farez1, M.E. Balbuena2, J. Correale3, 1FLENI/CIUDAD DE BUENOS AIRES/AR, 2Hospital de Clínicas José de San Martín/Buenos Aires/AR, 3Raúl Carrea Institute for Neurological Research, Fleni/Argentina/AR

P0986 - Online Medical Education Improves Knowledge of Age-Related Immune System Changes in Patients with MS Among Neurologists

T. Finnegan1, C. Murray2, J. Maeglin3, G. Giovannoni4, 1Medscape Education/Newtown Square/US, 2Medscape Education/New Yrok/US, 3Medscape Education/New York/US, 4The London School of Medicine and Dentistry/London/GB

P0987 - Pathological effects of primary progressive MS cerebrospinal fluid are antibody-mediated

J. Wong1, T. Shue1, J. Beaty2, J. Vernejoul3, J. Lin1, S. Sadiq3, 1Tisch Multiple Sclerosis Research Center of New York/New York/US, 2Tisch MS Research Center/New York/US, 3Tisch MS Research Center of New York/New York City/US

P0988 - Pentamidine as a new therapeutic strategy against Multiple Sclerosis-like pathology C. Barros1, A. Barateiro1, B. Soromenho1, A. Basto2, D. Brites2, L. Graça2, A. Fernandes1, 1Research Institute for Medicines (iMed.ULisboa)/Lisbon/PT, 2Instituto de Medicine Molecular João Lobo Antunes/Lisbon/PT

P0989 - PLP gene immunotherapy ameliorates disease and prevents epitope spreading in mouse models of RRMS

I. Cote1, A. Sagadevan2, C. Gaddie1, B. Hoffman1, G. Keeler1, 1University of Florida/Gainesville/US, 2Hoffman Lab/Gainesville/US

P0990 - Pro-inflammatory cytokines and autoantibodies induce dysfunctional RNA binding protein biology in primary cortical neurons

M. Li, R. Hamilton, H. Salapa, M. Levin, University of Saskatchewan/Saskatoon/CA

P0991 - Protective and Remyelinating Potential of Siponimod in a Xenopus Model of Demyelination and a Mouse Model of Experimental Autoimmune Encephalomyelitis

M. Dietrich1, C. Hecker1, E. Martin2, D. Langui2, M. Gliem1, B. Stankoff2, C. Lubetzki3, A. Issberner1, P. Ramseier4, C. Beerli4, C. Moebs4, C. Afatsawo4, S. Tisserand5, H.P. Hartung6, M. Bigaud5, B. Zalc2, P. Albrecht1, 1University Hospital Düsseldorf/Düsseldorf/DE, 2Sorbonne Université/Paris/FR, 3Hôpital Pitié- Salpêtrière/Paris/FR, 4Novartis Institutes for BioMedical Research/Basel/CH, 5Novartis Pharma AG/Basel/CH, 6/Dusseldorf/DE

P0992 - Psycho-thermogenic hypothesis of multiple sclerosis: Deregulation of cross-talk between adrenergic signaling and mitochondrial metabolic pathways.

T. Sukhomlin1, H. Westerhoff2, 1/Dolgoprunyy, Moscow region/RU, 2Infrastructure Systems Biology Europe at NL, Systems Biology and Nuclear Organization, University of Amsterdam/Amsterdam/NL

P0993 - Reconstitution of a pathogenic antibody of a unique case of human autoimmune encephalitis

M. Paunovic1, E. Beltran2, E. Cesur3, J. Malotka2, R. Höftberger4, S. Mader2, N. Kawakami2, E. Meinl5, K. Dornmair2, M. Bradl3, H. Lassmann6, 1Center for Brain Research/Medical University of Vienna/Vienna/AT, 2Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich/Planegg-Martinsried/DE, 3Department of Neuroimmunology, Center for Brain Research/Medical University of Vienna/Vienna/AT, 4Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna/Vienna/AT, 5LMU/Martinsried/DE, 6Medical University of Vienna/Vienna/AT

P0994 - RGC-32 regulates astrocyte differentiation during experimental autoimmune encephalomyelitis

A. Tatomir1, A. Beltrand1, D. Boodhoo1, V. Nguyen1, C. Cudrici2, T. Badea3, V. Rus1, H. Rus1, 1University of Maryland School of Medicine/Baltimore/US, 2NIH/Bethesda/US, 3National Eye Institute/Bethesda/US

P0995 - Sarm1 knockout delays but does not confer long-term protection from axonal degeneration in experimental allergic encephalomyelitis

U. Oh, Virginia Commonwealth University School of Medicine/Richmond/US

P0996 - Single-cell RNA-sequencing implicates venous endothelial cells as a source of neo- angiogenesis in acute and chronic EAE.

D. Agalliu1, S. Shahriar1, G. Gold2, C. Wayne1, H. Stuhlman3, V. Menon1, 1Columbia University Irving Medical Center/New York/US, 2Ardsley High School/Ardsley/US, 3Weill Cornell Medical College/New York/US

P0997 - Sphingosine 1-phosphate (S1P) inhibits astrocytic glutamate uptake through S1P receptor 2 (S1P2)

D. Jonnalagadda, Y. Kihara, R. Rivera, J. Chun, Sanford Burnham Prebys Medical Discovery Institute/La Jolla/US

P0998 - The immunological features of peripheral blood findings from multiple sclerosis patients sustaining NEDA-3.

M. Minote1, W. Sato2, T. Okamoto1, R. Takahashi3, T. Yamamura2, 1National Center of Neurology and Psychiatry/Kodaira-shi,Tokyo/JP, 2National Center of Neurology and Psychiatry/Kodaira/JP, 3Kyoto University Graduate School of Medicine/Kyoto/JP

P0999 - The role of neuronal CXCL13 chemokine expression in Multiple Sclerosis Pathology

R. James, H. Jacobs, X. Zhang, R. Reynolds, Imperial College London/London/GB

P1000 - Two novel medium-throughput assays for drug screening in multiple sclerosis.

R. Fern1, V. Mitchener1, C. Matute2, 1University of Plymouth/Plymouth/GB, 2EHU/Bilboa/ES

P1002 - “Don’t give up on us!”: Findings from progressive MS patients on disease-modifying therapy

A. Ahsan, S. Comito, B. Green, L. Lawhon, L. Herbert, Health Union/Philadelphia/US

P1003 - A cohort analysis of MS patients exposed to high-dose corticosteroids

M. Fronza1, L. Lorefice2, J. Frau2, G. Fenu3, G. Coghe2, D. Carmagnini4, M. Fois5, E. Casaglia5, S. Barca5, E. Cocco5, 1Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/cagliari/IT, 2Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/Cagliari/IT, 3Brotzu Hospital/Cagliari/IT, 4Multiple Sclerosis Center, Binaghi Hospital, University of Cagliari/Cagliari/IT, 5University of Cagliari/Cagliari/IT

P1004 - A real-world study characterizing symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis using a novel disease specific scale M. Azoulai1, T. Lévy-Heidmann1, V. Morisseau1, C. Jamieson2, L. Charvet3, L. Krupp3, L. Lair4, 1Carenity/Paris/FR, 2Janssen Research & Development/Milpitas/US, 3NYU Langone/New York City/US, 4Janssen/Titusville/US

P1005 - An electronic, unsupervised Patient Reported Expanded Disability Status Scale for Multiple Sclerosis

W. Rowles1, A. Romeo2, E. Schleimer2, P. Barba2, W.-Y. Hsu1, R. Gomez2, A. Santaniello2, C. Zhao2, J. Pearce3, J. Jones4, B. Cree2, S. Hauser2, J. Gelfand2, U.M.E.S. Group2, W. Stewart5, D. Goodin2, R. Bove1, 1University of California, San Francisco/San Francisco/US, 2University of California San Francisco/San Francisco/US, 3Plain Language Health/Pleasant Hill/US, 4Sutter Health/Walnut Creek/US, 5Medcurio, Inc./Oakland/US

P1006 - An investigation into the role and impact that carers play in consultations between healthcare professionals and people with MS

D. Langdon1, M.-L. Sumelahti2, S. Potra3, R. Alroughani4, E. Verdun Di Cantogno5, 1University of London//GB, 2University of Tampere/Finland/FI, 33Member of the MS in the 21st Century Steering Group/Bucharest/RO, 4Amiri Hospital/Kuweit/KW, 5Merck KGaA/Germany/DE

P1007 - Assessing the impact of fatigue, disability, depression on quality of life in adults with multiple sclerosis: a systematic review

N.A. Fillah1, N. Alkhaldi2, N. Nag2, S. Neate2, S. Simpson-Yap2, 1Melbourne School of Population and Global Health, The University of Melbourne/Melbourne/AU, 2The University of Melbourne/Melbourne/AU

P1008 - Brain volume loss is an important treatment attribute among RRMS patients: findings from a discrete choice experiment

K. Beusterien1, J. Kumar2, O. Will3, M.J. Cambron-Mellott3, D. Mackie3, T. Tencer2, 1Kantor/New York/US, 2Bristol Myers Squibb/Princeton/US, 3Kantar/New York/US

P1009 - Characteristics and patient-reported outcomes of patients initiating ocrelizumab in the NARCOMS Registry from 2017 to 2019

A. Salter1, S. Lancia2, R.A. Marrie3, R. Fox4, N. Engmann5, 1Washington University School in St. Louis/St Louis/US, 2Washington University School in St. Louis/St. Louis/US, 3University of Manitoba/Winnipeg/CA, 4Cleveland Clinic//US, 5Genentech, Inc./South San Francisco/US

P1010 - Comparison of Models for Disability Accumulation on the Expanded Disability Status Scale in Multiple Sclerosis

B. Healy1, B. Glanz2, E. Swallow3, J. Signorovitch3, K. Hagan3, D. Silva4, C. Pelletier4, T. Chitnis5, H. Weiner6, 1Harvard Medical School/United States/US, 2Brigham and Women's Hospital/Boston/US, 3The Analysis Group/Boston/US, 4Bristol-Myers Squibb Company/Princeton/US, 5Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US, 6Harvard University, Brigham & Women's Hospital/Boston/US

P1011 - Complications after lumbar puncture: a preliminary comparative analysis on the use of atraumatic vs standard needle

D. Carmagnini1, L. Lorefice2, G. Fenu3, J. Frau2, G. Coghe2, M. Fronza4, S. Barca5, E. Cocco5, 1Multiple Sclerosis Center, Binaghi Hospital, University of Cagliari/Cagliari/IT, 2Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/Cagliari/IT, 3Brotzu Hospital/Cagliari/IT, 4Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/cagliari/IT, 5University of Cagliari/Cagliari/IT

P1012 - Coping Strategies: Seeking personalized care in Multiple Sclerosis. A patient reported measure– Coping Responses Inventory.

S. Vanotti1, N. Ciufia1, M.B. Eizaguirre2, A. Marinangeli3, D. Rodrigo3, R. Alonso2, O. Garcea2, 1Buenos Aires University. Faculty of Psychology. Research Institute in Psychology./Buenos Aires/AR, 2Hospital Ramos Mejía/Buenos Aires/AR, 3Ramos Mejía Hospital/Buenos Aires/AR

P1013 - Dating with a diagnosis: The lived experience of people with Multiple Sclerosis.

K. Tabassum, J. Fox, S. Fuller, S.M. Hynes, National University of Ireland Galway/Galway/IE

P1014 - Decision Making Process in Argentinian Patients with Multiple Sclerosis

R. Alonso1, A. Chertcoff2, M.B. Eizaguirre1, B. Silva3, J. Bauer4, C. Curbelo2, F. Pagani Cassará5, V. Tkachuk6, G. Imhoff7, F. Leguizamon8, O. Garcea1, A. Carra9, 1Hospital Ramos Mejía/Buenos Aires/AR, 2Hospital Británico De Buenos Aires/Buenos Aires/AR, 3Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR, 4Esclerosis Múltiple Argentina (EMA)/Buenos Aires/AR, 5Hospital Universitario Fundación Favaloro/Buenos Aires/AR, 6Hospital de Clínicas José de San Martín/Buenos Aires/AR, 7Sanatorio Los Arcos/Buenos Aires/AR, 8Hospital de Agudos TEodoro Alvarez/Buenos Aires/AR, 9Hospital Britanico/CIUDAD DE BUENOS AIRES/AR

P1015 - Demonstrating the value of a patient support program for multiple sclerosis patients prescribed cladribine tablets in Ireland at the end of year 1

K. Morgan1, B. Joseph2, V. Williams2, M. Kelly3, 1Merck Serono Ltd/Feltham/GB, 2Beaumont Hospital/Dublin/IE, 3TCP Homecare/Dublin/IE

P1016 - Designing of a multicenter, non-interventional study to assess subjective disease perception in early-stage relapsing-remitting multiple sclerosis

S. Sainz De La Maza1, E. García-Arcelay2, M. Borges3, V. Sánchez-Menéndez2, C. Garcia-Bernaldez4, J. Mauriño4, G. Saposnik5, T. Castillo-Trivino6, 1Hospital Universitario Ramón y Cajal/Madrid/ES, 2Roche Farma/Madrid/ES, 3Hospital Universitario Virgen Macarena/Sevilla/ES, 4Roche/madrid/ES, 5Saint Michael´s Hospital/Toronto/CA, 6Hospital Universitario Donostia/San Sebastián/ES

P1017 - “Development and Validation of a New Questionnaire for Assessing Psychological Coping in Multiple Sclerosis Patients.”

Z. Panagopoulou1, A. Artemiadis2, G.P. Chrousos1, C. Darviri3, M. Anagnostouli4, 1National Kapodistrian University of Athens/Athens/GR, 2Medical School, University of Cyprus/Nicosia/CY, 3Postgraduate Program “The Science of Stress and Health Promotion”National Kapodistrian University of Athens/Athens/GR, 4Aeginition Hospital, Medical School, National and Kapodistrian University of Athens/Athens/GR

P1018 - Differences in perceptions of neurologists and patients about the challenges and outcomes in Multiple Sclerosis.

C.E. Marin1, D. Callegaro2, M.A. Lana-Peixoto3, Ó. Fernández4, A.P. Gomes Neto5, C.C.F. Vasconcelos6, J.A.C. D’Almeida7, M.V.M. Gonçalves8, M.F. Mendes9, M.K.F. Parolin10, O. Nascimento11, P.D. Gama12, R.P.C. Dias-Carneiro9, R.M. Dias13, A. Damasceno14, J. Becker15, 1Hospital São Lucas da PUCRS/000/BR, 2Hospital das Clínicas – Faculdade de Medicina de São Paulo/São Paulo/BR, 3Hospital das Clínicas de Minas Gerais - UFMG/Belo Horizonte/BR, 4Fundacion IMABIS, Hospital Universitario Carlos Haya/Málaga/ES, 5Santa Casa de Belo Horizonte/Belo Horizonte/BR, 6Universidade Federal do Estado do Rio de Janeiro/Rio de Janeiro/BR, 7Hospital Geral de Fortaleza/Fortaleza/BR, 8Universidade da Região de Joinville/Joinville/BR, 9Faculdade de Ciências Médicas da Santa Casa de São Paulo/São Paulo/BR, 10Associação Paranaense de Ciências Neurológicas/Curitiba/BR, 11Universidade Federal Fluminense/Rio de Janeiro/BR, 12Pontifícia Universidade Católica de São Paulo/São Paulo/BR, 13Hospital de Base do Distrito Federal/Brasília/BR, 14Universidade Estadual de Campinas/Campinas/BR, 15Pontifical Catholic University of Rio Grande do Sul/Brazil/BR

P1019 - Discordant patient and provider perceptions of care and shared decision-making practices in multiple sclerosis

R. Bermel1, C. Heggen2, J. Carter2, T. Sapir2, 1Cleveland Clinic/Cleveland/US, 2PRIME Education, LLC/Fort Lauderdale/US

P1020 - Disease perception and its determinants in Relapsing-Remitting Multiple Sclerosis patients

A.R. Silva1, H. Felgueiras2, A.I. Gonçalves3, A. Fernandes4, B. Meira5, D. Melância6, J. Rosa4, M.T. Silvério7, A. Macedo8, 1Hospital de Braga/Braga/PT, 2Centro Hospitalar de Vila Nova de Gaia/Espinho/Vila Nova de Gaia/PT, 3Hospital Beatriz Angelo/Loures/PT, 4Centro Hospitalar de Lisboa Central/Lisboa/PT, 5Hospital Egas Moniz/Lisboa/PT, 6Centro Hospitalar Universitário de Lisboa Central/Lisboa/PT, 7Hospital Garcia de Orta/Almada/PT, 8Keypoint/Lisbon/PT

P1021 - Does the WHODAS 2.0 comprehensively measure disability in multiple sclerosis?

R. Mills1, A. Tennant2, C. Young1, 1Walton Centre Foundation Trust/Liverpool/GB, 2University of Leeds/Leeds/GB

P1022 - Dutch registry

K. Harrison, Tergooi hospital/Blaricum/NL

P1023 - Early experience engaging patients in the use of a mobile application for tracking multiple sclerosis.

J. Jones1, X. Yan1, J. Liu1, I. Popova1, D. Mitchell1, M. Lindemann2, M. Baker2, J. Schjodt-Eriksen2, L. Julian3, 1Sutter Health/Walnut Creek/US, 2Hoffman-La Roche Ltd/Basel/CH, 3Genentech, Inc./South San Francisco/US

P1024 - Economic impact of the Secondary Progressive Multiple Sclerosis in Spain: Interim analysis of the DISCOVER study

C. Oreja-Guevara1, J. Río2, J.R. Ara Callizo3, M.A. Hernández Pérez4, J. Gracia Gil5, L. Ramió I Torrentà6, B. Pilo De La Fuente7, A.M. Alonso Torres8, S. Martínez-Yélamos9, F. Gascón Giménez10, S. Eichau Madueño11, B. Casanova-Estruch12, M.L. Martínez Ginés13, M.L. Aguado Valcárcel14, J.E. Martínez Rodríguez15, A.M. López Real16, C. López De Silanes17, V. González Quintanilla18, Y. El Berdei Montero19, A. Labiano20, M. Garcés Redondo21, L. Costa-Frossard22, J.A. García Merino23, F. Castellanos Pinedo24, C. Muñoz Fernández25, V. Meca-Lallana26, T. Castillo-Trivino27, A. Ródríguez-Antiguedad28, J. Peña Martínez29, J.M. Prieto González30, D.M. Solar Sánchez31, I. Pérez Molina32, E. Agüera Morales33, N. Herrera Varo34, J. Meca-Lallana35, 1Hospital Universitario Clínico San Carlos/Madrid/ES, 2CEMCAT, Hospital Universitario Vall d’Hebrón/Barcelona/ES, 3Hospital Universitario Miguel Servet/Zaragoza/ES, 4Hospital Universitario Nuestra Señora de la Candelaria/Santa Cruz de Tenerife/ES, 5Complejo Hospitalario Universitario de Albacete/Albacete/ES, 6Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 7Hospital Universitario de Getafe/Madrid/ES, 8Hospital Regional Universitario Carlos Haya/Málaga/ES, 9Hospital Universitari de Bellvitge/L'Hospitalet de Llobregat-Barcelona/ES, 10Hospital Clínico de Valencia/Valencia/ES, 11Hospital Universitario Virgen Macarena/Sevilla/ES, 12Hospital La Fe/Valencia/ES, 13Hospital Gregorio Marañón/Madrid/ES, 14Hospital Álvaro Cunqueiro/Vigo/ES, 15Hospital del Mar/Barcelona/ES, 16Complexo Hospitalario Universitario A Coruña/A Coruña/ES, 17Hospital Universitario de Torrejón/Madrid/ES, 18Hospital Universitario Marqués de Valdecilla/Cantabria/ES, 19Hospital Universitario de Salamanca/Salamanca/ES, 20Hospital Universitario 12 de Octubre/Madrid/ES, 21Hospital Clínico Universitario Lozano Blesa/Zaragoza/ES, 22Hospital Universitario Ramón y Cajal/Madrid/ES, 23Hospital Universitario Puerta de Hierro/Madrid/ES, 24Hospital Virgen del Puerto Plasencia/Cáceres/ES, 25Hospital Universitario Torrecárdenas/Almería/ES, 26La Princesa Hospital/Madrid/ES, 27Hospital Universitario Donostia/San Sebastián/ES, 28Hospital Universitario de Cruces/Barakaldo/ES, 29Hospital Universitario San Agustín/Asturias/ES, 30Hospital Clínico Universitario de Santiago/Santiago de Compostela/ES, 31Hospital Universitario de Cabueñes/Gijón/ES, 32Hospital Virgen de la Salud/Toledo/ES, 33Hospital Universitario Reina Sofia/Córdoba/ES, 34Hospital Universitario de Burgos/Burgos/ES, 35Hospital Clínico Universitario Virgen de la Arrixaca/Murcia/ES

P1025 - Effects of general nutrition vs small group education on dietary changes of individuals living with multiple sclerosis. Z. Edwards, T. Malone, J. Schafer, B. Hutchinson, Dignity Health - MS Achievement Center/Citrus Heights/US

P1026 - Employment outcomes in multiple sclerosis

M. Jaworski1, C. Wojcik2, M. Youngs1, M. Unverdi1, T. Fuchs1, B. Weinstock-Guttman3, M. Dwyer4, R. Benedict5, 1University at Buffalo, Jacobs School of Medicine/Buffalo/US, 2University at Buffalo/Buffalo/US, 3State University of New York at Buffalo/Buffalo/US, 4Buffalo Neuroimaging Analysis Center/Buffalo/US, 5University At Buffalo/Buffalo/US

P1027 - Establishing Meaningful Change Threshold in Multiple Sclerosis related Fatigue on Fatigue Symptoms & Impacts Questionnaire-Relapsing MS (FSIQ-RMS)

S. Hudgens1, N. Boyanova12, E. Davies2, C. Jamieson3, A. Keenan4, 1Clinical Outcomes Solutions/Tuscon/US, 2Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies/Allschwil/CH, 3Janssen Research & Development/Milpitas/US, 4Janssen Research & Development, LLC/19477/US

P1028 - Evolution of Mental Health in Multiple Sclerosis: a longitudinal perspective

I. Gil-González1, A. Martín-Rodríguez1, F. Mateen2, M.Á. Pérez-San-Gregorio1, 1Universidad de Sevilla/Sevilla/ES, 2Massachusetts General Hospital/Boston/US

P1029 - Examining the relationship between the Multiple Sclerosis Resiliency Scale and the Five Factor Model of Personality

E. Gromisch1, A. Turner2, L. Neto1, F. Foley3, 1Mount Sinai Rehabilitation Hospital, Trinity Health Of New England/Hartford/US, 2VA Puget Sound Health Care System/Seattle/US, 3Yeshiva University/Bronx/US

P1030 - Exploring factors that impact on quality of life: coping strategies.

M. Román1, C. Diven Arguello2, C. Yastremiz2, A. Merino2, B. Silva3, C. Pita4, S. Vanotti1, O. Garcea4, 1Buenos Aires University. Faculty of Psychology. Research Institute in Psychology./Buenos Aires/AR, 2Ramos Mejía Hospital/Buenos Aires/AR, 3Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR, 4Hospital Ramos Mejía/Buenos Aires/AR

P1031 - Exploring the relevance and validity of wellbeing measures that can be used in cost- effectiveness analysis in the context of multiple sclerosis

E. Goodwin1, C. Green1, K. Boddy2, J. Freeman3, S. Thomas4, J. Chataway5, A. Hawton1, 1University of Exeter Medical School, University of Exeter/Exeter/GB, 2NIHR Applied Research Collaboration (ARC) South West Peninsula, University of Exeter Medical School, University of Exeter/Exeter/GB, 3University of Plymouth/Plymouth/GB, 4Bournemouth University/bournemouth/GB, 5UCL Queen Square Institute of Neurology, University College//GB

P1032 - Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with MS, irrespective of MS phenotype

Y. Zhang1, I. Van Der Mei2, B. Taylor2, 1Zhujiang Hospital, Nanfang Medical University/Haizhu District, Guangzhou/CN, 2University of Tasmania/Hobart/AU

P1033 - Health-related quality of life in relapsing multiple sclerosis patients from Argentina: impact of clinical features and coping strategies

E. Carnero Contentti1, R. Alonso2, P. Lopez1, M.B. Eizaguirre2, S. Tizio3, V. Tkachuk4, J. Criniti1, J. Pettinicchi1, A. Caride1, 1Hospital Alemán/Buenos Aires/AR, 2Hospital Ramos Mejía/Buenos Aires/AR, 3Hospital Español de La Plata/La PLata/AR, 4Hospital de Clínicas José de San Martín/Buenos Aires/AR

P1035 - Impact of Natalizumab and Other High Efficacy Disease-Modifying Therapies on Productivity Loss in Multiple Sclerosis: A Systematic Literature Review.

Z. Khankhel1, I. Brewer2, A. Adeyemi3, K. Daniels2, K. Jomaa4, 1Precision Health Economics and Outcomes Research (PHEOR)/Boston/US, 2Precision Health Economics and Outcomes Research (PHEOR)/Oakland/US, 3Biogen/Cambridge/US, 4Biogen /Paris La Defense CEDEX/FR

P1036 - Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: results from MS PATHS

C. Hersh1, B. Kieseier2, C. De Moor2, D. Miller3, D. Campagnolo2, J. Williams4, K. Fitzgerald5, K. Xiong2, M. Mcginley6, M. Hyland7, R. Rudick2, T. Ziemssen8, I. Koulinska2, 1Cleveland Clinic/Las Vegas/US, 2Biogen/Cambridge/US, 3Mellen Center, Cleveland Clinic/Cleveland/US, 4Biogen/Boston/US, 5Johns Hopkins University School of Medicine/Baltimore/US, 6Cleveland Clinic Foundation/Cleveland/US, 7University of Rochester Medical Center/Rochester/US, 8Carl Gustav Carus University Hospital/Dresden/DE

P1037 - Impact of remoteness on patient-reported outcomes in Australians with multiple sclerosis

J. Chen1, H. Ahmad2, B. Taylor2, A. Palmer2, I. Van Der Mei2, 1Menzies/Hobart/AU, 2University of Tasmania/Hobart/AU

P1038 - Improved or maintained employment status in natalizumab-treated relapsing-remitting multiple sclerosis patients in the TYSABRI Observational Program

G. Kobelt1, M. Trojano2, T. Spelman3, H. Butzkueven4, L. Kappos5, H. Wiendl6, S. Liao7, C. Acosta8, P.-R. Ho9, S. Licata10, 1European Health Economics AB/Stockholm/SE, 2University of Bari/Bari/IT, 3Karolinska Institute/Stockholm/SE, 4Monash University/Melbourne/AU, 5University Hospital and University of Basel/Basel/CH, 6University of Münster/Germany/DE, 7Biogen/Cambride/US, 8Biogen/Baar/CH, 9Biogen at the time of these analyses/Cambridge/US, 10Biogen/Cambridge/US

P1039 - Improvements in patient-reported SymptoMScreen scores among ocrelizumab-treated patients with RRMS: 2-year results from the CASTING clinical trial

I. Kister1, G. Cutter2, R. Buffels3, S. Clinch3, T. Kuenzel4, P. Vermersch5, 1New York University/New York City/US, 2Mellen Center for Multiple Sclerosis Treatment and Research/Cleveland/US, 3F. Hoffmann-La Roche Ltd/Basel/CH, 4F Hoffmann-La Roche Ltd/Basel/CH, 5CHU de Lille/Lille/FR

P1040 - Lack of association between sexual dysfunction and spinal cord pathology in women with multiple sclerosis

K. Novotna1, L. Friedova2, J. Motyl2, M. Vaneckova3, D. Horakova4, M. Andelova5, 1First Faculty of Medicine and General University Hospital/Prague/CZ, 2First Faculty of Medicine, Charles University and General University Hospital/Prague/CZ, 3Charles University and General University Hospital/Prague/CZ, 4First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 5First Faculty of Medicine, Charles University and General University/Prague/CZ

P1041 - Longitudinal Changes in Expanded Timed Get Up and Go (ETGUG) and its Association with Patient-Reported Outomes and Other Measures of Disability

K. Kavak, C. Vaughn, K. Zakalik, C. Tymorek, B. Weinstock-Guttman, State University of New York at Buffalo/Buffalo/US

P1042 - Mental Health in Multiple Sclerosis: influence of clinical and demographic variables

I. Gil-González, M.Á. Pérez-San-Gregorio, A. Martín-Rodríguez, Universidad de Sevilla/Sevilla/ES

P1043 - Patient coaching to optimize management of delayed-release dimethyl fumarate-associated gastrointestinal events and flushing: Five years of experience

G. Niemczyk1, Y. Begus-Nahrmann2, S. Rolfes2, H. Rosenström1, M.-T. Grundler1, M. Mäurer3, 1Biogen GmbH/Ismaning/DE, 2Audimedes GmbH/Göttingen/DE, 3Juliusspital Würzburg/Würzburg/DE

P1044 - Patient demographics and disease characteristics predict likelihood of clinical benefit on patient-reported outcome measures in multiple sclerosis

J. Leary1, S. Sillau2, B. Vollmer2, K. Nair3, T. Vollmer2, 1/Denver/US, 2Rocky Mountain MS Center at the University of Colorado Anschutz Medical Campus/Aurora/US, 3Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus/Aurora/US

P1045 - Predicting fall risk in persons with Multiple Sclerosis utilizing the 12-Item Multiple Sclerosis Walking Scale

H. Delmastro1, E. Gromisch2, H. Dawes3, G. Deluca3, R. Krug2, A. Pick4, J. Ruiz2, 1Mount Sinai Rehabilitation Hospital/Hartford/US, 2Mount Sinai Rehabilitation Hospital, Trinity Health Of New England/Hartford/US, 3Nuffield Department of Clinical Neurosciences, University of Oxford/Oxford/GB, 4Oxford University Hospitals NHS Foundation Trust/Oxford/GB

P1046 - Psychometric validation of the Expanded Disability Status Scale in neuromyelitis optica spectrum disorder

G. Wallenstein1, C. Costantino2, T. Kuenzel3, D. Stokmaier3, E. Damonte3, G. Klingelschmitt3, H.C. Von Büdingen3, 1Genentech San Francisco/San Francisco/US, 2Roche Product Development Medical Affairs (PDMA) Genentech/South San Francisco/US, 3F. Hoffmann-La Roche Ltd/Basel/CH

P1047 - Quality of life (QoL) in treatment-refractory, disabled, multiple sclerosis (MS) during long- term repeated, alemtuzumab (ALE) as assessed by SF-36

D. Carrigan1, K. Geist2, D. Kantor3, S. Hunter1, 1Advanced Neurosciences Institute/Franklin/US, 2Iowa State University/Ames/US, 3Florida Atlantic University/Fort Lauderdale/US

P1048 - Quality of life and economic burden of fatigue in people with multiple sclerosis: a systematic literature review

A. Keenan1, A. Oliva Ramirez2, O. Kalau2, L. Cohen2, E. Worthington2, S. Singh3, 1Janssen Research & Development/Titusville/US, 2EVERSANA/Burlington/CA, 3Eversana/Burlington/CA

P1049 - "Quality of life in multiple sclerosis. Beyond disability: Resilience, fatigue, anxiety and depression as determinants"

D. Mora Cuervo1, C. Camargo2, D. Nakata2, M. De Castro Ribeiro2, C. Teixeira3, 1Hospital Moinhos de Vento/Porto Alegre/BR, 2Irmandade Santa Casa de Misericórdia/Porto Alegre/BR, 3Universidade Federal Ciências da Saúde - Porto Alegre/Porto Alegre/BR

P1050 - Quantifying the patient´s perspective in neuromyelitis optica spectrum disorders: Design of a multicenter, non-interventional study

J. Meca-Lallana1, D. Prefasi2, B. Casanova-Estruch3, C. Calles4, A. Saiz5, I. González-Suárez6, M.L. Martínez-Ginés7, L. Querol8, S. Boyero9, L. Costa-Frossard10, J.M. Prieto González11, L. Forero12, V. Meca- Lallana13, L. Romero-Pinel14, A. Sempere15, C. Garcia-Bernaldez16, J. Mauriño16, 1Hospital Clínico Universitario Virgen de la Arrixaca/Murcia/ES, 2Roche/Madrid/ES, 3Hospital La Fe/Valencia/ES, 4Hospital Universitari Son Espases/Palma de Mallorca/ES, 5Hospital Clínic i Provincial de Barcelona/Barcelona/ES, 6Complejo Hospitalario Universitario de Vigo/Vigo/ES, 7Hospital General Universitario Gregorio Marañón/Madrid/ES, 8Hospital de la Santa Creu i Sant Pau/Barcelona/ES, 9Hospital Universitario Cruces/Barakaldo/ES, 10Hospital Universitario Ramón y Cajal/Madrid/ES, 11Hospital Clínico Santiago de Compostela/Santiago de Compostela/ES, 12Hospital Universitario Puerta del Mar/Cadiz/ES, 13La Princesa Hospital/Madrid/ES, 14Hospital Universitari de Bellvitge/Barcelona/ES, 15Hospital General Universitario de Alicante/Alicante/ES, 16Roche/madrid/ES

P1051 - Real world practice patterns and patient experiences related to off-site therapy infusions in Multiple Sclerosis

B. Greenberg1, B. Mccartney2, L. Jarzylo3, C. Heggen4, J. Carter4, T. Sapir4, 1Department of Neurology and Neurotherapeutics/Dallas/US, 2UT Southwestern Medical Center/Dallas/US, 3PRIME Education/Fort Lauderdale/US, 4PRIME Education, LLC/Fort Lauderdale/US

P1052 - Real-world patient-level costs of administering infusion disease-modifying drugs: a US retrospective claims database analysis

C. Kozma1, N. Roberts2, A. Phillips3, 1CK Consulting Associates, LLC/Saint Helena Island/US, 2Kennedy Pharmacy Innovation Center/Columbia/US, 3EMD Serono, Inc./Rockland/US

P1053 - "Resilience in multiple sclerosis relationship with disability, fatigue, anxiety, depression and cognition"

D. Mora Cuervo1, C. Teixeira2, C. Camargo3, M. De Castro Ribeiro3, D. Nakata3, 1Hospital Moinhos de Vento/Porto Alegre/BR, 2Universidade Federal Ciências da Saúde - Porto Alegre/Porto Alegre/BR, 3Irmandade Santa Casa de Misericórdia/Porto Alegre/BR

P1054 - Sexual dysfunction in multiple sclerosis: who is at risk?

P. Altmann1, F. Leutmezer1, K. Leithner1, T. Monschein1, T. Zrzavy1, M. Ponleitner1, M. Stattmann1, P. Rommer1, G. Zulehner1, K. Berek2, T. Berger1, G. Bsteh1, 1Medical University of Vienna/Vienna/AT, 2Medical University of Innsbruck/Innsbruck/AT

P1055 - Sleep disorders and quality of life in patients with Relapsing-Remitting Multiple Sclerosis

D. Tavolini1, C. Mainella2, M. Oviedo1, S. Micchielli1, R. Torri1, F. Perone1, A. Zingale1, 1INECO Neurociencias Oroño/Rosario/AR, 2Hospital Español/ROsario/AR

P1056 - Student Outreach Programs as Strategies to Address MS Workforce Shortages in the United States: Results Across 3 States

S. Teixeira-Poit1, A. Flach2, P. Dalton3, P. Plummer4, B. Walker5, L. Coleman3, H. Kane6, S. Shah7, M. Skeen7, E. Burkill8, E. Gaskins9, A. Trammell10, W. Jarrett11, C. Bravinder12, M. Bostic13, 1North Carolina A&T State University/Greensboro/US, 2University of South Carolina/Columbia/US, 3National Multiple Sclerosis Society/Greensboro/US, 4MGH Institute of Health Professions/Boston/US, 5Duke University School of Medicine/Durham/US, 6RTI International/Research Triangle Park/US, 7Duke University/Durham/US, 8Tidewater Neuropsychology/Mount Pleasant/US, 9N/A/Raleigh/US, 10Roger C. Peace Rehabilitation Hospital/Greenville/US, 11Hugh Chatham Neurology/Elkin/US, 12Goldsboro Counseling Center, PA/Goldsboro/US, 13FoodMatters365/Greensboro/US

P1057 - The Dutch MS Patient Voice Survey: impact of disease on daily life. J. Muis1, C. Schouten2, E. De Wolf2, L. Avis3, L. Hoeijmakers4, A. Buurman5, 1/Hoef en Haag/NL, 2MS Association/Den Dolder/NL, 3DVJ/Utrecht/NL, 4Novartis/Amsterdam/NL, 5novartis/amsterdam/NL

P1058 - The Dutch MS Patient Voice Survey: Impact of Multiple Sclerosis on daily life activities; characteristics of disease phenotype and treatment

J. Muis1, C. Schouten2, E. De Wolf2, L. Avis3, L. Hoeijmakers4, A. Buurman5, 1/Hoef en Haag/NL, 2MS Association/Den Dolder/NL, 3DVJ/Utrecht/NL, 4Novartis/Amsterdam/NL, 5novartis/amsterdam/NL

P1059 - The effectiveness of mindfulness on quality of life in people with multiple sclerosis: a systematic review.

X. Yang1, S. De Silva2, S. Simpson-Yap3, S. Neate3, G. Jelinek3, N. Nag3, 1The university of Melbourne/Melbourne/AU, 2Neuroepidemiology Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne/Melbourne/AU, 3The University of Melbourne/Melbourne/AU

P1060 - The impact of invisible symptoms on self-perception, relationships, work and healthcare interactions from the perspectives of people with MS

M. Kirkland, C. Newell, K. Wadden, M. Ploughman, Memorial University of Newfoundland/St. John's/CA

P1061 - The interpretation and clinical application of the PROMIS® SF v1.0 - Fatigue (MS) 8b: a PROMIS short form for assessing fatigue in multiple sclerosis

P. Kamudoni1, J. Johns2, K. Cook3, R. Salem4, C. Henke1, S. Salek5, J. Raab1, R. Middleton6, P. Repovic7, K. Alschuler4, G. Von Geldern4, A. Wundes8, D. Amtmann4, 1Merck KGaA/Darmstadt/DE, 2Institute of Medicines Development/Cardiff/GB, 3Feral Scholars/Broaddus/US, 4University of Washington/Seattle/US, 5School of Life and Medical Sciences, University of Hertfordshire/Hatfield/GB, 6Swansea University/Swansea/GB, 7Swedish MS Center/Seattle/US, 8University of Washington Medical Center/Seattle/US

P1062 - The validity and applicability of a new PROMIS® physical function short form for use in relapsing and progressive multiple sclerosis

P. Kamudoni1, D. Amtmann2, J. Johns3, K. Cook4, R. Salem2, S. Salek5, J. Raab1, R. Middleton6, P. Repovic7, K. Alschuler2, G. Von Geldern2, A. Wundes8, C. Henke1, 1Merck KGaA/Darmstadt/DE, 2University of Washington/Seattle/US, 3Institute of Medicines Development/Cardiff/GB, 4Feral Scholars/Broaddus/US, 5School of Life and Medical Sciences, University of Hertfordshire/Hatfield/GB, 6Swansea University/Swansea/GB, 7Swedish MS Center/Seattle/US, 8University of Washington Medical Center/Seattle/US

P1063 - Treatment persistence and adherence to Ocrelizumab in the real-world setting- an ad-hoc analysis of the CONFIDENCE study S. Meuth1, M. Buttmann2, M. Weber3, P. Dirks4, J. Eggebrecht4, N. Joschko5, J. Leemhuis4, M. Martinec6, E. Muros-Le Rouzic7, K.A. Zalocusky6, T. Ziemssen8, 1University Hospital Münster/Münster/DE, 2Caritas Hospital Bad Mergentheim/Bad Mergentheim/DE, 3University Medical Center Goettingen/Goettingen/DE, 4Roche/Grenzach-Wyhlen/DE, 5Roche Pharma AG/Grenzach- Wyhlen/DE, 6F. Hoffmann-La Roche Ltd/Basel/CH, 7F. Hoffmann-La Roche Ltd,/Basel/CH, 8Carl Gustav Carus University Hospital/Dresden/DE

P1064 - Treatment Preferences of Patients with Relapsing Multiple Sclerosis: A Discrete Choice Experiment

T. Scherz1, N. Boyanova11, A. Brooks2, G.N. Chua3, A. Beyer4, B. Levitan5, B. Hennessy1, T. Tervonen6, 1Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies/Allschwil/CH, 2Evidera/Bethesda/US, 3Evidera/Edinburgh/GB, 4Innovus Consulting Ltd/London/GB, 5Janssen R&D/Washington Crossing/US, 6Evidera/London/GB

P1065 - Treatment Satisfaction Across Age Groups in Patients Who Switched to Teriflunomide: Analysis of the Real-world Teri-PRO Study

P. Coyle1, R. Gold2, J. De Seze3, B. Khatri4, B. Yamout5, Y. Pyatkevich6, E. Poole6, P. Vermersch7, 1SUNY Stony Brook Medical Center/Stony Brook/US, 2St. Josef-Hospital, Ruhr University Bochum/Bochum/DE, 3Strasbourg University, Hôpital Civil/Strasbourg/FR, 4Center for Neurological Disorders at Wheaton Franciscan Healthcare/Milwaukee/US, 5American University of Beirut/Beirut/LB, 6Sanofi/Cambridge/US, 7CHU de Lille/Lille/FR

P1066 - Treatment satisfaction in patients with highly-active relapsing multiple sclerosis treated with cladribine tablets: CLARIFY-MS study interim analysis

B. Brochet1, R.H. Raymond Hupperts2, D. Langdon3, A. Solari4, F. Piehl5, J. Lechner-Scott6, X. Montalban7, K. Selmaj8, M. Vališ9, K. Rejdak10, E. Kubala Havrdová11, F. Patti12, N. Alexandri13, A. Nolting13, B. Keller13, 1University of Bordeaux/Bordeaux/FR, 2Zuyderland Medisch Centrum SittardOrbis Medisch Centrum, Maastricht University Medical Center/Maastricht/NL, 3University of London//GB, 4Foundation IRCCS Neurological Institute C. Besta/Milan/IT, 5Karolinska Institute/Stockholm/SE, 6John Hunter Hospital, University of Newcastle/Newcastle/AU, 7Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron/Barcelona/ES, 8Department of Neurology, University of Warmia and Mazury/Olsztyn/PL, 9Charles University and University Hospital/Hradec Králové/CZ, 10Medical University of Lublin/Lublin/PL, 11Charles University//CZ, 12Azienda Ospedaliera-Universitaria, “Policlinico Vittorio Emanuele”/Catania/IT, 13Merck KGaA/Darmstadt/DE

P1067 - Understanding the patient and clinician perspective of ideal treatments for multiple sclerosis via group concept mapping

B.A. Singer1, A. Howerter2, S. Keith3, R. Mehta4, T. Pham4, H. Doll5, 1The MS Center for Innovations in Care, Missouri Baptist Medical Center/St Louis/US, 2Clinical Outcomes Solutions/Tucson/US, 3Clinical Outcomes Solutions/Chicago/US, 4Bristol-Myers Squibb Company/Princeton/US, 5Clinical Outcomes Solutions/Folkestone/GB

P1068 - Use of disease modifying therapies for improved quality of life among progressive MS patients

A. Ahsan, S. Comito, B. Green, L. Lawhon, L. Herbert, Health Union/Philadelphia/US

P1069 - Value-added benefits of a nurse/pharmacy-led service for patients with multiple sclerosis treated over 2 years with cladribine tablets in the UK

K. Morgan1, K. Vernon2, M. Ayer3, 1Merck Serono Ltd/Feltham/GB, 2Salford Royal NHS Foundation Trust/Salford/GB, 3Southampton General Hospital/Southampton/GB

P1070 - Age at disease onset influences grey matter and white matter integrity in MS

R. Bonacchi, A. Meani, E. Pagani, M. Filippi, M.A. Rocca, IRCCS San Raffaele Scientific Institute/Milan/IT

P1071 - Central Vein Sign in Pediatric Multiple Sclerosis and MOG Antibody Associated Disease.

K. Harrison1, C. Gaudioso2, S. Dunham2, V. Levasseur1, N. Schanzer2, A. Salter3, M. Goyal2, S. Mar2, 1Washington University/Saint Louis/US, 2Washington University/St. Louis/US, 3Washington University School in St. Louis/St Louis/US

P1072 - Cerebellar grey matter lesions are common in pediatric multiple sclerosis at clinical onset.

M. Margoni, S. Franciotta, D. Poggiali, A. Riccardi, F. Rinaldi, M. Nosadini, S. Sartori, M.G. Anglani, F. Causin, P. Perini, P. Gallo, University of Padua/Padova/IT

P1073 - Clinical Experience with Fingolimod in Pediatric Multiple Sclerosis Patients

V. Meca-Lallana1, C. Aguirre1, C. Díaz1, V. Cantarin2, B. Del Río1, J. Vivancos1, 1La Princesa Hospital/Madrid/ES, 2Niño Jesus Hospital/Madrid/ES

P1074 - Comparison of Treatment Choices in a Single Center Pediatric Onset Multiple Sclerosis Registry

N.P. Acar Ozen, I. Solmaz, S. Parlak, K. Karli Oguz, A. Tuncer, B. Anlar, Hacettepe University Faculty of Medicine/Ankara/TR

P1075 - Early clinical and MRI predictors of long-term disability in pediatric multiple sclerosis patients

E. De Meo1, R. Bonacchi2, L. Moiola2, F. Sangalli2, G. Dalla Costa1, B. Colombo2, V. Martinelli2, M.A. Rocca2, M.P. Amato3, M. Filippi2, 1San Raffaele Hospital/Milan/IT, 2IRCCS San Raffaele Scientific Institute/Milan/IT, 3University of Florence/Florence/IT

P1076 - Effect of Rituximab on Immunoglobulin levels in Pediatric Multiple Sclerosis Patients

N. Mehta1, A. Balasa2, N. Shukla3, K. Fisher3, T. Lotze3, 1/Pearland/US, 2West Virginia University/Morgantown/US, 3Baylor College of Medicine/Houston/US

P1077 - Evaluating visual evoked cortical magnetic responses in youth with demyelination

L. Kim1, E. Pang1, B. Maguire1, C. Jobst1, G. Longoni2, D. Mabbott2, E.A. Yeh2, 1Hospital for Sick Children/Toronto/CA, 2The Hospital for Sick Children/Toronto/CA

P1078 - Obesity in pediatric onset multiple sclerosis: a French cohort study

P. Milles1, T. Tully2, G. De Filippo3, K. Deiva4, 1/PARIS/FR, 2sorbonne university/PARIS/FR, 3Debre Hospital/PARIS/FR, 4Bicetre Hospital/LE KREMLIN BICETRE/FR

P1079 - Optic nerve head volume decreases in pediatric multiple sclerosis but not in pediatric MOG- related disorders

M.L. Kaseka1, G. Longoni2, T. Berenbaum2, E.M. Kadas3, S. Yadav3, A. Brandt4, E.A. Yeh2, 1/Toronto/CA, 2The Hospital for Sick Children/Toronto/CA, 3NeuroCure Clinical Research Center/Berlin/DE, 4Department of Neurology, University of California Irvine, Irvine, California, USA./Irvine/US

P1080 - Pediatric optic neuritis: Case series of a Neuropediatrics consultation

R. Rocha1, E. Santos2, R. Samões2, A. Martins Da Silva2, S. Figueiroa2, 1Hospital Pedro Hispano/Matosinhos/PT, 2Centro Hospitalar Universitário do Porto/Porto/PT

P1081 - Social networks in pediatric multiple sclerosis are associated with academic performance

W. Vargas1, S. Levin2, M. Glendinning2, K. Onomichi2, M. Bacchus3, B. Banwell4, P. De Jager5, 1Columbia University Medical Center/New York/US, 2Columbia University Irving Medical Center/New York/US, 3Children's Hospital of Philadelphia/Philadelphia/US, 4Children’s Hospital of Philadelphia/Philadelphia/US, 5Columbia University Medical Center/United States/US

P1082 - Therapeutic Response in Pediatric Neuromyelitis Optics Spectrum Disorder

R. Umeton1, M. Waltz2, G. Aaen3, L. Benson4, M. Gorman4, M. Goyal5, J. Graves6, Y. Harris7, L. Krupp8, T. Lotze9, S. Mar5, J. Ness7, M. Rensel10, T. Schreiner11, J.-M. Tillema12, S. Roalstad13, M. Rodriguez12, J. Rose14, E. Waubant15, B. Weinstock-Guttman16, T.C. Casper17, T. Chitnis18, 1University of Massachusetts Medical School/Worcester/US, 2University of Utah/Utah/US, 3Loma Linda University Children’s Hospital/Loma Linda/US, 4Boston Children’s Pediatric MS Center/Boston/US, 5Washington University/St. Louis/US, 6University of California, San Diego/San Diego/US, 7University of Alabama at Birmingham/Birmingham/US, 8NYU Langone/New York City/US, 9Baylor College of Medicine/Houston/US, 10Cleveland Clinic/Cleveland/US, 11Denver Children’s Hospital/Denver/US, 12Mayo Clinic Department of Neurology/Rochester/US, 13University of Utah/Salt Lake City/US, 14University of Utah School of Medicine/Salt Lake City/US, 15UCSF/San Francisco/US, 16State University of New York at Buffalo/Buffalo/US, 174University of Utah/Salt Lake City/US, 18Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US

P1083 - Youth with Multiple Sclerosis have Low Levels of Physical Fitness

S. Stephens1, T. Berenbaum1, R. Motl2, M. Finlayson3, E.A. Yeh1, 1The Hospital for Sick Children/Toronto/CA, 2University of Alabama//US, 3Queens University/Kingston/CA

P1084 - Adherence to OnabotulinumtoxinA Treatment in Multiple Sclerosis Patients with Spasticity from the ASPIRE Study

A. Esquenazi1, W. Feng2, G. Wittenberg3, P. Gallien4, A. Baricich5, K. Fanning6, A. Zuzek7, G. Francisco8, D. Bandari9, 1MossRehab Gait and Motion Analysis Laboratory/Elkins Park/US, 2Duke University School of Medicine/Durham/US, 3VA Pittsburgh Healthcare System, University of Pittsburgh/Pittsburgh/US, 4Pôle MPR Saint Hélier/Rennes/FR, 5Università del Piemonte Orientale “A. Avogadro”/Novara/IT, 6Vedanta Research/Wilmington/US, 7Allergan/Irvine/US, 8University of Texas McGovern Medical School and TIRR Memorial Hermann/Houston/US, 9Multiple Sclerosis Center of California & Research Group at the Hoag Neurosciences Institute/Newport Beach/US

P1085 - An innovative “Doodle” drawing tool for creative cognitive-motor training in patients with multiple sclerosis

M. Greenberg Abrahami1, A. Achiron2, 1Multiple Sclerosis Ccenter/Ramat Gan/IL, 2Multiple Sclerosis Center, Sheba Academic Medical Center/Ramat Gan/IL

P1086 - Botulinum toxin injections in multiple sclerosis versus post-stroke spasticity

A. Dinoto1, A. Sartori2, G. Mazzon1, P. Polverino1, M. Cheli1, M.E. Morelli1, F. Pasquin1, A. Bratina1, A. Bosco1, P. Manganotti1, 1Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Cattinara University Hospital ASUGI, University of Trieste/Trieste/IT, 2Neurology Unit, Azienda Sanitaria Univeristaria Integrata Clinica Neurologica, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Trieste/Trieste/IT

P1087 - Characterizing GI events in early versus recent dimethyl fumarate cohorts at two large MS centers.

K. Smoot1, E. Alvarez2, C. Chen3, B. Vollmer4, T. Stuchiner1, L. Grote1, 1Providence MS Center/Portland/US, 2University of Colorado/Aurora/US, 3Providence St. Joseph Health/Portland/US, 4Rocky Mountain MS Center at the University of Colorado Anschutz Medical Campus/Aurora/US

P1088 - Circuit class therapy in patients with Relapsing-Remitting Multiple Sclerosis J. Kolcava1, J. Kočica2, M. Musilova2, F. Dosbaba2, J. Kratochvílová2, D. Krizova2, P. Stourac2, 1Masaryk University /Brno/CZ, 2The University Hospital Brno/Brno/CZ

P1089 - Depressive Symptoms and Suicidal Ideation in Progressive Multiple Sclerosis Compared to Relapsing-Remitting Multiple Sclerosis

L. Knowles1, E. Esselman2, A. Turner1, K. Phillips2, T. Herring2, K. Alschuler3, D. Ehde2, 1VA Puget Sound Health Care System/Seattle/US, 2University of Washington/Seattle/US, 3University of Washington School of Medicine/Seattle/US

P1090 - Differences in correlates of fatigue between relapsing and progressive forms of multiple sclerosis

T. Herring1, K. Alschuler1, L. Knowles2, W. Morean3, K. Phillips1, A. Turner2, D. Ehde1, 1University of Washington/Seattle/US, 2VA Puget Sound Health Care System/Seattle/US, 3Seattle Pacific University/Seattle/US

P1091 - Effect of BDNF Val66Met polymorphism on motor recovery after rehabilitation in progressive MS

A. Giordano1, F. Clarelli2, L. Ferre'3, E. Mascia2, S. Santoro2, M. Sorosina2, M. Comola1, G. Comi4, M. Filippi2, L. Leocani5, F. Esposito2, 1San Raffaele Scientific Institute and University Hospital/Milan/IT, 2IRCCS San Raffaele Scientific Institute/Milan/IT, 3San Raffaele Scientific Institute/Milan/IT, 4San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 5Vita- Salute San Raffaele University/Milan/IT

P1092 - Effect of Dalfampridine on functional systems and its impact on Expanded Disability Status Scale

G. Alvarez Bravo, L. Ramió I Torrentà, R. Robles Cedeño, E. Quintana, J. Gich, M. González, Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES

P1094 - Effect of nabiximols cannabinoid oromucosal spray on depressive symptoms, suicidality, and cognition in patients with multiple sclerosis (MS)

J. Deluca1, D. Langdon2, J. Berwaerts3, J. Wagner3, 1Kessler Foundation/West Orange/US, 2University of London//GB, 3Greenwich Biosciences, Inc./Carlsbad/US

P1095 - Effectiveness of a cognitive behavioral program for fatigue (FACETS +) in 110 French patients with Multiple Sclerosis : a randomized, controlled trial

F. Hamelin1, M.C. Gay2, S. Thomas3, P. Thomas4, O. Heinzlef5, F. Barbot6, M. Blanchère7, 1Réseau SEP IDF Ouest/Saint Germain en laye/FR, 2Paris Nanterre University/Nanterre/FR, 3Bournemouth University/bournemouth/GB, 4Bournemouth University/Bournemouth/GB, 5CHI Poissy Saint Germain en Laye/Le pecq/FR, 6Raymond Poicaré Hospital of Garches/Garches/FR, 7Poissy Saint Germain Hospital/Poissy/FR

P1096 - Evaluating Effects of Global Proprioceptive Resonance on Gait in Multiple Sclerosis with Kinetic and Electromyography

S.-C. Huang1, G. Dalla Costa2, M. Pisa3, D. Talarico4, A. Tettamanti4, G. Comi5, L. Leocani3, 1San Raffaele Hospital - Vita-Salute San Raffaele University/Milan/IT, 2San Raffaele Hospital/Milan/IT, 3Vita-Salute San Raffaele University/Milan/IT, 4University Vita-Salute San Raffaele/Milan/IT, 5San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT

P1097 - Femoral neck bone loss and increased fracture risk in people with progressive MS compared to matched controls.

A. Devasahayam, S. Simms, W. Lasisi, E. Wallack, L. Kelly, M. Ploughman, Memorial University of Newfoundland/St.John's/CA

P1098 - Frequency and determinants of falls in persons with multiple sclerosis without a clinical disability

Z. Abasıyanık1, T. Kahraman1, O. Ertekin1, C. Baba1, S. Ozakbas2, 1Dokuz Eylül University/Izmir/TR, 2Dokuz Eylul University/Izmir/TR

P1099 - Functional improvement gained using the HAL® Exoskeleton Robotic Device in the Progressive MS vs Non- MS populations: An Interim Analysis

A. Mayadev1, J. Bowen2, J. Scalan3, K. Kobata2, Z. Cambier2, S. Babiarz2, J. Chapman3, 1Swedish Neuroscience /Seattle/US, 2Swedish MS Center/Seattle/US, 3Swedish Research/Seattle/US

P1100 - Identifying gaps in knowledge, skills and confidence among MS specialists to facilitate improved MS care

K. Schmierer1, M. Peniuta2, J. Oh3, T. Leist4, P. Lazure2, S. Péloquin2, 1Queen Mary University London/London/GB, 2AXDEV Group Inc./Brossard/CA, 3University of Toronto/Toronto/CA, 4Jefferson University/Philadelphia/US

P1101 - Information needs about bladder dysfunction in people with multiple sclerosis

I. Schiffmann1, C. Heesen2, 1University Medical Centre Hamburg Eppendorf/Hamburg/DE, 2Universitätsklinikum Hamburg-Eppendorf/Hamburg/DE

P1102 - Manual Dexterity Improves with Cognitive Remediation in Relapsing but not in Progressive Multiple Sclerosis G. Pilloni1, M. Shaw2, K. Sherman3, L. Krupp3, L. Charvet3, 1NYU Langone Health/ NYU Grossman School of Medicine/New York/US, 2Binghamton University/Binghamton/US, 3NYU Langone/New York City/US

P1103 - Moderators of improvements in fatigue impact following a self-management intervention in multiple sclerosis

L. Knowles1, C. Hugos2, M. Cameron2, J. Haselkorn1, D. Bourdette2, A. Turner1, 1VA Puget Sound Health Care System/Seattle/US, 2Oregon Health & Science University/Portland/US

P1104 - Pain in ambulatory people with multiple sclerosis and self-reported spasticity

N. Sajeev1, S. Joos1, M. Cameron2, J. Norton1, C. Hugos1, 1Portland VA Medical Center/Portland/US, 2Oregon Health & Science University/Portland/US

P1105 - Polypharmacy in MS: Correlations with pain, fatigue, and mood.

J. Thelen1, S. Baker2, J. Bruce3, A. Thuringer2, M. Nashatizadeh2, S. Lynch2, 1/Kansas City/US, 2University of Kansas Medical Center/Kansas City/US, 3University of Missouri - Kansas City/Kansas City/US

P1106 - Postprandial somnolence in multiple sclerosis: the invisible is real.

T. Christmas1, M. Ardissino2, N. Singh3, K. Allen-Philbey4, G. Giovannoni5, S. Reyes6, 1/London/GB, 2Northwick Park Hospital/London/GB, 3Royal London Hospital/FR/GB, 4The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London/AT/GB, 5The London School of Medicine and Dentistry/London/GB, 6Blizard Institute/London/GB

P1107 - Proactively evaluating and treating changes in function in people with multiple sclerosis: the CoachMS pilot study

V. Block1, A. Gopal2, W. Rowles2, C.-Y. Guo3, J. Gelfand3, R. Bove2, 1University of California San Francisco /San Francisco/US, 2University of California, San Francisco/San Francisco/US, 3University of California San Francisco/San Francisco/US

P1109 - Safety and efficacy of nabiximols in patients with multiple sclerosis-associated spasticity: post hoc analyses of a controlled enrichment design study

A. Ben-Zacharia1, J. Berwaerts2, D. Checketts3, K. Nichol2, J. Wagner2, J. Wolinsky4, 1Hunter-Bellevue School of Nursing at Hunter College/New York/US, 2Greenwich Biosciences, Inc./Carlsbad/US, 3GW Research Ltd/Cambridge/GB, 4The University of Texas Health Science Center at Houston/Houston/US

P1110 - The impact of lower limb strength on walking in persons with Multiple Sclerosis: a preliminary analysis

H. Delmastro1, H. Dawes2, G. Deluca2, R. Krug3, A. Pick4, J. Ruiz3, 1Mount Sinai Rehabilitation Hospital/Hartford/US, 2Nuffield Department of Clinical Neurosciences, University of Oxford/Oxford/GB, 3Mount Sinai Rehabilitation Hospital, Trinity Health Of New England/Hartford/US, 4Oxford University Hospitals NHS Foundation Trust/Oxford/GB

P1111 - Timely Intervention, Monitoring and Education MATTERS in MS (TIME MATTERS in MS): global piloting of the MS Brain Health quality improvement tool

J. Hobart1, H. Butzkueven2, J. Haartsen2, T. Vollmer3, T. Ziemssen4, T. Lane5, G. Giovannoni6, 1University of Plymouth/Plymouth/GB, 2Monash University/Melbourne/AU, 3Rocky Mountain MS Center at the University of Colorado Anschutz Medical Campus/Aurora/US, 4Carl Gustav Carus University Hospital/Dresden/DE, 5Clinical Research London/London/GB, 6The London School of Medicine and Dentistry/London/GB

P1112 - Transcranial Direct Current Stimulation (tDCS) Results in Lasting Reduction in MS-Related Fatigue

L. Walton Masters1, G. Pilloni2, M. Muccio1, Y. Ge3, L. Krupp4, L. Charvet4, 1NYU Langone Health/New York/US, 2NYU Langone Health/ NYU Grossman School of Medicine/New York/US, 3New York University/New York/US, 4NYU Langone/New York City/US

P1113 - Underutilization of Physical Therapy Resources for Symptomatic Women with MS During and Following Pregnancy

V. Block1, O. Mestas2, A. Anderson3, J. Singh2, L. Wylie2, C.-Y. Guo2, A. Green4, J. Gelfand2, R. Bove3, 1University of California San Francisco /San Francisco/US, 2University of California San Francisco/San Francisco/US, 3University of California, San Francisco/San Francisco/US, 4UCSF Multiple Sclerosis Center/United States/US

P1114 - Using technology to empower patients to manage and track symptoms of MS

E. Rudell1, P. Peterson2, A. Griffin3, M. Ingram1, T. Agrawal, Phd1, J. Bowen4, 1@Point of Care/Livingston/US, 2Projects In Knowledge/Livingston/US, 3Multiple Sclerosis Association of America/Cherry Hill/US, 4Swedish MS Center/Seattle/US

P1115 - A first characterization of placenta-derived extracellular vesicles in patients with multiple sclerosis.

S. Martire1, F. Montarolo1, M. Spadaro1, S. Perga1, L. Marozio2, F. Frezet2, S. Bruno2, G. Chiabotto2, A. Bertolotto3, M. Ludovica Sforza1, P. Valentino4, 1Neuroscience Institute Cavalieri Ottolenghi/Orbassano/IT, 2University of Turin/Torino/IT, 3San Luigi Gonzaga Hospital/Orbassano (TO)/IT, 4Neuroscience Institute Cavalieri Ottolenghi (NICO)/orbassano/IT

P1116 - Binge alcohol consumption in murine models of Multiple Sclerosis leads to sex-specific disease development. S. Bazzi1, B. Caslin2, M. Raskin2, A. Karmakar2, K. Mohler2, C. Maguire3, E. Melamed2, 1/Austin/US, 2University of Texas at Austin/Austin/US, 3The University of Texas at Austin/Austin/US

P1117 - Clinical and radiologic disease activity in pregnancy and postpartum in multiple sclerosis

A. Anderson1, K. Krysko2, A. Rutatangwa2, T. Krishnakumar3, C. Chen3, W. Rowles1, M. Houtchens4, R. Bove1, 1University of California, San Francisco/San Francisco/US, 2UCSF/San Francisco/US, 3University of California San Francisco/San Francisco/US, 4Partners MS Center, Brigham and Women's Hospital, Harvard Medical School/Boston/US

P1118 - Cumulative update on pregnancy outcomes after fingolimod treatment in patients with multiple sclerosis

L.M. Prach1, A. Moore1, B. Rezaallah1, G. Mcbride1, I.A. Khan2, M. Guennec3, A. Bhatt2, Y. Geissbuehler1, S. Lopez Leon4, S. Vukusic5, H. Butzkueven6, H. Tilson7, T.M. Macdonald8, K. Hellwig9, 1Novartis Pharma AG/Basel/CH, 2Novartis Healthcare Pvt. Ltd./Hyderabad/IN, 3IQVIA, Saint- Ouen/Paris/FR, 4Novartis Pharmaceuticals Corporation/East Hanover/US, 5Lyon University Hospital/BRON/FR, 6MS and Neuroimmunology Unit, Central Clinical School, Monash University, The Alfred Centre/Victoria/AU, 7UNC Gillings School of Global Public Health/CHapel Hill/US, 8Ninewells Hospital and Medical School/Dundee/GB, 9University of Bochum/Bochum/DE

P1119 - Disease activity in patients with multiple sclerosis treated with alemtuzumab due to a pregnancy desire

P. Tagliani1, A. Vidal-Jordana2, A. Zabalza1, G. Arrambide3, B. Rodríguez-Acevedo4, J. Río5, Í. Galán4, J. Castilló6, L. Midaglia7, A. Cobo Calvo8, M. Comabella9, C. Nos4, C. Auger3, A. Rovira10, J. Sastre- Garriga3, M. Tintore11, 1Vall d’Hebron Institut de Recerca/Barcelona/ES, 2Hospital Universitari Vall d’Hebron/Barcelona/ES, 3Vall Hebron University Hospital/Barcelona/ES, 4Dept. of Neurology- Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 5CEMCAT, Hospital Universitario Vall d’Hebrón/Barcelona/ES, 6Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 7Dept. of Neurology-Neuroimmunology; Vall Hebron University Hospital; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 8Centre d’Esclerosi Múltiple de Catalunya (Cemcat)/Barcelona/ES, 9Universitat Autònoma//ES, 10Vall d'Hebron University Hospital/Barcelona/ES, 11Multiple Sclerosis Centre of Catalonia/Barcelona/ES

P1120 - Disparities in access to health care for women with multiple sclerosis in Argentina

J. Rojas1, J. Pettinicchi2, P. Lopez2, J. Criniti2, R. Alonso3, O. Garcea3, M. Balbuena4, C. Bartoluzzi5, E. Silva6, L. Cabrera7, M. Curbelo8, J. Hryb9, J. Di Pace10, M. Perassolo10, S. Ianardi11, C. Mainella12, S. Mellinger13, M. Burgos14, D. Dias13, L. Migliacci15, F. Pagani Cassará16, V. Sinay16, A. Carra17, M. Questa Laudani18, E. Ruiz Romagnoli19, S. Liwacki20, R. Piedrabuena21, S. Tizio22, V. Tkachuk4, E. Carnero Contentti2, 1Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 2Hospital Alemán/Buenos Aires/AR, 3Hospital Ramos Mejía/Buenos Aires/AR, 4Hospital de Clinicas/Buenos Aires/AR, 5Neurology Department, Hospital Madariaga de Posadas, Misiones, Argentina/Posadas/AR, 6Predigma/Posadas/AR, 7Hospital Militar Campo de Mayo/Buenos Aires/AR, 8MS Section Hospital Britanico Buenos Aires, Argentina/Buenos Aires/AR, 9Hospital Carlos Durand/Buenos Aires/AR, 10Servicio de Neurología, Hospital Cárlos G. Durand, Buenos Aires, Argentina/Buenos Aires/AR, 11Neurology Department, Hospital Lagomaggiore, Mendoza, Argentina/Mendoza/AR, 12Hospital Español/ROsario/AR, 13Neurology Department, Hospital San Bernardo, Salta, Argentina/Salta/AR, 14Hospital San Bernardo/Salta/AR, 15-Clínica Pueyrredón Mar del Plata, Argentina./Mar del Plata/AR, 16Hospital Universitario Fundación Favaloro/Buenos Aires/AR, 17Hospital Britanico/CIUDAD DE BUENOS AIRES/AR, 18Centro integral de enfermedades neurológicas y neuroquirúrgicas, Santiago del Estero, Argentina/Santiago del Estero/AR, 19Centro integral de enfermedades neurológicas y neuroquirúrgicas, Santiago del Estero, Argentina/Cordoba/AR, 20Clínica Universitaria Reina Fabiola - Hospital Córdoba, Argentina./Cordoba/AR, 21Clinica Universitaria Reina SOfía/Córdoba/AR, 22Hospital Español de La Plata/La PLata/AR

P1121 - Effector T cells are selectively controlled and related to postpartum relapses during pregnancy in MS

S. Koetzier1, R. Neuteboom2, A. Wierenga-Wolf2, M.J. Melief2, R. Van Der Wal3, A. Van Rijswijk3, B. Broux4, S. Van Den Berg3, W. Dik3, J. Smolders3, M. Van Luijn5, 1Erasmus MC/Rotterdam/NL, 2MS Center ErasMS, Erasmus University Medical Center/Rotterdam/NL, 3Erasmus University Medical Center/Rotterdam/NL, 4Hasselt University/Diepenbeek/BE, 5MS Center ErasMS, Erasmus MC/Rotterdam/NL

P1122 - Family planning in women with multiple sclerosis: an important yet seldom approached issue

R. Alonso1, C. Quarracino2, C. Vrech3, O. Garcea1, B. Silva4, N. Deri5, A. Carrá6, A. Chertcoff6, V. Tkachuk7, M. Balbuena7, P. Lopez8, E. Carnero Contentti8, J. Pettinicchi8, D. Tavolini9, A. Barboza10, J. Rojas11, E. Cristiano12, L. Patrucco13, L. Lazaro14, N. Fernandez Liguori14, 1Hospital Ramos Mejía/Buenos Aires/AR, 2Instituto Alfredo Lanari. Hospital Universitario/Buenos Aires/AR, 3Sanatorio Allende/Cordoba/AR, 4Hospital Ramos Mejía- Leloir Institute/Buenos Aires/AR, 5Centro de Investigaciones DIABAID/Buenos Aires/AR, 6Hospital Británico De Buenos Aires/Buenos Aires/AR, 7Hospital de Clínicas José de San Martín/Buenos Aires/AR, 8Hospital Alemán/Buenos Aires/AR, 9INECO Neurociencias Oroño/Rosario/AR, 10Hospital Central/Mendoza/AR, 11Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina/Buenos Aires/AR, 12Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires/Buenos Aires/AR, 13Hospital Italiano/CIUDAD DE BUENOS AIRES/AR, 14Sanatorio Guemes/Buenos Aires/AR

P1123 - Gender dimorphism of hippocampal intrinsic networks and regional integrity in multiple sclerosis D. Ciolac1, G. Gonzalez-Escamilla1, V. Fleischer1, A. Radetz1, J. Krämer2, M. Muthuraman1, S. Meuth3, S. Groppa1, 1University Medical Center of the Johannes Gutenberg University Mainz/Mainz/DE, 2University Hospital Münster/Münster/DE, 3University of Munster/Munster/DE

P1124 - Health resource utilization in relapsing remitting multiple sclerosis from a gender perspective - evidence from more than 2000 patients in Germany

D. Schriefer1, N. Ness1, R. Haase2, T. Ziemssen2, 1Center of Clinical Neuroscience/Dresden/DE, 2Carl Gustav Carus University Hospital/Dresden/DE

P1125 - Hypersexual Behavior and Multiple Sclerosis: A Systematic Review

F. Aquino Gondim1, D. Lima Jr2, E. Maia Messias3, F. Thomas4, 1Universidade Federal do Ceará/FORTALEZA/BR, 2Universidade Federal do Ceará/Fortaleza/BR, 3University of Arkansas/Little Rock/US, 4Hackensack Meridian University Medical Center/Hackensack/US

P1126 - Impact of interferon-beta exposure during early pregnancy on relapse rate

M. Tokic1, S. Thiel2, N. Litvin3, A. Ciplea2, R. Gold4, K. Hellwig5, 1Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum/Bochum/DE, 2St. Josef Hospital, Katholisches Klinikum Bochum, Klinikum der Ruhr-Universität Bochum/Bochum/DE, 3/Bochum/DE, 4St. Josef- Hospital, Ruhr University Bochum/Bochum/DE, 5University of Bochum/Bochum/DE

P1127 - Menopause in multiple sclerosis

C. Oreja-Guevara1, S. Lopez-Coello2, R. Rodriguez-Rabanal2, I. Gómez-Estevez2, J. Díaz-Díaz2, 1Hospital Universitario Clinico San Carlos/Madrid/ES, 2Hospital Universitario Clínico San Carlos/Madrid/ES

P1128 - MOG antibody disease and pregnancy

M. Ysrraelit1, S. Ochoa2, M. Farez1, J. Correale2, 1FLENI/CIUDAD DE BUENOS AIRES/AR, 2FLENI/Buenos Aires/AR

P1129 - Peripartum depression and anxiety in women with MS. A population-based cohort study.

K. Eid1, Ø. Torkildsen1, J. Aarseth2, H. Flemmen3, T. Holmøy4, K. Lian5, Å. Lorentzen6, K.M. Myhr1, T. Riise7, C. Simonsen8, C. Torkildsen9, S. Wergeland10, J.S. Willumsen11, N. Øksendal12, N.-E. Gilhus1, M.-H. Bjørk1, 1University of Bergen/Haukeland University Hospital/BERGEN/NO, 2The Norwegian Multiple Sclerosis Registry and Biobank and The Norwegian Multiple Sclerosis Competence Centre and Research Group/BERGEN/NO, 3Telemark Hospital/Skien/NO, 4Akerhus University Hospital/Nordbyhagen/NO, 5St. Olavs Hospital/Trondheim/NO, 6Sørlandet Hospital and The Norwegian National Advisory Unit on Tick- borne diseases/Arendal/NO, 7University of Bergen/BERGEN/NO, 8Drammen Hospital/Drammen/NO, 9Stavanger University Hospital/Stavanger/NO, 10Haukeland University Hospital/BERGEN/NO, 11Molde Hospital/Molde/NO, 12Nordland Hospital Trust/Bodø/NO

P1130 - Post-partum radiological disease activity in women with multiple sclerosis

T. Uher1, E. Havrdova2, K. Vodehnalova1, J. Krasensky3, M. Vaneckova3, D. Horakova2, 1First Faculty of Medicine, Charles University and General University/Prague/CZ, 2First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 3Charles University and General University Hospital/Prague/CZ

P1131 - Pregnancy in a modern day multiple sclerosis cohort: Predictors of postpartum relapse and disability progression

V. Jokubaitis1, W. Yeh1, P. Widyastuti1, J. Stankovich1, M. Gresle1, E. Kubala Havrdová2, D. Horakova3, K. Vodehnalova4, S. Ozakbas5, S. Eichau Madueño6, P. Duquette7, T. Kalincik8, F. Patti9, C. Boz10, M. Terzi11, B. Yamout12, J. Lechner-Scott13, P. Sola14, O. Skibina15, M. Barnett, Md16, M. Onofrj17, M.J. Sá18, P. Mccombe19, P. Grammond20, R. Ampapa21, F. Grand'Maison22, R. Bergamaschi23, D. Spitaleri24, V. Van Pesch25, E. Cartechini26, S. Hodgkinson27, A. Soysal28, A. Saiz29, T. Uher4, D. Maimone30, R. Turkoglu31, R. Hupperts32, M.P. Amato33, F. Granella34, C. Oreja-Guevara35, A. Altintas36, R. Macdonell37, T. Castillo-Trivino38, H. Butzkueven1, R. Alroughani39, A. Van Der Walt1, T. Msbase Study Group40, 1Monash University/Melbourne/AU, 2Charles University//CZ, 3First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 4First Faculty of Medicine, Charles University and General University/Prague/CZ, 5Dokuz Eylul University/Izmir/TR, 6Universitary Hospital Virgen Macarena/Seville/ES, 7University of Montreal/Montreal/CA, 8Royal Melbourne Hospital/Melbourne/AU, 9Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT, 10KTU Medical Faculty Farabi Hospital/Trabzon/TR, 11Ondokuz Mayıs University/Sasun/TR, 12American University of Beirut/Beirut/LB, 13Department of Neurology, John Hunter Hospital, Hunter New England Health/Newcastle/AU, 14Azienda Ospedaliero-Universitaria di Modena Ospedale Civile di Baggiovara/Modena/IT, 15The Alfred Hospital/Melbourne/AU, 16Brain Mind Institute/Camperdown/AU, 17University G. d’Annunzio/Chieti/IT, 18Centro Hospitalar Universitario de Sao Joao/Porto/PT, 19University of Queensland/Brisbane/AU, 20CISSS Chaudière- Appalache/Levis/CA, 21Nemocnice Jihlava/Jihlava/CZ, 22Neuro Rive-Sud/Quebec/CA, 23IRCCS Mondino Foundation/Pavia/IT, 24Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino/Avellino/IT, 25Université Catholique de Louvain/Brussels/BE, 26UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3/Macerata/IT, 27Ingham Institute for Applied Medical Research, University of New South Wales Medicine/Sydney/AU, 28Bakırköy Prof. Dr. Mazhar Osman Education and Research Hospital for Psychiatry and Neurological Diseases/Istanbul/TR, 29Hospital Clínic i Provincial de Barcelona/Barcelona/ES, 30Garibaldi Hospital/Catania/IT, 31Haydarpasa Numune Training and Research Hospital/Istanbul/TR, 32Zuyderland Medical Center/Sittard-Geleen/NL, 33University of Florence/Florence/IT, 34University of Parma/Parma/IT, 35Hospital Universitario Clinico San Carlos/Madrid/ES, 36Koc University/Istambul/TR, 37Austin Health. University of Melbourne/Melbourne/AU, 38Hospital Universitario Donostia/San Sebastián/ES, 39Amiri Hospital/Kuweit/KW, 40MSBase/Melbourne/AU

P1132 - Pregnancy outcomes in patients treated with ocrelizumab

R. Bove1, C. Oreja-Guevara2, K. Hellwig3, R. Buffels4, N. Pasquarelli4, D. Zecevic4, S. Vukusic5, 1University of California, San Francisco/San Francisco/US, 2Hospital Universitario Clinico San Carlos/Madrid/ES, 3University of Bochum/Bochum/DE, 4F. Hoffmann-La Roche Ltd/Basel/CH, 5Lyon University Hospital/BRON/FR

P1133 - Pregnancy outcomes in the ozanimod multiple sclerosis clinical development program

N. Minton, A. Henry, A. Janjua, G. Reddy Poli, Bristol-Myers Squibb Company/Princeton/US

P1134 - Recovery of menstrual cycle in women with multiple sclerosis treated with autologous haematopoietic stem cell transplantation.

E. Sbragia1, G. Boffa2, C. Massarotti1, A. Raiola3, R. Varaldo3, E. Angelucci3, J. Frau4, G.B. Zimatore5, G.L. Mancardi1, P. Anserini1, M. Inglese6, 1University of Genoa/Genoa/IT, 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 3IRCCS Policlinico San Martino, Genoa/Genoa/IT, 4Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna/Cagliari/IT, 5U.O.C. Neurology, Ospedale Generale Regionale "F. Miulli", Acquaviva delle Fonti, BA, Italy/Bari/IT, 6University of Genoa//IT

P1135 - Risk factors for peripartum depression in women with multiple sclerosis

K. Krysko1, A. Anderson2, J. Singh1, K. Mcpolin1, A. Rutatangwa3, W. Rowles2, A.D. Sadovnick4, M. Houtchens5, R. Bove2, 1University of California San Francisco/San Francisco/US, 2University of California, San Francisco/San Francisco/US, 3UCSF/San Francisco/US, 4University of British Columbia/Vancouver/CA, 5Partners MS Center, Brigham and Women's Hospital, Harvard Medical School/Boston/US

P1136 - Severe neuroinflammatory relapse after ectopic pregnancy termination: a case report on MS patient with myelin oligodendrocyte glycoproteinantibodies.

H. Blad1, K. Kulmala2, R. Vaitiniemi3, V.D. Karrenbauer4, 1Nyköping hôpital/Nyköping/SE, 2Karolinska Institutet/Stockholm/SE, 3Gällivare hospital/Gällivare/SE, 4Karolinska Institutet, Karolinska university hospital/Stockholm/SE

P1137 - Sexual dysfunction in women with relapsing remitting multiple sclerosis in west Algeria

Z. Barka Bedrane, D. Bouchenak Khelladi, université Abou Bekr Belkaid Tlemcen -CHU Tlemcen/Tlemcen/DZ

P1138 - short-chain fatty acid during pregnancy in multiple sclerosis: a prospective cohort study

J.P. Cuello1, R. Alvarez-Lafuente2, M.L. Martínez-Ginés1, A. Tejeda-Velarde3, S. Medina Heras2, J.M. García-Domínguez1, J.I. Fernandez-Velasco3, A. Lozano-Ros1, Y. Higueras4, A. Meldaña-Rivera1, S. Garcia Tizon1, J. De-Leon Ruiz1, V. Ortega Abad1, S. Pérez-Pérez5, M.I. Domínguez-Mozo5, H. Goicoechea- Briceño1, L.M. Villar3, 1Hospital General Universitario Gregorio Marañón/Madrid/ES, 2Hospital Clínico San Carlos/Madrid/ES, 3Hospital Universitario Ramón y Cajal/Madrid/ES, 4IISGM/Madrid/ES, 5Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Madrid/ES

P1139 - Silent MRI progression in MS patients during clinically stable pregnancy and post-partum period

I. Rosciszewska-Zukowska1, M. Siger2, M. Stasiołek2, 1The Holy Family Specialist Hospital/Glogow Malopolski/PL, 2Medical University of Lodz/Lodz/PL

P1140 - Study of anthropometric measures of newborns of MS mothers

J. Díaz-Díaz1, P. López-Gómez2, I. Gómez-Estevez1, C. Oreja-Guevara3, 1Hospital Universitario Clínico San Carlos/Madrid/ES, 2Hospital Sant Joan de Deu/Barcelona/ES, 3Hospital Universitario Clinico San Carlos/Madrid/ES

P1141 - The 2D:4D ratio, a proxy for prenatal androgen levels, does not differ between Multiple Sclerosis patients and people without Multiple Sclerosis

A. Sánchez Soblechero, S. Castro Valdeolmillos, J. Villamor Rodríguez, J.M. García-Domínguez, M.L. Martínez-Ginés, Hospital General Universitario Gregorio Marañón/Madrid/ES

P1142 - “The contribution of sex hormones to disease incidence and phenotype in the spontaneous TCR1640 mouse model.”

R.-M. Rébillard1, M. Mercier1, S. Larouche1, O. Tastet1, C. Grasmuck1, C. Hoornaert1, L. Bourbonniere1, A. Prat2, 1CRCHUM/Montréal/CA, 2University of Montreal/Montreal/CA

P1143 - The relationship between multiple sclerosis attacks and menstrual cycle days

M. Poursadeghfard, S. Safavi, Shiraz University of Medical Sciences, Shiraz, Iran./Shiraz/IR

P1144 - Comparison of deep grey matter iron deposition assessed by 3T MRI R2* relaxometry in Multiple Sclerosis, Alzheimer´s disease and in normal controls

I. Colonna, A. Buchmann, A. Damulina, D. Pinter, B. Helmlinger, L. Pirpamer, M. Soellradl, C. Tinauer, S. Ropele, C. Enzinger, R. Schmidt, M. Khalil, Medical University of Graz/Graz/AT

Late Breaking On-Demand ePosters LB1144 - How does Coronavirus Disease 2019 (COVID-19) “Sheltering in Place” Affect Ambulatory Activity in People with Multiple Sclerosis?

V. Block1, R. Bove2, J. Gelfand3, B. Cree3, 1University of California San Francisco /San Francisco/US, 2University of California, San Francisco/San Francisco/US, 3University of California San Francisco/San Francisco/US

LB1145 - The 2020 COVID-19 pandemic and multiple sclerosis: Health behavior and lifestyle impacts in >1,000 people with MS

A. Vogel1, H. Schmidt2, S. Loud2, R. Mcburney2, F. Mateen1, 1Massachusetts General Hospital/Boston/US, 2Accelerated Cure Project/Waltham/US

LB1146 - Covid19 on U.S. and Canadian Neurologists’ Therapeutic Approach to Multiple Sclerosis: A Survey of Knowledge, Attitudes, and Practices

A. Vogel1, S. Rezai1, N. Alakel2, B. Gazdag2, A. Kumar2, F. Mateen1, 1Massachusetts General Hospital/Boston/US, 2ZoomRx/Boston/US

LB1147 - Multivitamin, Vitamin C and Vitamin D Pills Self-Medication in Multiple Sclerosis Patients in Montenegro During COVID-19 Pandemic

M. Roganovic, L. Radulovic, J. Erakovic, Clinical Centre of Montenegro/Podgorica/ME

LB1148 - Neuromyelitis optica (NMO) practice and prescribing changes in the setting of Covid19: A survey of neurologists

S. Rezaei1, A. Vogel2, B. Gazdag3, N. Alakel3, A. Kumar3, F. Mateen2, 1Massachusetts General Hospital/Cambridge/US, 2Massachusetts General Hospital/Boston/US, 3ZoomRx/Boston/US

LB1149 - Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: a cross-sectional study

Y. Zhang1, E. Staker1, G. Cutter2, S. Krieger1, A. Miller3, 1Mount Sinai/New York/US, 2The University of Alabama at Birmingham/Birmingham/US, 3Mount Sinai Hospital/New York City/US

LB1150 - Multiple sclerosis during COVID-19 pandemic in Santiago, Chile

C. Guevara, E. Villa, M. Cifuentes, M. Martinez, C. Garrido, V. Diaz, C. Silva-Rosas, R. Naves, J. De Grazia, University of Chile/Santiago/CL

LB1151 - Clinical outcomes in patients with COVID-19 infection during phase IV studies of cladribine tablets for treatment of multiple sclerosis

R. Karan1, S. Roy2, N. Alexandri1, 1Merck KGaA/Darmstadt/DE, 2Merck/Aubonne/CH

LB1152 - COVID-19 and lockdown in patients with multiple sclerosis: a descriptive study of prevalence and emotional impact

Y. Higueras1, A. Meldaña-Rivera1, J.M. García-Domínguez2, H. Goicochea Briceño2, J.P. Cuello2, A. Lozano-Ros2, M.L. Martínez-Ginés2, 1IISGM/Madrid/ES, 2Hospital General Universitario Gregorio Marañón/Madrid/ES

LB1153 - MS management during the COVID-19 pandemic

B. Moss1, K. Mahajan1, R. Bermel2, K. Hellisz1, L. Hua3, T. Hudec1, S. Husak1, M. Mcginley1, D. Ontaneda4, Z. Wang1, M. Weber-Grogan1, P. Tagliani5, S. Cárdenas-Robledo6, A. Zabalza5, G. Arrambide7, P. Carbonell-Mirabent5, M. Rodriguez-Barranco5, J. Sastre-Garriga7, M. Tintore8, X. Montalban8, M. Douglas9, E. Ogbuokiri9, B. Aravidis9, J. Cohen10, E. Mowry9, K. Fitzgerald11, 1Cleveland Clinic Foundation/Cleveland/US, 2Mellen Center for Multiple Sclerosis, Cleveland Clinic/Cleveland/US, 3Cleveland Clinic/Las Vegas/US, 4Cleveland Clinic//US, 5Vall d’Hebron Institut de Recerca/Barcelona/ES, 6Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron Barcelona Hospital Campus/Barcelona/ES, 7Vall Hebron University Hospital/Barcelona/ES, 8Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 9Johns Hopkins University/Baltimore/US, 10Mellen Center for MS Treatment and Research, Cleveland Clinic/Cleveland/US, 11Johns Hopkins University School of Medicine/Baltimore/US

LB1154 - COVID-19 in cladribine-treated patients with relapsing-remitting multiple sclerosis: a monocentric experience

P. Preziosa, M.A. Rocca, A. Nozzolillo, L. Moiola, M. Filippi, IRCCS San Raffaele Scientific Institute/Milan/IT

LB1155 - Vitamin D levels in the UK MS population and COVID-19 susceptibility

N. Vickaryous1, A. Garjani2, B. Jacobs3, M. Jitlal3, R. Middleton4, R. Das Nair2, K. Tuite-Dalton5, R. Hunter5, S. Chandran6, N. Macdougall7, R. Nicholas8, G. Giovannoni9, N. Evangelou2, R. Dobson10, 1Wolfson Institute of Preventive Medicine /BQ/GB, 2University of Nottingham/Nottingham/GB, 3Wolfson Institute of Preventive Medicine/BQ/GB, 4Swansea University/Swansea/GB, 5Swansea University Medical School/Swansea/GB, 6The University of Edinburgh/Edinburgh/GB, 7NHSGGC/NHSL/Glasgow/GB, 8Imperial College London/London/GB, 9The London School of Medicine and Dentistry/London/GB, 10Queen Mary University of London/London/GB

LB1156 - Physical activity behavior in people with multiple sclerosis during the COVID-19 pandemic in Israel: Results of an online survey

A. Kalron1, M. Greenberg-Abrahami2, S. Menascu2, R. Aloni2, L. Frid2, M. Dolev2, D. Magalashvili2, A. Achiron2, 1Sackler Faculty of Medicine, Tel-Aviv University/Herzelia, Israel/IL, 2Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer/Tel-Hashomer/IL

LB1157 - Experiences of Latin American MS and/or NMOSD experts in practice during the COVID-19 pandemic: focus in Telemedicine.

R. Alonso1, R. Carvajal2, M. Boaventura3, L. Galleguillos4, 1Hospital Ramos Mejía/Buenos Aires/AR, 2Hospital Universitario Nacional de Colombia/Bogotá/CO, 3Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo/São Paulo/BR, 4Clínica Alemana/Santiago/CL

LB1158 - COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management

T. Costabile1, A. Carotenuto1, L. Lavorgna2, G. Borriello3, L. Moiola4, M. Inglese5, M. Petruzzo6, F. Trojsi2, A. Ianniello7, A. Nozzolillo4, M. Cellerino8, G. Boffa9, L. Rosa1, G. Servillo1, M. Moccia10, S. Bonavita2, M. Filippi4, R. Lanzillo10, V. Brescia Morra1, M. Petracca1, 1University of Naples Federico II/Naples/IT, 2Clinic of Neurology, AOU - University of Campania “Luigi Vanvitelli”,/Napoli/IT, 33. MS Center, S. Andrea Hospital, Sapienza University/Rome/IT, 4IRCCS San Raffaele Scientific Institute/Milan/IT, 5University of Genoa//IT, 6Multiple Sclerosis Centre, Federico II University/Napoli/IT, 7MS Center, S. Andrea Hospital, Sapienza University/Rome/IT, 8University of Genoa/Genoa/IT, 9Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 10Federico II University of Naples, Italy/Napoli/IT

LB1159 - The Effect of COVID-19 Pandemic on Treatment Adherence of People with Multiple Sclerosis

M.F. Yetkin, M. Akcakoyunlu, M. Mirza, Erciyes University, Faculty of Medicine/Kayseri/TR

LB1160 - Multiple Sclerosis patients and Health Care accessibility during COVID-19 Pandemic

M. Seabra, A. Costa, D. Ferro, M. Pinto, B. Martins, T. Mendonça, J. Guimarães, P. Abreu, R. Reis, M.J. Sá, Centro Hospitalar Universitario de Sao Joao/Porto/PT

LB1161 - Teleneurology for MS care at two large academic centers before and during the-COVID-19 pandemic

M. Mcginley1, S. Gales2, Z. Wang1, W.-Y. Hsu3, W. Rowles3, R. Bove3, 1Cleveland Clinic Foundation/Cleveland/US, 2Cleveland Clinic/Cleveland/US, 3University of California, San Francisco/San Francisco/US

LB1162 - Rapid transfer of knowledge for multiple sclerosis clinical care during COVID-19: ECHO MS

K. Alschuler1, G. Von Geldern2, D. Ball3, K. Costello3, M. Skeen4, S. Chahin5, A. Wundes6, 1University of Washington School of Medicine/Seattle/US, 2University of Washington/Seattle/US, 3National Multiple Sclerosis Society/New York/US, 4Duke University/Durham/US, 5Washington University/St. Louis/US, 6University of Washington Medical Center/Seattle/US

LB1163 - Seroprevalence of SARS-COV-2 in multiple sclerosis patients under immunomodulatory treatment in Lleida (study EMCOVID-19).

J.V. Hervás-García1, A. Gil-Sanchez2, C. Gonzalez-Mingot1, L. Nogueras1, L. Quibus1, A. Sancho1, B. Quirant3, S. Peralta1, M.J. Solana1, C. Ramo3, E. Martínez-Cáceres3, L. Brieva4, 1Hospital Universitari Arnau de Vilanova de Lleida/Lleida/ES, 2Hospital arnau de vilanova/Lleida/ES, 3Hospital Universitari Germans Trias i Pujol/Badalona/ES, 4Hospital Arnau de Vilanova/LLEIDA/ES

LB1164 - "Awareness of Covid-19 in patients with MS in Saudi Arabia"

R. Jabbad1, H. Alnajashi2, 1King Abdulaziz University Hospital/Jeddah/SA, 2king Abdulaziz university /Jeddah/SA

LB1165 - COVID-19 in cladribine-treated patients with Multiple Sclerosis

C. Oreja-Guevara1, V. Meca-Lallana2, L. Brieva3, E. Fernandez-Diaz4, J.M. García-Domínguez5, D. Garcia- Estevez6, G. Llorens7, I. Moreno-Torres8, F.J. Valenzuela9, 1Hospital Universitario Clinico San Carlos/Madrid/ES, 2La Princesa Hospital/Madrid/ES, 3Hospital Arnau de Vilanova/LLEIDA/ES, 4Hospital General Universitario de Albacete/Albacete/ES, 5Hospital General Universitario Gregorio Marañón/Madrid/ES, 6Complexo Hospitalario Universitario de Ourense/Ourense/ES, 7Hospital General Mateu Orfila/Illes Balears/ES, 8Hospital Universitario Fundación Jiménez Díaz/Madrid/ES, 9Hospital Central de la Defensa Gómez Ulla/Madrid/ES

LB1166 - Risk and outcomes of COVID-19 in patients with multiple sclerosis in Madrid Spain

I. Moreno-Torres1, V. Meca-Lallana2, L. Costa-Frossard3, C. Oreja-Guevara4, C. Aguirre2, E. Alba Suárez5, M. Gómez Moreno6, L. Borrega Canelo7, J. Sabín-Muñoz8, Y. Aladro9, A. Cárcamo Fonfría9, E. Rodríguez García10, J.P. Cuello11, E. Monreal3, S. Sainz De La Maza3, F. Perez Parra12, F.J. Valenzuela13, C. Lopez De Silanes14, L.I. Casanova Peño14, M.L. Martínez-Ginés11, M.R. Blasco Quílez8, A. Orviz García1, L.M. Villar3, C. Santiuste3, M. Espiño3, G. Fernandez-Dono15, V. Elvira16, 1Hospital Universitario Fundación Jiménez Díaz/Madrid/ES, 2La Princesa Hospital/Madrid/ES, 3Hospital Universitario Ramón y Cajal/Madrid/ES, 4Hospital Universitario Clinico San Carlos/Madrid/ES, 5Hospital Universitario La Paz/Madrid/ES, 6Hospital Universitario Infanta Leonor/Madrid/ES, 7Hospital Universitario Fundación Alcorcón/Madrid/ES, 8Puerta de Hierro University Hospital/Madrid/ES, 9Hospital Universitario de Getafe/Getafe. Madrid/ES, 10Hospital Universitario Severo Ochoa/Madrid/ES, 11Hospital General Universitario Gregorio Marañón/Madrid/ES, 12Hospital Universitario del Henares/Madrid/ES, 13Hospital Central de la Defensa Gómez Ulla/Madrid/ES, 14Hospital Universitario de Torrejón/Madrid/ES, 15Universidad Complutense de Madrid/Madrid/ES, 16University of Edinburgh/Edinburgh/GB

LB1167 - Reported Covid19 symptoms in patients on oral Disease Modifying Treatmentss (DMTs) at a single centre

R. Dorsey-Campbell1, C. Radia2, A. Dewan2, R. Gokani2, T. Felongco2, D. Delacruz3, A. Nandoskar4, V. Singh-Curry4, A. Scalfari5, O. Malik4, R. Nicholas5, 1Imperial College NHS Trust/London/GB, 2Imperial College Healthcare NHS Trust/RF/GB, 3Imperial College Helathcare NHS Trust/RF/GB, 4Imperial College of London/London/GB, 5Imperial College London/London/GB

LB1168 - COVID-19 in MS patients: susceptibility and severity risk factors

A. Zabalza1, P. Tagliani1, S. Cárdenas-Robledo2, G. Arrambide3, S. Otero-Romero4, P. Carbonell- Mirabent1, M. Rodríguez5, B. Rodríguez-Acevedo5, J.L. Restrepo-Vera4, M. Resina-Sallés5, L. Midaglia6, A. Vidal-Jordana7, J. Río8, Í. Galán5, J. Castilló9, A. Cobo Calvo10, M. Comabella11, C. Nos5, J. Sastre-Garriga3, M. Tintore12, X. Montalban5, 1Vall d’Hebron Institut de Recerca/Barcelona/ES, 2Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron Barcelona Hospital Campus/Barcelona/ES, 3Vall Hebron University Hospital/Barcelona/ES, 4Vall d'Hebron University Hospital/Barcelona/ES, 5Dept. of Neurology-Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 6Dept. of Neurology- Neuroimmunology; Vall Hebron University Hospital; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 7Hospital Universitari Vall d’Hebron/Barcelona/ES, 8CEMCAT, Hospital Universitario Vall d’Hebrón/Barcelona/ES, 9Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 10Centre d’Esclerosi Múltiple de Catalunya (Cemcat)/Barcelona/ES, 11Universitat Autònoma//ES, 12Multiple Sclerosis Centre of Catalonia/Barcelona/ES

LB1169 - Psychological consequences of COVID-19 pandemic in Italian MS patients: a surprising resilience

M. Altieri1, R. Capuano2, A. Bisecco3, A. D'Ambrosio4, R. Docimo4, D. Buonanno4, F. Matrone4, F. Giuliano4, G. Tedeschi4, G. Santangelo4, A. Gallo5, 1Multiple Sclerosis Centre, I Division of Neurology, University of Campania “Luigi Vanvitelli”/Casalnuovo di Napoli/IT, 2Multiple Sclerosis Centre, I Division of Neurology, University of Campania “Luigi Vanvitelli”/SALERNO/IT, 3University of Campania /Naples/IT, 4University of Campania “Luigi Vanvitelli”/Naples/IT, 5University of Campania "L. Vanvitelli"/Naples/IT

LB1170 - Use of IVIG in three immunosuppressed patients hospitalized with COVID-19

E. Graham, J. Datar, C. Bevan, E. Grebenciucova, I. Koralnik, B. Cohen, R. Balabanov, Northwestern University/Chicago/US

LB1171 - Embracing resilience in Multiple Sclerosis: a new perspective from COVID-19 pandemic.

E. Sbragia1, E. Colombo2, C. Pollio2, M. Cellerino1, C. Lapucci2, M. Inglese3, G.L. Mancardi1, G. Boffa2, 1University of Genoa/Genoa/IT, 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 3University of Genoa//IT

LB1172 - MS and COVID-19: A Webinar Series for Healthcare Providers

D. Lill1, K. Costello2, J. Fiol3, J. Halper4, 1/Tampa/US, 2National Multiple Sclerosis Society/Castle Hayne/UM, 3National Multiple Sclerosis Society/Bel Aire/US, 4CMSC/Fair Lawn/US

LB1173 - Clinical COVID19 Data collection from the UK Multiple Sclerosis Register

R. Middleton1, N. Evangelou2, A. Garjani2, R. Das Nair2, R. Hunter3, K. Tuite-Dalton3, E. Craig3, D. Ford3, R. Nicholas4, 1Swansea University/Swansea/GB, 2University of Nottingham/Nottingham/GB, 3Swansea University Medical School/Swansea/GB, 4Imperial College London/London/GB

LB1174 - Patient and healthcare professional perspectives of immune dynamics and MS disease- modifying therapies mode of action throughout COVID-19 pandemic

J. Burtchell1, D. Clemmons2, J. Clemmons3, J. Graves4, M. Sweeney5, J. Kramer6, M. Ziehn7, B. Brown8, J. Weiss9, A. Obeidat10, 1HealthiVibe, a division of Corona, LLC/Arlington/US, 2N/A/N/A/US, 3N/A/South McKee/US, 4University of California, San Diego/San Diego/US, 5University of Louisville Hospital Multiple Sclerosis Clinic/Louisville/US, 6/Nashville/US, 7Novartis Pharma AG/Basel/CH, 8Novartis Pharmaceuticals Corporation/NJ/US, 9Novartis Pharmaceuticals Corporation/East Hanover/US, 10Department of Neurology – Medical College of Wisconsin/Milwaukee/US

LB1175 - Multiple Sclerosis patients and disease management during COVID-19 Pandemics

D. Ferro, A. Costa, R. Soares-Dos-Reis, M. Seabra, M. Pinto, B. Martins, C. Sousa, T. Mendonça, J. Guimarães, P. Abreu, M.J. Sá, Centro Hospitalar Universitario de Sao Joao/Porto/PT

LB1176 - Anxiety affects the general well-being of people with MS during the COVID-19 pandemic more than the infection itself

A. Garjani1, R. Hunter2, R. Nicholas3, R. Middleton4, K. Tuite-Dalton2, A. Coles5, R. Dobson6, M. Duddy7, D. Ford2, S. Hughes8, O. Pearson9, D. Rog10, E. Tallantyre11, G. Law12, R. Das Nair1, N. Evangelou1, 1University of Nottingham/Nottingham/GB, 2Swansea University Medical School/Swansea/GB, 3Imperial College London/London/GB, 4Swansea University/Swansea/GB, 5University of Cambridge School of Medicine/Cambridge/GB, 6Queen Mary University of London/London/GB, 7Newcastle upon Tyne Hospitals NHS Trust/Newcastle upon Tyne/GB, 8Royal Victoria Hospital/Belfast/GB, 9Swansea Bay University Health Board/Swansea/GB, 10Salford Royal NHS Foundation Trust/Salford/GB, 11Cardiff University/Cardiff/GB, 12University of Lincoln/Lincoln/GB

LB1177 - PAMRINO: International MRI and clinical data repository for neuromyelitis optica spectrum disorder

C. Chien1, H. Zimmermann2, S. Specovius2, F.C. Oertel3, D. Bichuetti4, M. Idagawa4, A. Altintas5, U. Tanriverdi6, S. Siritho7, L. Pandit8, A. D'Cunha8, M.J. Sá9, R. Figueiredo10, C. Tongco11, P. Qian12, I. Lotan13, V. Khasminsky14, M. Hellmann15, H. Stiebel-Kalish16, D. Rotstein17, L. Waxman18, D. Ontaneda19, K. Nakamura20, H. Abboud21, M.O. Subei21, Y. Mao-Draayer22, J. Havla23, N. Asgari24, I. Kister25, Z. Rimler26, A. Reid26, M. Ringelstein27, S. Broadley28, S. Arnett28, B. Marron29, A. Jolley30, M. Wunderlich29, S. Green29, L. Cook30, M. Yeaman31, T. Smith32, A. Brandt33, P. Skejø34, V. Cruz Silva35, J. Wuerfel36, F. Paul37, G. International Clinical Consortium For Nmosd38, 1Charité-Universitätsmedizin Berlin/Berlin/DE, 2Charité – Universitätsmedizin Berlin/Berlin/DE, 3/San Francisco/US, 4Universidade Federal de São Paulo/Sao Paolo/BR, 5Koc University/Istambul/TR, 6Istanbul University/Istanbul/TR, 7Siriraj Hospital and Bumrungrad International Hospital/Bangkok/TH, 8Nitte University/Mangalore/IN, 9Centro Hospitalar Universitario de Sao Joao/Porto/PT, 10Hospital de S. João Al. Hernâni Monteiro/Porto/PT, 11Swedish Neuroscience Institute Neuro- Ophthalmology/Seattle/US, 12Swedish Neuroscience Institute/Seattle/US, 13Rabin Medical Center/Tel Aviv/IL, 14Rabin Medical Center, Beilinson Hospital/Tel Aviv/IL, 158Rabin Medical Center, Belinson Hospital/Petach Tikva/IL, 16Tel Aviv University/Tel Aviv/IL, 17University of Toronto/Toronto/CA, 18University of Toronto, St. Michael’s Hospital/Toronto/CA, 19Cleveland Clinic//US, 20Cleveland Clinic Foundation/Cleveland/US, 21University Hospitals Cleveland Medical Center/Cleveland/US, 22Autoimmunity Center of Excellence/MI/US, 23Ludwig-Maximilians Universitaet Muenchen/Munich/DE, 24Institute of Regional Health Research/Odense/DK, 25New York University/New York City/US, 26NYU School of Medicine/New York/US, 27Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf/Düsseldorf/DE, 28Griffith University/Southport/AU, 29University of Utah/Salt Lake City/US, 30University of Utah School of Medicine/Salt Lake City/US, 31University of California/Los Angeles/US, 32University of Michigan Medical School/Ann Arbor/US, 33Department of Neurology, University of California Irvine, Irvine, California, USA./Irvine/US, 34Aleris-Hamlet Hopitaler/Søborg/DK, 35Medical Image Analysis Center (MIAC AG)/Basel/CH, 36Medical Image Analysis Center/Basel/CH, 37Charite-Universitatmedizin Berlin/Berlin/DE, 38GJCF International Clinical Consortium for NMOSD/Los Angeles/US

LB1178 - Monitoring of blood neurofilaments improves stratification of disease activity in multiple sclerosis

T. Uher1, E. Havrdova2, P. Benkert3, N. Bergsland4, J. Krasensky5, B. Srpová6, M. Dwyer7, M. Tyblova8, M. Vaneckova5, D. Horakova2, R. Zivadinov4, D. Leppert9, T. Kalincik10, J. Kuhle11, 1First Faculty of Medicine, Charles University and General University/Prague/CZ, 2First Faculty of Medicine, Charles University and General University Hospital in Prague/Prague/CZ, 3University Hospital Basel, University of Basel/Basel/CH, 4Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York/Buffalo/US, 5Charles University and General University Hospital/Prague/CZ, 6Charles University and General University/Prague/CZ, 7Buffalo Neuroimaging Analysis Center/Buffalo/US, 8Charles University/Prague/CZ, 9University Hospital Basel and University of Basel/Basel/CH, 10Royal Melbourne Hospital/Melbourne/AU, 11University of Basel/Switzerland/CH

LB1179 - Predictors of Disease Modifying Treatment Failure Amongst Neuromyelitis Optica Spectrum Disorder Patients, Stratified by Antibody Serostatus

K. Polito1, T. Islam2, L. Amezcua3, M. Burnett4, V. Patel1, 1Keck Medical Center of USC/Los Angeles/US, 2Keck School of Medicine/Los Angeles/US, 3USC/Los Angeles/US, 4University of Southern California/Los Angeles/US

LB1180 - Switching from ocrelizumab to cladribine: real world data

D. O'Neill1, M. Sharma2, B. Gonzales2, M. Vandenheuval2, B. Tse3, S. Hodgkinson4, 1Liverpool Hospital /Sydney/AU, 2Liverpool Hospital/Sydney/AU, 3Ingham Institute for Medical Research/Sydney/AU, 4Ingham Institute for Applied Medical Research, University of New South Wales Medicine/Sydney/AU

LB1181 - COVID-19 Outcomes among patients with Multiple Sclerosis: Experience from RWJBH Multiple Sclerosis Comprehensive Care Center M. Tremblay1, C. Greco1, V. Busko2, E. Dealca1, P. Del Boccio1, A. Sylvester1, 1RWJBarnabas Health Multiple Sclerosis Comprehensive Care Center/Livingston/US, 2RWJBH Multiple Sclerosis Comprehensive Care Center/Livingston/US

LB1182 - Multiple Sclerosis and the psychological impact of COVID-19

H. Morris-Bankole1, A. Ho2, 1University of Reading/Ireland/IE, 2University of Reading/Reading/GB

LB1183 - Utilizing Optical Coherence Tomography to Assess the Gender Role on Retinal Structures in Patients with Early MS

M. Hackett, M. Bross, C. Santiago-Martinez, E. Bernitsas, Wayne State University/Detroit/US

LB1184 - Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms

C. Barbour1, P. Kosa1, M. Varosanec1, M. Greenwood2, B. Bielekova1, 1National Institutes of Health/Bethesda/US, 2Montana State University/Bozeman/US

LB1185 - Real-world experience with Ocrelizumab in the German NeuroTransData Registry

S. Braune1, Y. Heer2, V. Tozzi3, P. Van Hoevell4, E. Muros-Le Rouzic5, P. Dirks6, A. Bergmann1, 1NeuroTransData GmbH/Neuburg an der Donau/DE, 2PwC/Zurich/CH, 3PwC/ZURICH/CH, 4PricewaterhouseCoopers AG/Zürich/CH, 5F. Hoffmann-La Roche Ltd,/Basel/CH, 6Roche/Grenzach-Wyhlen/DE

LB1186 - Investigating fractalkine as a potential remyelination therapy in the cuprizone MS mouse model

M.M. Alves De Almeida, A. Watson, F. Khan, J. Li, K. Goodkey, T. Footz, D. Galleguillos, S. Sipione, A. Voronova, University of Alberta/Edmonton/CA

LB1187 - Evaluation of multiple sclerosis progression with clinic parameters in Tomsk Region, Russian Federation

E. Kamenskih, V. Alifirova, E. Koroleva, D. Pashkovskaya, N. Brazovskaya, Siberian State Medical University/Tomsk/RU

LB1188 - Epidemiology of COVID-19 among persons with neuroimmunological disorders at the Columbia University MS Center in New York City

K. Fong1, S. Epstein2, K. Thakur1, A. Boehme1, P. De Jager3, L. Levine1, W. Vargas4, C. Riley1, R. Straus Farber3, 1Columbia University Irving Medical Center/New York/US, 2Columbia University Irving Medical Center; Neurologic Institute/New York/US, 3Columbia University Medical Center/United States/US, 4Columbia University Medical Center/New York/US

LB1189 - Diagnostic Value of DWI-MRI for Detecting Acute Plaqes in Relapse Phase of Multiple Sclerosis

M. Maghbooli, M. Yousefi, M. Panahali, Zanjan University of Medical Sciences/Zanajn/IR

LB1190 - The Emotional Impact of the COVID-19 Pandemic on Individuals with Progressive Multiple Sclerosis.

N. Chiaravalloti1, M.P. Amato2, G. Brichetto3, J. Chataway4, U. Dalgas5, J. Deluca1, C. Meza6, N. Moore1, P. Feys7, M. Filippi8, J. Freeman9, M. Inglese10, R. Motl11, M.A. Rocca8, B. Sandroff1, A. Salter12, G. Cutter13, A. Feinstein6, 1Kessler Foundation/East Hanover/US, 2University of Florence/Florence/IT, 3Italian Multiple Sclerosis Society/Genova/IT, 4UCL Queen Square Institute of Neurology, University College//GB, 5Aarhus University/Aarhus/DK, 6Sunnybrook Health Sciences Centre/Toronto/CA, 7Hasselt University/Diepenbeek/BE, 8IRCCS San Raffaele Scientific Institute/Milan/IT, 9University of Plymouth/Plymouth/GB, 10Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI, University of Genoa, Italy./Genova/IT, 11University of Alabama//US, 12Washington University School in St. Louis/St Louis/US, 13The University of Alabama at Birmingham/Birmingham/US

LB1191 - Validation of the Italian version of the Multiple sclerosis intimacy and sexuality questionnaire-19

A. Carotenuto1, L. De Giglio2, A. Chiodi1, M. Petracca1, L. Rosa1, M. Bianchi1, I. Ferrante3, F. Lauro1, M. Moccia4, A. Ianniello3, C. Pozzilli3, V. Brescia Morra1, R. Lanzillo4, 1University of Naples Federico II/Naples/IT, 2‘S. Filippo’ Hospital/Rome/IT, 3‘S. Andrea’ Hospital/Rome/IT, 4Federico II University of Naples, Italy/Napoli/IT

LB1192 - Effects of Perturbation-based Balance Training versus Conventional Balance Training on Balance and Falls in People with Multiple Sclerosis

S. Monjezi1, F. Molhemi2, M.-J. Shaterzadeh-Yazdi3, R. Salehi4, M. Mehravar3, D. Kashipazha5, 1/number,SorooshSharghi,Kianpars,Ahvaz/IR, 2Student Research Committee, Ahvaz Jundishapur University of Medical Sciences/Ahvaz/IR, 3Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences/Ahvaz/IR, 4Rehabilitation Research Center, Department of Rehabilitation Management, School of Rehabilitation Sciences, Iran University of Medical Sciences,/Tehran/IR, 5Department of Neurology, Ahvaz Jundishapur University of Medical Sciences/Ahvaz/IR

LB1193 - The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis

A. Reia1, M. Petruzzo2, G.T. Maniscalco3, F. Luiso4, R. Lanzillo5, C. Russo4, A. Carotenuto6, L. Allegorico3, R. Palladino7, V. Brescia Morra6, M. Moccia5, 1University of Naples Federico II/Napoli/IT, 2Multiple Sclerosis Centre, Federico II University/Napoli/IT, 3Neurological Clinic and Multiple Sclerosis Centre of “AORN A.Cardarelli”/Napoli/IT, 4Multiple Sclerosis Centre, Federico II University/Naples/IT, 5Federico II University of Naples, Italy/Napoli/IT, 6University of Naples Federico II/Naples/IT, 7Federico II University of Naples, Italy/Naples/IT

LB1194 - Analysis of count data in MS clinical trials

B. Healy, Harvard Medical School/United States/US

LB1195 - Changes in Mobility and Brain Connectivity following over-ground Robotic Exoskeleton Rehabilitation in Persons with MS

P. Niewrzol, G. Wylie, G. Yue, J. Deluca, G. Androwis, Kessler Foundation/West Orange/US

LB1196 - Enhancing myelin repair in MS preclinical models by modulating the cholesterol biosynthesis pathway

C. Pedraza, G. Sheng, K. Radzwill, L. Guo, C. Garron, S. Holley, K. Randall, T. Gladysheva, G. Merrriman, Sanofi/Framingham/US

LB1197 - Myelin water imaging provides evidence for unique anatomical-functional relationships between myelin damage and different cognitive domains in MS

S. Abel1, A. Dvorak2, S. Morris2, I. Vavasour2, P. Johnson2, S. Ristow2, L.E. Lee2, J. Chan2, C. Laule2, A. Schabas2, H. Cross3, R. Tam2, A. Kuan2, S. Morrow4, J. Wilken5, A.L. Sayao6, V. Devonshire6, D. Li7, R. Carruthers8, A. Traboulsee9, S. Kolind2, 1/Delta/CA, 2University of British Columbia/Vancouver/CA, 3University of British Columbia MS Clinic/Vancouver/CA, 4London Health Sciences Centre/London/CA, 5Neuropsychology Associates of Fairfax/Fairfax/US, 6University of British Columbia MS/NMO Center/Vancouver/CA, 7//CA, 8University of British Columbia Hospital/Vancouver/CA, 9The University of British Columbia/Canada/CA

LB1198 - Effects of Virtual Reality Training on Coordination, Executive Function, and Reaction Time in People with Multiple Sclerosis

F. Molhemi1, S. Monjezi2, M. Mehravar3, R. Salehi4, M.-J. Shaterzadeh-Yazdi3, H. Negahban5, N. Majdinasab3, 1Student Research Committee, Ahvaz Jundishapur University of Medical Sciences/Ahvaz/IR, 2/number,SorooshSharghi,Kianpars,Ahvaz/IR, 3Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences/Ahvaz/IR, 4Rehabilitation Research Center, Department of Rehabilitation Management, School of Rehabilitation Sciences, Iran University of Medical Sciences,/Tehran/IR, 5Department of Physical Therapy, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran / Orthopedic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran/Mashhad/IR

LB1199 - Marked increase of CSF sampling induced vasovagal response secondary to COVID-19 pandemic

A. Gagnon, clinique neuro-outaouais/Gatineau/CA

LB1200 - The SUNLIGHT Study: A telehealth intervention to address mental health in persons with MS during COVID-19

V. Leavitt1, A. Kever2, I. Aguerre1, C. Riley1, P. De Jager3, K. Fong1, L. Levine1, R. Straus Farber3, W. Vargas4, M. Vasquez1, 1Columbia University Irving Medical Center/New York/US, 2Columbia University Irving Medical Center/new York/US, 3Columbia University Medical Center/United States/US, 4Columbia University Medical Center/New York/US

LB1201 - SARS-CoV-2 associated Neuromyelitis optica

T.-Y. Chuang, D. Miskin, Thomas Jefferson University Hospital/Philadelphia/US

LB1202 - The effects of obesity on retinal structures in African American and Caucasian relapsing remitting multiple sclerosis patients

M. Bross, M. Hackett, E. Probst-Simmons, R. Darling, C. Santiago-Martinez, J. Rube, E. Bernitsas, Wayne State University/Detroit/US

LB1203 - Neuromyelitis optica spectrum disorders (NMOSD) attack triggered by COVID-19 infection (A case report)

A. Nasreldein, H. Ibrahem, A. Bahie, Assiut University/Assiut/EG

LB1205 - Covid-19 Infection in Patients with Multiple Sclerosis: an observational study by The New York COVID-19 Neuro-Immunology Consortium (NYCNIC)

S. Klineova1, A. Harel2, R. Straus Farber3, Y. Zhang4, T. Deangelis5, T.M. Leung6, K. Fong7, T. Smith8, R. Blanck9, S. Filomena1, M. Karran6, S. Gurgova10, K. Onomichi7, L. Zhovtis-Ryerson11, 1Icahn School of Medicine at Mount Sinai/New York/US, 2Donald and Barbara Zucker School of Medicine at Hofstra/Northwell/New York/US, 3Columbia University Medical Center/United States/US, 4Mount Sinai/New York/US, 5Neurological Associates of Long Island/New Hyde park/US, 6Northwell Health/New York/US, 7Columbia University Irving Medical Center/New York/US, 8NYU Langone Health, New York University/New York/US, 9Neurological associates of Long Island/New Hyde Park/US, 10Neurological associates of Long Island/New Hide Park/US, 11NYU Langone Health, New York University/New York City/US

LB1206 - Sars-Cov-2 infection releated inflammatory and demyelinating disease; a brief case series

N. Kaya Tutar1, S. Omerhoca1, E. Coban2, N. Kale2, 1bagcilar training and research hospital/Istanbul/TR, 2bagcilar training and research hospital/istanbul/TR

LB1207 - Elevated levels of serum CD5 antigen-like protein distinguish secondary progressive multiple sclerosis from other disease subtypes E. Kamma1, P. Becquart1, R. Carruthers2, A. Traboulsee3, I. Vavasour1, C. Laule1, J. Quandt1, 1University of British Columbia/Vancouver/CA, 2University of British Columbia Hospital/Vancouver/CA, 3The University of British Columbia/Canada/CA

LB1208 - Linking structural and functional brain alterations in relapsing-remitting MS

J. Zhang1, A. Giorgio2, C. Vinciguerra1, M.L. Stromillo1, M. Mortilla3, R. Tappa Brocci1, M. Battaglini1, E. Portaccio4, M.P. Amato5, N. De Stefano1, 1University of Siena/Siena/IT, 2Department of Medicine, Surgery and Neuroscience, University of Siena, Italy/Siena/IT, 3Anna Meyer Children’s University Hospital/Florence/IT, 4Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy/Florence/IT, 5University of Florence/Florence/IT

LB1209 - A tablet-based videogame for capturing slowing processing speed in multiple sclerosis patients: a pilot study

M. Pitteri, C. Dapor, S. Ziccardi, M. Guandalini, R. Meggiato, M. Calabrese, University of Verona/Verona/IT

LB1210 - Cerebrospinal fluid inflammatory profile of cognitive dysfunction in newly diagnosed multiple sclerosis patients

M. Pitteri, R. Magliozzi, S. Ziccardi, A. Pisani, M. Calabrese, University of Verona/Verona/IT

LB1211 - Histaminergic basis of fatigue in Multiple Sclerosis

K. Rammohan, N. Garg, L. Tornes, C. Zheng, S. Bhattacharya, University of Miami School of Medicine/Miami/US

LB1212 - Evaluating Multiple Sclerosis patients for gluten sensitivity – worthwhile or not?

S. Bentota, E. Crabtree, Tulane University School of Medicine/New Orleans/US

LB1213 - Attention-based deep learning identifies a new microstructural diffusion MRI contrast sensitive to focal pathology and related to patient disability

P.-J. Lu1, M. Barakovic2, M. Weigel1, R. Rahmanzadeh1, R. Galbusera1, S. Schiavi3, A. Daducci3, J. Kuhle4, L. Kappos5, P. Cattin6, C. Granziera1, 1University Hospital Basel and University of Basel/Basel/CH, 2University of Basel/Allschwil/CH, 3University of Verona/Verona/IT, 4University of Basel/Switzerland/CH, 5University of Basel//CH, 6Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering [Translational Imaging in Neurology (ThINk) Basel], University Hospital and University of Basel, Basel, Switzerland/Basel/CH

LB1214 - Antiviral activity of Interferon beta-1b to SARS-CoV-2 infection F. Leguizamón1, F. Knorre2, 1Hospital General de Agudos Dr Teodoro Alvarez/Ciudad Autonoma de Buenos Aires/AR, 2Hospital Alvarez/Ciudad Autonoma de Buenos Aires/AR

LB1215 - "Clinical course, Safety of Low-dose Rituximab for Vietnameses Patients with Neuromyelitis Optica Spectrum Disorder"

T. Le, Ha Noi Medical University Hospital/Ha Noi/VN

LB1216 - Cortical and deep grey matter volume loss is specifically linked to cerebrospinal fluid inflammation in early multiple sclerosis.

A. Bajrami1, R. Magliozzi2, A. Pisani2, F. Crescenzo2, D. Marastoni2, M. Calabrese2, 1/Pergine Valsugana, Trento/IT, 2University of Verona/Verona/IT

LB1217 - Macular pigment concentration and distribution in multiple sclerosis

G. Kalaitzidis1, A. Filippatou1, O. Murphy1, J. Lambe1, E. Vasileiou1, H. Ehrhardt1, N. Pellegrini1, E. Sotirchos2, P. Calabresi2, K. Fitzgerald1, S. Saidha1, 1Johns Hopkins University School of Medicine/Baltimore/US, 2Johns Hopkins University/Baltimore/US

LB1218 - Impact of COVID-19 on MS patients’ access to care and neurologists’ treatment practices worldwide: results from the ECTRIMS survey

E. Portaccio1, M. Fonderico2, B. Hemmer3, T. Derfuss4, B. Stankoff5, K. Selmaj6, M. Tintore7, M.P. Amato8, 1Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy/Florence/IT, 2University of Florence, Florence, Italy;/Florence/IT, 3University of Munich/Munich/DE, 4University of Basel//CH, 5Sorbonne Université/Paris/FR, 6Department of Neurology, University of Warmia and Mazury/Olsztyn/PL, 7Multiple Sclerosis Centre of Catalonia/Barcelona/ES, 8University of Florence/Florence/IT

LB1219 - Normal serum NFL levels: a proposal of cut-off strategy definition for the clinical practice

P. Valentino1, F. Marnetto1, S. Martire2, C. Bava2, M. Popovic3, A. Bertolotto4, 1Neuroscience Institute Cavalieri Ottolenghi (NICO)/orbassano/IT, 2Neuroscience Institute Cavalieri Ottolenghi/Orbassano/IT, 3University of Turin/Turin/IT, 4San Luigi Gonzaga Hospital/Orbassano (TO)/IT

LB1220 - Real-life experience with sNFL in Multiple Sclerosis patients, as monitoring and treatment decision biomarker

P. Valentino1, F. Marnetto1, C. Bava2, S. Martire2, A. Bertolotto3, 1Neuroscience Institute Cavalieri Ottolenghi (NICO)/orbassano/IT, 2Neuroscience Institute Cavalieri Ottolenghi/Orbassano/IT, 3San Luigi Gonzaga Hospital/Orbassano (TO)/IT

LB1221 - Applicability of sNFL in Multiple Sclerosis as additional measure in clinical practice and implications in NEDA-3 evaluation. A. Bertolotto1, S. Malucchi1, F. Marnetto2, S. Martire3, P. Valentino2, 1San Luigi Gonzaga Hospital/Orbassano (TO)/IT, 2Neuroscience Institute Cavalieri Ottolenghi (NICO)/orbassano/IT, 3Neuroscience Institute Cavalieri Ottolenghi/Orbassano/IT

LB1222 - Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders

C. Louapre1, E. Maillart2, C. Papeix3, S. Zeidan4, D. Biotti5, Z. Lepine6, A. Wahab7, M. Zedet8, P. Labauge9, C. Tilikete10, J. Pique10, A. Tourbah11, G. Mathey12, D. Dimitri Boulos13, P. Branger14, L. Kremer15, R. Marignier16, N. Collongues17, J. De Seze18, 1Pitié salpetrière/Paris/FR, 2Pitié-Salpêtriere /Paris/FR, 3pitié-salpêtrière hospital/PARIS/FR, 4Pitié-Salpêtrière hospital, APHP/PARIS/FR, 5AssistancCRC-SEP, Toulouse University Hospital, Toulouse, Francee Publique- Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France/Toulouse/FR, 6CRC-SEP, Toulouse University Hospital, Toulouse/Toulouse/FR, 7CHU Creteil/Creteil/FR, 8CHU Lille/Lille/FR, 9CHU de Montpellier/Montpellier/FR, 10Hospices civils de Lyon/Lyon/FR, 11Hôpital Raymond Poincaré, APHP/Garches/FR, 12CHU Nancy/Nancy/FR, 13Hôpital Kremlin Bicêtre, APHP/Kremlin Bicêtre/FR, 14CHU Caen/Caen/FR, 15CHU Strasbourg Hautepierre/Strasbourg/FR, 16Lyon Neuroscience Research Center/Bron/FR, 17Strasbourg University Hospital, Strasbourg, France/Strasbourg/FR, 18CHU de Strasbourg/Strasbourg/FR

LB1223 - Telehealth: another tool in the toolkit to provide usual care to people with Multiple Sclerosis during the COVID-19 pandemic.

A. Parkinson, J. Drew, S. Hall, K. Chisholm, M. Elisha, V. Fanning, C. Phillips, C. Lueck, J. Desborough, Australian National University/Acton/AU

LB1224 - Thalamic and whole brain atrophy are linked with white matter microglial activation: A [F- 18]PBR06-PET study in multiple sclerosis

K. Carter1, S. Cicero1, R. Chu2, S. Dubey2, S. Tauhid2, E. Rissanen2, H. Pan2, M.-A. Park2, M. Kijewski2, E. Stern2, D. Silbersweig2, R. Bakshi1, H. Weiner3, T. Singhal1, 1Brigham and Women's Hospital/Boston/US, 2Brigham & Women's Hospital/Boston/US, 3Harvard University, Brigham & Women's Hospital/Boston/US

LB1225 - Acute disseminated encephalomyelitis in a pediatric patient in the setting of SARS-CoV2 with histopathology

J. Lorenzo1, N. Gonzalez Caldito2, C. Wang3, 1University of Texas Southwestern/Dallas/US, 2UTSW/Dallas/US, 3University of Texas Southwestern Medical Center/dallas/US

LB1226 - Use and safety of interferon beta-1b during the COVID-19 outbreak: current data from a pharmacovigilance safety database A. Reder1, A. Adamo2, E.-M. Wicklein3, A. Bhatti4, 1University of Chicago/Burr Ridge/US, 2Bayer AG/Sao Paolo/BR, 3Bayer AG/Berlin/DE, 4Bayer AG/Whippany/US

LB1227 - Glatiramer Acetate Depot (extended-release) phase IIa study in patients with Primary Progressive Multiple Sclerosis: safety and efficacy snapshot

S. Flechter1, L. Popper2, N. Bleich Kimelman2, I. Demender2, S. Rubnov2, U. Danon2, E. Marom2, R. Milo3, R. Gilad4, B. Weller5, A. Vaknin-Dembinsky6, M. Hellmann7, A. Karni8, 1Sheba Medical Center/Ramat Gan/IL, 2Mapi Pharma Ltd/Ness Ziona/IL, 3Barzilai University Medical Center/Ashkelon/IL, 4Kaplan Medical Center/Rechovot/IL, 5Bnei Zion Medical Center/Haifa/IL, 6Hadassah Medical Center/Jerusalem/IL, 78Rabin Medical Center, Belinson Hospital/Petach Tikva/IL, 8Tel Aviv Medical Center/Tel Aviv/IL

LB1228 - Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with RRMS: Safety, Tolerability and Efficacy Four-Years Analysis

S. Flechter1, A. Miller2, L. Popper3, N. Bleich Kimelman3, S. Rubnov3, U. Danon3, E. Marom3, R. Milo4, J. Chapman5, A. Shifrin6, R. Gilad7, C. Hoffmann1, D. Karussis8, A. Karni9, 1Sheba Medical Center/Ramat Gan/IL, 2Technion-Israel Institute of Technology, Carmel Medical Center/Haifa/IL, 3Mapi Pharma Ltd/Ness Ziona/IL, 4Barzilai University Medical Center/Ashkelon/IL, 5Sheba Medical Center, Tel Aviv University/Ramat Gan/ Tel Aviv/IL, 6Rambam Medical Center/Haifa/IL, 7Kaplan Medical Center/Rechovot/IL, 8Hadassah-Hebrew University Medical Center/Jerusalem/IL, 9Tel Aviv Medical Center/Tel Aviv/IL

LB1229 - CLASSIC-MS: Long-term efficacy and real-world treatment patterns for patients receiving cladribine tablets - interim data with 8–14 years follow-up

G. Giovannoni1, T. Leist2, A. Aydemir3, E. Verdun Di Cantogno4, 1The London School of Medicine and Dentistry/London/GB, 2Jefferson University/Philadelphia/US, 3EMD Serono Research & Development Institute, Inc./Billerica/US, 4Merck KGaA/Darmstadt/DE

LB1230 - Longitudinally Extensive Transverse Myelitis in association with COVID-19

S. Siddiqi1, J. Perkash2, M. Thakre3, J. Inshasi2, A. Almadani2, Y. Malik2, R. Ahmed2, Y. Mohamed2, 1RAshid hospital /Dubai/AE, 2Rashid hospital/Dubai/AE, 3Al Zahra Hospital /154412/AE

LB1231 - Demographic and Clinical Profile of Pediatric patients with Multiple Sclerosis infected with SARS-Cov2

T. Schreiner1, T. Chitnis2, J.-M. Tillema3, L. Benson4, M. Gorman4, M. Goyal5, Y. Harris6, L. Krupp7, T. Lotze8, S. Mar5, J. Ness6, M. Rensel9, M. Rodriguez3, N. Shukla8, E. Waubant10, J. Rose11, S. Roalstad12, T.C. Casper13, 1Denver Children’s Hospital/Denver/US, 2Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US, 3Mayo Clinic Department of Neurology/Rochester/US, 4Boston Children’s Pediatric MS Center/Boston/US, 5Washington University/St. Louis/US, 6University of Alabama at Birmingham/Birmingham/US, 7NYU Langone/New York City/US, 8Baylor College of Medicine/Houston/US, 9Cleveland Clinic/Cleveland/US, 10UCSF/San Francisco/US, 11University of Utah, George E. Wahlen Department of Veterans Affairs Medical Center/Salt Lake City/US, 12University of Utah/Salt Lake City/US, 134University of Utah/Salt Lake City/US

LB1232 - Managing Multiple sclerosis patients diagnosed with COVID-19 infection; into the field of unknown

S. Omerhoca1, Z. Yıldırım2, N. Kaya Tutar2, N. Kale3, 1bagcilar training and research hospital/Istanbul/TR, 2Bağcılar Reseaerch and Trainig Hospital/İstanbul/TR, 3bagcilar training and research hospital/istanbul/TR

LB1233 - Blood brain barrier permeability and high dose corticosteroids for MS relapses: a pilot study

S. Morrow1, J. Ward2, H. Rosehart2, C. Casserly2, A. Macdonald3, T. Wales4, T.-Y. Lee5, 1London Health Sciences Centre/London/CA, 2London Health Sciences Center/London/CA, 3St Joseph's Health Care/London/CA, 4St Joseph's Health Care Center/London/CA, 5University of Western Ontario (Western)/london/CA

LB1234 - COVID-19 infections in NMOSD and MOGAD: a population based study

M. Capobianco1, G. Comi2, M.P. Sormani3, F. Patti4, 1San Luigi Gonzaga Hospital/Orbassano (TO)/IT, 2San Raffaele Scientific Institute, Vita-Salute San Raffaele University/Milan/IT, 3University of Genoa/Genoa/IT, 4Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania/Catania/IT

LB1235 - Frequency of SARS-CoV-2 antibodies and COVID-19 severity in a cohort of Italian multiple sclerosis patients on DMTs inhibiting immune cell trafficking

G. Mallucci1, A. Zito1, B. Dal Fabbro1, M. Gastaldi2, D. Franciotta2, R. Bergamaschi1, 1IRCCS Mondino Foundation/Pavia/IT, 2IRCCS Mondino Foundation/pavia/IT

LB1236 - The role of ten eleven translocase 2 (TET2) in the regulation of autoimmune demyelinating disease

A. Munie, B. Segal, The Ohio State University/Columbus/US

LB1237 - An Antigen-Specific Microparticle Formulation Therapeutically Treats a Mouse Model of Multiple Sclerosis

A. Kwiatkowski, J. Stewart, E. Helm, T. Drashansky, A. Zuniga, D. Avram, B. Keselowsky, University of Florida/Gainesville/US

LB1238 - Myelin Oligodendrocyte Glycoprotein-antibody positive transverse myelitis presenting as acute flaccid paralysis in a child with enterovirus infection

V. Salinas1, J. Lorenzo2, C. Wang3, 1University of Texas Southwestern Medical Center/Dallas/US, 2University of Texas Southwestern/Dallas/US, 3University of Texas Southwestern Medical Center/dallas/US

LB1239 - Pharmacodynamic modeling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders

L. Yan1, B. Wang2, D. She1, B. Mitchel2, R. Criste2, D. Cimbora1, E. Katz1, W. Rees1, 1Viela Bio/Gaithersburg/US, 2Amador Bioscience Inc/Pleasanton/US

LB1240 - A kappa free light chain index of 6.6 represents an alternative to positive oligoclonal bands in the 2017 McDonald criteria

G. Arrambide1, C. Espejo2, R. Dieli1, C. Auger1, M. Castillo3, M. Rodriguez-Barranco4, P. Carbonell- Mirabent4, J. Río5, J. Castilló6, A. Vidal-Jordana7, Í. Galán3, C. Nos8, M. Comabella9, B. Rodríguez- Acevedo3, L. Midaglia10, A. Zabalza4, A. Cobo Calvo11, P. Tagliani4, S. Cárdenas-Robledo12, J. Sastre- Garriga1, A. Rovira13, M. Hernández-González1, X. Montalban3, M. Tintore14, 1Vall Hebron University Hospital/Barcelona/ES, 2Hospital Universitario Vall D´Hebron/Barcelona/ES, 3Dept. of Neurology- Neuroimmunology; Vall d'Hebron University Campus; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 4Vall d’Hebron Institut de Recerca/Barcelona/ES, 5CEMCAT, Hospital Universitario Vall d’Hebrón/Barcelona/ES, 6Neuroimmunology and Multiple Sclerosis Unit of Girona/Girona/ES, 7Hospital Universitari Vall d’Hebron/Barcelona/ES, 8Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari/Bercelona/ES, 9Universitat Autònoma//ES, 10Dept. of Neurology-Neuroimmunology; Vall Hebron University Hospital; Multiple Sclerosis Centre of Catalonia (Cemcat)/Barcelona/ES, 11Centre d’Esclerosi Múltiple de Catalunya (Cemcat)/Barcelona/ES, 12Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron Barcelona Hospital Campus/Barcelona/ES, 13Vall d'Hebron University Hospital/Barcelona/ES, 14Multiple Sclerosis Centre of Catalonia/Barcelona/ES

LB1241 - Incidence and clinical outcome of COVID-19 in a cohort of 11.560 Brazilian patients with Multiple Sclerosis

M.F. Mendes1, M.L. Ferreira2, N.A. Sousa3, R. Thomaz4, S.L. Apóstolos-Pereira5, S. Alves-Leon6, A.C. Piccolo7, E.M. De Oliveira8, C.C. Vasconcelos9, A. Muniz10, A. Gomes Neto11, B.E. De Oliveira12, F. Da Rocha13, G. Martins14, G.A. Dos Santos15, H.H. Ruocco16, H. Soares Neto17, M.C. De Vecino18, M. Boaventura19, R.M. Dias20, S. Gomes21, A. Castro22, J.A. D'Almeida14, L. Rocha23, M.L. Pimentel24, M. Pitombeira14, O. Arambula25, V. Pereira6, H. Cabeça23, M.V. Gonçalves26, R. Dias-Carneiro27, L. Ferreira28, R. Guimarães29, C.M. Fortaleza30, D. Diniz31, A. Grzesiuk32, D.R. Kaimen-Maciel33, E. Comini- Frota34, G. Do Olival35, H.H. Siqueira36, H. Sato37, L. Calia38, L.D. Melges39, M.E. Dourado Junior40, M. Ribeiro41, M.A. Sousa42, M. Parolin37, P. Da Gama43, R. Morales44, S. Sobreira45, S. Machado46, T. Ribeiro31, T. Fukuda47, V. Costa48, V.L. Vieira49, M. Perin50, A. Da Nóbrega Junior51, A.J. Moreira2, C.C. Disserol52, C. De Oliveira E Silva53, C.A. Peixoto54, E. Pugliesi55, H. Miot13, J.A. Figueiredo Junior36, L. Amorim8, L. Scolari31, L. Feo56, L. Mendes14, M.I. Machado2, R. Catão54, R. Menon57, E. Donadi58, D. Callegaro52, Y. Fragoso22, T. Adoni38, F. Von Glehn59, D. Brum13, 1Faculdade de Medicina, Universidade de São Paulo/São Paulo/BR, 2Hospital da Restauração/Recife/BR, 3Hospital Universitário Getúlio Vargas/Manaus/BR, 4Hospital Israelita Albert Einstein/São Paulo/BR, 5Hospital das Clínicas - FMUSP/São Paulo/BR, 6Universidade Federal do Rio de Janeiro/Rio de Janeiro/BR, 7Hospital Santa Marcelina/São Paulo/BR, 8Universidade Federal de São Paulo/São Paulo/BR, 9Hospital Universitário Gaffrée e Guinle/Rio de Janeiro/BR, 10Clínica AMO/Salvador/BR, 11Santa Casa de Belo Horizonte/Belo Horizonte/BR, 12FUNAD/João Pessoa/BR, 13Universidade Estadual Paulista (Unesp), Faculdade de Medicina de Botucatu/Botucatu/BR, 14Hospital Geral de Fortaleza/Fortaleza/BR, 15Universidade Estácio de Sá e Universidade Federal Fluminense/Rio de Janeiro/BR, 16Universidade Federal Fluminense/Campinas/BR, 17IAMSPE/São Paulo/BR, 18MOINHOS DE VENTO HOSPITAL/Porto Alegre/BR, 19Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo/São Paulo/BR, 20Hospital de Base do Distrito Federal/Brasília/BR, 21Hospital Beneficência Portuguesa/São Paulo/BR, 22Universidade Metropolitana de Santos/Santos/BR, 23Hospital Ophir Loyola/Belém/BR, 24Santa Casa - Rio de Janeiro/Rio de Janeiro/BR, 25Universidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatu/Botucatu/BR, 26Universidade da Região de Joinville (Univille)/Joinville/BR, 27Santa Casa de São Paulo/São Paulo/BR, 28Tiradentes University/Aracaju/BR, 29Department of Geography, College of Science and Technology of Presidente Prudente State University of São Paulo, Brazil/Presidente Prudente/BR, 30Universidade Estadual Paulista (Unesp), Faculdade de Medicina de Botucatu, Botucatu/Botucatu/BR, 31Universidade Federal de Goiás/Goiânia/BR, 32Private Service/Cuiabá/BR, 33Santa Casa de Londrina/Londrina/BR, 34Private Service/Belo Horizonte/BR, 35ABEM e Santa Casa de São Paulo/São Paulo/BR, 36Universidade Federal do Mato Grosso/Cuiabá/BR, 37Private Service/Curitiba/BR, 38Private Service/São Paulo/BR, 39Faculdade de Medicina de Marília/Marília/BR, 40Universidade Federal do Rio Grande do Norte/Natal/BR, 41Universidade Federal Ciências da Saúde de Porto Alegre/Porto Alegre/BR, 42Private Service/Uberaba/BR, 43PUC/Sorocaba/BR, 44Universidade Federal de Uberlândia/Uberlândia/BR, 45Hospital Memorial São José , rede D’OR/Recife/BR, 46Private Service/Florianópolis/BR, 47Universidade Federal da Bahia/Ebserh/Salvador/BR, 48Hospital Neurológico de Goiânia/Goiânia/BR, 49Universidade Federal do Espirito Santo/Vitória/BR, 50PUC- Campinas/Campinas/BR, 51Hospital Universitário da Universidade Federal de Santa Catarina/Florianópolis/BR, 52Hospital das Clínicas – Faculdade de Medicina de São Paulo/São Paulo/BR, 53Hospital Moinhos de Vento/Porto Alegre/BR, 54Universidade Federal do Espírito Santo/Vitória/BR, 55Universidade Estadual Paulista, Faculdade de Ciência e Tecnologia Presidente Prudente/Presidente Prudente/BR, 56Faculdade de Medicina - FMUSP/São Paulo/BR, 57SANTA CASA DE LONDRINA/Londrina/BR, 58Universidade de São Paulo, Faculdade de Medina de Ribeirão Preto/Ribeirão Preto/BR, 59Faculty of Medicine, University of Brasilia/Brasília/BR

LB1242 - COViMS Registry: Clinical Characterization of SARS-CoV-2 Infected Multiple Sclerosis Patients in North America

A. Salter1, J. Halper2, B. Bebo3, P. Kanellis4, K. Costello5, G. Cutter6, S. Newsome7, D. Li8, R. Fox9, K. Rammohan10, A. Cross11, 1Washington University School in St. Louis/St Louis/US, 2CMSC/Fair Lawn/US, 3National Multiple Sclerosis Society (USA)/Portland/US, 4MS Society of Canada/Toronto/CA, 5National Multiple Sclerosis Society/New York/US, 6The University of Alabama at Birmingham/Birmingham/US, 7Johns Hopkins University School of Medicine/Baltimore/US, 8//CA, 9Cleveland Clinic//US, 10University of Miami School of Medicine/Miami/US, 11Washington University in St. Louis/St. Louis/US

LB1243 - Disease modifying treatment changes in pediatric onset multiple sclerosis patients over the past 10 years. A single center retrospective study.

N. Moore1, A. Balasa2, K. Fisher1, M. Codispoti3, N. Shukla1, T. Lotze1, 1Baylor College of Medicine/Houston/US, 2West Virginia University/Morgantown/US, 3Edward Via College of Osteopathic Medicine - Louisiana Campus/Monroe/US

LB1244 - Manifestations and Impact of the COVID-19 Pandemic in Neuroinflammatory Diseases

Z. Xia1, S. Levin2, S. Venkatesh1, K. Nelson2, Y. Li1, I. Aguerre2, W. Zhu1, K. Masown1, K. Fong3, C. Diaconu4, K. Onomichi3, V. Leavitt3, L. Levine3, R. Straus Farber5, W. Vargas4, B. Banwell6, C. Perrone7, A. Bar-Or8, J. Berger8, A. Goodman9, E. Longbrake10, J. Oh11, B. Weinstock-Guttman12, K. Thakur3, K. Edwards13, C. Riley3, P. De Jager5, 1University of Pittsburgh/Pittsburgh/US, 2Columbia University Irving Medical Center/New York City/US, 3Columbia University Irving Medical Center/New York/US, 4Columbia University Medical Center/New York/US, 5Columbia University Medical Center/United States/US, 6Children’s Hospital of Philadelphia/Philadelphia/US, 7Perelman School of Medicine, University of Pennsylvania/Philadelphia/US, 8University of Pennsylvania/Philadelphia/US, 9University of Rochester Medical Center/Rochester/US, 10Yale University/New Haven/US, 11University of Toronto/Toronto/CA, 12State University of New York at Buffalo/Buffalo/US, 13KMS Center of NE New York/Latham/US

LB1245 - BB-CRESM: a structured institutional biobank for quality research in Multiple Sclerosis.

F. Marnetto1, P. Valentino1, M. Caldano2, A. Ficorilli2, A. Paudice3, A. Bertolotto4, 1Neuroscience Institute Cavalieri Ottolenghi (NICO)/orbassano/IT, 2AOU San Luigi Gonzaga/orbassano/IT, 3AO Ordine Mauriziano/Turin/IT, 4San Luigi Gonzaga Hospital/Orbassano (TO)/IT

LB1246 - Future implementation of automated analysis tools for Multiple Sclerosis on conventional magnetic resonance imaging.

C. Lim1, H. Liaqat2, W. Siu3, G. Hamarneh2, G. Medvedev4, 1/LANGLEY/CA, 2Simon Fraser University/Burnaby/CA, 3Royal Columbian Hospital/New West Minister/CA, 4University of British Columbia/LANGLEY/CA

LB1247 - Clinical features of COVID-19 in patients with neuromyelitis optica spectrum disorders

M. Boaventura1, S. Apóstolos-Pereira2, L. Ferreira3, N. Sousa4, G. Martins5, J.A.C. D’Almeida5, M. Pitombeira5, L. Mendes5, T. Fukuda6, L. Rocha7, H. Cabeça7, B. Oliveira8, C. Vieira Stella9, E.M. Oliveira10, L. Amorim10, A. Castro11, A.P. Gomes Neto12, G. Silva13, L. Bueno14, M. Machado15, R.P.C. Dias-Carneiro16, R. Dias17, A. Moreira15, A.C. Piccolo18, A. Grzesiuk19, A. Muniz20, C. Disserol13, C.C. Vasconcelos21, D. Diniz22, D.L. Kaimen-Maciel23, E. Comini-Frota24, F. Rocha25, G. Sciascia Do Olival26, G.A. Santos27, H.H. Ruocco28, H.H. Siqueira29, H. Sato30, H. Soares Neto31, J. Figueiredo Jr29, L. Calia32, L. Scolari33, L.D. Melges34, M.V.M. Gonçalves35, M.L. Pimentel36, M.E. Dourado Junior37, M. De Castro Ribeiro38, O. Arambula39, P.D. Gama40, R. Menon41, R. Thomaz42, R. Morales43, S. Gomes44, S. Sobreira45, S. Alves-Leon46, S. Machado47, T.A. Ribeiro22, V. Pereira46, V. Costa48, M. Perin49, A. Nóbrega Junior50, Y. Fragoso51, E. Donadi52, T. Adoni53, M.L. Ferreira15, D. Callegaro54, M.F. Mendes16, D. Brum55, F. Von Glehn56, 1Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo/São Paulo/BR, 2Faculdade de Medicina, Universidade de São Paulo/Sao Paulo/BR, 3Tiradentes University/Aracaju/BR, 4Hospital Universitário Getúlio Vargas/Manaus/BR, 5Hospital Geral de Fortaleza/Fortaleza/BR, 6Thiago Fukuda/Salvador/BR, 7Hospital Ophir Loyola/Belém/BR, 8FUNAD/João Pessoa/BR, 9UNICAMP/Campinas/BR, 10Universidade Federal de São Paulo/São Paulo/BR, 11Universidade Metropolitana de Santos/Santos/BR, 12Santa Casa de Belo Horizonte/Belo Horizonte/BR, 13Facldade de Medicina, Universidade de São Paulo/São Paulo/BR, 14faculdade de Medicina, Universidade de São Paulo/São Paulo/BR, 15Hospital da Restauração/Recife/BR, 16Faculdade de Ciências Médicas da Santa Casa de São Paulo/São Paulo/BR, 17Hospital de Base do Distrito Federal/Brasília/BR, 18Hospital Santa Marcelina/São Paulo/BR, 19Private Service/Cuiabá/BR, 20Clínica AMO/Salvador/BR, 21Hospital Universitário Gaffree e Guinle/Rio de Janeiro/BR, 22Universidade Federal de Goiás/Goiânia/BR, 23Santa Casa de Londrina/Londrina/BR, 24Private Service/Belo Horizonte/BR, 25Universidade Estadual Paulista (Unesp), Faculdade de Medicina de Botucatu/Botucatu/BR, 26ABEM - Brazilian MS Patients Association/Sao Paulo/BR, 27Universidade Estácio de Sá/Rio de Janeiro/BR, 28Universidade Federal Fluminense/Campinas/BR, 29Universidade Federal do Mato Grosso/Cuiabá/BR, 30Private Service/Curitiba/BR, 31IAMSPE/São Paulo/BR, 32Private Service/São Paulo/BR, 33UNIVERSIDADE FEDERal do Mato Grosso/Cuiabá/BR, 34Faculdade de Medicina de Marília/Marília/BR, 35Universidade da Região de Joinville/Joinville/BR, 36Santa Casa - Rio de Janeiro/Rio de Janeiro/BR, 37Universidade Federal do Rio Grande do Norte/Natal/BR, 38Irmandade Santa Casa de Misericórdia/Porto Alegre/BR, 39Universidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatu/Botucatu/BR, 40Pontifícia Universidade Católica de São Paulo/São Paulo/BR, 41SANTA CASA DE LONDRINA/Londrina/BR, 42Hospital Israelita Albert Einstein/São Paulo/BR, 43Universidade Federal de Uberlândia/Uberlândia/BR, 44Hospital Beneficência Portuguesa/São Paulo/BR, 45Hospital Memorial São José , rede D’OR/Recife/BR, 46Universidade Federal do Rio de Janeiro/Rio de Janeiro/BR, 47Private Service/Florianópolis/BR, 48Hospital Neurológico de Goiânia/Goiânia/BR, 49Pontificia Universidade Católica de Campinas/Campinas/BR, 50Hospital Universitário da Universidade Federal de Santa Catarina/Florianópolis/BR, 5162Universidade Metropolitana de Santos/Santos/BR, 52Universidade de São Paulo, Faculdade de Medina de Ribeirão Preto/Ribeirão Preto/BR, 53Univ Sul/São Paulo/BR, 54Hospital das Clínicas – Faculdade de Medicina de São Paulo/São Paulo/BR, 55Universidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatu/BOTUCATU/BR, 56Universidade Brasilia/Brasília/BR

LB1248 - Proof-of-concept trial of a novel dietary supplement, Multicafe®, for fatigue in multiple sclerosis

G. Dos Passos1, A. Bressanim1, A.D.C. Dos Santos1, C. Trevisan1, G. Tavares1, L. Gonçalves1, L.E. Canton1, M. Olmi1, M. Urbanetto1, C. Teixeira2, V. Azzolin2, I. Da Cruz2, D. Sato1, 1Pontifical Catholic University of Rio Grande do Sul/Porto Alegre/BR, 2Federal University of Santa Maria/Santa Maria/BR

LB1249 - Types of pharmaceutical intervention in patients with Multiple sclerosis (MS): A fine line between immunosuppressive and risk of COVID-19 infection

M. Sadeghi1, A. Kanani1, E. Barouti2, S.M. Nabavi3, 1University of Tehran/Tehran/IR, 2Amirkabir University of Technology/Tehran/IR, 3Department of Brain and Cognitive Sciences, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology,/Tehran/IR

LB1250 - Neuronal integrity is associated to peripheral leukocyte dysfunction in asymptomatic Multiple Sclerosis (MS) first-degree relatives

H. Touil1, T. Roostaei1, C. White2, Z. Xia3, P. De Jager4, 1Columbia University Medical Center/New York/US, 2Broad institute/Boston/US, 3University of Pittsburgh/Pittsburgh/US, 4Columbia University Medical Center/United States/US

LB1251 - National Multiple Sclerosis Society Healthcare Provider Councils COVID-19 Survey

E. Morrison1, C. Hersh2, 1University of California at Riverside/Riverside/US, 2Cleveland Clinic/Las Vegas/US

LB1252 - COVID-19 and multiple sclerosis – prevalence and the impact of disease modifying therapies

B. Kieseier1, R. Rajbhandari1, A. Altincatal2, M. Kim1, A. Berdofe1, M. Radhakrishnan1, E. Jung1, A. Sandrock1, C. De Moor1, 1Biogen/Cambridge/US, 2Biogen/Boston/US

LB1253 - The Impact Of COVID19 Pandemic On NeuromyelitisOptica Spectrum Disorder Patients In Isfahan , Iran.

R. Mehdipour1, F. Ashtari2, 1Isfahan Neuroscience Research center , Isfahan University of Medical science , Kashani Hospital MS clinic/Isfahan/IR, 2Isfahan University of Medical Sciences/Isfahan/IR

LB1254 - A real-world data study of Coronavirus-2019 disease severity in patients with multiple sclerosis treated with ocrelizumab

P. Dillon1, A. Waqar2, S. Roumpanis1, M. Martinec3, E. Muros-Le Rouzic1, 1F. Hoffmann-La Roche Ltd,/Basel/CH, 2F. Hoffmann-La Roche Ltd/Welwyn Garden City/GB, 3F. Hoffmann-La Roche Ltd/Basel/CH

LB1255 - Influence of social isolation measures due to Covid-19 on the quality of life of people with Multiple Sclerosis

A. Dias, J. Telles, M. Bando, ABEM - Brazilian MS Patients Association/Sao Paulo/BR

LB1256 - New findings from the 2020 MS Barometer on MS prevalence, practicing neurologists and use of disease-modifying drugs across Europe C. Whicher1, N. Kriauzaite2, T. Albone3, E. Kasilingam4, A. Taylor3, D. Ratchford3, C. Merkel1, 1The Health Policy Partnership/London/GB, 2European Multiple Sclerosis Platform/Brussels/BE, 3Quality Health/Holmewood/GB, 4European Multiple Sclerosis Platform/Rue Auguste Lambiotte //BE

LB1257 - Nowcasting Covid-19 in patients with Multiple Sclerosis via social media

A. Hoepner1, A. Arimond2, A. Chan3, A. Salmen4, M. Graber5, R. Hoepner6, 1Smurfit Graduate Business School/Dublin/IE, 2SDGlabs.ai, Sociovestix Labs/Kaiserslautern/DE, 3Inselspital Bern, University Hospital and University of Bern/Bern/CH, 4Inselspital/Bern/CH, 5Inselspital /Bern/CH, 6Inselspital/Berne/CH

LB1258 - SARS-CoV-2 pandemic lockdown: perceived consequences on multiple sclerosis patients

A. Sartori1, A. Dinoto2, F. Pasquin2, A. Bratina2, A. Bosco2, P. Manganotti2, 1Neurology Unit, Azienda Sanitaria Univeristaria Integrata Clinica Neurologica, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Trieste/Trieste/IT, 2Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Cattinara University Hospital ASUGI, University of Trieste/Trieste/IT

LB1259 - Recurrent CNS Demyelination in a Pediatric Patient with History of Guillain-Barre Syndrome variant Being Treated with IVIG

B. Rhem1, C. Wang2, D. Castro3, 1UT Southwestern Medical Center/Dallas/US, 2University of Texas Southwestern Medical Center/dallas/US, 3University of Texas Southwestern Medical Center/Dallas/US

LB1260 - Optic neuritis in long standing clinically stable secondary progressive multiple sclerosis after SARS-CoV-2 infection: a mere coincidence?

A. Sartori1, A. Dinoto2, F. Pasquin2, A. Bratina2, A. Bosco2, P. Manganotti2, 1Neurology Unit, Azienda Sanitaria Univeristaria Integrata Clinica Neurologica, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Trieste/Trieste/IT, 2Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Cattinara University Hospital ASUGI, University of Trieste/Trieste/IT

LB1261 - Resting-state neural activity, cognitive functioning and reserve in relapsing-remitting multiple sclerosis: a microstates EEG study.

S. Baldini1, M.E. Morelli2, A. Sartori3, A. Dinoto2, A. Bratina2, A. Bosco2, P. Manganotti2, 1University Hospital and Health Services of Trieste/Trieste/IT, 2Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Cattinara University Hospital ASUGI, University of Trieste/Trieste/IT, 3Neurology Unit, Azienda Sanitaria Univeristaria Integrata Clinica Neurologica, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Trieste/Trieste/IT

LB1262 - Low Prevalence of SARS-CoV-2 Antibodies in People with Multiple Sclerosis Residing in Massachusetts

E. Klawiter1, J. Smith1, K. Brewer1, K. Stockel1, S. Fischinger2, C. Luedemann3, H. Bien1, A. Russo4, A. Vaeth1, R. Bakshi5, S. Bhattacharyya5, A. Cabot6, I. George7, R. Gillani7, M. Hickey8, M. Houtchens9, T. Bockow Kaplan5, D. Kimbrough10, I. Kister11, F. Mateen7, M. Matiello7, C. Severson5, T. Singhal5, J. Stankiewicz5, L. Stazzone5, H. Weiner12, J. Zurawski13, A. Eloyan14, T. Chitnis15, G. Alter3, 1Massachusetts General Hospital/Charlestown/US, 2Ragon Institute/Cambridge/US, 3Ragon Institute of MGH, MIT and Harvard/Cambridge/US, 4Massachusetts General Hospital /Charlestown/US, 5Brigham and Women's Hospital/Boston/US, 6Concord Hospital/Concord/US, 7Massachusetts General Hospital/Boston/US, 8Baystate Medical Center/Springfield/US, 9Partners MS Center, Brigham and Women's Hospital, Harvard Medical School/Boston/US, 10Harvard Medical School//US, 11New York University/New York City/US, 12Harvard University, Brigham & Women's Hospital/Boston/US, 13Brigham & Women's Hospital/Harvard Medical School/Boston/US, 14Brown University/Providence/US, 15Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US

LB1263 - Introduction of CSF immunoglobulin κ light chains testing as a complement to oligoclonal bands evaluation

G. Medvedev1, A. Garg2, K. Rodriguez Capote2, A. Fong3, 1University of British Columbia/LANGLEY/CA, 2Fraser Health Authority/New Westminster/CA, 3University of British Columbia/Vancouver/CA

LB1264 - Endocrine disrupting chemicals affect T cell phenotypes and show a role for environmental factors in MS pathophysiology.

M. Popescu1, T. Feldman2, H. Lokhande3, S. Saxena3, F. Saleh1, P. Gaitan-Walsh1, P. Castro- Mendoza4, T. Chitnis5, 1Harvard University, Brigham and Women's Hospital/Boston/US, 2Harvard University/Brigham and Women's Hospital/Boston/US, 3Harvard University, Brigham & Women's Hospital/Boston/US, 4Harvard University, Massachusetts General Hospital/Boston/US, 5Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School/Boston/US

LB1265 - "TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of CNS demyelination."

F. Filipello1, F. Cignarella1, B. Bollman1, C. Cantoni1, A. Locca1, R. Mikesell1, B. Bruno A. Benitez1, C. Cruchaga1, D. Licastro2, O. Harari1, A. Rosenthal3, T. Schwabe3, I. Tassi3, L. Piccio1, 1Washington University/St Louis/US, 2CBM Scrl ‐ Genomics/Trieste/IT, 3Alector/San Francisco/US

LB1266 - Descriptive data analysis of covid-19 among patients with multiple sclerosis; A cross- sectional study of southern Iran

M. Poursadeghfard1, M. Bayat1, A. Borhani Haghighi2, H. Molavi Vardanjani3, A. Fayyazpoor1, D. Salehi1, 1Shiraz University of Medical Sciences, Shiraz, Iran./Shiraz/IR, 2Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran./Shiraz/IR, 3MPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran./Shiraz/IR

LB1267 - Teriflunomide Enhanced Innate and Adaptive Immune Regulatory Function in Treating Multiple Sclerosis Q. Wu1, Q. Wang1, J. Yang1, A. Saad1, A. Ali2, C. Dowling1, C. Fisher1, Y. Mao-Draayer3, 1Autoimmunity Center of Excellence/Ann Arbor/US, 2University of Michigan /Ann Arbor/US, 3Autoimmunity Center of Excellence/MI/US

LB1268 - No evidence for SARS-CoV-2 transcripts and disease exacerbation in COVID-19 multiple sclerosis brain

V. Fuchs1, M. Kutza2, S. Wischnewski2, N. Deigendesch3, L. Lutz3, L. Kulsvehagen3, G. Ricken4, L. Kappos3, A. Tzankov3, S. Hametner4, S. Frank3, L. Schirmer2, A.-K. Pröbstel1, 1University Hospital Basel/Basel/CH, 2Medical Faculty Mannheim, Heidelberg University/Mannheim/DE, 3University Hospital and University of Basel/Basel/CH, 4Medical University of Vienna/Vienna/AT

LB1269 - Higher parietal and premotor cortex activation and connectivity during treadmill walking in Persons with Multiple Sclerosis versus healthy controls

S. Saleh1, M. Glassen1, A. Hoxha1, G. Yue1, J. Deluca2, 1Kessler Foundation/West Orange/US, 2Kessler Foundation/East Hanover/US

LB1270 - DICAM : A new cell adhesion molecule involved in myeloid cells infiltration in Multiple Sclerosis

C. Grasmuck1, S. Ghannam1, S. Zandee1, R.-M. Rébillard2, C. Hoornaert1, M. Charabati1, E. Peelen1, L. Bourbonniere2, S. Larouche2, C. Pittet1, A. Prat3, 1Centre de Recherche du CHUM/Montréal/CA, 2CRCHUM/Montréal/CA, 3University of Montreal/Montreal/CA

LB1271 - MRI insights into myelin damage in Susac Syndrome

P. Johnson1, J. Chan1, I. Vavasour1, S. Abel2, L.E. Lee1, H. Yong1, V. Wiggermann1, C. Laule1, A. Woolfenden1, A. Traboulsee3, D. Li4, R. Tam1, S. Kolind1, R. Carruthers5, 1University of British Columbia/Vancouver/CA, 2/Delta/CA, 3The University of British Columbia/Canada/CA, 4//CA, 5University of British Columbia Hospital/Vancouver/CA

LB1272 - Distinct co-varying functional-structural patterns in multiple sclerosis for physical disability and cognitive impairment

A. Giorgio1, J. Zhang2, C. Vinciguerra2, M.L. Stromillo2, M. Mortilla3, R. Tappa Brocci2, M. Battaglini2, E. Portaccio4, M.P. Amato5, N. De Stefano2, 1Department of Medicine, Surgery and Neuroscience, University of Siena, Italy/Siena/IT, 2University of Siena/Siena/IT, 3Anna Meyer Children’s University Hospital/Florence/IT, 4Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy/Florence/IT, 5University of Florence/Florence/IT

LB1273 - Telehealth Utilization in Four MS Centers During the COVID Pandemic: Real-world evidence from the MS-CQI improvement research collaborative. B. Oliver1, K. Walsh2, F. Mehta1, S. England3, 1DARTMOUTH HITCHCOCK MEDICAL CENTER/Lebanon/US, 2Thomas Jefferson University/Philadelphia/US, 3Biogen/Weston/US

LB1274 - Modeling subject-level disease progression for Multiple Sclerosis in clinical trials using machine learning

J. Walsh, Unlearn.AI/San Francisco/US

LB1275 - Enriching neuroimmunology telemedicine encounters with objective measures of vision during the SARS-CoV-2 pandemic

H. Stiebel-Kalish1, Y. Rabinovich2, A. Tiosano2, O. Bialer2, 1Tel Aviv University/Tel Aviv/IL, 2Tel Aviv University & Rabin Medical Center/Petah Tikva/IL

LB1276 - Contribution of antibodies against coagulation components in the circuit of coagulation- immune system: Potential biomarkers of Multiple Sclerosis?

M.S. Hadjiagapiou, G. Krashias, C. Christodoulou, M. Pantzaris, A. Lambrianides, The Cyprus Institute of Neurology and Genetics/Nicosia/CY

LB1277 - Evaluation of intermittent fasting diet in multiple sclerosis

K.L.A. Lau1, G. Medvedev2, 1/Vancouver/CA, 2University of British Columbia/LANGLEY/CA

LB1278 - Teriflunomide: An Immune Modulating Drug with Antiviral Properties

F. Gilli1, M. Linzey2, N. Welsh3, J. Chavin4, K. Disano1, A. Pachner1, 1Dartmouth Hitchcock Medical Center/Lebanon/US, 2Dartmouth College/Lebanon/US, 3Dartmouth College/Lebanon/UM, 4Sanofi- Genzyme/Boston/US

LB1279 - Initial Symptom at Onset in newly diagnosed Hispanic MS patients between 2017-2019: An Update

A. Dao1, R. Vega2, C. Rubi3, V. Martinez3, A. Diaz Quiñones4, F. Casillas4, A. Lopez4, I. Vicente5, A. Chinea Martinez4, 1San Juan Bautista Medical School/Bayamon/PR, 2/Sanjuan/PR, 3San Juan MS Center/Guaynabo/PR, 4Caribbean Center for Clinical Research/Guaynabo/PR, 5San Juan MS Center/San Juan/PR

LB1280 - COVID-19 among patients with Multiple sclerosis (MS) and Neuromyelitis optica spectrum disorders (NMOSD): A systematic review of current evidence

M. Barzegar, O. Mirmosayyeb, A. Afshari-Safavi, V. Shaygannejad, Isfahan neuroscience research center/Isfahan/IR

LB1281 - Experience of a northeast Brazilian demyelinating disorders center in remote screening of COVID-19 during the sars-cov-2 pandemic.

I. Santiago, M. Pitombeira, L. Mendes, I. Pereira Nobrega, I.H. Dantas, K.R. De Morais, P. D´almeida, C. Da Silva, P.S. Lisboa, M.L. De Melo, M. Gonçalves, G. Martins, J.A. Costa D'Almeida, Hospital Geral de Fortaleza/Fortaleza/BR

LB1282 - Machine learning of deep grey matter volumes on MRI for predicting new disease activity after a first clinical demyelinating event

M. Tayyab1, L. Metz2, A. Dvorak1, S. Kolind1, S. Au1, R. Carruthers3, A. Traboulsee4, R. Tam1, 1University of British Columbia/Vancouver/CA, 2University of Calgary/Canada/CA, 3University of British Columbia Hospital/Vancouver/CA, 4The University of British Columbia/Canada/CA